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Monocyte Subsets into the Circulation and Monocyte-specific  
Transcriptional Programs 
E Andersen-Nissen, DE Zak, TR Hensley, DJ Adams, X Hu, A Sato,  
M Elizaga, PA Goepfert, HL Robinson, A Aderem, MJ McElrath,  
the NIAID HIV Vaccine Trials Network
12:30 – 13:30 Lunch  BCEC Level 2, Rooms 252 AB / 254 AB / 257 AB 
12:30 – 13:30 Networking Lunch BCEC Level 2, Room 259 AB
 Join us in BCEC Level 2, Room 259 AB where lunch tables have been reserved for young and 
early-career investigators and community representatives to network with senior researchers.
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13:30 – 14:45 Oral Abstract Session 04:  BCEC Level 3, 
Mucosal Immunity Room 258 ABC
 Chairs: Daniel Douek and Jo-Ann Passmore
13:30 – 13:45 Immune Complexes Can Dampen Inflammatory Signaling at the  OA04.01 
Mucosal Surface During Protective SIV Vaccination 
AJ Smith, SW Wietgrefe, CS Reilly, PJ Southern, L Duan, KE Perkey,  
L Shang, R Johnson, AT Haase
13:45 – 14:00 Vaccine-elicited Systemic and Mucosal Humoral Responses of  OA04.02 
Lactating Rhesus Monkeys Vaccinated with the Transmitted/Founder  
HIV Envelope 1086C 
G Fouda, J Amos, AB Wilks, A Chand, D Montefiori, B Haynes, N Letvin,  
D Pickup, H Liao, SR Permar
14:00 – 14:15 Expanded Memory CD4+ T Cells in the Fetal and the Infant Gut;  OA04.03 
a Mucosal Route for Mother-to-Child-Transmission of HIV-1  
MJ Bunders, C van der Loos, PL Klarenbeek, J van Hamme, J Wilde,  
N de Vries, RA van Lier, N Kootstra, ST Pals, TW Kuijpers
14:15 – 14:30 Cell Free HIV-1 Virus Can Infect Inner and Outer Foreskin  OA04.04 
Polarized Explants 
MP Lemos, ML Perez, J Sanchez, J Lama, S Montano, J McElrath
14:30 – 14:45 Inflammation in the Male Genital Tract: Implications for HIV  OA04.05 
Acquisition and Transmission 
AJ Olivier, L Roberts, D Coetzee, A Williamson, JS Passmore, WA Burgers
13:30 – 14:45 Oral Abstract Session 05:  BCEC Level 2, 
Social/Ethical Issues Room 253 ABC
 Chairs: Barney Graham and Jonathan Fuchs
13:30 – 13:45 New Tools to Measure Community and Stakeholder Engagement  OA05.01 
and Its Impact on Outcomes of Clinical Research 
P Bahati, S Hannah, S Seidel, S Aggett, R Siskind, R Campbell, S Williams,  
A Downie, S Rosas
13:45 – 14:00 An Assessment of Good Participatory Practice Guidelines at HIV  OA05.02 
Prevention Research Clinical Centers in Eastern and Southern Africa 
BP Ngongo, S Hannah, J Mbogua, M Seyoum, M Warren, E Baas, F Priddy
14:00 – 14:15 Social and Ethical Considerations in Engaging American Indian and  OA05.03 
Alaska Native Communities in HIV Clinical Research  
J Velcoff, DL Humes, R Foley, M Ignacio
14:15 – 14:30 Knowledge/Attitude/Practices of HPV & Cervical Cancer, Willingness to Participate OA05.04 
in Vaccine Trial in Preparation for HIV & HPV Vaccine Trials in Mali 
D Poole, K Tracy, L Levitz, S Yekta, E Kossow, T Huang, M Rochas, K Sangare,  
K Tounkara, B Aboubacar, O Koita, F Siby Diallo, S Sow, I Téguété, A Dolo,  
F Bougoudogo, M Lurie, AS De Groot
14:30 – 14:45 Referral and Access to Care of HIV Prevalent Cases; Experience from  OA05.05 
the Early Capture HIV Cohort Study in Kampala 
LN Mutengu, H Kibuuka, M Millard, A Sekiziyivu, S Wakabi, J Nanyondo,  
G Kawooya, M Robb, N Michael
Monday, 10 September
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13:30 – 14:45 Oral Abstract Session 06:  BCEC Level 2, 
V1/V2 Antibody Responses Ballroom East
 Chairs: Susan Zolla-Pazner and Georgia Tomaras
13:30 – 13:45 A Short Segment in the HIV-1 gp120 V1/V2 Region Is a Major Determinant OA06.01 
of Neutralization Resistance to PG9-like Antibodies 
NA Doria-Rose, I Georgiev, RP Staupe, S O’Dell, G Chuang, J Gorman,  
JS McLellan, M Pancera, M Bonsignori, BF Haynes, DR Burton, WC Koff,  
PD Kwong, JR Mascola
13:45 – 14:00 Characterization of V1V2-Specific Antibodies Present in Broadly Neutralizing OA06.02 
Plasma Isolated from HIV-1 Infected Individuals 
C Krachmarov, K Revesz, R Prattipati, C Reichman, Z Lai, W Honnen, B Li, 
C Derdeyn, A Pinter
14:00 – 14:15 Design of an HIV Env Antigen That Binds with High Affinity to  OA06.03 
Antibodies Against Linear, Conformational and Broadly Neutralizing  
Epitopes Within V1/V2 
L Liao, M Bonsignori, K Hwang, AM Moody, R Park, S Crawford, H Chen,  
TL Jeffries, M Cooper, X Lu, R De, N Karasavvas, S Rerks-Ngarm, S Nitayaphan,  
J Kaewkungwal, S Tovanabutra, P Pitisuttithum, J Tartaglia, F Sinangil, J Kim,  
NL Michael, GD Tomaras, Z Yang, K Dai, M Pancera, GJ Nabel, JR Mascola,  
PD Kwong, A Pinter, S Zolla-Pazner9, MS Alam, BF Haynes
14:15 – 14:30 Evidence for Env-V2 Sieve Effect in Breakthrough SIVMAC251Infections  OA06.04 
in Rhesus Monkeys Vaccinated with Ad26/MVA and MVA/Ad26 Constructs 
S Sina, S Tovanabutra, E Sanders-Buell, A Bates, M Bose, S Howell,  
G Ibitamuno, M Lazzaro, A O’Sullivan, J Lee, T Cervenka, J Kuroiwa,  
K Baldwin, DH Barouch, M Robb, R O’Connell, NL Michael, JH Kim, M Rolland
14:30 – 14:45 Structural Basis for Germline Gene Usage of a Potent Class of Antibodies  OA06.05 LB 
Targeting the CD4 Binding Site of HIV-1 gp120 
AP West, Jr., R Diskin, MC Nussenzweig, PJ Bjorkman
14:45 – 16:00 Poster Session 1 with Tea and Coffee Break BCEC Level 3, 
See inside back cover for the poster presentation schedule. Ballroom West
 Poster Discussion 1a:  BCEC Level 3, 
B Cell Immunology and Antibody Function Ballroom West
 Chair: Mattia Bonsignori
15:00 – 15:07 V1/V2-Directed Antibodies Elicited in RV144 Vaccinees Bind to a  P03.64 LB 
Structurally Polymorphic Site 
JS McLellan, J Gorman, M Bonsignori, K Hwang, H Liao, S Rerks-Ngarm,  
S Nitayaphan, NL Michael, JH Kim, BF Haynes, PD Kwong
15:07 – 15:14 Structural Definition for a New Modality of Broad and Potent  P03.14 
Antibody Neutralization at the CD4-binding Site on HIV-1 gp120 
T Zhou, S Moquin, R Lynch, X Wu, J Zhu, Y Yang, B Zhang,  
JR Mascola, PD Kwong
Monday, 10 September
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15:14 – 15:21 The Breadth of Maternal HIV-1 Specific Neutralizing Antibodies  P03.01 
Is Not Associated with a Lower Risk of Mother-to-Infant Transmission 
A Chaillon, T Wack, M Braibant, L Mandelbrot, S Blanche,  
J Warszawski, F Barin
15:21 – 15:28 Structural Comparison of Somatically Related PG9 and PG16 in  P03.31 
Complex with Their Epitope Reveals Differences in Glycan Recognition 
M Pancera, JS McLellan, S Shahzad-ul-Hussan, N Doria-Rose, B Zhang,  
Y Yang, DR Burton, WC Koff, CA Bewley, PD Kwong
15:28 – 15:35 Antibody Subclass Skewing Predicts Enhanced ADCC Activity in Both  P03.39 
Natural Infection and Vaccination 
A Dugast, A Chung, Y Chang, A Licht, M Ackerman, G Alter
15:35 – 15:42 Hyperglycosylated gp120 Mutants Elicit Improved CD4-binding Site  P03.30 
Directed Antibodies in a Heterologous Prime:Boost Regimen 
FK Ahmed, BE Clark, R Pantophlet
 Poster Discussion 1b:  BCEC Level 3, 
HIV Transmission and Viral Diversity Ballroom West
 Chair: Carolyn Williamson
15:00 – 15:07 Dynamics and Frequency of Gag Transmitted Polymorphisms in Zambia P05.19 
M Schaefer, J Carlson, D Claiborne, J Prince, W Kilembe, J Tang, P Farmer,  
R Shapiro, T Ndung’u, J Frater, P Goulder, R Kaslow, S Allen, P Goepfert,  
D Heckerman, E Hunter
15:07 – 15:14 Deep Sequencing Reveals an Association Between HIV-1 Subtype  P05.17 
C Mutations in gp41 MPER Epitopes and Mother-to-Child Transmission 
L Yin, Y Cai, K Chang, BP Gardner, W Hou, K Nakamura, M Sinkala,  
C Kankasa, DM Thea, L Kuhn, GM Aldrovandi, MM Goodenow
15:14 – 15:21 Postnatally-transmitted HIV-1 Variants Are Efficient at Dendritic Cell  P05.11 
Trans-infection and Sensitive to Autologous and Heterologous Neutralization 
GG Fouda, T Mahlokozera, K Rizzolo, J Salazar-Gonzalez, M Salazar, G Learn,  
S Barotra, M Sekaran, E Russell, F Jaeger, F Cai, F Gao, B Hahn, R Swanstrom,  
S Meshnick, V Mwapasa, L Kalilani, S Fiscus, D Montefiori, B Haynes, J Kwiek,  
M Alam, S Permar
15:21 – 15:28 A New Transmission Map of HIV-1 CRF07_BC in China: Analysis of Sequences  P05.02 
from 12 Provinces over a Decade 
M Zhefeng, L Jingyun, Z Ping, X Jianqing, Z Xiaoyan
15:28 – 15:35 Limited Evidence for Alterations in Gag-mediated HIV Replication Capacity  P05.20 
Over the Course of the North American Epidemic (1979-Present) 
L Cotton, D Chopera, K Penney, J Carlson, E Martin, A Le, T Kuang, B Walker,  
J Fuchs, S Buchbinder, T Wagner, M John, S Mallal, B Koblin, K Mayer, A Poon,  
M Brockman, Z Brumme
15:35 – 15:42 Evolutionary Dynamics of HIV-1 Subtype C Accessory and Regulatory Genes  P05.05 
in Primary Infection 
R Rossenkhan, V Novitsky, TK Sebunya, R Musonda, BA Gashe, M Essex
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16:00 – 18:00 Symposium 01:  BCEC Level 3, 
Exploiting the Innate Immune Response Room 258 ABC
 Chairs: Christiane Moog and Galit Alter
16:00 – 16:25 Development of Dendritic Cell-based prophylactic and  S01.01 
Therapeutic HIV Vaccine 
Y Levy, A Palucka
16:25 – 16:50 Adjuvants Influence the Magnitude, Quality and Durability of  S01.02 
HIV Env Specific Humoral Immunity in Non-human Primates  
JR Francica, G Tomaras, M Alam, G Ferrari, J Mascola, DT O’Hagan, R Seder
16:50 – 17:15 Systems Analysis of HIV Vaccine Triggered Innate Immune Responses S01.03 
D Zak
17:15 – 17:40 Profiling Humoral Immunity: Determining Antibody Innate Immune  S01.04 
Recruiting Capacity 
M Ackerman
17:40 – 17:55 Natural Killer (NK) Cell Responses at Female Genital Mucosa to  S01.05 OA 
SIV Vaginal Challenge 
L Shang, J Duan, A Smith, S Wietgrete, M Zupancic, A Haase
16:00 – 18:00 Symposium 02:  BCEC Level 2, 
Lessons from Clinical Trials Room 253 ABC
 Chairs: Nina Russell and Lindsey Baden
16:00 – 16:25 RV144 Update: Insights from Correlates of Risk, Breakthrough Infections,  S02.01 
and Animal Studies in the Context of Future Vaccine Development 
J Kim
 16:25 – 16:50 Comparative Immunogenicity of HIV Vaccine Candidates in the HVTN S02.02 
N Frahm, G Tomaras, D Montefiori, P Gilbert, L Corey, JM McElrath
16:50 – 17:15 Clinical Studies with Adenovirus 26 Vectored Candidate HIV-1 Vaccines S02.03 
R Dolin, LR Baden, MS Seaman, DH Barouch
17:15 – 17:40 HIV Immunity and Reservoir Following Interventions in Acute HIV Infection:  S02.04 
Implication for Functional Cure 
J Ananworanich
17:40 – 17:55 Vector Induced Skewing of Antibody Fc-Effector Functions  S02.05 OA 
A Chung, A Dugast, H Robinson, Y Chan, ME Ackerman, J Cox, W Koff,  
D Barouch, S Rerks-Ngarm, N Michael, J Kim, G Alter
Monday, 10 September
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16:00 – 18:00 Symposium 03:  BCEC Level 2, 
New Env Immunogens Ballroom East
 Chairs: Joseph Sodroski and Rogier Sanders
16:00 – 16:25 Structural basis for HIV-1 Trimeric Env Immunogen S03.01 
Y Mao
16:25 – 16:50 Pure Native Env Trimers on VLP Surfaces and in Soluble Form S03.02 
JM Binley
16:50 – 17:15 Envelope Immunogen: Stable and Homogeneous HIV-1 gp140 Trimers S03.03 
B Chen
17:15 – 17:40 Epitope-focused Vaccines S03.04 
W Schief
17:40 – 17:55 Eliciting Broadly Neutralizing Antibodies Against HIV-1 That  S03.05 OA 
Target gp41 MPER 
D Han, H Habte, Y Qin, K Takamoto, C LaBranche, D Montefiori, MW Cho
18:30 – 23:00 Banquet at the Seaport World Trade Center 
 Just a short 5-minute walk from the hotel you will find the site for our 2012 banquet. All delegates 
are invited to join us for an outdoor reception offering views of Boston, champagne and a great 
opportunity to connect with colleagues. The banquet will offer dinner, a dessert buffet and 
dancing to the best band in Boston, Flipside.
Monday, 10 September
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Tuesday, 11 September
07:30 – 17:30 Speaker Check-in BCEC Level 2, Room 251
08:00 – 18:00 Registration  BCEC Level 3, Ballroom Foyer
08:30 – 10:00 Plenary 02:  BCEC Level 3, 
A New Look at the Transmission Event Ballroom East
 Chairs: Bruce Walker and Margie McGlynn
08:30 – 09:00 Barriers to Mucosal Transmission: Challenges and Opportunities PL02.01 
JD Estes
09:00 – 09:30 Viral Dynamics and Immune Response in Acute Infection and Their  PL02.02 
Impact on Viral Set-point 
M Robb
09:30 – 10:00 Viral Evolution in Early HIV Infection, and the Implications for Vaccines PL02.03 
B Korber
10:00 – 10:30 Tea and Coffee Break BCEC Level 3, Ballroom Foyer
10:30 – 12:30 Oral Abstract Session 07:  BCEC Level 3, 
B Cell Responses Ballroom East
 Chairs: Leo Stamatatos and Georgia Tomaras
10:30 – 10:45 Structure-guided Modification and Optimization of Antibody VRC07  OA07.01 
Y Kwon, I Georgiev, S O’Dell, W Shi, G Chuang, Y Yang, B Zhang, J Zhu,  
GJ Nabel, JR Mascola, PD Kwong
10:45 – 11:00 Isolation of a Clonal Lineage of IgA Broadly Neutralizing Antibodies  OA07.02 
from a Chronically Infected Tanzanian Subject 
M Moody, MS Drinker, TC Gurley, JD Amos, JA Eudailey, LC Armand, R Parks,  
ES Gray, L Morris, A Finzi, X Yang, J Sodroski, H Liao, GD Tomaras,  
DC Montefiori, BF Haynes
11:00 – 11:15 Deep Sequencing with Longitudinal Sampling of a VRC01-like Antibody  OA07.03 
Response in a Chronically Infected Individual 
Z Zhang, X Wu, N Longo, B Zhang, J Zhu, C Nisc, JC Mullikin, L Wu,  
GJ Nabel, M Connors, PD Kwong, JR Mascola, L Shapiro
11:15 – 11:30 Antibody Effector Function Is Regulated by a Combination of Adaptive and  OA07.04 
Innate Signals 
A Mahan, K Dionne, J Eusebio, G Alter
11
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11:30 – 11:45 Non-neutralizing IgG Anti-PID Antibodies Decreased Viral Load Following  OA07.05 
High Dose Vaginal Challenge of Non-human Primates 
C Moog, N Dereuddre-Bosquet, M Biedma, S Schmidt, T Decoville, I Mangeot,  
S Zolla-Pazner, B Vcelar, D Katinger, V Holl, R Le Grand
11:45 – 12:00 Vaccine-induced ADCC-mediating Antibodies Target Unique and Overlapping OA07.06 
Envelope Epitopes  
J Pollara, M Bonsignori, M Moody, M Alam, H Liao, K Hwang, J Pickeral, J Kappes,  
C Ochsenbauer, K Soderberg, TC Gurley, DM Kozink, DJ Marshall, JF Whitesides,  
D Montefiori, JE Robinson, J Kaewkungwal, S Nitayaphan, P Pitisuttithum,  
S Rerks-Ngarm, J Kim, N Michael, G Tomaras, BF Haynes, G Ferrari
12:00 – 12:15 454 Pyrosequencing and Bioinformatics Analysis of the Lineage of the  OA07.07 
Broad and Potent gp41-directed Antibody 10e8 
G Ofek, J Zhu, Y Yang, B Zhang, K Mckee, M Louder, J Huang, L Laub,  
M Connors, J Mascola, PD Kwong
12:15 – 12:30 Engineered Mice and B Cell Lines Expressing Broadly Beutralizing Antibodies  OA07.08 LB 
and Their Unmutated Precursors: Tools for HIV Vaccinology 
D Nemazee, C Doyle-Cooper, T Ota, AB Cooper, M Huber, E Falkowska,  
K Doores, L Hangartner, K Le, D Sok, J Jardine, J Lifson, X Wu, JR Mascola,  
P Poignard, JM Binley, BK Chakrabarti, WR Schief, RT Wyatt, DR Burton
10:30 – 12:30 Oral Abstract Session 08:  BCEC Level 2, 
T Cell Responses Room 258 ABC
 Chairs: Julie McElrath and Julian Schulze zur Wiesch
10:30 – 10:45 Cellular Immune Responses and Changes in VL After a Dendritic  OA08.01 
Cells (DC)-based Therapeutic Vaccine in cART Treated Chronic  
HIV-infected Patients with CD4 T Cells Above 450/mm 
F García, AC Guardo, M Maleno, L Papagno, M Bargalló, N Climent,  
B Autran, J Gatell, T Gallart, M Plana
10:45 – 11:00 Alterations in Function and Distribution of Regulatory T Cells (Tregs)  OA08.02 
May Blunt Vaccine Induced Immune Responses in HIV Infection  
J van Lunzen, I Toth, P Hartjen, J Schulze zur Wiesch
11:00 – 11:15 Identification of CD8+ T Cell Host Factors Involved in HIV Control OA08.03 
G Gaiha, K McKim, M Woods, M Lichterfeld, A Brass, B Wallker
11:15 – 11:30 PD-1, IL-10, IFN-γ and IL-12 Form a Network to Regulate HIV-1-specific  OA08.04 
CD4 T Cell and Antigen-presenting Cell Function 
F Porichis, L Barblu, DS Kwon, M Hart, J Zupkosky, GJ Freeman,  
DG Kavanagh, DE Kaufmann
11:30 – 11:45 Distinct Gene Expression Profiles Associated with the Susceptibility  OA08.05 
of Pathogen-specific CD4+ T Cells to HIV-1 Infection 
H Hu, M Nau, P Ehrenberg, A Chenine, Z Daye, Z Wei, N Michael,  
M Vahey, J Kim, M Marovich, S Ratto-Kim
12
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11:45 – 12:00 HIV Control Through a Single Nucleotide on the HLA-I Locus OA08.06 
H Kløverpris, M Harndahl, J Carlson, A Leslie, M van der Stok,  
G Huang, F Chen, L Riddell, D Steyn, D Goedhals, C van Vuuren,  
J Frater, B Walker, T Ndung’u’, S Buus, P Goulder
12:00 – 12:15 Accelerated Heterologous Prime-boost Adenovirus Vector-based SIV  OA08.07 
Vaccine in Neonatal Rhesus Monkeys 
J Liu, H Li, M Iampietro, DH Barouch
12:15 – 12:30 Intra-dermal Immunisation with SIV Gag-based Vaccines Alone Inhibits  OA08.08 
Acquisition of SIVmac251 
N Almond, R Stebbings, M Page, B Li, N Berry, C Ham, D Ferguson, N Rose,  
E Mee, C Stahl-Hennig, G Dickson, T Athanasapoulos, A Benlahrech, S Herath,  
A Meiser, S Patterson
10:30 – 12:30 Oral Abstract Session 09:  BCEC Level 2, 
Clinical Trials  Room 253 ABC
 Chairs: Yiming Shao and Sandhya Vasan
10:30 – 10:45 Safety and Immunogenicity of a Randomized Phase I Prime-boost Trial  OA09.01 
with ALVAC-HIV (vCP205) and gp160 MN/LAI-2 Adjuvanted in Alum  
or Polyphosphazene 
RJ O’Connell, VR Polonis, S Ratto-Kim, J Cox, LL Jagodzinski, J Malia,  
NL Michael, J Excler, ML Robb, JH Kim
10:45 – 11:00 In Vivo Targeting of HIV Gag to Dendritic Cells in Combination with Poly  OA09.02 
ICLC Is Safe and Immunogenic in Healthy Volunteers 
M Caskey, C Trumpfheller, S Pollak, L Sinnenberg, A Hurley, J Pring,  
I Shimeliovich, B Yipp, N Anandasabapathy, S Mehandru, P Sarma,  
R Koup, R Bailer, G Tomaras, A Sato, T Keler, R Steinman, S Schlesinger
11:00 – 11:15 First-in-Human Phase 1 Trial of the Safety and Immunogenicity of a  OA09.03 
Recombinant Adenovirus Serotype 5 HVR48 (rAd5HVR48) HIV-1 Vaccine 
SR Walsh, MS Seaman, JA Johnson, RP Tucker, KH Krause, M Weijtens,  
MG Pau, J Goudsmit, R Dolin, DH Barouch, LR Baden
11:15 – 11:30 Antibody-mediated Inhibition of HIV-1 Elicited by HIV-I DNA Priming and  OA09.04 
Boosting with Heterologous HIV-1 Recombinant MVA in Healthy Tanzanian Adults 
A Joachim, C Nilsson, S Aboud, M Bakari, EF Lyamuya, M Robb, M Marovich,  
C Ochsenbauer, B Wahren, F Mhalu, E Sandström, G Biberfeld, G Ferrari,  
VR Polonis
11:30 – 11:45 A First-in-Man, Double Blind, Placebo Controlled Study of the Candidate OA09.05 
Therapeutic Vaccine Opal-HIV-Gag(c) in HIV Infected Patients Receiving HAART 
AG Jackson, HN Kløverpris, A Handley, P Hayes, J Gilmour, M Atkins, B Walker,  
J Ackland, M Sullivan, P Goulder
11:45 – 12:00 Multiple Antibody Specificities (gp41, V1V2, and V3) Elicited in the Phase II  OA09.06 LB 
Multiclade (A, B, C) HIV-1 DNA Prime, rAd5 Boost Vaccine Trial 
WB Williams, K Jones, A Krambrink, D Grove, P Liu, NL Yates, MA Moody,  
G Ferrari, J Pollara, Z Moodie, CA Morgan, H Liao, DC Montefiori,  
C Ochsenbauer, J Kappes, S Hammer, J Mascola, R Koup, L Corey, G Nabel,  
P Gilbert, G Churchyard, M Keefer, BS Graham, BF Haynes, GD Tomaras
Tuesday, 11 September
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12:00 – 12:15 rAd5 Prime/NYVAC-B Boost Regimen is Superior to NYVAC-B Prime/rAd5  OA9.07 LB 
Boost Regimen for Both Response Rates and Magnitude of CD4 and CD8  
T-cell Responses 
P Bart, Y Huang, N Frahm, S Karuna, M Allen, NK Kochar, S Chappuis,  
J Gaillard, B Graham, G Pantaleo
12:15 – 12:30 Phase 2a Safety and Immunogenicity Testing of DNA and Recombinant  OA09.08 LB 
Modified Vaccinia Ankara Virus Vaccines Expressing Virus-like Particles 
P Goepfert, M Elizaga, D Montefiori, J Hural, S DeRosa, G Tomaras,  
K Seaton, A Sato, L Ouedraogo, Y Donastorg, M Cardinali, J Lama,  
L Baden, M Keefer, J McElrath, S Kalams, H Robinson
12:30 – 13:30 Lunch  BCEC Level 2, Rooms 252 AB / 254 AB / 257 AB 
12:30 – 13:30 Networking Lunch BCEC Level 2, Room 259 AB
 Join us in BCEC Level 2, Room 259 AB where lunch tables have been reserved for young and 
early-career investigators and community representatives to network with senior researchers.
13:30 – 14:45 Oral Abstract Session 10:  BCEC Level 3, 
HIV Transmission / Diversity  Room 258 ABC
 Chairs: Bette Korber and Zabrina Brumme
13:30 – 13:45 Impact of Transmitted CTL Escape Mutations on Replicative Capacity and OA10.01 
HIV Pathogenesis in Early Infection 
J Prince, D Claiborne, D Heckerman, J Carlson, H Prentice, M Schaefer,  
L Yue, J Mulenga, J Tang, P Goepfert, P Farmer, R Kaslow, S Allen, E Hunter
13:45 – 14:00 A Deeper View of Transmitted/Founder Viruses Using 454 Whole  OA10.02 
Genome Deep Sequencing 
DC Tully, KA Power, H Bedard, CL Boutwell, P Charlebois, EM Ryan,  
NJ Lennon, M Altfeld, MR Henn, TM Allen
14:00 – 14:15 Modeling Virus Exposure During Male to Female Transmission of HIV-1 OA10.03 
A Carias, M McRaven, M Anderson, RS Veazey, TJ Hope
14:15 – 14:30 Beneficial HLA-mediated Viral Polymorphisms on the Transmitted Virus  OA10.04 
Additively Influence Disease Progression in HIV-1, Subtype C Infection  
RS Ntale, DR Chopera, NK Ngandu, M Abrahams, A Debra, M Mlotswa,  
L Werner, Z Woodman, K Mlisana, S Abdool Karim, CM Gray, C Williamson, 
CAPRISA 002 AI Study Team
14:30 – 14:45 T-cell Based Sieve Analysis Ties HLA A*02 to Vaccine Efficacy and IgA-C1  OA10.05 LB 
Immune Correlate in RV144 Thai Trial 
T Hertz, A Gartland, H Janes, S Li, Y Fong, GD Tomaras, D Morris, D Geraghty,  
GH Kijak, PT Edlefsen, M Rolland, BB Larsen, S Tovanabutra, E Sanders-Buell,  
AC DeCamp, CA Magaret, H Ahmed, S Nariya, K Wong, H Zhao, W Deng,  
BS Maust, M Bose, S Howell, M Lazzaro, A Bates, E Lei, A Bradfield,  
G Ibitamuno, V Assawadarachai, RJ O’Connel, MS deSouza, S Nitayaphan,  
S Rerks-Ngarm, ML Robb, MJ McElrath, BF Haynes, NL Michael, PB Gilbert,  
JI Mullins, JH Kim
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13:30 – 14:45 Oral Abstract Session 11:  BCEC Level 2, 
Vaccine Immunogens / Delivery  Ballroom East
 Chairs: Harriet Robinson and Sallie Permar
13:30 – 13:45 HIV-1 Envelope Trimer Elicits Higher Neutralizing Antibody Responses  OA11.01 
Than Monomeric gp120 
JM Kovacs, JP Nkolola, H Peng, A Cheung, J Perry, CA Miller, MS Seaman,  
D Barouch, B Chen
13:45 – 14:00 Shaping Humoral Responses Against Mini-libraries of HIV Env Antigens via  OA11.02 
Lipid Nanoparticle Vaccine Delivery 
MC Hanson, J Mata-Fink, W Abraham, KD Wittrup, DJ Irvine
14:00 – 14:15 Vaccine Responses to Conserved Regions of the HIV-1 Proteome Are  OA11.03 
Associated with an Increased Capacity to Inhibit Multiple Virus Isolates  
Ex Vivo 
A Ashraf, J Kopycinski, H Cheeseman, F Lala, J Czyzewska-Khan, A Spentzou,  
DK Gill, M Keefer, J Excler, P Fast, P Hayes, JH Cox, J Gilmour
14:15 – 14:30 Antigen-specific T Lymphocyte Responses Elicited by a DNA – MVA HIV  OA11.04 
CN54gp140 Immunization Regime Are Significantly Altered by the TLR4  
Adjuvant GLA 
PF McKay, AV Cope, J Swales, S Joseph, M Esteban, R Tatoud, D Carter,  
J Weber, RJ Shattock
14:30 – 14:45 Quality of T-cell Responses Versus Reduction in Viral Load: Results from an  OA11.05 LB 
Exploratory Phase II Clinical Study of Vacc-4x, a Therapeutic HIV Vaccine 
K Ellefsen-Lavoie, J Rockstroh, R Pollard, G Pantaleo, D Podzamczer, D Asmuth,  
J van Lunzen, K Arastéh, D Schürmann, B Peters, B Clotet, D Hardy, A Lazzarin,  
J Gatell, MA Sommerfelt, I Baksaas, V Wendel-Hansen, B Sørensen
13:30 – 14:45 Oral Abstract Session 12:  BCEC Level 2, 
Vaccine Concepts – Vectors and Inserts  Room 253 ABC
 Chairs: Punnee Pitisuttithum and Karin Lore
13:30 – 13:45 DNA Vaccines Expressing Conserved Elements Provide Potent and Broad  OA12.01 
Immune Responses 
GN Pavlakis, V Kulkarni, A Valentin, M Rosati, NY Sardesai, B Mothe,  
C Brander, S LeGall, DB Weiner, M Rolland, JI Mullins, BK Felber
13:45 – 14:00 Reinventing the Nucleic Acid Vaccine with Self-amplifying RNA OA12.02 
AJ Geall, GR Otten, A Hekele, W Bogers, H Oostermeijer, P Mooij,  
K Gerrit, E Verschoor, K Banerjee, Y Cu, CW Beard, LA Brito, JB Ulmer,  
CW Mandl, SW Barnett
14:00 – 14:15 Adenovirus Serotype 26 Utilizes CD46 as Primary Cellular Receptor and  OA12.03 
Only Transiently Activates T Lymphocytes Following Vaccination of  
Rhesus Monkeys 
H Li, EG Rhee, K Masek-Hammerman, JE Teigler, P Abbink, DH Barouch
Tuesday, 11 September
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14:15 – 14:30 Full-length HIV-1 Immunogens Induce Greater T Lymphocyte Responses to  OA12.04 
Conserved Epitopes Than Conserved-Region-Only HIV-1 Immunogens 
in Monkeys 
KE Stephenson, A SanMiguel, NL Simmons, K Smith, JJ Szinger, BT Korber,  
DH Barouch
14:30 – 14:45 Rational Immunogen Design to Target Specific Germline B Cell Receptors  OA12.05 LB 
J Jardine, O Kalyuzhniy, T Ota, A McGuire, S Menis, J Julien, E Falkowska,  
S MacPherson, M Jones, DR Burton, IA Wilson, L Stamatatos, D Nemazee,  
WR Schief
14:45 – 16:00 Poster Session 2 with Tea and Coffee Break BCEC Level 3, 
See inside back cover for the poster presentation schedule. Ballroom West
 Poster Discussion 2a:  BCEC Level 3, 
Innate Immunity Ballroom West
 Chair: Dan Zak
15:00 – 15:07 HLA-Cw*0102-Restricted HIV-1 p24 Epitope Variants Can Modulate the  P07.09 
Binding of the Inhibitory KIR2DL2 Receptor and Primary NK Cell Function 
C Koerner, L Fadda, S Kumar, N van Teijlingen, A Piechocka-Trocha,  
M Carrington, M Altfeld
15:07 – 15:14 Frequent and Strong Antibody-mediated NK Cell Activation to HIV-1 Env in  P07.03 
Individuals with Chronic HIV-1 Infection 
C Thobakgale, L Fadda, K Lane, I Toth, F Pereyra, S Bazner, T Ndung’u,  
BD Walker, E Rosenberg, G Alter, M Carrington, T Allen, M Altfeld
15:14 – 15:21 HIV Triggers Immunoregulatory Dendritic Cells And Regulatory T Cells  P07.16 LB 
Through The Non-canonical NF-kB Pathway 
O Manches, MV Fernandez, J Plumas, L Chaperot, N Bhardwaj 
15:21 – 15:28 Biodistribution of Neutralizing Monoclonal Antibodies IgG1 b12 and  P08.17 
LALA in Mucosal and Lymphatic Tissues of Rhesus Macaques 
AJ Hessell, E Epson, B Moldt, E Rakasz, S Pandey, WF Sutton, Z Brower,  
VM Hirsch, DR Burton, NL Haigwood
15:28 – 15:35 Critical Role for Monocytes in Mediating HIV-specific Antibody-dependent  P03.08 
Cellular Cytotoxicity 
M Kramski, GF Lichtfuss, A Schorcht, AP Johnston, R De Rose, R Center,  
A Jawarowski, S Kent
15:35 – 15:42 KIR/HLA Genotype Combinations Are Determinants of Natural Killer (NK)  P07.19 LB 
Cell Mediated Antibody-dependent Cellular Cytotoxicity (ADCC) Potency 
MS Parsons, P Zanoni, B Tallon, S Miconiatis, N Shoukry, J Bruneau,  
CM Tsoukas, NF Bernard
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 Poster Discussion 2b:  BCEC Level 3, 
Clinical and Pre-Clinical Vaccine Trials Ballroom West
 Chair: Kathryn Stephenson
15:00 – 15:07 Rapid Development Of Cross-clade Neutralizing Antibody Responses After  P04.30 LB 
Clade B Gp120/Gp140 Protein Priming And Clade C Gp140 Protein Boosting 
P Spearman, G Tomaras, D Montefiori, Y Huang, H Ahmed, M Elizaga, J Hural,  
J McElrath, L Ouedraogo, M Pensiero, C Butler, S Kalams, ET Overton, S Barnett,  
N Group 
15:07 – 15:14 Uptake and Tolerability of Repeated Mucosal Specimen Collection in Two  P04.15 
Phase 1 AIDS Preventive Vaccine Trials in Kenya 
G Mutua, G Omosa-Manyonyi, H Park, P Bergin, D Laufer, PN Amornkul,  
J Lehrman, P Fast, J Gilmour, O Anzala, B Farah
15:14 – 15:21 Immunogenicity of a Universal HIV-1 Vaccine Vectored by DNA, MVA and  P04.11 
CHADV-63 in a Phase I/IIA Clinical Trial 
NJ Borthwick, T Ahmed, A Rose, U Ebrahimsa, A Black, E Hayton, H Yang,  
G Hancock, S Campion, N Frahm, S Colloca, A Nicosia, A McMichael,  
L Dorrell, T Hanke
15:21 – 15:28 A Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity  P04.20 
of a Replication-defective HIV-1 Vaccine-HIVAX 
F Tung, J Tung, M Fischl
15:28 – 15:35 Priming with a “Simplified Regimen” of HIV-1 DNA Vaccine Is as Good as a  P04.01 
“Standard Regimen” When Boosted with Heterologous HIV-1 MVA Vaccine 
P Munseri, A Kroidl, C Nilsson, C Moshiro, S Aboud, A Joachim, C Geldmacher,  
E Aris, D Buma, E Lyamuya, F Gotch, K Godoy-Ramirez, K Pallangyo, L Maboko,  
M Marovich, M Robb, M Hoelscher, M Janabi, P Mann, S Joseph, S Mfinanga,  
W Stoehr, F Mhalu, B Wahren, G Biberfeld, S McCormack, E Sandstrom, M Bakari
15:35 – 15:42 Increased Mucosal CD4+ T-cell Activation Following Vaccination with an  P11.25 
Adenoviral Vector in Rhesus Macaques 
I Bukh, R Calcedo, S Roy, DG Carnathan, R Grant, SJ Ratcliffe, JM Wilson, MR Betts
Tuesday, 11 September
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16:00 – 18:00 Symposium 04:  BCEC Level 3, 
Cross-cutting Issues in Clinical Trial Design  Room 253 ABC
 Chairs: Margaret McCluskey and Chidi Nweneka
16:00 – 16:15 PrEP and Vaccines: When and How to Respond to Positive Data S04.01 
M Warren
16:15 - 16:30 Evolving Standards of Prevention and Implications for Future Trials S04.02 
DR Wassenaar
16:30 - 16:45  Combination Prevention: Scaling Up Delivery While Accelerating Discovery,  S04.03 
Lessons From Medical Male Circumcision in Kenya 
K Agot, E Omanga
16:45 - 17:00 Combination Prevention: Designing and Implementing a New Era of Trials S04.04 
RV Barnabas
17:00 – 17:15 Combination Prevention: A Community Perspective on Complex Trial Results S04.05 
and Designs 
M Rose
17:15 – 18:00 Moderated Panel Discussion
16:00 – 18:00 Symposium 05:  BCEC Level 2, 
Mucosal Immunology  Room 258 ABC
 Chairs: Francoise Barré-Sinoussi and Doug Kwon
16:00 – 16:25 Vaccine-microbicide Combination Studies in a Rhesus Macaque Vaginal  S05.01 
Transmission Model 
JP Moore
16:25 – 16:50 Genital Tract Inflammation and Susceptibility to HIV Infection in Women  S05.02 
from the CAPRISA 004 Microbicide Trial of Tenofovir Gel 
JS Passmore, L Masson, L Werner, S Karim
16:50 – 17:15 The Current State of Mucosal Immunity Elicited by Vaccines S05.03 
R Shattock
17:15 – 17:40 Persistence Pays Off: Stringent Control and Potential Clearance of AIDS  S05.04 
Virus Infection by Persistent Vaccine-induced Effector Memory T Cells 
L Picker
17:40 – 17:55 HIV Interactions and the Perils of Epithelial Thinning in the Female  S05.05 OA 
Reproductive Tract 
A Carias, M McRaven, M Anderson, T Henning, E Kersh, J Smith, K Butler,  
S Vishwanathan, JM McNicholl, RM Hendry, R Veazey, T Hope
Tuesday, 11 September
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16:00 – 18:00 Symposium 06:  BCEC Level 2, 
Preclinical Studies and Vaccine Platforms  Ballroom East
 Chairs: Nelson Michael and Bonaventura Clotet
16:00 – 16:25 Novel HIV Vaccine Strategies S06.01 
JC Sadoff, H Schuitmaker, L Baden, L Digilio, M Grazia Pau, M Marovitch,  
M Robb, N Michael, J Goudsmit, D Barouch, R Dolin
16:25 – 16:50 Poxvirus-based Vectors as Immunization Vehicle: Past, Present and Future S06.02 
J Tartaglia
16:50 – 17:15 Pre-clinical Studies and Vaccine Platforms using Chimp Adenovirus Vectors S06.03 
T Hanke
17:15 – 17:40 Passive Immunization for HIV Prevention S06.04 
F McCutchan, F Randazzo
17:40 – 17:55 E-DNA IM or ID Delivery Prime Enhances Antibody and T cell Responses  S06.05 OA 
Following Recombinant gp120 Env Boost  
NA Hutnick, M Karuppiah, J Pollara, J Yan, DJ Myles, K Broderick, M Morrow,  
N Sardasai, D Montefiori, S Barnett, G Ferrari, DB Weiner
18:00 – 20:00 Poster Session 3 and Reception BCEC Level 3, 
See inside back cover for the poster presentation schedule. Ballroom West
 Poster Discussion 3a:  BCEC Level 3, 
T Cell Immunity Ballroom West
 Chair: Zaza Ndhlovu
18:30 – 18:37 Different Memory T Cell Phenotypes Are Elicited by Ad5 and Rare Adenoviruses P11.04 
P Penaloza, E Borducchi, A McNally, N Simmons, J Teigler, N Provine, W Tan,  
R Ahmed, DH Barouch
18:37 – 18:44 A High-dimensional Immune Monitoring Model of HIV-1-specific CD8 T Cell  P11.38 
Responses Accurately Identifies Subjects Achieving Spontaneous Viral Control 
ZM Ndhlovu, L Chibnik, J Proudfoot, S Vine, A McMullen, K Cesa, F Porichis,  
D Alvino, A Piechocka-Trocha, P De Jager, BD Walker, D Kaufmann
18:44 – 18:51 Maturation of Protective Immunity Induced by SIV∆nef Correlates with  P02.10 
Differential Expression of Transcription Factors in SIV-specific CD8+ T Cells 
JM Billingsley, PA Rajakumar, NC Salisch, YV Kuzmichev, HS Hong, MA Connole,  
RK Reeves, H Kang, W Li, RP Johnson
18:51 – 18:58 Preferential Targeting Of Co-evolving Gag Residues in Long-term  P11.36 
Non Progressors 
J Sunshine, K Shekhar, D Heckerman, AK Chakraborty, N Frahm
18:58 – 19:05 Early Changes in the CD8 T Cell Immunodominance Hierarchy in Primary  P11.02 
HIV Infection Prior to Seroconversion  
N Keane, C Almeida, A Chopra, D Cooper, E Demaine, S Mallal, M John
19:05 – 19:12 The Early Th17/Treg Ratio Predicts The Immune Activation Set Point In  P11.43 LB 
Patients With Primary HIV Infection 
MF Chevalier, G Petitjean, C Didier, P Girard, L Meyer, F Barré-Sinoussi,  
D Scott-Algara, L Weiss
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 Poster Discussion 3b:  BCEC Level 3, 
Vaccine Concepts and Design Ballroom West
 Chair: Eric Sandström
18:30 – 18:37 Targeting HIV-1 Envelope Glycoprotein Trimers to B Cells Using APRIL  P12.11 
Improves Antibody Responses 
M Melchers, I Bontjer, T Tong, N Chung, P Klasse, D Eggink, M Gentile,  
A Cerutti, D Montefiori, W Olson, B Berkhout, J Binley, J Moore, R Sanders
18:37 – 18:44 Extensive Glycoform Heterogeneity in the gp120 Envelope Proteins  P12.07 
Used in the RV144 Trial 
B Yu, JF Morales, SM O’Rourke, GP Tatsuno, PW Berman
18:44 – 18:51 Native Envelope-based Immunogens Derived from Critical Timepoints  P12.56 
in the Development of Breadth Elicit Rapid Neutralizing Antibodies in Rabbits 
DC Malherbe, AJ Hessell, ND Sather, B Guo, S Pandey, F Pissani, H Robins,  
S Kalams, L Stamatatos, NL Haigwood 
18:51 – 18:58 A Minimal T-cell Immunogen Designed to Cover HIV-1 Specificities  P12.16 
Associated with Control Is Immunogenic in Mice and Breaks  
CTL Immunodominance 
B Mothe, A Llano, M Rosati, S Perez-Alvarez, V Kulkarni, B Chowdhury,  
C Alicea, RK Beach, NY Sardesai, GN Pavlakis, BK Felber, C Brander
18:58 – 19:05 Preferential Targeting of Conserved Gag Regions After Vaccination  P12.41 
with a Heterologous DNA Prime Modified Vaccinia Ankara Boost  
HIV Vaccine Regime 
A Bauer, L Podola, A Haule, L Sudi, C Nilsson, P Mann, M Missanga,  
B Kaluwa, L Maboko, C Lueer, M Mwakatima, S Aboud, M Bakari,  
J Currier, M Robb, S Joseph, S McCormack, E Lyamuya, B Wahren,  
E Sandström, G Biberfeld, M Hoelscher, A Kroidl, C Geldmacher
19:05 – 19:12 CN54gp140: Product Characteristics, Preclinical and Clinical Use -  P12.62 LB 
Recombinant Glycoprotein for HIV Immunization 
D Katinger, S Jeffs, F Altmann, A Cope, P McKay, N Almond, E Sandström,  
B Hejdeman, G Biberfeld, C Nilsson, D Hallengärd, B Wahren, T Lehner,  
M Singh, DJ Lewis, C Lacey, R Shattock
Tuesday, 11 September
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07:30 – 12:30 Speaker Check-in  BCEC Level 2, Room 251
08:00 – 14:00 Registration  BCEC Level 3, Ballroom Foyer
08:30 – 10:30 Symposium 07:  BCEC Level 3, 
Priming Effective B Cell Responses Ballroom East
 Chairs: Lynn Morris and Ralph Pantophlet
08:30 – 08:55 The Unique T Cell Receptor Expressed by Each Naive Helper T Cell  S07.01 
Instructs Effector Cell Fate 
MK Jenkins
08:55 – 09:20 T Follicular Helper Cells in HIV Infection S07.02 
H Streeck
09:20 – 09:45 Evolution of Broadly Cross-neutralizing Antibodies During HIV-1 Infection S07.03 
PL Moore
09:45 – 10:10 Genetic and Structural Basis for Development of High Affinity Antibodies S07.04 
J Crowe
10:10 – 10:25 CD40L Adjuvant for DNA/MVA Vaccine: Enhanced Protection from  S07.05 OA 
Acquisition of Neutralization Sensitive & Neutralization Resistant  
Mucosal SIV Infections 
S Kwa, S Sadagopal, J Hong, S Gangadhara, R Basu, L Lai, S Iyer,  
K Araki, PL Earl, L Wyatt, F Villinger, B Moss, R Ahmed, RR Amara
08:30 – 10:30 Symposium 08:  BCEC Level 2, 
Therapeutic Vaccination and Strategies for the Cure Room 253 ABC
 Chairs: Janet Siliciano and Xu Yu
08:30 – 08:55 Therapeutic Approaches to Curing HIV Infection S08.01 
S Deeks
08:55 – 9:20 Therapeutic Vaccines in Strategies for Functional Cure of HIV S08.02 
B Autran
09:20 – 09:45 Barriers to HIV-1 Eradication S08.03 
R Siliciano
09:45 – 10:10 Persistence of Latently Infected CD4+ T Cells During HAART:  S08.04 
Keeping Memory, Keeping HIV 
N Chomont
10:10 – 10:30 Assembling the Tools to Clear HIV Infection: Contributions from  S08.05 
Virology and Immunology 
D Margolis
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10:30 – 11:00 Tea and Coffee Break BCEC Level 3, Ballroom Foyer
11:00 – 12:30 Plenary 03:  BCEC Level 3, 
New Concepts in Immune Induction Ballroom East 
 Chairs: Larry Corey and Dennis Burton
11:00 – 11:30 Follicular T Helper Cells in Vaccination and Lentivirus Pathogenesis PL03.01 
RA Koup
11:30 – 12:00 Maturation Pathways of Broad Neutralizing Antibodies: Blueprints for  PL03.02 
Vaccine Design 
B Haynes
12:00 – 12:30 Experimental HIV Vaccines Induce Immunological Memory in Murine and  PL03.03 
Human NK Cells 
S Paust
12:30 – 13:30 Rapporteurs BCEC Level 3, Ballroom East 
 Chairs: Galit Alter and Dan Barouch
12:30 – 12:45 The Target: How Do We Hit the Virus Where it Hurts? 
Morgane Rolland 
MHRP, HJF, USA
12:45 – 13:00 People: Where Do We Stand with Moving Towards Efficacy Trials? 
Magdalena Sobieszczyk 
Columbia University, USA
13:00 – 13:15 Vaccimmunology: Advances in Our Understanding of Immune Correlates 
Julie Boucau 
The Ragon Institute of MGH, MIT and Harvard, USA
13:15 – 13:30 Animal Models: What Can Our Furry Friends Teach Us? 
Nichole Klatt 
National Institute of Health, USA
13:30 – 14:00 Closing Session and Handover BCEC Level 3, Ballroom East
 Chairs: Galit Alter and Dan Barouch
13:30 – 13:35 Bill Snow  
Global HIV Vaccine Enterprise 
13:35 – 13:50 Galit Alter and Dan Barouch  
2012 Conference Chairs
13:50 – 14:00 José Gatell and Bonaventura Clotet  
2013 Conference Chairs
Wednesday, 12 September
22 AIDS Vaccine 2012
PL
EN
A
RY
 S
ES
SI
O
N
S
23
Plenary Sesions
AIDS Vaccine 2012
PL01.02
The Current State of Microbicides as Prevention
S. Abdool Karim1
1Centre for the AIDS Programme of Research in South Africa, 
Durban, South Africa
AIDS is particularly severe in Africa, where women bear a 
disproportionate burden of the epidemic. Worldwide, just over 
half of all people living with HIV are women and between 70-
90% of all HIV infections among women are due to heterosexual 
intercourse. Although the majority of new HIV diagnoses in the US 
are through male-to-male sexual contact, heterosexual contact 
accounts for 84% of new infections among women. Despite the 
greater vulnerability of women, they have few options to reduce 
their risk of acquiring HIV infection and new technologies to 
protect women from sexual transmission of HIV, are urgently 
needed. Topical microbicides are products designed to prevent 
HIV and other sexually transmitted infections. Potentially, they 
can be applied vaginally or rectally to prevent HIV transmission. 
Despite numerous disappointing efficacy trial results over 
the past 20 years, substantial progress is now being made in 
microbicide development after the release of the CAPRISA 004 
trial, which provided proof-of-concept that topical antiretroviral 
microbicides can prevent sexual transmission of HIV and herpes 
simplex type-2 infection. Currently, research on microbicides is 
dominated by antiretroviral agents. The candidate microbicide 
in the most advanced stages of effectiveness testing is tenofovir 
gel. In addition to the clinical trials of tenofovir, trials are also 
assessing other antiretroviral drugs, dapivirine (TMC-120) and 
maraviroc, formulated as a vaginal gel and a vaginal ring, and 
some early human studies on Amphora™ gel, a barrier and vaginal 
defense enhancer, and VivaGel™, an entry and fusion inhibitor, 
are ongoing.The development of microbicides for rectal use has 
gathered momentum recently but remains several years away. 
In addition to new formulations and delivery devices, future 
microbicide development is likely to focus on a combination of 
antiretroviral drugs and combinations of antiretroviral agents 
with contraceptives.
PL01.01
An HIV Vaccine: A Critical Component of a 
Comprehensive HIV Prevention Strategy
A Fauci1
1National Institute of Allergy and Infectious Diseases, National 
Institutes of Health, Bethesda, MD, USA
Traditionally, preventive vaccines have been stand-alone 
components of public health campaigns. Repeatedly, they have 
demonstrated extraordinary value as tools to prevent infectious 
diseases, stop epidemics, and save millions of lives, with rates 
of effectiveness as high as 80-95 percent. With regard to HIV 
infection, we are facing a relatively unique situation where this 
time-honored concept of a vaccine as a stand-alone prevention 
modality is unlikely. Rather, in global efforts to end the AIDS 
pandemic, an HIV vaccine would be a critical component of a 
comprehensive combination prevention strategy. In designing 
and testing candidate HIV vaccines, we must operate within a 
new paradigm that considers the additive as well as potentially 
synergistic effects of delivering an effective HIV vaccine in the 
context of implementing other scientifically proven HIV/AIDS 
treatment and prevention interventions. These interventions 
include condoms, education and counseling, and harm-reduction 
programs; treating infected individuals with antiretroviral therapy 
(ART) to prevent the spread of infection (treatment as prevention); 
preventing mother-to-child transmission; pre-exposure 
prophylaxis with oral ART or microbicides containing ART; and 
medically supervised male circumcision. An HIV vaccine could 
be a major factor in achieving an AIDS-free generation if added 
to a toolkit of other scientifically proven interventions that when 
used in combination and adhered to, could form a highly effective, 
integrated HIV prevention strategy that equals or surpasses the 
effectiveness of vaccines for other infectious diseases. 
Plenary Session 01: HIV Vaccines in the Broader HIV Prevention Landscape
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PL01.04
ART for Prevention of HIV: Glimmers of Success
M. Cohen1
1University of NC at Chapel Hill, Chapel Hill, NC, USA
Antiretroviral agents (ART) penetrate and sometimes concentrate 
in the male and female genital tract. The suppression of replication 
of HIV can be expected to reduce the sexual transmission of 
the virus. In several observational studies, people treated with 
ART appeared to be rendered less contagious. The HPTN 052 
study, a prospective randomized trial of early (median CD4 
count 446 cell/cubic mm blood) vs. delayed ART enrolled 1763 
HIV discordant couples at 13 sites in 9 countries. Suppression of 
HIV replication over 2 years in the early treatment group led to 
more than 96 per cent reduction of the sexual transmission of 
HIV. Subjects treated early also had improved personal health. 
These results led to rapid changes in PEPFAR, WHO and several 
country treatment guidelines. However, the individual benefits 
observed for ART may or may not translate into a population 
level benefit. Successful use of ART to prevent the spread of ART 
must depend on early identification of people with HIV infection, 
linkage to care, and durable suppression of viremia. In some 
setting it may also be necessary to detect and treat people with 
acute HIV infection because of the disproportionate contribution 
of people in this stage of disease to the spread of HIV. Some (but 
not all) ecological studies suggest that the benefits of ART may 
already be realized in several communities. However, to better 
understand this potential effect of ART prospective community 
randomized trials of earlier and broader ART have been launched 
in Tanzania, Botswana, Zambia and South Africa. At this point 
earlier and broader use of ART seems inevitable and desirable. 
With the right stewardship it seems likely that ART will help to 
mitigate the AIDS pandemic.
PL01.03
Oral PrEP for HIV Prevention: Next Steps
J. Baeten1
1University of Washington, Seattle, WA, USA
For HIV uninfected persons with repeated and ongoing sexual 
exposure to HIV, pre-exposure prophylaxis (PrEP) using oral 
antiretroviral medications offers a possible primary prevention 
intervention. Proof-of-concept that PrEP protects against sexual 
HIV acquisition has been demonstrated in three clinical trials, 
among men who have sex with men and heterosexual men and 
women. These trials used the antiretroviral medication tenofovir 
disoproxil fumarate, alone or co-formulated with emtricitabine, 
and the degree of HIV protection in these trials was strongly 
related to the level of adherence to PrEP. Two trials among African 
women did not demonstrate HIV protection with PrEP. Behavioral 
and biologic hypotheses have been proposed to explain the 
divergent findings across PrEP trials, with low adherence to daily 
use of PrEP the leading hypothesis to explain lack of efficacy 
in two trials and the range of efficacy across the other studies. 
The demonstration that PrEP works for HIV prevention provides 
new challenges and opportunities for HIV prevention, including 
how to deliver PrEP to those who could benefit most from this 
intervention, how to evaluate new HIV prevention strategies 
against a background in which some individuals at higher risk for 
HIV may choose to use PrEP, and how integrate PrEP into potent 
combination HIV prevention interventions to achieve maximal 
population benefits. Next steps in the field include rigorous 
evaluation of uptake and adherence to PrEP in implementation 
settings and research into next-generation PrEP agents with 
longer half-life and less user-dependence. The goals of this talk 
will be to evaluate the evidence for PrEP for HIV prevention, 
consider what can be learned to guide implementation of PrEP in 
non-clinical trial settings, and discuss PrEP within the context of 
the continued need to deliver and evaluate new HIV prevention 
strategies, particularly an effective prophylactic vaccine.
Plenary Session 01: HIV Vaccines in the Broader HIV Prevention Landscape
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PL02.02
Viral Dynamics and Immune Response in Acute 
Infection and Their Impact on Viral Set-Point
M. Robb1
1Henry M. Jackson Foundation, Bethesda, MD, USA
Understanding early viral and immune events during acute 
HIV infection is critical to inform prevention and treatment 
efforts. We characterized plasma viral load, peripheral blood 
mononuclear cell populations and cytokine/chemokine profiles 
at baseline and during early stages of acute infections from East 
Africa and Thailand in the prospective RV217 high-risk cohort. 
Individuals at high risk for HIV-1 were prospectively followed 
with twice weekly small blood volumes collected and tested for 
HIV-1 RNA (NAT) to detect acute infection prior to the advent 
of antibody. The relationship of events observed prior to and at 
peak viremia will be discussed in relation to the determination of 
viral load set-point and immune activation. 
PL02.01
Barriers to Mucosal Transmission: Challenges and 
Opportunities
J.D. Estes1
1SAIC-Frederick, Frederick National Laboratory, Frederick, MD, 
USA
During HIV-1 mucosal transmission, the viral diversity of the 
infecting virus is dramatically reduced as the virus transverses the 
various host barriers in order to establish a new infection. While 
the stringency of the mucosal blockade is now well documented, 
there is a paucity of understanding on where the bottleneck 
occurs including the contributions of various host components in 
determining the nature of transmitted founder viruses. A detailed 
understanding of the process of lentiviral transmission will likely 
be critical to guide the design of efficacious vaccine approaches 
that capitalize on opportunities to interdict productive infection 
of the host. This talk will discuss the development of new tools 
that can be used to elucidate the biological and immunological 
barriers surrounding mucosal transmission, the timing and 
process of establishment of infection, and progression to 
systemic infection. Using nonhuman primate models of mucosal 
transmission allows for extensive tissue analyses to define the 
early stages and host responses involved in the establishment and 
spread of virus in the first days following mucosal inoculation, and 
to determine the tissues, cells and pathways that are involved in 
transmission through systemic dissemination in order to better 
guide the development of preventative strategies.
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PL02.03
Viral Evolution in Early HIV Infection, and the 
Implications for Vaccines
B. Korber1
1Los Alamos National Laboratory, Los Alamos, NM, USA
Over the past few years, our understanding of events surrounding 
HIV transmission, early viral expansion, and the role of early 
T cell immunity in viral control and the evolution of immune 
escape, has become increasingly well resolved. Many aspects of 
acute human infection by HIV and infection of macaques with 
SIV are similar, and animal heterologous viral challenge models 
provide a good mimic of natural infection for exploring vaccine 
candidates, with some inevitable limitations due to differences 
in the host and viral biology. Here I will first review some of the 
aspects of acute HIV infection, focusing on aspects that relate to 
viral evolution and selection. Transmitted/founder viruses that 
establish new infections have some distinctive characteristics, 
and in the last part of this talk I will describe how we are using 
these viruses to inform strategies for vaccine design.
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PL03.02
Maturation Pathways of Broad Neutralizing 
Antibodies: Blueprints for Vaccine Design
B. Haynes1
1Duke University Medical Center, Durham, NC, USA
Most broad neutralizing antibodies (bnAbs) share one of several 
unusual characteristics: long heavy chain complementarity 
determining regions, high levels of somatic mutations, 
polyreactivity and VH restricted usage. All of these antibody 
characteristics reflect traits that disfavor bnAb induction. 
Antibody clonal lineages are being elucidated from chronically 
HIV-1 infected subjects who make bnAbs to define bnAb 
maturation pathways, and to design new prime, boost vaccine 
regimens based on bnAb lineages. For vaccine induction of 
bnAbs that are controlled by immune tolerance, deletional 
mechanisms must be incomplete, and the remaining bnAb B cells 
must be able to be activated by immunogens to make clinically 
relevant levels of plasma antibodies. This talk will discuss lessons 
learned from the study of bnAb clonal lineages and report results 
of immunization strategies to stimulate anergic bnAb B cells. 
PL03.01
Follicular T Helper Cells in Vaccination and Lentivirus 
Pathogenesis
R.A. Koup1
1Vaccine Research Center, Bethesda, MD, USA
Follicular CD4 T helper (TFH) cells promote the survival, isotype 
switching and selection of high affinity memory B cells and plasma 
cells. We investigated the phenotype, function, localization and 
molecular profile of TFH in rhesus macaques. Similar to human 
TFH, rhesus macaque TFH are characterized by a CCR7lowPD-
1highCTLA-4highICOShighCXCR4high phenotype and represent 
a heterogeneous population with regard to cytokine function. 
SIV infection leads to their expansion in lymphoid tissues, which 
is associated with increased frequency of activated germinal 
center B cells and SIV-specific antibodies. We have tested several 
adjuvant preparations (in association with HIV Env vaccination) to 
determine their potency in stimulating TFH cells, and any impact 
upon the magnitude and quality of the antibody response. 
We have also studied SHIV-infected monkeys and HIV-infected 
humans to determine the levels and duration of lentivirus 
antigen persistence that are associated with the induction of TFH 
and broadly neutralizing antibody responses.
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PL03.03
Experimental HIV-Vaccines Induce Immunological 
Memory in Murine and Human NK Cells
S. Paust1
1Harvard Medical School, Boston, MA, USA
Using mice and humanized mice, we found that a single 
vaccination with replication-deficient experimental HIV-1 
vaccines results in vaccination-dependent NK cell mediated 
recall responses to HIV-1 group antigen and envelope.
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S01.02
Adjuvants Influence the Magnitude, Quality and 
Durability of HIV Env Specific Humoral Immunity in 
Non-human Primates 
J.R. Francica3, G. Tomaras1, M. Alam1, G. Ferrari1, J. Mascola3, 
D.T. O’Hagan2, R. Seder3
1Duke Human Vaccine Institute, Durham, NC, USA; 2Novartis 
Vaccines, Cambridge, MA, USA; 3Vaccine Research Center, 
National Institutes of Health, Bethesda, MD, USA
An effective preventive vaccine against HIV will require potent 
and durable HIV Env specific antibody responses. Accordingly, 
immune adjuvants will be critical for optimizing HIV Env immunity 
with protein-based vaccines. We performed a comparative 
analysis of how adjuvants influence HIV Env specific immunity in 
non-human primates (NHP) when administered with a trimeric 
HIV Clade C Env protein. The adjuvants chosen were based either 
on their extensive clinical use (alum, MF 59) or their ability to 
mediate adaptive immunity through distinct toll-like receptor 
dependent or other innate pathways. NHP were immunized at 
week 0, 4, 12 and 24 with HIV Env protein and Alum or MF59 with 
or without TLR 4 (MPL) or TLR 7 ligands or Poly ICLC or ISCOMs. 
A comprehensive analysis of HIV binding titer, neutralization 
against Tier 1 and 2 viruses, CD4BS, ADCC, avidity and serum and 
mucosal IgG and IgA were performed. Moreover, HIV Env specific 
B cells were sorted and the Ig loci analyzed using high-throughput 
deep sequencing to determine the gene family usage, and levels 
of somatic mutation. Overall, the data presented highlight how 
adjuvants alter both the magnitude and quality of HIV Env 
specific antibody responses.
S01.01
Development of Dendritic Cell-based Prophylactic 
and Therapeutic HIV Vaccine
Y. Levy1, A. Palucka2
1CHU Henri Mondor, Creteil, France; 2Baylor Institute for 
Immunology Research, Dallas, TX, USA
Dendritic cells (DCs), as the most potent antigen-presenting cells, 
have a pivotal role in the initiation, regulation and maintenance 
of immune responses against cancers and pathogens. They form 
a unique link between the innate and adaptive immune system. 
DC subsets display different receptors and express different sets 
of cytokines/chemokines, leading to distinct immunological 
outcomes. For example, CD14+ dermal DCs preferentially 
control humoral immunity while epidermal DCs (Langerhans 
cells) preferentially induce cellular immunity. Several studies 
have tested ex vivo generated DC loaded with inactivated HIV 
or HIV peptides. We report the results of the DALIA trial testing 
autologous DCs generated ex vivo from monocytes cultured 
with GM-CSF/IFN-alpha and loaded with five lipidated HIV 
antigens (LIPO5). Vaccination elicited polyfunctional HIV-specific 
responses associated with a reduced peak of viral rebound upon 
HAART interruption. Targeting antigens directly to DCs via anti-
DC receptor monoclonal antibody-antigen fusion proteins (FP) 
is another promising approach to HIV vaccine development. We 
are developing anti-DC FP with the objective to target Langerin, 
CD40, DCIR and Lox-1 receptors. In vitro, CD40 and DCIR-HIV FP 
expanded a broad repertoire of Ag specific and multifunctional 
CD4+ and CD8+ T cells from HIV-infected patients. The final goal 
is to combine FPs targeting HIV Env and HIV T cell epitopes to 
different populations of DC with the aim to elicit B and T cell 
responses. These FP are now being tested in NHP in prime boost 
strategies in combination with MVA and Pox vectors.
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S01.04
Profiling Humoral Immunity: Determining Antibody 
Innate Immune Recruiting Capacity
M. Ackerman1
1Thayer School of Engineering, Hanover, NH, USA
In vivo, antibody responses to vaccination or natural infection 
are highly polyclonal, with multiple somatic variants directed to 
multiple epitopes on multiple antigens. This diversity of variable 
domain recognition characteristics is further complemented by 
diversity in constant domain subclass and ability to interact with 
innate immune receptors such as FcgR. Antibody based protection 
is thus derived from the sum of specificities and activities of this 
polyclonal humoral milieu. Here we demonstrate biophysical 
characterization of the innate immune recruiting capacity of 
polyclonal, antigen-specific antibodies capable of parsing the 
complex humoral milieu into components that can be associated 
with relevant clinical, genetic, or functional characteristics. 
Thousands of measurements of the humoral immune response 
can be determined, approaching the number of parameters 
achieved in genotyping and gene expression analyses--providing 
a comprehensive landscape of antibody activity and better 
understanding of the characteristics and development of both 
protective and pathological humoral immunity that may be 
critical to understanding vaccine-mediated protection.
S01.03
Systems Analysis of HIV Vaccine Triggered Innate 
Immune Responses
D. Zak1
1Seattle BioMed, Seattle, WA, USA
An efficacious HIV vaccine has the greatest potential to halt the 
HIV pandemic. Systems vaccinology – the application of systems 
biology analysis tools to vaccine trials – facilitates HIV vaccine 
development in four major ways. (1) It enables the identification 
of correlates of immunogenicity and protection; (2) it reveals the 
cellular regulatory networks that control host immune responses; 
(3) it can guide the re-engineering of vaccine regimens to enhance 
desired responses; and (4) it allows comprehensive analysis of 
failed candidate vaccines to identify what went wrong, opening 
new avenues of investigation. In this presentation, I describe 
our work applying systems vaccinology to clinical and preclinical 
trials of a broad range of candidate HIV vaccines - from novel 
viral vectors to Toll-like receptor (TLR) adjuvants in combination 
with HIV/SIV proteins. Our strategy derives from previous work 
demonstrating how innate immune responses, which develop 
very early after vaccination, shape the magnitude and quality of 
vaccine-induced adaptive immunity. There are two components 
of the approach. We first employ blood-level transcriptional 
profiling to extensively characterize systemic innate immune 
responses induced hours or days after vaccination. This analysis 
allows comparison between vaccines in terms of innate 
immunogenicity – the extent to which known and novel innate 
inflammatory pathways are triggered specifically or generically 
by different vectors or adjuvants. We then computationally 
integrate the systemic innate immune responses with vaccine 
induced adaptive immune responses and/or efficacy, which are 
measured months or years after vaccination. In this manner, we 
define innate response signatures that are predictive of desirable 
vaccine responses. These signatures provide insights into why 
certain vaccine regimens are more efficacious than others and 
help prioritize molecules and pathways to be targeted in the next 
generation of enhanced vaccines.
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S01.05 OA
Natural Killer (NK) Cell Responses at Female Genital 
Mucosa to SIV Vaginal Challenge
L. Shang1, J. Duan1, A. Smith1, S. Wietgrete1, M. Zupancic1,  
A. Haase1
1University of Minnesota, Minneapolis, MN, USA
Background: Previous studies of SIV transmission at rhesus 
genital mucosa have identified a vulnerable window of viral 
replication within the first 3 days post vaginal inoculation. This 
provides a potential opportunity for host mucosal innate immune 
responses to control viral infection.
Methods: In the current work, we examined NK cell (NKG2A+CD3-) 
responses to SIV vaginal challenge in vaginal and cervical mucosa 
using IHC and ISH.
Results: NK cells are maintained at a low baseline level in the 
genital tissue of naïve animals. In the first week post infection, a 
small number of NK cells (up to 1500 cells/cm sq) infiltrated into 
genital mucosa. The initial recruiting signal didn’t require viral 
replication as shown by equal NK influx in animals challenged with 
either WT or AT-2 inactivated viruses. The majority of infiltrating 
NK cells was Granzyme H+ and 40-60% was IFN-gamma+. However, 
viral inoculation also enhanced the expression of HLA-E in genital 
tissues, generating an inhibitory environment to NK functionality. 
In addition, mucosal NK cells appeared to be IL2Rbeta negative, 
indicating impaired IL-2 and IL-15 signaling. Therefore, the initial 
influx of NK cells was not able to eliminate early viral infection at 
genital mucosa. Surprisingly, in the second week, the number of 
mucosal NK cells rapidly decreased, which is inversely associated 
with the number of infected cells in genital tissues and is consistent 
with an increase in the level of sera IP10 and IL18. Interestingly, at 
the end of the fourth week (the VL set point), the number of NK 
cells in genital mucosa was partially recovered, probably because 
of less viral replication due to CD4 depletion and a reduction of 
sera IP10 and IL18.
Conclusion: In this study, we found that densities of cervical NK 
cells are inversely correlated with those of infected cells in animals 
at Day 5-10 post infection (n=7, p=0.0187).
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S02.02
Comparative Immunogenicity of HIV Vaccine 
Candidates In The HVTN
N. Frahm1, G. Tomaras2, D. Montefiori2, P. Gilbert1, L. Corey3, 
J.M. McElrath1
1Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 
2Duke University Medical Center, Durham, NC, USA; 3HIV 
Vaccine Trials Network, Seattle, USA
The partial success of the ALVAC/AIDSVAX vaccine in reducing 
HIV acquisition in RV144 led to an increased focus on pox/
protein vaccine regimens for the prevention of HIV infection, but 
few data exist in humans on the immunogenicity of the newer 
generation of poxvirus vectors, and no new GMP-grade proteins 
have entered the vaccine pipeline for several years. At the same 
time, several new vaccine strategies – vectors, combinations, 
adjuvants and delivery technologies – are in phase I studies in 
the HVTN, some with dramatic effects on immunogenicity. In 
the absence of correlates of protection from HIV acquisition, 
the HVTN laboratories aim at providing a broad understanding 
of vaccine-induced humoral and cellular immune responses, to 
allow for rational decisions on future product development in 
light of the recently proposed correlates of risk in RV144.
S02.01 
RV144 Update: Insights From Correlates of Risk, 
Breakthrough Infections, and Animal Studies In The 
Context of Future Vaccine Development
J. Kim1
1Walter Reed Army Institute of Research (WRAIR), Rockville, 
MD, USA
Of RV144 vaccine-induced immune responses measured at 
peak immunogenicity, 2 weeks post final vaccination, two were 
correlated with infection risk. IgA to HIV envelope correlated 
directly and IgG to gp120 V2 was inversely correlated with 
infection. Analysis of breakthrough viruses further identified 
two sites within V2 that showed, positions 169 and 181, that 
contained distinct genetic signatures comparing vaccine to 
placebo. A post-hoc analysis suggested that there might be 
an “early effect” – consistent with an inducible but transient 
antibody response. Further work defining the correlates of risk 
over time is ongoing. It is not known whether anti-V2 responses 
will serve as a correlate for other vaccines. A previous low-dose 
intrarectal challenge NHP study looking at Ad26 and MVA-based 
SIV vaccines highlighted anti-V2 (SIV) responses as a potential 
correlate, and preliminary sequencing of breakthrough SIV from 
that study demonstrates genetic signatures within the V2 region. 
Taken together these data suggest a hypothesis that anti-V2 
responses may have a more general role in protection, and this 
concept can be addressed in future clinical trials. The impact of 
these developments on current and planned studies of ALVAC 
and gp120 will be discussed.
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S02.04
HIV Immunity and Reservoir Following Interventions 
In Acute HIV Infection: Implication for Functional Cure
J. Ananworanich1
1SEARCH, The Thai Red Cross AIDS Research Centre; The 
U.S. Armed Forces Research Institute of Medical Sciences, 
Bangkok, Thailand
The acute HIV infection period, particularly during the first 
month of infection, represents a unique window of opportunity 
to intervene to mitigate massive immune destruction and rapid 
seeding of the reservoir. So far, with a few exceptions, antiretroviral 
therapy instituted during early infection has not altered the HIV 
disease course nor resulted in viremic control in the absence 
of antiretrovirals. The studies varied by stages of acute HIV 
infection, onset and types of interventions and endpoints. Many 
studied interventions in recent HIV seroconverters, likely missing 
the early critical window for an optimal effect. This presentation 
will provide a critical review of the published literature of clinical 
trials of interventions in acute HIV infection and its implication 
for functional cure. It will also include the latest data of systemic 
and mucosal immunity and reservoir from ongoing clinical trials 
including the RV254/SEARCH 010 study that investigates the 
use of multi-targeted antiretrovirals in the earliest stages of 
infection. The presentation will offer a perspective on examining 
interventions in acute HIV infection that may contribute to a 
functional cure of HIV.
S02.03
Clinical Studies With Adenovirus 26 Vectored 
Candidate HIV-1 Vaccines
R. Dolin1, L.R. Baden1, M.S. Seaman1, D.H. Barouch1
1Beth Israel Deaconess Medical Center, Boston, MA, USA
Adenovirus serotype 26 (Ad26) vectors have the potential 
advantages of relatively low seroprevalence, and have 
substantial biological differences from the more extensively 
studied adenovirus 5 vectors. These include differences in 
receptor usage, tissue tropism, innate immune profile and 
adaptive immune phenotype. In addition, Ad26 vectors have 
shown significant protection against acquisition of infection 
in the SIV macaque model. We conducted phase I studies of a 
prototype Ad26.EnvA vaccine candidate in healthy volunteers at 
doses of 109-1011 vp administered IM at 0, 1, and 6 months. 
The vaccine was generally well tolerated and immunogenic at all 
doses tested, and stimulated EnvA specific ELISA titers and EnvA 
specific ELISPOT responses. Colorectal biopsies from vaccinees 
demonstrated that Ad26.EnvA also stimulated EnvA specific 
mucosal responses, in addition to those detected in peripheral 
blood samples. 
In collaboration with IAVI, HVTN, and the Ragon Institute, we 
have also undertaken a study to compare homologous and 
heterologous immunization regimens utilizing Ad26.EnvA and 
an Ad35.EnvA candidate vaccine. Ad26 vectors with mosaic Env, 
Gag, and Pol inserts are under manufacture for testing in humans 
and should be considered as part of immunization regimens for 
larger clinical trials.
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S02.05 OA
Vector Induced Skewing Of Antibody Fc-Effector 
Functions 
A. Chung1, A. Dugast1, H. Robinson1, Y. Chan1, M.E. Ackerman2, 
J. Cox3, W. Koff3, D. Barouch4, S. Rerks-Ngarm5, N. Michael6,  
J. Kim6, G. Alter1
1Ragon Institute of MGH, MIT & Harvard, Boston, MA, USA; 
2Thayer School of Engineering, Dartmouth, Hanover, NH, USA; 
3International AIDS Vaccine Initiative, New York, NY, USA; 
4Beth Israel Deaconess Medical Center, Boston, MA, USA; 
5Department of Disease Control, Ministry of Public Health, 
Nonthaburi, Thailand; 6US Military HIV Research Program, 
Silver Spring, MD, USA
Background: The RV144 vaccine showed a moderate efficacy 
of protection from HIV infection. The major immune response 
induced by RV144 was non-neutralizing HIV-specific antibodies 
(Abs), that may have potentially mediated Ab Dependent Cellular 
Cytotoxicity (ADCC) and/or Ab dependent Cellular Phagocytosis 
(ADCP). However little is known about the potential role of 
different vaccine regimens on inducing these types of humoral 
immune responses, and whether particular vaccine approaches 
may preferentially induce robust innate immune recruiting 
antibody activity that could confer more protection against 
infection. We therefore aimed to characterize the antibody-
effector functional profiles of antibodies elicited by a number 
of different vaccine approaches including those induced in the: 
VAX003 trial (bivalent rgp120 clade B/E), RV144 (ALVAC vCP1521 
+ rgp120 B/E), IPCAVD001 (rAd26.ENVA.01), IAVI-C002 (MVA), 
IAVI-P002 (DNA + MVA) and IAVI-V001 (DNA + rAd5).
Methods: Abs were purified from the plasma or serum of vaccinees. 
IgGs were then assayed for ADCC, ADCP, NK degranulation and 
cytokine production, antibody isotype selection, and Ab affinity 
for Fc-receptors ( FcγRIIa, FcγRIIb and FcγRIIIa).
Results: IAVI-C002 and IAVI-P002 vaccination induced negligible 
Fc-mediated innate immune responses, while IAVI-V001 was 
able to induce ADCP in 33% of vaccines. IPCAVD001 was also 
able to induce strong ADCP in 90% of subjects, but only weak 
ADCC, NK degranulation or cytokine release. Interestingly, only 
RV144 and VAX003 vaccination induced strong ADCC, ADCP, 
NK degranulation and cytokine responses. Furthermore, Abs 
induced by RV144 and IPCAVD exhibited a more polyfunctional 
profile compared to VAX003, associated with a skewed isotype 
distribution of HIV-specific Abs and selective Fc-receptor affinity 
binding profile.
Conclusion: These data suggest for the first time that distinct 
vaccine regimens, and vaccine vectors, may selectively induce 
antibodies with Fc-enhanced functional profiles able to elicit 
polyfunctional antibody responses, that may provide improved 
protection from infection.
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S03.02
Pure Native Env Trimers On VLP Surfaces and in 
Soluble Form
J.M. Binley1
1TPIMS, San Diego, CA, USA
We hypothesize that as the target of nAbs, the native Env trimer 
is the most logical basis for a nAb vaccine. Two possible formats 
to present native trimer are in situ in lipid membranes (e.g. VLPs) 
or as a soluble recombinant. Different problems have limited 
progress in both areas: 1) Although VLPs and other particle 
based approaches present native trimer, they invariably also 
express non-functional forms of Env. The problem here is that 
non-functional Env is immunodominant and may interfere with 
responses against the more antibody-resistant native trimer. 2) 
Attempts to produce soluble trimers involve truncating gp160 
before the transmembrane spanning domain (i.e. gp140). The 
problem here has been inefficient gp120/gp41 maturation and 
a failure of gp140 to assemble into stable trimers. Although 
various innovative mutations have helped address these issues, 
none have so far have resulted in trimers that fully recapitulate 
the native complex. We have been working to solve these two 
problems. Regarding the first problem, we have developed 
pure native “trimer VLPs” in which junk Env is eliminated using 
protease digests together with specific mutations that improve 
trimer folding and stability. Ongoing immunogenicity trials in 
rabbits will be presented. Regarding the second problem, we 
have shown that soluble SOS mutant-based trimers but not WT 
trimers can be extracted from lipid membranes and are stable 
at 37°C for extended periods in certain buffers. These trimers 
retain an ability to bind to PG9 and PG16 and other broad nAbs, 
but do not bind to non-nAbs. We have generated a producer 
cell line and are currently developing purification procedures to 
yield mg quantities of trimer for structural and immunogenicity 
purposes. These new pure trimer platforms provide new tools 
for other research areas, including mapping broad HIV+ serum 
neutralization and for accessing new neutralizing mAbs from 
infected donors.
S03.01
Structural Basis For HIV-1 Trimeric Env Immunogen
Y. Mao1
1Dana-Farber Cancer Institute, Boston, MA, USA
The trimeric envelope glycoprotein complex of human 
immunodeficiency virus (HIV-1) is a membrane-fusing machine 
that mediates virus entry into host cells. Binding of the gp120 
exterior envelope glycoprotein to CD4 and the chemokine 
receptor on target cells triggers conformational changes that 
allow the gp41 transmembrane envelope glycoprotein to 
fuse the viral and cell membranes. We determined an atomic 
structure of the fully glycosylated HIV-1 envelope trimer in its 
unliganded, pre-fusion state, including the complete exterior 
and transmembrane regions, by cryo-electron microscopy. The 
atomic model reveals a dramatic conformational transition of 
gp120 between its unliganded and CD4-bound states, a torus-like 
fold of gp41 entirely different from its post-fusion conformation, 
and a conserved topology of the glycan shield. The quaternary 
structure of the trimer exhibits tensegrity that stores the free 
energy fuelling virus entry. The structure provides insights into 
virus-host interactions and represents an atomic reference for 
vaccine immunogen design. 
Symposium 03: New Env Immunogens
36
Symposia Sessions
SYM
PO
SIA
 SESSIO
N
S
AIDS Vaccine 2012
S03.04
Epitope-focused vaccines
W Schief1
1International AIDS Vaccine Initiative and The Scripps Research 
Institute, La Jolla, CA, USA
Conserved epitopes targeted by highly potent and broadly 
neutralizing antibodies provide starting points for reverse vaccine 
engineering. We will give an update on our structure-based 
immunogen design efforts employing some of these epitopes, 
and also describe a study that provides proof-of-principle for 
epitope-focused vaccines.
S03.03
Envelope Immunogen: Stable and Homogeneous 
HIV-1 gp140 Trimers
B. Chen1
1Children’s Hospital Boston/Harvard Medical School, Boston, 
MA, USA
HIV-1 envelope glycoprotein is the primary target for HIV-1-
specific antibodies. The native HIV-1 envelope spike on the virion 
surface is a trimer, but trimeric gp140 and monomeric gp120 are 
currently believed to induce comparable immune responses. We 
show that suitably prepared envelope trimers have nearly all 
the antigenic properties expected for native viral spikes. These 
stable, rigorously homogenous trimers have markedly different 
antigenic properties than do monomeric gp120s derived from 
the same sequences, and they induce potent neutralizing 
antibody responses for a cross-clade set of tier 1 and tier 2 
viruses with titers substantially higher than those elicited by 
the corresponding gp120 monomers. The implications for HIV-1 
vaccine development will be discussed.
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S03.05 OA
Eliciting Broadly Neutralizing Antibodies Against HIV-
1 that Target gp41 MPER
D. Han3, H. Habte3, Y. Qin3, K. Takamoto1, C. LaBranche2,  
D. Montefiori2, M.W. Cho3
1Albert Einstein College of Medicine, USA; 2Duke University, 
USA; 3Iowa State University, Ames, USA
Background: The membrane-proximal external region (MPER) 
of HIV-1 gp41 is highly conserved and is targeted by broadly 
neutralizing antibodies (bnAbs). Thus, it is an attractive target 
for AIDS vaccine development. Here, we describe a mini-protein 
that can induce bnAbs in rabbits.
Methods: We generated a mini-protein that is structurally rigid, 
yet efficiently recognized by 2F5, 4E10 and Z13e1. It contains the 
C-terminal 54 a.a. of gp41 ectodomain (gp41-54Q), which includes 
the HR2 and the MPER. A 6xHis tag at the C-terminus was used 
to attach gp41-54Q to Zn-chitosan, which served as an antigen 
carrier/adjuvant. Rabbits were immunized subcutaneously, 4 
times, using two different schedules (wks 0, 4, 9 and 16 vs. 0, 
8, 16 and 24). A total of 9 animals were immunized with gp41-
54Q in 3 independent experiments. Antibody responses were 
evaluated by ELISA and in neutralization assays using both TZM-
bl and A3R5.7 cells. 
Results: Eight of nine rabbits mounted bnAbs (89%). Neutralizing 
activity was observed against all but two of 44 viruses evaluated 
to date, including 27 Tier 2 viruses from clades A, B, C, D, AE, 
and CRF02_AG. Although Nabs could be detected after three 
immunizations, a fourth immunization was necessary for 
maximum neutralizing activity. The slower immunization regimen 
induced higher Nab titers, suggesting that longer rest periods 
improve affinity maturation. Neutralization inhibition analyses 
using various peptides identified one neutralizing epitope (N671, 
W672, F673 and D674) that overlaps with those recognized by 
Z13e1, 4E10 and 10E8 mAbs. Based on antibody absorption 
assays, there might be other non-linear epitopes. We are in the 
process of generating rabbit mAbs for more detailed analyses.
Conclusion: We have successfully demonstrated that we can 
reproducibly induce bnAbs in rabbits using a mini-protein 
containing gp41 MPER. These results suggest that gp41 can be a 
promising vaccine immunogen. 
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S04.02
Evolving Standards of Prevention and Implications 
for Future Trials
D.R. Wassenaar1
1SARETI, UKZN, Pietermaritzburg, South Africa
This presentation will discuss selected ethical issues charc-
terising the current HIV prevention landscape with particular 
reference to implications for standard of prevention in current 
and future HIV prevention trials. These issues will be discussed 
against a background of other general ethical issues in HIV pre-
vention research.
S04.01
PrEP and Vaccines: When and How to Respond to 
Positive Data
M Warren1
1AVAC, New York, NY, USA
Good news can bring tough questions. As biomedical prevention 
trials demonstrate effectiveness, there is intense attention on the 
gap between the end of the trial and the next step to access—
especially necessary implementation research and access for 
participants in the original study that provided positive results. In 
particular, recent positive results from the HPTN 052 “treatment 
as prevention” trial and a range of pre-exposure prophylaxis trials 
(PrEP) have transformed the HIV prevention field. In addition to 
possible public health implications of delivery, these results also 
raise important questions about the implications for how these 
results will influence HIV prevention trials in the future.
This presentation will review the current state of the field; 
present some of the critical issues that need to be considered by 
researchers, advocates, trial designers, program implementers 
and policy makers; and explore how the AIDS vaccine field might 
adapt to emerging results from PrEP and other biomedical 
prevention trials and responding to positive data with new ideas 
for trial design and combination prevention. In particular, this 
presentation will outline some of the critical issues related to the 
recent US FDA approval of PrEP, WHO guidance and how ongoing 
and future trials might respond to it.
Vaccine researchers and advocates need to explain and rally 
support for the continued search for a preventive vaccine, within 
the context of these other scientific advances. As PrEP and other 
prevention strategies are introduced, the niche that a partially 
effective vaccine might fill can become better defined in terms 
of geography, route of exposure, background combination 
package and so on, but the AIDS vaccine field will need to take 
the initiative in bringing this into focus.
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S04.04
Combination Prevention: Designing and 
Implementing a New Era of Trials
R. Barnabast1
1University of Washington, Seattle, WA, USA
How to measure the impact of HIV combination prevention 
programs is a central question for public health efforts to control 
HIV epidemic spread. Implicit in this question is how intensive 
do prevention programs need to be to reduce HIV incidence? To 
answer these questions, three large community randomized trials 
are planned to evaluate HIV combination prevention approaches 
in South Africa, Zambia, Tanzania and Botswana. All propose to 
use intensified methods of HIV testing (two are using home-
based testing) to increase testing coverage, knowledge of status 
and linkage to care including antiretroviral therapy. The main 
outcome for the studies is the change in HIV incidence in the 
intervention communities compared to the control communities. 
Ongoing monitoring, evaluation and modeling analyses could 
help studies reach their goals and adapt their design to achieve 
their primary objectives. Also, the data from these studies will 
provide insight into implementation strategies moving forward.
S04.03
Combination Prevention: Scaling Up Delivery While 
Accelerating Discovery, Lessons From Medical Male 
Circumcision in Kenya
K Agot1, E Omanga1
1University of Washington, Seattle, WA, USA
The presentation will focus on combination HIV prevention 
programs being implemented in Kenya, the complementary role 
each is playing individually and collectively and the synergies 
arising therefrom, as well as the challenges faced in scaling them 
up. Using the rollout of voluntary medical male circumcision 
(VMMC) in Kenya as a case study, the presentation will delve into 
how the positive results of VMMC was just the beginning of a 
series of new discoveries that have helped to strengthen the scale 
up to its current heights of inching towards the half-million mark 
by the close of 2012. Scaling up VMMC service delivery while 
accelerating further discovery underscore the point that the 
breakthroughs in the HIV prevention field in the last three years 
are refreshing news but are by no means a call to complacency. 
With each new discovery in HIV prevention should be a fresh call 
to design even more studies, look for newer/better answers, and 
improve the delivery and uptake of what we have available. 
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Combination Prevention: A Community Perspective 
on Complex Trial Results and Designs
M. Rose1
1Young Black Gay Men’s Leadership Initiative, Washington DC, 
USA
This will be a discussion key consideration when thinking about 
complex trial results and design with the community. Discussing 
the role of the community from the beginning of the process 
through the course of the trial. What are key take messages 
and lessons for helping to keep the community engaged in 
the process and in sharing the message. As trials become 
more complex in their design and undertaking how does the 
community weave into the larger narrative.
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S05.02
Genital Tract Inflammation and Susceptibility to 
HIV Infection in Women from the CAPRISA 004 
Microbicide Trial of Tenofovir Gel
J.S. Passmore1, L. Masson2, L. Werner3, S. Karim3
1CAPRISA and University of Cape Town, Cape Town, South 
Africa; 2University of Cape Town, Cape Town, South Africa; 
3CAPRISA, Durban, South Africa
Tenofovir gel, a vaginal microbicide, was found to reduce male-
to-female transmission of HIV by 39% overall and by 54% in 
those who used the gel consistently. We investigated the role of 
genital inflammation in increasing the risk of HIV infection and 
as a potential factor undermining the effectiveness of tenofovir 
gel. The concentrations of 12 cytokines were measured by 
Luminex in cervicovaginal lavage (CVL) samples collected during 
the CAPRISA 004 tenofovir gel trial from 62 women who later 
became HIV-infected (26 assigned to tenofovir gel) and 104 
women who remained HIV-uninfected during the study (49 
assigned to tenofovir gel). CVL cytokine concentrations did not 
differ between women using tenofovir and placebo gel. Elevated 
cervicovaginal concentrations of IL-1α, IL-1β, IL-8, MIP-1α, MIP-
1β and GM-CSF were associated with increased susceptibility 
to HIV infection, irrespective of gel assignment. Additionally, 
pre-infection inflammation was found to be sustained over 
time, with the CVL concentrations of 7/12 cytokines similar 
in individual women at two separate time-points in this study 
(8-104 weeks apart). Elevated genital inflammatory cytokine 
concentrations may increase the number of activated CD4+ T 
cell targets in the genital tract, thereby enhancing the risk of HIV 
infection following exposure. If so, improving the efficacy of the 
tenofovir microbicide gel will either require better management 
of genital inflammation or augmentation of the next generation 
of microbicides with agents to modulate inflammation. 
S05.01
Vaccine-Microbicide Combination Studies in a Rhesus 
Macaque Vaginal Transmission Model
J.P. Moore1
1Weill Cornell Medical College, New York, NY, USA
In two separate experiments, four groups of rhesus macaques 
were vaccinated with a T cell based adenovirus vectored vaccine 
aimed at reducing post-infection viral loads, and/or a partially 
effective dose of a vaginal microbicide that impedes transmission 
of a high dose of challenge virus. In the first study, the only 
two protected animals were in the group that received Ad26/
Ad5HVR48 vaccine vectors combined with the fusion inhibitor 
T-1249 as the microbicide before SIVmac251 challenge. In the 
second study, vaccination with Ad35/Ad26 vectors combined 
with the CCR5 inhibitor Maraviroc as the microbicide led to 
significant reductions of both acquisition of infection and post-
infection viral loads following SHIV-162P3 challenge. As expected, 
the vaccine by itself reduced viral loads but had no acquisition 
effect, whereas the microbicide had a partial acquisition effect 
but minimal impact on viremia. For both measures of protective 
efficacy, the vaccine-microbicide combination differed more 
from controls than did either separate intervention. Vaccines and 
microbicides are complementary HIV-1 prevention techniques 
that may protect better when used together than separately.
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S05.04
Persistence Pays Off: Stringent Control And Potential 
Clearance of AIDS Virus Infection by Persistent 
Vaccine-Induced Effector Memory T Cells
L. Picker1
1Vaccine and Gene Therapy Institute,Oregon Health & Science 
University, Portland, OR, USA
This presentation will discuss recent advances in understanding 
the efficacy of CMV/SIV vaccine vectors in protection against 
highly pathogenic SIV challenge. 
S05.03
The Current State of Mucosal Immunity Elicited By 
Vaccines
R. Shattock1
1Imperial College London, London, United Kingdom (Great 
Britain)
The development of a successful vaccine against HIV is likely 
to require induction of strong and long-lasting humoral and 
cellular immune responses at the mucosal portal of virus entry. 
Mucosal antibodies able to prevent initial target cell infection, 
reinforced by cellular responses that can control or eliminate 
the initial foci of infected cells may offer the best potential for 
robust sterilizing protection against HIV acquisition. While the 
design of vaccine strategies able to induce such responses may 
be crucial to development of effective vaccines, little has been 
done to define possible mucosal correlates of protection against 
vaginal or rectal exposure. Indeed, to date, most human clinical 
HIV vaccine trials have omitted to evaluate mucosal immune 
responses and have focused only on parenterally administered 
candidates. The observation that the modest protective efficacy 
of the RV144 trial did not correlate with neutralization but V1/
V2 binding antibodies has generated speculation that non-
neutralizing antibodies may have had some impact on HIV 
acquisition, most likely at the mucosal level. Indeed a range 
of other effector functions such as viral aggregation, mucus 
trapping, inhibition of transcytosis, antibody dependent cellular 
cytotoxicity (ADCC), and Fc-mediated inhibition of infection may 
all enhance mucosal protection by antibody. However there is a 
lack of definitive data to establish that localized responses offer 
additional benefit over and above effector functions mediated 
by mucosal expression of systemic induced responses. Drawing 
on the wider field of vaccinology this presentation will review 
current understanding of how adjuvants, delivery strategies and 
routes of immunization modify mucosal responses to vaccination 
in humans and non-human primates and will assess the relative 
strengths and weakness of different approaches as they relate to 
mucosal protection against HIV acquisition.
Symposium 05: Mucosal Immunology
SY
M
PO
SI
A
 S
ES
SI
O
N
S
43
Symposia Sessions
AIDS Vaccine 2012
S05.05 OA
HIV Interactions and the Perils of Epithelial Thinning 
in the Female Reproductive Tract
A. Carias1, M. McRaven1, M. Anderson1, T. Henning2, E. Kersh2, 
J. Smith2, K. Butler2, S. Vishwanathan2, J.M. McNicholl2,  
R.M. Hendry2, R. Veazey3, T. Hope1
1Northwestern University, Chicago, IL, USA; 2Center for Disease 
Control and Prevention, Atlanta, GA, USA; 3Tulane National 
Primate Research Center, Covington, LA, USA
Background: Currently, there is much debate on whether epi-
thelial thinning from hormonal contraceptives can increase HIV 
acquisition. Previously, we illustrated that HIV can penetrate to 
depths in squamous epithelium where it can interact with target 
cells, such as CD4+ T-cells and macrophages. Using a similar ap-
proach, we show that epithelial thinning affects virus penetra-
tion, along with target cell and cellular junction distribution.
Methods: To investigate how genital epithelial thickness may 
affect HIV penetration, ten female rhesus macaques were pre-
treated with 30mg depo-medroxyprogesterone acetate (Depo-
provera®) 4-5 weeks prior to vaginal photoactivatable (PA-GFP) 
HIV exposure. Additionally, eight female pigtail macaques 
were exposed to PA-GFP HIV at various menstrual cycle 
stages. Genital tracts were removed 4 hours post-exposure 
and immediately dissected and snap frozen in optimal cutting 
temperature (OCT) compound. Comparison of pre- and post-
photoactivation image z-stacks revealed the presence of virus, 
accounting for background. 
Results: Within 4 hours, PA-GFP virions were observed between 
squamous epithelial cells penetrating up to depths of 50μm. 
This is within the reach of target cell populations. Furthermore, 
current analysis illustrated epithelial thickness to be inversely 
proportional to the number of penetrating virions and target 
cells, independent of thinning mechanism. Also, cellular junction 
distribution in pigtail macaques with thinned squamous epithelia 
mirrored those results of progesterone-treated rhesus macaques. 
Conclusion: Our current results suggest that HIV acquisition 
in women may be influenced by menstrual cycle and hormonal 
contraceptives. CD4+ T-cells and CD68+ macrophage distribution 
and virus penetration were dependent on epithelial thickness, 
suggesting HIV interactions with female genital epithelia may 
differ in the luteal and follicular stages of the menstrual cycle. 
Our results also suggest that progestin-based contraceptives may 
alter the barrier properties of the stratified squamous epithelium, 
possibly increasing the risk of HIV acquisition in women. 
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S06.02
Poxvirus-based Vectors as Immunization Vehicle: 
Past, Present and Future
J. Tartaglia1
1sanofi pasteur, Swiftwater, PA, USA
An effective prophylactic HIV vaccine has eluded us for more 
than 30 years, with 33 million infected and 7000 new infections 
daily. The HIV vaccines field has taken an iterative vaccine 
design and development approach and have tested multiple HIV 
vaccine candidates, including peptides, proteins, nucleic acid, 
viral vectors and prime-boost combination regimens. Towards a 
globally relevant vaccine, multiple approaches will continued to 
be tested to elicit broadly reactive T and B-cells and generation 
of broadly reactive/neutralizing antibodies. The canary pox 
virus vector, ALVAC, was linked to modest efficacy in RV144 and 
will need further evaluation. Other poxvirus-based vectors i.e. 
Vaccinia virus strains (Tian Tian, MVA, NYVAC and replication 
competent NYVAC ) and Avipox (ALVAC, Fowl pox) are under 
development as HIV vaccine candidates. In this regard, historical 
perspective as well as current status of multiple poxvirus -based 
vectors as HIV vaccine candidates will be discussed.
S06.01
Novel HIV Vaccine Strategies
J.C. Sadoff1, H. Schuitemaker1, L. Baden2, L. Digilio1,  
M. Marovich3, M. Robb4, N. Michael3, J. Goudsmit1,  
D. Barouch5, R. Dolin5
1Crucell, Leiden, Netherlands; 2Brigham and Women’s 
Hospital, Boston, MA, USA; 3US Military HIV Research 
Program, Bethesda, MD, USA; 4Henry M. Jackson Foundation, 
Bethesda, MD, USA; 5Beth Israel Deaconess Medical Center, 
Boston, MA, USA
Alternative serotype adenovirus (Ad) vectors such as Ad26 and 
Ad35 are biologically substantially different than Ad5 vectors. We 
have advanced prototype Ad26 vectors expressing HIV-1 Env into 
phase 1 clinical trials, Ad35 expressing TB antigens in Phase II 
trials in adults and infants and Ad35 and Ad26 vectors expressing 
Malaria CS in human challenge trials. These vectors have proven 
safe and immunogenic in humans at doses of 109 vp, 1010 vp, 
and 1011 vp. We have evaluated Ad26, Ad35, and MVA vectors 
expressing SIV antigens in immunogenicity and challenge studies 
in rhesus monkeys, and we have shown that Ad35/Ad26 as well 
as Ad26/MVA prime-boost regimens elicit partial protection 
against acquisition of infection and partial virologic control 
following fully heterologous, intrarectal SIVmac251 challenges. 
Interestingly, blocking acquisition of infection correlated with env 
specific humoral immunity whereas control of viral replication 
was associated with gag specific cellular immunity. For our HIV 
vaccine candidate that will move into clinical trials shortly, we 
will use computationally optimized “mosaic” HIV-1 Gag/Pol/Env 
antigens that give rise to substantially expanded cellular immune 
breadth and depth and induce noninferior antibody responses as 
compared with consensus or natural sequence antigens in rhesus 
monkeys.To further improve quality of the humoral immune 
response, and thereby increase the chances of protection against 
acquisition of infection, we intend to also boost with a trimeric 
gp120 envelope protein. 
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Passive Immunization for HIV Prevention
F. McCutchan1, F. Randazzo1
1Bill & Melinda Gates Foundation, Seattle, WA, USA
Passive immunization with serum antibodies has long been used 
for temporary protection against infectious agents and toxins. 
At the current time, there is only one monoclonal antibody 
(mAb) product in clinical use for passive immunization against 
an infectious disease, and a single course of treatment over a 
few months costs thousands of dollars in the US. The broader 
application of mAbs for passive protection against an infectious 
disease in developing countries would require nothing short of a 
technical revolution, coupled with a critical public health need. 
The development of an HIV vaccine is such a public health need. 
The history of vaccines suggests that the elicitation of broadly 
neutralizing antibodies may be required for consistent, durable, 
high level protection with an HIV vaccine. Although some humans 
develop broad, potent HIV-neutralizing antibodies (bNabs) 2-3 
years after infection, the current candidate vaccines don’t seem 
to elicit them, despite sustained, focused effort on the problem. 
The first safe, highly effective, and durable HIV vaccine appears 
to be at least a decade away. At the same time, the discovery and 
optimization of natural HIV bNabs, isolated from HIV-infected 
individuals, has gathered momentum, with many new mAbs of 
increased potency and impressive breadth described just in the 
last 2 years. The available natural bNabs represent prototypes, 
with insufficient potency and/or breadth, in their current form, 
for widespread human clinical use.
Meanwhile, outside of the field of infectious diseases, impressive 
gains in potency of monoclonal antibodies for treatment have 
been made, in part by engineering them for bi-specificity, and 
lower-cost manufacturing approaches, and innovative delivery 
approaches with gene transfer, are being developed. Here we 
consider the gap between what mAbs cost today and what could 
be described as an affordable product for HIV prevention, and 
identify areas where major, rather than incremental, gains may 
be needed. 
S06.03
Pre-Clinical Studies And Vaccine Platforms Using 
Chimp Adenovirus Vectors
T. Hanke1
1University of Oxford, The Jenner Institute, Oxford, United 
Kingdom (Great Britain)
The frequency and quality of vaccine-induced immune responses 
are in part determined by intrinsic immunogenicity of HIV-1-
derived immunogens, but the most significant influence comes 
from the way these are presented to the immune system. 
The specificity of vaccine-induced adaptive responses is also 
critical because of the HIV-1 variability and escape. The most 
impressive protection in the macaque-SIV challenge model 
to date has been achieved by life-attenuated SIV and vaccines 
vectored by persisting rhesus CMV, however, both approaches 
face safety issues. Thus, the currently most studied platforms 
employ non-replicating vectors. Of these, adenoviruses are the 
most immunogenic, however, vaccine carriers based on common 
human adenovirus serotypes have several major disadvantages, 
which were highlighted in the proof-of-concept phase IIb STEP 
study. These include strong pre-existing immunity associated 
with potential safety issues and dampened induction of immune 
responses specific for the transgene product, and insufficient 
immunogenicity as stand-alone vaccines. Therefore, either rare 
human serotypes, chimeric, or animal adenoviruses are being 
explored for potential human use combined in heterologous 
prime-boost regimens with other vaccine modalities. Recently 
outstanding regimens incorporate chimp adenovirus prime 
and poxvirus boost. The current pre-clinical state of the ChAdV 
vaccines will be discussed keeping in mind that these results are 
trumped by human data. 
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S06.05 OA
E-DNA IM or ID Delivery Prime Enhances Antibody 
and T Cell Responses Following Recombinant gp120 
env Boost 
N.A. Hutnick4, M. Karuppiah4, J. Pollara1, J. Yan2, D.J. Myles4,  
K. Broderick2, M. Morrow2, N. Sardasai2, D. Montefiori1,  
S. Barnett3, G. Ferrari1, D.B. Weiner4
1Duke University, Durham, NC, USA; 2Inovio Pharmaceuticals, 
Blue Bell, PA, USA; 3Novartis, Cambridge, MA, USA; 4University 
of Pennsylvania, Philadelphia, PA, USA
Background: The results of the RV144 trial support the ability 
of vaccine induced Antibodies to protect from HIV acquisition. 
The STEP trial also appears to have impacted viral load in 
individuals who produced strong T cell immunity. The HVTN has 
recently reported that our enhanced DNA (Pennvax) can drive 
T cell immunity as robust as Adenoviral and Pox platforms in an 
accelerated format in humans. We have now focused on further 
driving T and B cell immunity by utilizing prime boost 
Methods: Groups of rabbits or Indian Rhesus macaques were 
vaccinated with enhanced DNA vaccine plasmids encoding 
pGAG, pPOL + combinations of 3-5 consensus or COT designed 
envelopes that were either gp140 or gp160 constructs. Both IM 
as well as a novel minimally invasive skin delivery EP arrays (MID) 
were studied. DNA vaccinated animals were boosted two months 
following the final DNA immunization with SF162 gp120 in MF59. 
Results: In rabbits, nAb titers against a broad panel of Tier 
1 viruses was observed by the combination immunization 
approaches. Titers in the hundreds were induced by DNA and 
these titers were enhanced almost a log by a protein boost. 
Similar data was also observed when these studies were 
extended to the non-human primate model. Importantly, DNA-
prime protein-boost had detectable ADCC activity as measured 
by the GTL and luciferase assay. A bias for improved antibody 
responses driven by the MID delivery array is also observed.
Conclusion: Building on the success observed in HVTN 080 we 
report that further enhancement of DNA constructs in a prime 
boost setting (E-DNA prime + protein Boost) is capable of eliciting 
high binding, broad antibody responses and neutralization titers 
against a panel of tier 1 viruses. Combining improved E-DNA with 
other strategies shown to enhance antibody responses such new 
gene adjuvants are being investigated.
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T Follicular Helper Cells In HIV Infection
H. Streeck1
1Ragon Institute of MGH, MIT and Harvard, Boston, MA, USA
Nearly all successful human vaccines induce significant, durable 
titers of high-affinity neutralizing antibodies. The generation of 
such antibodies is critically dependent on CD4 T cell help - in 
particular the signals mediated by T follicular helper (TFH) cells. 
Indeed, virtually all licensed vaccines elicit substantial levels of 
CD4 T cell responses. However, there is only little understanding 
of how and when TFH cells shape the humoral immune 
response. Given the preferential infection and depletion of HIV-
specific CD4 T cells, their role in the control of viral replication 
and the induction of neutralizing antibody responses has not 
been a topic of intensive HIV vaccine research. Interestingly, 
gp120-specific CD4 T cell responses are significantly expanded 
in subjects with high viremia, but are almost completely absent 
in individuals who control viral replication. This expansion is also 
reflected as a significant enlargement of TFH cell pool in the 
lymph nodes of chronically infected individuals. However, these 
TFH cells show signs of a unique functional dysregulation which 
is associated with a perturbed B cell compartment, including 
prematurely expanded germinal center B cells and plasma cells. 
A better understanding of the specific TFH signals involved in the 
development of neutralizing antibodies will be critical in guiding 
the identification of correlates of viral protection and control in 
future HIV vaccine design efforts.
S07.01
The Unique T Cell Receptor Expressed by Each Naive 
Helper T Cell Instructs Effector Cell Fate
M.K. Jenkins1
1University of Minnesota, Minneapolis, MN, USA
Polyclonal naïve CD4+ T cells with microbial peptide-specific T 
cell antigen receptors (TCR) produce two types of effector cells 
during infection, ones that activate macrophages and others that 
help B cells. This split in T cell differentiation is influenced by 
extrinsic factors from antigen-presenting cells such as cytokines 
and costimulatory signals. We used a single cell adoptive 
transfer method to determine if effector cell differentiation 
is also influenced by an intrinsic property of each naïve T cell. 
Remarkably, some single naïve T cells produced predominantly 
macrophage-activating effector cells; others produced mostly B 
cell helpers; while others produced both types. These differences 
were the result of the TCR since monoclonal cells with different 
TCRs had different patterns of effector cell generation. The 
strength of signal transduced by the TCR likely determined the 
effector cell pattern since increasing the amount of peptide 
increased the fraction of B cell helpers produced by a given naïve 
clone. These results suggest that the type of effector cell progeny 
produced by an individual naïve is influenced the strength of 
signals transduced by its unique TCR. An implication of this work 
is that antigen dose is a determinant of the quality of the helper 
T cell response.
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S07.04 
Genetic And Structural Basis For Development Of 
High Affinity Antibodies
J. Crowe1
1Vanderbilt University, Nashville, TN, USA
Several of the most broadly neutralizing HIV antibodies (bnAbs) 
contain unique genetic or structural elements, including long 
heavy chain complementarity determining region 3 (HCDR3) 
loops and large numbers of somatic mutations. The processes 
of generating long HCDR3s and of inducing large numbers of 
somatic mutations appear to be independent mechanisms 
of increasing antibody diversity. Induction of long HCDR3 
antibodies may be critical to the design of an effective vaccine 
strategy for HIV, however it is unclear at present how to induce 
such antibodies. There has been speculation that antibodies with 
long HCDR3s are generated primarily through the accumulation 
of somatic hypermutation-associated insertions. These short 
insertion events are rare, and design of an immunogen that 
efficiently induces multiple insertions in a single antibody 
sequence is likely to be extremely difficult. Through the use of 
high-throughput antibody sequencing, we identified genetic 
evidence that antibodies with long HCDR3s typically are formed 
at the original recombination event, not through accumulation 
of somatic hypermutation-induced insertions. Antibodies with 
long HCDR3s are found in all healthy individuals regardless of 
HIV status, and long HCDR3 antibodies typically use a restricted 
subset of D and J gene segments, resulting in the incorporation 
of highly conserved genetic elements in the majority of such 
antibody sequences. This work provides an important step 
toward the design of a vaccine that efficiently induces HIV bnAbs 
with long HCDR3s by identifying a conserved genetic target 
through which B cells encoding long HCDR3 antibodies may be 
induced. In contrast, HIV-specific neutralizing antibodies with 
shorter HCDR3s appear to achieve potency and breadth through 
extensive mutation.
S07.03
Evolution of Broadly Cross-Neutralizing Antibodies 
During HIV-1 Infection
P.L. Moore1
1National Institute for Communicable Diseases, Johannesburg, 
South Africa
Recent cohort studies have shown that broadly cross-neutralizing 
(BCN) antibodies develop during the natural course of infection in 
about a fifth of HIV-infected people. Mapping the specificities of 
these antibodies has enabled the identification of novel vaccine 
targets. However the pathway to the development of BCN 
antibodies, and the interplay between strain-specific antibodies, 
BCN antibodies and autologous viral evolution is not clear. We have 
characterized the longitudinal development of BCN antibodies in 
the CAPRISA cohorts. BCN antibodies developed in 10/74 (14%) 
of infected women by 3 years of infection. We describe changes 
in neutralizing specificity associated with the onset of breadth, 
and sequential waves of BCN antibodies targeting distinct 
epitopes, both likely reflecting affinity maturation and driven by 
the changing autologous viral populations. We show that in some 
individuals, the BCN epitope was not present on the transmitted/
founder virus, but evolved within 6 months of infection, often 
as a consequence of viral escape from an earlier strain-specific 
antibody targeting the same region. Overall these studies aim to 
determine whether maturation of early strain-specific binding 
or neutralizing antibodies gives rise to later BCN responses, or 
whether breadth is mediated by specificities targeting the same 
region that arise de novo in chronic infection.
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CD40L Adjuvant For DNA/MVA Vaccine: Enhanced 
Protection From Acquisition of Neutralization Sensitive 
& Neutralization Resistant Mucosal SIV Infections
S. Kwa1, S. Sadagopal1, J. Hong1, S. Gangadhara1, R. Basu1,  
L. Lai1, S. Iyer1, K. Araki1, P.L. Earl2, L. Wyatt2, F. Villinger1,  
B. Moss2, R. Ahmed1, R.R. Amara1
1Emory University, Atlanta, GA, USA; 2NIH, Bethesda, MD, USA
Background: Generating highly functional antibodies against 
HIV-1 is critical to prevent infection. Here we evaluated the 
ability of CD40L (a co-stimulatory molecule for B cells and 
dendritic cells) as an adjuvant to prevent mucosal infection 
from neutralization-susceptible (SIVE660) and neutralization-
resistant (SIV251) SIVs.
Methods: Groups of rhesus macaques (10-15 animals/group) 
were immunized intramuscularly at 0 and 8 weeks with 3mg 
of DNA/SIV or DNA/SIV-CD40L, and boosted with 108 pfu of 
MVA/SIV at 16 and 24 weeks. In addition, animals challenged 
with SIV251 received 106 pfu of MVA/CD40L premixed with 
MVA/SIV immunizations. Both the DNA and MVA immunogens 
expressed SIV239 Gag, Pol and Env. At about 24 weeks after final 
vaccination, animals were challenged intrarectally with either 
SIV251 (8 weekly doses) or SIVE660 (12 weekly doses) until all 
unvaccinated controls became infected. 
Results: Adjuvanting DNA with CD40L enhanced (p<0.05) the 
titer and avidity of antibodies against SIV239 and SIVE660 
Envs.Adjuvanting both DNA and MVA with CD40L enhanced 
(p<0.05) the frequency of B cell follicles with germinal centers 
(sites of antibody affinity maturation) in the lymph nodes. 
Following challenge, animals vaccinated with CD40L adjuvant 
showed markedly enhanced protection from virus acquisition 
against both SIVE660 (number of challenges for 50% infection 
was 2 in controls, 5 in DNA/MVA and 12 in DNA/MVA with 
CD40L; p=0.003, 76% vaccine efficacy) and SIV251 (number 
of challenges for 50% infection was 2 in controls, 2 in DNA/
MVA and 6 in DNA/MVA with CD40L; p=0.04, 55% vaccine 
efficacy). The enhanced protection against SIVE660 correlated 
directly with increased avidity of anti-SIVE660 Env antibody and 
correlation analyses for protection against SIV251 are ongoing. 
CD40L-adjuvanted animals also showed 100-fold reduction in 
peak virus replication in both infection models. 
Conclusions: These results demonstrate that CD40L enhances 
the functional quality of anti-Env antibody and protection 
from acquisition of neutralization sensitive and resistant 
mucosal SIV infections.
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S08.02
Therapeutic Vaccines in Strategies for Functional 
Cure of HIV
B. Autran1
1JINSERM U543 - Université Paris VI Pierre et Marie Curie, 
ORVACS, Paris, France
S08.01
Therapeutic Approaches to Curing HIV Infection
S Deeks1
1University of California, San Francisco, San Francisco, CA, USA
The current therapeutic strategy for established HIV infection is 
to control viral replication with combination antiretroviral drugs. 
This approach has limitations as it does not restore health and 
as many individuals have trouble accessing and/or adhering 
to these drugs on indefinite manner. Recognizing the need 
for a therapy that is short-term and scalable, there is intense 
interesting in potentially curative approaches. There are now a 
number of potential cure strategies being tested in pre-clinical 
animal models, with several now advancing into phase I human 
clinical trials. The status of these approaches will be summarized.
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S08.04
Persistence of Latently Infected CD4+ T Cells During 
HAART: Keeping Memory, Keeping HIV
N. Chomont1
1VGTI FL, Port Saint Lucie, FL, USA
The initiation of highly active antiretroviral therapy (HAART) in 
HIV-infected individuals infected results in a rapid drop in plasma 
viral load and in a substantial reduction in the number of cells 
carrying proviral DNA in both blood and tissues. After prolonged 
viral suppression, a low frequency of latently infected cells is 
still detectable and although several cellular reservoirs may 
contribute to HIV persistence, the vast majority of the proviral 
DNA is detected in memory CD4+ T-cells. This cellular reservoir 
decays very slowly with a half-life of 40 to 44 months, indicating 
than more than 70 years of intensive therapy would be required 
for its elimination. Interestingly, the lifespan of long-lived memory 
CD4+ T-cells is comparable to this duration, suggesting that the 
mechanisms involved in the maintenance of antigen (Ag)-specific 
memory CD4+ T-cells also ensure HIV persistence under HAART. 
These observations suggest that strategies aimed at reducing the 
pool of latently infected cells should interfere with the survival 
pathways responsible for the long-term maintenance of memory 
CD4+ T-cells. Because memory CD4+ T-cells are critical for 
appropriate immune defense, targeted approaches are needed 
to interfere only with the long-term survival of discrete fractions 
of memory T-cells carrying proviral DNA.
S08.03
Barriers to HIV-1 Eradication
R. Siliciano1
1Johns Hopkins University School of Medicine, Baltimore, MD, 
USA
This talk will summarize barriers to HIV eradication in patients 
on HAART, with a particular emphasis on the potential need for 
therapeutic HIV vaccines as part of eradication strategies.
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S08.05
Assembling the Tools to Clear HIV Infection: 
Contributions From Virology and Immunology
D. Margolis1
1University of North Carolina at Chapel Hill, Chapel Hill, NC, 
USA
Despite antiretroviral therapy, proviral latency of human 
immunodeficiency virus type 1 (HIV-1) remains a principal 
obstacle to curing the infection. Inducing the expression of 
latent genomes within resting CD4+ T cells is the primary 
strategy to clear this reservoir. We have recently shown that 
the histone deacetylase inhibitor suberoylanilide hydroxamic 
acid (also known as vorinostat, VOR) can disrupt HIV-1 latency 
in vivo. A single dose of VOR increased both biomarkers of 
cellular acetylation, and simultaneously induced an increase 
in HIV RNA expression in resting CD4+ cells. This demonstrates 
that a molecular mechanism known to enforce HIV latency can 
be therapeutically targeted in humans. However in HIV-infected 
patients, the frequency of circulating HIV-specific CTL declines 
during prolonged successful ART. If expression of latent HIV is 
induced by agents such as Vorinostat (SAHA), CTL response may 
temporally lag, preventing effective clearance of infected cells. 
Additionally, some patients with a history of advanced disease 
may have lost the ability to mount an HIV-specific CTL response 
relevant for the viral clones archived within their resting CD4+ 
T cell reservoir. In addition to developing purging strategies to 
clear latent reservoirs, therapeutic immunization or similar 
approaches may be needed to eradicated HIV infection.
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OA01.01
Significant Protection from Infection and AIDS 
Progression After Gastrointestinal and Oral 
Vaccinations, Respectively, with a SIV DNA/rMVA 
Vaccine
A. Aldovini1, M. Manrique1, A. Cobo-Molinos1, P. Kozlowski2,  
A. Carvlle3
1Children’s Hospital Boston, Harvard Medical School, Boston, 
MA, USA; 2Louisiana State University Health Sciences Center, 
New Orleans, LA, USA; 3New England Primate Research Center, 
Harvard Medical School, Southborough, MA, USA
Background: Nasal SIV vaccination can significantly protect 
from AIDS progression.
Methods: We compared four mucosal routes of vaccination 
in four groups of seven female Rhesus Macaques (RM) each, 
immunized in the oral cavity (O), gastrointestinally (GI), nasally 
(N) and vaginally (V) with mutated proviral SIV, IL-2 and IL-
15 DNAs and SIV rMVA. Vaccinated and control animals were 
challenged vaginally with repeated low-dose of SIVmac251.
Results: Only N vaccination induced a significant increase 
in plasma SIV-IgG titers. Significantly higher systemic, rectal 
and vaginal SIV-specific T-cell responses were detected in the 
oral group during the immunization. The median number of 
challenges required to become infected was significantly higher 
in the GI group (32; 16 for O, 12 for V, 9 for N, 11 for controls). 
Repeated SIV exposure expanded vaginal anti-SIV T-cells in 
some of the animals. Seven vaccinated RM (3 in the O, 3 in the 
N and 1 in the GI group) suppressed the viremia after the initial 
infection peak and maintained it undetectable over the course 
of the trial. Immunized, infected animals had significantly lower 
levels of systemic T-cell immune activation, better preservation 
of CD4+ central memory and α4β7high+ CD4+ T-cells, with 
consequent better protection from AIDS. However a lower 
protection from AIDS progression was observed in the GI group 
compared to the other vaccinated RM, with a median survival 
of 24 weeks. A significantly higher loss of CD4+ CM T-cells, 
detected early on in this group, correctly predicted its poor 
long-term outcome. 
Conclusion: Protection from infection in The GI group correlated 
with higher anti-SIV CD8+ T cells responses in vaginal T-cells 
on the day of first challenge. More than 50% of the O and N 
vaccinated RM were still disease-free 72 weeks after infection, 
and protection correlated with levels of systemic anti-SIV 
IFN-g+/CD8+ T-cells on the day of first challenge. 
OA01.02
Antibodies to the Envelope Protein Protect Macaques 
from SIVmac251 Acquisition in an Immunization 
Regimen That Mimics the RV-144 Thai Trial
G. Franchini1, P. Pegu1, S. Gordon1, B. Keele2, M. Doster1, Y. 
Guan3, G. Ferrari4, R. Pal5, M.G. Ferrari6, S. Whitney7, L. Hudacik7, 
E. Billings8, M. Rao8, D. Montefiori9, D. Venzon1, C. Fenizia1, J. 
Lifson2, D. Stablein2, J. Tartaglia10, N. Michael11, J. Kim11
1NCI/NIH, Bethesda, MD, USA; 2NCI-Frederick, Frederick, MD, 
USA; 3Institute of Human Virology Maryland University School of 
Medicine, Baltimore, MD, USA; 4Duke University, Durham, NC, 
USA; 5Advanced Bioscience Laboratories, Rockville, MD, USA; 
6ABL, Rockville, MD, USA; 7Advanced Biosciences Laboratories, 
Rockville, MD, USA; 8Army Institute of Research, Silver Spring, 
MD, USA; 9Duke University Medical Center, Durham, NC, USA; 
10Sanofi Pasteur Inc, Swifter, PA, USA; 11Walter Reed Army Intitute 
of Research, Silver Spring, MD, USA
Background: The canarypox vector ALVAC-HIV, together with the 
HIV gp120 envelope, has protected 31.2% of Thai heterosexual 
individuals from HIV acquisition in the RV144 HIV vaccine trial. 
This outcome was unexpected, given the limited ability of the 
ALVAC-HIV vaccine component to induce CD8+T-cell responses, 
and of the HIVgp120 envelope to elicit broad neutralizing 
antibodies. 
Methods: We vaccinated macaques with an immunization 
regimen that mimics the RV144 trial and exposed them to a 
mucosal dose of SIVmac251 that transmits few virus variants, similar 
to HIV transmission to humans. 
Results: Vaccination induced anti-envelope antibodies, modest 
CD4+ and CD8+ T-cell responses. One third of the vaccinated 
macaques were protected from SIVmac251 acquisition, whereas 
the remaining infected vaccinees progressed to disease. Vaccine 
induced SIVmac251 specific T-and B-cell responses were not different 
in protected or infected animals. The sera of the animals protected 
had higher avidity antibodies to the gp120 envelope protein, 
recognized the variable envelope region V2, and reduced SIVmac251 
infectivity in cells that express high level of α4β7, suggesting a 
functional role to antibodies to V2. 
Conclusion: The SIV mac251 infection macaque faithfully reproduces 
results in humans, and is instrumental in the development of 
more efficacious vaccines for HIV. 
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OA01.04
A Recombinant Attenuated Mycobacterium 
Tuberculosis-SIV Combination Vaccine Is Safe and 
Immunogenic in Immunocompromised, SIV-Infected 
Infant Macaques
K. Jensen5, U.D. Ranganathan1, P. Kozlowski2, K. Van Rompay3, 
D. Canfield3, R. Ravindran4, I. Khan4, P. Luciw3, G. Fennelly1,  
M. Larsen1, K. Abel5
1Albert Einstein College of Medicine, New York, NY, USA; 
2LSUHSC, New Orleans, LA, USA; 3UC Davis-CNPRC, Davis, CA, 
USA; 4UCD CCM, Davis, CA, USA; 5UNC Chapel Hill, Chapel Hill, 
NC, USA
Background: HIV and Tuberculosis show high co-prevalence and 
cause high morbidity and mortality, especially in infants. There 
is no HIV vaccine, and the only licensed TB vaccine, BCG, can 
cause disseminated disease in HIV-infected infants. We propose 
to develop a pediatric combination HIV-TB vaccine hypothesizing 
that a highly attenuated strain of M. tuberculosis (AMtb) (i) would 
result in improved safety, but similar immunogenicity compared 
to BCG, (ii) could be modified to co-express HIV genes (rAMtb-
HIV), and (iii) therefore induce HIV and Mtb specific immunity. 
Towards this goal, we tested distinct H37Rv Mtb mutants that 
differed in their attenuation for replication and immune evasion 
in infant rhesus macaques
Methods: Six infants that were SIV infected at birth, and 20 
healthy infants received rAMtb-SIV orally at one week of age, 
and were followed for 3-6 months. Vaccine safety was assessed 
by clinical monitoring, histopathology, and Mtb detection using 
multiple culture methods. SIV and Mtb-specific T cell responses 
were measured by flow cytometry. Plasma, saliva and stool were 
tested for SIV and Mtb antibody responses.
Results: Among three vaccine tested, the rAMtb-SIV strain mc6435 
with deletions in panCD, LeuCD, and secA2 was determined to 
be safe in healthy and SIV-infected infant macaques. Lungs and 
other tissues were free of TB pathology, and viable mycobacilli 
could not be recovered from any tissues despite severe immune 
suppression by SIV. 
Immunized animals showed increased dendritic cell activation, 
elicited polyfunctional SIV- and TB-specific CD4+ and CD8+ T 
cell responses in blood and tissues, and developed plasma IgG 
antibodies specific for Mtb and for SIV. The effectiveness of 
oral immunization was confirmed by detection of mucosal IgA 
responses to SIV in saliva and stool.
Conclusion: A rAMtb-SIV vaccine is a safe alternative to BCG, is 
immunogenic in infants, and could be developed as a combination 
vaccine against pediatric HIV and Mtb infections.
OA01.03
Immune Control of an SIV Challenge by a 
Heterolgous and Direct Mucosal Vaccination 
Regimen in Rhesus Monkeys
C. Sun1, Z. Chen2, X. Tang3, Y. Zhang4, L. Feng4, Y. Du3, L. Xiao4, 
L. Liu5, W. Zhu6, L. Chen4, L. Zhang7
1Guangzhou Institute of Biomedince and Health, CAS, 
Guangzhou, China; 2AIDS Institute, LKS Faculty of Medicine, 
Unversity of Hong Kong, China; 3AIDS Institute, LKS Faculty 
of Medicine, University of Hong Kong, China; 4Guangzhou 
Institute of Biomedicine and Health, CAS, China; 5AIDS 
Institute, LKS Faulty of Medicine, University of Hong Kong, 
China; 6AIDS Research Center, Chinese Academy of Medical 
Sciences, China; 7Comprehensive AIDS Research Center, 
Tsinghua University, Beijing, China
Background: The mucosal surface is the major route for HIV-1 
transmission, yet a safe and effective AIDS vaccine through direct 
mucosal immunization remains elusive. 
Methods: Here, we report a novel vaccination regimen consisting 
of a mucosal prime with replication-competent vaccinia 
Tiantan rMVTTSIVgpe and an intramuscular boost with non-
replicating rAd5SIVgpe expressing SIV Gag, Pol and Env. Twenty 
Chinese rhesus macaques were used to evaluate its safety, 
immunogenicity and protective potential. 
Results: Compared with three control groups, the rMVTTSIVgpe-
rAd5SIVgpe regimen elicited robust cellular immune responses 
with enhanced magnitude, sustainability and polyfunctionality, 
and higher titers of neutralizing antibodies against SIVmac1A11. 
Moreover, one rMVTTSIVgpe-rAd5SIVgpe vaccinated animal 
was fully protected, while the rest demonstrated 1.74-log 
and 1.2-log reductions in peak and set-point viral loads upon 
intrarectal challenge with a high dose (5x105 TCID50/animal) of a 
pathogenic and neutralization-resistant SIVmac239. Importantly, 
the rMVTTSIVgpe-rAd5SIVgpe vaccinated animals remained 
healthy up to 850 days post-challenge, while the majority (~75%) 
of controls progressed to simian AIDS. The protective effect was 
found to correlate with SIV-specific CD8+ T cell ELIspot responses 
against Gag and Pol, but not Env. 
Conclusion: Our findings indicate that vaccine strategy engaging 
the mucosal surface from the beginning of vaccination may 
provide protective immunity against HIV-1 infection in humans.
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OA01.06
Epitope Specificity Appears to Be an Important 
Determinant of In Vivo Killing Ability of Simian 
Immunodeficiency Virus (SIV)-Specific CD8+ T Cells 
L. Pozzi 1, A. Carville1, V. Varner1, J. Sen1, D. Knipe1, A. Kaur1
1Harvard Medical School, Southborough, MA, USA
Background: CD8+ cytotoxic T lymphocytes (CTL) are a critical 
component of antiviral immunity and play an important role in 
the control of lentiviral infection.
Methods: We have developed an in vivo CTL assay to directly 
measure the killing capacity of MHC-restricted SIV-specific CTL in 
rhesus macaques (RM). In order to evaluate the in vivo efficacy 
of different epitope-specific CTL, we compared the in vivo killing 
capacity of Mamu-A*02-restricted Nef YY9 and Gag GY9 CD8+ 
T lymphocytes in three RM vaccinated with a recombinant HSV 
prime/ DNA boost SIV vaccine regimen.
Results: Tetramer frequencies of Mamu-A*02-restricted Nef YY9-
specific CD8+ T-cells were at least 10-fold higher than Mamu-
A*02-restricted Gag GY9-specific CD8+ T-cells in individual 
animals both pre- and post-challenge. Prior to SIV challenge, both 
CTL populations showed poor and incomplete killing (22-35%) of 
target cells over 18 hours. Seven weeks post-challenge, there was 
a marked increase in the CTL killing capacity of both Nef YY9 and 
Gag GY9-specific CTL with 26-38% killing occurring over the first 
two hours and up to 100% killing over 18 hours. Surprisingly, Gag 
GY9-specific CTL consistently showed equivalent or greater in 
vivo killing when compared to Nef YY9-specific CTL even though 
the percentages of IFN-γ secreting and degranulating cells upon 
peptide stimulation were comparable.
Conclusion: These data suggest that epitope specificity rather than 
tetramer frequency determines the ability of SIV-specific CTL to 
kill infected cells. Taken together, these data may have important 
implications for the development of a successful HIV vaccine.
OA01.05
MAb PGT121 Protects Against Mucosal SHIV 
Challenge in Macaques at Concentrations 
Corresponding to Its Highly Potent In Vitro 
Neutralization Capacity
B. Moldt1, E.G. Rakasz2, N. Schultz1, P. Chan-Hui3, K. Swiderek3, 
D.I. Watkins2, D.R. Burton1, P. Poignard1
1The Scripps Research Institute, La Jolla, CA, USA; 2University 
of Wisconsin-Madison, Madison, WI, USA; 3Theraclone 
Sciences, Inc., Seattle, WA, USA
Background: We recently characterized several new broadly 
neutralizing monoclonal antibodies (bnMAbs) remarkable for 
their in vitro potency. A number of these bnMAbs are almost 10 
fold more potent than previously isolated bnMAbs such as PG9 
and VRC01 and hundred fold more potent than older prototype 
bnMAbs such as 2G12 and b12. Of the new antibodies, PGT121 
is one of the most broad and potent, and recognizes a glycan-
dependent epitope. Based on in vitro neutralization potency, 
we speculated that PGT121 may be protective in vivo at serum 
concentrations below those previously determined for other 
broadly neutralizing anti-HIV antibodies.
Methods: The neutralization potency of PGT121 against SHIV 
SF162P3 was evaluated using a TZMbl-based neutralization assay. 
To evaluate the protective potency of PGT121 in vivo, we then 
designed a protection study in rhesus macaques. Animals were 
administered intravenously with 3 different doses of antibody (5 
mg/kg, 1 mg/kg or 0.2 mg/kg) 24 hours before being vaginally 
challenged with a single high dose of SHIV SF162P3 (300 TCID50). 
Serum levels of antibody and viral loads were determined 
throughout the study.
Results: PGT121 potently neutralizes SHIV SF162P3 with an IC50 of 
about 0.005 µg/ml. Preliminary data suggest that an administered 
dose of PGT121 at 1 mg/kg is sufficient to induce sterilizing 
immunity against a single high dose vaginal challenge of SHIV 
SF162P3. A lower 0.2 mg/kg dose appears to be partially protective.
Conclusion: PGT121 is one of the most broad and potent 
neutralizing antibodies isolated to date. Here, we provide 
evidence that in vivo protection by PGT121 correlates with the 
high in vitro potency of the antibody. PGT121 can thus mediate 
sterilizing immunity at concentrations that are significantly lower 
than previously observed from passive protection studies with 
bnMAbs and may be readily achievable through vaccination.
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OA02.02
Prime-Boost Regimen Potency and Efficacy with 
Alphavirus Replicons (SIV Antigen) in Non-human 
Primates Challenged with Low-Dose Intra-rectal 
SIVsmE660
K. Banerjee1, S. Balsitis1, T. Jamil1, C. Jones1, A. Dey1, J. Flandez1, 
L. Brito1, Y. Cu1, C. Beard1, S. Santra2, R. Pal3, N. Miller4,  
N.M. Valiante1, P. Mason1, S.W. Barnett1, G.R. Otten1
1Novartis Vaccines and Diagnostics, Cambridge, MA, USA; 
2Beth Israel Deaconess Medical Center, Boston, MA, USA; 
3Advanced Biosciences Laboratories, Kensington, MD, USA; 
4Division of AIDS, NIAID, MD, USA
Background: Self-amplifying RNAs (replicons) of positive-strand 
viruses such as alphaviruses are potentially safe and useful 
vectors for delivering vaccine antigens. Recombinant alphavirus 
replicon particles (VRP), carrying the self-amplifying RNA, 
protects rhesus macaques against SHIVSF162P4 challenge when 
used in a prime-boost regimen.
Methods: Novartis VRPs are being further tested using a current 
state-of-the art physiologically relevant low-dose SIV virus swarm 
challenge. To meet the need for the large numbers of VRP an 
alphavirus packaging cell line (PCL) was used for VRP production. 
We manufactured, characterized, stability and small animal 
potency tested VRPs expressing SIVmac239 envelope (env) and 
gag/pol fusion proteins (VRP Env, VRP Gag/pol, respectively) for 
a large macaque vaccine study. Macaques were co-immunized 
with both VRPs thrice followed by two boosts with an MF59-
adjuvanted CHO cell-derived SIVmac239 trimeric env protein.
Results: Here we show that three VRP priming immunizations 
induce both env- and gag-specific IgG and T-cell responses, 
robustly. Binding env-specific IgG titers were demonstrable in 
100% of animals with titers ranging from ~10000-400000. T-cell 
responses to env and gag developed in 80% of macaques (env-
specific range ~100-1200, gag-specific range ~100-700 SFC/106 
PBMCs) when assayed using an IFNγ T-cell ELISpot. The MF59-
adjuvanted Env protein by itself was also robustly immunogenic 
with Env-specific IgG titers and T-cell responses ranging from 
~100000-1700000 (100% response) and ~100-1000 SFC/106 
PBMCs (90% response), respectively. No adverse events were 
reported upon immunization of either the VRP or the MF59-
adjuvanted env vaccines.
Conclusion: We provide further details on the currently ongoing 
efficacy evaluations of these safe and immunogenic vaccines in 
a prime-boost regimen using repeated low-dose heterologous 
SIVsmE660 intra-rectal challenges. NIH Grant N01-AI-50007.
OA02.01
Identification of a Clade A HIV Envelope Immunogen 
from Protocol G That Elicits Neutralizing Antibodies 
to Tier 2 Viruses
S. Hoffenberg1, S. Kosakovsky Pond2, A. Carpov1, D. Wagner1,  
A. Wilson1, R. Powell1, R. Lindsay1, H. Arendt1, J. DeStefano1,  
P. Poignard1, M. Simek1, S. Fling1, S. Phogat1, C. Labranche3,  
D. Montefiori3, D. Burton4, C. Parks1, C. King1, W. Koff1,  
M. Caulfield1
1International AIDS Vaccine Initiative, Brooklyn, NY, USA; 
2University of California San Diego, San Diego, CA, USA; 3Duke 
University, Durham, NC, USA; 4The Scripps Research Institute, 
La Jolla, CA, USA
Background: Broadly neutralizing antibodies PG9 and PG16 have 
been isolated from the B cells of one clade A-infected individual 
from IAVI Protocol G. PG16 is relatively trimer-specific whereas 
PG9 binds trimer preferentially, but can bind monomeric gp120 
from several viral isolates. Both antibodies are potent neutralizers 
that recognize greater than 70% of tier 2 pseudovirues in the 
TZM-bl assay. We sought to begin immunogen design efforts 
based on sequences from the Protocol G donor, however all 
viruses isolated from the donor were resistant to neutralization 
by PG9 and PG16. We used a bioinformatics approach to infer 
the most recent common ancestor (MRCA) sequence for the 
viral envelope (Env) to identify closely related viruses sensitive 
to PG9/16.
Methods: Alignment of the MRCA sequence with 99 subtype A 
gp160 sequences from the Los Alamos HIV database identified 
BG505 as the virus with the highest degree of homology (73%) 
to the MRCA sequence.
Results: Pseudoviruses prepared with this Env are sensitive to 
neutralization with a broad panel of bNAbs, including PG9 and 
PG16, indicating that BG505 has an antigen profile desirable in a 
vaccine candidate. When expressed as a soluble gp120 monomer 
from 293T cells, BG505 displayed a unique antigenicity profile 
– it bound well to both PG9 and PG16. We further show that a 
point mutation enables production of stable gp120 monomers 
that preserves the major neutralization epitopes on Env. Finally, 
we show that an adjuvanted formulation of this gp120 protein 
elicited neutralizing antibodies in rabbits (following a gp120 
DNA vaccine prime) and that the resulting antisera compete 
with the bNAbs from 3 non-overlapping epitope classes for 
binding to gp120.
Conclusion: The results indicate that BG505 Env warrants further 
investigation as an HIV vaccine candidate either as a protein or in 
a viral vector platform.
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OA02.04
Design of Lipid Nanoparticle Delivery Agents for 
Multivalent Display of Recombinant Env Trimers in 
HIV Vaccination
S. Pejawar-Gaddy1, J. Kovacs2, D. Barouch2, B. Chen2, D. Irvine1
1Massachusetts Institute of Technology, Boston, MA, USA; 
2Harvard University School of Medicine, Boston, USA
Background: Immunization strategies that elicit antibodies 
capable of neutralizing diverse strains of the virus will likely 
be an important part of a successful vaccine against HIV. The 
envelope trimer is the only neutralizing target on the virus, and 
strategies to promote durable, high avidity antibody responses 
against the native intact trimer structure are lacking. We recently 
developed chemically-crosslinked lipid nanocapsules as carriers 
of molecular adjuvants and encapsulated or surface-displayed 
antigens, which promote follicular helper T-cell responses and 
elicited high-avidity, durable antibody responses to a candidate 
malaria antigen (Moon et al. Nat. Mater. 10 243 (2011); Moon et 
al. PNAS 109 1080 (2012)). 
Methods: To apply this system to the delivery of HIV antigens, we 
developed a strategy to anchor recombinant envelope trimers to 
the surfaces of these particles under conditions preserving the 
antigenic integrity of the trimers, allowing multivalent display 
of these immunogens for immunization. To anchor trimers in 
their native orientation, gp140 trimers with terminal his-tags 
were anchored to the surface of lipid nanocapsules via Ni-NTA-
functionalized lipids. 
Results: Owing to their significant size (409 kDa) and heavy 
glycosylation, we found that liquid-ordered and/or gel-phase 
lipid compositions were required to stably anchor trimers to 
particle membranes. Trimer-loaded nanocapsules carrying 
monophosphoryl lipid A elicited durable antibody responses 
with titers comparable to a Complete Freund’s Adjuvant (CFA)-
like emulsion in mice, without the toxic inflammation associated 
with the latter adjuvant. Further, nanocapsules elicited strong 
helper T-cell responses associated with a steadily increasing 
avidity of trimer-binding antibody over 90 days, which was not 
replicated by other adjuvants. 
Conclusion: These results suggest that nanoparticles displaying 
HIV trimers in an oriented, multivalent presentation can promote 
key aspects of the humoral response against Env immunogens. 
This work was funded by the NIH (AI095109) and the Ragon 
Institute of MGH, MIT, and Harvard. 
OA02.03
Minimally Invasive and Surface Electroporation 
Delivery of DNA Vaccines for the Induction of Robust 
Humoral Immune Responses Against HIV Antigens 
N.Y. Sardesai1, A.S. Khan1, J. Mc Coy1, F. Lin1, J.M. Mendoza1,  
M. Yang1, J. Yan1, N. Hutnick2, K. Muthumani2, D.B. Weiner2, 
K.E. Broderick1
1Inovio Pharmaceuticals, Blue Bell, PA, USA; 2University of 
Pennsylvania School of Medicine, Philadelphia, PA, USA
Background: Clinical data from the HVTN-080 study demonstrated 
that intramuscular electroporation (EP) delivery of PENNVAX®-B 
DNA vaccine and the plasmid adjuvant IL-12 generated strong 
antigen specific cellular immune responses in humans with 
nearly 90% response rate. We have now developed minimally 
invasive EP delivery technologies (MID-EP) to target dermal 
tissue and demonstrate their ability to generate strong antibody 
(Ab) responses in animal models with DNA antigens – including 
small pox, influenza, dengue – and have shown protection from 
viremia and lethality following challenge.
Methods: We demonstrate MID-EP delivery of consensus 
HIV gp140 antigens and show the generation of cross-clade 
neutralizing responses in guinea pigs and rabbits. These EP 
enhanced humoral responses were significantly broader and 
higher than naked DNA delivery alone or with a protein antigen. 
We demonstrated NAb titers against a broad panel of 15 Tier-1 
HIV viruses from Clades A-D in the range of 20 -200 measured 
in the Tzm-Bl neutralization assay. The magnitude but not the 
breadth of the responses was boosted to 20-1000 range using a 
MID-EP DNA prime-protein boost regimen.
Results: We further developed a surface EP device (SEP) for 
the simultaneous, but spatially segregated, delivery of multi-
component HIV vaccines. The SEP device operates under 
substantially lower voltage parameters than conventional EP 
devices resulting in significant improvements in tolerability. The 
separation of multi-component HIV vaccines avoids potential 
issues with plasmid interference at the transcriptional or 
translational levels. SEP produces Ab responses comparable to the 
penetrating DNAEP devices.
Conclusion: Our results suggest that MID/SEP electroporation 
devices offer safe, tolerable and potent methods to administer 
HIV DNA vaccinations in a prophylactic clinical setting. Combined 
with the design of novel HIV consensus based Env antigens these 
DNA-EP combination vaccines are suitable for further HIV vaccine 
product development. 
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OA02.06 LB
Oral Immunization With A Recombinant Lactococcus 
Lactis Expressing HIV-1 Gag on the Tip of the Pilus 
Induces Strong Mucosal Immune Responses
V. Chamcha1, J.R. Scott1, R. Amara1
1Emory University, Atlanta, GA, USA
Background: The induction of a potent humoral and cellular 
immune response both in the peripheral and mucosal tissues is 
important for the development of an effective HIV vaccine. The 
present study explores the ability of a Lactococcus lactis (L. lactis), 
a probiotic organism, based oral vaccine to elicit HIV-specific 
immune responses in the mucosal and systemic compartments 
of mice and rhesus.
Methods: To express the HIV-1, Gag (p24) on the tip of the pilus, 
we made a fusion construct of Gag and Cpa protein of the type-3 
pilus found in Streptococcus pyogenes and expressed in L. lactis 
(rLL-Gag). Four monthly intragastric immunizations were given 
to the mice and macaques. In mice, we studied the humoral, 
cellular, and innate immune responses in mucosal and systemic 
compartments. In macaques, we completed analyses only on the 
cellular immunity.
Results: In mice, we observed a strong Gag specific IgG and IgA 
in serum, feces, and vaginal secretions following rLL-Gag oral 
immunizations. However, the Gag-specific CD8 T cell responses 
in the blood were at or below our detection limit. Following an 
intramuscular MVA/Gag boost, we observed a strong Gag-specific 
CD8 T cell responses both in systemic and mucosal tissue including 
IEL/LP of small intestine, peyer’s patches, and mesenteric lymph 
node. Consistent with immunogenicity, rLL-Gag induced a strong 
activation of CD8α+, CD11b+ DC in the peyer’s patches at 8 hours 
after oral immunization. Interestingly, the DC activation was not 
observed with L. lactis without the pilus. In rhesus macaques, 
vaccination with rLL-Gag elicited a strong Gag-specific CD4 T cell 
response both in the blood and rectum producing IL-2 and TNFα 
and moderate levels of IFNγ and IL-17. 
Conclusion: These results demonstrate that L. lactis expressing 
antigen on the tip of the pilus can serve as an excellent priming 
vector to induce a strong mucosal antibody and cellular immunity.
OA02.05
Eliciting Neutralizing Antibodies with gp120 Outer 
Domain
Y. Qin1, D.P. Han1, K. Takamoto2, M.W. Cho1
1Iowa State University, Ames, IA, USA; 2Albert Einstein College 
of Medicine, New York, NY, USA
Background: Although gp120 elicits strong antibody responses, 
it fails to induce broadly neutralizing antibodies (bnAbs). One 
strategy being evaluated is using immunogens based on gp120 
outer domain (gp120-OD). A number of gp120-OD constructs 
have been reported. However, none of them have been shown 
to induce potent nAbs. Here, we describe gp120-OD-based 
immunogens that can induce potent nAbs. 
Methods: We constructed gp120, gp120-OD, and a trimeric 
form of gp120-OD (ODx3) based on an M group consensus 
sequence. Proteins were expressed in 293 cells, and their 
antigenic properties were evaluated by immunoprecipitation 
using gp120 bnAbs (b12, 2G12 and 447-52D) and by surface 
plasmon resonance (SPR). Rabbits were immunized and antibody 
responses were characterized by ELISA and neutralization assays. 
Results: All three proteins were recognized by bnAbs b12, 2G12 
and 447-52D. SPR analyses indicated that b12 has lower affinity 
to gp120-OD compared to gp120 or ODx3, largely due to a faster 
dissociation rate. All immunogens induced potent nAbs against 
Tier 1 viruses from clades B, C and AE. Neutralizing activity 
against Tier 2 viruses was weaker and sporadic. The induction 
kinetic of nAbs by gp120-OD was slower than that for gp120 and 
ODx3. Although the V3 loop was a major target of nAbs, results 
suggested other epitopes are also targeted. A panel of about 100 
rabbit mAbs was generated, two of which exhibited neutralizing 
activity. One of them was molecularly cloned and sequenced. It 
exhibited a similar neutralization profile as the immune serum. 
Work is in progress to identify its epitope.
Conclusion: We have successfully generated OD-based 
immunogens that can induce nAbs. Although they were effective 
primarily against Tier 1 viruses, the breadth of neutralizing activity 
achieved is highly significant. Our trimeric ODx3 construct is novel 
and is a highly promising immunogen for further development of 
OD-based immunogen. 
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OA03.02
RV144-like Trial in Macaques Using ALVAC-SIV & 
gp120, Induces Innate Immunity and Increases the 
Frequency of NK22 & NKG2A+ Cells in Mucosal Tissues 
N.P. Liyanage1, P. Pegu1, S. Gordon1, M. Cameron2, K. Foulds3, 
M. Doster1, M. Vaccari1, R. Koup3, M. Roederer3, R. Sékaly2,  
G. Franchini1
1Animal Models & Retroviral Vaccines Section, Bethesda, MD, 
USA; 2Vaccine & Gene Therapy Institute -Florida, FL, USA; 
3Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA
Background: NK cells play a pivotal role in the innate immunity 
and patrol various tissues, including mucosal sites, the portal 
of entry of HIV. We recently reproduced in the SIV mac251- rhesus 
macaque (RM) model the limited protection reported in the 
RV144 HIV vaccine trial in humans (32% protection from HIV 
acquisition), using similar vaccines (ALVAC-SIV & gp120).
Methods: In here, we immunized, by the intramuscular route, 6 
RM with 108 PFU of ALVAC-SIV at weeks, 0 (V0), 4 (V2), and with 
both ALVAC SIV and the SIVgp120 envelope proteins, adjuvanted 
with ALUM at week 12 (V3) and 24 (V4) and analyzed the profile 
of gene expression at 24 hours after each vaccination. In parallel, 
we studied the phenotypical and functional changes in the NK 
cell subsets after vaccination by multi parametric flow cytometry.
Results: Microarray analysis in the PBMC after V1 and V2 showed 
the up regulation of anti viral (MX1, HERC-5) and IFN responsive 
genes and a down regulation of pro-inflammatory genes. 
Significant alteration in the gene expression profile was also 
observed after the gp120/Alum boost (V3). Interestingly, NK cells 
associated genes were up regulated after V3 vaccination. These 
finding paralleled our results observed by FACS analysis that 
demonstrated an increased frequency of NK22 cells at mucosal 
sites. These NK22 cells expressed CCR6 (a gut homing marker) 
and are thought to play a role in mucosal immunity. Similarly, 
vaccination also increased the frequency of NKG2A+ cells that 
were either cytotoxic (CD107a+) or cytokine producing (IFNg+).
Conclusion: Thus, the ALVAC SIV/gp120 vaccine regimen induces 
a significant activation of NK cells and other innate immune 
responses. Given that this vaccine platform has conferred some 
degree of protection from HIV infection in humans, understanding 
the role of innate immunity in protection from SIVmac251 may 
guide our effort in the development of novel vaccine strategies 
against HIV.
OA03.01
SIVΔnef Vaccination Mobilizes Systemic and Mucosal 
Natural Killer Cells in Mamu A*01+ Macaques
R. Reeves1, T. Evans1, J. Gillis1, M. Connole1, F. Wong1, Y. Yu1,  
R. Johnson1
1NEPRC, Harvard Medical School, Southborough, MA, USA
Background: Although vaccination with live attenuated SIV 
is the most effective means of inducing protection against 
lentiviruses, the immunologic mechanisms responsible remain 
unclear. Previous studies have yielded conflicting data regarding 
the role of adaptive immune responses in mediating protection, 
suggesting that innate immune responses, including natural 
killer (NK) cells, may play a role. 
Methods: Rhesus macaques were vaccinated with SIV∆nef and 
challenged with SIVmac239. Cellular dynamics were measured 
by polychromatic flow cytometry and absolute counts of 
lymphocytes in blood and rectal biopsies were determined by a 
bead-based, flow cytometry assay. 
Results: Following SIV∆nef vaccination, circulating NK cells 
increased 8-fold, peaking at 2 weeks post-vaccination and 
preceding SIV-specific T cell responses. Furthermore, the gut-
homing marker α4β7 was upregulated on circulating NK cells, 
coinciding with a 2.5-fold increase in NK cells in colorectal tissue. 
Ki67 expression was upregulated 2- to 5-fold in circulating, 
lymphoid, and mucosal NK cells. NK cell expansion was also 
stratified by MHC genotype — Mamu A*01+ macaques 
showed significant and sustained expansion of NK cells, but 
not Mamu A*02+ or Mamu B*17+ macaques. SIV∆nef also 
induced a significant expansion of KIR+ and cytotoxic NK cells 
in the colorectal mucosa. Interestingly, in vaccinated macaques 
challenged with wild-type SIV, α4β7 and Ki67 were both 
upregulated in circulating and mucosal NK cells, even in protected 
animals and in the absence of an obvious anamnestic response.
Conclusion: Although current lentiviral vaccines stress the 
importance of induction of SIV-specific T and B cell responses, 
NK cells could contribute to protection by inhibiting initial rounds 
of wild-type virus replication in the mucosa. Our data indicate 
SIV∆nef induces a robust and sustained expansion of NK cells 
that traffic to the gut mucosa, and that the protective SIV∆nef 
NK responses may be modulated, in part, by interaction of Mamu 
A*01 with an as of yet unidentified KIR. 
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OA03.04
Infiltration of Dendritic Cells and Antigen Uptake in the 
Muscle After Injection of HIV-1 Env gp120 in Adjuvant
F. Liang3, K.J. Sandgren3, H. Fausther-Bovendo 1, D. O’hagan2, 
A. Seubert2, E. De Gregorio2, S. Rao1, N. Sullivan1, R.A. Seder1, 
R.A. Koup1, K. Loré3
1Vaccine Research Center, NIH, Bethesda, MD, USA; 2Novartis 
Vaccines and Diagnostics, Cambridge, MD, USA; 3Karolinska 
Institutet, Stockholm, Sweden
Background: Most vaccines are delivered into the muscle 
although it contains very few potent antigen presenting cells, 
such as dendritic cells (DCs) that are critical for driving adaptive 
immune responses. Understanding the early mechanisms that 
dictate vaccine responses and why some adjuvants like the oil-in-
water emulsion MF59 are shown to be more potent than alum is 
important for the design of new vaccines. Here, we investigated 
the recruitment of immune cells to the vaccine injection site and 
uptake of a clinically relevant HIV-1 envelope glycoprotein (Env) 
and MF59 in a non-human primate (NHP) model.
Methods: Rhesus macaques received intramuscular injections 
of either fluorescently-labeled Env gp120 alone or together with 
MF59 in the deltoid and quadriceps muscles. Donor-matched 
injections of PBS and MF59 alone served as controls. At 24-72 hrs, 
blood, muscle and lymph nodes were sampled for flow cytometry 
and confocal microscopy. 
Results: There was a robust infiltration into the muscle of multiple 
immune cells by MF59+/-Env. CD66abce+ neutrophils were most 
frequent followed by CD14+ monocytes and CD11c+ myeloid DCs. 
CD123+ plasmacytoid DCs which do not normally reside in muscle, 
were also recruited by MF59. Internalization of Env and MF59 
was readily detectable in all DC subsets both in the muscle and 
in the draining lymph nodes. Although injection of Env alone did 
not lead to cell infiltration, the few resident DCs showed efficient 
Env uptake. Groups receiving Env together with distinctly different 
adjuvants (alum and TLR7 ligand) are underway. 
Conclusion: MF59 as an adjuvant leads to significant influx of cells 
that efficiently engulf vaccine protein antigen. Antigen/adjuvant 
carrying DC subsets appear early in the lymph nodes draining 
the injection site. As NHP DC subsets are similar to humans, this 
offers a powerful model that can yield data to be translated into 
optimizing future vaccine formulations and delivery strategies. 
OA03.03
Adenovirus Vectors from Various Serotypes Induce 
Distinct Cytokine Profiles
J.E. Teigler1, M. Iampietro1, D.H. Barouch1
1Division of Vaccine Research, Beth Israel Deaconess Medical 
Center, Boston, MA, USA
Background: Adenovirus (Ad) vectors from various serotypes 
which differ markedly in their basic biology are being pursued as 
candidate HIV vaccines. However, the innate immune responses 
elicited by different Ad vectors remain poorly characterized. We 
therefore evaluated cytokine responses to Ad vector stimulation 
both in vitro in human PBMC and in vivo following vaccination of 
rhesus monkeys.
Methods: Human PBMC were stimulated in vitro with 103 vp/
cell Ad5, Ad35, Ad26, Ad48, or Ad5/35 chimeric vectors. Rhesus 
monkeys were immunized with 3x1010 vp Ad5, Ad35, Ad26, Ad48, 
or Ad5HVR48. Cytokines in culture supernatant and serum from 
vaccinated monkeys were measured by luminex assays and ELISA.
Results: Ad35 and Ad26 induced higher levels of antiviral and 
proinflammatory cytokines (e.g. IFNα2, IFNγ, IL-1β) compared 
to Ad5 in human PBMC (p<0.01, Kruskal-Wallis test; Dunn’s 
correction). Replacement of Ad5 fiber with that of Ad35 (Ad5f35) 
increased cytokine induction, while Ad35f5 displayed decreased 
stimulation, indicating the importance of fiber-receptor 
interactions for innate immune stimulation. Similarly, monkeys 
vaccinated with Ad35 or Ad26 also displayed markedly higher 
levels of antiviral and proinflammatory cytokines compared to 
Ad5 on day 1 post-vaccination (p<0.05, Mann-Whitney U test). 
Conclusion: These data demonstrate that CD46-uilizing Ad35 
and Ad26 vectors induce profoundly different innate immune 
responses as compared to CAR-utilizing Ad5 vectors both in vitro 
and in vivo. These findings confirm that major biologic differences 
exist among Ad vectors and may help explain their different 
adaptive immune phenotypes.
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OA03.06 LB
Vaccination with MVA/HIV Induces Differential 
Recruitment of Monocyte Subsets Into The Circulation 
And Monocyte-Specific Transcriptional Programs
E. Andersen-Nissen1, D.E. Zak2, T.R. Hensley1, D.J. Adams1, X. Hu2, 
A. Sato1, M. Elizaga1, P.A. Goepfert3, H.L. Robinson4, A. Aderem2, 
M.J. McElrath1, The NIAID HIV Vaccine Trials Network1
1Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 
2Seattle BioMed, Seattle, WA, USA; 3University of Alabama, 
Birmingham, AL, USA; 4GeoVax, Smyrna, GA, USA
Background: Monocyte subpopulations are recruited from mar-
row to blood in response to infection and migrate into inflamed 
tissues to initiate adaptive immune responses. We sought to un-
derstand the effect of an MVA-vectored HIV vaccine on peripheral 
blood monocytes within the first week post-vaccination.
Methods: Volunteers were vaccinated with MVA/HIV62 gag/
pol/env (protocol HVTN 205/908); blood was collected pre-
vaccination and 1, 3, and 7 days post-vaccination. Serum cytokine 
analysis was performed (n=13). Monocytes were phenotyped by 
flow cytometry (n=14) and microarray transcriptional profiling 
was performed on freshly-sorted monocytes (n=7).
Results: MVA/HIV induced serum elevations of the monocyte 
chemoattractant CCL2, and seven proinflammatory cytokines at 
24 hours post-vaccination (p<0.001). Two waves of monocyte 
population changes occurred: concomitant with the rise 
in CCL2, CD14++ CD16- ‘classical’ monocyte concentrations 
increased at 24 hours post-vaccination (p=0.002). In contrast, 
CD14++CD16+ ‘intermediate’ and CD14+CD16++ ‘patrolling’ 
monocyte concentrations did not increase until 72 hours 
post-vaccination (p< 0.001). Vaccination induced expression 
of the activation markers CD86 and HLA-DR at the 72 hour 
timepoint on all subpopulations examined (p<0.01), indicating 
a phenotypic shift towards increased antigen presentation. 
Microarray analysis of sorted CD14+ monocytes (encompassing 
all three subpopulations) revealed that the majority of gene 
expression changes occurred at 24 hours (494 up- and 53 down-
regulated genes; FDR≤10% and average absolute log 2 (fold-
change) ≥0.5, including antigen-processing genes (PSMA2, 3, 
5), IL-6, and TLR-pathway genes (TLR1, LY96). Only 39 genes 
were up-regulated at 72 hours post-vaccination. 351/547 genes 
regulated at 24 hours were not observed in bulk PBMC profiles 
from the same individuals, indicating the value of early profiling 
of monocyte subpopulations.
Conclusion: These data provide the most detailed profile of the 
human in vivo monocyte response to an MVA poxviral vector to 
date. Analyses of transcriptional signatures that predict T-cell 
and antibody responses will enable the identification of innate 
immune response genes to target with future HIV vaccines.
OA03.05
Early Pro-inflammatory Host Response to Recombinant 
HSV-SIV Vaccination in Sooty Mangabeys 
N. Rout1, S. Yu1, V. Varner1, C. Kasala-Hallinan1, K. Rogers2, J. 
Sen3, D. Knipe3, F. Villinger2, A. Kaur1
1NEPRC-HMS, Southborough, MA, USA; 2YNPRC-Emory 
University, Atlanta, GA, USA; 3Harvard Medical School, Boston, 
MA, USA
Background: Naturally infected sooty mangabeys (SM) do not 
progress to AIDS unlike SIV-infected non-natural hosts including 
rhesus macaques (RM). Differences in the innate immune re-
sponse to SIV may be critical in avoidance of disease progression 
in SIV-infected SM. In this study we investigated innate and adap-
tive immune responses to recombinant HSV vectors expressing 
SIV Gag, Env, and a Rev-Tat-Nef fusion protein in six SIV-negative 
SM and four RM following single intramuscular inoculation. 
Methods: Plasma samples were analyzed using Luminex 28-plex 
assay. Innate immune cells and SIV-specific cellular immune 
responses were investigated by flow cytometry and IFN-γ 
ELISPOT assay. 
Results: A significant transient decline of circulating Natural 
Killer T (NKT) cells, pDCs, and NK cells was observed in SM on 
day one post vaccination, with a return to baseline levels by day 
3-7. Also an increased activation of SM NK cells was observed 
that returned to baseline by day 9. In contrast, RM displayed no 
significant change in circulating NKT cell and NK cell frequencies. 
Both RM and SM exhibited similar transient increases in plasma 
levels of several inflammatory cytokines/chemokines including 
IL-1RA, IFN-γ, IL-6, IL-8, macrophage migration inhibitory factor 
(MIF), monocyte chemotactic protein 1 (MCP-1), vascular 
endothelial growth factor (VEGF), and interferon-inducible T cell 
alpha-chemoattractant (I-TAC) by day one, suggesting activation 
of multiple immune cells including macrophages and DCs. By day 
14, plasma levels of analytes such as IL-6 and Eotaxin persisted at 
elevated levels in RM, but not SM, suggesting delayed resolution 
of immune activation in RM. SIV-specific cellular immune 
responses were detected in both species. 
Conclusion: These data confirm that SM mount a robust innate 
immune response and do not have blunted immune activation. 
Further investigation of the mechanism by which SM resolve 
the transient but higher immune activation would be helpful in 
improving vaccine strategy.
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OA04.02
Vaccine-Elicited Systemic and Mucosal Humoral 
Responses of Lactating Rhesus Monkeys Vaccinated 
with the Transmitted/Founder HIV Envelope 1086C
G. Fouda2, J. Amos2, A.B. Wilks1, A. Chand1, D. Montefiori2,  
B. Haynes2, N. Letvin1, D. Pickup2, H. Liao2, S.R. Permar2
1Beth Israel Deaconess Medical Center, Boston, MA, USA; 
2Duke University Medical Center, Durham, NC, USA
Background: We previously demonstrated that vaccination 
of lactating rhesus monkeys with a DNA prime/ vector boost 
strategy induces strong SIV-specific cellular immune responses, 
but limited Envelope-specific humoral responses in breast milk. 
Therefore, we sought to improve vaccine-elicited Envelope-
specific antibody responses in the milk compartment by using a 
transmitted/founder (T/F) HIV Envelope immunogen in a prime-
boost strategy modeled after that of the moderately-successful 
RV144 HIV vaccine trial.
Methods: Eight female, hormone-induced lactating rhesus 
monkeys were intramuscularly primed with either recombinant 
DNA (n = 4) or MVA pox virus vector (n = 4) expressing the T/F 
clade C HIV Envelope 1086C. All animals were intramuscularly 
boosted twice with the 1086C gp120 protein and the adjuvant 
MF59. Milk, vaginal, rectal and plasma samples were assessed 
for HIV Envelope-binding IgG and IgA responses. Anti-V1V2 
antibodies and neutralization responses were also measured in 
milk and plasma.
Results: Envelope 1086C-binding IgG responses were detected 
in plasma, milk, and vaginal samples of all vaccinated animals 
and two of four rectal samples from MVA-vaccinated animals. 
Moreover, anti-V1V2 IgG antibodies were detected in all 
plasma, but only one milk sample. Low magnitude Envelope 
1086C-specific IgA responses were detected in milk of two of four 
DNA-primed and three of four MVA-primed animals, but in none 
of the rectal samples. In contrast, all vaginal samples from MVA-
primed, but none from DNA-primed, animals had detectable 
Envelope-specific IgA. Remarkably, strong tier 1 and low to 
moderate tier 2 neutralization was detected in plasma and milk 
of each group. The plasma neutralization titers against MW965 
(clade C tier 1, p=0.03) and CAP45 (clade C tier 2, p=0.03) were 
significantly higher in MVA-primed than DNA-primed animals. 
Conclusion: MVA prime/ T/F Envelope protein boost strategy 
appears to induce stronger systemic and mucosal binding and 
neutralizing antibody responses than the DNA prime/protein 
boost regimen in lactating rhesus monkeys.
OA04.01
Immune Complexes Can Dampen Inflammatory 
Signaling at the Mucosal Surface During Protective 
SIV Vaccination
A.J. Smith1, S.W. Wietgrefe1, C.S. Reilly1, P.J. Southern1,  
L. Duan1, K.E. Perkey1, L. Shang1, R. Johnson2, A.T. Haase1
1University of Minnesota, Minneapolis, MN, USA; 2New 
England Primate Research Center, Southborough, MA, USA
Background: The long-term goal for an efficacious HIV vaccine 
is to provide sterilizing protection from HIV infection. Thus far, 
this scenario has only been achieved experimentally using live-
attenuated SIV vaccines. As such, great interest lies in identifying 
correlates of protection from a successful host response to 
pathogenic SIV. To this end, we have used a global genomics 
approach, tissue analysis, and explant cultures to identify 
immune complex (IC) signaling as an important component of a 
protective host response in the female reproductive tract (FRT) 
of animals vaccinated with the live-attenuated virus known as 
SIV mac239 ΔNef.
Methods: RNA from cervical tissue was purified for microarray 
analysis. Significant genes were functionally classified and protein 
expression determined using single-cell analytical procedures for 
tissue sections. FRT tissue was removed from healthy, uninfected, 
adult Rhesus macaques and cervix isolated/dissected into small 
tissue pieces for ex vivo culturing. WT SIVmac251 32H alone or 
SIV-specific ICs were added drop-wise to mucosal surfaces of 
explants and incubated for 24 hr at 37oC / 5% CO2. 
Results: A genome-wide transcriptomics analysis revealed 
selective enrichment of an anti-inflammatory program upon virus 
exposure in SIVmac239-∆Nef-vaccinated animals, with localized 
expression of these anti-inflammatory mediators in the mucosal 
epithelium of the FRT, coinciding with dampened inflammation, 
limited CD4+ T cell infiltration, and stunted virus replication. 
Explant cultures derived from the FRT of Rhesus macaques 
were used as a physiological platform to identify the inhibitory 
Fc receptor for IgG, FcγRIIB, and carbohydrates in the Fc portion 
of SIV-specific ICs as centrally important in mediating this anti-
inflammatory signaling program in mucosal epithelial cells.
Conclusion: These results highlight an unappreciated, non-
neutralizing role for antiviral antibodies at mucosal surfaces and 
implicates the mucosal epithelial cell as an important host sensor 
that integrates external signals to elicit a host program that either 
promotes (inflammatory) or suppresses (anti-inflammatory) 
immunodeficiency virus infection.
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OA04.04
Cell Free HIV-1 Virus Can Infect Inner and Outer 
Foreskin Polarized Explants
M.P. Lemos1, M.L. Perez1, J. Sanchez2, J. Lama2, S. Montano3,  
J. McElrath1
1Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 
2IMPACTA, Lima, Peru; 3Naval Medical Research Unit 6, Lima, Peru
Background: In sexually insertive men, HIV is predominantly 
transmitted at the penile surface. We report two mayor advances 
in the study of HIV infections at the foreskin. 
Methods: First, we have developed cryopreservation methods 
that allow infection of foreskin tissue explants after thawing 
(654 +/- 178.3 pg of p24/gr of tissue) and provide comparable 
infection rates to fresh samples( 716.5 +/- 446pg of p24/gr of 
tissue). Second, we have developed an ex vivo assay that uses 
human foreskin explants to replicate the polarized viral entry. 
After 12h of polarized exposure, HIV entering the explant 
is amplified for 6 days of culture with activated PBMCs and 
measured using p24 ELISA. 
Results: Preserving the epithelial barriers, we show that polarized 
infections permit the entry and expansion of less virus (68.28 +/- 
10.65pg of p24/gr of tissue) than non-polarized infections (650.4 
+/- 205.9pg of p24/gr of tissue) where the virus can enter the 
CD4 T cell rich epidermal-dermal interface (p=0.04). Using 10000 
TCID50 of HIV-1Bal per explants, we can detect infection in 100% 
of the non-polarized assays and 69% of the polarized explants. 
Lastly, comparing foreskin tissue from 4 donors, we demonstrate 
that the inner and outer foreskin are both equally able to support 
cell-free HIV infection in polarized assays (inner 77.67 +/- 64.7 vs. 
outer 92.82 +/- 66.81pg p24/gr of tissue p=0.369) and in non-
polarized assays (inner 730.9 +/- 323.7 vs. outer 625 +/ 301.2pg 
p24/gr of tissue p=0.41).
Conclusion: We hope that this approach could be used efficiently 
as a model to evaluate the efficacy of prevention strategies.
OA04.03
Expanded Memory CD4+ T Cells in the Fetal and the 
Infant Gut; a Mucosal Route for Mother-to-Child-
Transmission of HIV-1 
M.J. Bunders1, C. van der Loos1, P.L. Klarenbeek1, J. van Hamme1, 
J. Wilde1, N. de Vries1, R.A. van Lier1, N. Kootstra1, S.T. Pals1,  
T.W. Kuijpers1
1Academic Medical Centre, Amsterdam, Netherlands
Background: Cord blood-derived CD4+ T cells have a naïve 
phenotype and do not express CCR5, the mandatory co-
receptor for transmitted HIV-1 R5 strains in infants. This leaves 
the question unanswered: what are the target cells for MTCT of 
HIV-1 and where do they reside? We hypothesized that in infant 
mucosal tissues, CD4+CCR5+ T cells may be present to facilitate 
mucosal transmission of HIV-1.
Methods: Using multicolor immuno-histochemistry, flowcytometry 
and next-generation sequencing of the T cell receptor, we analyzed 
various human fetal and infant tissues to identify memory CD4+ T 
cells as targets for HIV-1.
Results: Here, we demonstrate the previously unrecognized 
abundance of memory CD4+CCR5+ T cells in the human fetal and 
infant gut mucosa. CD4+ T cells from mesenteric lymph node were 
mostly naïve, similar to blood. T helper differentiation profiles 
as determined by transcription factors differed by tissue, with 
T-bet and ROR_t predominantly expressed by memory T cells in 
the gut mucosa. Next-generation sequencing for high-resolution 
screening of the T-cell receptor _-chain repertoire of clonal T cells 
as a hallmark of memory cells, identified expanded T cell clones 
in the gut mucosa (30%) and not in lymph node or cord blood. 
The gut mucosal fetal and infant CD4+ T cells were extremely 
susceptible to HIV-1 without any prestimulation; pol proviral DNA 
levels were similar to infected PHA stimulated adult PBMCs. 
Conclusion: In conclusion, we show that extensive adaptive 
immunity, with a tissue-depended distribution is present before 
birth, resulting in the gut mucosa as the preferential site for 
memory CD4+ T cells. These memory CD4+CCR5+T cells provide 
a large pool of susceptible cells for ingested HIV-1 at birth and 
during breastfeeding, indicating a mucosal route of MTCT of HIV-
1, which can be targeted in future prevention strategies. 
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OA04.05
Inflammation in the Male Genital Tract: Implications 
for HIV Acquisition and Transmission
A.J. Olivier1, L. Roberts1, D. Coetzee2, A. Williamson1,  
J.S. Passmore1, W.A. Burgers1
1IIDMM, Division of Medical Virology, University of Cape 
Town, Cape Town, South Africa; 2Department of Public Heatlh, 
University of Cape Town, Cape Town, South Africa
Background: Elevated plasma levels of pro-inflammatory 
mediators such as TNFα, IL-1β, IL-6 and IL-8, MIP-1α, MIP-1β and 
RANTES have been demonstrated in HIV-infected individuals and 
HIV induces higher levels of pro-inflammatory cytokines in the 
female genital tract. We characterized levels of inflammation 
in semen, to gain an understanding of factors influencing 
transmission and acquisition in the male genital tract. Our 
hypothesis was that infected men would exhibit higher levels of 
inflammation in semen than uninfected men.
Methods: We investigated concentrations of 20 pro-inflammatory 
and other mediators in the semen and blood of 38 HIV-infected 
and 42 uninfected men forming part of an HIV-discordant 
heterosexual couples study. We measured plasma and seminal 
viral loads to examine the relationship between viral replication 
and inflammation.
Results: We found that the majority of cytokines/chemokines 
were at higher concentrations in semen than blood, both in 
HIV-infected and uninfected men. There were no significant 
differences between any cytokines/chemokines in the semen of 
HIV-infected vs uninfected men. We found that TNFα (p=0.013; 
r=0.55), G-CSF (p=0.0057; r=0.61), IL-10 (p=0.006; r=0.61) and 
IFNγ (p=0.01; r=0.57) seminal levels were significantly associated 
with increases in seminal viral load. Furthermore, subsequent to 
controlling for the effect of plasma viral load in a multivariate 
regression analysis, we found that both seminal IL-10 and IFNγ 
levels were associated with a significant rise in seminal viral load.
Conclusion: Taken together, the data demonstrate that the 
immune milieu of the genital tract differs substantially from 
blood, with the majority of cytokines/chemokines tested elevated 
in semen. However, there were no differences in the levels of 
pro-inflammatory mediators in the semen of HIV-infected and 
uninfected men, or HIV-infected men on suppressive ART. Thus, 
even in the absence of HIV infection, the male genital tract 
appears to maintain a state of inflammation, which may have 
been the result of undetected and untreated co-infections.
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OA05.02
An Assessment of Good Participatory Practice 
Guidelines at HIV Prevention Research Clinical 
Centers in Eastern and Southern Africa
B.P. Ngongo1, S. Hannah2, J. Mbogua1, M. Seyoum1, M. Warren2, 
E. Baas2, F. Priddy1
1International AIDS Vaccine Initiative, Nairobi, Kenya; 2AVAC, 
New York, NY, USA
Background: Compliance with ethical, regulatory, and scientific 
guidelines does not always guarantee consideration of external 
stakeholders’ concerns in research. In 2007, UNAIDS and AVAC: 
Global Advocacy for HIV Prevention developed the Good 
Participatory Practice (GPP) Guidelines to ensure community 
and stakeholder engagement in biomedical HIV prevention 
research. In 2010-2011, the International AIDS Vaccine Initiative 
(IAVI) and AVAC conducted the first comprehensive evaluation of 
perceptions, practices and recommendations for improvement 
of participatory practice at eight IAVI-sponsored research centers 
(RCs) in Eastern and Southern Africa. 
Methods: A total of 234 pre- and post-workshop questionnaires, 
20 focus group discussions (FGD), and nine interviews with 
research staff, community advisory board members and other 
stakeholders were administered by AVAC staff primarily, to 
eliminate potential bias. STATA11 and ATLAS.ti were used to 
analyze the quantitative and qualitative data respectively.
Results: Quantitative analysis showed a high level of baseline 
support regarding the relevance of 11 of 16 GPP focus areas. 
Lower relevance was placed at baseline on engagement in: 
protocol development, standards of HIV prevention, policies 
on non-HIV related harms, and trial accrual and follow-
up. Support increased for all 16 GPP areas post-workshop 
with statistical significance levels varying between p<0.05 – 
p<0.01. Preliminary findings from qualitative data revealed 
that stakeholder engagement in formative research, advisory 
mechanisms, and informed consent processes were considered 
effective at most RCs. Areas of needed improvement included 
communication and transparency of stakeholder engagement 
activities, formalized documentation of GPP practices, and 
funding for GPP activities at RCs. 
Conclusion: Findings suggest that evaluation workshops 
significantly increased RC buy-in of GPP relevance to research. 
Some GPP areas may require more emphasis than others in 
future evaluations and technical assistance. On-site participatory 
GPP evaluations were highly effective in identifying strengths 
and gaps, increasing ownership, and facilitating ease of GPP 
implementation for research centers.
OA05.01
New Tools to Measure Community and Stakeholder 
Engagement and Its Impact on Outcomes of Clinical 
Research
P. Bahati1, S. Hannah2, S. Seidel3, S. Aggett4, R. Siskind5, R. 
Campbell6, S. Williams5, A. Downie7, S. Rosas8
1International AIDS Vaccine Initiative, Nairobi, Kenya; 2AVAC, 
New York, NY, USA; 3Global Alliance for TB Drug Development, 
New York, NY, USA; 4Wellcome Trust, London, United Kingdom 
(Great Britain); 5National Institute of Allergy and Infectious 
Diseases, USA; 6Fred Hutchinson Cancer Research Center, 
USA; 7International HIV/AIDS Alliance, United Kingdom (Great 
Britain); 8Concept Systems, Ithaca, NY, USA
Background: Community and stakeholder engagement have 
increasingly been acknowledged as best practice in the 
design and implementation of global clinical research, results 
dissemination and strategies for access to new health products. 
Existing guidelines and best practices, however, provide little 
insight into the expected outcomes of engagement activities, 
indicators of success, or useful monitoring and evaluation (M&E) 
tools for assessing impact on research and communities.
Methods: To fill this gap, a consortium of organizations (AVAC, 
HANC, International HIV/AIDS Alliance, IAVI, NIAID, TB Alliance 
and Wellcome Trust), developed and field tested a user-friendly 
M&E Toolkit for engagement programs in clinical research 
settings in developing countries. From a broad review across 
clinical trial settings, the toolkit builds on existing practices and 
introduces new methods for M&E, indicators for impact and 
guidelines for effective use. The toolkit was piloted with TB and/
or HIV research sites in Africa and Asia that have a history of 
incorporating engagement strategies in research.
Results: New indicators for measuring the degree of engagement 
and its impact on clinical research were identified. Participants 
in pilot-testing utilized existing and new methods of evaluation, 
and assessed the relationship of these strategies on targeted 
outcomes of clinical research. Feedback and lessons learned are 
being incorporated into a final version of the M&E Toolkit.
Conclusion: Understanding the impact of stakeholder 
engagement on clinical research is critical for the development 
and implementation of effective strategies, and for planning 
and optimizing clinical trials and their outcomes in developing 
countries. Through the use of the toolkit site and sponsor staff 
can better evaluate strategies and activities, demonstrate benefit, 
reallocate resources to activities that were most productive, and 
make the case for engaging stakeholders in research.
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OA05.04
Knowledge/Attitude/Practices of HPV & Cervical 
Cancer, Willingness to Participate in Vaccine Trial in 
Preparation For HIV & HPV Vaccine Trials in Mali
D. Poole1, K. Tracy2, L. Levitz3, S. Yekta3, E. Kossow3, T. Huang3, 
M. Rochas3, K. Sangare4, K. Tounkara5, B. Aboubacar5,  
O. Koita4, F. Siby Diallo6, S. Sow7, I. Téguété8, A. Dolo8,  
F. Bougoudogo9, M. Lurie1, A.S. De Groot10
1Brown University, Providence, RI, USA; 2University of 
Maryland, College Park, MD, USA; 3GAIA Vaccine Foundation, 
Providence, RI, USA; 4University of Bamako, Bamako, Mali; 
5Fondation GAIA Mali, Bamako, Mali; 6Direction Regionale 
de la Sante, Bamako, Mali; 7Center for Vaccine Development, 
Bamako, Mali; 8Hopital Gabriel Touré, Bamako, Mali; 9Institut 
National pour la Santé Publique, Bamako, Mali; 10GAIA Vaccine 
Foundation, University of Rhode Island, Providence, RI, USA
Background: The GAIA Vaccine Foundation (GAIA VF) has been 
collaborating with the Malian regional DOH, local HIV clinicians, 
and scientists in Bamako to prepare a site for Phase I-III HIV 
vaccine trials. We recently performed two studies to evaluate 
HIV and HPV knowledge and willingness to participate (WTP) in 
an HIV or HPV vaccination trial.
Methods: Knowledge, Attitudes, and Practices (KAP) studies 
were performed in 2008 and 2011 to assess KAP related to HIV, 
HIV transmission, HIV prevention, HPV, cervical cancer, and WTP 
in vaccine trials. The 2008 KAP study examined HIV KAP and WTP 
(399 subjects), while the 2011 pilot study examined HPV KAP and 
WTP for 51 subjects in the same region of Bamako. Results from 
a more extensive HPV KAP (300 participants) are pending.
Results: HIV knowledge was high: over 73% of participants 
in the 2008 study were knowledgeable about modes of HIV 
transmission. 78% said they would participate in an HIV vaccine 
trial, 65% in a malaria vaccine trial, and 61% in a tuberculosis 
vaccine trial. In contrast, in 2011, less than 1% of individuals 
had heard of HPV. Yet 98% of participants were WTP in an HPV 
vaccine trial with the aim of obtaining approval of the vaccine in 
Mali.
Conclusion: WTP in vaccine trials is high among participants in 
these West African surveys. In previous African KAP and WTP 
studies, WTP ranged from 20% to 77% (average 47%). Even 
though participants were highly willing to participate in an 
HPV vaccine trial, levels of knowledge were very low. There is 
a significant need for expanded public education about the 
link between viruses and infection in West Africa. This study 
demonstrates challenges in implementing ethical clinical trials 
and highlights the need for a significant investment in health 
education if truly informed consent is to be obtained.
OA05.03
Social and Ethical Considerations in Engaging 
American Indian and Alaska Native Communities in 
HIV Clinical Research 
J. Velcoff1, D.L. Humes1, R. Foley2, M. Ignacio2
1Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 
2National Native American AIDS Prevention Center, Denver, 
CO, USA
Background: American Indians and Alaska Natives (AI/AN) have 
the 4th highest rate of new HIV diagnoses among racial/ethnic 
groups and the highest mortality rate after an AIDS diagnosis 
(CDC, 2012), yet continue to be underrepresented in HIV 
clinical research trials due to historical and cultural factors. This 
presentation will highlight social and ethical experiences that 
contribute to mistrust of Western research and medicine and low 
involvement in HIV clinical research trials, and provide effective 
strategies for respectfully engaging Native communities. 
The presentation will also describe the Native American 
Engagement in HIV Clinical Research (NAEHCR) project, a 
pilot aimed at increasing awareness and engagement in HIV 
clinical research with urban Indigenous communities using a 
participatory framework. NAEHCR was developed in partnership 
between the National Native American AIDS Prevention Center 
and the Legacy Project. NAEHCR is currently being conducted 
with DAIDS-funded research sites in Seattle, USA (HVTU, ACTU) 
and Denver, USA (HVTU, INSIGHT). 
Methods: Formative research assessed awareness, barriers, 
and facilitators of involvement in HIV clinical research using 
qualitative and quantitative methods. Focus groups were 
held with Native advisory boards to explore perceptions and 
experiences with clinical research. Individual interviews were 
conducted with clinical research site staff to assess perceptions 
and experiences with AI/AN communities. Surveys used to assess 
AI/AN community members’ awareness and experiences around 
clinical research. 
Results: Initial results indicate high levels of interest in the project 
among AI/AN community members and clinical research staff. 
Results also indicate low levels of awareness and engagement 
in HIV clinical research among the AI/AN community and a 
disconnect between the AI/AN community and HIV clinical 
research sites.
Conclusion: Using a multi-method participatory approach offers 
a holistic depiction of barriers, opportunities for engagement, 
and important considerations when engaging AI/AN communities 
in HIV clinical research given the social and ethical legacy of 
research conducted in AI/AN communities.
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OA05.05
Referral and Access to Care of HIV Prevalent Cases; 
Experience from the Early Capture HIV Cohort Study 
in Kampala
L.N. Mutengu1, H. Kibuuka1, M. Millard 1, A. Sekiziyivu 1,  
S. Wakabi1, J. Nanyondo1, G. Kawooya1, M. Robb2, N. Michael2
1Makerere University Walter Reed Project, Kampala, Uganda; 
2US Military HIV Research Program, Rockridge, MD, USA
Background: Trial sponsors and implementers are ethically 
obligated to refer HIV infected Individuals identified in a research 
study at screening for HIV care and treatment. Makerere 
University Walter Reed Project is conducting HIV surveillance 
among high risk uninfected female sex workers. We describe 
patterns in participants’ receipt of HIV results and response to 
referral for HIV care and treatment. 
Methods: Subsequent to informed consent, risk eligibility is 
determined using Audio Computer Assisted Self Interview 
(ACASI). Medical history, physical exam and blood draw are 
done to determine HIV sero-status and further eligibility. 
Participants determined HIV positive by ELISA/Western Blot 
require confirmatory testing before being screened out and 
referred for care. 
Results: HIV prevalence was 35% (221/631) at screening. Out 
of the 221 prevalent cases, only 96 participants (43%) received 
HIV confirmatory results and were referred for care, while 9(4%) 
declined referral. The majority did not return for either their initial 
or confirmatory HIV result; while a few declined a blood re-draw. 
Of the 96 participants referred, 58% are currently in care, 14% did 
not report for care predominately citing indecisiveness while 28% 
could not be tracked. Majority of acutely infected participants 
(6/8) are in care.
Conclusion: Although trial implementers may fulfil their 
obligation in referring study participants for HIV care, participants 
have a key role to play in facilitating this process. The large 
number of HIV prevalent female sex workers who did not return 
for their HIV results and may not be aware of their status could 
be a potential driver of the epidemic in Uganda.
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OA06.02
Characterization of V1V2-Specific Antibodies Present 
in Broadly Neutralizing Plasma Isolated from HIV-1 
Infected Individuals
C. Krachmarov1, K. Revesz1, R. Prattipati1, C. Reichman1, Z. Lai1, 
W. Honnen1, B. Li2, C. Derdeyn2, A. Pinter1
1Public Health Research Institute/UMDNJ, Newark, NJ, USA; 
2Emory Vaccine Center, Atlanta, GA, USA
Background: Recent studies of antibodies in human plasma from 
infected and immunized individuals revealed an important role 
of the V1V2 region of the gp120 protein in immune response. 
The function of V1V2-specific antibodies and their potential 
in blocking the HIV-1 infection are still not well established. 
In this study we present data about the appearance of such 
antibodies in plasma from hundreds of patients from North 
America and Africa, about their clade specificity, development 
and neutralization activity.
Methods: Human plasma was isolated from infected individuals 
and screened for anti V1V2 ELISA binding activity with gp70/
V1V2 fusion glycoproteins, representing clades B, C and A/E 
sequences. All samples were tested in virus neutralization 
assay for activity versus panel B, panel C, and other Tier 2, 
pseudoviruses. Immunoaffinity chromatography of selected 
plasma, on gp70/V1V2 protein columns, was used to isolate 
V1V2-specific antibodies.
Results: Most of the HIV-1 infected subjects (above 80%) have 
robust levels of V1V2 binding activity versus the three antigens. 
This activity was commonly detected in chronic HIV-1 infection. 
Interestingly, the development of V1V2-reactive antibodies 
tracked with the development of autologous neutralizing 
antibodies. Immunoaffinity purified V1V2-specific antibodies 
from selected broadly neutralizing plasma samples possessed 
broad neutralization activity with IC50’s generally in the 1 -20 
µg/ml range. 
Conclusion: Highly cross-reactive V1V2-specific Abs are present 
in almost all broadly neutralizing human plasmas. These 
antibodies are in large amounts and can be linear, conformational 
or quaternary epitope dependent. Such antibodies are induced 
in humans (Thailand trial) and because of that the region may 
be considered as immunogenic. In addition, isolated anti-V1V2 
antibodies show neutralization activity toward Tier 2 viruses. The 
above characteristics make the V1V2 region an important target 
for candidate HIV-1 vaccines.
OA06.01
A Short Segment in the HIV-1 gp120 V1/V2 Region Is 
a Major Determinant of Neutralization Resistance to 
PG9-Like Antibodies
N.A. Doria-Rose1, I. Georgiev1, R.P. Staupe1, S. O’Dell1,  
G. Chuang1, J. Gorman1, J.S. McLellan1, M. Pancera1,  
M. Bonsignori2, B.F. Haynes2, D.R. Burton3, W.C. Koff4,  
P.D. Kwong1, J.R. Mascola1
1National Institutes of Health, Bethesda, MD, USA; 2Duke 
University, Durham, NC, USA; 3The Scripps Research Institute, 
La Jolla, CA, USA; 4International AIDS Vaccine Initiative, New 
York, NY, USA
Background: Antibody PG9 is a prototypical member of a class 
of V1/V2-directed antibodies that effectively neutralizes diverse 
strains of HIV-1. The crystal structure of PG9 bound to scaffolded 
V1/V2 has provided insight into its mode of recognition. We 
sought to gain a more complete understanding of the interaction 
of PG9 with the functional viral spike, and to extend our 
understanding to other antibodies of this class.
Methods: We analyzed amino acid frequencies in the V2 region 
of PG9 sensitive and resistant strains to identify potentially 
important residues. We also used the crystal structure of PG9 
with scaffolded V1/V2 to identify potential contact sites. Based 
on these analyses we designed mutations in PG9 resistant 
strains with the goal of “knocking in” sensitivity. Parent and 
mutant Envs were used to make pseudoviruses. The potency 
of PG9 as well as V1/V2 antibodies PG16, CH01, CH04, PGT141, 
and PGT145 against the pseudoviruses was assessed by TZM-bl 
neutralization assay.
Results: For 20/20 of resistant strains, mutations in a short 
segment of V1/V2 resulted in gain of sensitivity to at least one 
antibody of the PG9 class, and 13/20 showed gain of sensitivity 
to 3 or more. Mutations in V2 strand C, particularly the addition 
or substitution of lysine at positions 168, 169, or 171, had the 
greatest effects.
Conclusion: These results highlight the importance of strand 
C contacts for neutralization by V1/V2 antibodies, provide 
functional confirmation of the crystal structure, and suggest a 
general mechanism of resistance to V1/V2-directed broadly 
neutralizing antibodies.
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OA06.04
Evidence for Env-V2 Sieve Effect in Breakthrough SIV 
MAC251 Infections in Rhesus Monkeys Vaccinated with 
Ad26/MVA and MVA/Ad26 Constructs
S. Sina2, S. Tovanabutra2, E. Sanders-Buell2, A. Bates2, M. Bose2, 
S. Howell2, G. Ibitamuno2, M. Lazzaro2, A. O’Sullivan2, J. Lee2,  
T. Cervenka2, J. Kuroiwa2, K. Baldwin2, D.H. Barouch1, M. Robb2, 
R. O’Connell2, N.L. Michael2, J.H. Kim2, M. Rolland2
1BIDMC, Harvard Medical School, and Ragon Institute, Boston, 
MA, USA; 2U.S. Military HIV Research Program/Henry M. 
Jackson Foundation, Bethesda, MD, USA
Background: We had previously shown that rhesus monkeys 
receiving Ad26/MVA and MVA/Ad26 vaccines expressing 
SIVSME543 were protected against SIVMAC251 challenge 
(doi:10.1038/nature10766). Protection was associated with 
Env-specific binding ELISA antibody responses, including V2-
specific antibodies.
Methods: We amplified 66 sequences from the SIV MAC251 challenge 
stock, and 409 near-full length genomes from 13 vaccine and 
13 control monkeys. A series of pre-specified phylogenetic and 
statistical tests for sieve effects was performed. 
Results: The mean pairwise AA diversity among the 66 SIVMAC251 
Env sequences was 0.38%, and they differed from the vaccine 
strain SIV SME543 (Env) by 21.94%. The repeated low-dose challenge 
resulted in infections with an average of 1.7 founder variants 
- with no evidence that the vaccine restricted the number of 
variants (p = 0.813). We explored whether the vaccine induced a 
sieve effect, i.e. whether breakthrough viruses differed between 
the vaccine and control groups. There was no difference for full-
length Env sequences. Focusing on Env segments preferentially 
recognized by vaccinated monkeys in antibody arrays, we 
identified a sieve effect in the Env-V2 segment AA163-193: 
sequences from vaccinated animals were more divergent from 
the vaccine SIVSME543 or from the challenge stock SIVMAC251 than 
sequences in control animals (p ≤ 0.002).
Conclusion: The sieve effect in Env-V2, combined with Env-V2-
specific binding antibodies identified as a correlate of protection 
against SIV MAC251 acquisition in the study, provide evidence 
supporting the importance of protective responses directed 
against the Env-V2 region. 
OA06.03
Design of an HIV Env Antigen That Binds with High 
Affinity to Antibodies Against Linear, Conformational 
and Broadly Neutralizing Epitopes Within V1/V2
L. Liao1, M. Bonsignori1, K. Hwang1, A.M. Moody1, R. Park1,  
S. Crawford 1, H. Chen1, T.L. Jeffries1, M. Cooper1, X. Lu1,  
R. De1, N. Karasavvas2, S. Rerks-Ngarm3, S. Nitayaphan4,  
J. Kaewkungwal5, S. Tovanabutra2, P. Pitisuttithum6,  
J. Tartaglia7, F. Sinangil8, J. Kim2, N.L. Michael2, G.D. Tomaras1, 
Z. Yang9, K. Dai9, M. Pancera9, G.J. Nabel9, J.R. Mascola9,  
P.D. Kwong9, A. Pinter10, S. Zolla-Pazner911, M.S. Alam1,  
B.F. Haynes1
1Duke University Medical Center, Durham, NC, USA; 2U.S. 
MHRP, Walter Reed Army Institute of Research, Silver Spring, 
MD, USA; 3Department of Disease Control, Ministry of Public 
Health, Nonthaburi, Thailand; 4Department of Retrovirology, 
US Army Medical Component, AFRIMS, Bangkok, Thailand; 
5BIOPHICS, Faculty of Tropical Medicine, Mahidol University, 
bangkok, Thailand; 6Faculty of Tropical Medicine, Mahidol 
University, Bangkok, Thailand; 7Department of Research and 
Development, Sanofi Pasteur, Swiftwater, PA, USA; 8Global 
Solutions for Infectious Diseases, South San Francisco, CA, 
USA; 9Vaccine Research Center/NIH, Bethesda, MD, USA; 
10Public Health Research Institute Center, New Jersey Medical 
School, Newark, NJ, USA; 11Veterans Affairs New York Harbor 
Healthcare System, Manhattan Campus, New York, NY, USA
Background: The RV144 HIV-1 vaccine trial showed protection 
from HIV-1 acquisition with vaccine efficacy of 31.2%. Study of 
the immune correlates demonstrated an inverse association of 
V1/V2 antibodies with infection risk. A key task for HIV-1 vaccine 
development is to improve the level of efficacy seen in the RV144 
trial with subsequent vaccine designs. 
Methods: E.A244 V1/V2 Env tags contains an N-terminal Ig 
leader sequence and C-terminal Avi- and His6-tags linked to 
the V1/V2 domain, was expressed in 293F cells and purified by 
nickel column. Binding of Tier 1 neutralizing mAb CH58 from 
RV144 vaccinees, V2 conformational mAb 697D and broadly 
neutralizing antibodies (bnAb) CH01 and PG9/PG16 to 33 HIV-1 
gp140/gp120s and 12 HIV-1 V1/V2 scaffold Envs was tested by 
ELISA and surface plasmon resonance.
Results: Among 45 HIV-1/SIV Envs tested, E.A244 V1/V2 tags and 
E.A244 gp120Δ11 Env were the only Env antigens recognized by 
all three types of mAbs: CH58, 697D, and bnAbs CH01, and PG9/
PG16. E.A244 V1/V2 tag bound CH58 with a Kd of 0.33 nM and 
697D with a Kd of 117 nM. Although PG9 preferentially recognizes 
trimers, PG9 bound well to both E.A244 gp120Δ11 (Kd = 47.3) and 
E.A244 V1/V2 tags (Kd = 83.3 nM). BnAb CH01 bound V1/V2 tags 
as well (Kd = 334 nM). E.A244 V1/V2 Env tags was also recognized 
by the unmutated ancestor antibodies (UAs) of CH58 with ELISA 
EC50 = 4.9 nM and CH01 with EC50 = ~1μM. E.A244 V1/V2 tags 
and AE.gp70 V1/V2 scaffold were the best recombinant Envs for 
detection of plasma V1/V2 antibodies in RV144 vaccinees. 
Conclusion: Recombinant E.A244 V1/V2 Env tags Env expresses 
linear as well as conformational determinants recognized by 
V1/V2 mAbs and some of their UAs. This V1/V2 construct is a 
candidate immunogen to target RUAs and intermediate ancestors 
of V1/V2 antibodies to drive their induction. 
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OA06.05 LB
Structural Basis for Germline Gene Usage of a Potent 
Class of Antibodies Targeting the CD4 Binding Site of 
HIV-1 gp120
A.P. West, Jr.1, R. Diskin1, M.C. Nussenzweig2, P.J. Bjorkman3
1California Institute of Technology, Pasadena, CA, USA; 2The 
Rockefeller University/Howard Hughes Medical Institute, New 
York, NY, USA; 3California Institute of Technology/Howard 
Hughes Medical Institute, Pasadena, CA, USA
Background: A large number of anti-HIV-1 antibodies targeting 
the CD4 binding site (CD4bs) on gp120 have recently been 
reported. These antibodies, typified by VRC01, are remarkable 
for both their breadth and potency. Crystal structures have 
revealed a common mode of binding for several of these 
antibodies; however, the precise relationship among CD4bs 
antibodies remains to be defined.
Methods: We analyze existing structural and sequence data, 
propose a set of signature features for potent VRC01-like 
(PVL) antibodies, and test the importance of these features 
by mutagenesis. 
Results: A group of highly potent CD4bs antibodies, previously 
isolated from 5 different individuals, all derive from the human 
VH1-2 gene segment and share a set of characteristic residues, 
including W50, N58, R71, and W100B. Mutagenesis studies 
on a half-germline version of a VRC01-like antibody confirm 
that these signature residues are critical for gp120 binding. 
Neutralization assays with viruses mutated at sites that contact 
these critical antibody residues also confirm the significance of 
these interactions.
Conclusion: The signature features explain why PVL antibodies 
derive from a single germ-line human VH gene segment and 
why certain gp120 sequences are associated with antibody 
resistance. This analysis also suggests that immunization 
experiments to elicit VRC01-like antibodies may be problematic 
in mice or rabbits since they lack germ-line VH genes with all the 
critical residues. Our results bear on vaccine development and 
structure-based design to improve the potency and breadth of 
anti-CD4bs antibodies.
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OA07.02
Isolation of a Clonal Lineage of IgA Broadly 
Neutralizing Antibodies from a Chronically Infected 
Tanzanian Subject
M. Moody1, M.S. Drinker1, T.C. Gurley1, J.D. Amos1, J.A. Eudailey1, 
L.C. Armand1, R. Parks1, E.S. Gray2, L. Morris2, A. Finzi3, X. Yang3, 
J. Sodroski3, H. Liao1, G.D. Tomaras1, D.C. Montefiori1,  
B.F. Haynes1
1Duke University Medical Center, Durham, NC, USA; 2National 
Institute for Communicable Disease, Johannesburg, South 
Africa; 3Dana-Farber Cancer Institute, Boston, MA, USA
Background: Only ~20% of HIV-1-infected subjects develop 
broadly neutralizing antibodies (bnAbs) and the origins of such 
antibodies remains obscure. To date, all isolated bnAbs have been 
of the IgG isotype.
Methods: Memory B cells from a chronically infected Tanzanian 
subject with plasma broad neutralizing activity were labeled with 
a consensus C envelope (Env) and Env+ cells sorted as single cells. 
Immunoglobulin heavy and light chain genes were amplified by 
PCR and analyzed for gene usage and isotype, and then were 
expressed as recombinant monoclonal antibodies (mAbs). MAbs 
were assayed for binding to Env proteins and for neutralization 
of multiple HIV-1 strains.
Results: We isolated 13 mAbs that bound Env proteins; of these, 
11 were members of three clonal lineages, each of which spanned 
two time points. Six mAbs in one lineage were all IgG1, used V H 
1~69, had an average mutation frequency of 12%, mapped to the 
CD4 contact region, and had modest neutralization activity. In 
contrast, three mAbs in a second lineage had two members that 
were IgA2, used VH3~66, had an average mutation frequency of 
16%, and neutralized 11/27 (41%) of tier 2 pseudoviruses tested.
Conclusion: We have isolated the first natural IgA mAbs with 
broad neutralizing activity. These data demonstrate that class 
switching to IgA can occur in the generation of bnAbs, an event 
that is essential for the generation of neutralizing IgA antibodies 
at mucosal surfaces.
OA07.01
Structure-Guided Modification and Optimization of 
Antibody VRC07 
Y. Kwon1, I. Georgiev1, S. O’Dell1, W. Shi1, G. Chuang1, Y. Yang1, 
B. Zhang1, J. Zhu1, G.J. Nabel1, J.R. Mascola1, P.D. Kwong1
1National Institutes of Health, Kensington, MD, USA
Background: Eliciting a neutralizing human antibody against 
HIV-1 still remains to be elusive. Nevertheless, a number of 
studies have reported isolation of potent and broadly reactive 
antibodies against HIV-1 from HIV-1 infected patient serum. 
Antibody VRC01 is one of these kinds that binds to the CD4 
binding site of gp120 and neutralizes the viruses. Recently, we 
identified antibody VRC07, which is more potent and broadly 
reactive anti-HIV-1 antibody than its derivative, VRC01.
Methods: In this study, we determined the crystal structure of 
gp120 in complex with VRC07 and utilized mechanistic insights and 
structure-guided modification to increase potency and breadth.
Results: A four amino acid insertion in the CDR H3 loop of 
VRC07 provided for more extensive contacts with gp120 than 
with VRC01. The structure also revealed that residue Gly54 of 
VRC07 could be replaced with amino acids with bulky side chains 
to mimic residue Phe43 of CD4. Indeed, all VRC07 variants, 
in which Gly54 was replaced with Arg, Leu, Phe, Trp, or Tyr, 
showed enhanced affinity to a panel of different HIV-1 gp120s. 
Furthermore, most of these Gly54 alterations showed enhanced 
potency and breadth against a panel of clade B and C viruses in 
TZM-bl cell-based neutralization assay. Crystal structures of gp120 
in complexes with these VRC07 Gly54 variants confirmed that 
their side chains mimicked Phe43 of CD4. Computational analysis 
of the VRC07-gp120 interface in the crystal structure identified 
residues Ile30 and Ser58 as likely targets for improvement (with 
Gln and Asn, respectively). These changes introduced additional 
hydrogen bonds to the VRC07-gp120 interfaces and further 
enhanced VRC07 potency.
Conclusion: Thus, our optimization of antibody VRC07 
demonstrated that a structure-guided approach can be used to 
increase both antibody potency and breath. The optimized VRC07 
developed here can be used as the basis for further structure-
guided improvement or for optimization via in vitro selection.
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OA07.04
Antibody Effector Function Is Regulated by a 
Combination of Adaptive and Innate Signals
A. Mahan1, K. Dionne2, J. Eusebio2, G. Alter2
1Harvard University, Charlestown, MA, USA; 2Ragon Institute, 
Charlestown, MA, USA
Background: The Fc region of IgG contains a single N-glycosylation 
site, which is known to be important for effecting immune 
activation through interaction with Fc receptors and complement 
molecules. Changes to the structure of these sugars can thus be 
very influential in determining the specific effector function of 
individual antibodies. Whereas therapeutic antibodies can be 
produced with particular effector functions in vitro, little is known 
regarding how glycosylation is regulated in primary B cells.
Methods: Purified B cells were stimulated with a variety of 
synthetic TLR ligands alone or in combination with soluble CD40L, 
anti-IgG, anti-IgM, or supernatants derived from stimulated 
antigen presenting cells. After 16 hours, quantitative RT-PCR was 
used to determine expression of genes known to be specifically 
involved in IgG N-glycan synthesis.
Results: We found that the expression of glycosylation genes 
is significantly impacted both by specific TLR stimulation alone 
and in combination with adaptive signals received either 
through the B cell receptor or CD40. Specifically, virus-derived 
stimuli that activate TLR 7, 8 or 9 can significantly decrease 
the expression of galactose adding enzymes, whereas TLR 9 
stimulation in combination with CD40 stimulation decreases 
the expression of both sialic acid– or GlcNac-adding enzymes. 
These changes in expression result in the production of 
antibodies with Fc glycan structures with increased NK cell– 
and monocyte-recruiting capabilities.
Conclusion: Overall, these results are the first to show that the 
production of antibodies with specific effector functions can be 
regulated by external stimuli, including both innate and adaptive 
immune signals, suggesting that antibodies with specific, strong 
effector functions can be induced in vivo following vaccination.
OA07.03
Deep Sequencing with Longitudinal Sampling of 
a VRC01-Like-Antibody Response in a Chronically 
Infected Individual
Z. Zhang1, X. Wu2, N. Longo2, B. Zhang2, J. Zhu2, C. Nisc 3,  
J.C. Mullikin3, L. Wu2, G.J. Nabel2, M. Connors4, P.D. Kwong2, 
J.R. Mascola2, L. Shapiro1
1Columbia University, New York, NY, USA; 2Vaccine Research 
Center, NIAID, NIH, Bethesda, MD, USA; 3National Human 
Genome Research Institute, Bethesda, MD, USA; 4National 
Institute of Allergy and Infectious Diseases, NIH, Bethesda, 
MD, USA
Background: VRC01-like antibodies use heavy chain mimicry of 
the CD4-receptor to achieve effective neutralization of HIV-1. The 
VRC01-like antibodies that have been observed in a number of 
HIV-1-infected individuals (i) display extensive somatic changes 
(70-100 nucleotide changes in VH-gene), (ii) can be detected only 
after several years of infection, (iii) derive from VH1-2, and (iv) 
are compatible with several different heavy J chains and different 
light chains. 
Methods: To understand the persistence, evolution, and lineage 
of VRC01-like antibodies, we sampled PBMCs from donor 45, 
the source of VRC01 and VRC03 antibodies, at approximately 
yearly intervals over a 15-year period, and performed deep 
sequencing on the heavy and light chain variable portions of 
expressed antibodies. Anti-idiotypic antibodies were used to 
correlate mRNA levels of antibodies identified by the deep 
sequencing with expressed levels of these antibodies in serum. 
Results: High expression levels of VRC01-like antibody 
sequences persisted over the entire 15-year period. Multiple 
lineages of VRC01-like antibodies were detected at each 
time point, and some of these, in particular the lineages 
that include VRC01 and VRC03, persisted over multiple time 
points, and displayed extensive branching in their evolution.
Conclusion: Deep sequencing provides a means to define the 
genetic record of the lineage and maturation of antibodies 
effective at neutralizing HIV-1. Precise definition of the natural 
ontogeny of broadly neutralizing antibodies may be essential 
in defining appropriate strategies to elicit such antibodies in 
vaccine settings.
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OA07.06
Vaccine-Induced ADCC-Mediating Antibodies Target 
Unique and Overlapping Envelope Epitopes 
J. Pollara1, M. Bonsignori1, M. Moody1, M. Alam1, H. Liao1,  
K. Hwang1, J. Pickeral1, J. Kappes2, C. Ochsenbauer2,  
K. Soderberg1, T.C. Gurley1, D.M. Kozink1, D.J. Marshall1,  
J.F. Whitesides1, D. Montefiori1, J.E. Robinson3,  
J. Kaewkungwal4, S. Nitayaphan5, P. Pitisuttithum6,  
S. Rerks-Ngarm7, J. Kim8, N. Michael8, G. Tomaras1,  
B.F. Haynes1, G. Ferrari1
1Duke University, Durham, NC, USA; 2University of Alabama 
at Birmingham, Birmingham, AL, USA; 3Tulane University 
School of Medicine, New Orleans, LA, USA; 4Tropical Hygiene, 
Mahidol University, Bangkok, Thailand; 5Armed Forces 
Research Institute of Medical Sciences, Bangkok, Thailand; 
6Clinical Tropical Medicine, Mahidol University, Bangkok, 
Thailand; 7Department of Disease Control, Ministry of Public 
Health, Nonthaburi, Thailand; 8US Military HIV Research 
Program, Rockville, MD, USA
Background: Antibody Dependent Cellular Cytotoxicity (ADCC) 
may be a contributing factor of immune responses controlling 
HIV-1 replication. Understanding the epitopes recognized by 
ADCC-mediating antibodies is likely to be important for the 
development of an effective AIDS vaccine. We characterized the 
epitope specificity and breadth of the ADCC-mediating antibody 
response elicited by the RV144 vaccine regimen. 
Methods: Twenty-three monoclonal antibodies (mAbs) were 
isolated from 6 vaccine recipients either from IgG+ memory B cells 
cultured at near clonal dilution for 14 days (n=115,200) followed 
by sequential screenings of culture supernatants for HIV-1 gp120 
Env binding, or from memory B cell (n=206,745) sorting for HIV-1 
group M consensus gp140Con.S Env binding. Target cells infected 
with infectious molecular clones expressing Clade A/E (CM235), 
B (BaL), and C (DU422 and DU151) env were used to characterize 
the specificity and breadth of the 23 mAbs that display ADCC 
activity. We defined the epitope specificity of the isolated mAbs 
by mapping with B.MN and/or AE.92TH023 linear peptides in 
ELISA and with Fab-competition in ADCC assays. 
Results: Linear mapping revealed that 2 mAbs recognized the 
V2, and 1 mAb the V3 regions of the gp120. Nineteen (19) 
mAbs recognized conformational epitopes overlapping the C1 
A32 epitope; one mAb (CH20) recognized a conformational 
epitope that was not blocked by any of the Fabs (A32, 19B, 17b) 
utilized in our assay. Fourteen of the 20 mAbs directed against 
conformational epitopes mediated ADCC against the clade B BaL 
Env; 4 recognized the clade C DU151 Env and 1 recognized the 
clade C DU422 Env.
Conclusion: The RV144 vaccine regimen induced broadly-reactive 
ADCC Abs that recognized both unique and overlapping regions 
of gp120. The mAbs with the greatest breadth may be useful for 
passive protection trials in rhesus macaques. If protective in non-
human primates, the epitopes recognized by these mAbs may 
inform immunogen design.
OA07.05
Non-neutralizing IgG Anti-PID Antibodies Decreased 
Viral Load Following High Dose Vaginal Challenge of 
Non-human Primates
C. Moog1, N. Dereuddre-Bosquet2, M. Biedma1, S. Schmidt1,  
T. Decoville1, I. Mangeot2, S. Zolla-Pazner3, B. Vcelar4,  
D. Katinger4, V. Holl5, R. Le Grand2
1INSERM, Strasbourg, France; 2CEA, Fontenay-aux-Roses, 
France; 3NYU, New York, NY, USA; 4Polymun Scientific GmbH, 
Vienna, Austria; 5Covance, Geneva, Switzerland
Background: Fc-mediated inhibitory activity of neutralizing 
antibodies has been shown to participate in HIV protection 
(Hessell et al. 2007). In addition, a non-neutralizing antibody 
F240 was found to partially protect macaques from SHIV vaginal 
transmission (Moore et al., 2011). However, mechanisms 
involved in this protection need further investigations. In this 
study, two non-neutralizing antibodies have been selected on 
the basis of their Fc-mediated inhibitory functions in vitro for 
further analysis of their protective role on vaginal challenge in 
non-human primate (NHP). 
Methods: We have assessed and scored various in vitro 
HIV-inhibitory activities of non-neutralizing antibodies: Fc-
mediated inhibition of macrophages through phagocytosis 
of immunecomplexes, ADCC in primary infected CD4+ T 
lymphocytes by autologous NK cells, capture of native primary 
virus particles. Efficacy of two anti-PID antibodies with high in 
vitro functional scores has been tested in NHP. The combination 
of two antibodies formulated in 1.6% HEC gel has been topically 
applied in the vagina of macaques (n=6), 1 hour before vaginal 
challenge with high dose (10 AID50) of SHIVSF162P3.Infection 
was followed by assessing viral load in the plasma.
Results: Although unable to block virus entry at mucosal site as 
all treated animals became persistently infected, the antibody 
treated macaques have significant decrease of plasma viral load 
(day 7, p=0.0479; day 14, p=0.0351, day 42: p=0.0370).
Conclusion: Decrease in viral load following antibody treatment 
strongly suggests that non-neutralizing inhibitory antibodies 
could interfere with early viral replication and dissemination 
through Fc-mediated inhibitory functions. Additional studies will 
be required to optimize this inhibition, and combined strategies 
should be developed to assess the potential synergy between 
neutralizing and non-neutralizing inhibitory antibodies. 
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OA07.08 LB
Engineered Mice and B Cell Lines Expressing Broadly 
Neutralizing Antibodies and Their Unmutated 
Precursors: Tools for HIV Vaccinology
D. Nemazee1, C. Doyle-Cooper1, T. Ota1, A.B. Cooper1,  
M. Huber1, E. Falkowska1, K. . Doores1, L. Hangartner1,  
K. Le1, D. Sok1, J. Jardine1, J. Lifson2, X. Wu3, J.R. Mascola3,  
P. Poignard1, J.M. Binley4, B.K. Chakrabarti5, W.R. Schief5,  
R.T. Wyatt5, D.R. Burton5
1The Scripps Research Institute, La Jolla, CA, USA; 2Frederick 
National Laboratory for Cancer Research, Frederick, MD, USA; 
3Vaccine Research Center NIAID, Bethesda, MD, USA; 4Torrey 
Pines Institute, La Jolla, CA, USA; 5IAVI Neutralizing Antibody 
Center, USA
Background: Eliciting broadly neutralizing antibodies (bNAbs) to 
HIV Env through immunization has been problematic.
Methods: To better understand the requirements for activation 
of B cells producing bNAbs, we generated a series of cell lines 
and transgenic mice expressing such antibodies or selected 
germline-reverted versions as B cell surface receptors. The 
bNAb cell lines included those that recognize the CD4 binding 
site (b12, VRC01, PGV04, PGV19, NIH45-46), the MPER of gp41 
(4E10), and additional glycan-dependent sites on the trimer 
(PG9, PG16, PGT145, 2G12, PGT128, PGT135, PGT121). Different 
Env-containing antigens and virions were tested for the ability to 
stimulate bNAb cell lines.
Mouse strains expressing germline or mutated forms of 4E10 
and b12 bNAb Ig genes were generated by gene targeting to the 
physiological loci. These “knock-in” mice were studied for their B 
cell development, and responses to HIV immunogens.
Results: Many HIV Env antigen preparations, notably including 
infection-competent pseudovirions, were poorly recognized by 
high affinity bNAb-expressing cells, as measured by calcium flux 
assay. However, other antigen forms were highly stimulatory: 
in particular, soluble gp140 foldon trimers and a multimerized, 
scaffolded epitope protein. 
4E10, but not b12 knock-in mice showed signs of abortive B cell 
development. b12 H mice had gp120-binding cells and responded 
well in vivo to gp140 trimers.
Conclusion: Analysis of bNAb cell line activation suggested that 
HIV is difficult to recognize by B cells, probably because of the 
low density of surface proteins. Based on these results, soluble 
gp140 trimers or epitope scaffolds might offer more promise 
as vaccine candidates. In knock-in mice, primary 4E10 B cell 
precursors appeared to be negatively selected, whereas b12 B 
cells were normal and readily stimulated with gp140 trimers. 
OA07.07
454 Pyrosequencing and Bioinformatics Analysis of 
the Lineage of the Broad and Potent gp41-Directed 
Antibody 10e8
G. Ofek2, J. Zhu*2, Y. Yang2, B. Zhang2, K. Mckee2, M. Louder2,  
J. Huang1, L. Laub1, M. Connors1, J. Mascola2, P.D. Kwong2
1Laboratory of Immunoregulation, NIAID, NIH, USA; 2Vaccine 
Research Center, NIAID, NIH, Bethesda, MD, USA
Background: The 10e8 antibody is a novel MPER-specific 
antibody that is both broad and potent, and lacks detectable 
autoreactivity. 454 pyrosequencing has recently been shown 
to allow for a bioinformatics analysis of the genetic record of a 
broadly neutralizing antibody, once its sequence is known.
Methods: 454 pyrosequencing of B cells from donor N152, 
from whom 10e8 was isolated, was undertaken to characterize 
additional variants of 10e8 and to define its lineage. PCR reactions 
using 10e8 germline-specific heavy and light chain primers were 
performed and 454 pyrosequencing results analyzed using a 
multi-step in-house bioinformatics pipeline. 
Results: 37,669 IGHV3-15 heavy chain sequences and 91,951 
IGLV3-19 light chain sequences were obtained and the 
distribution of these sequences analyzed by two key parameters 
– divergence from germline and sequence identity to 10e8. 
Grid-based clustering allowed for the selection of 61 heavy 
chain sequences and 48 light chain sequences. These were 
reconstituted with the appropriate 10e8 light or heavy chain 
partner, expressed and tested for MPER recognition. 12 heavy 
chain variants and 27 light chain variants were found to bind 
MPER, and several of the reconstituted antibodies neutralized a 
panel of HIV-1 isolates better than the original 10e8. Phylogenetic 
analyses identified clonally-related sequences, and at least three 
subgroups of 10e8-like heavy chains were observed. 10e8 light 
chains meanwhile also showed a few subgroups, though with 
less sequence variation.
Conclusion: 454 pyrosequencing was thus able to identify clonal 
variants of 10e8 with substantially improved neutralization 
potency. Corresponding phylogenetic analyses are providing 
insight into the ontogeny of 10e8, and structural and biophysical 
studies are underway to functionally characterize this lineage.
*These authors contributed equally to this work. 
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OA08.02
Alterations in Function and Distribution of 
Regulatory T Cells (Tregs) May Blunt Vaccine Induced 
Immune Responses in HIV Infection 
J. van Lunzen1, I. Toth1, P. Hartjen1, J. Schulze zur Wiesch1
1University Medical Center Hamburg-Eppendorf, Infectious 
Diseases Unit, Hamburg, Germany
Background: Conflicting data exist about the frequency and role 
of regulatory T cells (Tregs) during the course of HIV infection. 
Tregs may substantially contribute to T cell homeostasis and fine 
regulation of T cell mediated immune responses. 
Methods: Peripheral blood and individual lymph nodes of a 
large cohort of HIV+ patients (n=131) at different disease stages, 
including 15 long-term nonprogressors and 21 elite controllers, 
was analyzed to determine the frequency, phenotype and 
function of Tregs.
Results: A significantly increased relative frequency of Tregs 
within the CD4+ compartment of HIV+ patients in comparison 
with healthy controls (p<0.0001) was observed. The relative 
frequency of Tregs directly correlated with HIV viral load and 
inversely with CD4+ counts and was higher in corresponding 
lymph nodes. However, absolute Treg number was reduced in 
HIV infected patients vs. healthy controls (p<0.0001), but not 
in elite controllers (p>0.05). Loss of absolute Treg numbers was 
associated with increased markers of immune activation (HLA-DR, 
CD38 Ki-67)(p<0.0006). Initiation of antiviral therapy significantly 
increased absolute Treg numbers (p<0.0031). Moreover, we 
find that the expression of CD39 and CD73, newly defined 
ectonucleotidases involved in ATP degradation, correlated with 
progressive HIV disease, VL and immune activation. Of note, the 
capacity to suppress T cell proliferation in vitro was limited to 
the CD4+CD25highCD39+ T cell subset. Depletion of this distinct 
Treg subset in vitro resulted in a restoration of HIV specific T 
cell responses. Tregs of elite controllers exhibited the highest 
expression of CCR5, CTLA-4 and ICOS and the lowest level of 
CD39 indicating the functional importance of this ATP modulating 
enzymatic reaction. 
Conclusion: These data reconcile the seemingly contradictory 
results of previous studies on Tregs in HIV and highlight the 
complexity of Treg mediated immunoregulation. Blocking of ATP 
modulating molecules which are highly expressed on Tregs may 
restore HIV specific immune responses. 
OA08.01
Cellular Immune Responses and Changes in VL After 
a Dendritic Cells (DC)-Based Therapeutic Vaccine in 
cART Treated Chronic HIV-Infected Patients with CD4 
T Cells Above 450/mm 
F. García2, A.C. Guardo2, M. Maleno2, L. Papagno1, M. Bargalló2, 
N. Climent2, B. Autran1, J. Gatell2, T. Gallart2, M. Plana2
1INSERM U543 - Université Paris VI Pierre et Marie Curie, 
ORVACS, Paris, France; 2IDIBAPS - Hospital Clinic, Barcelona, Spain
Background: We have performed a blinded placebo-controlled 
study immunizing antiretroviral (cART) treated chronically HIV-
1 infected patients with autologous Myeloid-Derived Dendritic 
Cells (MD-DCs) pulsed with heat inactivated autologous HIV-1. 
Methods: 36 patients with CD4+ >450 cells/mm3 were randomized 
(2:1) to receive 3 immunizations every 2 weeks with DC pulsed 
with autologous heat-inactivated HIV-1 (Cases, n=24) or with non-
pulsed DC (Controls, n=12). Changes in viral load (VL) as well as 
changes in CD4 cell counts have been evaluated. Additionally HIV 
specific responses were measured in PBMC samples from different 
time-points by LPR and by IFN-_-Elispot against gag, nef and gp41 
HIV overlapping peptide pools, respectively. 
Results: VL rebounded to detectable level in all the patients. At 
week 12 and 24, a decrease of VL >= 1 log was observed in 12/22 
(55%) vs 1/11(9%) and in 7/20(35%) vs 0/10(0%) in cases and 
controls, respectively (p=0.02, p=0.03). CD4 drop to baseline value 
before any cART without differences between groups. Although 
only transient positive responses to HIV p24 were observed, the 
median change in LPR to HIV p24 at week 24 from baseline was 
0.96 vs -0.50 (p=0.02) in cases vs controls, respectively. Baseline 
median values of the total sum of HIV specific responses against 
HIV peptide pools were similar in both arms (2625 versus 2283 
SFC/106 PBMC, p=0.462). After vaccination, the median change 
of total sum of SFC/106 PBMC at week 24 was 3567 vs 838 
SFC/106 PBMC (p=0.0459) in cases and controls, respectively. 
This difference was more evident when analyzing responses 
against gag p17 and Nef peptide pools (p=0.0288 and p=0.03615, 
respectively). No statistically significant correlations between 
immune responses and VL were found. 
Conclusion: These results indicate that HIV-1 specific immune 
responses elicited by therapeutic DC vaccines could significantly 
change pVL set-point after cART interruption in chronic HIV-1 
infected patients.
Oral Abstract Session 08: T Cell Responses
76
Oral Abstract Sessions
O
R
A
L A
B
STR
A
CT SESSIO
N
S
AIDS Vaccine 2012
OA08.04
PD-1, IL-10, IFN-γ and IL-12 Form a Network to 
Regulate HIV-1-Specific CD4 T Cell and Antigen-
Presenting Cell Function
F. Porichis1, L. Barblu1, D.S. Kwon1, M. Hart1, J. Zupkosky1,  
G.J. Freeman2, D.G. Kavanagh1, D.E. Kaufmann1
1Ragon Institute of MGH, MIT and Harvard, Charlestown, MA, 
USA; 2Dana-Farber Cancer Institute, Harvard Medical School, 
Boston, MA, USA
Background: PD-1 and IL-10 blockade can restore antigen-specific 
T cell functions in chronic infections and cancer. However, not all 
subjects respond to inhibition of either pathway, the potential 
differences in functions restored by these interventions are 
unknown, and mechanistic interactions between these pathways 
are poorly understood.
Methods: We investigated 45 subjects with HIV-1 infection 
with different disease status. We used CFSE assays to measure 
proliferation of HIV-1-specific CD4 T cells and Luminex arrays to 
analyze IFN-γ(Th1), IL-2(Th0), IL-13(Th2) and IL-12 secretion in 
supernatants of CD8-depleted PBMC stimulated for 48h with Gag 
peptide pools in the presence of isotype control antibody, anti-
PD-L1 and/or anti-IL-10Ra, anti-IFN-γ or anti-IL-12. We used flow 
cytometry to evaluate the role of IFN-γ in regulating PD-L1, HLA-
DR, HLA-ABC and CD86 expression by monocytes. 
Results: Whereas PD-L1 blockade had a balanced impact on 
proliferation and cytokine secretion by HIV-1-specific CD4 T cells, 
anti-IL-10Rα preferentially restored IFN-γ production. Combined 
blockade resulted in a dramatic 9.8-median-fold increase of 
IFN-γ, contrasting with the moderate effect of single blockade 
(2.5 median-fold). Antigenic stimulation of HIV-1-specific CD4 
T cells upregulated PD-L1, HLA-DR and HLA-ABC on monocytes 
through an IFN-γ-dependent mechanism. Combined PD-L1/IL-
10Rα induced a striking increase in IL-12 production by antigen-
presenting cells(APCs) that was governed by IFN-γ derived from 
the Thelper cells. Neutralization of IL-12 reduced the dramatic 
effect of combined blockade on IFN-γ, demonstrating a positive 
feedback loop between IFN-γ produced by HIV-1-specific CD4 T 
cells and IL-12 produced by APCs.
Conclusion: These data provide important evidence on the 
therapeutic potential of combined interventions on the PD-1 and 
IL-10 pathways to restore HIV-1-specific CD4 T cell and antigen-
presenting cell function. We provide mechanistic insight on the 
mode of action of dual blockade by showing that IFN-γ produced 
by HIV-1-specific CD4 T-cells and IL-12 secreted by APCs regulate 
each other in a positive feedback loop
OA08.03
Identification of CD8+ T Cell Host Factors Involved in 
HIV Control
G. Gaiha1, K. McKim1, M. Woods1, M. Lichterfeld1, A. Brass1,  
B. Wallker1
1Ragon Institute of MGH, MIT and Harvard/Massachusetts 
General Hospital, Boston, MA, USA
Background: The goal of the is project was to further define our 
understanding of the critical antiviral effector molecules and 
cell signaling pathways involved in CD8 T cell mediated control 
of HIV infection. 
Methods: To accomplish this, we performed whole genome 
transcriptional profiling on sorted epitope-specific CD8 T cells, 
in the presence and absence of cognate peptide, from a total of 
8 B*2705 elite controllers and progressors. Epitope-specific CTLs 
were isolated using HLA class I tetramers and used to prepare 
mRNA for evaluation by gene expression profiles using whole 
genome Illumina bead arrays. Bulk CD8 T cells were used as an 
internal control for each patient. 
Results: Statistically significant genes enriched by our analysis 
include those involved in cellular cytotoxicity, cytokine signaling, 
T-cell receptor signaling, cell-cell adhesion molecules, and T cell 
homeostasis. Further analysis of the gene set identified 137 
unique genes that were both induced by peptide stimulation in 
epitope-specific CD8 T cells, and significantly different between 
peptide-stimulated controller and progressor CD8 T cells. Further 
refinement of this list of 137 genes using a protein-protein 
network analysis revealed that 13 of these genes are statistically 
significant in driving the network connectivity. We have now 
focused our efforts on one of these genes, Caspase 8. 
Conclusion: This study defines a novel set of 137 genes in 
epitope-specific CD8 T cells that are upregulated upon peptide 
stimulation and different between patients that control and have 
progressive infection. Further refinement of this list defines 13 
unique candidates that drive network connectivity, of which 
one was Caspase 8. Our initial studies also reveal that Caspase 8 
mRNA expression, which has a known role in T cell homeostasis, 
is upregulated in CD8 T cells in controllers, suggesting its potential 
role as a novel T cell correlate of control.
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OA08.06
HIV Control Through a Single Nucleotide on the  
HLA-I Locus
H. Kløverpris1, M. Harndahl2, J. Carlson1, A. Leslie1,  
M. van der Stok3, G. Huang1, F. Chen4, L. Riddell5, D. Steyn6,  
D. Goedhals6, C. van Vuuren6, J. Frater1, B. Walker7,  
T. Ndung’u’3, S. Buus2, P. Goulder1
1University of Oxford, Oxford, United Kingdom (Great Britain); 
2University of Copenhagen, Copenhagen, Denmark; 3University 
of KwaZulu-Natal, South Africa; 4Royal Berkshire Hospital, 
Reading, United Kingdom (Great Britain); 5Northampton 
General Hospital, United Kingdom (Great Britain); 6University 
of Free State, Bloemfontein, South Africa; 7Ragon Institute of 
MGH, MIT and Harvard, Boston, USA
Background: In correlative studies HLA class I type is consistently 
found to have the strongest impact on HIV disease progression. 
However, the exact mechanism involved is complicated by several 
factors; many alleles are ligands for NK cells as well as CD8 T-cells, 
and strong linkage disequilibrium between Class I alleles makes 
it difficult to distinguish the effect of individual alleles from other 
HLAs or from other important loci found on the HLA haplotype, 
such as the recently described -35 SNP.
Methods: Here we study two recently diverged HLA alleles, 
B*4201 and B*4202, which only differ by a single amino acid. 
Crucially, they occur primarily on identical Class I haplotypes 
and do not act as NK cell ligands. Therefore, they represent a 
unique opportunity to study the impact of a single HLA allele on 
HIV immune control not confounded by other genetic factors in 
a large outbred cohort (n=2,093) of C-clade infected individuals. 
Results: Here we show that the amino acid change in position 
9 of the HLA-B molecule, is critical for peptide binding and 
significantly alters the Gag CTL epitopes targeted (P=2x10-
10), measured both directly ex-vivo by ELISPOT and indirectly 
through CTL escape mutation (P=2x10-8). Strikingly, HLA-B*4201 
is associated with significantly lower viral load setpoint than 
HLA-B*4202 (P=0.02).
Conclusion: This naturally controlled experiment represents 
perhaps the clearest demonstration of the direct impact of 
particular HIV Gag specific CTL on disease control.
OA08.05
Distinct Gene Expression Profiles Associated with the 
Susceptibility of Pathogen-Specific CD4+ T Cells to 
HIV-1 Infection
H. Hu1, M. Nau1, P. Ehrenberg1, A. Chenine1, Z. Daye2, Z. Wei3, 
N. Michael1, M. Vahey1, J. Kim1, M. Marovich1, S. Ratto-Kim1
1U.S. Military HIV Research Program, Silver Spring, MD, USA; 
2University of Pennsylvania School of Medicine, Philadelphia, 
PA, USA; 3New Jersey Institute of Technology, Newark, NJ, USA
Background: HIV infection causes the progressive depletion 
of CD4+ T cells. Contrary to the early loss of CD4 response to 
opportunistic pathogens like Candida albicans, cytomegalovirus 
(CMV)-specific CD4 response is persistent when total CD4+ T cell 
number is low. The mechanism is less clear. Despite considerable 
knowledge for the impact of HIV infection on total CD4+ T cells 
and their subsets, little is known about HIV infection of CD4+ T 
cells of different pathogen/antigen (Ag) specificity. 
Methods: PBMC from HIV-negative donors were CFSE-labeled 
and stimulated ex vivo with pathogen-specific antigens 
including viral (CMV), bacterial (Tetanus Toxoid: TT) and fungal 
(Candida albicans) antigens. HIV infection of Ag-specific CD4+ T 
cells was determined by intracellular p24 production in CFSE-
low population. 
Results: While TT- and Candida-specific CD4+ T cells were 
permissive, CMV-specific CD4+ T cells are highly resistant 
to both X4 and R5 HIV independent of coreceptor useage. 
Quantification of HIV DNA in sorted, antigen-specific CD4+ T 
cells demonstrated a reduction of both strong-stop and full-
length HIV DNA in CMV-specific CD4+ T cells. β-chemokine 
neutralization enhanced HIV entry and viral replication in TT- and 
Candida-specific CD4+ T cells, whereas HIV infection in CMV-
specific CD4+ T cells remained low despite increased HIV entry 
by β-chemokine neutralization, suggesting both entry and post-
entry HIV restriction in CMV-specific cells. Microarray analysis 
revealed distinct gene expression profiles that involved selective 
upregulation of a broad array of antiviral genes in CMV-specific 
CD4+ T cells, whereas TT- and Candida-specific CD4+ T cells 
mainly upregulated a Th17 inflammatory response. 
Conclusion: Our data suggest a mechanism for the persistence 
of CMV-specific CD4 response and the earlier loss of mucosal 
Th17-associated TT- and Candida-specific CD4 response in AIDS 
patients. The model described is useful in HIV vaccine studies by 
evaluating the susceptibility of vaccine-specific CD4 responses 
to HIV infection.
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OA08.08 
Intra-dermal Immunisation with SIV Gag-Based 
Vaccines Alone Inhibits Acquisition of SIVmac251
N. Almond1, R. Stebbings1, M. Page1, B. Li1, N. Berry1, C. Ham1, 
D. Ferguson1, N. Rose1, E. Mee1, C. Stahl-Hennig2, G. Dickson3, 
T. Athanasapoulos3, A. Benlahrech4, S. Herath4, A. Meiser4,  
S. Patterson4
1NIBSC-HPA, Potters Bar, Hertfordshire, United Kingdom 
(Great Britain); 2DPZ, Göttingen, Germany; 3Royal Holloway, 
University of London, London, United Kingdom (Great Britain); 
4Imperial College, London, United Kingdom (Great Britain)
Background: It is increasingly recognised that effective anti-viral 
cell mediated immunity depends not only on the frequency of 
antigen specific T cells, but also on the quality of these T cells. 
We have evaluated a vaccine protocol involving DNA prime 
and Adenoviral vector boost to deliver SIV gag in MHC typed 
Mauritian derived Macaca fascicularis.
Methods: Groups of 8 macaques were immunised 3 times on 
weeks 0, 4, 8 with 100μg purified plasmid DNA designed to 
express SIVmac239 derived gag under the control of the CMV 
immediate early promoter. Three different SIV gag vaccines were 
compared. The DNA plasmids expressed native SIVmac239gag, 
ubiquinated SIVmac239 gag or fragmented, ubiquinated 
SIVmac239 gag derived peptides. On week 19, the groups were 
boosted with 10e7 infectious units recombinant Ad 5 expressing 
the same SIV Gag antigens. Cell mediated immunity was assessed 
after each immunisation and after virus challenge. At week 23, 
all vaccinated macaques, along with a group of naive challenge 
controls began 10 weekly, atraumatic challenges via the rectal 
mucosal with 150TCD50 SIVmac251.
Results: Delivery of this vaccine via the intra-dermal route elicited 
CD8 and CD4 T cell responses. Moreover, approximately 50% 
of antigen specific CD4+ T cells expressed the mucosal homing 
marker alpha4 beta7. When vaccinated macaques were exposed 
to a stock of uncloned SIVmac251 that had been propagated on 
simian PBMC’s, by repeated low dose challenge via the intra-
rectal route, a significant delay (Wilcoxon test; p=0.015) in 
acquisition of SIV was obtained amongst vaccinated macaques 
compared with naive controls challenged in a similar manner. 
Furthermore, peak viral loads amongst vaccinated macaques 
were significantly lower than challenge controls (Kruskal-Wallis 
test; p=0.010).
Conclusion: We are investigating whether the route of 
immunisation was crucial to the vaccine’s success.
OA08.07
Accelerated Heterologous Prime-Boost Adenovirus 
Vector-Based SIV Vaccine in Neonatal Rhesus Monkeys
J. Liu1, H. Li1, M. Iampietro1, D.H. Barouch1
1Beth Israel Deaconess Medical Center, Harvard Medical 
School, Boston, MA, USA
Background: A pediatric HIV-1 vaccine is required to protect 
infants against HIV-1 transmission from breastfeeding. Such a 
vaccine would need to induce protective immunity at mucosal 
surfaces in neonates as soon as possible after birth. Recombinant 
adenovirus (rAd) vectors have been shown to elicit potent 
systemic and mucosal virus-specific immune responses in adult 
non-human primates and humans but have not previously been 
studied in detail in infants. 
Methods: Newborn rhesus monkeys were injected intramuscular 
(i.m.) with 10^11 viral particles of rAd serotype 26 or 35 vectors 
expressing SIVmac239 Gag. Peripheral blood was collected to 
determine systemic Gag-specific cellular and humoral immune 
responses. At week 52, peripheral lymph nodes, bronchoalveolar 
lavage (BAL) and pinch biopsies of colorectal, duodenal and oral 
cavity mucosa were collected to evaluate mucosal Gag-specific T 
lymphocyte responses.
Results: A single injection of rAd26 encoding SIVmac239 Gag 
in rhesus monkeys on the day of birth elicited detectable SIV-
specific cellular immune responses, but these responses 
were transient and waned quickly. In contrast, an accelerated 
heterologous prime-boost regimen involving administration of 
rAd35 at birth and rAd26 at 4 weeks of life elicited potent and 
durable Gag-specific cellular and humoral immune responses 
in neonatal rhesus monkeys, including mucosal responses that 
remained detectable at one year of age.
Conclusion: These results suggest the potential of an accelerated 
heterologous rAd prime-boost regimen as a candidate neonatal 
HIV-1 vaccine in newborns.
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OA09.02
In Vivo Targeting of HIV Gag to Dendritic Cells in 
Combination with Poly ICLC Is Safe and Immunogenic 
in Healthy Volunteers
M. Caskey1, C. Trumpfheller1, S. Pollak1, L. Sinnenberg1, A. Hurley1, 
J. Pring1, I. Shimeliovich1, B. Yipp1, N. Anandasabapathy1,  
S. Mehandru1, P. Sarma1, R. Koup1, R. Bailer1, G. Tomaras2,  
A. Sato3, T. Keler4, R. Steinman1, S. Schlesinger1
1The Rockefeller University, New York, NY, USA; 2Duke 
University, Durham, NC, USA; 3Statistical Center for HIV/AIDS 
Research & Prevention (SCHARP), Seattle, WA, USA; 4Celldex 
Therapeutics, NJ, USA
Background: In vivo delivery of HIV antigens within α-DEC 205 
antibodies to maturing dendritic cells (DCs) in combination 
with maturation stimuli is a potential new vaccine platform. 
This phase-I study evaluates the safety and immunogenicity of 
DEC-targeting of HIV gag p24 in combination with poly ICLC in 
healthy volunteers. 
Methods: 45 volunteers aged 18-60 were enrolled. 9 
volunteers per dosage group (low: 0.3mg; mid: 1.0mg; high: 
3.0mg) received α-DEC205-HIVp24 mAb plus a fixed dose 
of poly ICLC s.c., 3 volunteers received poly ICLC only, and 3 
volunteers received saline, in a randomized double-blinded 
dose escalation design. Volunteers were vaccinated at weeks 0, 
4, 12 and followed for 12 months. 
Results: Study remains blinded. Transient local and systemic 
reactogenicity occurred, without vaccine-related serious adverse 
events to date. Gag p24-specific IgG was induced in 9/15 (60%, 
9 received vaccine plus adjuvant) volunteers in both low dose 
and mid dose groups at weeks 4, 8, 12, and 16. IgG titers were 
higher in the mid dose group and responses persisted for at least 
6 months after last low dose immunization. Gag-specific CD4+ T 
cells were also detected following immunizations. IL-2 and TNF-α 
were the predominant cytokines. For CD4+ cells producing IL-2 
or TNF-α, the response rates ranged from 33 to 46% (5-7/15 
volunteers, 9 received vaccine plus adjuvant) and 8 to 40% (1-
6/15 volunteers) post-vaccination in the low and mid dose groups 
respectively. Among positive responders, the median magnitude 
across visits ranged from 0.09% to 0.23% in the low dose group 
and from 0.06% to 0.17% in the mid dose group. 
Conclusion: This novel DC-targeted protein HIV vaccine in 
combination with poly ICLC is safe and immunogenic in humans. 
Cellular and humoral immune responses are induced. Antibody 
responses are durable, with antibody titers unchanged at 6 
months following last immunization.
OA09.01
Safety and Immunogenicity of a Randomized 
Phase I Prime-Boost Trial with ALVAC-HIV (vCP205) 
and gp160 MN/LAI-2 Adjuvanted in Alum or 
Polyphosphazene
R.J. O’Connell1, V.R. Polonis1, S. Ratto-Kim1, J. Cox2,  
L.L. Jagodzinski1, J. Malia1, N.L. Michael1, J. Excler1, M.L. Robb1,  
J.H. Kim1
1U.S.Military HIV Research Program, Bethesda, MD, USA; 
2International AIDS Vaccine Initiative, New York, NY, USA
Background: ALVAC-HIV prime/HIV-1 Env protein boost regimens 
have shown HIV-specific neutralizing antibody (NAb) and cell-
mediated immune responses, but the impact of protein subunit 
schedule and adjuvant requires further definition.
Methods: A Phase 1 trial was conducted in two parts. In Part 
A, (open-label) 19 volunteers received oligomeric gp160 MN/
LAI-2 (ogp160) with a dose escalation (25, 50, 100 μg). In Part 
B, 72 volunteers (60 active, 12 placebo) received placebo or 
recombinant canarypox expressing HIV-1 antigens, (ALVAC-HIV, 
vCP205) prime with different doses and schedules of ogp160MN/
LAI-2 in alum or polyphosphazene (PCPP). 
Results: The vaccines were safe and well tolerated with no 
vaccine-related serious adverse events. Cumulative chromium 
release CTL frequency was 37%, and 54% of volunteers showed 
proliferative responses to HIV antigens. Lymphoproliferative 
CD4+, HIV-specific responses were seen in 53% of ogp160 only 
and 57% of prime-boost recipients, respectively. Induced binding 
antibody to ogp160 was dose-dependent. NAb responses to 
vaccine homologous Tier 1 HIV-1 MN were seen in 99% of vaccine 
recipients. While NAb to the heterologous Tier 2 US-1 (R5, clade 
B) pseudovirus was negative in all volunteers tested using TZM-
bl cells, in a PBMC-based assay, US-1 primary isolate Nab was 
induced in 2/19 (10.5%) recipients of ogp160 protein alone and 
in 5/30 (16.7%) prime-boost volunteers who received ogp160 
in PCPP. Primary isolate neutralization was observed more 
frequently overall in recipients of ogp160 in PCPP, as compared 
with alum (p=0.027). Using an intracellular p24 flow-cytometry 
assay, sera from an ALVAC-HIV/ogp160 recipient demonstrated 
94% neutralization of US-1. 
Conclusion: A small percentage of vaccine recipients developed 
Nab to heterologous primary isolates, responses that to our 
knowledge have not been previously described. These results 
constitute proof of concept that Tier 2 NAb can be elicited by 
vaccination in humans, and underscore the importance of 
further optimization of prime-boost vaccination and adjuvanting 
strategies for HIV-1 prevention.
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OA09.04
Antibody-Mediated Inhibition of HIV-1 Elicited by 
HIV-I DNA Priming and Boosting with Heterologous 
HIV-1 Recombinant MVA in Healthy Tanzanian Adults
A. Joachim1, C. Nilsson2, S. Aboud1, E.F. Lyamuya1, M. Robb3,  
M. Marovich4, C. Ochsenbauer5, B. Wahren2, E. Sandström6,  
G. Biberfeld2, G. Ferrari7, V.R. Polonis5
1Muhimbili University of Health and Allied Sciences (MUHAS), 
Dar es Salaam, United Republic of Tanzania; 2Karolinska 
Institutet / Institute for Infectious Disease Control (SMI), 
Stockholm, Sweden; 3The Henry M. Jackson Foundation, 
Rockville, MD, USA; 4Walter Reed Army Institute of Research 
(WRAIR), Rockville, MD, USA; 5Department of Medicine, 
University of Alabama at Birmingham, Birmingham, AL, USA; 
6Venhälsan, Karolinska Institutet (KI) at Södersjukhuset, 
Stockholm, Sweden; 7Department of Surgery, Duke University 
Medical Center, Durham, NC, USA
Background: We evaluated HIV antibody (Ab) responses 
elicited by immunization, in a phase I/II placebo-controlled 
double blind trial using multiclade, multigene HIV-1-DNA prime 
boosted with HIV-MVA conducted among healthy volunteers in 
Tanzania (HIVIS03). 
Methods: Sixty HIV-uninfected volunteers, randomized into 
groups of 20 received placebo or 1 mg HIV-DNA intradermally 
(id) or 3.8 mg intramuscularly (im). DNA plasmids containing HIV-
1 gp160 subtypes A, B, C; rev B; p17/p24 gag A, B and RTmut B 
were given at months 0, 1 and 3 using a needle-free Biojector 
device. HIV-MVA expressing CRF01_AE HIV-1 env, gag, pol was 
administered im by needle at months 9 and 21. Sera were 
tested at baseline, two months post-first and four weeks post-
second HIV-MVA boosting. HIV Ab responses were tested using 
pseudoviruses and TZM-bl cells as well as luciferase-expressing 
infectious molecular clones (IMC-LucR) in PBMC-based 
assays. ADCC responses were tested using the flow cytometry 
GranToxiLux-based assay. 
Results: Neutralizing Ab activity was demonstrated only in the 
PBMC assay, and after the second MVA boost in 24 (83%) of 29 
vaccinees against the clade CRF01_AE CM235 IMC and in 21 (72%) 
of 29 vaccinees against clade B SF162-IMC. NK cell depletion 
from PBMC targets resulted in a significant loss of HIV inhibition 
by vaccinee sera, indicating a role of Ab-mediated Fcγ-receptor 
function. Vaccine-induced ADCC responses were detected in 21 
(75%) of 28 vaccinees after the second HIV-MVA boost. ADCC 
Ab titers did not differ significantly between id- (median 840, 
range 300-5400) and im-primed (median 880, range 400-3600) 
vaccinees (p=0.45). 
Conclusion: HIV-DNA priming followed by two HIV-MVA boosts 
elicited HIV-specific inhibitory and/or ADCC-mediating antibody 
responses in a high proportion of Tanzanian adults.
OA09.03
First-in-Human Phase 1 Trial of the Safety and 
Immunogenicity of a Recombinant Adenovirus 
Serotype 5 HVR48 (rAd5HVR48) HIV-1 Vaccine
S.R. Walsh1, M.S. Seaman1, J.A. Johnson2, R.P. Tucker2,  
K.H. Krause2, M. Weijtens3, M.G. Pau3, J. Goudsmit3, R. Dolin1, 
D.H. Barouch4, L.R. Baden2
1Beth Israel Deaconess Medical Center, Boston, MA, USA; 
2Brigham & Women’s Hospital, Boston, MA, USA; 3Crucell, 
Leiden, Netherlands; 4Ragon Institute of MGH, MIT and 
Harvard, Boston, MA, USA
Background: Adenovirus serotype 5 (Ad5) is a potent vector, 
but widespread seroprevalence may limit its potential use. 
Replacement of the hexon variable regions (HVR) of Ad5 with 
the HVR of the less prevalent Ad48 may result in a potent vector 
which bypasses pre-existing vector immunity.
Methods: Recombinant Ad5 with seven HVRs derived from 
Ad48 and expressing the VRC EnvA test antigen (rAd5HVR48.
ENVA) was made. 48 healthy volunteers who were seronegative 
to Ad5, Ad48, HIV-1, and HIV-2 were enrolled in a randomized, 
double-blind, placebo-controlled, dose-escalation phase 1 study. 
The first three groups of 12 subjects received doses of 109, 1010, 
or 1011 vp of rAd5HVR48.ENVA vector (n=10/group) or placebo 
(n=2/group) at weeks 0, 4, and 24 and the fourth group received 
a single injection of 1010 vp or placebo. We performed pre-
specified blinded immunogenicity analyses at day 56 and day 
196 after the first immunization.
Results: 31/48 (65%) of subjects were female; median age at 
enrollment was 24 (range: 18-50). Vaccination was generally well 
tolerated: mild to moderate local and systemic reactogenicity 
was observed after the initial immunization, more commonly 
in the highest dose group, but typically resolved within 24h. 
No vaccine-associated SAEs occurred. In all four dose groups, 
10 subjects per group developed positive EnvA-specific ELISA 
titers and EnvA-specific interferon-gamma ELISPOT responses 
following vaccination. Immune responses were seen two weeks 
following inoculation in the majority of subjects. Two subjects per 
group exhibited no vector- or insert-specific immune responses 
at any timepoint and are presumed placebo recipients.
Conclusion: The rAd5HVR48 vector is generally safe and 
immunogenic in humans at all three doses. Immune responses 
against EnvA could be detected two weeks following the first 
inoculation. Ad5HVR48 is a promising new chimeric vector to 
evaluate novel inserts in further clinical trials.
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OA09.06 LB
Multiple Antibody Specificities (gp41, V1V2, and V3) 
Elicited in the Phase II Multiclade (A, B, C) HIV-1 DNA 
Prime, rAd5 Boost Vaccine Trial
W.B. Williams1, K. Jones1, A. Krambrink2, D. Grove2, P. Liu1,  
N.L. Yates1, M.A. Moody1, G. Ferrari1, J. Pollara1, Z. Moodie2, 
C.A. Morgan2, H. Liao1, D.C. Montefiori1, C. Ochsenbauer3,  
J. Kappes3, S. Hammer4, J. Mascola5, R. Koup5, L. Corey6,  
G. Nabel5, P. Gilbert2, G. Churchyard7, M. Keefer8, B.S. Graham5, 
B.F. Haynes1, G.D. Tomaras1
1Duke Human Vaccine Institute, Duke University Medical 
Center, Durham, NC, USA; 2SCHARP, Fred Hutchinson Cancer 
Research Center, Seattle, WA, USA; 3Department of Medicine, 
University of Alabama at Birmingham, Birmingham, AL, USA; 
4Columbia University Medical Center, New York, NY, USA; 
5Vaccine Research Center, National Institute of Allergy and 
Infectious, Bethesda, MD, USA; 6University of Washington, 
Seattle, WA, USA; 7The Aurum Institute, Johannesburg, South 
Africa; 8Division of Infectious Disease, University of Rochester 
Medical Center, Rochester, NY, USA
Background: The phase II DNA prime, rAd5 boost vaccine (HVTN 
204) exhibited sufficient safety and immunogenicity to advance 
into a phase IIb efficacy trial (HVTN 505) in Ad5 seronegative 
volunteers in the US. In the RV144 ALVAC prime, A/E gp120 
protein boost trial, levels of V1V2 IgG antibodies significantly 
correlated with decreased risk of infection.
Methods: Sera from 203 vaccinees receiving VRC-HIVDNA016-
00-VP DNA (m 0,1,2), and VRC-HIVADV014-00-VP rAd5 (m 6), at 
two weeks post rAd5 boost, and 208 placebos were examined 
for binding gp140 and gp120 recombinant proteins, gp41, and 
an antigen panel of 16 V1V2 IgG scaffolds representing clades A, 
B and C V1V2 sequences. A subset of vaccinees and placebo was 
screened for binding CD4BS antigens. Monoclonal antibodies 
were generated from antigen specific memory B cell sorts and 
tested for binding, neutralization, ADCC and virion capture. 
Results: Clade A and B V1V2 IgG antibodies were elicited in 
38.4% and 19.2% of vaccinees, respectively. A clonal lineage 
of 3 gp41 mAbs (CH69, CH70, CH71), and a V3-specific gp120 
mAb (CH73) were generated from vaccinees. The gp41 mAbs 
captured infectious HIV-1 transmitted/founder viruses, while 
CH73 mediated ADCC activity against subtypes B and C infected 
cells, neutralized subtypes B and C tier 1A viruses, and bound 
multiple Envs of subtypes A, B and C.
Conclusion: The phase II multi-clade DNA prime, rAd5 boost 
vaccine regimen elicited antibody responses to multiple epitope 
specificities, including V1V2, V3, and gp41. CH69-CH71 and CH73 
mAbs represent the initial human mAbs from HVTN 204 vaccine 
recipients, and reflect the functional profile of vaccine-elicited 
antibodies. These data suggest that the HVTN 505 Phase IIb 
efficacy study using this same vaccine regimen may provide an 
opportunity to examine a diversity of antibody specificities that 
have been hypothesized as a correlate of HIV-1 infection risk.
OA09.05
A First-in-Man, Double Blind, Placebo Controlled 
Study of the Candidate Therapeutic Vaccine Opal-
HIV-Gag(c) in HIV Infected Patients Receiving HAART
A.G. Jackson1, H.N. Kløverpris1, A. Handley1, P. Hayes1,  
J. Gilmour1, M. Atkins1, B. Walker1, J. Ackland1, M. Sullivan1,  
P. Goulder1
1St. Stephen’s AIDS Trust, London, United Kingdom (Great 
Britain)
Background: Preclinical studies of overlapping 15mer peptides 
spanning SIV, SHIV or HIV pulsed autologously ex vivo have 
demonstrated high level, virus-specific T cells responses and viral 
load suppression in Macaca nemestrina. The objective of this 
study was to evaluate the safety and preliminary immunogenicity 
of Clade C consensus peptides administered ex vivo to HIV 
positive adults. 
Methods: Synthetic 15mer peptides (n=123, Opal-HIV-Gag(c)) 
spanning Clade C, consensus Gag were manufactured to current 
good manufacturing practice and evaluated in a good laboratory 
practice toxicology study in Macaca mulatta. A first-in-human, 
single centre, placebo-controlled, double-blind, dose escalation 
study was conducted. Twenty three people with well controlled 
HIV (CD4+ > 350cells/mm3 and a HIV < 400 copies/mL), 
stratified by clade, were enrolled in four groups: 12mg (n=6), 
24mg (n=7), 48mg (n=2) or matching placebo (n=8). Treatment 
was administered intravenously bedside (closed system) by 
enrichment of 120mL of whole blood for WBCs using a Sepax 
S-100 device, ex vivo mixing the peptides (or diluent alone) and 
incubation at 37°C for one hour prior to reinfusion. Subjects 
received 4 administrations at 4 weekly intervals followed by a 
12 week post-treatment follow up. Immunogencity was assessed 
by ELIspot. 
Results: Opal-HIV-Gag(c) was generally well tolerated at doses 
of 12 and 24mg. There was an increased incidence of temporally 
associated pyrexia, chills, rigor, and transient/self-limiting 
lymphopenia in Opal-HIV-Gag(c) recipients compared to placebo. 
Only 2 subjects were recruited to the 48mg cohort. A serious 
adverse event of anuria, hypotension and tachycardia secondary 
to diarrhoea occurred following a single dose of vaccine at 48mg. 
No difference in ex vivo IFN-γ ELISpot response was observed at 
any time. 
Conclusion: An infectious cause for the event could not be 
identified, leaving the possibility of immunologically-mediated 
reaction to the vaccine thus leading to early termination of 
the study.
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OA09.08 LB
Phase 2a Safety and Immunogenicity Testing of DNA 
and Recombinant Modified Vaccinia Ankara Virus 
Vaccines Expressing Virus-Like Particles
P. Goepfert1, M. Elizaga2, D. Montefiori3, J. Hural2, S. DeRosa2, 
G. Tomaras3, K. Seaton3, A. Sato2, L. Ouedraogo4, Y. Donastorg5, 
M. Cardinali4, J. Lama6, L. Baden7, M. Keefer8, J. McElrath9,  
S. Kalams10, H. Robinson11
1University of Alabama at Birmignham, Birmingham, AL, USA; 
2Fred Hutchinson Cancer Research Institute, Seattle, WA, USA; 
3Duke University, Durham, NC, USA; 4NIAID Vaccine Clinical 
Research Branch, Bethesda, MD, USA; 5Unidad de Vacunas 
IDCP-COIN-DIGECITSS, Santo Dominago, Dominican Republic; 
6Asociacion Civil IMPACTA Salud y Educacion, Barranco, Lima, 
Peru; 7Brigham and Women’s Hospital, Boston, MA, USA; 
8University of Rochester, Rochester, NY, USA; 9Fred Hutchinson 
Cancer Research Instituted, Seattle, WA, USA; 10Vanderbilt 
University, Nashville, TN, USA; 11GeoVax Inc., Smyrna, GA, USA
Background: The Phase 2a HVTN 205 trial was undertaken to 
further compare full-dose regimens of DNA priming with MVA 
boosting and MVA priming and boosting.
Methods: 150 vaccinia-naïve participants were inoculated i.m. 
via needle and syringe with 3 mg of pGA2/JS7 DNA at months 
0 and 2, and 1x108 TCID50 of MVA/HIV62B at months 4 and 6 
(DDMM regimen). 75 participants received 1x108 TCID50 of MVA/
HIV62B at months 0, 2, and 6 (MMM regimen) and 75 received 
placebo. While the safety data are still blinded, the vaccine 
regimens appeared safe and well tolerated. Immune studies 
were performed at 2 weeks following the final vaccination. 
Results: Similar to Phase 1 testing, the DDMM regimen induced 
higher rates of T cell responses whereas the MMM regimen 
induced higher rates of antibody responses. CD4 T cell responses 
were elicited in 65% of the DDMM and 43% of the MMM 
recipients (p=0.01) whereas CD8 T cells were induced in 22% and 
16%, respectively. The majority of T cells were directed against 
Gag with fewer against Env and only occasional responses to 
Pol. gp120 IgG antibodies were demonstrated in 45% and 68% 
of the DDMM and MMM recipients, respectively (p=0.001). 
gp41 IgG antibodies were seen in over 90% of both groups. The 
magnitudes of serum IgG responses exceeded the magnitudes of 
serum IgA responses by >10 fold with higher IgG to IgA responses 
being present in the MMM group (p=0.03). The antibody avidity 
index to the gp41 immunodominant epitope, a preclinical 
correlate of protection against infection demonstrated levels of 
affinity maturation comparable to preclinical studies. Sporadic 
weak neutralizing activity against Tier 1 and Tier 2 viruses was 
seen in both groups and was greater for MVA alone. 
Conclusion: The vaccine safety data and immune responses seen 
here are supportive of further testing. 
OA9.07 LB
rAd5 prime/NYVAC-B Boost Regimen is Superior 
to NYVAC-B prime/rAd5 Boost Regimen for Both 
Response Rates and Magnitude of CD4 and CD8 
T-Cell Responses
P. Bart1, Y. Huang2, N. Frahm3, S. Karuna3, M. Allen4,  
N.K. Kochar3, S. Chappuis1, J. Gaillard1, B. Graham5, G. Pantaleo1
1CHUV, Lausanne, Switzerland; 2SCHARP, Seattle, WA, USA; 
3HVTN, Seattle, WA, USA; 4DAIDS, NIAID, NIH, Bethesda, MD, 
USA; 5Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA
Background: HVTN 078 is a randomized, double blind phase 
1b clinical trial to evaluate the safety and immunogenicity of 
heterologous prime/boost vaccine regimens (NYVAC-B/rAd5 vs. 
rAd5/NYVAC-B) in healthy, HIV-1 uninfected, Ad5 seronegative 
adult participants.
Methods: The rAd5 vaccine expressed clade B Gag-Pol and the 
gp140 of HIV-1 92RW020 (clade A), HxB2/Bal-V3/∆V1V2 (clade 
B) and 97ZA012 (clade C). The NYVAC-B vaccine expressed clade 
B Gag-Pol-Nef and the gp120 of Bx08 (clade B). 80 healthy, HIV-1 
uninfected, Ad5 seronegative volunteers, aged 18 to 45 years, 
were randomized to the placebo arm (n=5) or one of 4 treatment 
(T) arms: T1 (n=30), 2xNYVAC-B/1xrAd5 (10E10); T2 (n=15), 
1xrAd5 (10E8)/2xNYVAC-B; T3 (n=15), 1xrAd5 (10E9)/2xNYVAC-B; 
T4 (n=15), 1xrAd5 (10E10)/2xNYVAC-B.
Intracellular cytokine staining responses (percent of CD4+ 
and CD8+ T cells producing IFN-γ and/or IL-2 in response to 
stimulation with global PTE peptides) were assessed two weeks 
after the final vaccination.
Results: For CD4+ T cells, the overall response rates for IFN-γ 
and/or IL-2 among the vaccinees were 42.9%, 93.3%, 92.3%, 
and 85.7% for T1-T4, respectively; and the median response 
magnitudes for positive responders were 0.26%, 0.76%, 
0.40%, and 0.76% for T1- T4, respectively. Both response rates 
(p<0.01) and magnitudes (p<0.03) of CD4+ T-cell responses were 
significantly lower in T1 compared to the other three treatment 
groups. For CD8+ T cells, the overall response rates were 65.5%, 
73.3%, 76.9% and 85.7% for T1-T4, respectively; and median 
response magnitudes for positive responders were 0.32%, 
0.99%, 1.86%, and 1.65%, respectively. Response rates were 
not significantly different between groups; however, response 
magnitudes were significantly lower in T1 compared to the other 
three arms (p<0.04). 
Conclusion: Priming with rAd5 followed by NYVAC-B boost 
is superior to priming with NYVAC-B followed by rAd5 boost 
for both response rates and the magnitude of CD4+ and CD8+ 
T-cell responses.
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OA10.02
A Deeper View of Transmitted/Founder Viruses 
Using 454 Whole Genome Deep Sequencing
D.C. Tully1, K.A. Power1, H. Bedard1, C.L. Boutwell1, P. Charlebois2, 
E.M. Ryan2, N.J. Lennon2, M. Altfeld1, M.R. Henn2, T.M. Allen1
1Ragon Institute of MGH, MIT and Harvard, Boston, MA, USA; 
2Broad Institute of MIT & Harvard, Cambridge, MA, USA
Background: Understanding the composition of transmitted/
founder viruses that represent the primary target for vaccine-
elicited responses is highly relevant to the design of an effective 
HIV-1 vaccine. The identification of transmitted and early founder 
viruses in primary infection has remained remarkably opaque, 
but recent advances in sequencing technologies have enabled a 
more comprehensive and sensitive assessment of the properties 
of transmitted/founder viruses. 
Methods: We applied full-length HIV-1 genome 454 deep 
sequencing of plasma virus to 22 clade B subjects from a cohort 
of men who have sex with men (MSM) identified during the 
earliest phase of acute HIV-1 infection (Fiebig stage II to III). 
Using novel assembly and variant detection algorithms coupled 
with a mathematical model we were able to comprehensively 
evaluate the viral diversity of transmitted/founder viruses in 
these individuals. 
Results: Using intra-host codon diversity frequencies, coupled 
with a mathematical model of random virus evolution during 
acute HIV-1 infection, we were able to unambiguously identify 
that 30% of subjects exhibited convincing evidence for multiple 
transmitted/founder viruses in line with prior reports on MSM 
transmission. Surprisingly, deep sequencing outside of the Env 
region identified additional low frequency variants possibly 
reflective of evidence of multiple transmitted/founder viruses in 
an additional 20% of subjects. 
Conclusion: Our study reveals that, in line with prior reports, 
approximately 30% of MSM subjects exhibit multiple transmitted/
founder viruses, with deep sequencing possibly identifying 
additional cases of multiple founder viruses which will require 
further validation. In summary, this data highlights the potential 
that whole deep sequencing has to uncover additional footprints 
originating from multiple transmitted/founder viruses. These 
findings, coupled with the knowledge that dual infections are 
associated with accelerated disease progression, demonstrate 
that the higher risk of virus acquisition in MSM could be a greater 
barrier for vaccine control which may have to contend with 
multiple transmitted variants.
OA10.01
Impact of Transmitted CTL Escape Mutations on 
Replicative Capacity and HIV Pathogenesis in Early 
Infection
J. Prince1, D. Claiborne1, D. Heckerman2, J. Carlson2, H. Prentice3, 
M. Schaefer1, L. Yue1, J. Mulenga4, J. Tang3, P. Goepfert3,  
P. Farmer1, R. Kaslow3, S. Allen1, E. Hunter1
1Emory University, Atlanta, GA, USA; 2Microsoft Research, 
Los Angeles, CA, USA; 3University of Alabama Birmingham, 
Birmingham, AL, USA; 4Zambia Emory HIV Research Project 
(ZHERP), Lusaka, Zambia
Background: Multiple HLA class I alleles have been shown to 
influence both HIV-1 transmission and viral load. In transmission 
pairs, viral loads of acutely infected partners correlate with viral 
loads (VL) of their chronically infected donors. This correlation 
becomes highly significant after adjustment for host factors 
known to modulate viral load. In addition, we have previously 
demonstrated that transmission of a virus containing multiple 
HLA-I associated polymorphisms resulted in a lower set point 
VL in Zambian linked recipients. These studies imply that 
transmitted viral characteristics play a role in defining early HIV-1 
pathogenesis, and it will be important for vaccine development 
to understand which viral characteristics are responsible for this. 
Methods: We investigated the role that the in vitro replicative 
capacity (RC) of the transmitted Gag plays in defining HIV-1 
clinical parameters, by cloning gag genes from the founder 
virus in newly infected partners of 149 epidemiologically linked 
transmission pairs into the subtype C, R5 tropic MJ4 provirus. 
Results: We observed a statistically significant positive correlation 
between the RC of Gag-MJ4 chimeras and set point VL in 
seroconverters (P=0.013). The RC of the transmitted Gag also 
correlated (P=0.025) to the viral load in the chronically infected 
donor, pointing to RC as the major viral characteristic responsible 
for the link between donor and linked recipient viral loads. The 
long term clinical benefit associated with the transmission of 
attenuated viruses was investigated by performing a Kaplan 
Meier analysis of time to CD4+ count less than 350. Individuals 
infected with attenuated gag sequences (RC< 1) were delayed in 
their progression to CD4+ counts < 350 compared to high (RC >2) 
replicating viruses (P = 0.034). 
Conclusion: Interestingly, this phenomenon seemed to be 
independent of viral load perhaps highlighting the role that early 
viral replication may play in defining HIV-1 pathogenesis. 
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OA10.04
Beneficial HLA-Mediated Viral Polymorphisms on 
the Transmitted Virus Additively Influence Disease 
Progression in HIV-1, Subtype C Infection 
R.S. Ntale1, D.R. Chopera1, N.K. Ngandu1, M. Abrahams1,  
A. Debra2, M. Mlotswa2, L. Werner3, Z. Woodman4, K. Mlisana3, 
S. Abdool Karim3, C.M. Gray5, C. Williamson1, CAPRISA 002 AI 
Study Team1
1Institute of Infectious Disease and Molecular Medicine, 
UCT, Cape Town, South Africa; 2National Institute for 
Communicable Diseases, Johannesburg, South Africa; 3Centre 
for AIDS Programme Research in South Africa, UKZN, Durban, 
South Africa; 4Department of Molecular and Cell Biology, 
University of Cape Town, Cape Town, South Africa; 5Division of 
Immunology, University of Cape Town, South Africa
Background: Transmitted viral factors have been shown to affect 
disease progression but whether infection with viruses carrying 
beneficial HLA-mediated escape polymorphisms affects disease 
progression in HLA-mismatched participants remains controversial. 
Methods: Gag was sequenced from 56 participants with acute HIV 
infection from the CAPRISA 002 cohort. For the newly identified 
mutation, replication fitness of viruses in PBMCs was compared 
in a subtype C infectious molecular clone. Disease progression 
was compared in participants infected with viruses carrying 
polymorphisms associated with beneficial HLA- B*57/58:01 and 
B7 supertype (B*39:10/81:01) allelic selective pressure in HLA 
mismatched participants. 
Results: In HLA-B*57/58:01-negative participants, 51% 
(25/49) were infected with viruses carrying at least one of the 
B*57/58:01 fitness cost-associated escape mutations in ISW9 
(A146P:19/49), KF11 (A163G: 10/49) or TW10 (T242N/S: 11/49) 
epitope. In HLA-B7 negative participants, only 9.4% (3/32) had 
viruses carrying mutations in the HLA-B7 immunodominant TL9 
epitope. Furthermore, we identified in viruses from HLA-B7 
participants and included in this analysis a novel mutation in 
Gag p17, Q65H; found in 9.4% (3/32) of B7 negative participants, 
and with mutant viruses replicating 11% slower than wild-type 
in tissue culture. Unlike a previous study in this cohort, infection 
with viruses carrying mutations in HLA-B*57/58:01 restricted 
epitopes alone did not impact on viral load setpoint in HLA-
mismatched participants, although there was a transient trend 
towards higher CD4 counts at 3 months post infection (p=0.0551). 
However, HLA-mismatched participants infected with viruses 
carrying 3 or more HLA footprints associated with fitness cost 
in Gag had significantly lower viral load and higher CD4 counts 
at 3 and 12 months post-infection (p=0.028 and p=0.0264, and 
p=0.0025 and 0.0689
Conclusion: These results suggest that multiple mutations 
generated when viruses are passaged through individuals with 
beneficial HLAs are needed to attenuate the virus, supporting 
vaccination methodologies that aim to render the virus less fit. 
OA10.03
Modeling Virus Exposure During Male to Female 
Transmission of HIV-1
A. Carias2, M. McRaven2, M. Anderson2, R.S. Veazey1, T.J. Hope2
1Tulane National Primate Research Center, Covington, LA, 
USA; 2Northwestern University, Feinberg School of Medicine, 
Chicago, IL, USA
Background: Previously, we illustrated that HIV is able to 
penetrate the intact female genital mucosal barrier. We found 
that HIV penetrates to depths where target cells reside. Using 
data obtained from tissues of more than 40 donors, we are able 
to generate an average for the ability of HIV to penetrate the 
mucosal. Using these averages we can extrapolate the number 
of HIV particles penetrating the mucosa per coital act for male 
to female HIV transmission for both acute and chronic infections.
Methods: Human cervical explants and macaque genital 
tracts were exposed to photoactivatable (PA-GFP) HIV. Rhesus 
macaques were inoculated intravaginally and genital tissues 
were removed 4 hours post-inoculation and dissected into 
relevant tissue specimens. Samples were snap frozen, sectioned, 
stained accordingly, and imaged for virus penetration. 
Results: We observed HIV penetration of the stratified squamous 
epithelium per image field to be 1.21 penetrating virions/scan 
when applied at 500ng/ml p24. Virus entered the tissue by 
diffusion/adsorption as revealed by fluid phase markers. Using 
these data, coupled with published determinations of average 
vaginal surface area and semen viral loads, we estimate that up to 
14,465 virions penetrate the mucosal barrier during transmission 
during acute phase infection and approximately 18 virions during 
HIV chronic infection. We estimate that approximately 1-2 cm2 of 
the endocervix is exposed without a thick mucus barrier allowing 
1-2 virions to penetrate.
Conclusion: This model is consistent with known characteristics 
of transmission. Having a very low number of virions with 
the ability to initiate transmission is consistent with the low 
transmission rate seen under conditions of chronic infection in 
monogamous heterosexual couples. Data is also consistent with 
the knowledge that typically, only 1 virion establishes systemic 
infection after male to female HIV transmission. These results 
provide a biological description of the functional virus dose of 
HIV during transmission.
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OA10.05 LB
T-Cell Based Sieve Analysis Ties HLA A*02 to Vaccine 
Efficacy and IgA-C1 Immune Correlate in RV144  
Thai Trial
T. Hertz1, A. Gartland1, H. Janes1, S. Li1, Y. Fong1, G.D. Tomaras2, 
D. Morris1, D. Geraghty1, G.H. Kijak3, P.T. Edlefsen1, M. Rolland3, 
B.B. Larsen4, S. Tovanabutra3, E. Sanders-Buell3, A.C. DeCamp1, 
C.A. Magaret1, H. Ahmed1, S. Nariya4, K. Wong4, H. Zhao4,  
W. Deng4, B.S. Maust4, M. Bose3, S. Howell3, M. Lazzaro3,  
A. Bates3, E. Lei3, A. Bradfield3, G. Ibitamuno3,  
V. Assawadarachai5, R.J. O’Connel3, M.S. deSouza5,  
S. Nitayaphan5, S. Rerks-Ngarm5, M.L. Robb3, M.J. McElrath1, 
B.F. Haynes6, N.L. Michael3, P.B. Gilbert1, J.I. Mullins4, J.H. Kim3
1Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 
2Duke University School of Medicine, Durham, NC, USA; 
3US Military HIV Research Program, Silver Spring, MD, USA; 
4University of Washington, Seattle, WA, USA; 5Royal Thai Army 
Component, AFRIMS, Bangkok, Thailand; 6Duke University, 
School of Medicine, Durham, NC, USA
Background: The RV144 trial showed an estimated 31% vaccine 
efficacy (VE) against HIV-1 infection. Two immunological 
correlates of risk were found in vaccine recipients: Envelope V1/
V2 antibody titers and IgA binding to Envelope (Haynes et al., 
2012). 
Methods: We conducted a CD8+ T-cell based sieve analysis of 
the V1/V2 region testing for differential escape from vaccine 
induced epitopes as predicted using computational methods. 
Breakthrough peptides that differed from predicted epitopes 
in the vaccine insert and had reduced HLA binding affinity were 
considered escapes.
Results: Three of twelve epitopes in V1/V2 of the MN protein 
boost showed evidence of escape (start-positions 147, 163, 
168 restricted by A*11 and A*02), with more escapes in 
vaccine recipients (p=0.018). We hypothesized that if escape 
was indicative of anamnestic responses, recipient’s HLA alleles 
should not modify VE. While VE was not different in A*11(+/-
) subgroups (p=0.45), it was higher in A*02(+) versus A*02(-) 
participants (VE=54% vs. 3%, interaction p-value=0.05). Previous 
analysis showed that HIV variants matching the vaccine insert 
at site 169 (K169) (in V2, implicated in antibody binding) were 
preferentially excluded from infections in vaccine recipients (VE 
against K169=48%, p=0.0036). We found significant VE against 
K169 in only the A*02(+) subgroup (74%, p=0.001; p-value for 
difference A*02(+/-)=0.01). Reanalyzing the immune correlates 
within A*02(+/-) subgroups, we found a direct correlation 
between IgA-C1 titers and infection rate in A*02(-) participants 
(OR=2.07, p=0.0002), but not in the A*02(+) participants 
(OR=1.12, p=0.71; A*02(+/-) interaction p-value=0.05). 
Conclusion: Our exploratory analysis, driven by a T-cell based 
sieve effect in envelope V1/V2, revealed an association between 
an HLA class I allele and VE, suggesting that VE was restricted 
to A*02(+) participants and that IgA-C1 antibodies inhibited 
protective effects of other responses in A*02(-) participants. 
This highlights the importance of considering the effects of host 
genetics on VE in future HIV vaccine trials.
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OA11.02
Shaping Humoral Responses Against Mini-libraries 
of HIV Env Antigens via Lipid Nanoparticle Vaccine 
Delivery
M.C. Hanson1, J. Mata-Fink1, W. Abraham1, K.D. Wittrup2,  
D.J. Irvine3
1Massachusetts Institute of Technology, Cambridge, MA, USA; 
2Ragon Institute of MGH, MIT and Harvard, Boston, MA, USA; 
3Howard Hughes Medical Institute, Chevy Chase, MD, USA
Background: Humoral immune responses elicited by an HIV 
vaccine would ideally be comprised of durable high titers of 
broadly neutralizing antibodies. Importantly, recent studies of 
broadly neutralizing antibodies isolated from infected patients 
have suggested that high degrees of somatic hypermutation 
(SHM) are a common feature of antibodies with high potency and 
good breadth. Thus, a successful vaccine will likely require both 
immunogens capable of focusing the humoral response against 
conserved neutralizing epitopes and appropriate adjuvants/
delivery systems capable of promoting elevated SHM and lasting 
responses against these epitopes.
Methods: We generated a small library of gp120 mutants 
engineered to have diverse surface compositions but a conserved 
CD4 binding pocket recognized by the broadly neutralizing 
antibody VRC01. These gp120 mutants were linked to “stealth” 
liposomes via 2KDa PEG linkers. These lipid nanoparticles were 
simultaneously loaded with immunostimulatory adjuvant 
molecules such as MPLA (TLR4 agonist) or CpG (TLR9 agonist) 
to support differentiation of helper T-cells and promote avidity 
maturation of the antibody response. Mice were immunized 
repeatedly with stealth liposomes carrying unique gp120 
mutants in each boost.
Results: Stealth liposomes carrying TLR4 agonists (TLRa) 
promoted long-lived humoral responses against env antigens 
superior to traditional adjuvants such as alum, montanide, or 
soluble protein mixed with TLRa. Studies of liposome/antigen 
trafficking in vivo suggest these enhanced responses reflect 
efficient trafficking of these nanoparticle vectors to lymph nodes. 
Notably, this heterologous immunization strategy elicited anti-
gp120 sera focused almost exclusively on the CD4 binding site 
and that competed with VRC01 for binding to gp120.
Conclusion: This approach of combined immunogen design with 
effective multivalent, nanoparticle-based antigen delivery may 
provide a strategy to promote strong and long-lived neutralizing 
antibody responses against HIV. 
This work was funded by the NIH (AI095109) and the Ragon 
Institute of MGH, MIT, and Harvard. DJI is an investigator of the 
Howard Hughes Medical Institute.
OA11.01
HIV-1 Envelope Trimer Elicits Higher Neutralizing 
Antibody Responses Than Monomeric gp120
J.M. Kovacs1, J.P. Nkolola2, H. Peng3, A. Cheung4, J. Perry4,  
C.A. Miller4, M.S. Seaman4, D. Barouch2, B. Chen1
1Harvard Medical School and Children’s Hospital Boston, 
Boston, MA, USA; 2Beth Israel Deaconess Medical Center and 
Ragon Institute, Boston, MA, USA; 3Children’s Hospital Boston, 
Boston, MA, USA; 4Beth Israel Deaconess Medical Center, 
Boston, MA, USA
Background: HIV-1 envelope glycoprotein is the primary target 
for HIV-1-specific antibodies. The native HIV-1 envelope spike on 
the virion surface is a trimer, but trimeric gp140 and monomeric 
gp120 are currently believed to induce comparable immune 
responses. Indeed, most studies on the immunogenicity of HIV-1 
envelope oligomers have revealed only marginal improvement 
over monomers. We report here that stable and homogenous 
envelope trimers with characteristics expected for the native 
viral spikes are substantially superior at eliciting neutralizing 
antibodies in guinea pigs.
Methods: Stable envelope gp140 trimer derived from clinical 
isolate sequences were stabilized with the T4-fibritin C-terminal 
trimerization tag and produced in stablely transfected 293T 
cells. Characterization of Env trimers was performed by Western 
blotting, size-exclusion chromatography (SEC), analytical-ultra 
centrifugation (AUC), multi-angle light scattering (MALS) and 
surface plasmon resonance (SPR). Guinea pigs were immunized 
six times with 100 µg of protein trimer or monomer in CpG/
Emulsigen adjuvants. Antibody responses were determined by 
ELISA and TZM.bl neutralizing antibody assays.
Results: Homogeneous trimer and monomer preparations 
exhibited high purity as measured by SEC and SDS-PAGE. AUC 
and MALS analyses revealed expected molecular weight for both 
trimer and monomer. SPR analyses revealed expected binding 
with CD4 and multiple broadly neutralizing antibodies. These 
trimers have markedly different antigenic properties than those 
of monomeric gp120s derived from the same sequences. They 
induce potent, cross-clade neutralizing antibody responses 
with titers substantially higher than those elicited by the 
corresponding gp120 monomers for a diverse set of both tier 1 
and tier 2 viruses.
Conclusion: We have demonstrated the importance of generating 
high-quality envelope trimers for antigenic and immunogenic 
studies; furthermore these results highlight the immunologic 
differences between monomers and high-quality envelope 
trimers, illustrating important implications for HIV-1 vaccine 
development and immunogen selection in large clinical trials.
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OA11.04
Antigen-Specific T Lymphocyte Responses Elicited by 
a DNA – MVA HIV CN54gp140 Immunization Regime 
Are Significantly Altered by the TLR4 Adjuvant GLA
P.F. McKay1, A.V. Cope1, J. Swales1, S. Joseph2, M. Esteban3,  
R. Tatoud1, D. Carter4, J. Weber1, R.J. Shattock1
1Imperial College, London, United Kingdom (Great Britain); 
2MRC Clinical Trials Unit, London, United Kingdom (Great 
Britain); 3Centro Nacional de Biotecnología, CSIC, Madrid, 
Spain; 4Infectious Disease Research Institute, Seattle, WA, USA
Background: We assessed the antigen-specific CD4 and CD8 
T lymphocyte responses elicited by a unique vaccine antigen 
matched and single Clade C DNA-poxvirus-protein regimen in 
mice and determined the immunomodulatory effect of the novel 
micellar formulation of a synthetic TLR4 ligand, GLA-AF (GLA) 
administered either sequentially or simultaneously with the 
MVA and protein.
Methods: Groups of 10 BALB/c mice were primed with plasmid 
DNA encoding CN54 env/gag-pol-nef and then boosted with 
MVA-C (env-gag-pol-nef) and CN54gp140 protein with or without 
GLA-AF. The MVA and protein were either given sequentially at 
3 weekly intervals or simultaneously in different legs at 3 and 
6 weeks. Cellular responses were assessed at necropsy three 
weeks after the final immunization. Splenocytes were harvested 
and analysed for antigen-specific T cell responses using peptide 
pools spanning the Env and Gag proteins by intracellular cytokine 
staining and CFSE labelling. Multiparametric flow profiles were 
analysed using FlowJo and data sets were organized and charted 
using the SPICE software.
Results: GLA adjuvanted CN54gp140 substantially influenced the 
antigen-specific T lymphocyte cytokine expression profiles and 
proliferative responses in animals primed with DNA and boosted 
by MVA or those immunized with MVA alone. We observed 
adjuvant-induced changes in the polyfunctional IFN-γ, TNF-α and 
IL-2 expression profiles of both the CD4 and CD8 T lymphocyte 
populations and differential responses to separate peptide pools.
Conclusion: We have shown that the GLA adjuvant alters both 
the degree and the nature of the antigen-specific T lymphocyte 
responses and that these immunomodulatory changes are 
critically dependent upon the timing of application. These effects 
are likely due to either the presence of systemic GLA providing 
a general immunostimulatory environment or enhanced T cell 
priming in the local draining lymph nodes. This ability to tailor 
CN54gp140-specific T cell immunity is a valuable tool to be 
exploited in vaccine design.
OA11.03
Vaccine Responses to Conserved Regions of the HIV-1 
Proteome Are Associated with an Increased Capacity 
to Inhibit Multiple Virus Isolates Ex Vivo
A. Ashraf1, J. Kopycinski1, H. Cheeseman1, F. Lala1, J. Czyzewska-
Khan1, A. Spentzou1, D.K. Gill1, M. Keefer2, J. Excler3, P. Fast3,  
P. Hayes1, J.H. Cox3, J. Gilmour1
1International AIDS Vaccine Initiative (IAVI), Imperial College, 
London, London, United Kingdom (Great Britain); 2University 
of Rochester School of Medicine & Dentistry, Rochester, NY, 
USA; 3International AIDS Vaccine Initiative (IAVI), New York, 
NY, USA
Background: The majority of assays currently used to assess HIV-
1 vaccine candidate immunogenicity in humans fail to predict 
protection against HIV-1 acquisition or control of viraemia. 
However, a correlation between in vivo and ex vivo control 
mediated by CD8+ T-cell populations has been described using 
an ex vivo virus inhibition assay (VIA) in chronically infected 
individuals and vaccinated non-human primates. Here we 
attempt to relate the specificity of vaccine-induced virus-specific 
CD8 responses to the inhibition of HIV-1 ex vivo.
Methods: Using peptide epitope mapping, we assessed the 
breadth and specificity of CD8 T-cell responses induced by 
vaccination using two adenovirus serotype 35 (Ad35) vectors 
containing gag, reverse transcriptase, integrase and nef (Ad35-
GRIN) and env (Ad35-ENV), respectively, derived from HIV-1 
subtype A isolates. The conserved regions targeted by these 
25 subjects were related to the capacity of vaccine-induced 
CD8 T-cells to inhibit replication of a cross-clade panel of HIV-1 
isolates using the VIA.
Results: A median of 4 peptides were recognised in vaccinated 
individuals (range 1-9). When related to the log reduction of p24 
production as measured in the VIA, mapping data suggest that 
targeting immunodominant responses towards highly conserved 
regions of the HIV-1 proteome tended towards an increased 
ability to inhibit multiple clades of HIV-1 ex vivo.
Conclusion: These data support the plausibility of inducing 
conserved CD8+ T cell responses using a consensus HIV-1 subtype 
A sequence in an adenovirus-based vector.
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OA11.05 LB
Quality of T-Cell Responses Versus Reduction In Viral 
Load: Results From An Exploratory Phase II Clinical 
Study Of Vacc-4x, A Therapeutic HIV Vaccine
K. Ellefsen-Lavoie1, J. Rockstroh2, R. Pollard3, G. Pantaleo1,  
D. Podzamczer4, D. Asmuth3, J. van Lunzen5, K. Arastéh6,  
D. Schürmann7, B. Peters8, B. Clotet9, D. Hardy10, A. Lazzarin11, 
J. Gatell12, M.A. Sommerfelt13, I. Baksaas14,  
V. Wendel-Hansen15, B. Sørensen15
1University of Lausanne, Lausanne, Switzerland; 2University 
of Bonn, Bonn, Germany; 3University of California at Davis, 
Davis, CA, USA; 4Universitari de Bellvitge, Barcelona, Spain; 
5Universitatsklinikum Hamburg-Eppendorf, Hamburg, 
Germany; 6EPIMED, Berlin, Germany; 7Charité Virchow-
Klinikum, Berlin, Germany; 8Guy’s and St. Thomas’ Hospital, 
London, United Kingdom (Great Britain); 9Hospital Germans 
Trias i Pujol, Badalona, Spain; 10Cedars-Sinai Medical Center, 
Los Angeles, CA, USA; 11Università Vita-Salute San Raffaele, 
Milan, Italy; 12Hospital Clinic i Provincial, Barcelona, Spain; 
13Bionor Pharma ASA, Oslo, Norway; 14Mericon, Skien, Norway; 
15Bionor Pharma, Oslo, Norway
Background: Immunization with Vacc-4x, a peptide-based 
therapeutic vaccine for HIV-1, has shown a statistically significant 
reduction in viral load set point compared to placebo during 
treatment interruption in an exploratory phase II clinical study 
enrolling 135 subjects (NCT00659789). This vaccine aims to 
induce sustained cell-mediated immune responses to conserved 
domains on HIV p24. 
Methods: After 6 immunizations on ART over 28 weeks, 
treatment was interrupted for up to 24 weeks (Vacc-4x n=88; 
placebo n=38). Immunological analyses (ELISPOT, proliferation, 
intracellular cytokine staining (ICS)) to HIV p24 were carried out 
at central laboratories. The HLA class I profile (Vacc-4x n=73, 
placebo n=32) was also determined. 
Results: For subjects that remained off ART until week 52 
(Vacc-4x n=56, placebo n=25), there was a log 0.44 reduction 
in viral load set point between the Vacc-4x and placebo groups 
(p=0.0397). There was a similar distribution of HLA class I alleles 
in the two treatment arms, with the exception of the B35 allele 
(27% of Vacc-4x subjects versus 8% placebo subjects). The viral 
load of ELISPOT positive Vacc-4x subjects was significantly lower 
than that of placebo subjects (p=0.023). There was no significant 
difference in T-cell proliferation responses between Vacc-4x and 
placebo groups, however, the percentage of subjects showing 
proliferative CD4 and CD8 T-cell responses to Vacc-4x peptides 
increased over time only for the Vacc-4x group. ICS analysis 
showed a predominance of CD8-mediated T-cell responses to 
p24 that were significantly increased from baseline for the Vacc-
4x group (p<0.043) but not for the placebo group(p>0.05). There 
was also a trend towards higher numbers of polyfunctional T-cells 
in the Vacc-4x group compared to the placebo group (p=0.188). 
Conclusion: These findings suggest Vacc-4x immunization can in-
fluence the quality of immune responses to HIV-1 p24 irrespective 
of HLA status, and contribute to a reduction in viral load. 
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OA12.02
Reinventing the Nucleic Acid Vaccine with Self-
Amplifying RNA
A.J. Geall1, G.R. Otten1, A. Hekele1, W. Bogers2, H. Oostermeijer2, 
P. Mooij2, K. Gerrit2, E. Verschoor2, K. Banerjee1, Y. Cu1,  
C.W. Beard1, L.A. Brito1, J.B. Ulmer1, C.W. Mandl1, S.W. Barnett1
1Novartis Vaccines and Diagnostics, Cambridge, MA, USA; 
2BPRC, Rijswijk, Netherlands
Background: Self-amplifying RNAs (replicons) of positive-strand 
viruses such as alphaviruses are potentially safe and useful 
vectors for delivering vaccine antigens. We previously showed 
that recombinant alphavirus replicon particles (VRP), used in 
prime-boost regimen with Env in MF59 protein protected rhesus 
macaques against mucosal challenge with SHIVSF162P4 (J. Virol. 
84:5975, 2010).
Novartis recently developed a synthetic self-amplifying mRNA 
(SAM™) vaccine platform, using cell-free RNA production and 
non-viral vaccine delivery systems. The SAM™ platform avoids the 
limitations of cell culture production that complicate production 
of the alphavirus VRPs and other viral vector systems. Safety 
concerns associated with the potential generation of replication 
competent virus (RCV) are eliminated, and the absence of viral 
structural proteins reduces issues associated with anti-vector 
immunity, a major limitation of other vectored vaccine systems.
Methods: HIV- SAM™ vaccines were evaluated in small animals 
and nonhuman primates (NHP). 
Results: Here we show that SAM™ vaccines encoding HIV 
antigens induced potent systemic and mucosal immune 
responses in small animals and nonhuman primates (NHP). 
Humoral and cellular responses elicited in mice with HIV-SAM™ 
vaccines were superior to naked DNA or RNA and comparable 
to those seen with alphavirus replicon particles (VRPs). Robust 
binding and neutralizing antibodies were seen following two 
immunizations with a HIV-SAM™ vaccine encoding subtype C 
TV1 gp140 in rabbits. The same vaccine elicited both IFNγ and 
IL2 T-cell responses, B-cell ELISpots, and Env-specific antibody 
responses in rhesus macaques, also after only two immunizations. 
Importantly, the vaccines were well-tolerated with no local or 
systemic adverse events observed.
Conclusion: These results provide the first evidence in a primate 
species that vaccination with formulated self-amplifying RNA is 
safe and immunogenic, eliciting robust immune responses.
The safety, immunogenicity, and ease of production provided by 
SAM™ vaccines provide a rationale for accelerated evaluations of 
this platform in the context of HIV vaccines.
OA12.01
DNA Vaccines Expressing Conserved Elements 
Provide Potent and Broad Immune Responses
G.N. Pavlakis7, V. Kulkarni7, A. Valentin7, M. Rosati7, N.Y. Sardesai1, 
B. Mothe2, C. Brander2, S. LeGall3, D.B. Weiner4, M. Rolland5, 
J.I. Mullins6, B.K. Felber7
1Inovio Pharmaceuticals, Inc., Blue Bell, PA, USA; 2IrsiCaixa-
HIVACAT, Barcelona, Spain; 3Ragon Institute of MGH, MIT 
and Harvard, Boston, MA, USA; 4University of Pennsylvania, 
Philadelphia, MD, USA; 5U.S. Military HIV Research Program, 
Rockville, MD, USA; 6University of Washington, Seattle, WA, 
USA; 7Frederick National Laboratory for Cancer Research, 
Frederick, MD, USA
Background: Immunodominance and sequence diversity are 
major hurdles in the development of effective HIV vaccines. 
We tested the hypothesis that a vaccine candidate composed 
of strictly Conserved Elements (CE) of the HIV proteome 
excluding the variable regions would help overcome problems 
of viral sequence diversity and potential negative effects 
of immunodominance. Seven CE were identified in p24gag. 
Vaccination of macaques with p55gagDNA failed to elicit cellular 
or humoral immune responses to the CE, while epitopes outside 
of the CE were immunogenic.
Methods: Two HIV p24gagCE DNA plasmids were generated, 
providing potential epitopes found in >99% of all HIV-1 M group 
sequences. DNA vectors, optimized for gene expression were 
used to immunize mice and macaques by IM injection followed 
by in vivo electroporation. 
Results: Vaccination with p24gagCEvac DNAs elicited potent, 
cross-clade cellular and humoral immune responses. Highly 
cytotoxic CE-specific T cells, capable of Granzyme B production 
and degranulation, were generated. Importantly, boosting of the 
CEvac-primed macaques with p55gagDNA greatly augmented the 
CE-specific cellular responses (up to 10-fold) as well as humoral 
responses, despite the failure of p55gagDNA vaccine to induce de 
novo CE-specific responses. CEvac DNA prime-p55gagDNA boost 
in mice led to similar conclusions. Interestingly, mapping analysis 
showed differential increase of the CE-specific responses by 
the p55gagDNA boost, demonstrating changed hierarchy of CE 
responses in macaques.
Conclusion: Vaccination with the p24gagCEvac DNA overcame 
the problem of diversity by generating strong cross-clade Gag-
specific immune responses, and of immunodominance, eliciting 
responses to subdominant but highly conserved elements, and 
also by broadening the p55gagDNA induced immunity. p55gagDNA 
did not induce de novo responses to the CE, but was able to 
significantly boost pre-existing CE-induced responses and alter 
the hierarchy of these responses. Translation of this concept into 
clinical trials may elicit cross-clade cellular immune responses 
against components of the viral proteome with limited capacity 
for immunological escape.
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OA12.04
Full-Length HIV-1 Immunogens Induce Greater 
T Lymphocyte Responses to Conserved Epitopes 
Than Conserved-Region-Only HIV-1 Immunogens in 
Monkeys
K.E. Stephenson1, A. SanMiguel1, N.L. Simmons1, K. Smith1,  
J.J. Szinger2, B.T. Korber2, D.H. Barouch1
1Beth Israel Deaconess Medical Center and Harvard University, 
Boston, MA, USA; 2Los Alamos National Laboratory, Los 
Alamos, NM, USA
Background: A global HIV-1 vaccine will need to induce broadly 
reactive immune responses against conserved HIV-1 regions. 
It is currently unclear how best to elicit these responses by 
vaccination. We therefore compared the immunogenicity of a 
bivalent full-length HIV-1 Gag/Pol/Env mosaic vaccine, a trivalent 
full-length HIV-1 Gag/Pol/Env mosaic vaccine, and a bivalent 
mosaic vaccine containing only conserved HIV-1 Gag/Pol/Env 
epitopes in rhesus monkeys.
Methods: We immunized 18 rhesus monkeys with rAd35 (prime) 
and rAd26 (boost) vectors expressing bivalent full-length (N=6), 
trivalent full-length (N=6), or bivalent conserved-region-only 
(N=6) HIV-1 Gag/Pol/Env mosaic immunogens. We assessed 
HIV-1-specific and conserved-region-specific cellular immune 
responses by ELISPOT using global PTE and vaccine-matched 
peptides. Responses were mapped to individual epitopes and 
were identified as CD4+ or CD8+ through cell-depletion assays. 
Comparisons were performed by Wilcoxon rank-sum tests.
Results: There was no difference in the breadth of HIV-1-specific 
T lymphocyte responses elicited by the bivalent and trivalent 
full-length mosaic vaccines (P=.686). However, the bivalent full-
length vaccine generated a greater breadth of HIV-1-specific 
CD8+ T lymphocyte responses than the conserved-region-only 
vaccine (P=.007). The bivalent full-length vaccine also generated 
equivalent breadth of CD8+ T lymphocyte responses to conserved 
HIV-1 epitopes compared to the conserved-region-only vaccine 
(P=1.000), and surprisingly, the responses generated by the 
full-length vaccine to conserved HIV-1 epitopes were greater in 
magnitude than those generated by the conserved-region-only 
vaccine (P=.008).
Conclusion: These data demonstrate that an HIV-1 mosaic 
vaccine expressing full-length antigens elicited greater responses 
to conserved epitopes than a mosaic vaccine expressing only 
concatenated conserved HIV-1 regions. In addition, the bivalent 
and trivalent full-length mosaic vaccines generated comparable 
breadth of HIV-1-specific CD8+ T lymphocyte responses. These 
results support the clinical development of the bivalent full-
length HIV-1 mosaic vaccine.
OA12.03
Adenovirus Serotype 26 Utilizes CD46 as Primary 
Cellular Receptor and Only Transiently Activates 
T Lymphocytes Following Vaccination of Rhesus 
Monkeys
H. Li1, E.G. Rhee1, K. Masek-Hammerman2, J.E. Teigler1,  
P. Abbink1, D.H. Barouch1
1Beth Israel Deaconess Medical Center, Boston, MA, USA; 
2New England Primate Research Center, Southborough, MA, USA
Background: Adenovirus serotype 5 (Ad5) utilizes coxsackievirus 
and adenovirus receptor (CAR) as its primary cellular receptor. 
However, the cellular receptor utilized by Ad26 and the 
inflammatory responses elicited following Ad26 vaccination 
remain unclear. 
Methods: Receptor usage was assessed using CD46 transgenic 
mouse cells, as well as by CAR- and CD46-specific mAb blocking 
studies using human PBMC. Twelve adult rhesus monkeys 
were inoculated with of 1011 viral particles (vp) of replication-
competent Ad5 and Ad26 (N=6) or saline (N=6) at weeks -8 and -4, 
and were vaccinated intramuscularly with 3×1010 vp replication-
incompetent Ad26-Gag/Pol/Env vectors. At week 2, monkeys 
were sacrificed to assess immunologic and inflammatory 
responses at mucosal surfaces. 
Results: Transduction by Ad26 and Ad35 vectors was markedly 
enhanced in CD46 transgenic mouse cells compared with wild 
type mouse cells. Moreover, transduction of human PBMC by 
Ad26 and Ad35 vectors was efficiently blocked by the anti-CD46 
mAbs 13/42, M177 and MEM-258, but not by the anti-CAR 
mAbs RmcB and E1-1. Monkeys with and without baseline Ad5/
Ad26 immunity exhibited similar magnitude and only transient 
activation (1-2 weeks) of vector-specific CD4+ T cell responses 
in both PBMC and colorectal biopsies. Inflammatory cell 
infiltrates in colorectal and foreskin mucosa were comparable 
in baseline and vaccinated animals regardless of baseline Ad5/
Ad26 immunity.
Conclusion: Ad26 utilizes CD46 and not CAR as a primary cellular 
receptor for infection. We also observed no increased mucosal 
cellular activation or vector-specific CD4+ T lymphocytes in 
baseline Ad5/Ad26-seropositive monkeys as compared with 
baseline seronegative monkeys following Ad26 vaccination. 
These data contribute to our understanding of the biology of 
Ad26 as a candidate vaccine vector. 
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OA12.05 LB
Rational Immunogen Design to Target Specific 
Germline B Cell Receptors 
J. Jardine1, O. Kalyuzhniy 1, T. Ota1, A. McGuire2, S. Menis1,  
J. Julien1, E. Falkowska1, S. MacPherson1, M. Jones1,  
D.R. Burton1, I.A. Wilson1, L. Stamatatos2, D. Nemazee1,  
W.R. Schief1
1The Scripps Research Institute, San Diego, CA, USA; 2Seattle 
BioMed, Seattle, WA, USA
Background: VRC01 and a number of other broad and potently 
neutralizing CD4 binding site antibodies have been isolated from 
HIV positive individuals. These antibodies utilize VH1-2 and 
make the majority of their contacts via the framework portion 
of the heavy chain. Recently, it has been noted that the germline 
precursors to these VRC01-like antibodies do not bind to HIV Env 
nor does Env stimulate B cell lines expressing these germline 
precursors. This lack of interaction between germline antibodies 
and Env may represent a significant block for re-elicitation of 
these antibodies. 
Methods: We engineered a modified Env to have affinity for 
the VH1-2 germline antibodies. We believe this antigen will 
selectively activate B cells that have the potential to elicit VRC01-
like antibodies.
Homology modeling and computational protein interface design 
was used to predict mutations to modify GP120 to have affinity 
for the VH1-2 germline antibodies. Mutations identified during 
the computational design were used to generate directed 
libraries that were screened on the surface of yeast to optimize 
binding against the germline predicted precursors of several 
VRC01-like antibodies as well as their mature counterparts. 
Results: Using the strategy outlined above, we have modified a 
GP120 outer domain to have sub-micromolar affinity for several 
VH1-2 germline antibodies while maintaining high affinity for the 
VRC01-like matured antibodies. We have shown in a cell-based 
assay that, when multimerized, the engineered immunogen 
stimulates B-cell lines expressing germline VRC01 and other VH1-
2 germline antibodies. 
Conclusion: Our immunogen offers a novel approach to re-elicit 
VRC01-like antibodies. We have demonstrated proof of principle 
that immunogens can be rationally directed to target specific 
germline B cell receptors. If this approach proves successful, 
it could become a generally applicable strategy to selectively 
activate desirable antibodies when creating new vaccines.
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P01.02
HIV-1 Capture and Antigen Presentation by Dendritic 
Cells: Enhanced Viral Capture Does Not Correlate 
with Better T-Cell Activation
M. Rodriguez-Plata1, A. Urrutia2, S. Cardinaud2, M. Buzon1,  
N. Izquierdo-Useros1, J. G. Prado1, M. Puertas1, I. Erkizia1,  
P. Coulon2, S. Cedeño1, B. Clotet1, A. Moris3, J. Martinez-Picado1
1AIDS Research Institute IrsiCaixa, Badalona, Spain; 2INSERM, 
UMRS-945, Infection and Immunity, Université Pierre et Marie 
C, Paris, France; 3INSERM, UMRS-945, Infection and Immunity, 
Univ. Pierre et Marie Curie, Paris, France
Background: During HIV-1 infection, dendritic cells (DC) facilitate 
dissemination of HIV-1 while trying to trigger adaptive antiviral 
immune responses. We examined whether increased HIV-1 
capture in DC matured with lipopolysaccharide (LPS) results in 
more efficient antigen presentation to HIV-1–specific CD4+ and 
CD8+ T cells. In order to block the DC-mediated trans-infection 
of HIV-1 and maximize antigen loading, we also evaluated a non-
infectious integrase-deficient HIV-1 isolate, the HIV
NL4-3ΔIN
.
Methods: Immature DC (iDC), mature DC (mDC) activated with 
IL-1β, TNF-α, IL-6, and PGE2 (ITIP) or LPS during viral uptake, 
and fully mDC matured with ITIP or with LPS for 48 h before 
viral loading were tested. Antigen presentation to HIV-1-specific 
CD4+ and CD8+ T cell clones was quantified by IFN-γ ELISPOT. DC-
associated p24Gag HIV-1 and DC-mediated HIV-1 trans-infection 
were also evaluated in parallel.
Results: We showed that higher viral capture of DC did not 
guarantee better antigen presentation or T-cell activation. 
Greater HIVNL4-3 uptake by fully LPS-matured DC resulted in 
higher viral transmission to target cells but poorer stimulation 
of HIV-1–specific CD4+ and CD8+ T cells. Conversely, maturation 
of DC with LPS during—but not before—viral loading enhanced 
both HLA-I and HLA-II HIV-1–derived antigen presentation. On 
the other hand, DC maturation with ITIP during viral uptake only 
stimulated HIV-1–specific CD8+ T cells. Integrase-deficient HIVNL4-
3ΔIN
 was also efficiently captured and presented by DC through 
HLA-I and HLA-II pathways, but in absence of viral dissemination.
Conclusion: Hence, DC maturation state, activation stimulus, 
and time lag between DC maturation and antigen loading 
impact HIV-1 capture and virus antigen presentation. Our results 
demonstrate a dissociation between the capacity to capture 
HIV-1 and to present viral antigens. HIV
NL4-3ΔIN
 seems to be an 
attractive candidate to be explored. These results provide new 
insights into DC biology and have implications in the optimization 
of DC-based immunotherapy against HIV-1 infection.
P01.01
Live, Attenuated Rubella Vectors Expressing HIV and 
SIV Vaccine Antigens
I. Berkower1, Y. Ni1, K. Virnik1
1Center for Biologics, U.S. Food and Drug Administration, 
Bethesda, MD, USA
Background: Despite progress in identifying targets of 
neutralizing antibodies and T cell immunity, many HIV antigens 
have been weak immunogens. We have developed rubella as a 
live viral vector to enhance immunogenicity by presenting HIV 
and SIV antigens in the context of an acute infection. These 
vectors are based on the rubella vaccine strain RA27/3: safety 
and immunogenicity have been established in millions of 
children around the world. If the vector loses its insert, it would 
revert to the vaccine strain. It is immunogenic: one dose protects 
for life (against rubella). It elicits mucosal and systemic immunity. 
Rubella readily infects rhesus macaques, and these animals can 
test vector growth, immunogenicity and protection against SIV 
or SHIV challenge. 
Methods: Starting from the live, attenuated vaccine strain, we 
have identified two insertional sites, where foreign genes can 
be expressed without compromising rubella protein expression 
or titer. 
Results: Rubella can accommodate foreign inserts at either of two 
sites. Inserts at the nonstructural site were expressed as a fusion 
protein with rubella nonstructural protein p150. At the structural 
site, inserts were expressed with the structural polyprotein, 
processed to free protein, and incorporated into virions. Foreign 
antigens, including GFP, SIV Gag, and HIV MPER, were stably 
expressed for >10 passages. Six recombinant rubella vectors were 
selected for testing in vivo. Two of these grew well, infecting 3 out 
of 3 macaques while expressing HIV or SIV antigens. 
Conclusion: Live, attenuated rubella vectors provide a good 
vaccine platform for evaluating SIV and HIV antigens in vivo 
and comparing prime/boost strategies for immunogenicity and 
protection. The results may also apply to man, since the same 
vectors grow well in human cells and could be substituted for 
current rubella vaccines, or they could be given prior to the age 
of natural rubella infection (9 years). 
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P01.04
Cross-Clade Neutralization of HIV-1 by a Monoclonal 
Antibody Obtained by Immunization with Liposomes 
Containing Lipid A and a Synthetic MPER Peptide
G.R. Matyas1, O. Jobe2, L. Wieczorek2, K.K. Peachman2,  
Z. Beck2, V.R. Polonis1, M. Rao1, C.R. Alving1
1Walter Reed Army Institute of Research, Silver Spring, MD, 
USA; 2MHRP, WRAIR and Henry Jackson Foundation, Silver 
Spring, MD, USA
Background: Development of vaccine formulations that induce 
cross clade neutralizing antibodies to the membrane proximal 
external region (MPER) of gp41 similar to 4E10 and 2F5 have 
been extensively investigated. We previously demonstrated 
that immunization with liposomes containing MPER and lipid 
A as an adjuvant could induce antibodies to the MPER and IgM 
monoclonal antibodies obtained from the mice bound to both 
lipids and MPER and neutralized HIV-1 (Matyas et al., 2009 AIDS 
23, 2069-77). We now report a new IgG monoclonal antibody 
WR324 obtained from mice immunized with a similar vaccine 
formulation that binds to MPER and can neutralize multiple 
clades of HIV-1. 
Methods: Mice were immunized with liposomes containing 
phosphatidyl inositol-4-phosphate and MPER with lipid A as an 
adjuvant. The peptide, LELDKWASLWNWFDITNWLWYIK (aa 661-
684) was derived from gp41 (HXB2 stain). Spleen cells were fused 
with SP2/O cells and cloned. WR324 was purified and the binding 
specificities were assessed by ELISA. HIV-1 neutralization was 
assessed in PBMC using replication competent, Renila reniformis 
luciferase (LucR)-expressing HIV-1 reporter viruses (LucR-IMC) 
and in a human monocyte derived macrophage (MDM) assay 
with purified viruses.
Results: WR324 is an IgG2b with a kappa light chain and it bound 
to the MPER peptide, but not to lipids or recombinant gp41. 
WR324 neutralized clade B, BaL and SF162, clade CRF01_AE, 
CM235, and clade C, GS 014 IMC viruses in the PBMC assay 
using two different donors. It also neutralized primary viruses, 
US-1, BaL, and clade CRF01_AE, M066 in the MDM assay using 
3 different donors. WR324 did not bind to the surface of MDM 
cells, but binding to HIV-1 was observed by electron microscopy 
with immuno-gold labeling.
Conclusion: Immunization with liposomes containing MPER and 
lipid A as an adjuvant induced an IgG monoclonal antibody with 
specificity to the MPER that neutralized multiple clades of HIV-1 
in two different assay systems.
P01.03
CYPA, a Novel and Potential Genetic Adjuvant 
Enhanced HIV-1 DNA Vaccine Immunoreactivity
J. Hou1, Y. Liu1, Y. Shao1
1China CDC, Beijing, China
Background: Recent research highlight that newly synthesized 
HIV-1 capsid protein is required to induce dendritic cell activation 
through a pathway involving interaction with peptidyl-prolyl cis-
trans isomerase cyclophilin A (CYPA),which subsequently induce 
an antiviral type I interferon response and activation of T cells. 
Previous studies also revealed HIV Gag-CYPA interaction inhibited 
recognition by host restriction factors. In another perspective, the 
inhibition effect might be benefit for HIV Gag immunogenicity. 
Consequently, we assume CYPA might be a potential genetic 
adjuvant co-inoculation with HIV-1 Gag DNA vaccine, which not 
only circumvent the restriction of host factors, but also activate 
dendritic cell and enhance adaptive immune response. 
Methods: In this study, 6-8-week-old female BALB/C mice were 
administrated thrice intramuscularly with pDRVI4.0-Gag HIV-1 
DNA vaccine co-formulated with pDRVI4.0-CYPA plasmid at two 
weeks interval. IFN-γ ELISPOT, Gag-specific ELISA, IgG isotype 
ELISA detected cellular and humoral immunological response.
Results: The regimen of HIV-1 Gag DNA premixed with CYPA 
DNA induced robust immune responses in mouse model. IFN-γ 
ELISPOT result demonstrated Gag DNA alone only generated 180 
± 63(mean ± SD) SFCs/million. However, Gag DNA combined with 
CYPA DNA strategy produced 353 ± 80(mean ± SD) SFCs/million. 
In humoral immune response, Gag DNA co-inoculation with CYPA 
DNA showed high level antibody titer (GMT=22800),whereas 
Gag DNA alone induced slight antibody response (GMT=8000). 
IgG isotype results confirmed that co-vaccination with CYPA DNA 
induced Th1-bias immune response, however, Gag DNA alone 
activated Th1/Th2 response in balance.
Conclusion: This is the first report demonstrating that mixture 
of CYPA DNA and HIV-1 gag DNA vaccine could induce robust 
cellular and humoral immune response in the mouse model. 
Ongoing studies are focusing on construction of dual expression 
cassette DNA vaccine, which including both Gag and CYPA gene. 
Further research will also construct others HIV DNA vaccine 
involving human or non-human primates CYPA.
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P01.06
Engineered gp120 Immunogens That Elicit VRC01-like 
Antibodies by Vaccination
J. Mata-Fink1, M. Hanson1, B. Kriegsman1, D. Irvine1, K. Wittrup1
1Massachusetts Institute of Technology, Cambridge, MA, USA
Background: One of the great challenges for an HIV vaccine is 
to elicit broadly neutralizing antibodies specific for conserved 
epitopes from which the virus cannot easily escape. The CD4 
binding site is one such epitope against which several antibodies 
(e.g. b12, VRC01) have been isolated. In macaques infected 
with SHIV, passive immunization with these CD4-directed 
neutralizing antibodies fails to control the virus, but prophylactic 
administration is highly protective. Similarly, patients who 
generate neutralizing antibodies over the course of an HIV 
infection derive no clinical benefit from them, but eliciting such 
antibodies prophylactically by vaccination may prevent the virus 
from establishing its lethal foothold.
Methods: Yeast surface display is a powerful method for rapidly 
engineering complex glycoproteins. We have developed a 
stripped core gp120 that presents a functional CD4 binding site 
when displayed on yeast, and an accompanying suite of tools with 
which to map conformational epitopes of neutralizing antibodies, 
design novel immunogens, and monitor the specificity of serum 
following immunization.
Results: We map the epitopes of the anti-gp120 antibodies 
VRC01, b12, and b13, and uncover subtle energetic differences 
in their nearly-overlapping epitopes that are not obvious from 
existing crystal structures. With this information, we design 
novel gp120 immunogens that share the VRC01 epitope but 
whose other surface amino acids are highly diverse. When mice 
are immunized with these immunogens in a heterologous prime-
boost format they elicit VRC01-competitive antibodies and not 
the competing immunodominant specificities seen with a single 
immunogen. The antisera are tested for their binding to a panel 
of gp120, and their neutralization potential is assayed.
Conclusion: We have engineered a novel set of immunogens that 
elicit CD4 binding site-directed antibodies upon immunization. 
The yeast display tools may be used to design future immunogens.
P01.05
IL-12 Plus CTB in Intranasal DNA-MVA Schemes 
Improved Magnitude and Quality of Both Systemic 
and Mucosal HIV Cellular Immune Responses 
A.M. Rodriguez1, C. Maeto1, J. Falivene1, M.P. Holgado1,  
M.M. Gherardi1
1INBIRS (ex Centro Nacional de Referencia para el SIDA), 
Buenos Aires, Argentina
Background: Mucosal tissues are the major route of HIV 
transmission. Therefore, designing immunization regimes aimed 
to induce mucosal immune response is needed. The aim of this 
study was to analyze the activity of IL-12 alone or in combination 
with the cholera toxin B subunit (CTB), applied in DNA-prime/
MVA-boost intranasal immunizations.
Methods: Balb/c mice were intranasally immunized with DNA 
expressing HIV-1 EnvB plus DNAIL-12 alone or in combination with 
CTB (10ug, applied at prime and booster doses). Groups receiving 
CTB, complete cholera toxin (CT) or non-adjuvants (control) were 
included. All groups received MVAEnvB as boost dose. Immune 
responses were evaluated 14, 30 or 53 days after immunization.
Results: IL-12 plus CTB generated the highest response, showing 
a synergistic effect for both adjuvants, measure by IFN-g and 
IL-2 ELISPOT, in spleen (7-fold increment), in regional (cervical) 
lymph nodes (LN), genital LN (iliac, GLN) and, more importantly, 
in genital tract mucosa (GT). At memory phase, we found that in 
the IL-12+CTB group IFN-g and IL-2 secreting cells were two to 
three-fold higher in both systemic and mucosal compartments 
(GLNs and GT) (p=0.001). 
IL-12+CTB improved several quality features of the response: 
i) Higher levels of T-cell polyfunctionality in spleen and GT. ii) 
% of specific proliferating cells was increased at 10, 30 and 53 
days. iii) Enhanced in vivo citotoxicity: median 53% vs 16.4% for 
control group. iv) Higher T-cell avidity in spleen cells (p=0.01). v) 
T-cell responses with a superior breadth: cross-reactivity against 
different Env subtypes was superior.
Conclusion: We demonstrated that IL-12 plus CTB generated a 
cooperative adjuvant effect on the cellular immune response 
against Env applied in DNA-MVA intranasal immunizations. The 
improvement observed was not only in magnitude, but also in 
the breadth and quality of the responses induced. These results 
are important due to the need to develop mucosal vaccine 
strategies against HIV.
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Fusion of CTA and CTB Gene to Immunogen 
Significantly Enhances the Immunogenicity of DNA 
Vaccine
X. Ren1, Y. Wan1, X. Xie2, J. Xu1
1Fudan University, Shanghai, China; 2SuZhou University, 
SuZhou, China
Background: Cholera toxin and its two subunits (CTA,CTB) have 
been intensively investigated as mucosal adjuvants for protein 
based vaccine. In this study we evaluated the adjuvanticity of 
CTA and CTB in modality of either mixing their encoding plasmids 
with DNA vaccine or fusing their encoding genes to immunogen 
encoding gene.
Methods: DNA and recombinant vaccinia vaccines expressing 
HIV-1 AE strain tat, rev, intergrase(C-half), vif, nef fusion 
gene(designated as TRIVN) have been constructed. For the 
construction of fusion gene of CTA/CTB to TRIVN, overlapping 
PCR was employed to link CTA/CTB and TRIVN gene, the fused 
genes(TRIVN-CTA and TRIVN-CTB)were cloned into eukaryotic 
expression plasmid vector(pSV1.0). Six groups of female BALB/c 
mice were immunized with mock control, pSV-TRIVN, pSV-TRIVN-
CTA, pSV-TRIVN-CTB, pSV-TRIVN mixed with CTA or with CTB 
respectively in a DNA priming-recombinant vaccinia boosting 
regimen. Two weeks after the final injection, mice splenocytes 
were collected and IFN-γ ELISPOT assay were used as readout 
for specific T cell response. Statistical analysis was performed by 
using Prism5.0 software.
Results: Our data showed that all constructed plasmids are 
capable of efficiently expressing their inserted genes. All 
groups immunized with vaccines raised significant more T-cell 
response than mock control. T-cell responses elicited by pSV-
TRIVN-CTB(1548±330SFCs/106splenocytes) and pSV-TRIVN-CTA 
(1642±514SFCs/106splenocytes) were significantly higher than 
that by pSV1.0-TRIVN (520±150SFCs/106splenocytes), pSV1.0-
TRIVN mixed with CTA (692±220SFCs/106splenocytes) and 
pSV1.0-TRIVN mixed with CTB (734±240SFCs/106splenocytes). 
Though TRIVN-CTA and TRIVN-CTB fusion vaccines mounted 
comparable level of total IFN-γ+ T-cell responses, only TRIVN-
CTB elicits significantly T-cell responses against Tat, which 
is a subdominant component in the fusion immunogen. No 
significant differences were observed among groups inoculated 
with TRIVN alone or adjuvanted by CTA/CTB subunit proteins.
Conclusion: CTA and CTB could serve as potent adjuvants 
for DNA vaccine in immunogen-CTA/CTB fusion modality. 
Compared with CTA, CTB may enhance T-cell responses against 
subdominant epitopes in the immunogen and broaden the 
T-cell immune responses.
P01.07
TLR-3 and TLR-7/8 Ligands Indirectly Activate 
Langerhans Cells When Intradermally Injected by 
Triggering the Recruitment of Inflammatory Cells
O. Epaulard1, L. Adam1, R. Le Grand1, F. Martinon1
1CEA/Division of Immuno-virology, Institute for Emerging 
Diseases and Innovative Therapy, Fontenay aux Roses, France
Background: TLR-3 and TLR-7/8 agonists are promising vaccine 
adjuvants but their effects on immune cells remain to be define 
in vivo. We analysed the modifications in the Langerhans cell (LC) 
network after intradermal injection of these TLR ligands in non-
human primates used as a model for assessing human vaccines. 
LCs, which are the only antigen-presenting cells in the epidermis, 
are endowed with great ability to induce immune responses.
Methods: Intradermal injection of poly(I:C), R848 or PBS in 
cynomolgus macaques was followed by biopsy of the injection 
site at different time points. Epidermal and dermal sheets were 
dissociated, and epidermal and dermal cells were extracted 
before flow cytometry and culture. In situ immunofluorescence 
was performed on snap-frozen skin biopsies. Macaque 
polymorphonuclear neutrophils (PMNs) and monocytes were 
isolated from blood.
Results: Cynomolgus macaque epidermis contains CD45+, DR+, 
CD1a, CD207+ LC, and dermis contains DR+, CD11c+ dermal 
dendritic cells (featuring CD1a + CD14- dermal DCs and CD1a- 
CD14+ DCs) and DR+, CD11c-, CD163+ macrophages. R848 
intradermal injection results in LC maturation and activation 
(increased expression of CD80, CD83 and CD86) and migration 
(in situ immunofluorescence) out of the skin. PMNs and 
macrophages were massively recruited locally (up to 17% and 
20% of total leucocytes, respectively, whereas steady state 
values are below 3%); PMN recruitment and LC activation were 
significantly correlated suggesting the role of R848 induced 
inflammation on LC changes and migration. Similar results, with 
lower intensity, were obtained after poly(I:C) injections. The 
involvement of inflammatory cells was confirmed by the lack of 
TLR-7/8 expression in LCs and the effect of secreted cytokines.
Conclusion: Better understanding of the dynamics of local 
inflammation induced by TLR ligands in relevant animal models 
is critical for improving human vaccine adjuvants.
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Soluble and Bacteriophage T4 Displayed gp41 
Mutant Proteins as HIV-1 Vaccine Candidates
G. Gao1, K.K. Peachman2, L. Wieczorek2, V. Polonis2, C.R. Alving2, 
M. Rao2, V.B. Rao1
1The Catholic University of America, Washington, DC, USA; 
2USMHRP, Walter Reed Army Institute of Research, Silver 
Spring, MD, USA
Background: HIV-1 envelope protein gp41 is a very attractive 
vaccine target as its epitopes are recognized by three broadly 
neutralizing antibodies. However, the extreme hydrophobicity 
and very transient exposure of neutralizing epitopes during 
infection has hampered its usage in HIV-1 vaccine development. 
Our goal is to design a soluble trimeric gp41 vaccine stabilized as 
a pre-hairpin intermediate.
Methods: A gp41AVERY-minus recombinant was constructed, 
which contained both gp41 ecto-domain and cyto-domain, 
while the immunodominant AVERY region was deleted to reduce 
elicitation of non-neutralizing antibodies. Another protein, 
gp41-5M, was constructed by introducing 5 point mutations to 
gp41AVERY-minus, at the exposed hydrophobic residues of the 
trimeric coiled coil region, in order to destabilize the interaction 
between HR1 and HR2 helices and therefore mimic the gp41 pre-
hairpin intermediate. A ‘foldon’ structural tag was fused at the 
C-terminus of gp41-5M to facilitate trimer formation, and phage 
T4 small outer capsid (Soc) protein was fused at the N-terminus 
for arraying gp41 on T4 capsids. The ability of purified Soc-gp41-
5M proteins to inhibit 4E10 and 2F5 neutralizing activity was 
tested in the TZM-bl assay. Immunization experiments were 
performed in rabbits using soluble as well as T4 displayed gp41 
antigens to determine their immunogenicity.
Results: gp41 mutant proteins were over-expressed in E. coli and 
purified in soluble form following denaturation, renaturation, 
and Histrap affinity chromatography. The Soc-gp41-5M protein 
formed trimers and other oligomers, and effectively competed 
with native epitopes present on HIV-1 virus for binding to 
4E10 and 2F5 antibodies in the TZM-bl assay. The sera from all 
immunized rabbits showed binding antibodies to gp41 while 
some also showed neutralizing antibodies.
Conclusion: Soluble near full-length trimeric gp41 immunogens 
can be produced by interfering with the HR1-HR2 interactions 
while retaining the 4E10 and 2F5 binding epitope conformations. 
These proteins might be good vaccine candidates to elicit broadly 
neutralizing antibodies.
P01.09
HIV-1 gp120 Impairs the Induction of B Cell Responses 
by TLR9-Activated Plasmacytoid Dendritic Cells 
N.P. Chung1, K. Matthews1, R.W. Sanders1, J.P. Moore1
1Weill Cornell Medical College, New York, NY, USA
Background: Plasmacytoid dendritic cells (pDCs) play a central 
role in innate and adaptive immunity to viral infections, 
including HIV-1. pDCs produce substantial quantities of type I 
IFN and proinflammatory cytokines upon stimulation by Toll-
like receptors (TLR), specifically TLR7 or TLR9. We have studied 
how gp120 affects human pDC responses to TLR9 agonists, and 
the subsequent ability of the pDCs to stimulate B cells, with the 
goal of learning how better to induce B cell responses to Env 
protein vaccines. 
Methods: pDCs were isolated from human peripheral blood 
using CD304 magnetic beads, and then treated with endotoxin-
free recombinant gp120 during stimulation with TLR9 agonists. 
IFN-α, IL-6, TNF-α, IRF-7 and BAFF were quantified at the protein 
or mRNA level. Co-cultures were performed to study how gp120-
treatment of the pDCs affected their abilities to stimulate B cell 
responses, specifically proliferation, differentiation to plasma 
cells and IgG/IgM production. 
Results: We found that gp120 impaired IFN-α production by 
pDCs in response to TLR9 (CpG-ODN), but not TLR7, stimulation. 
Receptor-blocking studies showed the inhibitory effects were 
mediated via CD4 and the C-type lectin receptor BDCA-2, but 
not via CCR5 or CXCR4. Treatment with gp120 inhibited CpG-
induced pDC maturation, TNF-α and IL-6 production and IRF-7 
and BAFF mRNA expression. The gp120-treated, CpG-activated 
pDCs also had impaired abilities to induce B cell proliferation, 
plasma cell differentiation and Ig production, due at least in part 
to decreased expression of BAFF and other cytokines.
Conclusion: Taken together, our data show that HIV-1 gp120 
impairs pDC functions and B cell activation, and imply that TLR9 
ligands may not be good adjuvants to use in combination with 
Env-based vaccines.
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Potent Induction of Antibody-Secreting B-Cells 
by Human Dermal-Derived CD14+ Dendritic Cells 
Triggered by Dual Toll-like Receptor Ligation
K. Matthews1, N.P. Chung1, P.J. Klasse1, J.P. Moore1,  
R.W. Sanders2
1Weill Cornell Medical College, New York, NY, USA; 2Academic 
Medical Center, Amsterdam, Netherlands
Background: A goal of HIV-1 vaccine development is to induce 
broadly neutralizing antibodies. However, the Env complex is 
poorly immunogenic and requires potent adjuvants. Given the 
pivotal role of TLRs and DCs in initiating and tuning adaptive 
immune responses, TLR agonists are attractive adjuvants. 
CD14+ dermal DCs (CD14+ DDCs) have a natural capacity to 
stimulate naïve B-cells, so targeting these cells with TLR ligands 
is a rational approach to inducing humoral responses.
Methods: Migratory cells were collected after culturing skin 
for 24 h. CD14+ DDCs were purified using CD14 magnetic 
beads, stimulated with TLR ligand(s) and analyzed for cytokine 
expression (ELISA/qPCR) and phenotype after 48 h. Naïve 
B-cells were stimulated with TLR ligand(s) plus CD40L and IL-2, 
either alone or in the presence of CD14+ DDCs, and analyzed 
for proliferation, phenotype and IgG/IgA secretion. TLR-ligand 
stimulated DDCs were incubated with allogeneic naive CD4+ 
T-cells for 6 days before T-cell derived cytokines were quantified.
Results: CD14+ DDCs express mRNA for TLRs 1−9, but respond 
differentially to single or paired TLR ligands. Compared to 
single ligands, some combinations were particularly effective, 
increasing the expression of B-cell stimulatory cytokines and 
maturation of the DDCs. These combinations were R-848 plus 
Poly(I:C); R-848 plus LPS; Pam3CSK4 plus Poly(I:C); LPS plus 
Poly(I:C). Selected TLR agonist pairs (R-848 plus either LPS or 
Poly(I:C)) were superior to individual agents at boosting the 
capacity of CD14+ DDCs to induce naïve B-cells to proliferate and 
differentiate into CD27+CD38+ B-cells that secrete high levels 
of IgG and IgA. These selected TLR ligand combinations also 
induced CD14+ DDCs to promote differentiation of Th1, but not 
Th2, Th17 or TFH cells.
Conclusion: Two TLR ligand combinations potently activate CD14+ 
DDCs to have enhanced B-cell stimulatory capacity, and could be 
used to improve humoral immune responses to HIV-1 Env.
P01.11
Evaluation of Latent Membrane Protein 1 as a Novel 
Vaccine Adjuvant
J.M. Termini1, S. Gupta1, G.W. Stone1
1University of Miami, Miami, FL, USA
Background: The EBV protein Latent Membrane Protein-1 
(LMP1) is known to constitutively activate B cells. The LMP1 
signaling pathway mimics that of CD40, a molecule involved in 
dendritic cell activation and maturation. Therefore we decided to 
evaluate the use of LMP1 as a vaccine adjuvant for both dendritic 
cell therapeutic vaccines and DNA-based vaccines for HIV.
Methods: To determine activity, LMP1 was analyzed using a 
luciferase report assay for NF-kB and IFN-β. To establish if LMP1 
could activate human monocyte-derived dendritic cells (DC), 
LMP1 transfected DC were analyzed for activation/maturation 
markers and cytokines. DC migration was determined using a 
transwell-migration assay. LMP1 was also evaluated in a DNA 
vaccination/flu challenge mouse model. To determine the 
benefits of incorporating LMP1 into a DC therapeutic vaccine, 
LMP1 was tested in a tumor DC therapy mouse model.
Results: LMP1 activated high levels of NF-kB and IFN-β when 
evaluated using a luciferase reported assay. On primary DC, 
LMP1 induced DC activation, maturation, and proinflammatory 
cytokines. LMP1 induced 2-fold higher migration rates compared 
to the mature-DC control. As a DNA vaccine for flu, the addition 
of LMP1 provided superior TNF-α and IFN-γ responses. LMP1 
vaccinated animals cleared virus more quickly and in the high-
dose lethal flu challenge, LMP1 afforded more protection. Finally, 
LMP1 enhanced a DC therapeutic vaccine in a tumor model. 
Tumor progression was slowed compared to antigen-loaded DC 
alone and positive control mimic-matured DC.
Conclusion: These data suggest that LMP1 is an effective vaccine 
adjuvant. LMP1 can enhance the activation, maturation, and 
functional activity of DC. LMP1 can inducing a strong CD8+ T 
cell response in several mouse models, most notably the flu 
viral challenge model. LMP1 increased antigen-specific CD8+ T 
cells, improved survival to lethal flu high-dose challenge, and 
slowed tumor progression. These results suggest that LMP1 is a 
promising adjuvant for prophylactic vaccines for HIV.
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Inverse Dose-Response to gp140 YU2 Foldon 
Trimer Formulated with Aluminum Phosphate and 
ISCOMATRIX® Adjuvants
A. Wilson1, R. Powell1, S. Hoffenberg1, A. Carpov1, H. Arendt1,  
J. DeStefano1, M.J. Caulfield1
1International AIDS Vaccine Initiative, Brooklyn, NY, USA
Background: Conventional vaccine approaches based on 
delivery of HIV-1 envelope (Env) proteins or peptides derived 
from Env sequences have failed to generate broadly neutralizing 
antibodies (bNAbs) to the virus. Even with large doses (200 ug) 
of adjuvanted gp120 proteins administered multiple times to 
human volunteers, the subsequent antibody response boosts 
only moderately with each succeeding vaccination, and titers 
drop precipitously thereafter. We hypothesized that the usual 
practice of administering a moderate to high antigen doses 
may be counter productive to the goal of eliciting durable, high-
affinity antibody responses. 
Methods: We conducted a rabbit immunogenicity study in 
which we compared the anti-gp120 antibody response of 
rabbits immunized with low (1 ug), medium (10 ug) and high 
(100 ug) quantities of gp140 YU2 foldon trimer (FT) formulated 
with aluminum phosphate (alum) alone or in combination with 
ISCOMATRIX® adjuvant. In addition, we used a more protracted 
vaccination regimen by administering the vaccine at 0, 8, and 24 
week time points. 
Results: Antibody responses elicited by the different YU2 FT 
vaccination regimens were quantified by ELISA against JRCSF 
gp120 protein after vaccination showing weak responses after 
the first two vaccine doses. However, after 3 doses, the responses 
to vaccines co-formulated with both ISCOMATRIX® and alum 
were markedly higher than the corresponding responses to the 
antigen formulated with alum only. Interestingly, at 4 weeks post-
dose 3, there was a reverse dose response effect, with the 1 ug 
dose group having higher titers than the 10 and 100 ug groups. 
At 12 weeks post-dose 3, the antibody GMTs were 28,078 (1 ug), 
9,681 (10 ug) and 7,253 (100 ug). 
Conclusion: The results showing that the low dose group 
maintained a response ~4 fold higher than the high dose group 
suggests that durability of the antibody response to HIV Env may 
be a function of antigen dose. 
P01.13
Recombinant IL-21 Induces Perforin and Granzyme 
B in Total and Virus Specific CD8 Tcells in Acute and 
Early Stages of SIV Infection in Rhesus Macaques
S. Pallikkuth1, L. Micci2, Z. Ende2, K. Rogers2, G. Silvestry2,  
F. Villinger2, M. Paiardini2, S. Pahwa3
1University of Miami, Miami, FL, USA; 2Yerkes National Primate 
Research Center, Emory University, Atlanta, GA, USA; 3University 
of Miami Miller School of Medicine, Miami, FL, USA
Background: We have recently demonstrated that the cytokine 
IL-21 enhances the cytotoxic potential of CD8 T cells in chronically 
SIV infected rhesus macaques (vaccines 2011). 
Methods: In this study, 12 RM were infected with SIVmac239 (i.v., 
300 TCID50). rMamu IL 21-Fc fusion protein (50mg/kg) was given 
s.c on a weekly basis post infection (pi) for 5 doses on days14, 
21, 28, 35 and 42pi to 6 animals, designated as “treated”, with 3 
mamuA01+ animals each in treated and control groups. Samples 
of PBMC, bone marrow (BM), rectal biopsy (RB) and peripheral 
LN (LN) were collected before infection (d-11), and at various 
times post infection.
Results: Compared to controls, IL-21 treated animals 
demonstrated increases in frequency and MFI of Perforin (Perf) 
and granzyme B (GrB) at d45 in total CD8 T cells in PBMC, LN 
and RB, particularly in CM and Effector subsets; these were 
sustained up to d70pi. Perf and GrB levels increased in virus 
specific Tet+ CD8 T cells at d 45 in PBMC (p=0.029), LN (p=0.015), 
and RB (p=0.024). In the CD4 T cells, GrB induction was more 
prominent in the PBMC, LN, BM and RB. Frequencies of CD4 
(p=0.011) and CD8 (p=0.031) CM T cells increased in PBMC at 
d70pi. T cell inhibitory molecule PD-1 and proliferation marker 
Ki67 were similar in treated and control animals. In treated 
animals, 2/6 showed a decline in post-peak viremia that was 
sustained up to d70pi follow up.
Conclusion: In summary, IL-21 given s/c to SIV infected RM 
during early stages of infection led to augmented T cell cytotoxic 
granules perf and GrB in total and virus specific CD8 T cells in 
various anatomical sites. IL-21 should be explored further in 
vaccine strategies as an immunomodulating adjuvant. 
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Adjuvant-Dependent Cytokine Profiles in the Context 
of a DNA Prime-Protein Boost HIV-1 Vaccine
R. Buglione-Corbett1, K. Pouliot1, R. Marty-Roix1, K. West1,  
S. Wang1, E. Lien1, S. Lu1
1University of Massachusetts Medical School, Worcester, MA, 
USA
Background: Heterologous prime-boost vaccinations have 
emerged as a promising strategy to generate protective 
immunity against a variety of pathogens. Our previous clinical 
work has demonstrated that an HIV-1 gp120 DNA prime-protein 
boost vaccine, DP6-001, elicits enhanced neutralizing antibody 
responses as well as cell-mediated immune responses in humans. 
However, the roles of adjuvants remain largely unknown in the 
context of such combination vaccines. 
Methods: In a mouse model, we studied the effects of adjuvants 
QS-21, Alum, and MPL, in the context of DP6-001. Both gp120-
specific antibody and T cell responses were monitored by 
ELISA and intracellular cytokine staining (ICS), respectively. 
Innate cytokine profiles were determined in sera collected 6 
hours post-immunization by Cytometric Bead Array (CBA) and 
Luminex assays.
Results: Serum anti-Env IgG titers were comparable between 
adjuvant groups. All immunized animals demonstrated 
comparable positive gp120-specific CD4+ and CD8+ T cell 
responses by ICS. Adjuvant profiles were largely determined 
by sera cytokines following protein boosting. QS-21 was 
distinguished by elevated IL-4, IFNγ, MIP-1β, and IL-1β. MPL was 
characterized by elevated G-CSF, KC, and RANTES. Both adjuvant 
groups demonstrated elevated IL-6. Production of these sera 
cytokine profiles required DNA priming. 
Conclusion: Our data indicated that different adjuvants 
generate unique patterns of biomarkers, indicating that 
different mechanisms are involved in their action. Our results 
also provided useful guidance in the selection of an adjuvant 
for inclusion in future prime-boost strategies, with the goal of 
enhancing immunogenicity while minimizing reactogenicity. 
P01.15
Robust Antibody and Cellular Responses with an 
Improved DNA Vaccine Alone
N. Hutnick1, D.J. Myles1, K. Muthumani1, M. Morrow2, J. Yan2, 
A.S. Khan2, N.Y. Sardasai2, D.B. Weiner1
1University of Pennsylvania, Philadelphia, PA, USA; 2Inovio 
Pharmaceuticals, Blue Bell, PA, USA
Background: The recent results of the RV144 trial demonstrate 
that HIV-specific antibodies may provide protection from 
infection. DNA vaccines may represent an important HIV 
vaccine platform since they are safe, relatively inexpensive to 
manufacture, and stable at room temperature. However, the 
platform has been used largely as a prime modality limited to 
induce low level CD4 T cell responses in NHP and humans. In this 
study we sought to improve our current DNA vaccines to induce 
HIV-specific antibodies with plasmid vaccination alone.
Methods: Groups of 5 Indian Rhesus Macaques were vaccinated 
with pHIV consensus gag, pol, and clade C envelopes delivered IM 
with in-vivo electroporation at weeks 0, 4 and 12. Immunogenicity 
was measured two weeks after each dose. 
Results: Three doses of an HIV DNA vaccine alone induced 
robust cellular and antibody responses. Despite using clade C 
based enveloped, high binding titers were detectable against 
gp120s from multiple clades. Neutralizing titers were in the 
100’s range to a panel of clade B and C tier 1 viruses. These 
data establish that designed DNA envelop antigens can drive 
functional immunity in NHP. 
Conclusion: Multiple improvements to DNA vaccine technology 
have significantly enhanced the immunogenicity of the platform. 
Just three doses of a plasmid based HIV vaccine induced robust 
binding and neutralizing antibodies as well as effector T-cell 
responses in NHP. We are currently expanding the immunity 
induced by these constructs through novel DNA adjuvants as 
well as in prime-boost combinations.
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Rationally Designed HIV Envelope Glycoproteins 
Delivered in a Novel Adjuvant Elicited More Broadly 
Reactive Antigen-Specific Antibody Responses 
A.K. Dey1, A. Kassa1, A. Nandi1, Y. Sun1, C. Labranche2, K. Hartog1, 
D. Montefiori2, A. Carfi1, I. Srivastava1, S.W. Barnett1
1Novarits Vaccines & Diagnostics, Cambridge, MA, USA; 
2Department of Surgery, Duke University Medical Center, 
Durham, NC, USA
Background: The identification of optimal antigen(s) and 
adjuvant combination(s) to elicit potent, protective, and long-
lasting immunity has been a major challenge for the development 
of effective vaccines against HIV-1.
Methods: Here, we designed disulfide-stabilized recombinant 
HIV-1 subtype B (SF162) envelope glycoproteins (Env), gp120 
and gp140, by insertion of site-specific cysteine pairs between 
two layers (layer 1 and 2) in inner domain of gp120. In addition, 
we identified a novel adjuvant approach using Carbopol 971P, 
a cross-linked polyanionic carbomer, in combination with the 
Novartis proprietary oil-in water adjuvant, MF59, to augment 
humoral immune responses to the Env glycoprotein. We 
performed thorough in vitro analysis of the disulfide-stabilized 
Env glycoprotein followed by in vivo evaluations of the 
adjuvanted-Env glycoprotein boost in rabbits. 
Results: Intramuscular immunization of rabbits with disulfide-
stabilized Env glycoproteins formulated in Carbopol 971P 
plus MF59 gave significantly higher titers of binding and virus 
neutralizing antibodies as compared to immunization using 
Env glycoprotein with either MF59 or Carbopol 971P alone. 
In addition, the antibodies generated were of higher avidity. 
Mapping of serum antibodies to determine epitope specificities 
showed that the disulfide-stabilized gp140 proteins elicited 
broader Env glycoprotein-specific antibody responses directed 
against epitopes that included the CD4-binding site, CD4-induced 
site and V1V2-loop. Importantly, the use of the novel adjuvant, 
Carbopol plus MF59, did not appear to present any obvious 
tolerability issues in animals upon intramuscular administration. 
Conclusion: Hence, the use of rationally stabilized Env-antigens 
in potent Carbopol 971P plus MF59 adjuvant may provide a 
benefit for evaluations of future vaccine against HIV-1.
P01.17 LB
Neutralizing Antibodies Elicited In Rabbits By Patient-
Derived Env Trimer Immunization
L. Heyndrickx1, G. Stewart-Jones 2, H. Schuitemaker3,  
E. Bowles2, L. Buonaguro4, M. Jansson5, B. Grevstad6,  
L. Vinner6, M. Ramaswamy7, P. Biswas8, G. Scarlatti8,  
G. Vanham1, A. Fomsgaard6
1Institute of Tropical Medicine, Antwerp, Belgium; 2Human 
Immunology Unit, Weatherall Institute of Molecular Medicine, 
Oxford, United Kingdom (Great Britain); 3Academic Medical 
Center, University of Amsterdam, Amsterdam, Netherlands; 
4Istituto Nazionale Tumori “Fond. G. Pascale”, Naples, 
Italy; 5Department of Laboratory Medicine, University of 
Lund, Lund, Sweden; 6Statens Serum Institut, Copenhagen, 
Denmark; 7National Institute for Biological Standards and 
Control, Hertfordshire, United Kingdom (Great Britain); 8DIBIT 
- San Raffaele Scientific Institute, Milan, Italy
Background: Eliciting broad cross neutralizing antibodies 
(bNAb) remains the primary and most challenging goal in HIV-1 
vaccine development. So far no vaccine candidate has induced 
such bNAb. Selecting Env vaccine candidates will require both 
antigenic and immunogenic optimization and testing in relevant 
animal models.
Methods: Based on in-vitro neutralizing activity in serum, 
patients (n=6, subtype A and B infected) were selected 
and Env sequences of early HIV-1 variants, still sensitive to 
autologous neutralization, were used to generate soluble Env 
as immunogens. Gp140 trimeric proteins were expressed (293T 
cells) and purified. Rabbits (4/group) were immunized s.c. at 
weeks 0, 2, 4, 8 with 100µg trimer adjuvanted with cationic 
CAF01. Control groups received 20µg and 100µg trimer plus/
minus CAF01 respectively. Sera collected at weeks 0, 2, 4, 8, 12 
and 14 were screened in gp120-IIIB ELISA and IgG was analyzed 
in the TZMbl neutralization assay. 
Results: All rabbits generated a gp120-IIIB specific IgG response 2 
weeks after the first immunization and titers were boosted after 
each subsequent immunization. IgG titers measured 4 weeks 
after the last immunization clearly differed between groups (n=5) 
receiving 100µg/immunization (Geometric mean titer (GMT) 
: 152.601) and the group receiving 20µg/immunization (GMT : 
13.262) or the group omitting CAF01 (GMT : 27.262). Only IgG 
from rabbits receiving the highest dose and in the presence of 
CAF01 were able to neutralize Tier 1 pseudoviruses of different 
subtypes.
Neutralizing activity was detected after the 2nd immunization 
and was boosted after each immunization. No significant 
differences were observed between the different trimers.
Conclusion: Gp140 trimers based on HIV-1 variants of patients 
with bNAb in serum elicited gp120-IIIB specific IgG and NAb given 
that enough immunogen was administrated in the presence of 
CAF01. These results indicate that the development of HIV-1 Env 
specific NAb is dose dependent and strengthen the rabbit model 
for HIV vaccine studies.
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NMR Spectroscopy of HIV-1 gp120 Outer Domain
M. Sastry1, L. Xu1, S. Bhattacharya2, G.J. Nabel1, C.A. Bewley3, 
P.D. Kwong1
1Vaccine Research Center, NIAID/NIH, Bethesda, MD, USA; 
2New York Structural Biology Center, New York, NY, USA; 
3NIDDK, National Institutes of Health, Bethesda, MD, USA
Background: The outer domain (OD) of HIV-1 gp120 has been 
proposed as a minimal immunogen to elicit broadly neutralizing 
antibodies. However, OD is heavily glycosylated, contains many 
flexible regions, and immunization with a number of different OD 
variants has thus far failed to elicit neutralizing antibodies. An 
understanding of the conformational space sampled by the OD 
in its unliganded state, however, may assist in the use of OD as 
an immunogen.
Methods: We developed a method to isotopically enrich 
glycoproteins using a mammalian expression system that exploits 
the high level of protein expression obtained from an adenoviral 
vector, and employed heteronuclear NMR spectroscopy to 
obtain structural and dynamic information of unliganded OD. 
Multidimensional NMR experiments were recorded on uniformly 
labeled 15N/13C OD as well as on samples selectively enriched 
in 15N-labeled Gly, Ile, Leu and Val. Experiments for backbone 
assignments were also recorded on an OD sample enriched in 
15N/13C for Ile, Leu and Val.
Results: We successfully produced isotopically labeled OD 
samples, suitable for NMR analysis. We also identified Gly, Ser, 
Val, Leu and Ile residues using samples selectively enriched in 
15N for Gly, Val, Leu and Ile. Standard triple resonance NMR 
experiments on the isotopically labeled OD were combined with 
backbone experiments recorded on a second sample – that was 
selectively enriched in 15N/13C for Ile, Leu and Val – to assign 
HN, C’, Calpha and N backbone resonances in about 80 of the 220 
residues of OD.
Conclusion: We succeeded in assigning ~1/3 of the backbone for 
unliganded OD with triple resonance experiments. Extension of 
these assignments with NOESY experiments is now proceeding. 
Our results indicate that a solution structure of the highly 
glycosylated HIV-1 gp120 OD is feasible.
P01.19 LB 
CCL28 Induces Mucosal Homing of HIV-1-Specific Iga-
Secreting Plasma Cells in Mice Immunized With HIV-1 
Virus-Like Particles
V. Rainone1, G. Dubois2, V. Temchura3, K. Uberla3, M. Nebuloni1, 
E. Lauri1, D. Trabattoni1, F. Veas2, M. Clerici4
1University of Milan, Milan, Italy; 2Faculty of Pharmacy, 
University of Montpellier, Montpellier, France; 3Ruhr 
University Bochum, Bochum, Germany; 4Don G. Gnocchi 
Foundation, Milan, Italy
Background: MEC/CCL28 (CCL28) binds to CCR3 and CCR10 and 
recruits IgA-secreting plasma cells (IgA-ASCs) in the mucosal 
lamina propria. Virus-like Particles (VLPs) are a novel vaccine 
approach based on non-pathogenic particles that mimic the 
structure of virus particles with effective induction of both arms 
of the immune response. The suitability of CCL28 as an adjuvant 
for the elicitation of optimal mucosal and systemic immunity was 
assessed in mice immunized with HIV-1 VLPs. 
Methods: Balb/c mice were immunized intramuscularly with a 
prime-boost regime based on VLP containing gp160 from HIV-
1 IIIB in the presence/absence of CCL28 and of the parental 
control CCL19. Flow citometry evaluation of CCR3 and CCR10 
expression was performed on purified splenocytes. Th1 and Th2 
cytokine production was performed on splenocytes and either 
colon, lungs or uterine cervix, whereas antigen-specific IgG and 
IgA antibodies were evaluated in sera and mucosal secretions 
by ELISA. Immune sera and mucosal secretions were tested for 
ex vivo neutralization activity against HIV-1 either subtype B or 
C strains. IgA-ASC recruitment at the mucosal level was verified 
with immune-histochemistry. 
Results: The following parameters were significantly augmented 
in VLP-CCL28 mice compared to control groups: the percentage 
and the surface density of CCR3 and CCR10 on CD19+ 
splenocytes; IFN-γ, IL-4 and IL-5 production in splenocytes 
and mucosal specimens; total IgA titers in sera and in mucosal 
secretions; antigen-specific IgG and IgA titers in sera and in 
mucosal secretions. Sera and mucosal secretions from VLP-CCL28 
mice showed a significantly augmented neutralizing activity 
against homologous and heterologous viruses. IgA-ASCs were 
significantly increased in mucosal tissues of VLP-CCL28 mice. 
Conclusion: CCL28 used as an adjuvant has a robust 
immunomodulatory effect on potentially beneficial mucosal and 
systemic immune responses. These findings suggest that CCL28 
could play a useful role in increasing the efficacy of preventive 
vaccines for mucosally transmitted viral infections.
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Multivalent Adenoviral Vectors which use an Antigen 
Capsid-Incorporation Strategy for HIV Vaccination
L. Gu1, Z.C. Li1, V. Krendelchtchikova1, A. Krendelchtchikov 1, 
Q.L. Matthews1
1The Univeristy of Alabama at Birmingham, Birmingham, AL, 
USA
Background: Adenoviral (Ad) vectors have been used for a 
variety of vaccine applications. Traditionally, Ad-based vaccines 
are designed to express antigens through transgene expression. 
However, in some cases these conventional Ad-based vaccines 
have had sub-optimal clinical results. These sub-optimal 
results are attributed in part to pre-existing Ad serotype 5(Ad5) 
immunity. To circumvent the need for transgene antigen 
expression, the “antigen capsid-incorporation” strategy has 
been developed and used for Ad-based vaccine development. In 
addition, to increase the magnitude and/or breadth of antigen-
specific antibody response, this strategy can be utilized. The 
major capsid protein hexon has been utilized for antigen display 
due to hexon’s natural role in the generation of anti-Ad immune 
response and its numerical representation within the Ad virion. 
Methods: Based on our abilities to manipulate Ad5 HVR2 and 
HVR5, we sought to manipulate Ad5 HVR1 in the context of HIV 
antigen display. More importantly, peptide incorporation within 
HVR1 was utilized in combination with other HVRs. In order to 
create a multivalent vaccine vector, we created vectors that 
display antigens within HVR1 and HVR2 or HVR1 and HVR5. To 
date this is the first report where dual antigens are displayed 
within one Ad hexon particle. These vectors utilize HVR1 as 
an incorporation site for a seven amino acid region of the HIV 
glycoprotein 41; in combination with a six Histidine (His6) 
incorporation within HVR2 or HVR5. 
Results: Our study, illustrates that these multivalent antigen 
vectors are viable, present HIV antigen as well as His6 within one 
Ad virion particle. Furthermore, mouse immunization with these 
vectors; demonstrate that these vectors can elicit a HIV and His6 
epitope-specific humoral immune response. 
Conclusion: Our study focuses on generation of proof of 
concept vectors that can ultimately result in the development of 
multivalent vaccine vectors displaying dual antigens within the 
hexon of one Ad virion particle. 
P01.21 LB 
Immunogenicity of Native And CD4 Liganded 
Monomeric And Trimeric Envelope Glycoproteins 
Based on HIV-1 Subtype C Consensus Founder Virus 
Sequences
M.A. Killick1, A. Capovilla1, M.A. Papathanasopoulos1
1HIV Pathogenesis Research Laboratory, Johannesburg,  
South Africa
Background: The ability to induce a broadly neutralizing antibody 
(bNAb) response following vaccination is regarded as a crucial 
aspect in developing an effective HIV-1 vaccine. This study 
describes the design and construction of a subtype C founder 
virus consensus Env immunogen derived from newly transmitted/
founder virus sequences, and its immunogenicity testing in the 
presence or absence of liganded CD4, in small animals.
Methods: Monomeric (gp120), dimeric (gp120GCN4) and 
trimeric (gp140GCN4 +/-) founder virus conformations were 
expressed in mammalian cell culture. Unliganded or 2dCD4S60C 
liganded Env glycoproteins were purified by lectin affinity 
chromatography, followed by conformation and complex 
purification using size exclusion chromatography. Immunogens/
immune complexes were evaluated by ELISA, SDS-PAGE, Native 
PAGE and Surface Plasmon Resonance. Immunogenicity of each 
conformation alone or complexed to 2dCD4S60C was evaluated 
in rabbits. Breadth and potency of the rabbit sera was tested 
against 12 pseudoviruses (Tiers 1-3), derived from HIV-1 subtype 
B and C Env, using the PhenoSense Neutralizing antibody assay 
(Monogram Bioscience Inc.).
Results: Minimal neutralizing breadth was obtained from 
animals immunized exclusively with Env conformations. 
However, animals that received the Env/2dCD4S60C complex 
showed extensive neutralizing capacity against all 12 viruses 
tested, including the tier 2 and 3 virus strains. End-point ELISA 
titre results revealed that the rabbits that were immunized with 
Env/2dCD4S60C produced both Env and 2dCD4 specific titres, 
but those directed towards 2dCD4 were on average 10x lower 
than the 2dCD4 control group. This implies a proportion of the 
neutralizing antibody activity is directed towards conserved 
epitopes exposed on the Env/2dCD4S60C immunogens.
Conclusion: The ability to induce bNAb activity in previous 
immunization studies utilizing Env/CD4 complexes was attributed 
to the induction of high anti-CD4 titres. By contrast, in our study 
the relatively low anti-CD4 titres compared to anti-Env titres 
and neutralization profiles suggest an alternative mechanism of 
neutralization other than a response directed to CD4 alone.
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Hyperglycosylated Resurfaced Stabilized gp120 Core 
as an Immunogen Elicits Antibodies Targeted at the 
CD4-Binding Site
K. Dai1, J.C. Boyington1, W. Shi1, S.D. Schmidt1, I. Georgiev1,  
D. Lingwood1, P.D. Kwong1, J.R. Mascola1, Z. Yang1, G.J. Nabel1
1Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA
Background: HIV-1 utilizes multiple mechanisms to evade immune 
surveillance. This has hindered the development of an effective 
vaccine. The CD4bs represents a highly conserved vulnerable site 
on HIV envelope that serves as an important target in HIV vaccine 
development. Novel concepts, such as resurfacing and glycan 
masking are some of the current approaches used to refocus the 
immune responses.
Methods: In this study, we used structural information of HIV 
gp120 core, together with the computer-assisted protein design 
tool to strategically add various glycosylation sites on the protein 
surface and create a panel of resurfaced stabilized core (RSC3)-
based derivatives. The modified proteins were expressed in 293F 
or GnTi(-/-) cells and purified by Nickel-affinity and gel-filtration 
chromatography. To verify the glycosylation sites and antigenic 
analysis, the purified proteins were subject to mass spectrometry 
and SDS PAGE analysis using a panel of well-defined monoclonal 
antibodies. The proteins with desirable antigenicity and well-
tolerated glycan additions were tested for their immunogenicity 
in mice and NHPs.
Results: Two hyperglycosylated mutants containing five or six 
extra glycans (RS3.Y5 and RSC3. Y6.1) elicited CD4bs antibodies in 
significant quantities. Variant Y6.1 was further tested in the NHP 
model, in which Y6.1 elicited non-neutralizing CD4bs antibodies. 
In addition, a novel glycan mutant Y8.2_1 was developed based 
on Y6.1 by incorporating 3 extra glycans. Antigenic analysis 
indicated that the protein was able to eliminate the binding of 
non-neutralizing or less potent CD4bs antibodies such as b12 
and b13, but still retain the binding capacities to potent CD4bs 
antibodies such as VRC01 and VRC-PG04. 
Conclusion: It is now feasible to induce CD4bs antibodies by 
vaccination with immunogens that have exogenous N-linked 
glycans added to mask the “undesired” regions of the 
immunogen and have an exposed surface that targets the CD4bs 
epitope. Further optimization will be necessary to obtain CD4bs 
antibodies with neutralizing activity.
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GM-CSF Co-expressing DNA/MVA Vaccine, 
Prevention of Acquisition by Two Series of SIVE660 
Challenges Followed by a Series of SIV251 Challenges 
H. Robinson1, S. Kannanganat2, S. Gangadhara2, L. Lai2, T. Yu2, 
P. Kozlowski3, P. Earl4, B. Moss4, R.R. Amara2
1GeoVax Inc., Smyrna, GA, USA; 2Emory University, Atlanta, GA, 
USA; 3Louisiana State University Health Sciences Center, New 
Orleans, LA, USA; 4National Institute of Allergy and Infectious 
Diseases, Bethesda, MD, USA
Background: In 2010 we reported prevention of acquisition of a 
repeated SIVE660 challenge in rhesus macaques vaccinated with 
a SIV239 DNA/MVA vaccine that co-expressed GM-CSF and VLP 
in the DNA prime. The reduced risk of infection correlated with 
the avidity of Env-specific IgG. Here we report studies on the 
longevity and breadth of this protective response. 
Methods: Following the initial 12 challenges, 5 uninfected rhesus 
were monitored for one year, boosted with 1x108 pfu of MVA/
SIV239, and re-challenged 6 months later with 12 weekly rectal 
doses of SIVE660. The resulting four uninfected macaques were 
held an additional 6 months and challenged with 12 weekly rectal 
doses of SIV251. Avidity of Env-specific IgG was determined using 
a NaSCN elution ELISA. Per exposure efficacy was estimated using 
a leaky effects model.
Results: Per exposure efficacies were 90% and 94% for the 1st and 
2nd SIVE660 series, respectively, and 72% for the SIV251 series 
of challenges. For the SIVE660 series, 50% infection was reached 
by the 3rd challenge for controls, but never reached in vaccinated 
animals. For the SIV251 series, 50% infection was reached by 
the 2nd challenge for controls but not until 10 challenges for 
vaccinated animals. Both SIVE660 and SIV251 series showed 
transient low “blips” of virus. None of five E660 “blips” resulted 
in anamnestic systemic Ab, whereas two of three SIV251 blips 
resulted in such. Correlates also differed for the two infections 
with the avidity of Env-specific IgG correlating with prevention of 
acquisition for SIVE660 but not SIV251.
Conclusion: A DNA/MVA vaccine in which GM-CSF is co-
expressed in the DNA prime can provide substantial prevention 
of acquisition against serial challenges over a three year period of 
time. Our results also reveal SIVE660 and SIV251 rectal challenges 
differing in their ability to initiate systemic Ab responses and in 
their correlate for prevention of acquisition.
P02.01
Macaques Primed with Self-Amplifying RNA 
Vaccines Expressing HIV-1 Envelope and Boosted 
with Recombinant Protein Show Potent T- and 
B-Cell Responses
W.M. Bogers1, H. Oostermeijer1, P. Mooij1, G. Koopman1,  
E. Verschoor1, D. Davis1, J.L. Heeney2, Y. Cu3, K. Banerjee3,  
B. Burke3, A. Dey3, A. Geall3, S.W. Barnett3
1Biomedical Primate Research Centre, Rijswijk, Netherlands; 
2University of Cambridge, Cambridge, United Kingdom 
(Great Britain); 3Novartis Vacccines and Diagnostics, Inc., 
Cambridge, USA
Background: Self-amplifying RNAs (replicons) of positive-strand 
viruses are useful vectors for delivering vaccine antigens. Novartis 
has developed a self-amplifying mRNA (SAM™) vaccine platform 
to take advantage of cell-free RNA production and synthetic non-
viral delivery systems. In this study, the safety, immunogenicity, 
and efficacy of HIV-SAM™ vaccines encoding HIV-1 clade C TV1 
gp140 envelope glycoprotein were evaluated in rhesus macaques 
using two non-viral delivery systems: lipid nanoparticle (LNP) and 
a Novartis proprietary 2nd generation delivery technology (CNE).
Methods: Five groups of six macaques were primed at weeks 
0, 4 and 12 with HIV-SAM™ vaccine formulated with LNP or 
CNE, alphavirus replicon particles (VRP), recombinant TV1 
gp140 glycoprotein in MF59 adjuvant, or with vector controls 
encoding an irrelevant Ag. All treatment groups were boosted 
intra-muscularly at weeks 24 and 36 with TV1 gp140 in MF59, 
and controls with irrelevant protein in the same adjuvant. 
Systemic and mucosal responses were measured throughout 
the study. All macaques will be given a repeated low dose 
intra-rectal challenge with the heterologous clade C SHIV-
1157ipd3N4 challenge.
Results: After priming immunizations, both IFNγ and IL2 T-cell 
responses and B-cell ELISpots were higher in HIV-SAM™-CNE 
macaques than those in HIV-SAM™-LNP, VRP and glycoprotein 
alone groups. Systemic Env-specific antibody responses were also 
detected by ELISA at week 6 in the RNA-immunized groups and 
increased after subsequent immunizations. Neutralization, ADCC, 
epitope mapping, and antibody isotyping assays are underway 
to further evaluate the antibody responses in these animals. No 
adverse responses to RNA immunizations were observed.
Conclusion: These studies provide the first evidence in nonhuman 
primates that vaccination with formulated self-amplifying RNA 
is safe and immunogenic, eliciting both humoral and cellular 
immune responses.
This study was supported by NIH grant 5 PO1 AI066287-02.
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Induction of HIV-1 Gag-Specific Memory T Cells 
in Chacma Baboons by MVA Prime and VLP Boost 
Vaccine Regimen 
V. Singh1, G. Chege1, E. Shephard1, A. Williamson1
1University of Cape Town, Cape Town, South Africa
Background: We previously reported induction of HIV-specific 
responses in Chacma baboons following immunization with 
SAAVI MVA-C (MVA) and HIV-1 Pr55 Gag virus-like particles 
(VLPs) in a prime-boost vaccination strategy. In the current 
study, we characterised the vaccine specific memory T cells by 
flow cytometry.
Methods: Peripheral blood mononuclear cells (PBMC) from 
baboons primed with MVA and boosted with VLPs (n=3) or 
vaccinated with VLPs only controls (n=2) were stimulated with 
HIV-1 Gag peptide pools. T cell cytokine production (multiplex 
TNF-a, IFN-y and IL-2) and memory phenotype was determined 
by flow cytometry. Human anti-CD28 and CD95 antibodies were 
used to delineate effector memory (Tem) and central memory 
(Tcm) T cells.
Results: Vaccine specific memory responses were detectable one 
week after MVA prime. At peak T cell response (four weeks after 
VLP boost), the frequency of cytokine producing cells in prime-
boost animals (mean response: 0.21%±0.012 and 0.242% ±0.049 
of CD4+ and CD8+ cells respectively) was higher than in control 
animals (mean response: 0.066%±0.005 and 0.034%± 0.016 of 
CD4+ and CD8+ cells respectively). Gag-specific CD4+ cells from 
the prime-boost animals were significantly skewed towards a 
Tcm phenotype (>95%) of total cytokine responses compared 
to the Tem phenotype (<2%). A similar memory distribution 
profile of Gag-specific CD4+ cells was maintained 20 weeks after 
the VLP boost. At this time, Gag-specific CD8+ cells were evenly 
distributed between Tcm (~40%) and Tem (~60%) phenotypes. 
Vaccine specific memory responses were preserved 20 weeks 
after the VLPs boost (mean: 0.128%±0.025 and 0.147%± 0.039 
of CD4+ and CD8+ cells respectively) in the prime-boost animals. 
Conclusion: In conclusion, the MVA prime and VLP boost 
induced Gag-specific cytokine producing Tcm and Tem defined 
by expression of CD28 and CD95. These cells were detected up 
to 20 weeks post vaccination suggesting these vaccines could 
be potential HIV-1 vaccine candidates. 
P02.03
Efficacy of Vaccine-Induced Vif-Specific CTL 
Responses Against SIVmac239 Infection: Implications 
for Antigen Design in AIDS Vaccines
N. Iwamoto1, N. Takahashi1, T. Nomura1, H. Yamamoto2,  
T. Matano1
1National Institute of Infectious Diseases, & IMS, University of 
Tokyo, Tokyo, Japan; 2National Institute of Infectious Diseases, 
Tokyo, Japan
Background: Optimization of antigens as well as delivery system is 
crucial for development of an effective T-cell based AIDS vaccine. 
Our recent results suggested higher anti-viral efficacy of Vif- and 
Nef-specific CTLs as well as Gag-specific ones (JEM 199:1709, 
2004; AIDS 24:2777, 2010). Here, we examined efficacy of Gag-
specific or Vif/Nef-specific CTL induction by vaccination against 
SIV infection.
Methods: All 17 animals used in this study were Burmese rhesus 
macaques sharing MHC-I haplotype 90-010-Ie, which mostly show 
typical AIDS progression after SIVmac239 challenge (geometric 
means of setpoint plasma viral loads: 10^5 copies/ml; mean 
survival periods: 2 years). These animals were divided into three 
groups consisting of unvaccinated (n = 6), Gag-vaccinated (n = 5), 
and Vif/Nef-vaccinated (n = 6); the latter two were subjected to 
DNA-prime/Sendai virus vector-boost vaccination. We compared 
these three groups after an intravenous SIVmac239 challenge.
Results: After challenge, 3 out of 5 Gag-vaccinated and 3 out of 
6 Vif/Nef-vaccinated animals controlled SIV replication. The SIV 
control was associated with Gag-specific CTL responses in the 
former and Vif-specific CTL responses in the latter.
Conclusion: This is the first report indicating efficacy of vaccine-
induced Vif-specific CTL responses against SIV replication. Our 
results imply that not only Gag but also Vif may be a promising 
antigen for T-cell based AIDS vaccines.
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SIVconsv DNA Prime - TLR7/IFNα Adjuvanted Long 
Peptide Boost Induces Potent CD4+ Ab Responses and 
Protects Against High Dose Intrarectal SIV Challenge
G. Koopman4, N. Beenhakker4, I. Nieuwenhuis4, G. Doxiadis4,  
P. Mooij4, J.W. Drijfhout1, J. Koestler2, T. Hanke3, R.E. Bontrop4, 
R. Wagner2, W.M. Bogers4, C.J. Melief1
1Leiden University Medical Center, Leiden, Netherlands; 
2University of Regensburg, Regensburg, Germany; 3The Jenner 
Institute, University of Oxford, Oxford, United Kingdom (Great 
Britain); 4BPRC, Rijswijk, Netherlands
Background: Because of the extreme variability of the HIV-1 
genome, a successful vaccine has to effectively recognize diverse 
infecting HIV-1 strains in the population and must deal with 
ongoing virus escape in infected individuals. We have selected 
conserved regions within SIV, corresponding to HIVconsv 
(Letourneau PLoS ONE 2007) that show little variation across 
the different isolates and incorporated these in a peptide based 
vaccine strategy. 
Methods: In this protocol rhesus macaques were immunized 
subcutaneously with 46 synthetic peptides of about 30 amino 
acids in length, which contain epitopes that can trigger helper as 
well as cytotoxic T-cell responses. Peptides were formulated in 
Montanide ISA-720. Pegylated Type I interferon plus Imiquimod, 
which triggers innate responses via toll like receptor 7, were given 
locally at the vaccine sites as additional immune stimulatory 
signals. Peptides were either given alone or after two times 
priming with DNA expressing the same conserved regions from a 
RNA and codon optimized gene.
Results: After two immunizations with only peptides strong 
immune responses of 2000-3000 spot forming units (SFU) per 
10*6 PBMC were observed. DNA priming followed by peptide 
boosting generated up to 8000 SFU/10*6 PBMC, comparable 
to what is achieved in reported adenoviral vector systems. 
Predominantly CD4 T-cell responses were generated (up to 
10% of cells reactive to SIVmac251), which were polyfunctional 
(30% IFNgamma/IL-2/TNFalpha triple production), and mainly 
mediated by central memory T-cells. Furthermore, peptide 
specific antibody responses were induced, capable of recognition 
of Env protein. Eight weeks after the last immunization, animals 
received a high dose intrarectal SIVmac251 challenge. 2/6 
animals in the DNA prime/peptide boost group were protected 
against infection, while all 6 animals in the control group and 
the peptide only group were infected. 
Conclusion: Vaccine induced strong CD4/antibody focused im-
mune responses directed against conserved regions of SIV afford 
protection against high dose intrarectal SIVmac251 challenge.
P02.05
Construction of SHIVs Expressing Quaternary 
Neutralization Epitopes in Env and Mimicking the 
Neutralization Phenotype of Typical HIV-1 Isolates
J.F. Theis1, A. de Parseval1, W.J. Honnen1, A. Phogat1,  
U.C. Ganapathi1, Z. Lai1, L. Peng1, C. Reichman1, P.L. Moore2, 
L. Morris2, Y. Li3, S. Hu3, A. Pinter1
1University of Medicine and Dentistry of New Jersey, Newark, 
NJ, USA; 2Centre for HIV and STIs, NICD - NHLS, Johannesburg, 
South Africa; 3Department of Pharmaceutics, University of 
Washington, Seattle, WA, USA
Background: Infection of macaques with chimeric Simian/Human 
Immunodeficiency Viruses (SHIVs) provides a powerful model for 
HIV pathogenesis and vaccine development. A limitation of the 
SHIVs routinely used for vaccine studies, e.g. SHIV-1157ipd3N4, 
SHIV-SF162P3, and SHIV-BaL, is that they don’t express 
quaternary neutralization epitopes (QNEs) that are targets of 
broadly neutralizing antibodies like PG9, PG16, and CAP256 sera. 
We sought to introduce the QNEs into functional SHIVs to study 
how such antibodies develop during infection and help guide the 
creation of antigens capable of eliciting such antibodies.
Methods: Pseudovirus neutralization assays were used to map 
the QNE-resistance determinants of SHIV-1157ipd3N4 Env and 
to test the sensitivities of mutant derivatives of SHIV-1157ipd3N4 
and SHIVSF162P3 to anti-QNE antibodies. Full-length SHIVs 
expressing the mutant Envs were tested for growth in PBMCs, 
and high titre stocks from those that grew were used to infect 
pigtail macaques.
Results: The double mutant SHIV1157 Env, Q170K/I192R, 
gained sensitivity to PG9, PG16, and CAP256 while maintaining 
resistance to CD4bs and anti-V3 antibodies. The full-length SHIV 
expressing this Env was able to replicate in macaque PBMCs 
while maintaining sensitivity to these antibodies, indicating there 
was no selection against these targets in the monkey cells. An 
update on the course of infection will be provided. Six changes 
in V2 (S164E, G166R, N167D, M169K, Q170K and N192R) were 
required to introduce the QNEs into SHIV-SF162P3 Env, and 
these dramatically increased sensitivity to anti-QNE antibodies. 
However, the full-length SF162P3 SHIV carrying this mutant Env 
failed to grow in macaque PBMCs; the basis of this growth defect 
is being studied.
Conclusion: We created an infectious QNE-expressing SHIV with 
overall neutralization phenotypes similar to those of typical 
primary HIV-1 isolates. This SHIV will allow the analysis of the 
development of anti-QNE antibody responses during the course 
of infection, and should provide an improved model for HIV-1 
vaccine evaluation.
Topic 2:  Animal Models and Preclinical Trials
110
Posters
PO
STERS
AIDS Vaccine 2012
P02.08
Optimizing Delivery of HIV-1 Conserved Region-
Derived Immunogen for Induction of T and B Cell 
Responses in Rhesus Macaques
M. Rosario1, G. Koopman1, A. Mbewe-Mvula1, M.L. Knudsen1, 
E.D. Quakkelaar1, N. Borthwick1, R. Wagner1, D.A. Price1,  
P. Liljestrom1, C.J. Melief1, J.W. Drijfhout1, S. Colloca1,  
A. Nicosia1, T. Hanke1
1University of Oxford, Oxford, United Kingdom (Great Britain)
Background: The complexity of candidate HIV-1 vaccine 
formulations is increasing due to extreme challenges faced when 
trying to prevent or control HIV-1 infection. 
Methods: Immunogen HIVconsv based on the most conserved 
regions of the HIV-1 proteome was used to explore combinations 
of seven distinct vaccines modalities in heterologous prime-boost 
regimens delivered to rhesus macaques to optimize induction of 
T cell and antibody responses. These include plasmid DNA (P), 
Semliky Forest virus replicons delivered as DNA (DREP; D) or 
virus particles (VREP; V), modified vaccinia virus Ankara (MVA; 
M), adenoviruses of human (HAdV-5; A) and chimpanzee origin 
(ChAdV-63; C) and adjuvanted synthetic long peptides (SLP; S).
Results: A number of observations were made. Thus, a very potent 
combination for induction of HIV-1-specific T cells was an adenovirus 
vector (A or C) followed by poxvirus M. S boost broadened T cell 
responses, but did not prime T cells efficiently. D was a stronger prime 
than P. PPP was the best prime for T cells, while PSS was best for 
induction of antibodies. Even very complex regimen PPPAMSSCMV 
continued to recruit new T cell clones into the response to a single 
epitope, although a ceiling for immunodominant responses was 
reached; subdominant responses could be boosted up to the last V 
delivery. Finally, PPSS, but not SSSS could protect 2/6 animals from 
SIVmac251 acquisition. 
Conclusion: These results will guide initial design of human trials. 
So far, human studies in Oxford testing CM, PPPCM and PPPMC 
regimen concur with observations made in rhesus macaques.
P02.07
Modelling the Neuropathological Consequences of 
HIV Vaccines That Confer Partial Protection
D. Ferguson1, S. Clarke1, C. Ham1, A. Das2, B. Berkhout2,  
A. Meiser3, S. Patterson3, N. Berry1, N. Almond1
1National Institute of Biological Standards and Control - HPA, 
Potters Bar, United Kingdom (Great Britain); 2Academic 
Medical Centre, University of Amsterdam, Amsterdam, 
Netherlands; 3Imperial College, London, United Kingdom 
(Great Britain)
Background: Effective management of peripheral viral loads 
with anti-retroviral drugs can delay or halt CD4 cell loss for 
decades. However, patients still face the potential of developing 
significant HIV-1 associated neurocognitive disorders (HAND). 
Challenges obtaining relevant clinical samples limit the detailed 
investigation of the aetiology and neuropathology of HAND and 
therefore we do not understand the impact of vaccines that 
confer partial protection on long term neuropathology. 
Methods: We are using immunohistochemical analysis of brain 
sections from the experimental infection of macaques with SIV 
to model neuropathology in situations where peripheral viral 
loads are under effective control.
Results: We have established that chronic infection with 
attenuated SIV, where peripheral viral loads are below detection, 
still results in pathological changes (astrogliosis, microglial 
activation, viral persistence). We have now extended these 
studies using a unique conditional live attenuated, doxycycline 
dependent virus, SIVrtTA. Removal of doxycycline 3 weeks after 
infection, at the end of the primary viremia results in detectable 
neuropathological changes in astrocytes, oligodendrocytes, 
microglia and perivascular macrophage 40 weeks later. 
We are also investigating the effects of vaccines that confer 
partial protection on the neuropathology of wild-type SIV 
infection. A vaccine study using SIV Gag based vaccines 
comprising three primes with rDNAgag followed by a rAdgag 
boost resulted in significant delay in acquisition of SIVmac251 
administered by low-dose intra-rectal challenge. Furthermore, 
there was a significant blunting of the primary viremia, but 
no significant suppression of set-point viral loads compared 
with naive challenge controls. We are determining the impact 
of vaccination on the frequency of virus infected cells in the 
brain collected 20-30 weeks after infection and also comparing 
the frequency and intensity of neuropathological changes in 
infected vaccinated and control macaques. 
Conclusion: These data will enable us to establish the likely 
neurological benefit of vaccines that do not provide protection 
against detectable infection.
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P02.10
Maturation of Protective Immunity Induced by 
SIV∆nef Correlates with Differential Expression of 
Transcription Factors in SIV-specific CD8+ T Cells
J.M. Billingsley1, P.A. Rajakumar1, N.C. Salisch1, Y.V. Kuzmichev1, 
H.S. Hong1, M.A. Connole1, R.K. Reeves1, H. Kang2, W. Li2,  
R.P. Johnson1
1New England Primate Research Center Harvard Medical 
School, Southborough, MA, USA; 2University of Massachusetts 
Medical School, Worcester, MA, USA
Background: Protective immunity against vaginal challenge 
in SIV∆nef-vaccinated macaques develops at 20 weeks after 
vaccination, whereas the magnitude of SIV-specific CD8+ 
T cell responses peaks at 5 weeks. SIV-specific CD8+ T cells 
phenotypically mature from week 5 to 20, as characterized by 
upregulation of CCR7 and CD127, suggesting that the quality of 
the CD8+ T cell response may correlate with protection. 
Methods: Highly parallel qRT-PCR was used to characterize the 
expression of 21 transcription factors (TFs) in T cells sorted into 
naïve, central, transitional, and effector memory subsets, and in 
SIV Gag CM9 and Tat SL8-specific CD8+ T cells obtained at wk5 
and wk20 after SIV239∆nef vaccination.
Results: Unsupervised clustering organized T cell samples into 
groups concordant with cell surface phenotype. SIV-specific 
CD8+ cells segregated into wk5 and wk20 clusters. 11 of 21 TFs 
were expressed at significantly different levels at wk20 than at 
wk5. Wk20 cells exhibited increased levels of TFs associated 
with both quiescence and maintenance of effector function. 
Furthermore, 7 TFs were significantly differentially expressed 
between SIV Gag and SIV Tat-specific wk20 populations. Principal 
component analysis suggests the Gag-specific cells may be more 
effector-like and the Tat-specific cells more transitional or central 
memory-like.
Conclusion: Our data indicate distinct transcriptional profiles of 
different memory T cell subsets and clear differences between 
wk5 and wk20 SIV-specific CD8+ T cell transcriptomes. The 
mature wk 20 CD8+ T cell response temporally correlated with 
protection is characterized by the expression of transcription 
factors associated with both central memory and effector 
memory T cells. Additionally, wk20 Gag-specific cells exhibit 
a more effector-like expression profile than Tat-specific cells, 
which is consistent with the Tat epitope exhibiting more 
rapid CTL escape kinetics than the Gag epitope. Analysis of 
transcription factor expression therefore provides a valuable 
complement to the analysis of memory cell differentiation 
based on classical phenotypic markers.
P02.09
A Single Dose of SAAVI MVA-C Re-boosts Rhesus 
Macaques After More Than 3 Years Post DNA-MVA 
Prime-Boost Vaccination
G.K. Chege1, W. Burgers1, T. Muller1, E.G. Shephard1,  
C. Williamson1, A. Williamson1
1University of Cape Town, Cape Town, South Africa
Background: We have previously reported induction of robust 
immune responses in rhesus macaques following a prime boost 
immunization with candidate HIV-1 vaccines, SAAVI DNA-C (DNA) 
and SAAVI MVA-C (MVA). These vaccines are already in clinical 
evaluation. In the current study, we investigated whether re-
boosting these animals with a single MVA inoculation after more 
than 3 years was sufficient to restore previous magnitudes of 
HIV-specific immune responses. 
Methods: Seven rhesus macaques which had been vaccinated 
with three doses of DNA vaccine (4mg DNA/dose) and two doses 
of MVA (109 pfu MVA/dose) in a past study, >3 years previously, 
were re-boosted with a single dose of MVA. HIV-1-specific 
responses were quantified in the peripheral blood using an IFN-
gamma ELISPOT assay.
Results: A peak magnitude of response (1146±240 sfu/106 PBMC) 
was reached 1 week after vaccination with the first dose of MVA. 
The second MVA inoculation did not increase these responses 
which declined to undetectable levels by 1 year post vaccination. 
After re-boosting with MVA after 3.5 years post the second 
MVA, all animals responded, with a peak response (1824±672 
sfu/106 PBMC) being reached 1 week after vaccination. Although 
the mean magnitude of the second peak was not significantly 
higher than the one seen in the first peak, boosting of responses 
in 3 of 7 animals with an apparent broadening of the breadth of 
responses was observed.
Conclusion: These preliminary data suggest a long-term 
preservation of vaccine memory following a prime-boost 
vaccination regimen with SAAVI DNA-C and SAAVI MVA-C vaccines.
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P02.12
Development of a HIV-1 Vaccine Using an Orally-
Administered, Replication-Competent Adenovirus 
Serotype 4 Vector Expressing Env Clade C Glycoprotein
J. Alexander1, M. Gurwith1, J. Mendy1, L. Vang1, D. Manayani1, 
J. Avanzini1, B. Guenther1, P. Farness1, B.F. Haynes2, H. Liao2, 
D.C. Montefiori3, C.C. LaBranche3, T. Mayall1
1PaxVax, San Diego, CA, USA; 2Duke Human Vaccine Institute, 
Duke University School of Medicine, Durham, NC, USA; 
3Department of Surgery, Duke University Medical Center, 
Durham, NC, USA
Background: Our hypothesis is that the replicating Ad4 vector 
approach, may be the best strategy for an effective HIV-1 
vaccine due to advantages of demonstrated clinical safety and 
immunogenicity of both the Ad4 backbone and an Ad4 H5N1 
vector influenza vaccine evaluated in Phase 1. Unlike other 
vectors, it can be bioengineered to express full-length HIV-1 
Env gp160. More than 50% of global HIV-1 infections are caused 
by clade C viruses and therefore we initiated development of 
Ad4-Env160 vaccine using an Env clade C sequence obtained 
from CHAVI.
Methods: The Ad4-Env viruses were evaluated for: 1) genetic 
stability; 2) Env protein expression by Western blot analysis; 3) 
cell-surface Env recognition by broadly neutralizing antibody 
(bnAb); and 4) immunogenicity in rabbits.
Results: Genetically stable Ad4 recombinant viruses were 
generated which expressed the Env gp120, gp140, and gp160 
proteins. A549 cells infected with Ad4-Env160 virus expressed 
cell-surface Env that was recognized by bnAb specific for MPER, 
CD4bs, V2-V3 loop sequences. Following immunization of rabbits, 
Env-specific binding antibodies were induced as measured by 
ELISA; 160>140>120.
Conclusion: An Ad4 virus expressing full-length Env160 was 
generated and evaluated for genetic stability, protein expression, 
recognition by bnAb and immunogenicity. These results 
represent substantial progress towards defining a replicating 
Ad4 vector, recombinant protein vaccine prime/boost approach 
for HIV-1 that could eventually undergo clinical testing. Funding: 
NIH/NIAID SBIR 1R43AI091546-01; NIH/NIAID Contract No. 
HHSN266200400045C.
P02.11
Mapping of SIVmac T-Cell Epitopes in Cynomolgus 
Macaques Immunized with Auxo-GTU-MultiSIV 
DNA by the Intradermal Route Followed by 
Electroporation
A. Corneau3, B. Maciel Da Silva3, S. Even3, J. Morin3, N. Sylla3,  
F. Martinon3, A. Aarninck1, A. Blancher1, I. Stanescu2,  
R. Le Grand3, N. Dereuddre-Bosquet3
1Laboratoire D’Immunogénétique Moléculaire EA 3034, 
Faculté de Médecine, Toulouse, France; 2FIT Biotech, Tampere, 
Finland; 3CEA, Fontenay-aux-Roses, France
Background: Intradermal immunization with electroporation 
using auxo-GTU-MultiHIV DNA encoding Gag, Nef, Rev and Tat 
induces strong and sustained T cell responses in cynomolgus 
macaques. Here, we used an equivalent vaccine encoding 
SIVmac239 antigens (Gag, Nef, Rev, Tat, Vif, Vpx and Vpr) and we 
described the breath of this T cell response.
Methods: Naïve male mauritian cynomolgus macaques were 
immunized with auxo-GTU-MultiSIV DNA encoding Gag, Nef, Rev 
and Tat (n=14) or by a combination of auxo-GTU-MultiSIV DNA 
and auxo-GTU-SIV-vifvprvpx (n=12) by the intradermal route 
followed by electroporation. MHC class I and class II haplotypes 
were determined by microsatellite analysis. T-cell epitopes were 
mapped by IFN-γ ELISPOT in PBMC by using matrix of 15-mer 
(overlapping by 11) SIVmac239 Gag, Nef, Rev, Tat, Vif, Vpx and 
Vpr peptides. Sequence and length of candidate epitopes were 
further optimized.
Results: Immunization induced intense and sustained IFN-γ 
ELISPOT responses in peripheral blood. T-cell responses against 
MHC class I epitopes were evidenced: two in Gag p15 (KA10(28-
37) presented by Mafa-B*011:01 and EL10(58-68) presented by a 
MHC-Ia molecule from haplotype M3), two in Gag p27 (HL9(146-
154) presented by Mafa-B*075:01 and LA9(189-197) presented 
by a MHC-Ib from haplotype M1), three in Nef (AS10(4-13) 
presented by a MHC-Ib molecule from haplotype M3; RM9(103-
111) presented by Mafa-A1*063:02; LD10(146-155) presented 
by a MHC-Ia from haplotype M1M2M3), one in Rev (SP10(59-68) 
presented by Mafa-B*075:01), one in Tat (CF9(59-67) presented 
by Mafa-A1*063:02), four in Vif and two in Vpx. One MHC class 
II epitope was identified in Gag p27 (haplotype M3). Among 
these, to our knowledge, AF11 is a newly described epitope in 
cynomolgus macaques.
Conclusion: Auxo-GTU-MultiSIV DNA vaccination followed 
by electroporation induced multi-epitopic T cell responses, 
essentially CD8+ but also CD4+. Determination of SIV T-cell 
epitopes in cynomolgus macaques facilitates the monitoring of 
specific immune responses and pre-clinical vaccine development 
in this model.
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P02.14
Assessing the Protective Efficacy of Antibodies to the 
HIV gp41 Region by Active Vaccination 
S.K. Sharma1, J. Pokorski2, M.G. Finn2, J. Jacqueline1, E. Rakasz3, 
D. Burton1, R. Wyatt1
1International AIDS Vaccine Initiative, La Jolla, CA, USA; 2The 
Scripps Research Institute, La Jolla, CA, USA; 3Wisconsin 
National Primate Research Center, Univ. of Wisconsin-
Madison, WI, USA
Background: The gp41 cluster I is a conserved immunodominant 
loop connecting the heptad repeat 1 (HR 1) and heptad 
repeat 2 (HR2) of the HIV-1 the envelope glycoproteins (Env). 
Following HIV-1 infection or vaccination with gp41-containing 
Env immunogens, this region elicits relatively high titers of 
antibodies generally considered to be non-neutralizing in 
nature. However, in a recent passive immunization study using 
a cluster 1 antibody, partial protection against SHIV SF162 P4 
challenge was observed. In the present study, we sought to 
determine if vaccine-elicited cluster 1 antibodies might afford 
some protective capacity by active vaccination, presumably by 
binding to non-functional spikes on the virus and slowing the 
viral entry process in vivo. 
Methods: To generate cluster 1-specific antibodies, we added 
residues flanking the cluster I cysteine-loop region to allow it to 
assume its preferred structural conformation. The resultant 20 
residues peptides were expressed on the genetically modified 
Q-beta bacteriophage particles and also chemically coupled to 
KLH. Sera from rabbits immunized with these antigens were 
analyzed by ELISA for the binding to cluster 1 peptides and by 
cross-competition with the known cluster I antibodies. 
Results: The cluster I region was found to be immunogenic and, 
interestingly, a version of the epitope in which alanines were 
substituted in place of the small cysteine-linked loop was found 
to be more immunogenic than the wild-type cysteine-cysteine 
motif. The sera from rabbits inoculated with either carrier cross-
competed with the known cluster I antibodies such as F240. 
Though the sera did not neutralize JR-FL viruses, they serum 
antibodies were able to capture many different viruses in vitro. 
Conclusion: We conclude that we have specifically elicited 
antibodies directed to the cluster 1 region of gp41 possessing 
properties similar to the known monoclonal antibodies. Active 
immunization of non-human primates by both the intranasal and 
intramuscular routes, followed by SHIV 
P02.13
Differential Induction of Activation and Apoptosis 
by TCR Signaling in Sooty Mangabeys and Rhesus 
Macaques
S. Yu1, K. Rogers2, F. Villinger2, A. Kaur1
1Harvard Medical School, Southborough, USA; 2Emory 
University, Atlanta, GA, USA
Background: We previously showed that an increase in CD4+ T 
lymphocyte apoptosis and elevation of plasma tumor necrosis-
receptor associated apoptosis-inducing ligand (TRAIL) occurs in 
rhesus macaques (RM) but not sooty mangabeys (SM) during 
acute SIV infection.
Methods: To further examine the mechanisms underlying 
differential apoptosis in SIV-infected RM and SM, we compared 
the in vitro responses to TCR signaling in seven SIV-negative SM 
and seven SIV-negative RM. PBMC were cultured for 18 hours 
with cross-linked CD3 and CD28 and subsequently analyzed 
by flow cytometry for upregulation of CD69, TRAIL and active 
Caspase 3, and for production of cytokines. 
Results: Following TCR stimulation, there was a significant 
increase in TRAIL on T cell subsets, NK cells and myeloid DC cells 
(mDCs) in both species. However, levels of membrane TRAIL 
were significantly higher in CD8+ T lymphocytes and NK cells of 
SM compared to RM suggesting that they may be more cytotoxic 
on activation. TCR stimulation also resulted in an upregulation 
of CD69 and production of IFNγ, IL-2 and TNFα by T cell subsets 
in both species with greater levels being observed in SM. In 
contrast to SM, RM showed significantly higher frequencies of 
apoptotic mDCs both ex vivo and following TCR stimulation. In 
vivo inoculation of RM with SIVmac239 resulted in increased 
frequency of ex vivo apoptotic mDCs at 2-3 weeks post-infection. 
Increased apoptosis was also observed after overnight culture in 
medium but was abrogated by addition of soluble death receptor 
5 indicating that it was TRAIL-mediated. 
Conclusion: Overall, these data show an increased susceptibility 
to apoptosis of mDCs in RM, and a disconnect between T cell 
activation and apoptosis in SM. Elucidating the mechanisms by 
which SM are protected from apoptosis will be important for 
understanding the basis of nonpathogenicity in natural hosts of 
SIV infection.
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P02.16
Protection Against Highly Pathogenic SIV by BCG-SIV 
Recombinant Priming and Attenuated Replicating 
Vaccinia-SIV Recombinant Boosting
X. Zhang1, H. Sakawaki2, T. Miura2, T. Igarashi2, S. Horibata3,  
K. Yokomizo3, K. Matsuo3, N. Yamamoto4, I.B. Fofana5,  
W. Johnson5, T. Ohashi1, H. Shida1
1Institute for Genetic Medicine, Hokkaido University, Sapporo, 
Japan; 2Institute for Virus Research, Kyoto University, Kyoto, 
Japan; 3Japan BCG Laboratory, Tokyo, Japan; 4National 
University of Singapore, Japan; 5NEPRC, Harvard Medical 
School; Boston College, Boston, USA
Background: We constructed recombinants of the Japanese-
licensed Tokyo 172 strain of BCG and the replication-competent 
vaccinia virus strain LC16m8∆ (m8∆) (a genetically stable variant 
of Japanese licensed smallpox vaccine LC16m8) to express 
SIV genes. We then evaluated the protective efficacy of these 
recombinants against challenge with pathogenic, neutralization 
resistant SIVmac251. 
Methods: Indian rhesus macaques were immunized with rBCG-
SIV expressing SIV Gag, Env, or Rev-Tat-Nef (RTN) fusion proteins 
via subcutaneous injection, followed with two boosts with the 
Gag-, Env-, RT-, or RTN-expressing m8∆ by skin scarification. Eight 
weeks after the 2nd boost, macaques were challenged up to 5 
times with a low dose of SIVmac251 by the rectal route. Cellular 
and humoral immune responses were analyzed by standard 
methods. Plasma SIV RNA and cell-associated SIV proviral DNA 
in peripheral blood and various tissues were monitored by 
quantitative PCR. 
Results: Env binding antibodies were elicited at similar levels in 
all vaccinated macaques after m8∆ boost, but neutralizing Ab 
against SIVmac239 was not detected. Robust SIV-specific CD4+ 
and CD8+ effecter memory T cell responses were elicited and 
maintained at high level until SIV challenge. One vaccinated 
animal had potent CD8+ T cells that suppressed SIVmac239 
replication in vitro. Plasma viraemia was not detected in this 
animal, even after CD8+ T cell depletion throughout the follow-
up period. Protection was confirmed by lack of detectable 
cell-associated provirus in various organs. A second vaccinated 
monkey became infected, but viral load remained from one to 
two logs lower than control monkeys. 
Conclusion: Vaccine-induced SIV specific T cell responses appear 
to be effective against SIV challenge. Importantly, our results 
suggest that a vaccine regimen based on an rBCG prime and 
vaccinia m8∆ boost (both liscensed vaccine platforms with a long 
track record of safety in humans) should be explored as a safe 
and valuable means for efficacious HIV/AIDS vaccine 
P02.15
Expression and Function of FcγRII on NK Cells in 
Rhesus Macaques
X. He1, H. Peng1, Z. Luo1, D. Liu1, H. Liang1, Y. Shao1
1National Center for AIDS/STD Control and Prevention, China 
CDC, Beijing, China
Background: Natural Killer (NK) cells play a crucial role in ADCC 
response through FcγRⅢa (CD16), which is able to bind to Fc 
region of IgG displayed on target cells. The presence of another 
class of low-affinity receptor for IgG, called FcγRⅡ(CD32), has 
also been reported in human. It raises the possibility of CD32 
expression on NK cells in non-human primate models. Efforts to 
get a clearer understanding of the CD32 marker which might be 
related to ADCC function of NK cells in rhesus macaques will be 
helpful in evaluation of vaccines in non-human primate models.
Methods: PBMCs were obtained from a total of 42 healthy 
macaques in the study and cellular immunology of NK cells was 
analyzed by flow cytometry. CD32 Blocking antibodies were 
added to PBMCs for FcγRⅡ blockade assay.
Results: The expression of CD32 was observed on macaque NK 
cells (Median, 1.45%; range, 0.96%-2.20%) and was negatively 
correlated with CD16 expression (P<0.001). The downregulation 
of CD16 after stimulation by antibody-coated target cells was 
viewed as an important indicator of NK-cell activation, for 
its strong positive relationship with CD107a, IFN-γ or TNF-α 
measured in ADCC assay (P<0.001 for all). Either the percentage 
or MFI of CD16 expression on NK cells decreased in the presence 
of CD32 blocking antibodies, especially in early stage of ADCC. 
Surprisingly, after CD32 blocking, the percentage of CD107a+ NK 
cells shifted from increase at the very beginning of ADCC activity 
(P<0.05) to decrease when NK cells approached the complete 
activation by antibody-coated target cells (P<0.01). 
Conclusion: CD32+ NK cells defined a novel NK-cell subset in 
macaques and we found that CD32 had dual function with a 
time-course manner in ADCC activity. CD32 may attenuate or 
slow down the activation of macaque NK cells at first, then up-
modulate function of NK cells at the late stage of ADCC.
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P02.18 LB 
Passive Immunization With Polyclonal Anti-SHIV 
Igg: Partial Protection or Increased Acquisition of 
Heterologous Tier 2 SHIV – Depending on Igg Dose
A.M. Sholukh9, N.B. Siddappa9, V. Shanmuganathan1,  
S.K. Lakhashe9, R.A. Rasmussen9, J.D. Watkins9, H.K. Vyas9, 
M.M. Mukhtar9, G. Hemashettar1, S. Thorat9, J.K. Yoon1,  
F. Villinger2, F.J. Novembre2, G. Landucci3, D.N. Forthal3,  
S. Ratcliffe4, M. Robert-Guroff5, V. Polonis6, D.C. Montefiori7, 
H.C. Ertl8, R.M. Ruprecht9
1Dana-Farber Cancer Institute, Boston, MA, USA; 2Yerkes 
National Primate Research Center and Emory University, 
Atlanta, GA, USA; 3Division of Infectious Disease, University of 
California Irvine, Irvine, CA, USA; 4University of Pennsylvania, 
Philadelphia, PA, USA; 5Vaccine Branch, NCI, NlH, Bethesda, 
MD, USA; 6The Military HIV Res. Program, Walter Reed Army 
Inst. of Research, Silver Spring, MD, USA; 7Department of 
Surgery, Duke University School of Medicine, Durham, NC, 
USA; 8The Wistar Institute, Philadelphia, PA, USA; 9Dana-Farber 
Cancer Institute/Harvard Medical School, Boston, MA, USA
Background: While passively administered broadly neutralizing 
monoclonal antibodies (bnmAbs) prevented SHIV acquisition, 
polyclonal Abs with high neutralizing titers provided only 
moderate protection in primates. 
Methods: We tested whether passive immunization with 
polyclonal IgG raised in rhesus monkeys (RMs) with chronic clade C 
SHIV infection, termed SHIVIG, could protect RMs against multiple 
low-dose intrarectal challenges with the R5 tier-2 SHIV-2873Nip 
carrying an HIV clade C envelope heterologous to the viruses/
envelopes against which the IgG responses had been elicited. We 
compared in vitro SHIVIG characteristics with in vivo protection. 
Results: In vitro, SHIVIG demonstrated binding to SIV Gag, HIV 
Tat and Env of different clades, contained b12 and 4E10-like Abs 
and neutralized tier-1 and 2 viruses, including SHIV-2873Nip. 
NK-cell depletion decreased neutralizing activity in PBMC assays 
20-fold. SHIVIG completely inhibited viral replication by ADCVI 
assay, but showed only 35% target-cell killing by ADCC assay. 
Four groups of RMs were given SHIVIG at different doses: 
Group 1 (400 mg/kg), Group 2 (675 mg/kg), Group 3 (25 mg/
kg) and Group 4 (none; virus-only control) followed by weekly 
low-dose challenges with SHIV-2873Nip. All controls and all 
SHIVIG-treated animals became systemically infected. RMs given 
400 mg/kg of SHIVIG showed significantly lower peak viral RNA 
loads compared to controls. Surprisingly, single-genome analysis 
revealed a significant increase in the number of transmitted 
variants in Group 3 compared to controls (P=0.032), suggesting 
increased acquisition. Complement-mediated Ab-dependent 
enhancement of infection (C’-ADE) at low SHIVIG concentrations 
was observed in vitro. 
Conclusion: Lack of protection and possibly increased acquisition 
has been reported for a passive immunization study that tested 
the efficacy of HIV hyperimmune globulin in preventing infection 
in Ugandan infants born to HIV-positive women (Onyango-
Makumbi, JAIDS 2011). Thus, our primate model data paralleled 
clinical phase III results and suggest that polyclonal anti-HIV-1 
Abs play a dual role upon virus encounter.
P02.17
A Prime-Boost Immunization with rBCG Expressing 
HIV-1 Gag, RT and gp120 and SAAVI MVA-C Elicits 
Immune Responses in Blood and MALT of Rhesus 
Macaques
G.K. Chege1, R. Chapman1, E.G. Shephard1, A. Williamson1
1University of Cape Town, Cape Town, South Africa
Background: BCG pantothenate auxtroph (ΔpanCD) is safer to 
use as a live vaccine vector than wild-type BCG. We constructed 
3 recombinant BCGΔpanCD candidate vaccines expressing 
HIV-1 subtype C Gag, RT and Env (gp120). The current study 
investigated immune responses in rhesus macaques following a 
prime with a mixture of these rBCG vaccines and a boost with 
SAAVI MVA-C (MVA).
Methods: Chinese rhesus macaques (n=8) were primed twice 
with a mixture of rBCG, 12 weeks apart. A control group (n=4) 
was mock-primed with a control BCG. Both groups were boosted 
with MVA. Two weeks after the MVA vaccination, two macaques 
from the rBCG-primed group were euthanased and jejunum, 
spleen and inguinal, mesenteric, iliac and bronchial lymph nodes 
were harvested for isolation of mononuclear cells. HIV-1-specific 
IFN-gamma ELISPOT responses were measured in the blood and 
these tissues using pools of overlapping HIV-1 peptides. 
Results: Vaccination with rBCG elicited modest HIV-specific 
responses in the blood in 5 of 8 animals, 4 of which responded 
after the first rBCG vaccination. These responses were to 
either Env or to both Env and Gag proteins and the cumulative 
responses ranged from 50 to 172 sfu/106 PBMC. After boosting 
with MVA, HIV-specific responses were detected in 6 of the 8 
animals (mean: 932±1100 sfu/106 PBMC). These responses 
were directed to Gag, RT, and Env proteins but not Nef or Tat. 
No responses were detected in the control animals before or 
after MVA vaccination. At necropsy, HIV-specific responses 
were detected in the peripheral blood, spleen, inguinal, iliac 
and bronchial lymph nodes of 1 of 2 animals. The cumulative 
responses ranged from 112 to 714 sfu/106 cell input.
Conclusion: These data demonstrate that our rBCGΔpanCD 
candidate vaccines, when given in a prime-boost combination 
with SAAVI MVA-C, induce vaccine-specific immune responses in 
both the peripheral blood and MALT.
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Characterization in Rabbits & Nonhuman Primates Of 
The Neutralizing Antibody Response Elicited by DNA 
& Protein Vaccination With SIVmac251 & SIVsmE660
V.P. Menon1, S. Whitney1, J. Francis1, L. Ajayi1, N. Petrovsky2,  
D. Montefiori3, R. Pal1, K. Vaniambadi 1
1Advanced Biosciences Laboratories, Rockville, MD, USA; 
2Flinders Medical Centre, Bedford Park,SA, Australia; 3Dept of 
Surgery, Duke University Medical Center, Durham, NC, USA
Background: Partial success of the human RV144 clinical trial 
underscored the importance of envelope antibody responses 
for an effective HIV-1 vaccine. Immunogenicity studies with SIV 
envelope proteins typically neutralize TCLA isolates. Properly 
folded trimeric envelope proteins delivered with appropriate 
adjuvants may successfully elicit antibodies with broad 
neutralization specificity
Methods: We evaluated immunogenicity of DNA and protein 
vaccines encoding SIVmac251 and SIVsmE660 gp145 in rabbits 
and rhesus macaques. DNA vaccines encoding wild type gp145 or 
mutated gp160 truncated at Q708 were used. Trimeric wildtype 
gp145 proteins, stably expressed and purified from 293T cells, 
were used with Advax delta inulin adjuvant to boost after DNA 
immunization. Macaques were electroporated with wild type 
DNA of both isolates followed by adjuvanted homologous 
protein boosts. Rabbits received DNA vaccine alone, delivered by 
electroporation. Neutralization assays were performed in TZM-bl 
cells with SIVmac251 and SIVsmE660 isolates that are partially 
resistant to neutralization.
Results: Anti-envelope responses to SIV mac251gp145 and 
SIVsm660 gp145 were detected in macaque sera following DNA 
immunizations and response were enhanced significantly after 
adjuvanted homologous gp145 protein boost. At peak response, 
low to moderate neutralizing activity was observed against 
SIVmac251/M766, SIVsmE660-BR/CG7V and SIVmac251.30 
clones. Immunization of rabbits with DNA encoding, either wild 
type or mutated envelope elicited strong antibody responses 
and sera neutralized both SIVmac251/766 and SIVsmE660-BR/
CG7V to a limited extent, with a comparable response noted for 
both wild type and mutant envelope.
Conclusion: Antibody response elicited by DNA prime/Advax 
adjuvanted protein boost vaccine with oligomeric envelopes 
from both SIVmac251 and SIVsmE660 neutralized SIVmac251 
and SIVsmE660 isolates of partially resistant phenotype. 
These envelopes together with other antigens that elicit 
cellular responses will be tested against SIV challenge in 
future efficacy studies.
P02.19 LB 
Vectored ImmunoProphylaxis Protects Humanized 
Mice from Mucosal HIV Transmission
A.B. Balazs1, J. Chen1, C. Hong1, S. Ouyang1, D. An2, D. Baltimore1
1California Institute of Technology, Pasadena, CA, USA; 
2University of California at Los Angeles, Los Angeles, CA, USA
Background: Recently, a number of antibodies capable 
of broadly neutralizing HIV have been isolated from HIV 
infected patients, stimulating efforts to develop vaccines 
capable of eliciting their production in naive individuals. As 
an alternative to vaccination, we recently described vectored 
immunoprophylaxis (VIP) as an approach capable of generating 
high serum concentrations of a desired monoclonal antibody in 
mice following a single intramuscular injection of a specialized 
adeno associated viral vector (AAV). Mice that received VIP 
encoding b12 and VRC01 antibodies demonstrated long-term 
circulating antibody expression in serum, and VIP-treated 
humanized mice exhibited remarkable protection against high 
dose, intravenous challenge with CXCR4-tropic HIV. However, 
most human infections are initiated by transmission of CCR5-
tropic strains through mucosal tissues.
Methods: To measure the efficacy of VIP against clinically 
relevant strains, we humanized VIP-treated mice by adoptive 
transfer of peripheral blood mononuclear cells (PBMC) and 
challenged these animals with CCR5-tropic HIV strains including 
JR-CSF, as well as REJO.c, a transmitted molecular founder. To 
determine the ability of VIP to prevent mucosal transmission of 
HIV, we developed a repetitive intravaginal challenge model in 
VIP-treated BLT humanized mice that were challenged weekly 
with JR-CSF and monitored for infection.
Results: PBMC humanized mice expressing either b12 or VRC01 
were protected from intravenous challenge with JR-CSF. In 
contrast, the b12-resistant REJO.c strain readily infected PBMC 
humanized mice expressing b12 antibody, while mice expressing 
VRC01 demonstrated nearly complete protection following 
challenge. Intravaginally challenged BLT animals expressing a 
luciferase negative control protein all became infected over 
the study period while a majority of animals expressing VRC01 
had no detectable HIV infection despite fourteen intravaginal 
challenges with JR-CSF.
Conclusion: VIP is capable of protecting humanized mice from 
challenge by diverse HIV strains and can substantially inhibit 
mucosal transmission. These findings warrant continued 
development of VIP as a novel approach for HIV prevention 
in humans.
Topic 2:  Animal Models and Preclinical Trials
PO
ST
ER
S
117
Posters
AIDS Vaccine 2012
P03.02
Continuous Evolution of HIV-1 More Than Ten Years 
After Infection in an Elite Neutralizer
A. Chaillon1, M. Braibant2, S. Hué3, S. Bencharif2, A. Moreau2, 
D. Enard4, A. Samri5, H. Agut6, F. Barin2
1INSERM U966 Resaerch Unit, F. Rabelais University, Tours, 
France, Metropolitan; 2INSERM U966 Research Unit, F. 
Rabelais University, Tours, France, Metropolitan; 3Centre 
for Medical Molecular Virology, University College London, 
Londres, United Kingdom (Great Britain); 4Ecology and 
Evolution Laboratory, CNRS UMR 7625, ENS, Paris, France, 
Metropolitan; 5INSERM U945, Pierre et Marie Curie University, 
Paris, France, Metropolitan; 6Virology Laboratory, Pitié-
Salpétrière Hospital, Paris, France, Metropolitan
Background: The viral evolution of HIV-1 and its escape to 
autologous neutralizing antibodies (Nabs) during the early 
years of infection have been analyzed in depth. In contrast, 
little is known about neither the long-term evolution of the 
virus in patients who developed broadly Nabs (bNabs) nor the 
mechanism of escape in presence of these bNabs.
Methods: We have studied the viral population infecting an HIV-
1 infected long term non progressor (LTNP) who had developed 
Nabs toward all tier 2/3 viruses (6 clades) tested, 9 years after 
infection, and was then followed up over 7 years. Sixty-nine 
env clones issued from sequential blood samples collected 
from 9 years to 16 years post-infection were obtained. Thirteen 
infectious clones representative of the genetic diversity of 
variants present at the different time-points were selected. 
Pseudotyped viruses harboring these different envelopes were 
generated and their sensitivity to neutralization was analyzed.
Results: Evidence of ongoing viral evolution was found, supported 
by both the phylogenetic analyses that showed a continuous 
diversification and an increasing divergence overtime. The mean 
autologous neutralization titers of the sequential sera toward 
the 13 env variants significantly increased during the period of 
late follow-up. The env pseudoviruses displayed a broad range 
of sensitivity to the autologous sera, with the most resistant 
variant identified at the last visit suggesting that it represented 
a late emerging escape variant. We identified 5 amino acids 
substitutions that appeared associated with escape to bNabs. 
They were V319I/S, R/K355T, R/W429G, Q460E and G/T463E, in 
V3, C3 and V5 regions.
Conclusion: This study showed that HIV-1 may continue to 
evolve in presence of both broadly neutralizing antibodies 
and increasing autologous neutralizing activity more than 10 
years post-infection. Such material may provide opportunities 
to reveal the molecular determinants of escape of HIV-1 to 
highly potent broadly neutralizing antibodies.
P03.01
The Breadth of Maternal HIV-1 Specific Neutralizing 
Antibodies Is Not Associated with a Lower Risk of 
Mother-to-Infant Transmission
A. Chaillon1, T. Wack2, M. Braibant1, L. Mandelbrot3, S. Blanche4, 
J. Warszawski5, F. Barin1
1INSERM U966 Research Unit, F. Rabelais University, Tours, 
France, Metropolitan; 2INSERM U1018, Le Kremlin-Bicêtre, 
Paris, France, Metropolitan; 3Louis Mourier Hospital, Paris-
Diderot University, Paris, France, Metropolitan; 4Necker 
Hospital, EA 3620, Paris-Descartes University, Paris, France, 
Metropolitan; 5Inserm U1018, Le Kremlin-Bicêtre, Paris, 
France, Metropolitan
Background: It has been hypothesized that neutralizing 
antibodies (nAbs) should have broad specificity to be effective 
in protection against diverse HIV-1 variants. The mother-to-child 
transmission of HIV-1 is a model that provides the opportunity 
to examine whether the breadth of maternal nAbs would be 
associated with protection of infants from infection.
Methods: Samples were obtained at delivery from 57 transmitting 
mothers (T) matched with 57 non-transmitting mothers (NT) 
enrolled in the multicenter French Perinatal Cohort (ANRS EPF CO1) 
between 1990 and 1996. The mothers did not receive antiretroviral 
therapy during pregnancy, and did not breastfeed their infants. 
Sixty-eight (59.6%) and 46 (40.4%) women were infected by B and 
non-B viruses, respectively. Neutralization assays were carried out 
in TZM-bl cells using a panel of 10 primary isolates of 6 clades (A, 
B, C, F, CRF01_AE, CRF02_AG) selected for their moderate (tier 2) 
or low (tier 3) sensitivity to neutralization. The presence and titers 
of Nab to each strain, and the breadth of maternal nAbs at delivery 
were compared between T and NT mothers.
Results: Although there was a trend for both higher frequency 
and higher titers of nAbs in NT mothers vs T mothers for almost 
all the primary isolates that were tested, the differences were 
not statistically different when considering the entire population. 
However a few statistically significant differences were observed 
with higher frequency or higher titers of nAbs toward several 
individual strains in NT mothers when analyzing separately the 
B-infected or non-B infected mothers.
Conclusion: Our study confirms that the breadth of maternal 
nAbs is not associated with protection of infants from infection. 
However it suggests that, depending of the population, some 
primary isolates could be indicators of nAbs associated with a 
lower risk of MTCT.
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P03.04
Comprehensive Mapping of SIVmac239 Envelope 
Antigenic Determinants Recognized by Specific 
Polyclonal Antibodies in Vaccinated and/or Infected 
Macaques
J. Guo1, T. Zuo2, L. Zhang2, Z. Chen1
1AIDS Institute, LKS Faculty of Medicine, The University of 
Hong Kong, Hong Kong, China; 2AIDS Research Center, School 
of Medicine, Tsinghua University, Beijing, China
Background: The RV144 trial has demonstrated a modest level 
of protection against HIV infection, which was partially related 
to binding antibodies targeting V2 loop. Along with several 
broad HIV-neutralizing antibodies identified recently, it is of 
great importance to understand the major differences between 
vaccination and infection in eliciting humoral immune responses.
Methods: We adopted a robust mapping technique for a 
quantitative measurement of antigenic determinants of entire 
SIVmac239 envelope glycoprotein displayed on the surface of 
the yeast as a combinatorial antigen library. Positive yeast clones 
recognized by the immunized and/or infected serum were 
identified and obtained by FACS followed by sequencing and 
structural analysis.
Results: The finding of reactive determinants ranges from 
30 to 240 amino acids, which allows some conformational 
determinants being evaluated as a major technical improvement. 
The antigen profile of the two types of vaccine-induced sera 
before viral challenge shared two dominant domains that 
concentrated at the V1V2 stem of gp120 and the ecto-domain of 
gp41. Interestingly, using a FACS-based antibody binding assay, 
there were no significant differences of titer and MFI of anti-
V1V2 antibodies between the two vaccination groups, suggested 
a minimal role of these antibodies in controlling viral replication 
post SIVmac239 challenge. A major distinct domain, however, 
was identified near the V3 loop and the main CD4 binding region 
which was significantly recognized by the immune serum of 
the effective vaccination regimen but not of the non-effective 
vaccination regimen or natural SIV infection. Unexpectedly, the 
anti-V1/V2 antibody responses were shifted to the ecto-gp41 
region when infected macaques developed AIDS.
Conclusion: We present a comprehensive analysis of antigenic 
determinants recognized by specific antibody responses 
generated by vaccination and/or SIVmac239 infection. Our 
findings have significant implications to help understanding the 
humoral immunity against neutralization-resistant SIVmac239 
infection and simian AIDS, and to guide rational vaccine 
immunogen identification and design.
P03.03
V5 Region in the HIV-1 Envelope Glycoprotein 
Determines Viral Sensitivity to the Broadly 
Neutralizing Monoclonal Antibody VRC01
D. Guo1, X. Shi2, K. Arledge3, D. Song4, L. Jiang3, L. Fu3,  
S. Zhang5, X. Wang5, L. Zhang3
1Institute of Pathogen Biology,Chinese Academy of Medical 
Sciences, Beijing, China; 2Comprehensive HIV/AIDS Research 
Center, Tsinghua University, Beijing, China; 3Comprehensive 
HIV/AIDS Research Center, Tsinghua University, Beijing, China; 
4China Agricultural University, Beijing, China; 5School of 
Medicine, Tsinghua University, Beijing, China
Background: VRC01, a broadly neutralizing monoclonal antibody 
(bnmAbs), is capable of neutralizing a diverse array of HIV-1 
isolates through recognition of the loop D and the V5 regions 
within the CD4 binding site on envelope glycoprotein gp120. 
Nonetheless, resistant strains have been identified. Here, we 
examined two closely related envelope clones derived at a single 
time point from a CRF08_BC infected patient which displayed an 
over 20-fold difference in VRC01 neutralization sensitivity.
Methods: A total of 15 chimeric envelope clones were generated 
by interchanging the loop D and/or V5 regions between the 
original envelopes or by single alanine substitutions within each 
region. The resultant effects on VRC01 neutralization sensitivity 
were subsequently studied in the context of pseudotyped viruses.
Results: Our results showed that interchanging the V5 region 
between the two clones completely swapped their neutralization 
sensitivity profiles, while exchanging the loop D region alone 
had minimal impact. Mutagenesis analysis revealed that the 
potential N-linked glycosylation site (PNGS) at position 460 in 
the V5 region contributed to over 90% of observed resistance, 
while other amino acid changes made no discernible differences. 
Furthermore, changes in resistance were found to positively 
correlate with VRC01 binding activity to the corresponding 
envelope glycoprotein. None of the substitutions, however, 
significantly altered binding and neutralization sensitivity to 
bnmAb b12 or soluble CD4. Of note, a mutation that removed 
the PNGS at position 463 in the V5 region increased resistance 
to ibalizumab, a non-immunosuppressive monoclonal antibody 
that binds CD4 and has been shown to inhibit entry of diverse 
HIV-1 isolates.
Conclusion: In summary, our data indicates that amino acid 
residues in the V5 region play a critical role in determining viral 
sensitivity to VRC01. Increased length, glycosylation and long 
side-chain of amino acids in the V5 region may collectively create 
steric hindrance that lowers binding affinity, thereby increasing 
resistance to VRC01 neutralization.
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P03.06
Neutralization and Enhancement of Trans Infection 
by Erythrocyte-Bound HIV with Antibodies and 
Complement
Z. Beck1, G.R. Matyas2, V.R. Polonis2, C.R. Alving2
1HJF / WRAIR / US Military HIV Research Program, Silver 
Spring, MD, USA; 2Walter Reed Army Institute of Research, 
Silver Spring, MD, USA
Background: Antibodies to HIV envelope glycoproteins, with or 
without neutralization when assayed in standard neutralization 
assays, are reported to have potential to exert either inhibitory or 
enhancing effects through interactions with complement and/or 
Fc receptors. Although most of the standard neutralization assays 
use free virus rather than carrier-bound HIV as the infectious 
agent; a cell line as the target for infection; and no complement 
(C), these conditions may not reflect in vivo events that would 
include antibody-dependent innate effector mechanisms.
Methods: We investigated the Fc-receptor-mediated and the 
complement-mediated antibody-dependent enhancement 
in trans infection neutralization assays using two broadly 
neutralizing monoclonal antibodies, 4E10 and b12; primary 
HIV; PBMC target cells naturally expressing Fc receptors and 
complement receptors; and with or without complement.
Results: In the absence of complement, the 4E10 mAb did not 
neutralize erythrocyte-bound HIV, and the b12 mAb neutralized 
erythrocyte-bound HIV less effective than the free virus. At 
low concentrations, 4E10 caused enhancement of infection. 
In contrast, in the presence of complement, 4E10 neutralized 
erythrocyte-bound HIV, or caused enhancement of trans infection 
of erythrocyte-bound HIV, depending on the mechanism of 
binding of HIV to erythrocytes.
Conclusion: Our results are consistent with the concept that 
the binding of HIV to erythrocytes represents a mechanism of 
establishing a “safe harbor” for HIV from the adverse effects of 
antibodies and complement that might otherwise be detrimental 
to free circulating HIV. Our data shows that broadly neutralizing 
antibody 4E10 can cause both C-mediated neutralization and 
enhancement of trans infection. This suggests that erythrocyte-
bound HIV-1 serves as a sort of battleground between 
neutralization and enhancement by antibodies in the presence 
of C. Because of this, we propose that induction of neutralizing 
vs. enhancing antibodies can only be differentiated by utilization 
of a trans infection neutralization assay that might yield more 
relevant results for in vivo conditions. 
P03.05
Recognition and Penetration of the HIV-1 Env Glycan 
Shield by Potent Broadly Neutralizing Antibodies
J. Julien8, L. Kong8, R. Pejchal8, R. Khayat1, J. Lee1, R.S. Stanfield8, 
L.M. Walker2, K.J. Doores3, E. Folkowska3, P. Poignard2,  
R. Depetris4, R.W. Sanders5, W.C. Koff6, J.P. Moore4, A.B. Ward1, 
D.R. Burton7, I.A. Wilson8
1Dept. of Molecular Biology, The Scripps Research Institute, 
La Jolla, CA, USA; 2Dept Imm & Microbial Sci & IAVI NAC, The 
Scripps Research Institute, La Jolla, CA, USA; 3The Scripps 
Research Institute, Ragon Institute MIT, Boston, MA, USA; 
4Weill Medical College of Cornell University, New York, NY, 
USA; 5Weill Medical College of Cornell University, Academic 
Medical Center, Amsterdam, Netherlands; 6The International 
AIDS Vaccine Initiative, New York, NY, USA; 7Dept. Imm & 
Microbial Sci and IAVI NAC TSRI, Ragon Institute MIT, USA; 
8The Scripps Research Institute, La Jolla, CA, USA
Background: Human monoclonal antibodies have been 
characterized recently that potently neutralize HIV-1 isolates 
across all clades. These exciting new antibodies (PGT series) 
were derived from direct functional screening of B cells from IAVI 
protocol G donors (Theraclone/Monogram) and are unusually 
potent with binding predicted to be to novel glycan-dependent 
epitopes on Env. 
Methods: Structures of these new PGT antibodies are being 
determined by x-ray crystallography and electron microscopy with 
further characterization using binding and mutagenesis assays. 
Results: The crystal and EM structures so far have been 
elucidated for many of these antibodies. Work on the others are 
in progress, focusing on Fab complexes with glycans, gp120 core 
and fragment constructs, as well as Env trimers.
Conclusion: Structural characterization and biochemical analysis 
of these antibodies have uncovered novel specificities to new 
glycan-dependent epitopes and reveal further mechanisms 
for viral neutralization. These new epitopes provide additional 
insights for neutralization of HIV-1 and how antibodies can bind 
and penetrate the glycan shield, a novel framework for structure-
assisted vaccine design. 
This study was supported by the International AIDS Vaccine 
Initiative (IAVI), Ragon Institute of MGH, MIT and Harvard, and 
NIH AI84817.
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P03.08
Critical Role for Monocytes in Mediating HIV-Specific 
Antibody-Dependent Cellular Cytotoxicity
M. Kramski1, G.F. Lichtfuss2, A. Schorcht1, A.P. Johnston1,  
R. De Rose1, R. Center1, A. Jawarowski2, S. Kent1
1University of Melbourne, Melbourne, Australia; 2Burnet 
Institute, Melbourne, Australia
Background: Antibodies (Abs) that mediate antibody-dependent 
cellular cytotoxicity (ADCC) activity against HIV-1 are of major 
interest. Considerable evidence supports a role for ADCC activity 
in the control of HIV-1 infection and in the context of vaccination. 
One method widely used to assess the role of ADCC is the rapid 
and fluorometric antibody-dependent cellular cytotoxicity 
(RFADCC) assay. In the RFADCC assay specific killing of target cells 
by PBMC is assessed by loss of intracellular CFSE but retention 
of membrane dye PKH26 (CFSE-PKH26+), which is assumed to 
be derived from CFSE+PKH26+ target cells killed by NK cells. We 
have revisited this assay to assess the role of effector cells in 
mediating ADCC.
Methods: Multi-color flow cytometry was used to analyse gp140-
pulsed, CFSE and PKH26 double labeled CEM.NKr-CCR5 cells 
incubated with HIV+ plasma or purified IgG samples (n=57) and 
co-cultured with PBMC, purified NK cells, or monocytes prepared 
from healthy donor blood. Effector/target cell interaction was 
visualized using image stream flow cytometry and live cell imaging.
Results: Backgating analysis and phenotyping of CFSE-PKH26+ 
cells identified CD3-CD14+ monocytes as the major effector cell 
type. This was confirmed for all 57 HIV+ plasma samples tested. 
Emergence of the CFSE-PKH26+ cell population was observed 
following co-culture with purified monocytes but not purified 
NK cells. No significant IFNγ production or CD107a degranulation 
was detected in NK cells in this assay. Image flow cytometry 
and microscopy confirmed a monocyte-specific interaction 
with target cells. Monocytes acquire PKH26+ cell membrane 
presumably derived from killed target cells without typical 
morphological changes associated with phagocytosis, suggesting 
monocyte-mediated ADCC.
Conclusion: Our studies advance the understanding of the 
cellular events underlying HIV-specific ADCC. The RFADCC assay 
primarily reflects Ab-mediated monocyte function and has to be 
treated with caution in regard to NK cell-mediated ADCC. Further 
studies on the biological importance of HIV-specific monocyte-
mediated ADCC are warranted.
P03.07
Design of Epitope-Specific Probes for Sera Analysis 
and Antibody Isolation
I. Georgiev1, P. Acharya1, S.D. Schmidt1, Y. Li2, D. Wycuff3,  
G. Ofek1, N. Doria-Rose1, T.S. Luongo1, Y. Yang1, T. Zhou1,  
B.R. Donald4, J.R. Mascola1, P.D. Kwong1
1Vaccine Research Center/NIAID/NIH, Bethesda, MD, USA; 
2The Scripps Research Institute, La Jolla, CA, USA; 3National 
Institutes of Health, Bethesda, MD, USA; 4Duke University, 
Durham, NC, USA
Background: The design of gp120 monomeric probes with 
modified antigenic profiles that are specific for a target epitope 
has been successfully used for the isolation of broadly neutralizing 
HIV-1 antibodies. Existing probes, however, do not possess 
sufficient specificity and can bind antibodies with undesired 
properties (e.g., weakly neutralizing antibodies targeting an 
overlapping epitope). To achieve improved epitope specificity, 
positive and negative design stages can be incorporated into the 
probe design process.
Methods: Here, we apply a combination of structure- and 
sequence-based methods for improving the epitope specificity 
of gp120 monomeric probes. Specifically, structure-based 
redesign using the OSPREY protein design software suite 
was used to predict gp120 knock-out mutations for selected 
antibodies. Additionally, using a sequence-based mutual 
information approach, knock-out mutations were designed by 
identifying gp120 residues that are predicted to associate with 
neutralization resistance for a given antibody. 
Results: Using stabilized (Ds12F123) and resurfaced stabilized 
(RSC3) HXB2 gp120 cores as templates, we designed a set of 
mutants with improved epitope specificity. In particular, RSC3 (a 
prototypic probe previously used for the isolation of VRC01 and 
other CD4-binding-site antibodies) was redesigned to specifically 
bind CD4-binding-site antibodies that are broadly neutralizing 
(VRC01, VRC-PG04: positive design) but not moderately/weakly 
neutralizing (b12, b13, HJ16: negative design). Additionally, 
CD4i-specific probes were designed by introducing mutations 
that destabilize binding to the entire class of CD4-binding-site 
antibodies (negative design), while retaining binding to CD4i 
antibodies (positive design). The desired epitope specificity of 
the redesigned probes was confirmed by ELISA binding. The 
probe design approach was further validated with knock-out 
mutations for a diverse set of antibodies, including PG9 and 2F5.
Conclusion: Probes with enhanced epitope specificity can select 
more precisely for antibodies with desired properties. A set 
of our redesigned probes are currently being utilized for the 
isolation of antibodies targeting different epitopes of interest on 
the HIV-1 Envelope.
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P03.10
Cross-Group Neutralization of HIV-1 and Evidence 
for Conservation of the PG9/PG16 Epitopes Within 
Divergent Groups of HIV-1
M. Braibant3, E. Gong3, J. Plantier1, F. Simon2, F. Barin3
1Charles Nicolle University Hospital, Rouen, France; 2St Louis 
Hospital, Paris, France; 3Universite François Rabelais, and 
INSERM U966, Tours, France
Background: HIV-1 has been classified into 4 groups: M, N, 
O and P. The aim was to revisit the cross-group neutralization 
using a highly diverse panel of primary isolates (PI) and human 
monoclonal neutralizing antibodies (mAb).
Methods: The panel of viruses included 9 HIV-1 group O PIs, 
1 recombinant M/O PI, 1 group N PI, 1 group P PI, 2 group M 
(subtype B) PIs and the HIV-1 group M adapted strain MN. All 
the viruses were tested for neutralization in TZM-bl cells, using 
a panel of sera issued from patients infected by HIV-1 group M 
viruses (n=11), HIV-1 groups O (n=12) and P (n=1). The mAbs 
were b12, 2G12, 2F5, 4E10, PG9, PG16, VRC01, VRC03 and HJ16. 
Results: The 12 group O sera neutralized from 1 to 6 group O 
viruses, and 6 of them cross-neutralized one group M PI. Five 
of the 10 group M sera cross-neutralized from 4 to 9 group O 
PIs. The group N and P viruses were neutralized by 1-4 of 12 
and 4-5 of 11 sera from groups O and M patients, respectively. 
The human mAbs did not show any cross-group neutralization, 
except PG9 and PG16. Two group O PIs were neutralized by both 
PG9 and PG16, and one group O PI was neutralized by PG9 only. 
The group N PI was highly sensitive to neutralization by PG9 and 
PG16. The N-linked glycans at positions 156 and 160 and the 
cationic residues of strand C of the V1/V2 domain that have been 
identified as part of the PG9 epitope are conserved among the 
group N. 
Conclusion: The cross-group neutralization of HIV-1 has been 
demonstrated. The conservation of the PG9 and PG16 epitopes 
between groups provides an argument for their relevance as 
components of a potentially efficient HIV vaccine. 
P03.09
HIV-1 Envelope Glycoprotein Characteristics That 
Correlate with the Development of Cross-Reactive 
Neutralizing Activity in HIV-1 Infected Individuals
T.L. van den Kerkhof1, Z. Euler1, M.J. van Gils1, B.D. Boeser-
Nunnink1, N.L. Verwer1, H. Schuitemaker1, R.W. Sanders1
1Academic Medical Center University of Amsterdam, 
Amsterdam, Netherlands
Background: Cross-reactive neutralizing activity (CrNA) is elicited 
in around 30% of HIV-1 infected individuals and is most likely 
directed against conserved regions of the envelope glycoprotein 
complex (Env). We hypothesized that the induction of CrNA 
may at least to a certain extent depend on the phenotypic 
characteristics of Env from viruses early in infection.
Methods: We selected 34 patients from the Amsterdam Cohort 
Studies (ACS) who had varying levels of CrNA at 2-4 years after 
seroconversion (SC). We retrospectively generated Env sequences 
from clonal HIV-1 variants that were isolated between 2 and 14 
months after SC and analyzed the length of the variable regions 
and the number of potential N-linked glycosylation sites (PNGS).
Results: For 31 out of 34 patients we observed a correlation 
between a higher level of CrNA and on one hand a shorter 
variable region 1 (P=0.04) and on the other hand a increased 
number of NXS sequons relative to the number of PNGS (P=0.04), 
which decreases the probability of glycosylation at that site. In 
contrast, in the 3 patients with the most potent CrNA, defined 
as elite neutralizers, the viral V1 region was longer with a higher 
number of NXT sequons relative to the number of PNGS. These 
viral characteristics are similar to those in patients with low 
potency of CrNA, rather than to those in patients with higher 
potency of CrNA in their serum.
Conclusion: Our results suggest that in general the development 
of CrNA in HIV-1 infected patients is associated with a more open 
structure of the viral Env, mediated by a short V1 loop and a low 
probability of glycosylation. However, our three elite neutralizers 
were exceptions to this rule. The identification and understanding 
of Env characteristics that are involved in the development of 
CrNA should help the rational design of an effective antibody-
based vaccine immunogen.
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P03.12
Plasma Antibodies That Cross React to Subtype-B 
and C Third Variable (V3) Region Develop in Indian 
HIV-1 Infected Individuals with Time
R. Andrabi1, A. Gupta1, M. Bala2, K. Luthra1
1All India Institute of Medical Sciences (AIIMS), New 
Delhi, India; 2Regional STD Teaching Training and Research 
Centre,Safdarjung Hospital, New Delhi, India
Background: Subtype-C alone accounts for approximately 50% 
of global and more than 95% human immunodeficiency virus-
1(HIV-1) infection in India. Identification of antigenic epitopes 
that induce antibodies with cross-clade activity will be crucial to 
address the HIV-1viral diversity.
Methods: 80 HIV-1 infected drug naive patients were recruited 
for this study. The study was approved by the institute ethics 
committee and informed consent was obtained from all the 
participants. The relative binding of anti-V3 polyclonal plasma 
antibodies to 35 mer consensus¬-B and C V3 peptides was done 
by ELISA binding assay. Statistical analysis was performed by 
Graphpad Prism 5.
Results: Assessment of the relative binding revealed that 86% 
(69/80) of the plasma were able to reach an IC50 binding titer 
with consensus-B V3 peptide with substantially low antibody 
titers compared to binding with consensus-C V3 (mean IC50 
V3-C=12611 versus V3-B=2736) (p<0.0001), implying that 
although majority of the antibodies were subtype specific, a 
good proportion of cross reactive anti-V3 antibodies also exist 
in these plasma (range=1-97%, mean=23%). We observed 
a strong correlation between percent cross reactive anti-V3 
antibodies and days from first diagnosis (n=80: r=0.29 p=0.008) 
while no such association was found with other clinical and 
immunological parameters like plasma viral load (n=53: r=0.16 
p=0.24), CD4 count (n=80: r=0.10 p=0.34), total plasma IgG levels 
(n=65: r=-0.09 p=0.45) and eventually with the V3 sequence of 
donor viruses.
Conclusion: This is the first study to demonstrate the presence of 
cross-clade reactive anti-V3 antibodies and their association with 
time in the plasma of HIV-1 infected Asian Indians from north India.
P03.11
Residue 315 Regulates V3 Exposure and V3 Antibody 
Recognition on HIV Subtype B and C Viruses 
S. Manhas1, B. Clark1, M.K. Gorny2, S. Zolla-Pazner2,  
R. Pantophlet1
1Simon Fraser University, Burnaby, Canada; 2New York 
University School of Medicine, New York, NY, USA
Background: V3 mAbs often neutralize HIV subtype B viruses but 
exhibit poor neutralizing activity against subtype C viruses. This 
limited activity is typically attributed to masking of the V3 region 
on subtype C viruses. However, while relatively much effort 
has been devoted to exploring accessibility of the V3 region 
on subtype B viruses, V3 exposure and the mechanism(s) that 
might restrict V3 exposure on subtype C viruses has yet to be 
understood. Here we have focused on exploring the significance 
of the conserved V3 tip motifs GPGR and GPGQ of subtype B and 
C viruses for antibody recognition.
Methods: Position 315 in representative subtype B (SS1196) 
and subtype C viruses (ZM249M, CAP45) was switched to Gln 
and Arg, respectively, to assess the effect of the conserved Arg/
Gln at position 315 on V3-specific neutralization. Neutralization 
sensitivities of the parental and mutant viruses were assessed in 
a single-round pseudovirus neutralization assay using a panel of 
neutralizing V3-specific mAbs with varying fine specificities for 
the V3 tip.
Results: Subtype B virus SS1196 was neutralized by all V3-specific 
mAbs tested here (B4e8, 2219, 268-D, 2557, 3074 and HGN194). In 
contrast, though as expected, mutant SS1196_R315Q was resistant 
to neutralization by mAbs B4e8 and 268-D, both of which require 
the Arg at position 315 for binding. Unexpectedly, the remaining 
V3 mAbs were also unable to neutralize SS1196_R315Q, despite 
not requiring an Arg residue at position 315 for binding. For the 
subtype C viruses the exact opposite was observed; both ZM249M 
and CAP45 were generally insensitive to antibody neutralization 
yet the Q315R mutants were strikingly sensitive.
Conclusion: The results suggest that V3 may be more accessible 
to antibody than previously appreciated in at least some 
subtype C viruses. However, the data also suggest that a Gln at 
position 315 modulates exposure of V3. Further elucidation of 
this mechanism is underway.
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P03.14
Structural Definition for a New Modality of Broad 
and Potent Antibody Neutralization at the CD4-
Binding Site on HIV-1 gp120
T. Zhou1, S. Moquin1, R. Lynch1, X. Wu1, J. Zhu1, Y. Yang1,  
B. Zhang1, J.R. Mascola1, P.D. Kwong1
1National Institute of Allergy and Infectious Diseases/NIH, 
Bethesda, MD, USA
Background: The initial site of CD4-attachment on HIV-1 gp120 
is vulnerable to neutralizing antibodies, and a number of such 
antibodies have been found that target this site. One set of 
antibodies, represented by VRC01, mimic CD4 in their recognition 
and utilize a common V-gene origin (VH1-2*02). Another set of 
antibodies, represented by the recently identified VRC13, derives 
from VH1-69*01 and is able to neutralize over 90% of circulating 
HIV-1 isolates, including isolates resistant to VRC01. Do the 
VRC13-like antibodies also mimic CD4, or do they represent a 
new modality of effective CD4-binding-site neutralization?
Methods: To define the mode of recognition used by VRC13, we 
crystallized its antigen-binding fragment in complex with HIV-1 
gp120, from both VRC01-sensitive and VRC01-resistant strains, 
and determined these X-ray structures.
Results: The structure of VRC13 indicates a mode of recognition 
rotated by 45 degrees and translated ~10 Å from that of VRC01, 
although both VRC01 and VRC13 utilize similar angles of 
approach. Unlike VRC01-like antibodies, which feature gp120 
contacts primarily in the heavy chain 2nd complementarity 
determining region (CDR H2), VRC13 utilizes a long heavy chain 
CDR H3 to contact the CD4-binding site. Overall, the structural 
details of VRC13 do not mimic those of CD4. 
Conclusion: Broad and potent neutralization at the CD4-binding 
site is not limited to the VRC01-mode of CD4 mimicry. A new 
mode of effective HIV-1 neutralization, which is defined by the 
VRC13-gp120 structure and utilizes CDR H3 recognition, may 
serve as an additional template for the design of an effective 
HIV-1 vaccine. The natural diversity of the CDR H3 – a product of 
V-D-J recombination – may provide advantages in the elicitation 
of VRC13-like antibodies.
P03.13
Cross-Reactive Neutralizing Activity in HIV-1 Infected 
Injecting Drug Users
Z. Euler1, M.J. van Gils1, H. Schuitemaker1
1Academic Medical Center, University of Amsterdam, 
Amsterdam, Netherlands
Background: Vaccine elicited HIV-1 specific cross-reactive 
neutralizing humoral immunity may provide protection against 
acquisition of HIV-1. Several studies have focussed on a better 
understanding of cross-reactive neutralizing activity (CrNA) in 
natural infection, but only in homosexual and heterosexual HIV-1 
transmission cases. 
Methods: To analyze the prevalence and characteristics of CrNA 
in HIV-1 infected individuals who reported injecting drug use as 
the only risk factor, we screened serum samples from 50 male 
and 35 female participants of the Amsterdam Cohort Studies 
(ACS) on injecting drug users (IDU) for CrNA across a heterologous 
6-viral panel. For comparison, similar data from the ACS on men 
who have sex with men (MSM) were available.
Results: HIV-1 infected IDU showed significantly lower geometric 
mean IC50 values and a lower proportion of individuals that 
was capable of neutralizing the majority of viruses in the panel 
as compared to MSM. This difference was however no longer 
observed when women were excluded from the IDU group. 
Interestingly, three out of 50 in the male IDU population qualified 
as elite neutralizer as compared to 1 out of 299 among MSM. 
Multivariate analysis with viral load at setpoint, CD4+ count at 
setpoint, gender and transmission route as co-variates revealed 
only CD4+ count at setpoint as independently associated with 
CrNA in serum. 
Conclusion: CrNA prevalence and potency in HIV-1 infected 
IDU was lower than in MSM. This could be attributed to the 
presence of women in the cohort, rather than the route of 
exposure, which could be explained by the fact that women 
had a higher CD4+ T cell count at setpoint, which was the only 
independent predictor for the presence of CrNA. Our data may 
implicate that the ability of an HIV-1 vaccine to elicit CrNA may 
be lower in women and testing for gender dependent future 
vaccine efficacy may be recommended. 
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P03.16
Rate and Affinity Binding Constants Determined by 
SPR Spectroscopy Reveal Differential Antigenicity of 
HIV gp120 and gp140
T.L. Gearhart1, J.D. Steckbeck1, J.K. Craigo1, R.C. Montelaro1
1University of PIttsburgh, Pittsburgh, PA, USA
Background: The development of a practical, effective AIDS 
vaccine that can produce enduring broadly protective immunity 
to natural exposure by diverse strains of HIV-1 remains the 
ultimate goal for controlling the ongoing AIDS epidemic. The 
success of an effective AIDS vaccine will likely depend on 
designing immunogens that elicit broadly neutralizing antibodies 
to circulating HIV-1 strains, and it is important to thoroughly 
understand the mechanism of binding of HIV antigens and 
neutralizing antibodies. The current study was designed to 
determine differences in the specificity and quantitative 
properties of antibody binding to gp120 or gp140 envelope 
proteins derived from natural HIV isolates.
Methods: We previously described novel assays of Env-specific 
serum antibodies elicited by animal lentiviral and HIV infections 
and immunizations that measure qualitative properties of avidity 
and conformational dependence in an ELISA format. However, 
recent data have emphasized limitations of this format. To 
provide a more sensitive, specific, and reproducible format 
for our antibody assays, we have recently developed novel 
procedures using SPR spectroscopy as measured in the Biacore 
system to characterize real time reaction kinetics (association/
dissociation rates).
Results: The assays conducted under physiological conditions 
(37°C, nondenaturing conditions, etc.) clearly indicate the 
potential of these kinetic measurements of antigen-antibody 
binding to provide novel data not achieved with standard 
assays. We have used these binding assays and a panel of 
well-characterized monoclonal antibodies both to linear and 
conformational binding domains to characterize differences 
in reactivity between variant gp120 and gp140 antigens as 
determined by kinetic rates and affinity of antibody binding. We 
have identified significant distinguishing differences in several 
binding characteristics of monoclonal antibody binding to gp120 
vs gp140 antigens.
Conclusion: These kinetic parameters offer novel insights into the 
fundamental interactions of reference monoclonal antibodies 
and variant Env proteins and have the potential to provide novel 
correlates of neutralization in vitro and protection in vivo.
P03.15
The Impact of Differences in Viral Entry and 
Trafficking on the Mechanism of HIV-1 Neutralization 
C.D. Macedo Cincotta1, L.M. Wieczorek1, B. Barrows1,  
B. Brown2, L. Asher1, N. Michael3, M. Marovich3, V.R. Polonis3
1Henry M Jackson Foundation/ U.S. Military HIV Research 
Program (MHRP), Silver Spring, MD, USA; 2Termofisher, USA; 
3Military HIV Research Program (MHRP)/ WRAIR, USA
Background: Cellular entry of HIV-1 occurs through fusion at the 
plasma membrane (PM) or via endocytosis. PM fusion, resulting in 
deposit of nucleocapsid into the cytoplasm, typically establishes 
productive infection. In contrast, entry through endocytosis 
results in either lysosomal degredation, or productive infection 
through endosomal membrane fusion. While viral entry and 
permissivity are known to differ between host cells, the influence 
of these differences on antibody-mediate neutralization is 
unknown. Here we explore the relationships between HIV-1 
entry, neutralization sensitivity, and the mechanisms by which 
antibodies act.
Methods: Differences in viral entry pathways between 
peripheral blood mononuclear cells (PBMC) and TZM-bl cells 
were visualized by electron microscopy (EM). Cells were 
incubated with HIV, with or without antibody, for 1 hour at 
4oC, then viral entry was allowed for 5 min at 37oC. Cells were 
treated with pronase and either separated into cytosolic and 
membrane fractions, or cultured to assess viral growth and 
neutralization. The fraction where nucleocapsid localized was 
determined by antigen capture and microscopy techniques 
were used to visualize HIV-1 within cells. 
Results: TZMbl cells are 30-fold more efficient at internalizing 
HIV-1 than PBMC with differences in entry observed between 
viruses. In TZMbl cells, a greater fraction of p24 localized in the 
membrane indicating endocytic entry, whereas in PBMC, SF162 
localized predominantly in cytosol, indicating PM fusion, while Bal 
localized equivalently in membrane and cytosolic fractions. Both 
viruses are neutralized by 2G12 and b12, however, neutralization 
by 2G12 was not associated with entry inhibition; in fact, after 
the 5 minutes infection, entry appeared to be enhanced. In 
contrast, b12 decreased viral entry. 
Conclusion: Our data suggest that, for certain antibodies, 
inhibition of HIV-1 may occur post-entry, and differences in 
entry mechanisms may impact neutralization. Experiments 
to elucidate the role of host restriction and post-entry 
neutralization on inhibition of HIV-1 are ongoing. 
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P03.18
A Comprehensive Binding and Neutralization 
Analysis of Plasma of HIV-1 Subtype-C Infected 
Donors from India Suggest MPER Directed 
Neutralization
R. Andrabi1, M. Bala2, R. Kumar3, K. Luthra3
1All India Institute of Medical Sciences (AIIMS), New Delhi, 
India; 2Regional STD Teaching Training & Research Centre, 
Safdarjang Hospital, New Delhi, India; 3AIIMS, New Delhi, India
Background: Dissecting the specificities of the anti-HIV-1 
neutralizing antibodies will assist in identifying targets for an HIV-
1 subunit vaccine which undoubtedly remains ultimate goal for 
vaccine development.
Methods: We tested 30 HIV-1 drug naive plasma samples for 
neutralization against a broad panel of subtype-A, B and C tier 
1 and tier 2 viruses in a TZM-bl assay. Three broadly neutralizing 
plasma (bNP) samples (AIIMS206, AIIMS239 and AIIMS249) were 
tested for ELISA binding with a set of 211 consensus-C gp160 
overlapping peptides (NIH AIDS Research and Reference Reagent 
Program). The competition and depletion experiments (for 
neutralization) were carried out with peptides corresponding to 
consensus-C V3 (35mer), IDR (19mer) and MPER (24mer).
Results: Approximately 25% of the plasma/virus combinations 
showed neutralizing activity with a predominance of subtype 
C specific neutralization compared to subtype B (p=0.001). 
Immunoglobulin-G fractions from bNP were shown to mediate 
neutralization exclusively and were shown to retain the binding 
to subtype-A, B and C recombinant gp120 proteins. Based on the 
Max50 ELISA binding titers, the immunoreactivity of the three 
bNP mapped to second variable (V2), second constant (C2), third 
variable (V3), fourth constant-fifth variable (C4-V5), fifth constant 
(C5) regions of gp120 and fusion protein (FP), immunodominant 
region (IDR), C-heptad region (CHR), membrane proximal external 
region (MPER) and C-terminal (CT) of gp41 protein. In the depletion 
and competition assays, the bNP AIIMS206 and AIIMS239 showed 
dependence on MPER directed antibodies with four and six (out of 
eight) viruses respectively while the V3 and IDR peptides showed 
minimal effect on neutralization as compared to untreated and 
mock depleted plasma controls. Further, the mapping of IgG 
fractions from bNP with overlapping MPER peptides showed 2F5 
like binding specificity for AIIMS206 plasma.
Conclusion: Our study demonstrates that MPER directed 
antibodies in HIV-1 subtype-C infected patients play a crucial role 
in viral neutralization.
P03.17
Neutralizing Anti-HIV Antibodies Develop In a 
Humanized Mouse Model of HIV-1 Infection
E. Seung1, A. Dugast2, T. Dudek2, H. Mattoo3, V. Vrbanac1,  
T. Tivey1, T. Murooka1, A. Cariappa3, A.D. Luster1, S. Pillai3,  
A.M. Tager1
1Massachusetts General Hospital, Charlestown, MA, USA; 
2Ragon Institute of MGH, MIT, and Harvard, Charlestown, MA, 
USA; 3MGH Cancer Center, Charlestown, MA, USA
Background: In BLT (bone marrow-liver-thymus) humanized mice, 
human thymocytes are educated by autologous human thymic 
tissue, resulting in functional human T cells capable of rapidly 
selecting for CTL escape mutations in HIV. In contrast, limitations 
to B cell maturation have been noted. But despite this, we show 
for the first time that HIV infected BLT mice can produce class-
switched anti-HIV antibodies with neutralizing activities.
Methods: Humanized BLT mice were generated by transplanting 
irradiated NOD-scid/IL2rgnull (NSG) mice with fetal thymus and 
liver fragments and then injecting them with autologous human 
CD34+ stem cells. BLT mice were then infected with HIVJRCSF 
and bled at various time-points. HIV neutralizing activity was 
measured using Tat-induced luciferase reporter TZM-bl cells.
Results: Human transitional B cells were present in greater 
frequencies in BLT mice than adult humans. Most of these cells 
had a T1 phenotype in the blood and spleen. But despite this 
B cell maturation defect, class-switched IgG Abs against various 
HIV proteins were detected by Western Blot in HIV-infected BLT 
mice. Using ELISA to determine anti-p24 IgG Ab titers, Abs were 
present as early as 8 weeks post infection (p.i.), with peak Ab 
titers seen after 15 weeks. One infected mouse demonstrated 
a peak titer similar to that seen in a chronically infected human. 
Finally, plasma samples from infected BLT mice after 22 weeks 
p.i. demonstrated neutralizing activities against the challenge 
virus. Average IC50 neutralizing titers in these mice were similar 
to those from infected human samples.
Conclusion: The ability of humanized BLT mice to generate 
functional humoral immune responses may be further improved 
by strategies to improve their B cell maturation, which will 
further improve the potential of these mice to become a model 
system to study candidate HIV vaccines and therapies.
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P03.20
Modulation of Antibody Secreting Cells and 
Neutralizing Ab Activity in HIV Infected Individuals 
Undergoing Structured Treatment Interruptions
A. Llano1, J. Carrillo1, B. Mothe1, S. Marfil1, E. García1, L. Ruiz1, 
E. Yuste2, V. Sanchez2, J. Blanco1, C. Brander1
1IrsiCaixa AIDS Research Institute, Barcelona, Spain; 2Institut 
d`Investigacions Biomediques August Pi i Sunter, Barcelona, 
Spain
Background: HIV-1 infection generates numerous abnormalities 
in the B cell population. The majority of these defects are reverted 
by antiretroviral therapy. Our aim was to evaluate the effects of 
re-exposure to HIV antigens on the frequency and functionality of 
antibody secreting cells (ASC) in patients undergoing structured 
treatment interruptions (STI). As re-exposure to viral antigens 
may also boost the production of (neutralizing) antibodies, we 
also assessed the neutralizing activities during STI cycles.
Methods: Retrospective study of 10 patients undergoing 3 cycles 
of STI with 2 weeks on and 4 weeks off HAART. ASC frequencies 
were determined by flow cytometry in samples obtained at the 
beginning and the end of STI. Neutralization capacity, total IgG 
concentration and anti-gp120-IgG titres were evaluated.
Results: Median viral loads were higher at the end of STI 
compared to time of treatment stop: 20[20-1200] vs 615[20-
452000] respectively for the first STI, 20[20-654] vs 3655[20-
45900] (p<0.05) for the second and 35[20-82] vs 290[20-17400] 
(p<0.05) for the third STI. The frequency of ASC followed the same 
trend: 0.35%[0.17-1.15] at the beginning of first STI vs 0.27[0.20-
4.95] at treatment restart, 0.35[0.10-1.40] vs 0.82[0.30-3.25] 
for the second and 0.30[0.10-0.70] vs 0.40[0.15-1.85] for the 
third STI. Eight out of 10 patients maintained stable total IgG 
levels during the study. HIV-neutralizing activity was observed in 
two patients concomitantly with high anti-gp120 titters. In one 
patient the neutralizing activity remained constant while the 
second patient showed elevated neutralizing Ab after first STI 
and once treatment was reinitiated after the 2nd STI. 
Conclusion: Our data suggest that STI and its associated transient 
increases in viral load drive the frequencies of ASC in an antigen-
specific manner. In some subjects, this re-exposure to autologous 
virus boosts the presence of neutralizing antibodies, albeit in a 
somewhat delayed manner.
P03.19
Highly Efficient Neutralization of Human 
Immunodeficiency Viruses by Plasma from 
Antiretroviral Drug Treated Patients Is Mediated by 
IgG Fractions 
R. Andrabi1, M. Makhdoomi1, R. Kumar1, M. Bala1, T. Velpandian1, 
K. Luthra1
1All India Institute of Medical Sciences (AIIMS), New Delhi, 
India
Background: Little is known about the neutralizing activity in 
patients on antiretroviral therapy (ART), as most recent studies 
have focused on drug naïve individuals. ART may lead to a 
significant increase in B cell numbers and normalization of B cell 
subpopulations, providing a possible explanation for improved B 
cell responses after ART.
Methods: Thirty-four HIV-1 seropositive patients on ART (25 
males and 9 females) within the age range of 20-55 years were 
recruited in this study. The patients had a median CD4 count and 
viral load of 283 cells and 178 RNA copies respectively, and were 
on treatment for a few days up to two years. Heat inactivated 
plasma samples were tested for neutralization against a panel of 
14 subtype-A, B and C tier 1 and tier 2 viruses in TZM-bl assay.
Results: Of the 34 plasma samples, remarkably all the plasma 
samples were able to neutralize at least one virus while 32 (94%) 
samples were found to neutralize ≥50% viruses tested. Clustering 
analysis revealed that AIIMS253 (a clade-C virus) was the most 
sensitive while RHPA4259.7 (a clade-B isolate) was most resistant 
to antibody neutralization. The Immunoglobulin-G fractions from 
two representative samples AIIMS221 and AIIMS265 were shown 
to mediate neutralization exclusively. The IgG fractions retained 
binding to subtype-A, B and C recombinant gp120 proteins. We did 
not find any association of mean reciprocal ID50 neutralization titers 
with the plasma levels of ART drugs and clinical and immunological 
variables like CD4 count (p=0.35), viral load (p=0.37) and plasma 
total IgG (p=0.46). However we observed a positive association of 
neutralization with duration of ART (p=0.02) with a similar trend in 
two follow up patient samples.
Conclusion: Plasma antibodies from patients on ART display 
high neutralizing activity most likely due to an improved B cell 
function induced by ART despite low antigenic stimulation.
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P03.22
Affinity Maturation Pathway of an Anti-MPER 
Neutralizing mAb, CAP206-CH12
N.L. Tumba1, E.S. Gray1, B.E. Lambson1, S.S. Abdool Karim2,  
H. Liao3, B.F. Haynes3, M. Alam3, L. Morris1
1NICD- HIV/STI Center, Johannesburg, South Africa; 2Centre for 
the AIDS Programme of Research in South Africa (CAPRISA), 
Durban, South Africa; 3Duke Human Vaccine Institute, 
Durham, NC, USA
Background: The membrane proximal external region (MPER) 
of HIV-1 is an important target of broadly cross-reactive mAbs. 
CAPRISA participant, CAP206, developed anti-MPER antibodies 
early that became cross-neutralizing at 18 months post-infection. 
This coincided with neutralization of the C4 HIV-2/HIV-1 chimera 
containing the W670 residue, suggesting changes in an antibody 
paratope may have resulted in the acquisition of breadth. 
A neutralizing mAb (CAP206-CH12) was isolated, providing 
an opportunity to determine which somatic hypermutations 
contribute to breadth.
Methods: The putative CAP206-CH12 reverted unmutated 
ancestor (RUA) was inferred using SoDA (www.dulci.org). Batch 
transient transfections were used to generate recombinant 
antibodies. Neutralization breadth and potency was tested 
against autologous, Tier 2, and HIV-2/HIV-1 MPER chimeric 
viruses using the TZM-bl assay. Binding to MPER peptides was 
assessed by ELISA and surface plasmon resonance (SPR). 
Results: CAP206-CH12_RUA bound the MPER.03 peptide with 
a Kd of 120nM, 15-fold weaker than CAP206-CH12 binding, but 
had no neutralizing activity. Since CAP206-CH12 and its RUA 
differed by 19 residues in the heavy chain and 9 in the light chain, 
we designed an intermediate precursor (IP) where changes near 
the CDRs in CAP206-CH12 were reverted back to the germline 
sequence (11 in the heavy and 5 in the light chain). This CAP206-
CH12_IP did not neutralize the C4 chimera suggesting that 
changes responsible for the affinity-matured CAP206-CH12 
neutralizing capacity were among these 16 residues. Chimeric 
pairs of the light chain IP with the heavy chain of CAP206-CH12 
or CAP206-CH12_RUA showed binding to MPER with differences 
in binding kinetics. 
Conclusion: The reduced binding and neutralizing activity of 
CAP206-CH12_RUA and CAP206-CH12_IP compared to CAP206-
CH12 suggests a correlation between affinity maturation, 
neutralization breadth and potency. Ongoing work will assess 
the affinity maturation of CAP206-CH12 by determining moieties 
in the antibody paratope associated with effective epitope 
recognition and the effects of somatic mutations on the evolution 
of neutralization.
P03.21
Construction and Characterization of Neutralizing 
Antibody Fragments for Efficient Access to V3 
Epitope
Y. Maruta1
1Center for AIDS Research, Kumamoto University, Kumamoto, 
Japan
Background: The neutralizing antibody against HIV-1 is important 
for the vaccine development. However, primary isolates of HIV-1 
have resistance to antibody neutralization. While a neutralization 
epitope in V3 is exposed by conformational change of gp120 
following CD4-binding, anti-V3 IgG molecules are too large to 
access V3-epitope. The purpose of our study is to develop Fab 
and scFv fragments from the anti-V3 monoclonal neutralizing 
antibody 5G2 for efficient access to V3-epitope.
Methods: RNA was extracted from clonal cells producing 5G2, 
and cDNA was prepared by reverse transcription. Using primers 
for variable region of heavy and light chains, the antibody genes 
were amplified by PCR, and inserted into pComb3X vector. Fab 
and scFv were produced in the transformed E. coli by induction 
with isopropyl-β-D-thiogalactoside, and purified by nickel chelate 
chromatography. 
Results: Binding of recombinant 5G2 Fab and scFv to V3 epitope 
was shown by enzyme-linked immune-sorbent assay against V3 
peptide. The flow cytometry analysis using cells expressing HIV-1 
Env revealed the higher intensity by smaller antibody fragment, 
suggesting the increased accessibility of small fragment to 
V3 epitope. Neutralizing activity of these 5G2 fragments were 
observed against both primary HIV-1JR-FLwt and neutralization-
sensitive variant, JR-FLL175P. In the case of JR-FLwt, scFv showed 
a significant improvement of neutralization. 
Conclusion: The use of smaller antibody fragments, such as scFv 
and Fab, may be one strategy to overcome steric constraints that 
confer neutralization resistance of primary isolates. We are now 
evaluating an effect of small antibody fragments on neutralization 
against various primary isolates.
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P03.24
Biophysical Dissection of the Antigen-Antibody 
Interaction of the Broadly Reactive Anti-V3 Human 
mAb 447-52D
A. Killikelly1, H. Zhang1, B. Spurrier1, C. Williams2, M.K. Gorny2, 
S. Zolla-Pazner2, X. Kong1
1New York University Medical Center, New York, NY, USA; 
2Veterans Affairs New York Harbor Healthcare System, New 
York, NY, USA
Background: The immunogenic third variable region (V3) of HIV-
1 gp120 is a target for AIDS vaccines. V3 is recognized by mAb 
447-52D, known for its ability to neutralize viruses with a GPGR 
beta turn motif at the apex of V3, which is characteristic of clade 
B viruses. Interestingly, 447-52D can also bind non-clade B V3 
peptides containing a GPGQ motif. A detailed biochemical and 
biophysical dissection of the antigen-antibody interaction of 447-
52D was undertaken to understand this disparity.
Methods: We cloned and produced large amounts of the 
Fv fragment of 447-52D and a panel of mutations. We then 
measured their epitope binding characteristics by Isothermal 
Titration Calorimetry (ITC).
Results: We assessed the Fv-V3 binding by ITC for the following 
mutations in residues of the mAb that are thought to mediate 
three key interactions: (i) YH100j of the heavy chain (H) to T 
(YH100jT) or YH33A. These two aromatic residues form a pi-cation 
interaction, sandwiching the side chain of R315 of the GPGR motif 
in the V3-peptide. These mutations reduce binding affinity by 
56 and 171-fold, respectively. (ii) WL91 of the light chain (L) to A 
(WL91A). This residue packs against P313 of the V3 GPGR turn. This 
mutation reduces binding 230-fold. (iii) DH95R of the heavy chain 
or R315Q of the epitope. These two residues form a salt bridge 
between the antigen and the antibody. These mutations reduce 
binding by 224 and 171-fold, respectively. These data suggest a 
hierarchy of interactions and the salt bridge plays an important 
role in the affinity.
Conclusion: mAb 447-52D binds non-clade B peptides with 
the R315Q variation with much less affinity, explaining why 
it cannot neutralize non-clade B viruses. Through probing 
specific contributions of individual residues by mutagenesis 
and ITC, we were able to fully characterize the interactions 
between V3 and 447-52D.
P03.23
Comparison of the Neutralization Sensitivity of South 
African and Indian HIV-1 Subtype C Viruses to South 
African Plasma Antibodies
T. Hermanus1, N. Mkhize1, P. Moore1, M. Nonyane1,  
J. Battacharya2, S.A. Karim3, L. Morris1
1National Institute for Communicable Diseases, Johannesburg, 
South Africa; 2National AIDS Research Institute, Pune, India; 
3Center for AIDS Program of Research in South Africa, Durban, 
South Africa
Background: HIV-1 subtype C is the predominant subtype in 
India and South Africa (SA) responsible for explosive epidemics. 
An understanding of the neutralization sensitivity of viruses from 
these regions will help to define shared epitopes in the envelope 
protein, which may be important for inclusion in an effective 
subtype C-specific vaccine. 
Methods: Plasma from 44 chronically HIV-1 subtype C infected SA 
individuals in the CAPRISA 002 Acute Infection cohort were used 
to assess the neutralization sensitivity of 10 SA and 9 Indian Tier 
2 viruses in a TZM-bl assay. Intra-subtype neutralization activity 
between SA and Indian viruses was determined. The envelope 
sequence of the Indian panel was analyzed in order to identify 
epitopes known to be targeted by the neutralizing antibodies in 
a subset of the CAPRISA plasmas.
Results: South African and Indian viruses were generally sensitive 
to the most potent plasmas. However, SA viruses showed overall 
greater sensitivity compared to Indian viruses; neutralization 
of 50% of the SA virus panel was achieved by 15/44 (34%) of 
the plasmas compared to only 6/44 (14%) against the Indian 
panel. Furthermore, neutralization titers against SA viruses 
were higher, with 9/44 (21%) of plasmas neutralizing at >1:200 
compared to 5/44 (11%) against the Indian panel. An analysis of 
the gp160 sequences suggested that genetic differences in key 
neutralization epitopes between SA and Indian viruses were in 
part responsible for differences in sensitivity. 
Conclusion: These data suggest the presence of common 
neutralization epitopes between SA and Indian viruses although 
there is also evidence for regional neutralization determinants 
within subtype C. The finding that SA viruses were generally 
neutralized at higher titers, suggests that the exposure of 
common epitopes on envelope may vary between SA and 
Indian viruses. Overall, these data support the development of a 
subtype C-specific vaccine that can be used in both SA and India. 
Topic 3:  B Cell Immunology and Antibody Functions
PO
ST
ER
S
129
Posters
AIDS Vaccine 2012
P03.26
Optimization and Validation of the HIV-1 Neutralizing 
Antibody Assay in A3R5 Cells
M. Sarzotti-Kelsoe1, X. Daniell1, C.A. Todd1, M. Bilska1,  
C. LaBranche1, L.G. Perez1, C. Ochsenbauer2, J. Kappes2,  
W. Rountree1, D.A. Ozaki1, J.H. Kim3, R. McLinden3, T. Denny1, 
D.C. Montefiori1
1Duke University Medical Center, Durham, NC, USA; 2University 
of Alabama, Birmingham, AL, USA; 3U.S. Military HIV Research 
Program, WRAIR, Silver Spring, MD, USA
Background: A3R5 is a highly sensitive cell line for the detection 
of neutralizing antibodies (Nabs) against tier 2 strains of HIV-
1. This cell line is particularly useful for the detection of weak 
Nab responses in preclinical and clinical trials of candidate HIV-
1 vaccines. All methods used for endpoint analyses in clinical 
trials should be validated and demonstrably fit for purpose, in 
compliance with ICH Q2 (R1) guidelines. Here we describe the 
optimization/qualification and validation of the HIV-1 Nab Assay 
in A3R5 cells. 
Methods: A3R5 is a human lymphoblastoid cell line naturally 
expressing CD4 and CXCR4 and engineered to express CCR5. 
Nab assays in A3R5 cells are performed with Env.IMC.LucR 
viruses containing a reporter gene in the viral genome, whose 
expression is induced by viral Tat protein soon after infection. 
Luciferase activity is quantified by luminescence and is directly 
proportional to the number of infectious virus particles present 
in the viral inoculum. The assay is performed in 96-well culture 
plates for high throughput capacity. 
Results: We determined the stability of the cell line over time 
in culture for receptor and coreceptor expression, susceptibility 
to infection, and sensitivity to neutralization. The assay was 
optimized for cell density, input virus dose, length of incubation 
time and use of DEAE-dextran. We also determined the stability 
of a set of reference reagents, for validation experiments and 
for future competency and proficiency testing that express a 
broad spectrum of neutralization phenotypes. A prospective 
validation plan with pre-set pass/fail criteria was composed 
and implemented that addressed key assay parameters, 
including accuracy, precision, limit of detection and quantitation, 
specificity, linearity and range, robustness and specificity. Results 
of validation experiments were statistically analyzed and used to 
generate a final validation document. 
Conclusion: This validated assay will be used to identify correlates 
of protection in HIV vaccine trials conducted globally. 
P03.25
Characteristics of HIV-1 gp120 Molecules That Bind 
Ancestor, Intermediate and Mature Forms of VRC01-
like Antibodies
M. Joyce1, B. Zhang1, T. Zhou1, S. Moquin1, X. Wu1, M. Louder1, 
Z. Zhang1, I. Georgiev1, J. Zhu1, L. Shapiro1, J.R. Mascola1,  
G.J. Nabel1, P.D. Kwong1
1Vaccine Research Center, NIAID/NIH, Bethesda, MD, USA
Background: A group of highly effective neutralizing antibodies, 
which target the site of CD4 binding on HIV-1 gp120, have recently 
been identified. These antibodies – called VRC01-like antibodies 
– all originate from the same VH1-2*02 germline gene and, while 
the mature antibodies have undergone extensive maturation via 
non-homologous pathways, their recognition of the CD4-binding 
site of gp120 is similar. An efficacious vaccine that elicits VRC01-
like antibodies will likely be required to bind to VH1-2*02-derived 
B cells to initiate their expansion and subsequent maturation, 
however, binding studies with reverted-ancestor VRC01-like 
antibodies and HIV-1 gp120 molecules typically show binding 
that is too weak to initiate B cell maturation.
Methods: To identify HIV-1 gp120 molecules capable of 
interacting with reverted-ancestor molecules with sufficient 
affinity to initiate B cell maturation, we screened large panels of 
HIV-1 pseudoviruses for sensitivity to reverted-ancestor forms 
of VRC01-like antibodies. Identified HIV-1 strains (and related 
gp120s) were then analyzed for recognition to a panel of diverse 
VRC01-like antibodies.
Results: No HIV-1 strains were identified which could be neutralized 
by reverted heavy chain- and light chain-ancestors of VRC01-like 
antibodies. Chimeric forms of the VRC01-like antibodies with 
reverted and mature heavy/light chain mixtures did, however, 
neutralize a small subset of HIV-1 isolates. Characterization of 
gp120s from the sensitive subset found measurable affinity to 
the ancestral forms of VRC01-like antibodies. In comparison, 
typical gp120 molecules, e.g. YU2 gp120, fail to bind low-
divergent forms of the VRC01-like antibodies, i.e. those with less 
than 10% divergence from germline.
Conclusion: Select strains of HIV-1 can interact with ancestral 
forms of VRC01-like antibodies. Defining the specific 
characteristics of these select strains should enable identification 
of gp120-derived immunogens capable of productive interactions 
with VH1-2*02-derived B cells.
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Detection of Antibodies to the α4β7 Integrin Binding 
Site on HIV-1 gp120 V2 Loop Using A Novel Cell 
Adhesion Assay
M. Rao1, N. Karasavvas2, A. Pinter3, H. Liao4, M. Bonsignori4,  
B. Mathieson5, S. Zolla-Pazner6, B.F. Haynes4, N.L. Michael1, 
J.H. Kim1, C.R. Alving1, K.K. Peachman7
1U.S. Military HIV Research Program, WRAIR, Silver Spring, 
MD, USA; 2Armed Forces Research Institute of Medical Science 
(AFRIMS), Bangkok, Thailand; 3The Public Health Research 
Institute Center at the International Cente, Newark, NJ, USA; 
4Duke Human Vaccine Institute Duke University Medical 
Center, Durham, NC, USA; 5Office of AIDS Research, National 
Institutes of Health, Bethesda, MD, USA; 6NYU School of 
Medicine, New York, NY, USA; 7United States Military HIV 
Research Program, WRAIR / HJF, Silver Spring, MD, USA
Background: The gut mucosal homing integrin receptor α4β7 
present on activated CD4+ T-cells interacts with the HIV-1 gp120 
second variable loop (V2). Case control analysis of the RV144 phase 
III vaccine trial showed that antibodies induced by the vaccine 
bound to a MuLV-gp70 scaffolded V1V2 loop of gp120 (V1V2-
gp70) and correlated inversely with infection. These, and other 
data, generate the hypothesis that the vaccine-elicited antibodies 
may have been involved in limiting HIV-1 acquisition. We have 
developed a high-throughput assay to evaluate antibodies that 
block α4β7 binding. We have named this the RAP assay.
Methods: Plates were coated with either MAdCAM-1, the 
natural ligand of α4β7, or streptavidin followed by the addition 
of biotinylated cyclic-V2 peptides (strain 92TH023 or MN). 
Plasma and purified IgG antibodies from RV144 volunteers, 
conformational mAbs specific for V2 (697), for V2 and V3 (PG9, 
PG16), or for V2 linear epitopes (CH58 and CH59, cloned from 
RV144 vaccinee B cells) were then added to the peptide-coated 
plates followed by RPMI8866 cells, which constitutively express 
α4β7. Cell binding/inhibition was assessed by AlamarBlue. 
Anti-α4β7-specific mAb (ACT-1) served as a control. In separate 
experiments, plasma, IgG, or mAbs were tested in a competition 
assay using V1V2-gp70. 
Results: ACT-1 inhibited the binding of both MAdCAM-1 and 
cyclic-V2 peptides to α4β7 by 65-85%, while CH58 and CH59 
inhibited the α4β7-cyclic-V2 peptide binding by 37-45% in a 
dose-dependent manner. PG9, PG16, and 697 did not inhibit the 
binding of V2-peptides to the cells. However, in the competition 
assay, 697 and PG9 mAbs inhibited V1V2-gp70 binding to α4β7. 
Some of the RV144 plasma and IgG inhibited binding to 92TH023 
or MN-V2-peptides.
Conclusion: We have developed a novel high-throughput 
reproducible assay for assessing α4β7-specific blocking antibodies. 
The above results raise the hypothesis that anti-V2 loop antibodies 
may play a role in regulation of gp120-α4β7 interaction.
P03.27
Crystal Structure Analysis of Anti-V2 Mab 2158 
Suggests a Conformational Epitope Involving an 
N-Linked Glycan
B. Spurrier1, R. Pan1, J. Sampson1, C. Williams1, M. Gorny1,  
S. Zolla-Pazner2, X. Kong1
1NYU School of Medicine, New York, NY, USA; 2Veterans Affairs 
New York Harbor Healthcare System, New York, NY, USA
Background: Many structural elements of HIV-1 gp120 have been 
revealed by X-ray crystallography, NMR and electron microscopy; 
however, several key immunogenic regions are still not well 
understood. Data from the recent RV144 trial indicated that 
antibodies targeting the V1V2 region correlate with a lower risk 
of infection. A detailed characterization of anti-V2 antibodies, in 
concert with recent V1V2 structural information is critical to the 
design of a V2 immunogen.
Methods: We have determined a crystal structure of the 
uncomplexed Fab fragment of anti-V2 mAb 2158. To understand 
the antigen binding mode of mAb 2158, we computationally 
created twenty V1V2 models from a panel of gp120s that were 
tested previously in ELISA for binding reactivity with mAb 2158. 
Subsequently, we docked these models in silico to the antigen 
binding site of mAb 2158.
Results: The structure of Fab 2158 revealed that its antigen 
binding site consists of a hydrophobic surface comprised with 
residues from CDRs H2 and H3 with a deep pocket between CDRs 
H1 and H3. Surface energy analysis suggests that the heavy chain 
and the binding pocket are likely to dictate the antigen binding 
mode of Fab 2158. Our model-building of the 20 V1V2 structures 
revealed that the residues previously suggested as the mAb 2158 
epitope all mapped to a single face on the V2 domain next to 
glycosylation site N186. Correlating our computational analysis 
with ELISA data suggests that the glycosylation of N186 plays 
a key role in binding and our docking results indicates that the 
mAb 2158 binding pocket can accommodate the mannose glycan 
harbored by N186.
Conclusion: Structural analyses of Fab 2158 suggest that binding 
to a conformational epitope containing an N-linked glycan. Our 
results allow us to hypothesize a binding motif signature for anti-V2 
mAb 2158 and form a framework for designing V2 immunogens.
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Hyperglycosylated gp120 Mutants Elicit Improved 
CD4-Binding Site Directed Antibodies in a 
Heterologous Prime:Boost Regimen 
F.K. Ahmed1, B.E. Clark2, R. Pantophlet1
1Simon Fraser University, New Westminster, Canada; 2StemCell 
Technologies, Vancouver, Canada
Background: The CD4-binding site (CD4bs) on gp120 is targeted 
by broadly neutralizing antibodies (nAbs) and is therefore of 
interest for vaccine design. Insight derived from molecular 
interactions of CD4bs-specific antibodies with gp120 has 
guided structure-based protein design and the development 
of a number of immunogens. Of equal interest are strategies 
to improve potency and durability of desired nAb responses to 
such immunogens. 
Methods: We generated truncated, hyperglycosylated gp120 
mutants designed to selectively present nAb epitopes overlapping 
the CD4bs. To help focus antibody responses to these epitopes, 
we conducted a heterologous prime:boost immunization using 
two mutants (termed ∆N2mCHO and ∆N2mCHO(Q105N)) in 
combination with a resurfaced gp120 core protein (RSC3) that 
preferentially presents the CD4bs neutralizing face. Groups 
of animals were primed with ∆N2mCHO, unappended or 
N-terminally appended with one of three immunostimulatory 
sequences known to amplify humoral responses – PADRE, 
N10 or C3d. The animals were boosted with RSC3 and then 
∆N2mCHO(Q105N). Serum specificities were dissected using 
CD4bs and non-CD4bs mAbs and responses were followed at the 
cellular level by phenotyping the memory B cell compartment 
after each injection.
Results: Relative to other groups, PADRE-∆N2mCHO elicited 
significantly more rapid and higher titres against gp120 
and the immunogens, suggesting that PADRE has superior 
immunoactivating properties. The PADRE- antibodies also bound 
greatest to epitopes overlapping the CD4bs. Unexpectedly, only 
sera from N10- animals exhibited significant neutralizing activity 
against select tier 1B and 2 viruses. Unanticipatedly also, no 
significant differences were observed at the memory B cell level 
between the groups for gp120 specificity.
Conclusion: Our results show that selective exposure of conserved 
epitopes through the use of varied immunogens fused with 
immunostimulatory sequences, in particular PADRE, can boost 
desired antibody responses. Together, our data highlight the 
importance of not only immunogen design but also formulation 
on directing antibody responses to conserved epitopes.
P03.29
Superinfection by Discordant Subtypes of HIV-1 Does 
Not Enhance the Neutralizing Antibody Response 
Against Autologous Virus
L.M. Mayr1, R.L. Powell1, J.N. Ngai2, A. Nádas3, P.N. Nyambi4
1NYU School of Medicine, New York, USA; 2Medical Diagnostic 
Center, Yaounde, Cameroon; 3Institute of Environmental 
Medicine, NYU School of Medicine, USA; 4Veterans Affairs New 
York Harbor Healthcare Systems, New York, USA
Background: Recent studies have demonstrated that both the 
potency and breadth of the humoral anti-HIV-1 immune response 
in generating neutralizing antibodies (nAbs) against heterologous 
viruses are significantly enhanced after superinfection by 
discordant HIV-1 subtypes, suggesting that repeated exposure 
of the immune system to highly diverse HIV-1 antigens can 
significantly improve anti-HIV-1 immunity. We investigated 
whether sequential plasma from subjects superinfected with 
discordant HIV-1 subtypes, who exhibit broad nAbs against 
heterologous viruses, also neutralize either or both of their 
discordant early autologous viruses with increasing potency. 
Methods: Sequential blood samples were collected from 
superinfected and singly infected subjects in Cameroon. 
RNA was extracted; env was amplified by nested RT-PCR 
and cloned in env-expression vectors. Purified vector was 
used to co-transfect 293T cells with the Q23-delta-env HIV-1 
backbone vector. The pseudovirus supernatant was tested in 
neutralization assays with TZM-bl cells using patient plasma 
samples before and after superinfection.
Results: Comparing the neutralization capacities of sequential 
plasma obtained before and after superinfection of 4 subjects to 
those of matched plasma obtained from 4 singly infected control 
subjects, no difference in the increase in neutralization capacity 
was observed (p=0.328). Overall, neutralization increased over 
time in 3 of the 4 singly infected patients (mean change in IC50 
titer from first to last plasma sample: 183.4) and in 3 of the 4 
superinfected subjects (mean change in IC50 titer from first to last 
plasma sample: 66.5). Analysis of the Breadth-Potency Scores 
confirmed that there was no significant difference in the increase 
in superinfected and singly infected study subjects (p=0.234). 
Conclusion: These studies suggest that while superinfection 
by discordant subtypes induces antibodies with enhanced 
neutralizing breadth and potency against heterologous viruses, 
the potency to neutralize their autologous viruses is not better 
than those seen in singly infected patients.
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Neutralizing and Non-Neutralizing Antibody 
Responses in HIV-1 Subtype C Chronically Infected 
Patients with Divergent Rates of Disease Progression
D. Archary1, R. Rong2, M.L. Gordon1, S. Boliar3, E.S. Gray4,  
A. Dugast5, T. Hermanus6, P.J. Goulder7, H.M. Coovadia8,  
L. Morris6, G. Alter5, C.A. Derdeyn3, T. Ndung’u1
1University of KwaZulu-Natal, Durban, South Africa; 2Jiaotong-
Liverpool University, Suzhou, China, China; 3Emory University, 
Atlanta, GA, USA; 4University of Western Australia, Australia; 
5Ragon Institute, Boston, MA, USA; 6National Institute for 
Communicable Diseases, Johannesburg, South Africa; 7Oxford 
University, United Kingdom (Great Britain); 8University of 
KwaZulu Natal, Durban, South Africa
Background: Development of an efficacious HIV-1 vaccine able 
to elicit the production of broadly neutralizing antibodies (nAbs), 
capable of retaining potent activity against a diverse panel of viral 
isolates remains a significant challenge. The evolutionary forces 
that shape envelope and ensuing nAb and non-neutralizing 
antibodies in HIV-1 subtype C are incompletely understood and 
these two parameters have been rarely studied concurrently.
Methods: We characterized patterns of virus-specific nAbs 
and non-neutralizing antibodies in four slow progressors and 
four progressors with chronic HIV-1 subtype C infection, over 
a median of 21 months. Single cycle neutralization assays was 
performed. In addition, the binding affinities of HIV-specific 
immunoglobulins (IgGs) and the affinities of the IgGs to various 
Fcγ receptors (FcγRs) were assessed.
Results: NAbs evolved significantly in progressors (p=0.003) from 
study entry to study exit. NAb IC50 titers significantly correlated 
with amino acid lengths for V1-V2 (p=0.04), C3-V5 (p=0.03) and 
V1-V5 (p=0.04). Both groups displayed preferential heterologous 
activity against the subtype C panel. Both groups displayed 
preferential heterologous activity against the subtype C panel. 
There were no significant differences in breadth of responses 
between the groups for either subtype A or C. Neutralization 
breadth and titers to subtype B reference strains was significantly 
higher in progressors compared to slow progressors (both 
p<0.03) with increasing nAb breadth from study entry to study 
exit in progressors. Progressors had cross-reactive neutralizing 
antibodies that targeted V2 and V3. Binding affinities of non-
neutralizing antibodies to HIV-specific gp120, gp41 and p24 
and to activating and inhibitory Fcγ receptors (FcγRs) were 
similar in both groups. However, in slow progressors, CD4 T-cell 
counts correlated inversely with antibody binding affinity for the 
activating FcγRIIa (p=0.005).
Conclusion: Overall, the data suggest that neither nAbs nor 
non-neutralizing antibodies could be directly associated with 
disease attenuation. However, continuous evolution of nAbs was 
a potential marker of disease progression.
P03.31
Structural Comparison of Somatically Related PG9 
and PG16 in Complex with Their Epitope Reveals 
Differences in Glycan Recognition
M. Pancera1, J.S. McLellan1, S. Shahzad-ul-Hussan1, N. Doria-
Rose1, B. Zhang1, Y. Yang1, D.R. Burton1, W.C. Koff1, C.A. 
Bewley1, P.D. Kwong1
1NIH/NIAID/VRC, Bethesda, MD, USA
Background: The somatically related antibodies, PG9 and PG16, 
neutralize 70-80% of HIV-1 isolates and bind a glycosylated 
epitope in the V1/V2 domain of HIV-1 gp120. Mutations in 
V1/V2, and sometimes V3 depending on the HIV-1 strain, 
affect neutralization and a glycan on Asn160 is required for 
neutralization. Both antibodies also preferentially bind the native 
trimer over monomeric gp120, especially PG16. The structure of 
PG9 in complex with its epitope, a scaffolded V1/V2 from HIV-1 
strain ZM109, was recently solved and showed that PG9 targets a 
site of vulnerability comprising 2 glycans and a β-strand.
Methods: To understand the differences in binding properties 
from these two somatically related antibodies, we first assessed 
their binding to monomeric gp120 and scaffolded V1/V2 proteins 
with different glycan types (oligomannose, hybrid, and complex). 
In order for PG16 to bind the scaffolded V1/V2, the protein had to 
be expressed in mammalian cells in the presence of swainsonine, 
which inhibits glycan maturation past the hybrid state. A stable 
complex could be obtained between PG16 and a scaffolded V1/
V2 domain from ZM109, and this complex was crystallized. 
Results: Although the structure of PG16 bound to scaffolded V1/
V2 resembled that of PG9, some differences were seen: 1) PG16 
binding to the β-strand is weaker than PG9 with fewer charged 
interactions, 2) PG16 interacts with a hybrid glycan at position 
N173. The difference in binding recognition of PG9 and PG16 
to monomeric gp120 depends on the type of glycans present. 
PG16 binds the protein portion of V1/V2 weaker than PG9 and 
this might explain the higher affinity of PG9 for the monomer. 
PG16 has evolved a second glycan site to compensate for weaker 
peptide interaction. 
Conclusion: The results show the importance of polyclonal 
response in infected individual to combat HIV-1, and in this case, 
to differential glycosylation. 
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Refined Identification of Neutralization-Resistant 
CRF02_AG Viruses and Their Sensitivity to Anti-MPER 
Neutralizing Antibodies
R.A. Jacob1, F. Abrahams1, M. Tongo2, M. Schomaker3, P. Roux4, 
E. Mpoudi Ngole5, W.A. Burgers2, J.R. Dorfman1
1International Centre for Genetic Engineering and 
Biotechnology, Cape Town, South Africa; 2Division of Medical 
Virology, University of Cape Town, Cape Town, South Africa; 
3Centre for Infectious Disease Epidemiology & Research, UCT, 
Cape Town, South Africa; 4School of Child and Adolescent 
Health, University of Cape Town, Cape Town, South Africa; 
5Centre de Recherche sur les Maladies Émergentes et 
Réémergentes, Yaoundé, Cameroon
Background: The first antibody-inducing HIV-1 vaccines are 
unlikely to protect against all HIV-1 isolates. There is thus a 
danger that a vaccine will select for HIV-1 viruses that are highly 
resistant to antibody-mediated neutralization. We sought to 
identify and characterize such viruses. 
Methods: A diverse panel of 24 HIV-1 pseudoviruses was tested 
for neutralization resistance using two sets of samples from ARV-
naive HIV-1-infected individuals selected for good neutralizers: 
sera from South Africa donors (n=68, infected >1 year, subtype 
C predominant area) and CRF02_AG-infected plasma samples 
from Cameroon donors (n=12, good neutralizers selected from 
22 samples). 
Results: Sensitivity to South Africa sera by subtype was 
C>B≈CRF02_AG>A. Importantly, and in contrast to previous 
reports, CRF02_AG plasma neutralized CRF02_AG viruses better 
than other panel viruses (“within-subtype neutralization”). This 
included three (257-31, 251-18 and 33-7) of five CRF02_AG 
viruses previously designated as tier 3 (most resistant). This 
within-subtype neutralization testing showed that the other 
two tier 3 CRF02_AG panel viruses, 253-11 and 278-50 were 
highly resistant. Most CRF02_AG viruses, including 253-11 and 
278-50 were sensitive to two membrane proximal external 
region (MPER)-specific monoclonal antibodies and soluble CD4 
(sCD4), suggesting targets for neutralization of even these highly 
resistant viruses. This information may help design a global HIV-
1 vaccine. We also propose testing viruses with within-subtype 
samples selected for good neutralizers in order to evaluate their 
neutralization resistance.
Conclusion: Some but not all CRF02_AG viruses are sensitive 
to neutralisation by CRF02_AG-derived plasma, even though 
most are previously reported as highly resistant (Tier 3). Further 
work is necessary to properly characterize such Tier 3 viruses. If 
research focus is not placed on such resistant viruses, a future 
partially effective HIV-1 vaccine may select for them. 
P03.33
Structural Analyses of Antigen Binding Similarities 
and Differences Between Rabbit and Human Anti-
gp120 V3 mAbs
R. Pan1, J.M. Sampson1, Y. Chen2, M. Vaine2, S. Wang2, S. Lu2,  
X. Kong1
1New York University Medical Center, New York, NY, USA; 
2University of Massachusetts Medical School, Worcester, MA, 
USA
Background: The rabbit is a commonly used animal model 
to study antibody responses in AIDS vaccine development. 
However, little is known about the relationship between epitopes 
recognized by the rabbit and human immune systems. Structural 
knowledge of antigen-antibody interactions of rabbit and human 
mAbs will help us understand the similarity of these two immune 
systems in recognizing HIV antigens, thus provides a guidance in 
using the rabbit for AIDS vaccine development.
Methods: Complex structures of anti-V3 mAbs R56 and R20, 
generated by immunizing a rabbit with JR-FL gp120 using a DNA 
prime-protein boost regimen, were determined and analyzed 
in comparison with human mAbs from HIV-1 infected patients 
against the same V3 immunogenic regions.
Results: The epitope of R56 is structurally mapped to the 
N-terminal region of the V3 crown, overlapping with the epitopes 
recognized by human IGHV5-51 germline anti-V3 mAbs. Both 
R56 and the human mAbs bind the highly conserved V3 residues, 
consistent with their broad neutralization activities. However, 
while the human antibodies can bind the whole beta-hairpin of 
the crown, R56 only binds the N-terminal half of the hairpin. The 
epitope of R20 is located in the V3 C-terminal region near the two 
highly conserved glycosylation sites at the V3 base. This epitope 
overlaps with that of human mAb PGT128. A long beta-hairpin 
CDR H3 of R20 stands at the center of its antigen-binding site in 
a manner similar to several potent human mAbs such as 2909, 
and interacts with the epitope by a beta-sheet-type interaction.
Conclusion: Structural analyses of immunization-generated 
rabbit antibodies show that they can recognize immunogenic 
regions of gp120 and mimic the binding modes of human 
antibodies. However, optimized immunization schemes need 
be tested in rabbits to produce antibodies with sufficient affinity 
maturation to recognize Env epitopes as complex as that of 
human antibodies generated in chronic infected patients.
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High-Resolution Crystal Structure of the Fv of 
Quaternary Neutralizing Epitope mAb 2909 Reveals 
Atomic Details of Its Antigen-Binding Site
J.M. Sampson1, A. Killikelly1, H. Zhang1, M.K. Gorny1, S. Zolla-
Pazner1, X. Kong1
1NYU School of Medicine, New York, NY, USA
Background: Human mAb 2909 is in a class of potently 
neutralizing mAbs against the HIV-1 quaternary neutralizing 
epitope (QNE) preferentially presented by the native Env trimer 
complex. Its distinctive feature is a long CDR H3 loop with 2 
sulfated tyrosines that are suggested to play a key role in antigen 
binding. Two structures of the Fab fragment of 2909 have been 
published, but at only 3.3Å and 3.2Å resolution, respectively, 
some atomic-level details of the antigen binding sites of these 
structures are contradictory.
Methods: After crystallizing a recombinant Fv (rFv) of mAb 2909, 
expressed as a single chain in E. coli and refolded from inclusion 
bodies, we solved and refined its structure to 1.9Å resolution. 
We also characterized the neutralizing activity of the rFv against 
pseudotyped virus SF162.
Results: Despite lacking the native sulfation of 2 tyrosine residues 
at the apex of CDR H3, rFv 2909 retains neutralization activity 
against SF162 pseudoviruses. Our high-resolution structure 
features a series of 5 tyrosine residues decorating one face of H3 
like rungs of a spiral staircase, as seen in the Spurrier structure. 
The presence of this feature, despite different crystal packing 
around the H3 loop, suggests that the stacking pattern is not an 
artifact of crystallization, and that these tyrosine side chains play 
an important role in epitope recognition.
Conclusion: Our structure of rFv 2909 at 1.9Å resolution reveals 
additional atomic-level details of its antigen-binding site, allowing 
further analysis of its binding mode. Our data demonstrate that 
rFv can be used as a tool to obtain high-resolution structures 
of antigen-binding regions, and may be useful for experiments 
requiring molecular weights smaller than that of a full Fab 
fragment, such as ITC and NMR spectroscopy.
P03.35
Antibody-Dependent Cellular Cytotoxicity-Mediating 
Antibodies from an HIV-1 Vaccine Efficacy Trial 
Preferentially Use the VH1 Gene Family
M. Bonsignori1, J. Pollara1, M.A. Moody1, T.B. Kepler2, X. Chen1, 
T.C. Gurley1, D.M. Kozink1, D.J. Marshall1, J.F. Whitesides1,  
J. Kaewkungwal3, S. Nitayaphan4, P. Pitisuttithum5, S. Rerks-
Ngarm6, J.H. Kim7, N.L. Michael7, D.C. Montefiori1, H. Liao1,  
G. Ferrari1, B.F. Haynes1
1Duke University Medical Center, Durham, NC, USA; 2Boston 
University School of Medicine, Boston, MA, USA; 3Tropical 
Hygiene, Mahidol University, Bangkok, Thailand; 4Armed 
Forces Research Institute of Medical Sciences, Bangkok, 
Thailand; 5Clinical Tropical Medicine, Mahidol University, 
Bangkok, Thailand; 6Department of Disease Control, Ministry 
of Public Health, Nonthaburi, Thailand; 7US Military HIV 
Research Program, Rockville, MD, USA
Background: The ALVAC-HIV/AIDSVAX-B/E RV144 vaccine efficacy 
trial showed an estimated efficacy of 31%. The immune correlates 
analysis raised the hypothesis that the observed protection in 
RV144 may be partially due to Antibody-Dependent Cellular 
Cytotoxicity (ADCC)-mediating antibodies in the presence of 
low levels of Env IgA antibodies. In this study we analyzed the 
Ig VH family usage of vaccine-induced ADCC mAbs isolated from 
memory B cells of vaccinees.
Methods: From a total of 321,945 memory B-cells of 6 vaccinees 
we obtained 23 mAbs that mediated ADCC using IgG+ memory 
B-cell cultures (n=9) and Env-specific flow cytometric single 
memory B-cell sorting (n=14). ADCC activity was measured using 
both E.CM243 gp120-coated and E.CM235-infected target cells 
in a flow-based assay.
Results: ADCC-mediating mAbs displayed a disproportionate 
usage of VH1 family genes (17/23; 74%), in particular the VH1-
2 gene segment (10/17; 59%), as recently observed for CD4bs 
broadly neutralizing antibodies (HAAD bNAbs). In contrast, only 
17.1% of 111 heavy chains isolated from cultures that did not 
mediate ADCC used the VH1 gene. VH1 ADCC-mediating mAbs 
showed a high degree of V(D)J amino acid similarity to both the 
VH (68-84%) and VL (70-87%) HAAD motifs. V(D)J rearrangements 
displayed modest levels of affinity maturation (0.5-5.1% for 
heavy chains and 0.4-4.3% for light chains). While none of the 
VH1 ADCC-mediating mAbs was capable of mediating HIV-1 
neutralization, the strength of their ADCC activity correlated 
with the levels of heavy chain somatic mutations (p=0.02). We 
produced the reverted unmutated ancestor antibodies of two 
VH1 ADCC-mediating mAbs: one bound to B.MN Env and both 
reacted against autoantigens.
Conclusion: ADCC-mediating antibodies induced by the ALVAC-
HIV/AIDSVAX-B/E vaccine underwent limited affinity maturation, 
and preferentially used VH1 gene segments which share the 
HAAD motif with CD4bs bNAbs. These observations raise the 
hypothesis that HIV-1 Env preferentially selects VH1 family usage 
for distinct subsets of antibodies with different functions.
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P03.38
Low Levels of Anti-MPER Antibodies Are Detectable 
in Viremic HIV Infected 
J. Carrillo1, M. Massanella1, S. MArfil1, E. Garcia1, B. Clotet1,  
J. Blanco1
1IrsiCaixa/HIVACAT, Badalona, Spain
Background: Antibodies against the CD4 binding site (CD4bs) in 
gp120 and the membrane proximal extracellular region (MPER) 
of gp41 are associated with broadly neutralization capacity. 
While the former have been identified in a large number of HIV 
infected individuals, the latter show a much lower prevalence.
Methods: 31 HIV-infected individuals with detectable viremia 
were selected for the study. Two samples separated by at least 
one year were analyzed for each individual. The presence of 
anti-CD4bs was screened using a competitive flow cytometric 
assay with a CD4 IgG fusion protein. The presence of anti-MPER 
antibodies was screened using a sensitive flow cytometric 
assay that measures antibody binding to different cell lines 
stably expressing two different truncated forms of gp41. These 
molecules properly expose the MPER epitope, as assessed by 
staining with control antibodies 4E10 and 2F5.
Results: Detectable levels of both anti-CD4bs antibodies and 
anti-MPER antibodies were observed in plasma samples from 
all groups. Of note, most samples showed recognition of MPER 
with a strong correlation between the recognition of the two 
different forms of truncated gp41 used (r=0.65, p<0.0001), 
suggesting that the assay was robust enough for the detection of 
these antibodies. However, no correlations were found between 
the level of anti-MPER antibodies, the neutralizing capacity of 
plasma samples, the viral load and the CD4 T-cell counts.
Conclusion: Anti-MPER antibodies can be detected in viremic 
chronic HIV infected individuals. The level of these antibodies 
does not appear to correlate with control of viremia or clinical 
progression. These data may suggest that anti-MPER antibodies 
are elicited in the course of HIV infection, but they do not reach the 
necessary threshold to be easily detectable or to impact infection.
P03.37
Gaining Access to the Sterically Occluded CD4-
Induced Epitopes 
M. Mengistu1
1University of Maryland School of Medicine, Baltimore, MD, 
USA
Background: A preventive vaccine is potentially the most 
effective way to control the HIV pandemic. Such a vaccine needs 
to successfully harness humoral immunity and produce cross-
reactive anti-envelope antibodies that mediate direct virus 
neutralization and/or Fc receptor-dependent killing. The targeted 
HIV envelope spikes are covered by a glycan shield, which masks 
most of the surface from the humoral immune system, leaving very 
few sites that are antigenic. Among the vulnerable sites of HIV Env 
are intermediate structures formed after gp120 interaction with 
target CD4+ cell. The capacity of these CD4i antibodies to carry 
out their functions in clearing HIV infection is dependent on the 
timing, duration and extent of cognate epitope exposure during 
the attachment and entry processes. 
Methods: We employed confocal microscopy to visualize the 
temporal appearance and disappearance of CD4i epitopes 
during HIV-1 JRFL – TZM-bl cell interaction. We also examined 
the location of these exposed epitopes with ~20nm precision 
using super resolution microscopy. 
Results: We find that CD4i epitopes recognized by A32, 17b, and 
C11 were exposed on HIV-1JRFL within 5 minutes of interaction 
with TZM-bl cells, and persisted up to 60 minutes. 3D examination 
of confocal images revealed that these epitopes were exposed at 
sites distal to the virus – cell interface. CD4i epitope exposure 
was greatly reduced on mutant HIV-1 JRFL with a defective virus 
matrix (MA) as it interacts with TZM-bl cells.
Conclusion: CD4i antibodies are thought to be sterically occluded 
from the virus – cell interface. Our results show that these 
epitopes appear distal to this site, where they can be accessed by 
antibodies involved in humoral and/or cell-mediated immunity. 
HIV Env gp120 engagement of target cell CD4 led to perturbations 
of virus MA that resulted in CD4i epitope exposure on other 
spikes of the virus away from gp120 – CD4 contact points.
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A Novel Rabbit Monoclonal Antibody Platform to 
Dissect the Diverse Repertoire of Antibody Epitopes 
for HIV-1 Env Immunogen Design
Y. Chen1, M. Vaine1, X. Kong2, D. Montefiori3, S. Wang1, S. Lu1
1University of Massachusetts Medical School, Worcester, MA, 
USA; 2New York University School of Medicine, New York, NY, 
USA; 3Duke University Medical Center, Durham, NC, USA
Background: The majority of available monoclonal antibodies 
(mAbs) in the current HIV vaccine field are generated from 
HIV-1 infected people. In contrast, preclinical immunogenicity 
studies have mainly focused on polyclonal antibody responses in 
experimental animals. Although rabbits have been widely used 
for antibody studies, there has been no report of using rabbit 
mAbs to dissect the specificity of antibody responses for AIDS 
vaccine development.
Methods: Here we report the production of a panel of 12 mAbs 
from one NZW rabbit that was immunized with a HIV-1 JR-FL 
gp120 DNA prime and protein boost vaccination regimen. 
Results: These rabbit mAbs recognized a diverse repertoire of 
epitopes. Besides the traditional highly immunogenic V3 region, 
these mAbs recognized several previously underappreciated 
epitopes in the C1, C4, and C5 regions. Nine mAbs showed 
cross-reactivity against gp120s of clades other than clade B. At 
least three mAbs showed neutralizing activities with various 
breadth and potency. Increased somatic mutation percentage 
and long CDR3 were observed with some of the rabbit mAbs. 
More interestingly, phylogenic tree analysis showed that the 
heavy chain of mAbs recognizing the same region on gp120 
were segregated into an independent subtree, implicating that 
these mAbs may derive from the same B cell precursor. Crystal 
structures of several rabbit mAbs suggested that these rabbit 
mAbs generated from vaccines mimic the binding modes of well-
characterized human mAbs isolated from infected individuals. 
Conclusion: Therefore, isolation of mAbs from vaccinated 
rabbits provides us an opportunity to study the evolution 
and affinity maturation of HIV-1 Env-specific mAbs elicited by 
candidate AIDS vaccines. 
P03.39
Antibody Subclass Skewing Predicts Enhanced ADCC 
Activity in Both Natural Infection and Vaccination
A. Dugast1, A. Chung1, Y. Chang1, A. Licht1, M. Ackerman2,  
G. Alter1
1Ragon Institute, Charlestown, MA, France; 2Thayer School of 
Engineering, Dartmouth College, Hanover, NH, USA
Background: The innate immune recruiting property of 
antibodies are elicited following an Fc/Fc-receptor interaction. 
We previously demonstrated that HIV-specific antibodies 
from elite controllers (ECs) robustly recruit NK cells to mediate 
antibody dependent cellular viral inhibition (ADCVI) compared 
to antibodies from chronic progressors. To gain further insights 
into the biophysical properties of EC antibodies that enable 
them to recruit Fc-effector functions so robustly, we performed 
at 24 dimensional analysis (including specificity, isotype, Fc-
receptor affinity, and function) of the antibody profiles mounted 
in ECs and HIV-progressors to define the humoral signature(s) 
associated with most robust innate immune recruiting activity
Methods: A total of thirty donors were included in this study 
(10 untreated chronics, 10 treated chronics, 10 ECs). Anti-gp120, 
p24, gp41 and gp140 antibody binding titers were quantified 
by ELISA and a customized-multiplex HIV binding assay against 
HIV recombinant gp120, p24, gp41 and gp140. Fc-receptor 
affinity was analyzed by Biacore. ADCVI, ADCC, and ADCP were 
quantified as previously described
Results: While no differences were observed in the antibody 
binding titer between ECs and chronic progressors against 
gp120 or gp41, we showed that ECs exhibited a higher level of 
p24-specific antibodies, associated with robust ADCVI activity. 
Moreover, humoral responses in ECs were skewed toward IgG1 
and IgG3 responses, compared to chronic progressors, that 
strongly predicted enhanced ADCVI activity. Similar skewing of 
antibody responses were observed in RV144 vaccinees, strongly 
suggesting that specific cues elicited within this vaccine trial may 
have resulting in the induction of highly potent innate immune 
recruiting antibodies similar to those found in ECs
Conclusion: Overall, ECs elicit a skewed humoral immune 
response marked by the preferential selection of HIV specific 
IgG1 and IgG3 antibody subclasses, that parallels the humoral 
immune responses observed in RV144 vaccinees. Therefore, 
characterizing these unique antiviral capacities may provide 
critical information on humoral responses that could potentiate 
vaccine-induced responses
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P03.42
Antibody Lineages with Evidence of Somatic 
Hypermutation Persisting for >4 Years in a South 
African Subject with Broad Neutralizing Activity
M. Moody1, A.M. Trama1, M. Bonsignori1, C. Tsao1, M.S. Drinker1, 
T.C. Gurley1, J.D. Amos1, J.A. Eudailey1, L.C. Armand1, R. Parks1, 
K.E. Lloyd1, S. Wang1, K. Seo2, J. Lee2, K.J. Jackson3, R. Hoh2,  
T. Pham2, K.M. Roskin2, S.D. Boyd2, A.Z. Fire2, E.S. Gray4,  
L. Morris4, H. Liao1, G.D. Tomaras1, T.B. Kepler5, G. Kelsoe1,  
B.F. Haynes1
1Duke University Medical Center, Durham, NC, USA; 2Stanford 
School of Medicine, Stanford, CA, USA; 3University of New 
South Wales, Sydney, Australia; 4National Institute for 
Communicable Disease, Johannesburg, South Africa; 5Boston 
University, Boston, MA, USA
Background: The origins and maturation pathways of broadly 
neutralizing antibodies (bnAbs) are unknown. Only ~20% of HIV-
1-infected subjects develop bnAbs, suggesting their development 
may require unusual or protracted maturation pathways.
Methods: Two subjects were followed from the time of HIV-
1 infection to >3 years; one developed broad neutralization 
(CAP206) while the other did not (CH040). Memory B cells were 
sorted as single antigen-specific cells, Ig heavy and light chain 
genes were amplified by PCR, and recombinant mAbs produced. 
Variable heavy chain gene (VH) 454 pyrosequencing was 
performed on 5-10 samples spanning the 3-5 years of infection.
Results: From CAP206 we isolated 13 Env-reactive mAbs of 
which 6 (46%) used VH1-69; from these we identified three VH1-
69 clonal lineages. One clonal lineage contained a neutralizing 
antibody (CAP206-CH12) while the other two lineages had non-
neutralizing antibodies (CH64, CH82). All three clonal lineages 
were mutated (range 5.2-11.8% VH mutation), and members of 
these lineages could be detected by 454 sequencing as early 
as one month after infection, with persistence as late as 57 
months after infection. In contrast, an autologous neutralizing 
antibody clonal lineage from CH040 was found only over a one 
month period, and was not detected in three additional samples 
over 48 months. Of 18 additional CH040 Env clonal lineages, 
lineage members from 9 were found only at a single time point, 
8 lineages had members found over two time points, and only 
1/18 lineages were detected spanning 48 months.
Conclusion: Multiple Env-reactive antibody clonal lineages 
persisted for up to 5 years in broad neutralizer CAP206 while the 
autologous neutralizing antibody clonal lineage and other Env-
reactive lineages did not persist in non-neutralizer CH040. These 
data raise the hypothesis that a high degree of clonal persistence 
was required for the development of broad neutralization, and 
imply a predisposition for this trait in broad neutralizers.
P03.41
Recombinant Env Proteins That Bind the Quaternary-
Specific, V1/V2-Directed PGT Antibodies
J. Gorman1, J. McLellan1, Y. Yang1, T. Zhou1, J. Zhu1, S. Bangaru2, 
N. Bayless2, P. Alff2, C.P. Marshall2, P.D. Kwong1
1National Institutes of Health, Bethesda, MD, USA; 2Avatar 
Biotechnologies, Brooklyn, NY, USA
Background: Antibodies PGT141-145 are broadly neutralizing and 
recognize a glycan-dependent epitope in the V1/V2 loop, similar 
to antibodies PG9 and PG16. Collectively, this class of antibodies 
binds preferentially to the functional viral spike. Although PG9, 
and to a lesser extent, PG16, bind monomeric gp120s and V1/
V2 scaffolds, to date no recombinant env-derived proteins have 
been identified that bind to antibodies PGT141-145. 
Methods: As a first step toward obtaining structural information 
of the epitope recognized by PGT141-145, we have created and 
characterized novel gp140s and epitope scaffolds designed to 
present the V1/V2 conformation recognized by PGT141-145. To 
date, over 70 recombinant proteins have been expressed and 
tested for antibody binding.
Results: We have identified one V1/V2-scaffold protein that binds 
to PGT142. The binding is dependent on the HIV-1 strain used 
in the scaffold. We have also produced trimeric, cleaved gp140 
constructs and evaluated them for binding to PGT141-145. 
Conclusion: Proteins that accurately mimic V1/V2 conformations 
of the functional viral spike are crucial to obtaining structures 
of the PGT antibodies in complex with their epitopes, and may 
be ideal immunogens for eliciting broadly neutralizing, V1/V2-
directed antibodies in a vaccine setting.
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Characterizing the Fitness Cost of Viral Escape from 
the HIV-1 Broadly Neutralizing Monoclonal Antibody 
VRC01
R.M. Lynch1, L. Tran1, X. Wu1, Y. Li2, B. Lee3, J. Mascola1
1NIH/NIAID, Bethesda, MD, USA; 2The Scripps Research 
Institute, La Jolla, CA, USA; 3UCLA School of Medicine, Los 
Angeles, CA, USA
Background: The receptor-binding site on the HIV glycoprotein 
gp120 is a highly conserved epitope, and certain antibodies 
directed against this CD4 binding site (CD4bs) can potently 
neutralize the majority of circulating HIV-1 isolates. One such 
antibody, VRC01, was isolated from a slow progressor HIV-
1 infected donor who maintained low to moderate viral load 
without treatment. We recently described that almost all viruses 
in this donor plasma had escaped VRC01 neutralization. This 
raised the question of whether viral escape from a broadly 
reactive CD4bs antibody results in reduced affinity for CD4 and 
thus, a fitness cost to viral replication. 
Methods: Env-pseudoviruses and infectious molecular clones 
(IMC) were constructed using near-full length gp160 env 
genes from three circulating VRC01-resistant viruses and their 
complementary revertants (where VRC01-sensitivity was 
restored through mutations in the CD4 binding loop, Loop D and 
V5) as well as from autologous env genes from the VRC01 donor 
(both sensitive and resistant to VRC01 neutralization). Cell entry 
was quantified by infectivity into cell-lines expressing varying 
levels of the CD4 receptor, and replication kinetics of IMC were 
assessed by in vitro infection of primary CD4 T cells.
Results: Two of the three reverted VRC01-sensitive viruses 
demonstrated more efficient CD4 receptor mediated entry and 
greater replication in CD4 T cells, than the parental VRC01-
resistant Envs. However, analysis of five VRC01-resistant and four 
VRC01-sensitive autologous Envs from the VRC01 donor revealed 
no significant difference in replication kinetics or efficiency of 
CD4 usage in infectivity assays. 
Conclusion: Some VRC01-resistant viruses appear to have 
impaired replicative fitness, possibly caused by reduced CD4-
mediated cell entry. However, VRC01-resistant Envs derived from 
the VRC01 donor did not display this deficiency, suggesting that 
compensatory changes over time may partially or fully restore 
CD4 usage and replication. 
P03.43
Systematic Profiling of Polyclonal HIV Antibodies and 
Prediction of Effector Functions
E. Brown1
1Dartmouth College, Hanover, NH, USA
Background: Antibody-dependent effector functions (ADEF) 
with the ability to recruit the innate immune response may 
play an important role for the spread of HIV infections. ADEF 
are mediated by the antibody Fc and depend on antibody class 
and glycosylation status. We describe the systematic profiling of 
the Fc regions of HIV-specific antibodies isolated from different 
patient sera.
Methods: A LuminexTM-based suspension array was used to 
capture HIV antibody fractions binding to various HIV antigens 
on beads and probe them for binding to (1) antibody class-
specific binding reagents, (2) Fc receptors, (3) complement 
proteins and (4) different lectins. The obtained binding profiles 
are correlated with other measures of effector function and may 
help to understand which ADEF are crucial to provide protection.
Results: Subclassing data has been used to correlate patients with 
enhanced measures of effector function such as phagocytosis or 
ADCVI. In addition, results of the Fc-gamma-receptor binding 
assay have been correlated to traditional measures of affinity 
such as SPR, showing that our method is giving useful results. 
We have also used epitope-specific reagents like the resurfaced 
stabilized core form of gp120 to isolate and probe eppitope-
specific antibodies.
Conclusion: We hope to use our system as a means to quickly 
evaluate antibodies induced in an HIV vaccine setting. Being able 
to get a rapid profile of the polyclonal antibody response should 
be a useful predictor of vaccine efficacy. In addition, the assay we 
have devised is easily customizable, as antigens and receptors 
can be tailored to fit our interests.
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P03.46
Short Constrained Peptides Derived from Phage 
Display Libraries as Epitope Models: The Case of mAb 
2F5
Y. Palacios-Rodriguez1, T. Gazarian2, L. Huerta2, K. Gazarian2
1Mexican National Autonomous University, Mexico,  
D.F., Mexico; 2Institute of Biomedical Research UNAM, 
Mexico DF, Mexico
Background: Since the monoclonal antibody 2F5 (mAb 2F5) was 
isolated in the early 90’s, its epitope have continued to be the 
focus of extensive investigations attempting to elucidate the 
mechanism by which impedes viral entry into host cells. Because 
the DKW-flanking amino acids are strongly conserved in viruses, 
it is not clear whether the DKW only satisfies the 2F5 epitope 
recognition demand.
Methods: We used phage display technology involving 
biopanning of a pIII-type 7-mer constrained peptide library 
(not screened in previous experiments with 2F5) for its epitope 
mimics. After peptides selection and widely characterization 
of several phage-peptide clones, some of them were used as 
immunogens. Polyclonal antibodies were evaluated as cell-cell 
fusion inhibitors of the CD4-Env complex interactions. 
Results: We found that the specificity of recognition of the 
epitope depends on the structural context in which the cognate 
epitope sequence is presented. The antibody does not tolerate 
any replacements of the DKW-flanking epitope amino acids and 
binds exclusively to the (L)DKWA sequence provided by a 7-mer 
constrained peptide exposed by the M13 phage pIII protein. 
Additionally, immunization data supports the notion that the 
binding and neutralizing immunogenic structural features of the 
described epitope model do not coincide.
Conclusion: In this study, we show that when mAb 2F5 screens 
a pIII-type phage display 7-mer constrained peptide library for 
its epitope mimics, it demands an epitope sequence longer than 
DKW and does not tolerate substitutions in the epitope amino 
acid sequence as has been suggested in previous reports.
P03.45
Conformational Study of Quaternary Epitope Region 
of V1/V2 Loop: Influence of Disulfide Bonds and 
Glycosylations
G. Gnanakaran1, J. Tian1, A. Sethi1
1Los Alamos National Labs, Los Alamos, USA
Background: The HIV-1 envelope spike, which consists of a 
compact, heterodimeric trimer of the glycoprotein gp120 and 
gp41, is the sole viral target of neutralizing antibodies. The gp120 
component of the viral spike is known to be heavily glycosylated, 
and glycosylation can affect the conformation of envelope spikes. 
V1/V2 variable loops of gp120 are key target regions for a number 
of broadly neutralizing human antibodies, such as PG9 and PG16, 
CH01-CH04, and PGT141-145. Two glycosylation sites (N156 and 
N160) have been shown by mutagenesis studies to be important 
in forming the PG9 and PG16 epitopes. Recently, Peter Kwong 
and coworkers have resolved crystal structure of V1/V2 domain 
of HIV-1 gp120 from strains CAP45 and ZM109 complexes with 
antigen-binding fragment of PG9. 
Methods: We employ enhanced molecular dynamics sampling 
methods (eg. replica exchange molecular dynamics) to dissect 
the influence of disulfide bond and glycosylation on the 
conformational landscape of an indel free epitope region of V1/
V2 loop. These methods are expected to capture the influence 
of glycosylation, solvent, rest of the gp120 protein and scaffold 
constructs on the conformation of V1/V2.
Results: We evaluate the backbone conformational preferences 
and solvent accessibility of each residue in the selected V1/V2 
region and compare them to the antibody-bound conformation 
of this region. Both the disulfide bond that links V1 and V2 loops 
and the nearby glycosylations affect the beta sheet formation 
propensity of that region. Further characterization indicates that 
glycans predominantly influence the entropy of the V1/V2 loops. 
Conclusion: Our studies reveal how glycans can impact the 
electrostatic and hydrophobic surfaces of the V1/V2 regions that 
have been proposed to form the epitope for broadly neutralizing 
antibodies. Along with proximal disulfide bonds, glycans tend 
to affect the local beta-sheet propensities that can further 
contribute to the quaternary nature of the epitope.
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Isolation of Broadly Neutralizing HIV-1 Antibodies 
from High-Throughput Single B Cell Culture
N.S. Longo1, N. Doria-Rose1, K. McKee1, S. O’Dell1,  
M.K. Louder1, Z. Yang1, R. Bailer1, J.R. Mascola1
1NIH, Vaccine Research Center, Bethesda, MD, USA
Background: The isolation of broadly neutralizing HIV-1 
antibodies that arise during infection has provided insights 
into the design of vaccine immunogens capable of eliciting 
similar antibody response. The use of HIV-specific sorting 
probes resulted in the isolation of antibodies to vulnerable 
viral epitopes, such as the CD4-binding site, but the use of 
such probes does not explore the subject’s immunoglobulin 
repertoire breadth. 
Methods: To identify new HIV-1 monoclonal antibodies 
(mAbs), we developed a B-cell culture system to isolate and 
screen thousands of B cells. Memory B cells were isolated 
by negative selection and individually cultured in 384 well 
plates with irradiated feeder cells expressing CD40 ligand. The 
addition of cytokines IL-2 and IL-21 stimulated proliferation and 
immunoglobulin secretion. 
Results: After 14 days in culture, approximately 35% of the B 
cell clones secreted >100 ng/ul of IgG which met the sensitivity 
threshold to screen each clone in an automated micro-
neutralization assay. B cell clonal expansion allowed recovery 
of the immunoglobulin heavy and light chains by RT-PCR, with 
subsequent cloning into expression vectors and mAb testing 
against a large panel of viruses. In one experiment screening 
approximately 8600 B cells, 9 clones were identified as potential 
contributors to the neutralization detected in the patient’s 
serum. One of the isolated clones produced mAb VRC22 with 30% 
neutralization breadth and moderate potency. Further studies 
revealed that VRC22 was sensitive to JRCSF glycan mutants 
N332A and N301A but not N160K. VRC22 utilizes VH4-34 with 
a single amino acid CDR1 deletion and a mutation frequency of 
7% which is a lower level of affinity maturation than observed for 
most known HIV-1 neutralizing antibodies. 
Conclusion: This B-cell culture system allows efficient screening 
of thousands of individual B cells and the recovery of antigen 
specific mAbs. This approach can be used to isolate human 
mAbs to diverse pathogens. 
P03.47
Mapping Epitopes on CRF01_AE Viruses Recognized 
by Broadly Neutralizing Antibodies in Sera from Elite 
Neutralizers from North America and Thailand
S.M. O’Rourke1, R. Sutthent2, K.L. Limoli3, P. Phung3, G.P. Tatsuno1, 
B. To1, K.A. Mesa1, N. Frigon1, K.W. Higgins4, T. Wrin3, P.W. Berman1
1University of California, Santa Cruz, Santa Cruz, CA, USA; 
2Microbiology Department, Siriraj Hospital, Mahidol 
University, Bangkok, Thailand; 3Monogram Biosciences, 
South San Francisco, CA, USA; 4Global Solutions for Infectious 
Diseases, South San Francisco, CA, USA
Background: The RV144 trial has rekindled interest in defining 
the epitopes responsible for the neutralization of CRF01_AE 
(clade E) viruses. In this study we used a novel method, swarm 
analysis, to map epitopes on Thai viruses recognized by broadly 
neutralizing (bN) antibodies in HIV+ sera. Swarm analysis relies 
on the swarm of closely related quasi-species that evolve in each 
HIV+ individual. In these studies we analyzed the bN activity in 
sera from elite neutralizers (ENs) against Thai viruses. 
Methods: Libraries of envelope genes were amplified from 30 
Thai subjects who became infected with HIV in the VAX003 clinical 
trial. 12-24 clones from each individual were tested for sensitivity 
and resistance to neutralization by HIV+ EN sera obtained in 
Thailand and the USA. Pairs of neutralization sensitive and 
resistant viruses were identified from each individual, and the 
amino acids responsible for neutralization sensitivity localized by 
mutagenesis. 
Results: Novel mutations were identified that conferred 
neutralization sensitivity or resistance to antibodies from ENs. 
Unlike previous studies with clade B viruses, the mutations 
in clade E viruses that altered neutralization sensitivity and 
resistance did not appear to affect the CD4 binding site or gp41. 
The mutations identified were located in V1, V2, and V3 domains 
of gp120 and had no effect on neutralization by bN monoclonal 
antibodies such as VRC01, b12, PG9, PG16, and 2G12. 
Conclusion: Clade E viruses from Thailand can be neutralized 
by HIV+ sera from ENs infected with clade B or clade E viruses. 
The epitopes on clade E viruses recognized by bNAbs from ENs 
appear to be distinct from those defined with most of the bN 
monoclonal antibodies described to date. The results suggest 
that antibodies to the V1 domain as well as the V2 domain should 
be considered in the RV144 correlates analysis.
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P03.50
Impact of IgA Constant Domain on HIV-1 Neutralizing
Function of Monoclonal Antibody F425-A1g8
X. Yu1, M. Duval2, C. Lewis2, L. Cavacini1
1Beth Israel Deaconess Medical Center and Harvard Medical 
School, Boston, MA, USA; 2Beth Israel Deaconess Medical 
Center, Boston, MA, USA
Background: With the majority of HIV infections resulting from 
mucosal transmission of HIV, induction of an effective mucosal 
immune response would be pivotal in preventing transmission. 
HIV-specific IgA but not IgG has been detected in genital tract, 
seminal fluid, urethral swabs, urine and vaginal wash samples 
of HIV-negative sex workers and HIV-status discordant couples. 
Although present at low levels, purified mucosal and plasma IgA 
from HEPS individuals demonstrated cross-clade neutralizing 
activity and were able to inhibit HIV mucosal transcytosis. 
Methods: The monoclonal antibody F425-A1g8 was generated 
in our laboratory by hybridoma technique and showed binding 
activity to the CD4i site of gp120. We isolated the variable genes 
of heavy chain (VH) and light chain (VL) from the hybridoma cell 
line and cloned the VH fragment into the vectors pHC-HuCγ1 
and pHC-huCα1 individually, as well as cloned VL into the vector 
pLC-huCk. Both of VH and VL plasmids were co-transfected into 
CHO-K1 cells in equimolar amounts and established F425-A1g8 
IgG1 and IgA1 expressing cell lines. We characterized the impact 
of different isotype variants of F425-A1g8 to HIV neutralizing 
activity by direct HIV viral neutralizing assay and antibody 
dependent cell-mediated viral inhibition.
Results: The switching constant domain of F425-A1g8 to 
construct IgG1 and IgA1 isotypes do not impact their binding 
activity with the CD4 site binding site of HIV. The result of 
neutralization showed that in contrast to little neutralization by 
F425-A1g8 IgG1 in the absence of sCD4, the IgA1 variant of the 
antibody displayed significant neutralization activity against a 
range of HIV clade B isolates. 
Conclusion: This research clearly suggests that IgA isotype 
utilizing its unique molecular structure plays an important role in 
HIV neutralization. The studies of the neutralizing function of IgA 
isotypes may also serve to inform the design of vaccine strategies 
that may be more effective at preventing mucosal transmission.
P03.49
Characterization of V1/V2-Specific Antibodies 
Present in Broadly Neutralizing Plasma Isolated from 
HIV-1 Infected Individuals
C. Krachmarov1, K. Revesz1, R. Prattipati1, C. Reichman1, B. Li2, 
C. Derdeyn2, J. Sarlo3, B. Zingman3, W. Honnen1, A. Pinter1
1PHRI/UMDNJ, Newark, NJ, USA; 2Emory Vaccine Center, 
Atlanta, GA, USA; 3Montefiore Medical Center, Bronx, NY, USA
Background: Recent studies of antibodies in human plasma 
from HIV-1-infected and immunized individuals have revealed 
an important role for the V1/V2 region of gp120 in an antiviral 
response, and recent evidence that protection in the RV144 
vaccine trial correlated with the presence of V1/V2-specific 
antibodies suggests that the V1V2 region is an important target 
for candidate HIV-1 vaccines. However, the function of V1V2-
specific antibodies is not well understood. In this study we 
present data about the development, subtype specificity, and 
neutralization activity of such antibodies present in plasma from 
several hundred infected North American and African subjects.
Methods: Human plasma from infected individuals were 
screened for neutralization activity versus a panel of subtype 
B, subtype C, and other Tier 2 pseudoviruses, and were titrated 
for binding activity against the consensus subtype B, C and A/E 
V1/V2 fusion glycoproteins, expressed via fusion to a fragment 
of the MuLV gp70 sequence. This system expresses V1/V2 
domains in their native glycosylated and conformational forms. 
V1V2-specific antibodies were isolated from selected plasma 
by immunoaffinity chromatography on gp70-V1/V2 antigen 
columns, and characterized for neutralizing activity against 
various HIV-1 pseudoviruses. 
Results: Most (>80%) of the HIV-1 infected subjects possessed 
robust levels of V1/V2 binding activity versus the three antigens. 
Interestingly, the development of V1/V2-reactive antibodies 
tracked with the development of autologous neutralizing 
antibodies in several subjects infected with subtype C viruses. 
Immunoaffinity-purified V1/V2-specific antibodies from 
selected broadly neutralizing plasma samples also possessed 
broad neutralization activities, with IC50s generally in the 1-20 
μg/ml range. 
Conclusion: Highly cross-reactive V1V2-specific antibodies were 
present in almost all broadly neutralizing human plasmas at large 
concentrations, and frequently possessed modest neutralizing 
activities against a range of isolates, including tier 2 viruses. 
Additional information about the nature of these antibodies and 
their target epitopes would help elucidate their potential roles in 
protection against infection.
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Humoral Immune Response Profiling with Peptide 
Microarrays 
U. Reimer1, H. Wenschuh1, L.R. Baden2, M. Pau3, M. Weijtens3, 
D.H. Barouch2
1JPT Peptide Technologies, Berlin, Germany; 2Div. of Vaccine 
Res., Beth Israel Deaconess Medical Center, HMS, Boston, MA, 
USA; 3Crucell Holland BV, Leiden, Netherlands
Background: In a case-controlled analysis designed to identify 
immune correlates of infection risk in the RV144 HIV vaccine 
trial, 2/6 primary variables showed significant correlation. One, 
the binding of IgG antibodies to the V1/V2 loop of HIV-1 env 
protein appears to protect against HIV-1 infection. Consequently, 
data from a detailed mapping of antibody reactivities in response 
to vaccination on a sub-protein level might be a predictor 
for vaccine efficacy. In contrast to assays relying on whole 
antigens, peptide microarrays are efficient tools to deliver such 
information. Besides, complex peptide libraries can cover the HIV 
sequence diversity. We present peptide microarray data from a 
human clinical trial.
Methods: A library representing Env-gp160 consensus sequences 
from clades A,B,C,D,M,CRF1, and CRF2 was produced. Serum 
samples of vaccinees from groups receiving different doses of a 
prototype Ad26 vector-based vaccine expressing clade A-HIV-1 
Env (Ad26.EnvA.01) were evaluated. For the calculation of signals 
the signal intensity per peptide at baseline was substracted from 
the signal intensity at week 28 after vaccination.
Results: All groups of vaccinees show a clear pattern of antibody 
reactivity after vaccination. This pattern depends on the dose 
and the number of doses given. From the lowest doses of 1x109 
viral particles (vp) a cross-clade reactivity towards the V3 region 
of gp120 is observed. At doses above 1x1010 vp the magnitude 
of signals is enhanced and new regions of gp120 are targeted 
by patient antibodies, e.g. towards the V2 loop region. The 
representation of different clades on the peptide microarray 
allows for a detailed investigation of the clade specificity of the 
antibody response after vaccination.
Conclusion: Costly vaccination studies require consideration of 
all possible factors for success. The results of peptide microarray 
experiments may facilitate the design and dosing regimen 
of vaccines in clinical trials and shed light on the underlying 
protective mechanisms.
P03.51 LB 
Broad and Potent Neutralization of HIV-1 by Human-
Llama Fusion Antibodies Derived from Immunized 
Llamas
L.E. McCoy1, L. Rutten2, G. Dekkers1, C. Blanchetot3,  
N.M. Strokappe4, A. Forsman-Quigley1, M.S. Seaman5,  
H. de Haard3, T. Verrips4, R.A. Weiss1
1University College London, London, United Kingdom 
(Great Britain); 2Biomolecular Imaging, Department Biology, 
University of Utrecht, Utrecht, Netherlands; 3arGEN-X BVBA, 
Ghent, Belgium; 4Biomolecular Imaging, Department Biology, 
Utrecht University, Utrecht, Netherlands; 5Division of Viral 
Pathogenesis, Beth Israel Deaconess Medical Center, Boston, 
MA, USA
Background: Llamas naturally produce heavy chain only 
antibodies in addition to conventional antibodies. The variable 
regions of the heavy chain (VHH) demonstrate comparable affinity 
and specificity for antigens with conventional immunoglobulins. 
To date, immunizations in human and animal models have 
yielded only antibodies with limited ability to neutralize human 
immunodeficiency virus (HIV)-1. 
Methods: A VHH (J3) isolated from a llama multiply-immunized 
with recombinant trimeric HIV-1 envelope proteins (Env) was 
found to neutralize 96 of 100 HIV-1 strains, encompassing 
subtypes A, B, C, D, BC, AE, AG, AC, ACD, CD and G. Isolation 
involved expression of VHH in E. coli and analysis of neutralization 
ability in TZM-bl reporter cells.
Results: Newly isolated VHH from multiple immunized llamas also 
have broad and potent HIV-1 neutralization activity. J3 targets 
HIV-1 via the CD4-binding site and neutralization is seen when 
J3 is used in combination with VHH targeting other Env epitopes. 
VHH-human FC fusion heavy-chain only antibodies (VHH-FC) 
have been constructed and J3 activity is not only preserved in 
this context but enhanced.
Conclusion: This study shows that experimental immunization 
with recombinant HIV-1 Env can elicit broad neutralizing heavy-
chain only antibodies and supports the development of VHH and 
VHH-FC as anti-HIV-1 microbicides and therapeutics.
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Pre-existing Humoral Immunity In Military Smallpox 
Vaccinees Temporally Effects MVA-Vectored 
Transgene Expression in Dendritic Cells
V. Ngauy1, B. Slike2, M. Marovich2
1Armed Forces Research Institute of Medical Sciences, 
Bangkok, Thailand; 2US Military HIV Research Program, MD, 
USA
Background: Modified Vaccinia Ankara (MVA), a vector-based 
vaccine that targets dendritic cells (DC) and induces cell-
mediated immunity, is a promising HIV vaccine candidate. As 
MVA vaccination strategies continue to be explored, concerns 
arise regarding transferability to individuals with pre-existing 
immunity to vaccina, particularly military personnel. Prior 
reports suggest long-lasting vaccinia immunity after childhood 
vaccination. This study, conducted in a unique cohort of adult 
primary vaccinees, explores how pre-exisiting humoral immunity 
to vaccinia affects entry and transgene expression of MVA-
vectored vaccines in a primary human DC infection model. 
Methods: Serum from military personnel vaccinated against 
smallpox with either Dryvax or ACAM2000 vaccines were 
obtained at 4 time points post-vaccination (n=50 per time point, 
400 total). As a comparator, n=25 individuals with longitudinal 
sera available at corresponding time points were studied to 
compensate for inter-individual variability in response over time. 
Sera were tested for inhibition of infection of DCs in vitro using 
either MVA-GFP or MVA-CMDR, an HIV vaccine candidate with 
env/gag/pol inserts, currently in clinical trials. Vaccinia naïve 
sera served as a negative control. Vaccinia binding titers were 
measured by ELISA. 
Results: Vaccinia binding antibody titers waned after 5 years and 
were undetectable 10 years after vaccination. Neutralizing activity, 
as measured by transgene expression in DCs, confirmed this finding. 
Expression and neutralization of HIV p24 (gag) expression data in 
DC were equivalent to that of GFP. No differences in neutralization 
activity were detected between Dryvax and ACAM2000 vaccinee 
sera at corresponding time points. 
Conclusion: In an adult, military, primary vaccinee population, 
humoral responses to smallpox vaccination do not persist as 
long as reported in the civilian population vaccinated during 
childhood. This data suggests that pox-vector based vaccines 
may be used in the military population, and that the age of 
primary vaccination influences durability of humoral immunity.
P03.53 LB 
Study on the Functional Role of Immunoglobulin E as 
Surrogate Marker for HIV/AIDS Infection
B. Sonaimuthu1, V. Baghyanathan1
1King Institute of Preventive Medicine & Research, Chennai, 
India
Background: IgE class of antibodies has been found in mammals 
and plays an important role in allergic and hypersensitivity 
reactions. Certain viral infections are known to produce specific 
IgE antibodies, to the extent that significant changes in the level 
of total serum IgE may occur. Study attempts to associate the 
Level of Ig E in HIV progression.
Methods: The study involves fifty HIV seropositive patients 
attending Anti-Retroviral Therapy Centre, Department of 
Sexually Transmitted Disease, Rajaji Government Hospital, and 
Madurai,India subjected for the present study. The individual 
involves 27 HIV/ AIDS Male patients, 23 HIV/ AIDS Female 
patients. The control sample comprises 15 HIV sero negatives. 
The samples were collected at the informed consent of the 
patients. Serum sample were collected and IgE was quantified 
using MAGIWELL IgE quantitative solid phase Enzyme- linked 
Immunosorbent assay (ELISA). 
Results: The study documents highest percentage of deviation 
from the control observed in Male HIV seropositives (43.7%) and 
age-wise influence documents highest percentage of deviation in 
the age group 15- 29 years (56%).
Conclusion: Serum IgE level in the present study found to be 
elevated from the normal range documents the existence of 
imbalance between Th 1 and Th 2 and associated with T-cell 
dysfunction and a hypergammaglobulinemia. The present results 
suggest that elevation of circulating IgE levels may be due, at least 
in part, to specific IgE directed to the HIV virus rather than as a 
result of a nonspecific phenomenon. HIV infected adults indicate 
that total IgE is also increased during the early stages of disease, 
and this elevation appears to be independent of CD4 counts 
and is not correlated with the levels of other immunoglobulins, 
suggesting an important role for IgE as a surrogate marker of 
disease progression Further research need to be exploited to 
bring out the exact role of IgE in HIV pathogenesis.
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HIV-1 Neutralizing Antibodies Display Dual Specificity 
for the Primary and Coreceptor Binding Sites and 
Preferential Recognition of Fully-Cleaved Env
Y. Li1, S. O’Dell2, R. Wilson1, X. Wu2, S.D. Schmidt2, C. Hogerkorp2, 
M.K. Louder2, N. Longo2, C. Poulsen1, J. Guenaga1,  
B. Chakrabarti1, N. Doria-Rose2, M. Roederer2, M. Connors3,  
J.R. Mascola2, R.T. Wyatt1
1IAVI/TSRI, LA Jolla, CA, USA; 2VRC/NIAID/NIH, Bethesda, MD, 
USA; 3NIAID/NIH, USA
Background: The gp120 CD4 binding site (CD4bs) and coreceptor 
binding site (CoRbs) are two functionally conserved elements of 
the HIV-1 envelope glycoproteins (Env). We previously defined 
the presence of CD4bs neutralizing antibodies (nAbs) in the 
serum of an HIV-1 infected individual and subsequently isolated 
the CD4bs-specific monoclonal antibodies (mAbs) VRC01 and 
VRC03 from the memory B cell population. From the same 
patient sera, we detected that there was also a fraction of potent 
nAbs specific for elements of the Env CoRbs by differential 
protein adsorption followed by neutralization analysis.
Methods: In this study, we employed a differential FACS-based 
sorting strategy using a stabilized gp120 core and a mutant gp140 
possessing a CoRbs “knockout” mutation (I420R) to isolate CoRbs 
specific B cells.
Results: The mAb VRC06 was recovered from these cells and 
its genetic sequence allowed us to identify a clonal relative, 
VRC06b, which had been isolated from a prior cell sort using a 
resurfaced core gp120 probe. VRC06 and VRC06b neutralized 
22% and 44% of circulating viruses tested, respectively. Virus 
neutralization assays revealed that VRC06/VRC06b better 
neutralized autologous viruses compared to VRC01 and VRC03. 
More potent autologous neutralization was associated with a 7 
amino acid residues insertion in the framework of the VH gene-
coding region. Epitope mapping studies demonstrated that the 
two mAbs were sensitive to mutations in both the gp120 CD4bs 
and the CoRbs, including the gp120 bridging sheet and the base 
of the third major variable region (V3). Interestingly, cell-surface 
binding assays demonstrated their preferential recognition of 
fully-cleaved Env trimers compared to un-cleaved trimers.
Conclusion: VRC06 and VRC06b are novel neutralizing mAbs that 
bind to a region of gp120 that overlaps with both the primary and 
secondary HIV-1 receptor binding sites, preferentially recognize 
fully-cleaved Env, and complement the neutralizing capacity of 
other CD4bs bNAbs isolated from the same individual.
P03.55 LB 
Light Chain Plays A Role In Neutralizing Antibody In 
b12 H Chain Knock-In Mouse
T. Ota1
1The Scripps Research Institute, La Jolla, CA, USA
Background: HIV vaccine design has focused on epitopes seen by 
broadly neutralizing antibodies (bNAbs). The key to developing 
a robust vaccine capable of eliciting bNAbs is to identify the 
epitopes appropriate for incorporation into vaccines and to 
exclude irrelevant or harmful epitopes. 
Methods: To assess bNAb B cell responses, we have developed 
series of bNAb B cell lines and b12 ‘knock-in’ mouse. 
Results: Antibodies targeting the CD4 binding site, including 
PGV04 and b12, expressed higher levels of surface Ig compared 
to MPER targeting antibody 4E10. Correlating with the cell line 
data, in b12 heavy chain knock-in mice, B cells could develop 
robustly (this was not the case in 4E10 mice). 10-20% of b12 
transgenic B cells bound to YU2 gp120 monomer and lacked 
expression of CD93, indicating that they matured normally and 
were non-anergic. Upon immunization with YU2 trimer, b12 mice 
exhibited strong gp120-specific IgG responses. Gp120-binding 
cells used Vk10-96 and Vk19-93, but were skewed to usage of 
Jk2 and Jk4, which are normally used less frequently than Jk1 
and Jk5. Cells in the gp120- non binding fraction frequently 
expressed Vk1-135. Interestingly, the CDR1 length of Vk1-135 is 
11 amino acids in length, whereas in Vk10-96 and Vk19-93 genes 
it is 6 amino acids, suggesting that a short CDR1 is important for 
gp120 binding. Several anti-gp120 hybridomas were established 
from LPS-stimulated B cells. However, compared to the original 
b12 antibody, these hybridoma cells did not show strong 
neutralization activity. 
Conclusion: The antibodies targeting CD4 binding site are 
apparently not autoreactive, supporting the notion that this is a 
desirable epitope for vaccine target. B12 H chain knock in mouse 
data showed light chain is important for bNAb function. B12 
knock in mice and recently generated b12 germline strains are 
suitable for vaccine study.
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Partial Germline Reversions Can Increase VRC07 
Potency and Breadth
R.S. Rudicell1, I. Georgiev1, Z. Yang1, S. O’Dell1, Y. Kwon1, J. Zhu1, 
X. Wu1, P.D. Kwong1, J.R. Mascola1, G.J. Nabel1
1Vaccine Research Center, NIAID, NIH, Bethesda, MD, MD, USA
Background: VRC01 and related antibodies target the CD4 
binding site (CD4bs), are broadly neutralizing and highly potent, 
and have undergone high levels of somatic hypermutation. 
To optimize such antibodies for passive immunization and 
to further understand antibody development, we reverted 
three CD4bs antibodies towards their putative germlines and 
analyzed the effects on breadth and potency. Interestingly, we 
also identified key germline reversion mutations that increased 
neutralization potential. 
Methods: Structure/function-based analyses were used to 
design partially reverted heavy and light chains based on the 
clonally-related antibodies VRC01, NIH45-46, and VRC07. 
Mature CDRs were maintained and framework regions were 
back-mutated. The antibodies were expressed, purified, and 
tested for binding to gp120 by ELISA. Neutralization against a 
panel of tier 2 HIV-1 pseudotyped viruses was determined for 
select antibodies.
Results: The heavy chains of VRC01, NIH45-46, and VRC07 are 
42%, 41%, and 44% somatically mutated from their germline 
precursor, while the light chains are 29% (VRC01/07) and 27% 
(NIH45-46) somatically mutated. We began by reverting over 
half of the heavy chain somatic mutations and over one-third 
of the light chain somatic mutations to their germline residue 
identities. An iterative design approach was used, and we 
systematically re-introduced mature residues to the partial 
germline reversions. Most mutants retained the ability to bind 
gp120 and neutralize diverse HIV-1 pseudoviruses, albeit with 
lower breadth and/or potency than their mature counterparts. 
Additionally, we found 3 partial-germline reversion mutations 
that increased VRC07 potency. 
Conclusion: Here, we showed that in most cases mature 
framework regions in addition to mature CDRs were required 
for highest neutralization potency and breadth. However, three 
framework germline reversion mutations increased potency 2-3 
fold. These partial reversions are being combined with other 
mutations, including those that modulate Fc effector function, 
to optimize the antibody function for passive transfer in NHPs 
and humans. 
P03.57 LB 
Antibody responses to V2 loop Are Induced by 
CRF01_A E and not Clade B Envelopes
N. Karasavvas1, C. Karnasuta1, S. Madnote1, D. Arworn1,  
F. Sinangil2, S. Rerks-Ngarm1, R.J. O’Connell1, S. Nitayaphan1,  
V. Ngauy1, J.H. Kim1, N.L. Michael1, M.S. de Souza1
1AFRIMS, Bangkok, Thailand; 2Global Solutions for Infectious 
Diseases, South San Francisco, CA, USA
Background: The RV144 vaccine trial of canarypox vCP1521 
(ALVAC-HIV) prime and bivalent HIV-1 envelop gp120 protein 
subtype B/CRF01_AE boost (AIDSVAX B/E) demonstrated a 
significant effect in preventing HIV-1 infection. A case-control 
analysis suggested that variable loops 1 and 2 (V2) of gp120 may 
have contributed to protection against HIV-1 acquisition. Two 
other vaccine trials using gp120 only– VAX003 (AIDSVAX B/E) and 
VAX004 (AIDSVAX B/B) failed to show protection
Methods: Binding antibody responses induced by the RV144, 
VAX003 and VAX004 vaccine regimens were compared using 
ELISA. Recombinant gp120 envelope proteins MN (subtype B), 
92TH023 (CRF01_AE), A244 (CRF01_AE) and cyclic V2 peptides 
were used as capture antigens
Results: After two protein injections, VAX004 had the highest 
geometric mean titers (GMT) against MN (25,600), VAX003 
against A244 (21,378) and RV144 against 92TH023 (6,263). 
Antibody responses against V2 (CRF01_AE) were detected in 
plasma samples from RV144 and VAX003 with GMTs of 972 and 
1100, respectively. However, VAX004 failed to generate antibodies 
against CRF01_AE V2. None of the three vaccines generated 
antibodies against MN V2 after two protein immunizations. 
Compared to VAX004, VAX003 had higher antibody responses 
against all three recombinant proteins: 2-fold (MN), 4-fold 
(A244) and 4-fold (92TH023) when two additional protein 
injections were administered. Two additional protein 
inoculations in the VAX trials failed to increase antibody titers 
against, CRF01_AE V2, but generated a small response against 
MN V2 (GMT, 76) in VAX003
Conclusion: Antibody responses against V2 were induced by 
CRF01_A E recombinant proteins as there were no responses 
induced by the AIDSVAX B/B vaccine regimen. Repeated protein 
immunization increased the magnitude of responses against 
recombinant proteins in VAX003 but failed to increase titers 
against CRF01_AE V2. If antibodies against V2 are protective 
against HIV-1 acquisition, designing antigens with greater V2 
antigenicity would be critical
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Heterologous Neutralization Breadth Persists Despite 
B-Lymphocyte Dysfunction in Chronic HIV-1 Infection
M.K. Murphy1, S. Boliar1, T.C. Tran1, D.G. Carnathan1,  
W.S. Armstrong1, G. Silvestri1, C.A. Derdeyn1
1Emory University, Atlanta, GA, USA
Background: Of the millions globally infected with HIV-1, only 
20-30% will develop broadly neutralizing antibodies. To date, no 
one has measured this phenomenon in a cohort of subjects for 
which multiple aspects of B-lymphocyte dysfunction have been 
evaluated in parallel.
Methods: In 16 viremic seroconverters, the cross-clade 
neutralizing activity of plasma was investigated using a panel 
of thirteen clade A, B, and C HIV-1 envelope (Env) pseudotyped 
virions, which represented three tiers of sensitivity. The 
neutralization IC50 was calculated for each plasma-Env 
combination, and these data were used to determine a breadth 
(how many Envs were neutralized) and potency (the strength of 
neutralization) score for each seroconverter. Additionally, the 
level of plasma antibodies that bound to the monomeric form of 
a subtype B Env gp120 (HIV-1 BaL) was quantitated.
Results: A range of neutralization breadth emerged: three plasma 
samples (19%) demonstrated widespread neutralizing activity 
against this panel of Envs, while five subjects (31%) exhibited 
a complete lack of detectable neutralization at the lowest 
dilution of plasma tested (1:100). No correlation was observed 
between neutralization breadth or potency and parameters of 
B-lymphocyte dysfunction (PD-1, BTLA), immune activation (Ki-
67, CD95), or disease progression (CD4 T cell count, plasma viral 
load). The level of total IgG in each plasma sample, however, 
did significantly correlate with both neutralization breadth 
and potency. Like total IgG, anti-gp120 binding antibodies also 
positively correlated, but, in this case, the correlations only 
trended toward significance. Anti-gp120 binding antibodies did 
not correlate with parameters of B-lymphocyte dysfunction, 
immune activation, disease progression, or total IgG level.
Conclusion: These findings demonstrate that even in chronically 
HIV-1-infected subjects in whom B-lymphocytes display multiple 
indications of dysfunction, antibodies that mediate cross-clade 
neutralization breadth (particularly anti-gp120 binding and other 
IgG antibody specificities) continue to circulate in plasma.
P03.59 LB 
Regulatory B Cells Are Induced In Untreated HIV-1 
Infection and Suppress HIV-1 Specific T Cell Responses 
J. Liu1, W. Zhan1, C. Kim1, E. Lee1, J. Cao1, B. Ziegler1, A. Gregor1, 
F. Yue1, S. Huibner1, S. Macparland1, K. Clayton1, J. Schwartz1, 
H. Song1, E. Bento2, C. Kovacs2, R. Kaul1, M. Ostrowski1
1University of Toronto, toronto, Canada; 2Maple leaf clinic, 
toronto, Canada
Background: Regulatory B cells (Breg), the B cells producing 
interleukin 10 (IL-10), have been identified in mice and humans. 
Mouse Breg can suppress innate and T cell responses and are 
implicated in pathogenesis of some autoimmune diseases and 
immune evasion of some pathogens. However, the role of Breg 
in humans is less clear. 
Methods: PBMC and gut biopsy samples were obtained from 
healthy donors and HIV infected individuals. Flow cytometry 
and Luminex were used to quantify cytokine production. Flow 
cytometry were used to analyze Breg’s phenotype.
Results: Breg were elevated in both peripheral blood and gut 
tissue of untreated HIV-1 infected individuals and the elevation 
correlated with viral load in early HIV-1 infection. Breg from 
HIV-1 infected individuals were CD19+TIM-1+.Anti-retroviral 
therapy could reduce elevated Breg frequency. Treatment of B 
cells from healthy donors with microbial translocation products 
could differentiate them toward a Breg phenotype. Ex vivo 
Bregs from HIV-1 infected individuals suppressed cytokine 
production /degranulation of HIV-1 specific T cells that was in 
part IL-10 dependent.
Conclusion: Our findings show that Bregs are induced early in 
HIV-1 infection, which may play a role in inhibiting effective HIV-
1-specific T cell responses.
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Analysis of gp41 Epitopes in Model Viral Membranes 
to Study HIV-1 Neutralization
T. Reichart1, M. Baksh1, M. Zwick1, M. Finn1, P. Dawson1
1The Scripps Research Institute, La Jolla, CA, USA
Background: The membrane proximal external region 
(MPER) of the HIV surface glycoprotein gp41 is the binding 
site for several potent broadly neutralizing antibodies. These 
antibodies recognize highly conserved linear peptide epitopes 
and antigens derived from this region have the potential to 
be important components of a vaccine directed against HIV-
1. Highly conserved peptide epitopes for these antibodies are 
sterically obscured from the immune system by an intimate 
association with the viral membrane and by the presence of a 
large trimeric glycoprotein spike. As a result, previous attempts 
to immunize with linear peptides have failed to elicit broadly 
neutralizing antibodies. 
Methods: In order to better mimic the structural features of 
the MPER domain with an eye towards better understanding of 
epitope-antibody interactions near membranes, peptide mimics 
derived from HIV gp41 have been synthesized with a variety 
of structural changes including positioning of the epitope with 
respect to the membrane as well as the presence and nature of 
an anchoring transmembrane domain. These peptide mimics 
have been incorporated into membrane bilayer mimics called 
“Nanodiscs,” which are ~10 nm-diameter structures composed 
of a phospholipid bilayer ringed by an apolipoprotein-derived 
scaffold protein. 
Results: We have examined the affinity of HIV-1 neutralizing 
antibodies to these membrane-bound peptides to better 
understand the binding of these neutralizing antibodies to 
epitopes on or near a membrane. Significant differences in 
binding have been observed between peptides with different 
transmembrane domains.
Conclusion: We have chemically synthesized peptide mimics 
of gp41 and incorporated them into artificial membrane 
bilayers. The peptides are anchored with both native and 
artificial transmembrane domains, and both the presence and 
nature of the transmembrane domain modulates antibody 
binding. Membrane presentation of peptide antigens with an 
appropriate transmembrane domain may be an important 
feature of vaccine design.
P03.61 LB 
Sequential Exposure to Specific Antibody Escape 
Mutations May Program Neutralization Breadth 
During Subtype A HIV-1 Infection 
M.K. Murphy1, L. Yue1, R. Pan2, S. Boliar1, A. Sethi3, E. Karita4, 
S.A. Allen1, E. Cormier5, J.E. Robinson6, S. Gnanakaran3,  
E. Hunter1, X. Kong2, C.A. Derdeyn1
1Emory University, Atlanta, GA, USA; 2New York University 
School of Medicine, New York, NY, USA; 3Los Alamos National 
Laboratory, Los Alamos, NM, USA; 4Projet San Francisco, 
Kigali, Rwanda; 5International AIDS Vaccine Initiative, London, 
United Kingdom (Great Britain); 6Tulane University School of 
Medicine, New Orleans, LA, USA
Background: Mechanisms that expand the otherwise narrow 
neutralization capacity observed during early HIV-1 infection 
are currently undefined, but multiple lines of evidence 
suggest that the ability to elicit broad and potent neutralizing 
antibodies (nAbs) via vaccination could increase the protective 
efficacy of immunization.
Methods: Here we characterized the initial nAb response 
in a subtype A HIV-1-infected Rwandan seroconverter and 
investigated how consequent immune events influenced the 
downstream development of cross-clade breadth. Autologous 
envelope (Env) glycoproteins from the transmitted/founder 
virus and twenty longitudinal nAb escape variants were utilized 
to define the neutralization targets of autologous plasma and 
monoclonal antibodies (mAbs), the latter of which were also 
examined genetically and structurally through crystallization. 
Heterologous Env glycoproteins from nine cross-clade variants 
were used to determine neutralization breadth.
Results: Initially, nAbs targeted a single region of gp120 at the 
base of V3 involving the alpha2 helix. A single amino acid change 
at one of three positions conferred early escape from plasma 
nAbs. Then, two autologous mAbs, revealed to have flat epitope 
contact surfaces, typified the second wave of nAb pressure and 
neutralized escape Envs carrying the defined V3/alpha2 helix 
substitutions in a manner dependent on immunoglobulin light 
chain variable domain modifications. Subsequent mAb resistance 
arose in later Envs through alteration of two glycan motifs 
previously implicated in the development of nAb breadth. Finally, 
three-year autologous plasma displayed moderate neutralization 
breadth and most potently neutralized heterologous Envs 
containing the altered glycan motifs.
Conclusion: Our data demonstrate that the V3-proximal nAb 
epitope originally recognized in this individual elicited strain-
specific mAbs and that glycan-mediated escape from these mAbs 
likely initiated the development of heterologous neutralization 
breadth. These findings suggest that epitope localization and the 
resultant routes of viral immune evasion, which include exposure 
to a specific sequence of nAb escape variants, drive humoral 
immune responses toward cross-clade viral recognition.
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V1/V2-Directed Antibodies Elicited in RV144 
Vaccinees Bind to a Structurally Polymorphic Site
J.S. McLellan1, J. Gorman1, M. Bonsignori2, K. Hwang2, H. Liao2, 
S. Rerks-Ngarm3, S. Nitayaphan4, N.L. Michael5, J.H. Kim5,  
B.F. Haynes2, P.D. Kwong1
1National Institutes of Health, Bethesda, MD, USA; 2The Duke 
Human Vaccine Institute, Durham, NC, USA; 3Department 
of Disease Control, Bangkok, Thailand; 4Department of 
Retrovirology and AFRIM, Bangkok, Thailand; 5U.S. Military HIV 
Research Program, Rockville, MD, USA
Background: An immune correlates study of the RV144 vaccine 
trial demonstrated that elicitation of V1/V2-directed antibodies 
was inversely associated with infection risk. In addition, a sieve 
analysis of breakthrough infections identified residue 169 in 
the V2 loop as a site of immune pressure. Antibodies CH58 and 
CH59 were isolated from RV144 vaccinees and were shown to 
neutralize some Tier 1 isolates.
Methods: The epitopes for CH58 and CH59 were identified 
by peptide-mapping and alanine-scanning. Antigen-binding 
fragments (Fabs) were generated by proteolysis, and crystal 
structures of the CH58 and CH59 Fabs in complex with a linear 
V2 peptide were determined to 1.7 and 1.5 Å, respectively. 
Surface plasmon resonance was used to determine the kinetics 
of antibody binding to recombinant env-derived proteins.
Results: The crystal structures reveal that CH58 recognizes 
V2 residues 167-176 as an α-helix and residues 177-181 as an 
extended coil. In contrast, CH59 recognizes residues 168-173 as 
coil, with residues 174-176 as a short 310 helix. Both antibodies form 
hydrogen bond or salt-bridge interactions with the side chain of 
Lys169, the imputed site of immune pressure. The conformations 
of V2 recognized by CH58 and CH59 differ markedly from the 
β-strand conformation recognized by the broadly neutralizing 
antibody PG9. All three antibodies bound with high affinity to 
the same gp120 protein, suggesting that V2 residues 167-176 can 
adopt multiple conformations on a shed gp120.
Conclusion: Since PG9 is broadly neutralizing and recognizes V2 
as a β-strand, and because CH58 and CH59 neutralize only some 
Tier 1 isolates and recognize alternative conformations of V2, 
these data suggest that the β-strand conformation of V2 may be 
favored in the viral spike, whereas alternative V2 conformations 
may be favored on shed gp120s. If true, then vaccine immunogens 
may need to have the V1/V2 region stabilized in the β-strand 
conformation in order to elicit broadly neutralizing antibodies.
P03.63 LB 
Mutations in the V1 Domain of Thai CRF01-AE 
Viruses That Confer Sensitivity/Resistance to Broadly 
Neutralizing Antibodies
S. O’Rourke1, G. Tatsuno1, B. Yu1, P. Phung2, K. Mesa1, B. To1,  
K. Limoli2, T. Wrin2, P. Berman1
1Dept. of Biomolecular Engineering, University of California 
Santa Cruz, Santa Cruz, CA, USA; 2Monogram Biosciences, San 
Francisco, CA, USA
Background: Antibodies to the V1/V2 domain of gp120 have 
recently been identified as a correlate of protection in the RV144 
clinical trial. To better understand the specificity of broadly 
neutralizing antibodies) to the V1/V2 domain of Thai CRF01_AE 
viruses, we analyzed the specificity of antibodies in HIV+ elite 
neutralizer (EN) sera by swarm analysis.
Methods: Swarm analysis makes use of the swarm of closely 
envelope variants that evolve in each HIV-1 infected individual, 
as a source of naturally occurring and biologically relevant 
mutations that confer neutralization sensitivity/resistance. 
Envelopes from clade B and CRF01_AE viruses were tested for 
neutralization sensitivity/resistance with sera from ENs infected 
with clade B and CRF01_AE viruses.
Results: We found five mutations in the V1 domain that affected 
neutralization sensitivity/ resistance of CRF01_AE viruses. 
This differed from clade B viruses in which mutations altering 
neutralization sensitivity/resistance clustered in the V2 domain. 
Structural studies have shown that the V1/V2 domain of gp120 
consists of a four-stranded _-sheet structure. We found that 
mutations affecting neutralization sensitivity/resistance in 
Thai CRF01_AE viruses clustered around the exposed turn at 
the junction of the A-B strands. In contrast, the mutations that 
altered neutralization sensitivity/resistance in clade B viruses 
clustered around exposed turns at the junction of the B-C and 
the C-D strands.
Conclusion: The present studies suggest that there is a major 
difference in the antigenic structure of the V1V2 domain 
between clade B and CRF01_AE envelope proteins. These 
results suggest that antibodies to the V1 domain of CRF01_
AE envelope proteins should be evaluated as a correlate of 
protection in the RV144 trial. For this purpose, studies using 
novel proteins and scaffolds, that replicate the structure of 
conformation- and glycoform- dependent epitopes in the V1/
V2 domain, are under investigation.
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Barriers to Participation in HIV Vaccine Trials and 
Cancer Trials: A Cost-Gain Analysis
S. Dhalla1, G. Poole2
1University of British Columbia, Vancouver, Canada; 2School of 
Population and Public Health, University of British Columbia, 
Vancouver, Canada
Background: Previous studies examining barriers and willingness 
to participate in HIV vaccine trials have demonstrated the role 
of factors identified by the Health Belief Model. Barriers to 
cancer trials can also be understood in terms of a theoretical 
framework consisting of the locus of the barrier (personal 
vs. social) and the nature of the barrier (risk vs. cost). In this 
systematic review of review articles, we extend this framework 
to another life-threatening disease, cancer. The purpose is to 
improve conceptual clarity about volunteering in clinical trials by 
comparing and contrasting barriers in these two areas.
Methods: In 2012, two people independently searched the 
Cochrane Database for Systematic Reviews, Pubmed, Embase, 
and Google Scholar to identify review articles examining cancer 
trial barriers to participation. Search terms used were: “cancer”, 
“oncology”, “cancer trials”, “oncology trials”, “clinical trials”, 
“medical research”, “willingness to participate”, “barriers”. 
Review articles were also retrieved from our search examining 
motivators to participation in cancer research and from 
bibliographic references.
Results: We retrieved 19 review articles from 2000-2012 
examining barriers to participation in cancer trials. “Reduced 
quality of life” / “distrust of institutions” / “loss of control” were 
personal risks (PR). “Perceptions of the provider” / “subjective 
norms” were social risks (SR). “Side effects” / “experimental 
nature of the trial” were personal costs (PC). Misconceptions 
included “confidentiality concerns”. Consistent with HIV vaccine 
trials, most barriers with regards to cancer trials were related to 
PR and PC. More misconceptions were identified in HIV vaccine 
preparedness studies (VPS). 
Conclusion: Personal risk, PC, and SR barriers were similar to 
those identified in HIV VPS, but more misconceptions were 
identified in the latter. Understanding barriers can result in 
better recommendations on how to overcome these barriers. 
A limitation is that cancer populations are different than those 
affected by HIV.
P04.01
Priming with a “Simplified Regimen” of HIV-1 DNA 
Vaccine Is as Good as a “Standard Regimen” When 
Boosted with Heterologous HIV-1 MVA Vaccine
P. Munseri1, A. Kroidl2, C. Nilsson3, C. Moshiro1, S. Aboud1,  
A. Joachim1, C. Geldmacher4, E. Aris1, D. Buma1, E. Lyamuya1,  
F. Gotch5, K. Godoy-Ramirez6, K. Pallangyo1, L. Maboko7,  
M. Marovich8, M. Robb9, M. Hoelscher2, M. Janabi1, P. Mann7, 
S. Joseph10, S. Mfinanga11, W. Stoehr1, F. Mhalu1, B. Wahren12, 
G. Biberfeld13, S. McCormack14, E. Sandstrom15, M. Bakari1
1Muhimbili University of Health and Allied Sciences, Dar 
es Salaam, United Republic of Tanzania; 2Department for 
Infectious Diseases and Tropical Medicine, Munich, Germany; 
3The Swedish Institute for Communicable Disease Control, 
SMI, Stockholm, Sweden; 4Division for Infectious Diseases and 
Tropical Medicine, Germany; 5Imperial College, United Kingdom 
(Great Britain); 6Swedish Institute of Communicable Disease 
Control (SMI), Stockholm, Sweden; 7Mbeya Medical Research 
Programme, United Republic of Tanzania; 8Walter Reed Army 
Institute of Research (WRAIR), USA; 9The Henry M. Jackson 
foundation, USA; 10MRC, Clinical Trials Unit, United Kingdom 
(Great Britain); 11National Institute for Medical Research, United 
Republic of Tanzania; 12Karolinska Institutet, Sweden; 13Swedish 
Institute for Communicable Disease Control (SMI), Sweden; 
14MRC Clinical Trials Unit, United Kingdom (Great Britain); 
15Venhalsan, Karolinska Institutet, Sodersjukhuset, Sweden
Background: Intradermal priming with DNA prior to MVA boosts 
gives strong and broad immunogenicity, however that required 5 
injections at each immunization. A higher concentration of DNA 
might allow a simpler administration. 
Methods: This double blind, placebo-controlled trial, enrolled 
120 (12 placebo) HIV-uninfected volunteers, in Dar es Salaam and 
Mbeya. Two pools of DNA plasmids were used (pool1 EnvABC + 
RevB, pool2 GagAB + RTB) boosted with MVA CMDR EnvE, GagA, 
PolA. Volunteers were randomized in three groups of 40, primed 
with either two injections of 300ug, one in each arm, (total 600ug) 
of DNA with combined plasmids (group IA) or two injections of 
300ug with one pool in each arm (total 600ug) of DNA (group IIA) 
“simplified regimens” or five injections, 2 (pool1) and 3 (pool2) 
injections in the right and left arm respectively, (total 1000ug) 
of DNA (IIIA) “standard regimen”. DNA/Placebo priming was 
administered by a needlefree (Biojector) device intradermally at 
weeks 0, 4 and 12. All volunteers were boosted intramuscularly 
with 10 pfu of recombinant MVA/placebo at weeks 30 and 46. 
The primary end point was the number of ELISpot responders to 
Gag and Env, 2 weeks post the last vaccination. 
Results: There were no safety concerns. The response rate to 
Gag and/or Env was 27/32 (84%) in group IA vs 31/33 (94%) in 
group IIA (p=0.26). The response rate to Gag and/or Env when 
comparing the ‘simplified regimens’ vs ‘standard’ regimen was 
58/65 (89%) vs 32/32 (100%) p=0.09. In responders the median 
magnitude (IQR) response to Gag was 165 (100,365) SFC/million 
PBMC vs 210 (120,320), p=0.46 while the magnitude for Env 
was 150 (92,225) vs 110 (80,160) p=0.17 for the ‘simplified’ vs 
‘standard’ regimens. 
Conclusion: The simplified HIV-1 DNA regimens primed as well 
as the standard regimen for cellular immune responses following 
boosting with with MVA.
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A Social Ecological Model of Willingness to 
Participate in HIV Vaccine Trials Among Men Who 
Have Sex with Men in Chennai and Mumbai, India
V. Chakrapani1, P.A. Newman2, J. Jerajani3, M. Shanmugam1,  
N. Singhal3
1Centre for Sexuality and Health Research and Policy; 
Humsafar Trust, Chennai and Mumbai, India; 2University of 
Toronto, Toronto, Canada; 3The Humsafar Trust, Mumbai, India
Background: Recruitment of low- and middle-income country 
volunteers from most-at-risk-populations in HIV vaccine trials is 
essential to vaccine development. In India, men who have sex 
with men (MSM), at 20-fold higher risk for HIV infection than 
the general population, are a crucial population for recruitment. 
Research on willingness to participate (WTP) in HIV vaccine trials 
has focused predominantly on individual-level determinants 
(e.g., safety concerns, mistrust, altruism) in high-income 
countries. We used a social ecological framework to explore 
multi-level determinants of WTP among MSM in India.
Methods: We conducted 9 focus groups (n=49) with low 
socioeconomic MSM (aged 20-46 years, mean=28), including 
peer outreach workers, in Chennai (in Tamil) and Mumbai (in 
Marathi/Hindi), and 7 key informant interviews with MSM 
community leaders and healthcare professionals. Focus groups/
interviews were recorded, transcribed and translated into 
English. Two independent bilingual investigators conducted 
narrative thematic analysis using line-by-line coding and a 
constant comparative method, with member-checking by 
community representatives.
Results: Structural-level determinants of WTP included poverty, 
compensation for trial-related harms and having financially-
dependent family members. Community-level factors were 
negative societal attitudes about same-sex sexuality and 
community engagement in HIV vaccine research. Interpersonal 
factors included anticipated peer and familial reactions and 
perceived HIV stigma. Individual-level determinants of WTP 
included knowledge about vaccines, openness about one’s 
sexuality and altruistic beliefs.
Conclusion: WTP in HIV vaccine trials among MSM in India is 
associated with multi-level factors. Ubiquitous interpersonal 
and community-level concerns characteristic of the sociocultural 
context may complicate individual-focused conceptualizations of 
WTP. Interventions to reduce stigma and discrimination against 
MSM and PLHIV, capacity-building of MSM service organizations, 
and sustained and transparent communications tailored to the 
knowledge, concerns and educational level of local communities 
may support meaningful engagement of MSM in HIV vaccine 
trial preparedness. Attention to providing fair yet non-coercive 
compensation and healthcare benefits are warranted to support 
ethical conduct of trials.
P04.03
Motivators to Participation in HIV Vaccine Trials and 
Cancer Trials: The Application of Personal and Social 
Categorization
S. Dhalla1, G. Poole2
1University of British Columbia, Vancouver, Canada; 2School of 
Population and Public Health, University of British Columbia, 
Vancouver, Canada
Background: The Health Belief Model provides a framework to 
understand motivators for volunteering for medical research. 
Motivators can take the form of social benefits, including 
macrosocial (pertaining to one’s greater society), mesosocial 
(pertaining to one’s larger social world), and microsocial 
(pertaining to one’s immediate social network). Personal benefits 
can be sub-divided into psychological, physical, and financial well-
being. In this systematic review of review articles, we extend our 
conceptual framework from motivators regarding participation 
in HIV vaccine trials to another life-threatening disease, cancer.
Methods: In 2012, two people independently searched the 
Cochrane Database for Systematic Reviews, Pubmed, Embase, 
and Google Scholar to identify review articles examining cancer 
trial motivators to participation. Search terms were: “cancer”, 
“oncology”, “cancer trials”, “oncology trials”, “clinical trials”, 
“medical research”, “willingness to participate”, “motivators”, 
“incentives”. Review articles were also retrieved from our search 
examining barriers to participation in cancer research and from 
bibliographic references.
Results: We retrieved 12 review articles from 2000-2012 examining 
motivators to participation in cancer trials. Personal benefits were 
most often psychological such as “coping with symptoms”. Social 
benefits included “advancing research”, “helping other cancer 
patients”, and “for their family”. These categories also apply well 
in HIV vaccine trials. Personal/psychological benefits are most 
commonly cited as motivators for both types of research. In cancer 
research, “coping with symptoms” and “extending life expectancy” 
were motivators; in HIV vaccine trials, it was to “reduce the risk of 
becoming HIV positive”. 
Conclusion: While specific motivators vary between considerations 
of cancer research and HIV vaccine trials, these motivators fall into 
similar categories at similar frequencies. Personal / psychological 
benefits are most common in each. Altruistic factors found at a 
macrosocial level outnumber factors relevant to more proximal 
levels, such as family and other patients. Participant recruitment 
must be mindful of these categories of motivators for both HIV 
vaccine and cancer research.
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Electroporation (EP)-Related Technical Errors 
Experienced During an HIV Vaccine Clinical Trial 
Conducted in Rwanda and Uganda: Lessons Learned 
R. Bayingana1, A. Nanvubya2, E. Karita1, J. Nyombayire1,  
R. Ingabire1, K. Chinyenze3, J. Lehrman3, C. Schimidt3,  
D. Hannaman4, S. Allen5, P. Fast3
1Project San Francisco/International AIDS Vaccine Initiative, 
Kigali, Rwanda; 2Uganda Virus Research Institute, Entebbe, 
Uganda; 3International AIDS Vaccine Initiative, Nairobi, Kenya; 
4ICHOR Medical Systems Inc, USA; 5Emory University, Atlanta, 
GA, USA
Background: Intracellular DNA vaccine delivery is essential 
for antigen expression and induction of immune response. 
Unfortunately, conventional intramuscular injection provides 
low efficiency DNA uptake and suboptimal immunogenicity. 
Electroporation-based DNA vaccination can enhance potency by 
100-1000 fold. In this trial we used the TriGrid Delivery System 
by Ichor Medical Systems. We describe the electroporation 
technical errors that occurred during administration of an HIV 
pDNA vaccine in a clinical trial conducted at sites in Rwanda and 
Uganda and how those errors were resolved.
Methods: The site physicians were trained and qualified to use 
the EP procedure during site initiation visits and further practiced 
mock EPs later. We examined the technical errors that occurred 
by reviewing volunteer files between 19th December 2011 and 
27th March 2012.
Each administration of the HIV pDNA intramuscularly by 
electroporation required two injections (one in each deltoid 
muscle) at each vaccination time point. Should an error occur 
during EP procedure, the respective error codes are shown on the 
monitor. Once the procedure is complete, ‘procedure complete’ is 
indicated on the monitor. 
Results: Six errors out of 90 eletroporations occurred. Four 
occurred because of improper insertion of the electrodes or 
injection needle. These errors were resolved by repeating the 
procedure. Two occurred because of improper insertion of the 
cartridge into the applicator and on both occasions the errors 
were captured before switching on the enable button on the 
pulse stimulator. These were resolved by properly re-inserting 
the cartridge into the applicator. Most of the other potential 
errors were caught before the procedure started by the second 
person observing the set up
Conclusion: We conclude that errors related to EP procedure 
can be minimized or avoided when there is appropriate quality 
control immediately prior to vaccination. We advise to have 
two trained and qualified staff present during the procedure 
for quality control purposes
P04.05
A Decade of Partnering to Stop HIV in West Africa: 
GAIA VF Prevention, Education, Access to Care and 
Vaccine Trial Site Development in Bamako, Mali
A. De Groot1, K. Tounkara2, B. Aboubacar2, F. Siby Diallo3,  
F. Bougoudogo4, O. Koita5, O. Koita6, S. Dao5, S. Diallo5, Y. Traoré7, 
L. Diarra2, L. Diarra8, G. Diarra8, Y. Koné8, R. Mali1, L. Steven 1
1GAIA Vaccine Foundation and the University of Rhode Island, 
Providence, RI, USA; 2GAIA Vaccine Foundation, Bamako, 
Mali; 3Direction Régionale de la Santé, Bamako, Mali; 4INRSP, 
Bamako, Mali; 5FMPOS, Bamako, Mali; 6FAST U. Bamako, 
Bamako, Mali; 7Hôpital Toure, Bamako, Mali; 8ASACOMSI, 
Sikoro, Mali
Background: GAIA Vaccine Foundation (GAIA VF) has been 
working alongside the Department of Health (DRS), HIV expert 
clinicians, and basic scientists in Mali to prepare a site for Phase 
I-III HIV vaccine trials. The proposed location for the Phase I-III 
trials to be conducted in this collaboration is Sikoro, a multi-
ethnic village with a population of over 40,000 located near 
Bamako, Mali.
Methods: To date, GAIA VF, the DRS, and Malian clinicians and 
scientists have collaborated on: (1) HIV education in Sikoro and 
Bamako, (2) HIV prevention in Sikoro, (3) access to HIV treatment 
in Sikoro, and (4) vaccine readiness studies in Bamako and 
Sikoro. Regular meetings and extensive collaborations have been 
established among GAIA VF, regional scientists, and government 
officials.
Results: An HIV transmission prevention (MTCTP) program was 
established in the Sikoro prenatal care clinic (Chez Rosalie) in 
2005; the Hope HIV Care Center (Bloc Espoir) was completed in 
2008, and GAIA VF established the first ‘primary-care-setting’ 
HIV treatment program in Mali in 2009. >10,000 pregnant 
women have been screened for HIV infection, >200 have 
been diagnosed with HIV; continuing access to HIV treatment 
and nutritional support was made available for these women 
and their spouses and children in Bloc Espoir. Peer educators 
distributed >47,000 condoms and provided peer-to-peer 
education to >22,000 individuals over 5 years. >300 ‘walk-
in’ patients have been screened for treatment at the on-site 
care center, and >195 individuals are currently receiving 
antiretroviral therapy in this low resource setting.
Conclusion: GAIA VF has established successful local and regional 
partnerships in Mali, performed vaccine readiness research, and 
implemented a comprehensive HIV care program in anticipation 
of performing HIV vaccine trials. A Phase IV HPV vaccine trial in 
Mali is anticipated in 2012, which will build local expertise and 
capacity for future HIV vaccine trials.
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Immune Response After Vaccination of HIV Infected 
Individuals Receiving HAART with Overlapping Gag 
Peptides Pulsed on Autologous Cells
H. Kløverpris1, A. Jackson2, A. Handley3, P. Hayes4, J. Gilmour4, 
M. Atkins5, B. Walker6, J. Ackland7, M. Sullivan3, P. Goulder8
1University of Oxford, Oxford, United Kingdom (Great 
Britain); 2St Stephens Clinic Chelsea and Westminister 
Hospital, London, United Kingdom (Great Britain); 3Medicines 
Development Limited, Melbourne, Australia; 4Imperial College 
London, IAVI Human Immunology Laboratory, London, United 
Kingdom (Great Britain); 5Imperial College Healthcare, London, 
United Kingdom (Great Britain); 6Ragon Insitute, Boston, USA; 
7GlobalBiosolutions, Craigieburn, Australia; 8Oxford University, 
Paediatrics, Oxford, United Kingdom (Great Britain)
Background: HIV Gag specific CD4+ and CD8+ T cell responses 
are important for HIV immune control. Pulsing overlapping Gag 
peptides on autologous cells (Opal) has proven immunogenic 
and effective in reducing viral loads in multiple macaque studies, 
warranting clinical evaluation.
Methods: We performed a phase I, single centre, placebo-
controlled, double-blinded and dose-escalating study to evaluate 
the safety and preliminary immunogenicity of a novel vaccine 
approach Opal-HIV-Gag(c). This vaccine is constituted by 120 
15mer peptides, overlapping by 11 amino acids spanning the 
entire HIV Gag C Durban consensus sequence proteome, pulsed 
on white blood cells enriched from whole blood using a closed 
system, followed by intravenously reinfusion. Patients with well 
controlled HIV on HAART received four vaccinations administered 
at week 0, 4, 8 and 12, and were followed up for 12 weeks post-
treatment. Eighteen people were enrolled in three groups: 12mg 
(n=6), 24mg (n=6) or matching placebo (n=6). An additional group 
(48mg, n=2) was not evaluable. Immunogenicity was assessed by 
IFNγ ELIspot/ICS.
Results: The constituent peptides in Opal-HIV-Gag(c) were 
antigenic in vitro using peptide stimulated PBMCs (median 30 
fold increase). However, after vaccination with Opal-HIV-Gag(c), 
1/6 at 12mg and 1/6 at 24mg had a 2 to 3 fold increase from 
Baseline of Gag specific CD8+ T cells at Week 14, compared to 
0/6 placebo recipients. No Gag specific CD4+ T cell responses or 
overall change in Rev, Nef, Tat and CMV specific responses were 
detected. Marked, transient and self-limiting lymphopenia was 
observed immediately post-vaccination (4 hours) in Opal-HIV-
Gag(c) but not placebo recipients, with median 1.72 to 0.67 
million lymphocytes/mL for active groups (P<0.001), compared 
to 1.70 to 1.56 for placebo group (P=0.16).
Conclusion: Despite the promising effect found in several Macaca 
nemestrina studies using this approach, Opal-HIV-Gag(c) was 
not significantly immunogenic in this population and improved 
methods of generating Gag-specific T-cell responses are required.
P04.07
High Prevalence of ECG Variations and Abnormalities 
in Young and Healthy TaMoVac 01 HIV Vaccine Trial 
Volunteers from Tanzania
P.J. Mann1, P. Munseri2, B. Kaluwa1, M. Missanga1, J. Lwakatare2, 
M. Hoelscher3, M. Bakari2, M. Janabi4, L. Maboko1, E. Sandström 
5, A. Kroidl3
1Mbeya Medical Research Programme, Mbeya, United 
Republic of Tanzania; 2Muhimbili University of Health and 
Allied Sciences (MUHAS), Dar es Salaam, United Republic of 
Tanzania; 3Department of Tropical Medicine and Infectious 
Diseases, University of, Munich, Germany; 4Muhimbili 
National Hospital, Dar es Salaam, United Republic of Tanzania; 
5Karolinska Institutet, Stockholm, Sweden
Background: Vaccinia immunizations have caused peri-/
myocarditis. As a result, volunteers receiving Modified Vaccinia 
Ankara(MVA) are monitored with ECGs. Early Repolarization 
Syndrome(ERS) has been reported in 1-2% and Left Ventricular 
Hypertrophy(LVH) in <10% of young, healthy populations across 
different ethnicities. These changes have been described as 
normal ECG variations, and according to early reviews, are more 
frequent in African and Asian populations. A prevalence of 90% 
has been reported for ST-Elevation in young males in several 
studies from industrialized and developing countries.
Methods: ECG was performed in healthy HIV negative volunteers 
during screening for the Phase II ”TaMoVac01” HIV Vaccine Trial 
in DarEsSalaam and Mbeya, Tanzania. ECG variations that could 
potentially interfere with the later interpretation of myocarditis/
pericarditis were confirmed by a panel of international 
cardiologists and led to exclusion from the study. These were ST-
segment elevation, T-wave abnormalities, signs of LVH and ERS.
Results: 263 Volunteers (mean age 24.4 years, 63.5% males) 
had a baseline ECG evaluation performed. 19% of ECGs showed 
ERS, 20.3% showed LVH and 77% showed ST-elevation. 22.1% 
of volunteers were screened out due to ECG findings, none of 
whom had a history of cardiac disease, although one participant 
had a systolic murmur which led to echocardiogram. Dilation of 
the left ventricle was diagnosed.
Conclusion: Although the prevalence of ST elevation was no 
higher than expected in young males, ERS and LVH was far more 
common than the literature suggested in this cohort of clinically 
healthy, young Tanzanians.Exclusions were due to the presence 
of more than one abnormality. None had symptoms that were 
clinically relevant, although a significant cardiac finding was 
revealed through echocardiogram in one participant.
The clinical benefit of ECG screening in the context of vaccine 
studies in healthy volunteers remains to be determined, but it is 
clear from this study that it added considerably to the number 
of screenouts.
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P04.10
Developing Standards of Care for HIV Prevention 
Research in Developing Countries – A Case Study of 
Ten Research Centers in Eastern and Southern Africa
B.P. Ngongo1, F. Priddy1, H. Park1, B. Bender1, P. Fast1, O. Anzala2, 
G. Mutua2, E. Ruzagira3, A. Kamali4, E. Karita5, P. Mugo6,  
E. Chomba7, L. Bekker8, S. Roux8, A. Nanvubya9, T. Mebrahtu9
1International AIDS Vaccine Initiative, Nairobi, Kenya; 2Kenya 
AIDS Vaccine Initiative, Nairobi, Kenya; 3Medical Research 
Council – UVRI, Entebbe, Uganda; 4MRC-UVRI, Entebbe, 
Uganda; 5Projet San Francisco, Kigali, Rwanda; 6KEMRI-
CGMRC, Kilifi, Kenya; 7Zambia Emory HIV Research Program, 
Lusaka, Zambia; 8Desmond Tutu HIV Foundation, Cape 
Town, South Africa; 9Uganda Virus Research Institute – IAVI, 
Entebbe, Uganda
Background: Standards of care in general vary across countries 
and communities and thus may affect decisions about standards 
of care provided by research centers in HIV prevention research. 
To serve as a basis for clarifying and improving standards, a 
systematic survey of practices at 10 experienced research centers 
affiliated with the International AIDS Vaccine Initiative in Eastern 
and Southern Africa was conducted between 2008 and 2010. 
Methods: A survey tool was developed to collect qualitative 
and quantitative data on types of services provided, recipients 
of services, referral systems and barriers to referral uptake. 
Focus group discussion and semi-structured interviews were 
conducted with key research centre staff. Qualitative data were 
coded and enumerated where appropriate. Quantitative data 
were categorized and tabulated using STATA. 
Results: All research centres consistently provided HIV prevention 
and care services but had varied practices on family planning 
options, and general medical care to research volunteers, screen 
out volunteers, partners of volunteers, and former volunteers. 
Services that were less consistently provided included 
provision of female condoms and anti-retroviral post-exposure-
prophylaxis to volunteers in case of rape. All research centres 
either had referral points for treatment and care for volunteers 
who become infected with HIV or provided the services on-site. 
Limited referral points were available for psychosocial services 
and adult male circumcision. The greatest challenges for referral 
uptake included transportation and health care costs, poor 
quality and inconsistency of services at some referral points. 
While all research centres covered the cost of health services for 
study-related adverse events, policies varied on covering the cost 
of other health services. 
Conclusion: These findings informed the development of 
standards of care across the 10 research centers and for IAVI-
sponsored research. In developing such standards, balance 
should be made between scientific priorities, considerations 
of fairness, contextual realities, community expectations, and 
cost-effectiveness of conducting clinical trials 
P04.09
Sexual Behavior Among Volunteers Enrolled in a 
Phase I HIV Vaccine Trial:
Experience of Projet San Francisco in Kigali, Rwanda 
J. Mukamuyango1, E. Karita1, R. Bayingana1, J. Nyombayire1,  
R. Ingabire1, S. Allen2, A. Tichacek2, P. Fast3, M. Price3, C. Schmidt3
1Projet San Francisco, Kigali, Rwanda; 2Emory University, 
Atlanta, GA, USA; 3International AIDS Vaccine Initiative, New 
York, NY, USA
Background: Phase 1 HIV vaccine trials are conducted among 
HIV-uninfected, healthy volunteers at low risk for HIV. Study 
volunteers are counseled to maintain low risk behavior for HIV 
acquisition. The objective of this study was to assess sexual 
behavior of volunteers in a Phase 1 vaccine trial, conducted in 
Kigali, Rwanda.
Methods: Concordant HIV-negative couples who were counseled 
and tested together were considered as low risk group for HIV 
acquisition and were invited to participate in Phase 1 HIV vaccine 
trial to evaluate safety and immunogenicity of a multiclade HIV-
1 DNA plasmid vaccine followed by a recombinant, multiclade 
HIV-1 adenoviral vector vaccine (IAVI V001). HIV risk reduction 
counseling, assessment of sexual behavior and screening for 
sexually transmitted infections (STI) were conducted quarterly. 
After completion of the vaccine trial, participants and their 
partners were invited to participate in a long-term 5-year follow-
up study from their last vaccination for further assessment of 
sexual behavior and continuous risk reduction counseling. 
Results: Between November 2005 and May 2006, 57 volunteers 
(36 men and 21 women) were enrolled in the clinical trial. All 
volunteers completed their trial visits. During the first twelve 
months following the first vaccination, none of the study 
participants reported sex with other partners nor was treated 
for STI. After unblinding, 55 volunteers agreed to continue in 
long-term follow up study. Through January 2012 6 men and 2 
women reported having sex at least once with other partners; 
two were treated for STI, and one subsequently acquired HIV. 
(HIV incidence rate: 0.3/100 person-years).
Conclusion: This trial and subsequent follow-up study confirm 
our previous findings that concordant HIV-negative couples are at 
low risk of HIV infection and suitable for enrolling in Phase 1 HIV 
prevention trials. Ongoing HIV risk reduction counseling should be 
provided during the trial as well as after the trail, if possible. 
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P04.12
Using an Internet Consumer Marketing Strategy to 
Reach Men Who Have Sex with Men for Participation 
in a Preventive HIV Vaccine Clinical Trial
C.D. Voytek1, K.T. Jones1, B.L. Curtis2, D.T. Fiore1, D. Dunbar1,  
I. Frank3, D.S. Metzger1, The NIAID HIV Vaccine Trials Network1
1University of Pennsylvania, Philadelphia, PA, USA; 2University 
of Pennsylvania Annenberg Public Policy Center, Philadelphia, 
PA, USA; 3University of Pennsylvania Perelman School of 
Medicine, Philadelphia, PA, USA
Background: Sustaining research subject recruitment in 
biomedical HIV prevention trials requires continual innovation. 
Since June 2009, the University of Pennsylvania HIV Vaccine 
Trials Unit (UPenn HVTU) has employed multiple strategies to 
recruit men who have sex with men (MSM) for a phase IIb HIV 
vaccine trial, HVTN 505. 
Methods: Between 12/1/2011 and 1/3/2012, the HVTU 
contracted with a consumer marketing company to recruit 
potential trial participants. For $3000, the company emailed 
MSM a scripted message inviting them to participate in a clinical 
HIV vaccine trial, and the company provided the trial site with 
contact information for those who responded. Site staff emailed 
and phoned each respondent to provide study information and 
conduct a phone-screen interview for the trial. Those eligible 
were scheduled for in-office screening appointments. 
Results: 266 MSM were emailed; 118 viewed the message, and 
109 responded that they were interested in participating. 83% 
of responders were White, and 71% earned >$50,000/year. 
Staff successfully contacted 64 individuals, and 58 completed 
phone-screens. Of these, 17 were eligible for, and 9 completed, 
screening visits. Five enrolled in HVTN 505 during January-
February, 2012. Of 41 phone-screened ineligible, primary 
reasons for ineligibility were: being HIV-positive (n=20; 49%), 
not meeting protocol-specified sexual risk criteria (n=11; 27%), 
out of age range (n=6; 15%), and/or being uncircumcised (n=5; 
12%). Ineligible participants were referred to phase I or future 
prevention trials as appropriate. 
Conclusion: This strategy reached MSM not engaged by previous 
efforts, and doubled site HVTN 505 enrollment over two months. 
Respondents included a higher proportion of White MSM 
than the population screened for HVTN 505 at the HVTU. This 
approach has wider potential use for recruitment in biomedical 
HIV prevention trials. To understand the true utility of this 
approach, respondent HIV risk data and financial costs associated 
with this strategy must be carefully examined. 
P04.11
Immunogenicity of a Universal HIV-1 Vaccine 
Vectored by DNA, MVA and CHADV-63 in a Phase I/
IIA Clinical Trial
N.J. Borthwick1, T. Ahmed1, A. Rose1, U. Ebrahimsa1, A. Black1, 
E. Hayton1, H. Yang1, G. Hancock1, S. Campion2, N. Frahm3,  
S. Colloca4, A. Nicosia4, A. McMichael5, L. Dorrell5, T. Hanke1
1University of Oxford, Oxford, United Kingdom (Great Britain); 
2University of Oxford, Human Immunology Unit, Oxford, 
United Kingdom (Great Britain); 3HIV Vaccine Trials Network, 
University of Washington, Seattle, USA; 4Okairos, Rome, Italy; 
5Oxford University, Human Immunology Unit, Oxford, United 
Kingdom (Great Britain)
Background: The major challenge facing both antibody and T 
cell-eliciting vaccines against HIV-1 is the extreme variability of 
the HIV-1 genome: a successful vaccine has to effectively target 
diverse HIV-1 strains circulating in the population and then must 
deal with ongoing virus escape in infected individuals. To address 
these issues, we assembled a vaccine immunogen HIVconsv from 
the functionally most conserved regions (not epitopes) of the 
HIV-1 proteome. 
Methods: A gene coding for the HIVconsv immunogen was 
inserted into plasmid DNA (D), modified vaccinia virus Ankara 
(MVA; M) and non-replicating adenovirus of a chimpanzee origin 
ChAdV-63 (C). Currently, combined heterologous prime-boost 
regimens of these vaccines, namely CM, DDDCM and DDDMC, 
are being evaluated in a phase I/IIa trial HIV-CORE002 in healthy 
HIV-1/2-negative volunteers in Oxford
Results: Preliminary data indicate that the vaccines are well 
tolerated and show high immunogenicity. Following the CM 
regimen, vaccine-induced T cell frequencies reached a median 
of 5150 (range 1475 to 16495) SFU/106 PMBC ex vivo one week 
post MVA vaccination. DNA priming increased subsequent T cell 
responses to ChAdV-63 vaccination (median: C 577 and DDDC 
1328 SFU/106 PBMC) and ELISpot responses again peaked 1 week 
following MVA (median 4500; range 2260-7960 SFU/106 PBMC). 
Matrix analyses of the participants following CM vaccination 
showed that T cells responded to a range of peptides across 
the length of HIVconsv. The CM regimen elicited IFN-γ in both 
CD4+ and CD8+ T cell subsets and polyfunctional (IFN-γ & TNF-α) 
responses to HIVconsv peptides. 
Conclusion: Presented data will be very much work in progress. 
Nevetheless, the HIVconsv vaccines have so far induced T cell 
responses superior to other HIV-1 vaccine candidates tested to 
date. ChAdV-63 is the first adenovirus of chimp origin delivering 
an HIV-1-derived immunogen that has reached the clinic.
The work is supported by Medical Research Council UK.
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P04.14
A New Method for Integrated Analysis Applied 
to Gene Expression and Cytokines Secretion 
in Response to LIPO-5 Vaccine in HIV-Negative 
Volunteers
R. Thiebaut1, B. Liquet1, H. Hocini1, S. Hue1, L. Richert1,  
M. Raimbault1, K. Lê Cao1, Y. Levy1
1INSERM U897, Bordeaux, France
Background: We present an integrated analysis of gene 
expression and cytokine secretion using a novel statistical 
method applied to the ANRS VAC18 trial.
Methods: The statistical approach combines multilevel and 
multivariate analyses. The statistical approach is based on a 
variance decomposition followed by a sparse Partial Least Square 
Discriminant Analysis (sPLS-DA) to select the discriminative 
features (genes, cytokines) separating the classes in a supervised 
framework, or sPLS to select subsets of correlated features 
(genes and cytokines) in an integrative framework.
HIV-LIPO-5 vaccine is a mix of five synthetic HIV-1 peptides 
(from Gag, Pol, Nef), each coupled to a palmytoil tail. PBMCs 
from 12 HIV-negative volunteers were collected before (W0) 
and after vaccination (W14). PBMC were stimulated with either 
i) the HIV-LIPO-5 vaccine; or ii) a pool of 15-mer Gag peptides 
included in the HIV-LIPO-5 vaccine (Gag+); or iii) a pool of 15-mer 
peptides not included in LIPO-5 vaccine (Gag-). Production of 10 
cytokines was assessed at day 11 (MILLIPLEX MAP kit, Millipore). 
Gene transcription in PBMC was assessed after 6- and 24-hour 
stimulations (Illumina Human HT12-v4 chips).
Results: After vaccination, the multilevel discriminant analysis 
led to the selection of 290 genes over three components that 
gave a good separation of the four groups of stimulation. The first 
component that distinguished LIPO5 stimulation from the others 
included a cluster of genes belonging to the metallothionein 
family (MT1M, MT2A,…) possibly linked to the effect of the 
palmytoil tail. The second component separated Gag+ from 
other stimulations. The multilevel sPLS showed similar profiles of 
correlations between gene expression and cytokine secretion for 
TH2 (IL5 and IL13), IL21 and IL1b, TNF and IL6.
Conclusion: This new statistical approach helps in analyzing 
complex designs. In VAC18, it revealed the differential responses 
to vaccine peptides and the lipid adjuvant. Gene expression 
signatures associated with cytokine responses were identified.
P04.13
New HIV Peptide-Based Immunoassay Resolves 
Vaccine-Induced Seropositivity in HIV Vaccine (Phase 
III) Trial Participants
O. Penezina1, D. Clapham1, J. Collins1, V. Kovalenko1, N. Krueger1, 
I.R. Rodriguez-Chavez2, M.P. Busch3, A.E. Levin1
1Immunetics, Boston, MA, USA; 2NIH/NIDCR, Bethesda, MD, 
USA; 3Blood Systems Research Institute, San Francisco, CA, 
USA
Background: HIV Vaccine trials bring the significant risk of 
vaccine-induced HIV seropositivity(VISP) resulting in negative 
personal consequences for vaccinees. The overall rate of VISP 
in licensed EIA tests is reported as 41.7%(JAMA 2010;304:275-
283). We have developed and modified the peptide-based HIV 
Selectest immunoassay(J.Virol 2006;80:2092-2099), which 
discriminates VISP from true HIV infection, in a format suitable 
for routine laboratory use, and have evaluated its performance 
on samples from three Phase III HIV vaccine trials.
Methods: The HIV Selectest incorporated five synthetic peptides 
in a single well microplate ELISA. Serum panels evaluated 
comprised well-characterized HIV-positive sera from clades A,B 
and C, worldwide panels comprising all major clades, blood 
donor controls, and sera from vaccine and placebo recipients in 
RV144, Vax003 and Vax004 trials.
Results: 360 serum samples from the RV144 vaccine trial, 
including 170 samples from vaccinated subjects at the peak 
immune response, 120 pre-immune samples, and 70 subjects 
from the placebo group were tested on the HIV Selectest. One 
(1) subject(0.6%) among the vaccine recipient group yielded 
false-positive results, while 3 placebo recipients (4.3%) and 
1 pre-immune serum sample (0.8%) were also false positive 
in the HIV Selectest. All false-positive samples demonstrated 
broad non-specific cross-reactivity that was not restricted to a 
particular HIV-specific peptide.
Similar results were obtained with samples from the VAX003 and 
VAX004 vaccine trials. One subject out of 87(1.2%) tested after 
the final vaccination(7thvisit) at the peak of the immune response 
was detected as false positive. Two additional samples out of 
96(2.1%) taken after the 4thvisit were likewise detected as false-
positive, bringing the average false-positive rate for both groups 
to 1.6%.
Blood donors yielded a statistically equivalent false-positive rate 
of 1.2%. Detection sensitivity for HIV positive samples was 96% 
among 648 serum samples representing different clades.
Conclusion: The HIV Selectest ELISA has demonstrated 
significantly better discrimination of VISP than currently licensed 
HIV serologic assays.
Topic 4:  Clinical Vaccine Trials and Trial Site Challenges
156
Posters
PO
STERS
AIDS Vaccine 2012
P04.16
Feasibility of Recruiting High-Risk Women in the US 
for HIV Vaccine Efficacy Trials (HVTN 906)
B. Koblin1, B. Metch2, C. Morgan3, R. Novak4, E. Swann5,  
D. Metzger6, D. Lucy1, D. Dunbar6, P. Graham4, T. Madenwald3, 
G. Escamia2, I. Frank6
1New York Blood Center, New York, NY, USA; 2SCHARP / Fred 
Hutchinson Cancer Research Center, Seattle, WA, USA; 3HIV 
Vaccine Trials Network / Fred Hutchinson Cancer Research 
Center, Seattle, WA, USA; 4University of Illinois at Chicago, 
Chicago, IL, USA; 5Division of AIDS, NIAID, NIH, Bethesda, MD, 
USA; 6University of Pennsylvania, Philadelphia, PA, USA
Background: Identifying women in the US with sufficient risk of 
HIV infection for inclusion in HIV vaccine efficacy trials has been 
challenging. Using geography and sexual network characteristics 
to inform new recruitment strategies, HVTN 906 determined 
the feasibility of recruiting and retaining women at high risk and 
assessed HIV incidence.
Methods: HIV uninfected women were enrolled in Chicago, New 
York City and Philadelphia if they were 18-45 years, not pregnant 
or intending to become pregnant for 18 months and reported 
unprotected vaginal/anal sex in the prior six months and either 
i) resided or engaged in risk behavior in local geographical HIV 
risk pockets; and/or ii) had a male partner who had either been 
incarcerated or injected drugs in the last year or had concurrent 
sex with another partner in the last six months. Behavioral risk 
assessment, risk reduction counseling, HIV and pregnancy testing 
were done at baseline, 6, 12 and 18 months.
Results: Among 799 women, 71% were from local high-risk pockets 
and had high-risk male partners, 18% were from local high-risk 
pockets only and 10% had high-risk male partners only. Median 
age was 37 years; 79% were Black and 15% Latina. At baseline, 
the median number of male partners was 3 (25%,75%: 2,7), 76% 
had unprotected sex while intoxicated (alcohol or drugs), and 
52% exchanged sex for money or drugs. Retention at 18-months 
was 80%. Pregnancy incidence was 11% with 48% of pregnancies 
occurring during the first 6 months of follow-up. HIV incidence 
was 0.31% (95% CI: 0.06,0.91). Risk behaviors decreased between 
screening and 6 months with little change thereafter.
Conclusion: Women recruited using new strategies based on 
geography and sexual network characteristics did not have 
a substantial HIV incidence, despite baseline levels of risk 
behaviors. New strategies to identify women at high risk in the 
US are needed.
P04.15
Uptake and Tolerability of Repeated Mucosal 
Specimen Collection In Two Phase 1 AIDS Preventive 
Vaccine Trials In Kenya
G. Mutua1, G. Omosa-Manyonyi1, H. Park2, P. Bergin3,  
D. Laufer2, P.N. Amornkul2, J. Lehrman2, P. Fast2, J. Gilmour3,  
O. Anzala1, B. Farah1
1Kenya AIDS Vaccine Initiative, Nairobi, Kenya; 2International 
AIDS Vaccine Initiative, New York, NY, USA; 3International AIDS 
Vaccine Initiative Human Immunology Laboratory, London, 
United Kingdom (Great Britain)
Background: Mucosal specimens are useful to evaluate local 
immune responses in AIDS preventive vaccine trials, but the 
acceptability and tolerability of mucosal sampling in Africa 
remains unknown.
Methods: The Kenya AIDS Vaccine Initiative (KAVI) initiated two 
AIDS preventive vaccine trials in Nairobi in 2011. After informed 
consent for a mucosal substudy, participants were asked to 
provide any of several types of mucosal secretions: saliva, oral 
fluids, semen, cervico-vaginal and rectal. Specimens were 
collected at baseline, one month after final vaccination, and at 
the next scheduled trial visit. A tolerability questionnaire was 
administered at the final visit.
Results: Of 80 trial participants, 65(81.3%) consented to 
the mucosal sub-study and provided at least one specimen, 
7/65(10.8%) gave all specimens at least once and 2/65(3.1%) 
gave all possible specimens at all visits. Saliva and oral fluids 
were given at all time-points by 62/65(95.4%) participants. Of 48 
men, 21(43.8%) provided semen at baseline, 18/21 completed 
all 3 time-points. Of 17 women, 15(88.2%) gave vaginal sponge 
and SoftCup specimens at least once; 8/15(53.3%) gave both at 
all eligible time-points. Rectal sampling was the least acceptable 
method: 13/65(20%) participants agreed at baseline [4/17 
women (23.5%), 9/48 men (18.8%)]. Of these, 4 men and 2 
women gave samples at all time-points. The most common reason 
for accepting mucosal sampling was a desire to contribute to HIV 
research and for refusal, embarrassment/emotional discomfort. 
Conclusion: Repeated saliva, oral fluid, semen and cervico-vaginal 
mucosal sampling in AIDS vaccine preventive trials in Kenya is 
feasible; this study however re-affirms the challenge of repeated 
rectal mucosal sampling in low-risk participants, noted in an 
earlier observational study at KAVI (AIDS Vaccine 2010 P10.07). 
Possible explanations include cultural and religious reasons 
contributing to embarrassment and emotional discomfort in low-
risk participants. Including more qualitative research in vaccine 
trials with mucosal sampling could help elucidate these findings.
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P04.18
Experience in Recruiting Youths in HIV Vaccine Trials 
in Tanzania: The TaMoVac 01 Study
T. Massawa1, A. Swalehe1, D. Niima1
1Muhimbili University of Health and Allied Sciences, Dar es 
Salaam, United Republic of Tanzania
Background: Muhimbili University of Health Allied Science has 
been conducting HIV Vaccine trials since 2007. The first trial the 
HIVIS 03 study began in February 2007 that recruited Police. We 
believe that the population to be prevented from HIV would be 
youths. We describe our experice in recruiting youths
Methods: Sensitization meetings were conducted at the youth 
clinic.Pre screening workshops were conducted at Muhimbili 
National Hospital. Youths who showed interest in volunteering 
were asked to come for screening at the clinic located at 
Muhimbili National Hospital.
Results: Enrolment of youth volunteers in the study was not a 
problem. Among 60 volunteers recruited 25 were youths. We 
recruited 5 males and 20 females who were recruited over 1 
year. There were challenges encountered in recruiting youths. 
These included inability for independent decision to join the 
trail though we noted that the parents were supportive after 
being well informed. 4/25 youths relocated in search for jobs 
this resulted in additional costs to call in the volunteer for safety 
assessments. 2/25 female youths became pregnant during the 
study period. 
Conclusion: We noted that it was easy to recruit youths in the 
trial after the parents were well informed. However, there is need 
for continuous education so as to address pregnancy prevention.
P04.17
Pattern of HIV Risk Behavior in a Cohort of High Risk 
Women in East Africa 
H.N. Kibuuka1, K. Rono2, L. Maganga3, M. Millard1, A. Sekiziyivu1, 
L. Maboko3, D. Shaffer2, A. Valenzuela4, N. Michael4, M. Robb4
1Makerere University-Walter Reed Project, Kampala, Uganda; 
2Walter Reed Project, Kericho, Kenya; 3Mbeya Medical 
Research Program, Mbeya, United Republic of Tanzania; 4US 
Military HIV Research Program, Bethesda, MD, USA
Background: Development of high risk cohorts is critical for 
advanced HIV vaccine testing. Prevention interventions during 
follow up of such cohorts could influence the pattern of risk 
behavior leading to unmet study outcomes. We examined risk 
behaviors among high risk women enrolled in a prospective 
cohort to determine changes over time. 
Methods: Adult women self identified as sex workers or bar 
workers were enrolled in an open cohort at three sites in East 
Africa. HIV risk factors were assessed at baseline and every 
six months for 1½ years, using Audio Computer Assisted Self 
Interview (ACASI). Participants were also evaluated twice 
weekly to identify HIV infection. HIV counseling was done every 
3 months and when required during twice weekly visits. Male 
condoms were made available at all visits. Data was analyzed 
using Fisher’s exact test. 
Results: Data is available for 1158 HIV negative participants at 
baseline and 771(66.6%), 537 (46.4%), 403 (34.8 %) participants 
at 6, 12 and18 months respectively and 37 acute HIV infections. 
Overall, the risk status of Tanzania women was lower compared 
to Kenya and Uganda. There was a significant drop in proportion 
of participants reporting sex with ≥ 3 Non-spouse/Non-
cohabitating male partners and sex with high risk partners at 6 
months (25.3%, 39.0%) compared to baseline (55.4 %, 62.0%)( p< 
0.0001, <0.0001 ) but no decline subsequently. Most participants 
(76.8%) used alcohol during sex with male partners at baseline 
and throughout the study (73.3%, 72.8%, and 72.9% at 6, 12 and 
18 months). There was a significant increase in proportion of 
participants using condoms at 6 months in Tanzania (p<0.006). 
Incidence rates were 3.3, 2.7 and 1.5 per 100PYs during 0-6, >6-
12 and >12-18 months. 
Conclusion: HIV prevention interventions among high risk 
individuals may result in significant decreases in risky behavior 
that could have implications for future trials
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P04.20
A Dose-Escalation Clinical Trial to Evaluate the Safety 
and Immunogenicity of a Replication-Defective HIV-1 
Vaccine-HIVAX
F. Tung1, J. Tung1, M. Fischl2
1GeneCure Biotechnologies, Norcross, GA, USA; 2University of 
Miami, Miami, FL, USA
Background: Replication-defective SIV elicited protective 
immunity in animals. In this first-in-human therapeutic 
vaccination study, a replication-defective HIV-1 vaccine was 
tested in HIV-1 infected subjects under antiretroviral therapy.
Methods: A010 is an ongoing randomized, placebo-controlled 
dose-escalation clinical trial to evaluate the safety and the 
immunogenicity of two doses of a replication defective HIV-
1 vaccine (HIVAX™) in subjects receiving stable highly active 
antiretroviral therapy (HAART) who have an HIV-1 RNA <50 
copies/ml and CD4 cell count >500 cells/mm3. Following the 
randomized placebo-controlled vaccination phase subjects who 
received active vaccine and who meet eligibility will undergo a 
12-week analytical antiretroviral treatment interruption. 
Results: HIVAX™ is well tolerated in HIV infected subjects. Only 
mild injection site reaction occurred with transient duration. 
No medical treatment is necessary. High level of cell-mediated 
immune responses measured by ELISPOT assay was noticed 
after vaccination. 
Conclusion: The replication defective HIV vaccine appears no 
severe adverse effect in HIV-1 infected subjects. High level of 
cell-mediated immune response was elicited in the vaccinees. 
HIVAX™ is worth for further evaluation of protective efficacy. 
P04.19
Tolerability and Acceptability of Electroporation 
During a Phase 1 Vaccine Trial at Two Sites in Uganda 
and Rwanda
J. Mpendo1, R. Bayingana2, A. Nanvubya1, E. Karita2,  
A. Ssetaala1, N. Kiwanuka1, J. Lehrman3, C. Schmidt4,  
D. Hannaman5, S. Allen2, P. Fast3
1UVRI-IAVI HIV Vaccine Program, Entebbe, Uganda; 2PSF, 
Kigali, Rwanda; 3International AIDS Vaccine Initiative, NY, USA; 
4Interantional AIDS Vaccine Initiative, NY, USA; 5Ichor Medical 
Systems, CA, USA
Background: DNA vaccines are weakly immunogenic in 
humans and one way of increasing their immunogenicity is by 
administering the vaccines using electroporation (EP). This 
technique increases the uptake of the DNA into the cell by 
producing an electrical field which makes the cellular membrane 
more permeable. In the ongoing trial, we are using the ICHOR 
TriGrid Delivery system (TDS-IM) to administer bilateral injections 
of an HIV pDNA vaccine by EP into the medial deltoid muscles. 
Methods: We assessed the acceptability and tolerability of 
Electroporation among 37 volunteers who received two injections 
by EP/IM at their first vaccination time point by administering a 
questionnaire after the procedure. Tolerability was assessed at 4 
time points: i) before the vaccine was injected, ii) at the time of 
electrical stimulation, iii) 10 minutes and iv) 30 minutes after the 
procedure. The pain was graded as none, light, uncomfortable, 
intense, severe or very severe.
We also sought their opinion on acceptability of the procedure as 
a method of vaccine administration.
Results: Of the 37 volunteers, 45.9% felt no pain at time before 
vaccine was injected. At time of electrical stimulation, 59.5% felt 
light pain, 29.7 felt uncomfortable and 10.8% felt intense pain. 
Ten minutes after the procedure, 56.8% felt light pain, 29.7 felt 
uncomfortable and 13.5% felt no pain. Thirty minutes after 
procedure, 70.3% felt light pain, 13.5% felt uncomfortable and 
2.7% felt intense pain but this was associated with multiple device 
applications to the site prior to achieving administration. Majority 
of the volunteers (94.6%) thought that vaccination by EP would be 
acceptable if the vaccine protected people from acquiring HIV and 
contributed to scientific knowledge on vaccine administration.
Conclusion: Electroporation among African volunteers in this 
trial is tolerable and acceptable. EP may be considered in future 
for the administration of HIV vaccines.
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P04.22
Developing Community Advisory Board Guidelines 
for AIDS Vaccine Trials in China
J.A. Kaufman1, C. Liu2, A. Menezes3
1Harvard Medical School, Boston, MA, USA; 2Chinese Academy 
of Medical Sciences, Beijing, China; 3Global Health Strategies, 
Rio de Janiero, Brazil
Background: Community Advisory Boards (CABS) have played 
an important role in ensuring community oversight of AIDS 
vaccine trials and are an accepted part of the ethical conduct 
of AIDS vaccine trials. China’s political system limits community 
engagement in trial communities and wholesale application of 
western CAB approaches does not accomplish the intent of a 
CAB. We adapted the CAB concept to China’s political system 
through a multi year process of research and pilot testing 
in collaboration with six provincial CDCs conducting AIDS 
prevention research studies. 
Methods: Using questionnaires developed by IAVI for a global 
CABS study, we carried out an assessment of existing CABS in 
six provinces in China. The questionnaire examined membership, 
process, and governance along with other aspects of CABS 
operations. The results were used to revise standard CABS 
guidelines developed by IAVI for use in Africa and India. The 
revised guidelines were pilot tested in three sites, in Yunnan, 
Guangxi, and Shanxi. In depth interviews were also conducted 
with CAB members and local CDCS. 
Results: A revised version of Chinese CABS guidelines was 
published in October 2011 and publicized at China’s AIDS 
Prevention Conference by China’s AIDS Ethical Review Board and 
IAVI. The CABS guidelines are now being promoted as part of the 
ethical requirements for AIDS prevention clinical trial research by 
China’s National Center for AIDS Prevention and Control.
Conclusion: Developing and adapting ethical tools for ensuring 
community input and oversight of clinical trial research in 
China is necessary given China’s political system. These newly 
adapted CABS guidelines provide a mechanism to accomplish the 
intention of a CAB even while different in form and governance 
from standard CABS elsewhere. 
P04.21
Evaluating Short-Term Patient Outcomes After 
HIV Care Interventions in a Low Resource Setting: 
Preparing for an HIV Vaccine Trial Site in Bamako, Mali
Z. Koty1, A. Bicki1, Y. Koné2, L. Diarra2, K. Tounkara1,  
F. Siby Diallo3, L. Levitz1, B. Aboubacar1, M. Rochas1, S. Dao4, 
A. De Groot5
1GAIA Vaccine Foundation, Bamako, Mali; 2ASACOMSI, Mékin-
Sikoro, Mali; 3Ministry of Health, Bamako, Mali; 4Department 
of Infectious Diseases, University of Bamako, Bamako, Mali; 
5GAIA Vaccine Foundation and the University of Rhode Island, 
Providence, RI, USA
Background: HIV treatment in Mali is constrained by limited 
access to HIV experts. In 2009, GAIA Vaccine Foundation’s “Hope 
Center Clinic” (HCC), a community health center in Mékin-Sikoro, 
became one of the first “front-line” clinics to offer HIV treatment 
in Mali. To assess our HIV prevention strategies and prepare 
for an eventual HIV vaccine trial, we performed a retrospective 
study of ten clinical parameters in patient charts. 
Methods: The charts of 54 patients receiving antiretroviral 
therapy (ART) at HCC between 04/2009-09/2011 (30 months) 
were reviewed. Information on the presence of opportunistic 
infections (OIs), weight changes, CD4 counts, BMI, viral load (VL), 
CD4 T-cell counts, hemoglobin (Hb), alanine aminotransferase, 
leukocyte counts, and platelet counts were tabulated and 
analyzed in Excel.
Results: The mean age of the subjects in the study was 33; 
85% were women, of whom 57% received mother-to-child 
transmission prevention at HCC. 93% had HIV-1; 33% were WHO 
Stage I, 11% Stage 2, 24% Stage 3, and 4% Stage 4. 48 (89%) 
patients improved in at least one parameter. 35 (65%) patients 
gained weight. 28 (70%) patients had increased CD4 counts (74% 
of patients had two counts recorded). 13 (59%) patients had 
decreased VL (41% of patients had two VL recorded). OIs were 
common among subjects (61%) prior to clinical intervention, 
but decreased significantly by months 7-15 to affect only 17% 
of subjects. 
Conclusion: These data affirm that village-level HIV care is both 
feasible and associated with positive patient outcomes. Providing 
care allowed GAIA VF to reinforce the rapport between clinic 
staff and community members and assess clinical interventions 
for HIV-positive patients. Importantly, this develops strategies 
for treatment distribution and adherence monitoring, patient 
follow-up and retention, and study implementation and analysis 
that lay the groundwork for the development of a Phase I-III HIV 
vaccine trial site in this region of Mali.
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HIV Vaccine Trial Safety And Retention Among 18-20 
Year Olds In The HVTN 503/Phambili Study Support 
The Inclusion Of Adolescents In Future Trials
J.E. Volk1, N.A. Hessol2, G.E. Gray3, J.G. Kublin4, G. Churchyard5, 
K. Mlisana6, M. Nchabeleng7, S.P. Buchbinder8, L. Bekker9
1University of California, San Francisco, San Francisco, CA, 
USA; 2Departments of Clinical Pharmacy and of Medicine, 
UCSF, San Francisco, CA, USA; 3Perinatal HIV Research 
Unit, University of Witwatersrand, Johannesburg, South 
Africa; 4HIV Vaccine Trials Network, Fred Hutchinson Cancer 
Research Center, Seattle, WA, USA; 5Aurum Institute for 
Health Research, Klerksdorp, South Africa; 6Department of 
Medical Microbiology, University of KwaZulu-Natal, Congella, 
South Africa; 7Medunsa HIV Clinical Research Unit, University 
of Limpopo, Limpopo, South Africa; 8Department of Public 
Health, HIV Research Section, San Francisco, CA, USA; 9The 
Desmond Tutu HIV Centre, University of Cape Town, Cape 
Town, South Africa
Background: Worldwide, many adolescents, especially women, 
acquire HIV before age 18. Yet to date, no HIV vaccine trials have 
enrolled adolescents. Reasons for excluding adolescents from 
these trials include regulations protecting vulnerable subjects 
and concerns regarding informed consent, social harms, adverse 
events, and loss to follow-up.
Methods: Using data from the HVTN 503/Phambili study, a 
multisite phase 2b double-blind RCT in South Africa, motivations 
for joining the trial, adverse events, social harms, and loss to 
follow-up were compared between young adults (18-20 years-old) 
and adults ≥21 years-old using bivariate and multivariate analyses.
Results: Young adults (n=238) were less likely than older 
participants (n=563) to report joining the vaccine trial for 
monetary incentives (10.5% vs. 16.3%, p<0.05), and no 
differences were seen for altruistic motivations such as the 
desire to help the community (95.4% vs. 93.1%, p=.22) or to 
find an effective vaccine (98.3% vs. 97.0%, p=.34). There was 
no significant difference in social harms by age (3.8% vs. 6.9%, 
p=0.09). No differences were seen between 18-20 year-olds 
and older participants for adverse events that were definitely, 
probably, or possibly related to study product (5.0% vs. 7.8%, 
p=0.16) or for adverse events that required expedited reporting 
to the study sponsor (2.1% vs. 2.5%, p=0.74). Furthermore, loss 
to follow-up did not differ between 18-20 year-olds and older 
participants in either bivariate analysis (21.4% vs. 24.2%, p=.40) 
or in a multivariate model that controlled for both gender and 
study site (OR .95, CI .65-1.38).
Conclusion: Participants who were 18-20 years old were less 
likely to report financial motivations for joining the HVTN 503/
Phambili study and were no more likely to experience adverse 
events, social harms, or loss to follow-up than participants ≥21 
years-old. These data are reassuring and support the safe and 
feasible inclusion of younger adolescents in future HIV vaccine 
efficacy trials.
P04.23 LB 
Screen Failure in Phase I HIV Clinical Trials In Soweto, 
South Africa: An Opportunity For Care
F. Laher1, M. Mamba1, K. Otwombe1, G.E. Gray1
1Perinatal HIV Research Unit, Johannesburg, South Africa
Background: Reasons for screen failures are evaluated for 
three phase 1 HIV vaccine clinical trials recruiting healthy low-
risk participants at the Perinatal HIV Research Unit: SAAVI102/
HVTN073 and SAAVI103/HVTN086 (the first trials evaluating 
a Clade C vaccine, Novartis Subtype C gp140 with MF59 
adjuvant boosting SAAVI DNA-C2 and SAAVI MVA-C vaccine) 
and IAVIB003/HVTN091 (Ad26 and Ad35 ENV vaccines). 
Recruitment strategies involved a pre-screening programme, 
clinics and community outreach.
Methods: Protocol-specific eligibility was determined using 
assessments of understanding, risk behaviour, medical 
history, physical examination, blood and urine testing, and for 
HVTN073 and 086, electrocardiograms. Descriptive analysis and 
multivariate logistic regression of age, trial group and gender 
were performed.
Results: Between June 2009-2012, 225 participants(females=24%), 
median age 22 years(IQR:20-25) were screened. Overall 53% 
were ineligible, 60% of females vs. 51% of males (p=0.2). Site 
screening-to-enrolment ratios for 073, 086 and 091 were 
2.1:1, 2.3:1 and 1.7:1 respectively. Medical abnormalities 
contributed 59% (n=70) of ineligibility reasons, chiefly urine 
abnormalities (n=12/70 where eleven displayed microscopic 
blood/haemoglobin, seven with leucocyte esterase and one had 
proteinuria), abnormal ECG (n=12), raised liver enzymes (n=10), 
raised blood pressure (n=9), low white cells (n=8) and hepatitis 
B (HBsAg+ve) or C (anti HCV+) (n=7). Other criteria excluded 
41%(n=49) e.g. incomplete screening before enrolment closure 
(n=16), high-risk sexual behaviors (n=15), inability to comply with 
protocol (n=11), enrolment in another study (n=3), substance 
abuse (n=2, both cannabis-users), and poor understanding (n=2). 
In multivariate analysis, increasing age (OR 1.081, CI:1.007-1.16, 
p=0.032) predicted ineligibility but gender did not (OR: 0.67, CI: 
0.35-1.3, p=0.24). HVTN073&086 participants were more likely 
to be ineligible than HVTN091 (OR 2.2, CI:1.1-4.5, p=0.023).
Conclusion: Screen failures in phase 1 vaccine trials in Soweto 
provide young people opportunities for care, especially through 
blood pressure, urine, risk behaviour and hepatitis B/C screening. 
Older participants and those in protocols stipulating ECG criteria 
were more likely to fail screening.
Topic 4:  Clinical Vaccine Trials and Trial Site Challenges
PO
ST
ER
S
161
Posters
AIDS Vaccine 2012
P04.26 LB 
DNA Plasmid HIV Vaccine Design, Number Of Doses, 
Participant Gender, And Body Mass Index Affect 
T-Cell Responses Across HIV Vaccine Clinical Trials
C. Morgan1, X. Jin2, X. Yu1, S. De Rosa1, J. Kublin1, B. Metch1,  
M. Keefer2, The NIAID HIV Vaccine Trials Network1
1HIV Vaccine Trials Network / Fred Hutchinson Cancer 
Research Center, Seattle, WA, USA; 2University of Rochester 
Medical Center, Rochester, NY, USA
Background: Numerous studies have evaluated individual DNA 
plasmid vaccines. We evaluated data from 10 HIV vaccine clinical 
trials that utilized common, validated immunogenicity assays 
to objectively investigate factors that influence DNA plasmid-
induced T-cell responses.
Methods: This retrospective analysis included data from 1218 
healthy, HIV-1 uninfected adults enrolled in 10 DNA HIV vaccine 
clinical trials conducted within the HIV Vaccine Trials Network. 
HIV-specific T-cell responses from peripheral blood mononuclear 
cells were measured using validated IFN-γ ELISpot and 
intracellular cytokine staining assays. The effects of DNA vaccine 
HIV antigens, number of doses, gender, body mass index (BMI), 
and age were evaluated.
Results: When plasmids expressing Gag, Env and Pol were co-
administered, the highest T-cell response rate was against Env 
(38.1%) and much less to Gag (4.6%) or Pol (4.5%). Comparing 2, 
3, and 4 DNA injections, 3 vaccinations compared to 2 improved 
the magnitude of Env-specific CD8+ T-cell response (p=0.048), but 
not CD4+ T-cell responses, and a 4th vaccination had no additional 
effect. HIV-specific CD4+ T-cell response rates were higher in 
females (50.9%) than in males (27.7%, p=0.0002). Having lower BMI 
(p=0.025) was independently associated with higher HIV-specific 
CD4+ T-cell response rates. There were no significant differences 
in HIV-specific CD8+ T-cell response frequencies by gender or BMI. 
Lower HIV-specific CD4+ T-cell responses were seen with the 18-
20 (36.4%) and 41-50 (23.3%) age groups compared to the 21-30 
(44.0%) and 31-40 (41.%) groups, but these differences were not 
significant (p=0.0565) and no differences were seen in HIV-specific 
CD8+ T-cell responses by age.
Conclusion: Pooled data across DNA HIV vaccine clinical trials 
indicate that plasmid inserts, number of doses, gender, and BMI 
can affect T-cell responses. These factors should be considered in 
vaccine research.
P04.25 LB 
rAd5/NYVAC-B is Superior to NYVAC-B/rAd5 and is 
Dependent on rAd5 Dose for Neutralizing Antibody 
Responses Against HIV-1
D.C. Montefiori1, Y. Huang2, S. Karuna3, M. Allen4, N. Kochar2,  
S. Chappuis5, J. Gaillard5, G. Tomaras1, B. Graham6, P. Bart5,  
G. Pantaleo5
1Duke University Medical Center, Durham, NC, USA; 2SCHARP, 
Seattle, WA, USA; 3Fred Hutchinson Cancer Research Center/
HVTN, Seattle, WA, USA; 4NIAID-NIH, Bethesda, MD, USA; 
5Lausanne University Hospital, Switzerland; 6Vaccine Research 
Center, NIH, Bethesda, MD, USA
Background: HVTN 078 is a phase 1b clinical trial of heterologous 
vector prime/boost vaccine regimens (NYVAC-B/rAd5 vs. rAd5/
NYVAC-B) in healthy, HIV-1 uninfected, Ad5 seronegative adults. 
The rAd5 expressed a clade B Gag-Pol fusion protein and secreted 
gp140s of HIV-1 strains 92RW020 (clade A), HxB2/Bal-V3/_V1V2 
(clade B) and 97ZA012 (clade C). The NYVAC-B expressed a clade 
B Gag-Pol-Nef polyprotein and the secreted gp120 of Bx08 
(clade B). A total of 80 participants were randomized into a 
placebo group (P) and four treatment groups: T1, 2x NYVAC-B/1x 
rAd5 (1010); T2, 1x rAd5 (108)/2x NYVAC-B; T3, 1x rAd5 (109)/2x 
NYVAC-B; T4, 1x rAd5 (1010)/2x NYVAC-B.
Methods: Binding and neutralizing antibodies were assessed at 2 
weeks post-final boosting. Neutralization was assessed with tier 
1 and tier 2 Env-pseudotyped viruses in TZM-bl cells, and with 
tier 2 Env.IMC.LucR viruses in A3R5 cells.
Results: A dose effect for increasing anti-Env binding antibodies 
was seen, with higher doses of rAd5 being optimal. For neutralizing 
antibodies, positive response rates/median titers across the 
treatment groups were highest against MN.3 (69.3%/116) 
followed by SF162.LS (42.1%/54), BaL.26 (18.4%/15.5), 
MW965.26 (14.5%/31) and Bx08.16 (11.8%/19.5). Five subjects 
neutralized all 5 tier 1 viruses, 5 subjects neutralized 4 viruses, 7 
subjects neutralized 3 viruses, 14 subjects neutralized 2 viruses 
(MN.3 and SF162.LS) and 18 subjects neutralized 1 virus (MN.3). 
Aggregate magnitude-breadth scores across the tier 1 panel 
were strongest for T4 followed by T3, T1 and T2. Differences 
were significant for T1 vs. T3 (p=0.048) and T1 vs. T4 (p=0.004). 
Responses against tier 2 viruses were weak and sporadic in the 
A3R5 assay and were nearly absent in the TZM-bl assay.
Conclusion: A 1010 dose of rAd5 was superior to the two lower 
doses of 109 and 108 for both binding and neutralizing antibodies. 
At the highest rAd5 dose tested, rAd5/NYVAC-B was superior to 
NYVAC-B/rAd5 for neutralizing antibodies.
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A Mixed-Methods Assessment Of Understanding 
(AoU) Tool For AIDS Vaccine Trials In Sub-Saharan 
Africa: Results From A Pilot Study
G. Lindegger1, M. Quayle1, S. Singh2, S. Welsh7, D. Mark3,  
M. Wallace3, S. Roux3, L. Bekker3, L. Mwananyanda4, W. Kilembe4, 
E. Chomba5, S. Allen6, F. Priddy7, P. Fast7
1School of Psychology, University of Kwa-Zulu Natal, 
Pietermaritzburg, South Africa; 2GHAR Consulting Inc, New 
York, NY, USA; 3Desmond Tutu HIV Foundation, University 
of Cape Town, Cape Town, South Africa; 4Zambia-Emory HIV 
Research Project, Lusaka, Zambia; 5Zambia-Emory HIV Reseach 
Project, Lusaka, Zambia; 6Emory University, Atlanta, GA, USA; 
7International AIDS Vaccine Initiative, New York, NY, USA
Background: Assessments of understanding (AoUs) in clinical 
trials are often composed of true/false multiple choice questions, 
however, these tools can be difficult for volunteers with limited 
education or without prior testing experience.
Methods: 35 adults were recruited at two research centers in 
Southern Africa. A within-subjects, repeated measures design 
was used, whereby each volunteer served as his /her own 
control. An AoU tool with closed- and open-ended questions 
was administered within a hypothetical AIDS vaccine trial 
setting. Performance on closed- and open-ended questions was 
compared using correlations and repeated-measure t-tests, 
limited to 4 complex concepts: false sense of security, risk of false 
positive test, need for contraception, and potentially enhanced 
susceptibility.
Results: Mean scores of understanding for each concept 
assessed by closed-ended questions ranged from 0.73 (need for 
contraception) to 0.84 (risk of false positive test); and by open-
ended questions from 0.4 (risk of false positive test) – 0.6 (need 
for contraception). Scores for the open-ended measure were all 
lower than the equivalent closed-ended measure. Correlations 
between the closed- and open-ended measures were generally 
low, achieving significance for false sense of security (r=0.377), 
potentially enhanced susceptibility (r=0.393), and total score 
across concepts (r=0.617). Volunteers’ understanding as assessed 
by the closed- and open-ended methods differed significantly: 
false sense of security= -3.862; risk of false positive test= -7.210; 
need for contraception= -2.303; and potentially enhanced 
susceptibility= -8.007. The correlation with years of education 
was consistently and significantly higher for the open-ended 
measure than the true/false questionnaire with the exception of 
need for contraception.
Conclusion: The results suggest the qualitative measure 
better assesses understanding than the quantitative measure. 
The scores from the two assessment methods have limited 
interchangeability. The standard closed-ended questions appear 
to provide an inflated measure of volunteers’ understanding. An 
assessment tool with closed- and open-ended questions is better 
suited to determine genuine understanding.
P04.27 LB 
First-In-Human Phase I Clinical Trial Of A 
Recombinant Vesicular Stomatitis Virus (rVSV)-Based 
Preventive HIV-1 Vaccine
J.D. Fuchs1, I. Frank2, N. Kochar3, M. Elizaga3, M. Allen4,  
D. Carter3, N. Frahm3, S.A. Kalams5, M. Mulligan6, R. Sheets4, 
M. Pensiero4, D. Clarke7, J. Eldridge7, and the NIAID HIV Vaccine 
Trials Network 
1San Francisco Dept. of Public Health, San Francisco, CA, 
USA; 2University of Pennsylvania, USA; 3Fred Hutchinson 
Cancer Center, USA; 4Division of AIDS, NIH, USA; 5Vanderbilt 
University, USA; 6Emory University, USA; 7Profectus 
Biosciences, USA
Background: Replicating viral vectors are promising HIV 
vaccine candidates that may enhance immunogenicity through 
prolonged antigen expression. VSV is the first replicating viral 
vector after vaccinia to be tested clinically as an HIV vaccine; here 
we present preliminary safety and immunogenicity data from a 
phase 1a trial.
Methods: HVTN 090 enrolled sixty healthy, HIV-1-uninfected 
adults in a randomized, double-blinded, placebo-controlled dose 
escalation study. Groups of 12 participants received rVSV Indiana 
HIV Gag vaccine at 5 dose levels (4.6 x 103 to 3.4 x 107 PFU) (N=10/
group) or placebo (N=2/group), delivered intramuscularly at 0 
and 2 months. Reactogenicity over 7 days, adverse events (AEs), 
and viral cultures from whole blood, urine, saliva and swabs of 
oral lesions were collected. HIV-1-specific CD4+ and CD8+ T-cell 
responses to Gag peptides were measured 1 and 2 weeks post-
boost by intracellular cytokine staining.
Results: The study is ongoing and data are blinded. The median 
age was 24; 47% were female and 37% were non-white. Local 
and systemic reactogenicity was self-limited, mild to moderate in 
intensity and increased with dose, with headache reported most 
commonly (52%). At the highest dose, 92% reported systemic 
symptoms, including flu-like syndrome (41%), fever (41%), and 
moderate chills (33%). Lymphadenopathy, decreased neutrophil 
count, oral ulceration, and presyncope were each seen in > 1 
participant. No severe reactogenicity, encephalitis, or product-
related SAEs were reported, and all VSV cultures were negative 
at all doses tested. Low frequency HIV-specific CD4+ (9%) and 
CD8+ (3%) T-cell responses were detected post-boost at the first 
3 dose levels.
Conclusion: Immunization with an attenuated, replicating rVSV 
Indiana HIV-1 vaccine has an acceptable reactogencity and safety 
profile to date. Preliminary data reveal few T-cell responses at 
lower doses. Immunogenicity of the vaccine at the highest doses 
and in heterologous prime-boost regimens will guide future 
vector development.
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Rapid Development of Cross-Clade Neutralizing 
Antibody Responses After Clade B gp120/gp140 
Protein Priming And Clade C gp140 Protein Boosting
P. Spearman1, G. Tomaras2, D. Montefiori2, Y. Huang3,  
H. Ahmed3, M. Elizaga3, J. Hural3, J. McElrath3, L. Ouedraogo4, 
M. Pensiero4, C. Butler4, S. Kalams5, E.T. Overton6, S. Barnett7, 
N. Group1
1Emory University, Atlanta, GA, USA; 2Department of Surgery, 
Duke Human Vaccine Institute, Durham, NC, USA; 3Fred 
Hutchinson Cancer Research Center, Seattle, WA, USA; 
4Division of AIDS, NIAID, NIH, Bethesda, MD, USA; 5Vanderbilt 
University School of Medicine, Nashville, TN, USA; 6University 
of Alabama at Birmingham, Birmingham, AL, USA; 7Novartis 
Vaccines and Diagnostics, Cambridge, MA, USA
Background: Immunization with heterologous Env protein 
immunogens following an immunologic rest period has 
the potential to generate cross-clade neutralizing antibody 
responses. We identified individuals who had received a clade 
B Env protein with MF59 4-17 years earlier, most in combination 
with a DNA or ALVAC prime, and administered a clade C protein 
boost in an open label phase 1 trial.
Methods: Sixteen previously primed volunteers and 20 naïve 
volunteers each received 2 doses of a clade C TV1 trimeric Env 
protein with MF59 given 6 months apart. HIV-1 specific CD4+ and 
CD8+ T cell responses were measured by an intracellular cytokine 
staining (ICS) assay. Antibody responses were measured with 
a Luminex binding antibody assay and a neutralizing antibody 
assay in TZM-bl Cells. 
Results: Despite the long interval, 31% of primed participants 
demonstrated CD4+ T cell responses to Env at baseline, which 
increased to 75% after a single protein boost. IgG and IgA 
responses to TV1 trimeric Env were present in 64% (IgG) and 7% 
(IgA) of primed participants at baseline, and rose to 93% and 85%, 
respectively, after one dose of protein. 71% of primed participants 
demonstrated neutralizing antibodies against Tier 1 clade B isolate 
MN at baseline. After a single booster dose of protein, 100% of the 
primed participants neutralized MN and 93% showed neutralizing 
activity against a clade C isolate, MW965.26. Unprimed participants 
did not demonstrate CD4+ responses or antibody responses to Env 
until after the second dose, which elicited IgG and IgA responses 
to TV1 trimeric Env in 88% and 50%, respectively. Neutralizing 
antibody developed to MN in 38% and to MW965.26 in 88% of the 
unprimed participants.
Conclusion: These results demonstrate the durability of vaccine-
elicited HIV-1 specific antibody responses and support current 
efforts to enhance the breadth and magnitude of neutralizing 
antibodies through heterologous protein prime-boost regimens. 
P04.29 LB 
DNA And Recombinant Adenovirus Serotype 35 And 
5 Preventive HIV-1 Vaccines With Env A Inserts Elicit 
Cross-Clade Binding And V1V2 Antibodies
J.D. Fuchs1, C. Morgan2, P. Bart3, N. Kochar2, N. Frahm2,  
E. Swann4, P. Gilbert2, S. DeRosa2, B. Graham5, G. Nabel5,  
H. Liao6, B. Haynes6, G. Tomaras6, and the NIAID HIV Vaccine 
Trials Network
1San Francisco Dept. of Public Health, San Francisco, CA, USA; 
2Fred Hutchinson Cancer Center, USA; 3Centre Hospitalier 
Universitaire Vaudois, Switzerland; 4Division of AIDS, NIH, USA; 
5Vaccine Research Center, NIH, USA; 6Duke University, USA
Background: We previously reported that combinations of 
DNA, recombinant adenovirus serotype 5 (rAd5) and 35 (rAd35) 
HIV-1 vaccines with clade A Env inserts elicit strong T-cell 
responses. Here we investigate their ability to induce cross-
clade IgG binding antibody (bAb) responses. Based on recent 
evidence that Ab to the V1V2 loop in Env were correlated with 
reduced risk of HIV infection in the RV144 efficacy trial, we also 
evaluated those responses.
Methods: HVTN 077 was a placebo-controlled, double-
blinded trial that randomized 192 healthy, HIV-uninfected, 
Ad35 neutralizing antibody (nAb) seronegative participants 
into placebo (n=28) and 4 vaccine groups: rAd35/rAd5 (T1, 
n=34), DNA/rAd5 (T2, n=48), and DNA/rAd35 (T3, n=48) -- in 
persons seronegative for Ad5 nAb; and DNA/rAd35 (T4, n=34) 
seropositive for Ad5 nAb. Vaccines were given at 0,6 months (T1) 
and 0,1,2, and 6 months (T2-4). IgG bAb responses by multiplex 
assay against Group M Consensus (Con S), clade A (00MSA 
4076), clade B (B.con.env03), and clade C (C.con.env03) gp140 
and novel gp70 V1V2 scaffolds, V1V2 VRC A and V1V2 (Case A2), 
were measured 4 weeks post boost.
Results: High frequency responses were elicited against clade 
A (T1 95.8%, T2 100%, T3 97.4%, T4 100%), clade B (T1 95.8%, 
T2 95.0%, T3 92.1%, T4 96.3%), clade C (T1 92%, T2 76%, T3 
76%, T4 78%), and Con S (T1-4 100%). There were no significant 
between-group differences in response frequency or magnitude. 
The majority also had responses to V1V2 clade A (T1 100%, T2 
87.8%, T3 83.8%, T4 85.2%) and clade B (T1 58.3%, T2 65.9%, T3 
54.1%, T4 51.9%). The mean fluorescent intensity was higher in 
T2 vs T1 (p=0.005) for clade A V1V2. No significant differences 
were observed between other groups.
Conclusion: All vaccine regimens tested elicited cross-clade 
bAb responses, including those that target V1V2. rAd-based 
HIV-1 vaccines, particularly using rare serotypes, warrant 
further development.
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A New Transmission Map of HIV-1 CRF07_BC in 
China: Analysis of Sequences from 12 Provinces over 
a Decade
M. Zhefeng1, L. Jingyun2, Z. Ping3, X. Jianqing1, Z. Xiaoyan1
1Shanghai Public Health Clinical Center, Shanghai, China; 
2Academy of Military Medical Science, Beijing, China; 
3Shanghai Municipal Centers for Disease Control and 
Prevention, Shanghai, China
Background: HIV-1 CRF07_BC descended from subtypes B’ and 
C represents one of the most prevalent HIV-1 strains in Asia and 
has been devastating in IDUs for more than a decade in China. 
Recently, several groups made their effort to address its origin 
and migration pattern, and had generated several enlightening 
conclusions, however, the limited available sequences may have 
restrained the precise depiction of global migration pattern of 
CRF07_BC. In this study, epidemic evidences and sequences 
analysis was combined to investigate the transmission linkages 
among 12 CRF07_BC epidemic regions in China and their 
tMRCA(time of most recently common ancestor).
Methods: 138 of 769 sequences covered 12 provinces (including 
newly generated 45 sequences) was identified as independent 
sequences and used for subsequent phylogeographic tree 
analysis, Bayes Factor test. Almost all Chinese literatures on early 
HIV-1 epidemic history are reviewed to confirm the results of 
sequences analysis. 
Results: The initial transmission occurred in Guangxi (eastern 
neighbor to Yunnan) in 1994 and Xinjiang (northwest) in 1995 
and Sichuan (northern neighbor to Yunnan) in 1996 after 
CRF07_BC generated in Yunnan around 1993. The subsequent 
transmissions occurred from Yunnan to Liaoning (northeast) in 
1997 and Jiangsu in 1998. Interestingly, after the initial epidemic 
regions, including Guangxi, Xinjiang and Sichuan, served as 
secondary epicenters for further spreading, triggered further 
transmission into Gansu, Ningxia, Qinghai, Beijing and Hunan 
during 1999-2001. These analyzed results are in accordance with 
early epidemic investigations of HIV-1. 
Conclusion: Our data indicated that both the origin site and 
secondary epicenters played important roles in the dynamic 
migration of CRF07_BC in China, and both drug traffic and 
population migration (which largely occurred from west to 
east and from other regions to capital city during last two 
decades) may have significantly contributed to the complicated 
transmission pattern of CRF07_BC.
P05.01
Rising Epidemic of HIV-1 Infections Among General 
Populations in Fujian, China
H. Wang1, X. Yao2, P. Yan3, Z. Chen1
1AIDS Institute, LKS Faculty of Medicine, The University of 
Hong Kong, hongkong, Hong Kong; 2Fuzhou Center for Disease 
Control and Prevention, Fuzhou, China; 3Fujian Center for 
Disease Control and Prevention, Fuzhou, China
Background: Monitoring HIV transmission and viral diversity has 
significant impacts on guiding effective vaccine development. 
Until now, few large-scale studies have investigated HIV infections 
among the general populations of China.
Methods: 915,830 and 2,152,658 blood samples from various 
groups were collected in 2006-2007 and 2008-2009, respectively, 
in Fujian, a low prevalent region in China. Comprehensive HIV-1 
epidemiology and molecular epidemiology studies were conducted.
Results: Our data revealed a significant rise of the overall 
prevalence of infections within a short time period, from 0.064% 
in 2006-2007 to 0.074% in 2008-2009 (p=0.003), which resulted 
in the double numbers of infections from 528 in 2006-2007 
to 1129 in 2008-2009. Critically, the prevalence rate among 
general populations such as voluntary blood donors, recipients 
of blood transfusion and people during pre-surgery screening 
had significantly increased in recent years (p<0.001). Besides 
CRF01_AE as the dominant circulating subtype (61/86, 70.9%), 
25 non-CRF01_AE strains were found contributing to increased 
HIV-1 genetic diversity including C/CRF07_BC/CRF08_BC (5.8%), 
B/B’ (15.1%) and unique recombinant forms (8.1%). More than 
30% (26/81) of subjects were found to contain various drug-
resistant mutations.
Conclusion: The rising epidemic in recent years in Fujian is likely 
due to the increased prevalence of HIV-1 infections among general 
populations and multiple viral subtypes circulating. Our findings 
will be useful for helping to enhance the current surveillance 
system and to generate strategic prevention programs targeting 
general populations in China. Moreover, these results also have 
implications for AIDS vaccine research. 
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The Efficiency of Bridging Sheet Recruitment 
Determines HIV-1 R5 Envelope Sensitivity to Soluble 
CD4 and Macrophage Tropism
O. O’Connell6, A. Repik6, J.D. Reeves1, M.P. Gonzalez-Perez6,  
B. Quitadamo6, M. Duenas-Decamp6, P. Peters6, R. Lin2,  
E.D. Anton1, S. Zolla-Pazner3, D. Corti4, A. Wallace6, S. Wang6, 
X. Kong5, S. Lu6, P.R. Clapham6
1Monogram Biosciences, San Francisco, CA, USA; 2University 
of Massachusetts, Amherst, MA, USA; 3New York University 
Langone School of Medicine, New York, NY, USA; 4Humabs 
Biomed SA, Bellinzona, Switzerland; 5New York University 
School of Medicine, New York, NY, USA; 6University of 
Massachusetts Medical School, Worcester, MA, USA
Background: HIV-1 R5 viruses vary extensively in their capacity 
to infect macrophages. R5 viruses that confer efficient infection 
of macrophages are able to exploit low levels of CD4 for infection 
and they predominate in brain tissue where macrophages are a 
major target for infection. HIV-1 R5 variants that are transmitted 
are generally non-macrophage-tropic. Here, we investigated the 
sensitivity of macrophage-tropic and non-macrophage-tropic R5 
envelopes to neutralizing antibodies. 
Methods: Env+ pseudovirion neutralization assays were carried 
out using HeLa TZM-bl cells. Envelope capture ELISAs assessed 
monoclonal antibody binding to monomeric gp120. 
Results: We observed striking differences in the sensitivity of 
Env+ pseudovirions to soluble CD4 compared to neutralizing 
monoclonal antibodies that target the CD4 binding site. 
Macrophage-tropic R5 envelopes were sensitive to sCD4, while 
non-macrophage-tropic envelopes were significantly more 
resistant. In contrast, all envelopes were sensitive to VRC01 
regardless of tropism, while mab b12 conferred an intermediate 
neutralization pattern with all the macrophage-tropic and about 
half of the non-macrophage-tropic envelopes sensitive. 
Conclusion: CD4, b12 and VRC01 share binding specificities on the 
outer domain of gp120. However, these reagents differ in their 
ability to induce conformational changes on the trimeric envelope 
and in specificity for residues on the V1V2 loop stem and β20-21 
junction that are targets for CD4 in recruiting the bridging sheet. 
These different binding specificities of CD4, b12 and VRC01 likely 
explain the striking differences in envelope sensitivity to inhibition 
by these reagents. However, they also provide an insight into the 
envelope mechanisms that control macrophage-tropism. We 
present a model where the efficiency of bridging sheet recruitment 
by CD4 is a major determinant of HIV-1 R5 envelope sensitivity to 
soluble CD4 and macrophage tropism.
P05.03
Low Selection Rate of HLA-Anchor Escape Mutations 
in HIV After Transmission of Subtype B and 
Recombinants BF Strains Patients from Argentina
G. Damilano1, E. Socias2, C. Magneres2, G. Turk1, M. Gomez-
Carrillo1, H. Salomon1, D. Dilernia1
1Argentinean Reference Center for AIDS, Buenos Aires, 
Argentina; 2HUESPED Foundation, Buenos Aires, Argentina
Background: The immune response of HIV-infected individuals 
shapes the evolution of the virus by selecting escape mutation. 
After transmission to a new host, the HLA-mediated immune 
pressure changes. The objective of our study was to characterize 
the dynamics of HLA-anchor escape mutations after transmission.
Methods: We studied 6 transmission events between members 
of serodiscordant couples collecting blood samples from the 
donor and the previously seronegative-partner at the moment 
of seroconversion, and a second sample at least 6 months post-
infection. HLA-I typing was performed by the SSOP-PCR method. 
The viral gene gag was amplified by RT-PCR and cloned into the 
pGEM-T vector for viral quasiespecies analysis. Transmitted 
strain was identified by phylogenetic analysis. Escape mutation 
was defined as viral polimorphisms located in HLA-anchor 
position that eliminate an epitope predicted by the NetMHC (CBS 
Prediction Server). Significant variations in the number of escape 
mutations were assessed by Poisson´s probability distribution.
Results: Of the total epitopes available in transmitted gag for 
recognition by the recipient HLA alleles, a mean 7.25% of them 
selected escape mutations by the moment of the second sample 
collection in an anchor position of the epítope. Of the total of HLA-
anchor escape mutations present in the second sample and absent 
in the subtype consensus, a mean 79,8% were already present in 
the first sample of the recipient and in the sample of the donors. 
Also, the majority (84%) of the escape mutations to the donor’s 
HLA alleles persisted in time after transmission without reversion, 
even in the absence of the selecting HLA allele.
Conclusion: The low rate of newly selected escape mutations 
could be due in part to lack of immune pressure, but considering 
the high rate of transmission and persistence, our results suggest 
a high level of viral adaptation to the HLA system in subtype B 
and recombinants BF circulating in Argentina.
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Incident Cases Characterization and Deep Sequencing 
Provide New Insight into Multiplicity of Infection and 
HIV Evolution in Very Early Acute Infection
G. Kijak1, E. Sanders-Buell1, M. Rolland1, H. Li2, A. Bates1,  
M. Bose1, A. O’Sullivan1, L. Eller1, R. O’Connell3, G. Shaw2,  
N. Michael3, J. Kim3, M. Robb1, S. Tovanabutra1
1U.S. Military HIV Research Program/Henry M. Jackson 
Foundation, Silver Spring, MD, USA; 2Perelman School of 
Medicine, University of Pennsylvania, Philadelphia, PA, USA; 
3U.S. Military HIV Research Program/WRAIR, Silver Spring, MD, 
USA
Background: RV217/ECHO aims at capturing HIV-1 incident cases 
during the very earliest stages of acute HIV-1 infection(AHI). 
Limitations in single genome amplification(SGA) sampling depth 
have the potential to confound the study of multiplicity of 
infection and viral evolution during AHI. Here we combined SGA 
and deep, next-generation sequencing(NGS) to investigate the 
prevalence of minor viral variants during pre-peak viremia and 
characterize subsequent viral evolution.
Methods: A male CSW from Thailand with documented nucleic 
acid testing(NAT)-conversion and seroconversion, and with 
measured viremia peak, was studied. Plasma viruses from pre-
peak viremia(9 days after last negative NAT and 2 days after first 
positive NAT; pVL=891,251), immediate post-peak viremia(38 
days after last negative NAT; pVL=512,861), and 6 months 
post-infection(pVL=181,970) were characterized by SGA and 
targeted NGS. A library prepared from 1,500 PCR-equivalent 
copies was analyzed using IonTorrent(LifeTechnologies).Reading 
coverage was>20K and the experimentally-measured error rate 
was<0.0028/base.
Results: Based on 47 env SGA sequences from pre-peak viremia, 
the infection was initiated by a single T/F virus (mean env pair-
wise nt diversity:0.047%).A second variant, highly similar but 
distinguishable from the T/F (env nt distance:2.4%;env AA 
distance:3.4%), was detected during immediate post-peak 
viremia(18/56 SGA sequences). By 6 months post-infection, the 
viral population was dominated by the second variant along with 
numerous recombinants.
NGS analysis of multiple, independent subgenomic areas with 
concentrated sequence variation, revealed that the second 
variant was already established at 1% at pre-peak viremia. 
Outgrowth of the second variant, along with its derivatives, was 
confirmed by longitudinal NGS.
Conclusion: Supplementing SGA analysis with NGS allowed us to 
demonstrate the presence of two T/F viruses at pre-peak viremia 
with substantial frequency differences, in the study participant. 
Due to its implications, the prevalence of this phenomenon needs 
to be further explored. The application of NGS to the study of 
HIV-1 evolution during AHI promises to foster the advancement 
of vaccine development.
P05.05
Evolutionary Dynamics of HIV-1 Subtype C Accessory 
and Regulatory Genes in Primary Infection
R. Rossenkhan1, V. Novitsky2, T.K. Sebunya3, R. Musonda4,  
B.A. Gashe3, M. Essex2
1HSPH/UB/BHP, Boston, MA, Botswana; 2Harvard School of 
Public Health (HSPH)/ BHP, Boston, MA, USA; 3University of 
Botswana (UB), Gaborone, Botswana; 4Botswana Harvard AIDS 
Institute Partnership (BHP), Gaborone, Botswana
Background: Studies addressing the dynamics of accessory and 
regulatory viral gene diversity and selection during early stage 
of HIV-1 infection are limited but crucial for progress towards 
vaccine research.
Methods: Intra-patient diversity and evolution was assessed 
during primary HIV-1C infection, viral quasispecies were obtained 
by single genome amplification (SGA) at multiple sampling time 
points up to one year post-seroconversion (p/s). 
Results: The mean intra-patient diversity was found to be 0.11% 
(95%CI; 0.02 to 0.20) for vif, 0.23% (95%CI; 0.08 to 0.38) for 
vpr, 0.35% (95%CI; -0.05 to 0.75) for vpu, 0.18%(95%CI; 0.01 
to 0.35 ) for tat exon 1 and 0.30% (95%CI; 0.02 to 0.58) for rev 
exon 1 during the time period 0 to 90 days p/s. The intra-patient 
diversity increased gradually in all non-structural genes over 
the first year of HIV-1 infection, which was evident from the vif 
mean intra-patient diversity of 0.46% (95%CI; 0.28 to 0.64), vpr 
0.44% (95%CI; 0.24 to 0.64), vpu 0.84% (95%CI; 0.55 to 1.13), 
tat exon 1 0.35% (95%CI; 0.14 to 0.56 ) and 0.42% (95%CI; 0.18 
to 0.66) for rev exon 1 during the time period of 181 to 500 
days p/s. Statistically significant increases in viral diversity were 
observed for vif (p=0.013) and vpu (p=0.002). Weak and sporadic 
associations between levels of viral diversity within the non-
structural genes and HIV-1 RNA load during primary infection 
were found. Positive and negative selection patterns over the 
first year post-seroconversion were assessed in each of these 
genes, providing insight into the selection pressures on these 
genes which are crucial for viral replication in-vivo.
Conclusion: Our study highlights differential diversity and slower 
diversification across these HIV-1 genes. The most likely cause is 
different selection pressure imposed by host immune response 
to the encoded viral gene products that may result in different 
evolutionary rates. 
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Subtype-Specific Differences in Human 
Immunodeficiency Virus Type 1 Co-receptor Usage in 
Northern Kenya
J.M. Kingoo1, .M. Muriuki2, M. Gicheru2, Z. Ng’ang’a3,  
V. Okoth2, J. Kinyua3, N. Lagat2, Z.O. Lagat3, R. Lwembe 2,  
S.A. Khamadi2
1US Military HIV Research Program, KEMRI/WRP CRC, Kericho, 
Kenya; 2Kenya Medical Research Institute, Nairobi, Kenya; 
3Jomo Kenyatta University of Agriculture and Technology, 
Nairobi, Kenya
Background: HIV-1 phenotype variability plays an important 
role in HIV-1 transmission and pathogenesis of AIDS. The basis 
of heterogeneity between the phenotypes is known to be the 
differential use of chemokine receptors as co-receptors for 
viral entry. Beta Chemokine receptor-5 (CCR5) using variants 
are associated with acute infections, macrophage tropism, non 
syncytium inducing (NSI) phenotype and slow progression to 
AIDS. Alpha chemokine receptor-4 (CXCR4) using variants evolve 
later in infection in about 50 % of the patients and are associated 
with T cell lines tropism, syncytium induction, accelerated T 
cell depletion and Rapid progression to AIDS. HIV-1 co-receptor 
usage and phenotypes are mapped in the third variable region 
(V3) of the gp120 env gene.
Methods: One hundred and thirty five (135) whole blood 
samples were collected from HIV-1 infected patients in Northern 
Kenya. Proviral DNA was extracted using DNazol and ethanol 
precipitation. HIV-1 V3 region was amplified by nested PCR using 
C2V3 primers. Amplicons were sequenced directly using Big Dye 
technology in the ABI Prism Genetic Analyzer to generate gp120 
V3 loop sequences. Bioinformatics tools were used to determine 
co-receptor usage from the sequences obtained.
Results: CXCR4 usage was most dominant with 94 out of 135 
samples(69.6 %) using this co-receptor compared to CCR5 which 
was used by 29 of the 135 (21.8 %) samples and dual co-receptor 
usage found in 12 of the 135(8.6%)samples tested. 
Conclusion: Most patients were inferred to be in late stages 
of infection and likely to be rapidly progressing to AIDS. Based 
on these results from co-receptor usage data, HIV-1 incidence 
rate was likely to be low. Co-receptor usage was observed to be 
associated with HIV-1 subtypes. Poor alignment of the Northern 
Kenya sequences with the training data for the classifier software 
necessitates the need for development of Bioinformatic software 
relevant for locally circulating HIV-1 subtypes.
P05.07
Characterization of Envelope Function of Transmitted 
Viruses Circulating in Mbeya, Tanzania, and Its 
Impact on Disease Progression
A. Nofemela1, G. Bandawe1, R. Thebus1, J. Marais1, L. Maboko2, 
M. Hoelscher3, C. Williamson1, Z. Woodman4
1University of Cape Town, Cape Town, South Africa; 2Mbeya 
Medical Research Programme, Ministry of Health, Mbeya, 
United Republic of Tanzania; 3Department of Infectious 
Diseases and Tropical Medicine, Ludwig-Max, Munich, 
Germany; 4Department of Molecular and Cell Biology, 
University of Cape Town, South Africa
Background: An understanding of the biological characteristics 
of transmitted viruses provides important insights into HIV 
pathogenesis and informs vaccine development. The aim of the 
study was to characterize env function of transmitted viruses and 
its role in disease progression.
Methods: Ten sequences were generated from single genome 
amplicons from 10 individuals at acute infection (range = 3 - 6 
months post-infection) and the sequence representative of the 
consensus was cloned and functional env clones from subtypes 
C (n= 6), D (n =1) and recombinants CD (n = 2), AC (n = 1) were 
generated. Pseudovirions were generated, and entry efficiency 
in TZM-bl cells, tropism, dependency on CD4 and CCR5 using 
HEK 293 dual-inducible Affinofile cells, and sensitivity to entry 
inhibitors, was measured.
Results: Half the envelope clones showed high levels of entry 
(52 -164% infection relative to Du151a, a reference env clone), 
and the remaining five had low entry efficiency (1- 18 %). We 
found an association between entry efficiency and viral load at 3 
months (p = 0.0022) and 12 months postinfection (p = 0.0347). 
There was no significant correlation between entry efficiency 
and the IC50 of sCD4 (p = 0.5074), TAK779 (p = 0.4366) and 
enfurvitide (p= 0.5821), suggesting that the difference in entry 
efficiency was not due to CD4 and CCR5 binding, or membrane 
fusion. However, only 3/10 transmitted viruses from the group 
with high entry efficiency were able to infect cells with low of 
levels of CD4 and high levels of CCR5 receptors. 
Conclusion: Transmitted viruses have a range of entry efficiency 
in TZM-bl cells (with high CD4 and CCR5 levels) with high entry 
efficiency associated with higher viral loads. When the expression 
of CD4 was lowered, only three viruses were able to enter target 
cells, suggesting that transmitted viruses most likely target cells 
with high CD4 levels. 
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HIV-1 Diversity in Cameroon: New Insights on the 
Evolution of the Virus
T. Aime Marcel Simon1, Z. Lycias2, M. Eitel3, W. Carolyn2,  
B.A. Wendy2, M.P. Darren2
1Institute of Infectious Disease and Molecula, University of 
Cape Town, Cape Town, South Africa; 2IIDMM, University of 
Cape Town, Cape Town, South Africa; 3Institute of Medical 
Research and Study of Medicinal Plants, Yaounde, Cameroon
Background: Given the central role of HIV-1 diversity in the HIV 
pandemic and its impact on vaccine development, it is imperative 
that global molecular epidemiology surveillance continues. 
Constantly improving phylogenetics-based analytical techniques 
and rapidly expanding HIV sequence datasets promise to yield 
important insights into the origin, evolution and spread of HIV-1.
Methods: In an effort to study the phylogeography and 
phylodynamics of the HIV-1 M epidemic in the early 20th century, 
we analysed 50 plasma samples from HIV-infected blood donors 
from Cameroon. Full length gag sequences were generated and 
aligned using MUSCLE along with a representative selection of 
HIV sequences from the rest of the world and all published gag 
sequences from Cameroon and other West African countries. 
A maximum likelihood phylogenetic tree was constructed from 
these sequences following removal of recombinant sequence 
fragments by a blinded fully exploratory screen for recombination 
using RDP3. 
Results: All the Cameroonian sequences were derived from HIV-1 
M viruses. The phylogenetic tree indicated that at least one of the 
newly-sequenced CRF02_AG viruses is an outlier of the CRF02_
AG clade and may help resolve the controversy surrounding 
the origins of this clade. Furthermore, isolates from Cameroon 
were spread throughout the phylogenetic tree clustering with 
different subtypes and circulating recombinant forms, a finding 
consistent with West Africa being the geographic origin of the 
global HIV epidemic. Importunately, our blind recombination 
screen suggested that many divergent Cameroonian viruses 
previously identified as being unique recombinant forms, may 
be divergent, relatively non-recombinant, but under-sampled 
subtype-level lineages.
Conclusion: Lineages diverging early after the origin of HIV-1 
M are likely still circulating in Cameroon and could be suitable 
for retracing the movement and evolutionary dynamics of HIV-1 
during the earliest stages of the pandemic. These lineages will be 
useful for reconstructing ancestral HIV-1M sequences for use as 
vaccine immunogens.
P05.09
Analysis of HIV-1 gp120 Quasispecies Suggests High 
Prevalence of Intra-subtype Recombination
I.E. Kiwelu1, V. Novitsky1, L. Margolin1, J. Baca1, R. Manongi2,  
N. Sam2, J. Shao3, M.F. MacLane1, S.H. Kapiga4, M. Essex1
1Harvard School of Public Health, Boston, MA, USA; 
2Kilimanjaro Christian Medical College, Moshi, United Republic 
of Tanzania; 3Kilimanjaro Medical Christian College, Moshi, 
United Republic of Tanzania; 4London School of Hygiene and 
Tropical Medicine, London, United Kingdom (Great Britain)
Background: Recombination between viruses of the same HIV-
1 subtype has been understudied primarily due to the lack of 
reference sequences, as well as appropriate bio-informatics tools. 
The introduction of recombination detection program (RDP3) 
made the detection of HIV-1 intra-subtype recombination feasible
Methods: This study determined the prevalence and patterns 
of HIV-1 intra-subtype recombinants among female bar and 
hotel workers in Moshi, Tanzania. The HIV-1 env gp120 V1-C5 
quasispecies from 45 subjects classified as pure HIV-1 subtypes 
A1, C, or D were analyzed for recombination events by RDP3.
Results: HIV-1 quasispecies with evidence for recombination 
were found in 89% of subjects infected with pure HIV-1 subtypes 
A, C, and D. Recombinant viruses were observed at both the 
baseline and the 12 month visits in 88% of the subjects; in 12% 
of subjects recombination was identified only at the later time 
point. Two major patterns were observed: 70% of subjects had 
unique recombination breakpoints without dominance of any 
particular variant, while in 30% of subjects a specific recombinant 
variant dominated in the pool of viral quasispecies. 
Conclusion: A large proportion of female bar and hotel workers 
were infected with intra-subtype recombinant viruses. These 
results suggest that HIV-1 co- and super-infections are common 
in this population, and occur more frequently than previously 
thought. Intra-subtype recombination contributes to the increased 
viral diversity which poses a challenge to HIV-1 vaccine design.
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Envelopes Found Early After Acquisition Compared 
to Those in the Chronically Infected Partner Do Not 
Have Enhanced Alpha4 Beta7 Binding or Utilization
B. Etemad1, A. Redd2, D. Serwadda3, T. Lutalo3, S. Reynolds4,  
R. Gray5, T. Quinn2, M. Sagar6
1Brigham and Women’s Hospital, Harvard Medical School, 
Cambridge, MA, USA; 2Lab of Immunoregulation, NIAID/ NIH, 
Baltimore, MD, USA; 3Makerere University, Kampala, Uganda; 
4Johns Hopkins University School of Medicine, Baltimore, MD, 
USA; 5Johns Hopkins University Bloomberg School of Public 
Health, Baltimore, MD, USA; 6Brigham and Women’s Hospital 
affiliated of Harvard Medical School, Cambridge, MA, USA
Background: It has been hypothesized that the RV144 immune 
correlate, V1V2 antibodies, block binding to gut homing receptor, 
alpha4 beta7, which may limit virus access to gut associated 
lymphoid tissue. We hypothesized that if alpha4 beta7 binding 
is important during HIV-1 acquisition, viruses with envelopes 
isolated from newly infected subjects should have enhanced 
ability to bind the alpha4 beta7 integrin and/or infect cells 
with high levels of alpha4 beta7 receptor compared to variants 
present in the chronically infected transmitting partner.
Methods: Envelopes isolated from newly infected subjects and 
the transmitting partner were incorporated into NL4-3. Virus 
stocks were generated from peripheral blood mononuclear cell 
cultures. CD8+ and CD4+ T cells were activated with PHA, IL-2, 
and retinoic acid (RA). Binding was examined with quantitative 
PCR, and replication was assessed by estimating produced 
infectious virus on TZM-bl cells. Comparisons were done using 
Wilcoxon matched-pairs signed rank test.
Results: Samples from 9 newly infected subjects were collected 
a median of 93 days after estimated HIV-1 seroconversion (range 
17 – 324 days), and all the transmitting partners had chronic 
persistent infection of more than two years duration at the time 
of estimated transmission. The alpha4 beta7 receptor expression 
increased in both CD8+ and CD4+ T cells by day 6. Viruses with 
recipient (median 9 copies, range 0 – 632) versus donor (median 
9 copies, range 0 – 313) demonstrated no significant difference 
(p = 0.9) in binding to alpha4 beta7 expressing CD8+ T cells. 
Recipient viruses also demonstrated similar replication in CD4+ T 
cells compared to the donor envelope viruses (p = 0.4).
Conclusion: Enhanced alpha4 beta7 binding does not distinguish 
envelopes found early after acquisition compared to those 
circulating in chronically infected partners. Thus, the V1V2 
antibodies found as a RV144 immune correlate likely does not 
provide protection by blocking access to the alpha4 beta7 integrin.
P05.11
Postnatally-Transmitted HIV-1 Variants Are Efficient 
at Dendritic Cell Trans-infection and Sensitive to 
Autologous and Heterologous Neutralization
G.G. Fouda1, T. Mahlokozera1, K. Rizzolo2, J. Salazar-Gonzalez3, 
M. Salazar3, G. Learn3, S. Barotra4, M. Sekaran1, E. Russell5,  
F. Jaeger1, F. Cai1, F. Gao1, B. Hahn6, R. Swanstrom5, S. Meshnick5, 
V. Mwapasa7, L. Kalilani7, S. Fiscus5, D. Montefiori1, B. Haynes1,  
J. Kwiek4, M. Alam1, S. Permar1
1Duke Human Vaccine Institute, Durham, NC, USA; 2Beth Israel 
Deaconess Medical Center, Boston, MA, USA; 3University of 
Alabama at Birmingham, Birmingham, AL, USA; 4Ohio State 
University, Columbus, OH, USA; 5University of North Carolina, 
Chapel Hill, NC, USA; 6University of Pennsylvania, Philadelphia, 
PA, USA; 7University of Malawi, Blantyre, Malawi
Background: Postnatal transmission via breastfeeding is a leading 
cause of infant HIV infection in the developing world. However, 
only a small minority of breastfed infants born to HIV-infected 
women become infected. As a genetic bottleneck severely 
restricts the number of postnatally-transmitted variants, genetic 
or phenotypic differences in the virus Envelope (Env) may play 
a role in its ability to breech the mucosal barrier in the infant 
gastrointestinal tract. 
Methods: We examined the biologic properties of HIV Env 
pseudoviruses cloned from breast milk of postnatally-transmitting 
mothers (n=14 viruses), clinically-matched nontansmitting 
mothers (n=16 viruses), and early viruses from postnatally-
infected infants (n = 6).
Results: There was no difference in epithelial cell attachment, 
internalization, or gp120 interaction with the putative HIV 
epithelial cell receptor, galactosylceramide, between milk HIV Env 
variants from transmitting and nontransmitting mothers. Similarly, 
there was no difference in the efficiency of milk Env variants to 
bind to monocyte-derived dendritic cells (DC). However, there 
was trend towards more efficient DC-mediated trans-infection of 
CD4-expressing target cells by milk Env variants of transmitting 
women compared to those of non-transmitting women (p = 
0.06). Moreover, early infant Env variants were more efficiently 
transferred from DC than milk variants of nontransmitting 
women (p = 0.0009). The high-efficiency DC trans-infection was 
not attributable to higher infectivity or fusion efficiency of the 
postnatally-transmitted viruses. Infant Env variants were more 
sensitive to neutralization by broadly- neutralizing antibodies 
(HIVIG-C: p=0.02, PG-9: p=0.04, and VRC01: p=0.02) than Env 
variants from milk of nontransmitting women. In addition, Env 
variants from transmitting and nontransmitting mothers were 
equally-sensitive to neutralization by autologous plasma. 
Conclusion: While resistance to broadly-neutralizing antibodies 
does not appear to be a defining feature of postnatally-
transmitted Env variants, efficient HIV Env co-interaction with 
DCs and CD4-expressing target cells may be required for postnatal 
HIV transmission via breastfeeding. 
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Emergence of Unique Recombinant Forms (URFs) in 
Indian HIV-1 Epidemic: Data from Nationwide Clinical 
Cohort Between 2007 and 2011
U. Neogi1, S. Gupta1, A. Shet2, A. De Costa3, R.L. Laishram4,  
A. Wanchu5, V. Diwan6, A.C. Banerjea7, A. Sonnerborg8
1St. John’s Medical College, Bangalore, India; 2Department 
of Pediatrics, St. John’s Medical College Hospital, Bangalore, 
India; 3Division of Global Health, Karolinska Institutet, 
Stockholm, Sweden; 4Regional Institute of Medical Science, 
Imphal, India; 5Department of Internal Medicine, PGIMER, 
Chandigarh, India; 6Department of Public Health and 
Environment, R.D. Gardi Medical Colleg, Ujjain, India; 
7National Institute of Immunology, New Delhi, India; 8Divisions 
of Infectious Diseases, Department of Medicine Huddinge, 
Karolinska Institutet, Sweden
Background: Current epidemiological studies in India have been 
limited to single or localized geographic settings within the 
country. In this study we aim to cherecterised the nationwide 
distribution pattern of the HIV-1 subtypes based on the data 
collected from clinical cohorts from 7 provinces from four regions 
in India (northern, north-eastern, central and southern)
Methods: Blood samples were collected from 212 HIV-1 
seropositive subjects between 2007 and 2011. HIV-1 subtypes 
were determined using at least two or three viral genes, gag, pol, 
and env using maximum likelihood tree. Recombination events 
were identified using RIP ver 3 tools followed by breakpoints 
analysis in Simplot version 3.5.1 and fragment-specific 
phylogenetic analysis. 
Results: When a single gene was used for subtype determination, 
the mean proportion of HIV-1C, B and A1 were 95.9%, 1.9% 
and 0.2% respectively while recombinants constituted 2.1%. 
The overall prevalence of URFs (BC/A1C) increased significantly 
to 10% when two (p<0.01) or three genes (p=0.02) were used. 
All the A1 and B strains, identified in the single-gene approach, 
were re-identified as URFs. Detailed analysis indicated that 
the B segment of the URF_BC probably originated from China/
Thailand, while the A1 segments originated from eastern 
Africa. Among the four geographical regions examined, a high 
proportion of the recombinant strains based on the two-gene 
approach were identified in north-eastern (46.7%) and northern 
(18.5%) followed by southern India (5%), while central India 
appeared to have a concentrated subtype C epidemic (100%). 
Conclusion: The rapid and continuous evolution of the HIV-1 
epidemic in India was evidenced by the increase of recombinant 
strains. The use of multiple genes, rather than a single gene 
to identify HIV-1 subtypes can reduce the chances of false 
identification. These results warrant an urgent need for continued 
molecular surveillance to guide efficient disease intervention 
strategies and develop an effective subunit-based vaccine.
P05.13
HIV-1 Subtype B- and F1-Infected Subjects Display 
Higher Cross-Clade T-Cell Response Than Subtype 
C-Infected Subjects
F.H. Côrtes1, G. Bello1, C. Vorsatz2, J.H. Pilotto3, B. Grinsztejn4, 
V.G. Veloso2, A.R. Pinto5, M.G. Morgado1
1Oswaldo Cruz Institute/FIOCRUZ, Rio de Janeiro, Brazil; 
2Evandro Chagas Clinical Research Institute/FIOCRUZ, Rio 
de Janeiro, Brazil; 3Nova Iguaçu General Hospital, Nova 
Iguaçu, Brazil; 4Evandro Chagas Clinical Research Institute/
FIOCRUZ, Rio de Janeiro, Brazil; 5Department of Microbiology, 
Immunology and Parasitology/UFSC, Santa Catarina, Brazil
Background: The impact of the extensive genetic diversity of the 
HIV-1 group M isolates and its implications for vaccine design 
have long been discussed. Studies indicate that Gag and Nef 
conserved epitopes are commonly recognized and give rise to 
high cross-clade responses. The aim of this study was to compare 
T-cell responses to peptide pools derivate from subtype B, C and 
F1 consensus, among Brazilian subjects infected with those three 
HIV-1 subtypes. 
Methods: The study included 32 subjects infected with HIV-1 
subtypes B (n=13), C (n=11) and F1 (n=8). Gag and Nef-specific 
T cell responses were evaluated by IFN-γ ELISpot assay, using 
peptide pools based on subtype B, C and F1 Brazilians consensus. 
Results: A high cross-clade response between subtypes B and 
F1 for both Gag and Nef regions was observed among HIV-1 
subtype B- and F1-infected subjects. We also found no significant 
difference in magnitude of responses between subtype B and C 
consensus peptides in subtype B-infected subjects.In contrast, 
the magnitude of T cell responses to consensus C peptides in 
Gag region was significantly higher than to consensus B peptides 
among HIV-1 subtype C-infected subjects. In Nef, subtype 
C-infected subjects showed higher T cell responses to C than to 
F1 consensus peptides. Moreover, subtype F1-infected subjects 
presented lower responses to subtype C peptides than to 
subtype F1 and B ones.
Conclusion: Overall, the level of cross-clade response between 
subtypes B and F1 was higher than between subtype C and B or 
between subtype C and F1. Our data suggest that significance of 
the HIV-1 group M genetic diversity for vaccine design may be 
dependent of the subtypes involved.
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Enrolment and Logistical Challenges in TaMoVac 01 
Phase I/II HIV Trial Despite the Completion of an 
Earlier (HIVIS-03 trial trial) in Dar es Salaam
M. Ngatoluwa1, P. Munseri1, M. Janabi1, F. Mhalu1,  
E. Sandstrom2, M. Bakari1
1Muhimbili University of Health and Allied Sciences, United 
Republic of Tanzania; 2Karolinska Institutet, Sweden
Background: Participation of sub-Saharan countries in HIV 
vaccine trials is important in the fight against HIV/AIDS, and has 
to be sustained by continued trials. Experiences from earlier 
trials are expected to influence the design and the performance 
of subsequent trials. Following completion of HIVIS-03 trial, 
TaMoVac- 01 trial was initiated. We compare enrolment 
experiences between the two trials.
Methods: The HIVIS-03 trial, conducted between 2007 - 2010 
recruited 60 volunteers from the Police force in Dar es Salaam. 
The subsequent TaMoVac- 01 trial has recruited 62 volunteers 
from the Police and Prisons force, and youths at IDC.
Results: Enrollment of volunteers into the HIVIS-03 took 12 
months while the TaMoVac-01 trial took 13 months.
Screened: enrolled ratio was 3:1for HIVIS-03 trail, while for 
TaMoVac-01 8:1. Reasons for screen-out in the TaMoVac-01 trial 
were influence of family, misconception, clinical and laboratory 
abnormalities.
Recruitment of females was a challenge in the HIVIS-03 trial, but 
was unnoticed in the TMV-01 trial, this could be due to inclusion 
of youths. Misconceptions in the Police force remain an obstacle 
to recruitment despite regular education sessions.
Other challenges were: Poor adherence to schedules, due 
to competing prioritization of employment requirements; 
difficulties in communication with volunteers without phones.
Most challenges were addressed through collaboration with the 
concerned authorities in the respective cohorts
Conclusion: Recruitment challenges continued in the TMV-
01 trial despite our experiences with HIVIS-03 trial. Enhanced 
Community engagement and timely action by the researchers is 
necessary to ensure a smooth conduct of the trials.
P05.15
Genetic Characterization of HIV-1 Subtype G 
Envelope Sequences by Single Genome Analysis 
E. Rene Ghislain1, M. Tongo2, E. Ngolle3, W. Burgers2, J. Dorfman1
1International Centre for Genetic Engineering and 
Biotechnology, Cape Town, South Africa; 2Division of Medical 
Virology, University of Cape Town, Cape Town, South 
Africa; 3Centre de Recherche en Maladies Emergentes et 
Reemergente (CREMER), Yaounde, Cameroon
Background: Subtype G is the sixth most prevalent subtype of 
HIV-1 and is responsible for an estimated 1,500,000 infections 
worldwide. Although systematic analyses of a wide range of HIV-
1 envelope sequences and neutralization have been performed, 
subtype G viruses are severely underrepresented in these 
studies. There is thus an important need to study subtype G 
envelope sequences and their neutralization capacities.
Methods: 64 Plasma samples from Cameroon were used and 
6 were found to be Subtype G by sequencing of gag and nef 
including one typed only for gag. Single genome analysis (SGA)-
PCR was then performed and full length envelope genes were 
generated, which were then sequenced in the V1-V5 region
Results: Phylogenetic analysis of V1-V5 envelope sequences 
confirmed that 5 samples grouped within the expected subtype 
G and 1 with subtype A which we had been unable to type for 
nef. Sequences from within one sample were genetically related 
to each other, while samples were genetically distinct from each 
other. This suggests that the sequenced HIV-1 from any donor 
were generally from a single infection. Sequences from 4 of 5 
samples grouped most closely to other West African subtype 
G sequences, while the fifth grouped in a cluster populated by 
sequences from Spain and few other African sequences. The V1-
V5 region of the sixth sample clustered with subtype A and is 
thus presumed to be a recombinant.
Conclusion: These results suggests that our samples capture a 
substantial amount of the diversity within the subtype G envelope 
sequences and are largely different from each other. Therefore, 
forthcoming data concerning the neutralization patterns of these 
viruses will be able to give some of the sense of the diversity of 
neutralization pattern of subtype G viruses that will be needed to 
design a truly global vaccine.
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First Report on HIV Molecular Epidemiology in 
a Native Community from Argentina Reveals 
Transmission Clades in the Context of a Unique HLA 
Background
D. Monaco1, D. Dilernia1, L. Yue2, M. Quipildor3, A. Di Paolo3,  
E. Hunter2, H. Salomon1
1Argentinean Reference Center for AIDS, Buenos Aires, 
Argentina; 2Emory Vaccine Center, Atlanta, GA, USA; 3Hospital 
San Vicente de Paul, San Ramón de la Nueva Oran, Argentina
Background: The Department of Orán is located on the North of 
Argentina and is populated by native settlements and urbanized 
areas. During the last twelve years, an increasing number of HIV 
infections have been detected. We previously reported a highly 
limited HLA diversity with a reduced number of HLA-A and B 
alleles present at high prevalence. The objective of the present 
study was to characterize the HIV epidemic through full-length 
genome sequencing of the virus in this population.
Methods: Samples from 147 HIV positive individuals collected in 
three campaigns to Orán were analyzed. Viral load, CD4-count 
and drug resistance were assessed and reported to the clinicians. 
Limiting-dilution full genome sequencing was performed from 
plasma on 65 of the samples. Viral diversity was analyzed 
by recombination (SimPlot) and Neighbor-Joining trees with 
bootstrap. HLA-A, B and C were characterized by SBT.
Results: HLA typing showed a limited genetic diversity even at 
the four-digits high-resolution typing. This allele distribution 
resembles the one reported previously for this community with 
two-digits and confirms that the individuals included were in fact 
native. SimPlot analysis of the 65 complete and nearly-complete 
genomes showed a high prevalence of BF recombinants(70.77%) 
and the presence of subtype B(23.08%), C(3.08%) and F(3.08%) 
virus. 7 main recombination structures were found repeatedly in 
not-epidemiologically-linked individuals within highly supported 
monophyletic clades suggesting transmission of these particular 
viral strains within the community.
Conclusion: This HIV epidemic seems to be characterized by 
a few introductions of viral variants that had spread on the 
community. Most of them have been BF recombinants with 
particular recombination structures. This work will allow us to 
further investigate the impact of the genetic features of this 
native community on viral evolution but also has facilitated the 
access of these individuals to clinical studies and counseling.
P05.17
Deep Sequencing Reveals an Association Between 
HIV-1 Subtype C Mutations in gp41 MPER Epitopes 
and Mother-to-Child Transmission
L. Yin1, Y. Cai1, K. Chang1, B.P. Gardner1, W. Hou1, K. Nakamura2, 
M. Sinkala3, C. Kankasa4, D.M. Thea5, L. Kuhn6, G.M. Aldrovandi7, 
M.M. Goodenow1
1University of Florida, Gainesville, FL, USA; 2Childrens 
Hospital of Los Angeles, Los Angeles, CA, USA; 3Lusaka 
District Management Team, Lusaka, Zambia; 4University 
Teaching Hospital, University of Zambia, Lusaka, Zambia; 
5Boston University School of Public Health, Boston, MA, USA; 
6Columbia University, New York, NY, USA; 7Childrens Hospital 
of Los Angeles, Los Angeles, CA, USA
Background: Enhanced HIV-1 mother-to-child transmission (MTCT) 
by high maternal anti-gp41 antibody titer led to the hypothesis that 
transmitting mothers would have greater diversity in membrane-
proximal external region (MPER) and mutated amino acid residues 
associated with resistance to gp41 antibodies. 
Methods: Pyrosequences of HIV-1 subtype-C gp41 heptad 
repeat-region 2 (HR2), MPER, and membrane-spanning domain 
(MSD) were generated from 2,000 plasma viral copies/subject 
from four mothers who transmitted via breast feeding (TM) and 
four non-transmitting mothers (NTM) in a matched case control 
study. A bioinformatic pipeline with rigorous quality controls 
generated ~50,000 quality pyrosequences/subject and provided 
25-fold coverage of input virus populations. Population genetic 
algorithms clustered pyrosequences at 3% genetic distance 
to study biodiversity using rarefaction/Chao1. Frequency 
distribution of cluster sizes defined population structure. 
Consensus sequences constructed from bioclusters for each 
subject were aligned to an HIV-1 subtype-C consensus sequence 
to determine number and frequency of nonsynonymous 
substitutions at each position and to identify mutations by HIV 
Molecular Immunology Database. Groups were compared using 
paired t-test. 
Results: Sequences in MPER were more polymorphic than in 
HR2 or in MSD. TM had more diverse MPERs than NTM (p = 
0.02). The number of clusters calculated from rarefaction curves 
was 62(±35) for TM vs 35(±28) for NTM. The Chao1-estimated 
maximum number of variants within populations was 106(±51) 
for TM vs 59(±65) for NT. Low fit viruses (≤5 sequences/
biocluster) contributed to differences in biodiversity between 
TM [71.1(±9.7)%] and NTM [63.5(±14.2)%]. Polymorphisms at 
residues within 4E10 (W672V, F673L, D674S, T676I, and W680G) 
and 2F5 (D664S) were confined exclusively to viruses from TM 
mothers. Viral variants with positively charged hydrophilic MPER 
occurred more frequently in TM than in NTM. 
Conclusion: HIV-1 subtype-C variants with high biodiversity 
correlated with polymorphisms in MPER and were associated 
with MTCT, which may reflect increased immune selection and 
have implications for vaccine design. 
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Limited Evidence for Alterations in Gag-Mediated 
HIV Replication Capacity Over the Course of the 
North American Epidemic (1979-Present)
L. Cotton1, D. Chopera1, K. Penney1, J. Carlson2, E. Martin1, A. Le1, 
T. Kuang1, B. Walker3, J. Fuchs4, S. Buchbinder4, T. Wagner4,  
M. John5, S. Mallal5, B. Koblin6, K. Mayer7, A. Poon8,  
M. Brockman1, Z. Brumme1
1Simon Fraser University, Burnaby, Canada; 2Microsoft 
Research, Los Angeles, CA, USA; 3Ragon Institute, Charlestown, 
MA, USA; 4San Francisco Dept of Public Health, San Francisco, 
CA, USA; 5Murdoch University, Perth, Australia; 6New York 
Blood Center, New York, NY, USA; 7Fenway Community Health, 
Boston, MA, USA; 8BC Centre for Excellence in HIV/AIDS, 
Vancouver, Canada
Background: The extent to which HIV replication capacity (RC) 
has changed over the epidemic’s course, and the influence of 
HLA-associated immune pressure as its driving force remains 
unknown. We performed a comparative study of immune 
escape and RC in historic (1979-1989) and modern Gag subtype 
B sequences from North America.
Methods: Using phylogenetically-informed methods, we 
identified HLA-associated Gag polymorphisms in a historic 
cohort (N=239; 1979-1989). We also generated recombinant 
NL4-3 viruses encoding clonal plasma RNA Gag from 80 historic 
and 58 modern (2002-2008) sequences. Viral RC was measured 
using a GFP reporter T-cell assay and results were normalized to 
NL4-3 controls. 
Results: 95% of HLA-associated polymorphisms identified in 
the historic cohort were consistent with published modern 
escape pathways. Overall, the prevalence of HLA-associated 
polymorphisms in the general population increased a median 
1.3-fold between historic and modern sequences; however 
in many cases this was influenced by differences in HLA allele 
frequencies between HIV-infected populations examined. Of 
note, the prevalence of the B*27-associated R264K escape 
mutation increased from 0.4 to 1.3% in the general population 
over time despite B*27 allele frequency remaining constant at 
2.5%. Modestly lower viral RC was observed for Gag recombinant 
viruses constructed from pre-1985 sequences (median 0.86 [IQR 
0.78-0.97], N=24) compared to those from 1985-1989 (median 
0.98 [IQR 0.87-1.05], N=56) and 2002-2008 (median 0.96 [IQR 
0.83-0.1.10], N=58) (p=0.049). In both historic and modern 
cohorts, host expression of HLA-B*27 was associated with lower 
RC (p=0.007). Gag codons associated with lower RC, including 
S67A, were identified in an exploratory analysis. 
Conclusion: Gag-mediated viral RC may have increased modestly 
since the beginning of the North American epidemic, despite 
limited evidence for HLA-driven viral sequence evolution 
during this time. Although mechanisms driving RC differences 
remain unclear, results do not support rapid and substantial 
accumulation of HLA-driven escape mutations in circulating 
North American HIV-1 sequences.
P05.19
Dynamics and Frequency of Gag Transmitted 
Polymorphisms in Zambia
M. Schaefer1, J. Carlson2, D. Claiborne1, J. Prince1, W. Kilembe3, 
J. Tang4, P. Farmer1, R. Shapiro5, T. Ndung’u6, J. Frater7,  
P. Goulder7, R. Kaslow8, S. Allen1, P. Goepfert8, D. Heckerman2, 
E. Hunter1
1Emory University, Atlanta, GA, USA; 2Microsoft Research, 
Redmond, USA; 3Zambia Emory HIV Research Project, Lusaka, 
Zambia; 4University of Alabama-Birmingham, Birmingham, 
USA; 5Harvard School of Public Health, Boston, USA; 
6University of KwaZulu-Natal, Durban, South Africa; 7Oxford 
University, United Kingdom (Great Britain); 8Unviersity of 
Alabama-Birmingham, USA
Background: HIV immune escape is not random and follows 
a predictable mutational path in response to the HLA alleles 
carried by an individual. 
Methods: Using 143 epidemiologically linked transmission 
pairs from a Zambian cohort we assessed: (1) the frequency 
of Gag polymorphisms circulating in the population, (2) if 
the polymorphisms could be associated with the infected 
individual’s HLA alleles, (3) the frequency at which polymorphisms 
are transmitted, and (4) the relevance of the transmitted 
polymorphisms (TP) to the newly infected individual’s HLA-I alleles. 
Results: We observed a median of 35 (range 23-66) 
polymorphisms per chronically infected individual in Gag and 
42% of these polymorphisms could be associated with the 
individual’s HLA (16% statistically linked, 26% epitope analysis). 
When transmission of these polymorphisms was assessed, we 
observed that the majority of these polymorphisms (84%) are 
transmitted to the epidemiologically linked partner and, of these 
TP, an equivalent fraction (43%; 11% statistically linked, 32% 
epitope analysis) were relevant to the newly infected individual’s 
HLA-I alleles. In 81 transmission pairs observed during the first 
two years of infection, we observed a very low overall reversion 
rate (4%/year) of the TP. Reversion was not uniform and when 
p17, p24, p2, p7, p1, and p6 are examined individually, TP in p17 
and p2 exhibited the highest frequency (2.5x) of reversion events 
based on amino acid length. Four CTL-targeted positions were 
identified where a majority of TP reverted to consensus over 
the two years of follow up, consistent with a reduction in fitness 
following transmission. 
Conclusion: These data indicate: (1) HLA-I associated 
polymorphisms are stable and circulating frequently in the 
Zambian population, (2) individuals are acquiring HIV-I variants 
with a high frequency of polymorphisms relevant to their HLA-I 
alleles, and (3) reversion is slow and not evenly distributed 
across Gag. 
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Intrasubtype C Superinfected Individuals Mount 
Delayed and Low-Titer Autologous Neutralizing 
Antibody Responses Prior to Superinfection
D. Basu1, C. Kraft1, P. Campbell1, M. Murphy1, T. Yu1, P. Hraber2, 
E. Chomba3, J. Mulenga3, W. Kilembe3, S. Allen4, C. Derdeyn1,  
E. Hunter1
1Emory University, Atlanta, GA, USA; 2Los Alamos National 
Laboratory, Los Alamos, NM, USA; 3Zambia Emory HIV 
Research Project, Lusaka, Zambia; 4Department of Global 
Health, Emory University, Atlanta, GA, USA
Background: The potential role of neutralizing antibody in 
protecting against intra-subtype HIV-1 superinfection remains 
to be understood. We compared the early neutralizing antibody 
responses in three individuals, who were superinfected within 
one year of primary infection, to ten case-matched non-
superinfected controls from a Zambian cohort of subtype 
C transmission cases. Sequence analysis of single genome 
amplified full-length env showed minimal diversification in the 
individuals who became superinfected with the same subtype 
of HIV-1 within year one post-seroconversion. We hypothesized 
that these superinfected individuals had a muted neutralizing 
antibody response that elicited little pressure on the founder 
virus to escape. 
Methods: We molecularly cloned envs from virus at the 
time of seroconversion and from virus at the time point that 
superinfection was detected. Using a TZM-BL pseudovirus 
reporter assay, we tested plasma neutralization of these 
autologous variants over the first year of infection. 
Results: Neutralization assays showed that autologous plasma 
NAb titers to founder virus were low to undetectable in all three 
superinfected individuals prior to superinfection. In contrast, 
neutralizing antibodies with a median IC50 of 1:1896 were 
detected as early as three months post-seroconversion in non-
superinfected matched controls. There was no evidence, prior to 
superinfection, of cross-neutralization of superinfecting variants 
in any of the three cases, although cross-neutralization breadth 
and potency to the subtype C pseudovirus reference panel was 
also limited in the plasma from non-superinfected individuals. 
Although there was a trend towards superinfected individuals 
having reduced levels of gp120 binding antibodies prior to 
superinfection compared to non-superinfected controls, this 
difference was not statistically significant between the groups. 
Conclusion: These data suggest that development of antibodies, 
as reflected in autologous neutralizing antibodies to the primary 
infection variants, may provide protection and decrease 
susceptibility to superinfection. 
P05.21
Genetic Variability and Drug Resistance Mutations in 
HIV-1 Infected Individuals on HAART or Drug Naïve in 
Limbe, Cameroon
L. Agyingi1, D. Barengolts1, L. Mayr1, T. Kinge2, M. MBida3,  
P. Nyambi1
1New York University School of Medicine, New York, NY, 
USA; 2Limbe Regional Hospital, South West Region, Limbe, 
Cameroon; 3Faculty of Biomedical Sciences, University of 
Dschang, Dschang, Cameroon
Background: Cameroon is a country in West Central Africa with a 
population of about 20 million inhabitants, with an estimated HIV 
prevalence of 5.1% in the general population. The HIV epidemic 
in this region is marked by a broad genetic diversity dominated 
by Circulating Recombinant Forms (CRFs). 
Methods: To characterize HIV-1 genotypes circulating in HIV 
positive individuals in Limbe, Cameroon, we phylogenetically 
analyzed blood samples from 116 HIV positive patients. Of 116 
samples tested, 110 were amplified by nested PCR at the Gag, 
Pol and Env genes. Sequences obtained were phylogenetically 
analyzed with reference sequences from the Los Alamos 
database. The RT region of samples was also amplified to 
identify mutations that conferred resistance to Reverse 
Transcriptase inhibitors (RTIs) using the Stanford University 
Drug resistance database. 
Results: Our results revealed a broad genetic diversity, dominated 
by circulating recombinant forms as follows: CRF02_AG 50.4% 
(n=54), CRF22_01A1 7.4% (n=8) F2 3.7% (n=4), D 2% (n=2), 
CRF43_02G 2.8% (n=3), CRF18_CPX 2.8% (n=3) and recombinant 
forms (RFs) 31.7 %( n=34). Most RFs contained CRF02_AG in 
one or two HIV loci analyzed. RT sequences of 3 patients on 
HAART and 15 drug naïve individuals harbored mutations which 
conferred resistance to RTIs. 
Conclusion: CRF02_AG continues to be the most predominant 
strain in Cameroon, CRF22_01A1 on the increase. Identification 
of drug resistance strains in drug naïve patients suggest these 
viruses are being transmitted in the study population and 
highlights the need of drug resistance testing before start of ART 
for HIV patients. 
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HIV Disease Progression Compared by Linkage Status 
in Rwanda and Zambia
W. Kilembe1, C. Dinh1, S. Lakhi1, E. Karita1, R. Bayingana1,  
M. Price2, S. Allen3, E. Hunter4
1Rwanda Zambia HIV Research Group, Lusaka, Zambia; 
2International AIDS Vaccine Initiative, San Fransisco, CA, USA; 
3Emory University School of Medicine, Atlanta, GA, USA; 
4Emory Vaccine Center and Yerkes Primate Center, Atlanta, GA, 
USA
Background: Recently HIV infected individuals are followed up at 
Rwanda-Zambia HIV Research Group (RZHRG) sites to establish 
markers of disease progression. Here we compare disease 
progression between seroconverters infected by their spouses 
(linked transmission) to those infected by non-spousal partners 
(unlinked transmission) where a greater fraction of individuals 
are infected by multiple virus variants.
Methods: Seroconverters (SC) were identified from HIV discordant 
couples enrolled from the Couples’ VCT program into a prospective 
cohort study. Linkage of transmission was established by 
comparing viral DNA sequences in the SC to that of the suspected 
index partner. SCs were followed up to six years to collect clinical 
and laboratory data. Data analysis using STATA was done on CD4 
and viral load trajectories and a comparison of disease progression 
with respect to time to endpoints of CD4 <350 cells/uL and 
initiation of ARVs. Log rank test of equality for survival function 
was performed for each endpoint and p-values calculated. 
Results: From February 2006 to December 2011, 88 unlinked 
and 225 linked transmissions were identified. Across all RZHRG 
sites, SC males represented 56% of the unlinked and 55% of the 
linked group. Overall mean age at seroconversion was 33 years 
and 69% of HIV transmissions were acute infections (identified 
within 90 days of infections). Mean CD4 count and viral load at 
specified time points during a six year follow up period of the 
two groups were similar. Disease progression in the two groups 
(CD4 <350cell/uL or initiation of ARVs) showed no significant 
difference (p=0.21 and p=0.26) respectively.
Conclusion: Despite the fact that previous studies have shown 
that there is faster disease progression in individuals who were 
infected by multiple genetic variants from their partner, we show 
here that linkage status does not predict HIV disease progression 
in HIV seroconverting couples. 
P05.23
Immunodominance and Viral Fitness in Gag May 
Contribute to Differential Viral Control in HLA-B*7 
Supertype Individuals Acutely Infected with HIV-1C
K. Gounder1, M. Leshwedi1, J. Wright1, M. van der Stok1,  
F. Chonco1, N. Padayachee1, B. Ndimande1, M. Mokgoro1,  
M. Jaggernath1, P. Goulder2, B.D. Walker3
1University of KwaZulu-Natal, Durban, South Africa; 2University 
of Oxford, Oxford, United Kingdom (Great Britain); 3Ragon 
Institute of Massachusetts General Hospital, MIT and Harvard, 
Boston, MA, USA
Background: HLA-B*7 supertype alleles are common among 
people of African descent and are associated with viral control. In 
particular, HLA-B*81 has been previously associated with reduced 
viral fitness. We analyzed the immunodominance of CD8+ T cell 
responses targeted by the B*7 supertype alleles, viral evolution 
and fitness dynamics over 1yr in acutely infected patients.
Methods: Six HLA-B*7 supertype participants [HLA-B*81 (n=2), 
HLA-B*4201 (n=3) and HLA-B*4202 (n=1)] identified with acute 
HIV-1 infection (antibody negative, vRNA positive) in KwaZulu-
Natal, South Africa were studied. CD8+ T cell responses were 
measured by the IFN-γ ELIspot assay. Replication capacities of 
viruses encoding Gag-protease were measured. Full-length HIV-1 
Gag clonal sequencing of plasma was performed at ~14 days post 
infection and 1yr later.
Results: The average viral set point of the 4 HLA-B*42 individuals 
was higher than the 2 HLA-B*81, 4.89 vs 4.16 respectively. 
Approximately 28 days after viral infection, CD8+ T cell responses 
were directed to an average of 2/5 (range 2-4) HLA-B*42 Gag-
specific epitopes, median magnitude of 490 (range 170–2,480 
SFC/million PBMCs). None of these 4 individuals had selected 
for escape mutations in the immunodominant TL9 epitope at 
1yr post-infection. Interestingly, CD8+ T cell responses were 
only against the TL9 epitope for the 2 HLA-B*81 patients with a 
median magnitude of 950 (range 300–1780 SFC/million PBMCs). 
One patient had a single wild type epitope in the transmitted 
virus, compared to 4/5 wild type epitopes in the second patient. 
However, CD8+ T cell responses were only elicited at the TL9 
epitope with a low magnitude against T186S in the 1 patient with 
a much lower viral fitness.
Conclusion: Strong, rather than broad immunodominant responses 
in HLA-B*7 individuals is desirable in viral control. Furthermore, 
this study emphasizes the advantage of early dominant CD8+ T cell 
immune responses and an attenuated virus in conferring clinical 
benefit among HLA-B*7 supertype individuals.
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Transmitted HIV-1 variants in HIV infected Mother-
Child Pairs, Carrying Different Subtypes
R. Caridha1, K. Gieng1, U. Fried1, S. Lindgren2, P. Clevestig1,  
A. Ehrnst1
1Karolinska Institutet, Stockholm, Sweden; 2Karolinska 
Institutet, Unit of Obstetrics and Gynecology, Huddinge, 
Stockholm, Sweden
Background: Mother-to-child transmission is the predominant 
route of HIV-1 infection in children. Prevention strategies are 
available in industrialized countries, but are limited in developing 
countries. Defining pertinent characteristics of transmitted HIV-1 
from mother-child pairs, where the actually transmitted virus has 
been traced, is important in creating better preventive measures 
against transmission of HIV-1. 
Methods: Two mother-child pairs of subtype A, three of subtype 
C, and three of CRF01_AE, were included. The V3-loop and 
flanking regions of the HIV-1 env gene were amplified from 
PBMC and plasma lysates. Virus isolates from several time points 
of pregnancy and in the child were sequenced, as well as 50 to 
100 single HIV genomes per case. 
Results: A total of 543 single genome sequences were obtained. 
The sequences were analysed phylogenetically, demonstrating 
at least one maternal sequence, identical to the child’s first 
detected viruses or clones. In all cases an infant isolate sequence 
co-localized with maternal sequences, most probably related to 
transmission. The localization of other sequences from clones 
and/or virus isolates in the phylogenetic tree and their detailed 
amino acid composition provided a clear indication of the V3 
loop amino acids of the respective transmitted virus. The fact 
that these sequences included an isolate will allow a greater 
genetic analysis of the complete envelope of transmitted HIV-1.
Conclusion: Since the sequence of the gp120 V3 loop is of 
paramount importance for virus entry, we can compare the 
amino acid properties across subtypes and test these viruses 
in neutralization assays. This knowledge can be exploited in 
prevention strategies and vaccine design. 
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Sequence Based Typing of HLA-A and B Exons-2 and 
-3 in a HIV-Positive Native Community with Limited 
HLA Diversity from the North of Argentina 
D.A. Dilernia1, D. Mónaco1, R. Coloccini1, M. Pando1,  
M. Quipildor2, A. Di Paolo2, E. Hunter3, H. Salomon1
1Argentinean Reference Center for AIDS, Buenos Aires, 
Argentina; 2Hospital San Vicente de Paul, San Ramón de la 
Nueva Oran, Argentina; 3Emory Vaccine Center, Atlanta, GA, 
USA
Background: We previously reported a limited diversity of HLA-
class I alleles in two-digits typing studies of HIV-positive native 
populations from Oran, North of Argentina. In the present study 
we determine whether the restricted diversity observed at 
low-resolution reflects also a restricted genetic diversity in HLA 
peptide groove.
Methods: We studied 65 HIV-positive patients whose HLA-A 
and -B genes were previously typed by SSOP technique. We 
set-up a sequence-based typing of the most prevalent alleles 
in Oran. HLA-A and B were initially PCR-amplified and exons-2 
and -3 were sequenced. NCBI-SBT-Interpretation tool was used 
to confirm the two-digits typing with previous SSOP data. We 
designed a set of primers specifics for HLAs highly prevalent in 
Oran to achieve differential PCR-amplification of each allele in 
heterozygote patients. Phylogenetic analysis was used to assign 
exons-2 and -3 sequences to a high-resolution HLA group.
Results: Our results show that for HLA-A alleles, 85.1% of A*02 
are A*02:01:01:01, 96.7% of A*31 are A*31:01:02 and 92.8% of 
A*24 are A*24:02:01:01. In the case of A*68, 50% are A*68:01:02 
and 31.2% are A*68:17. For HLA-B alleles, B*35 was diverse: 
B*35:01:01:01 (15.8%), B*35:04:01 (15.8%), B*35:05:01 (21.1%) 
and B*35:19 (21.1%). 43.8% of B*39-alleles were B*39:05:01 
and 25% were B*39:03. 52.9% of B*48-alleles were B*48:01:01 
and 35.3% were B*48:03:01. 62.5% of B*51 alleles were 
B*51:01:01. The mentioned alleles represent the 73.1% of HLA-A 
genetic diversity and the 45.4% of HLA-B. All the polimorphisms 
observed lead to non-synonymous changes.
Conclusion: Our results show that two-digits typing of HLA-A 
usually corresponds with a specific allele in our population. For 
HLA-B alleles, observed within-subtype diversity was higher. The 
different protein sequence encoded by exons-2 and -3 may lead 
to different peptide specificities among alleles from the same 
HLA-B subtype that would be miss-classified as homogeneous in 
a low-resolution typing study.
P06.01 
The Viral Set Point in Primary HIV Infection Is 
Associated with Specific Amino Acids in Position 97 
of MHC Class I
S.A. Vaidya1, H. Streeck1, F. Pereyra1, E.S. Rosenberg1, B.D. 
Walker1, M. Altfeld1
1Ragon Institute of MGH, MIT, and Harvard, Boston, MA, USA
Background: Sequence variations which affect the peptide 
binding groove of the major histocompatibility complex (MHC) 
class I allele HLA-B are strongly associated with viral control 
in chronic HIV infection. We sought to determine if these 
differences affect primary HIV infection and establishment of the 
early viral set point.
Methods: We longitudinally followed 428 individuals during 
primary HIV infection. In 110 individuals, we were able to 
determine the viral set point at six months following diagnosis. 
Associations between known genetic polymorphisms in HLA class 
I residues and HIV viral load and viral set point were identified.
Results: The identity of the amino acid at position 97 in the 
peptide binding groove of HLA-B was significantly associated 
with the level of initial viremia in acute infection (p=0.04) and the 
viral set point (p=0.025). Individuals with valine at position 97 
had a nearly 10-fold lower mean viral set point than those with 
serine. This association was dependent on presence of the B*57 
allele, which was also associated with a lower viral set point. The 
initial viral load at the time of primary HIV diagnosis was closely 
correlated with the level of the subsequent viral set point (R=0.4, 
p=<0.0001).
Conclusion: Control of HIV during acute infection and the 
viral set point are strongly associated with the amino acid in 
position 97 of HLA-B. These results provide evidence for genetic 
predictors of HIV control in primary infection and highlight the 
importance of sequence polymorphisms in the binding pocket of 
MHC class I which may be relevant to the development of future 
HIV vaccines.
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The Prognostic and Diagnostic Use of MicroRNA 
Expression in Chronic HIV Infection
L. Zhu1, C. Qiu1, C. Ma2, X. Zhang1, J. Xu3
1Fudan University, Shanghai Public Health Clinical Center, 
Shanghai, China; 2Chinese Academy of Sciences, Shanghai, 
China; 3Fudan University, Institutes of Biomedical Sciences, 
Shanghai, China
Background: MicroRNA (miRNA) is engaged in the regulation of 
host immunity during HIV infection and may play an important 
role in the disease progression. We sought to identify a 
diagnostic/prognostic miRNA signature to diagnose/predict the 
outcome of chronic HIV infection.
Methods: The expression levels of 754 known human microRNA 
were quantified in whole peripheral blood by TaqMan low 
density array for 23 chronically HIV-infected subjects. Significance 
analyses of miRNA expression profiles were performed on 
groups with varied levels of CD4+ T cell counts or viral loads. The 
identified prognostic miRNA signature was further validated in a 
51 HIV+ patient cohort naïve to ART with following up for 2 years. 
In addition, we assessed their association with progression-free 
rate. For the latter, various prediction algorithms were computed 
on the basis of weighted levels of the miRNAs forming the 
outcome signature.
Results: Of the 10 differentially expressed miRNAs (p<0.001), 3 
were validated to contribute to the predictive value and thereby 
used as prognostic signature. Based on different prediction 
models (binary discrete model and linear models), the prediction 
accuracy ranged from 84.31% to 88.24% compared with 
subsequent 2-year follow-up. When applied all the computed 
classifiers to serial time-point samples of seven progressors and 
five non-progressors collected during the 2-year follow up, binary 
discrete model show a better prediction stability. Low miR-31, 
miR-29b, miR-590-5p were associated with poor progression-
free rate, independent of age, gender and known prognostic 
factors including viral load and immune activation.
Conclusion: A unique microRNA signature has been associated 
with advance disease and identified as potential prognostic 
marker, and provides a new strategy to select patients who 
would benefit from earlier ART.
P06.03 
Interactions Between HLA-B and Leukocyte 
Immunoglobulin Like Receptors B2 (LILRB2) Correlate 
with HIV-1 Disease Outcomes
E. Martin Gayo1, D. Jones2, F. Pereyra1, M. Lichterfeld3,  
R.L. Allen2, X.G. Yu1
1Ragon Institute of MGH, MIT and Harvard, Boston, MA, USA; 
2St George’s, University of London, London, United Kingdom 
(Great Britain); 3Infectious Disease Division, Massachusetts 
General Hospital, Boston, MA, USA
Background: Recently, a genome-wide association study identified 
3 amino acids (residues 67, 70, 97) in the HLA-B peptide binding 
groove that explain the classical HLA class I associations with 
HIV-1 immune control. However, how amino acid substitutions 
at these positions affect HIV-1 immune defense remains unclear. 
Leukocyte Immunoglobulin Like Receptors (LILR) are a class of 
immunoregulatory molecules that are expressed on myeloid 
dendritic cells and interact with HLA class I molecules as their 
physiologic ligands. Here, we assessed how different amino acids 
in the HLA-B binding groove may influence their binding to LILRs.
Methods: Using a cell-free assay, the binding strength between 
50 HLA-B alleles and recombinant LILRB2-Fc fusion protein was 
experimentally determined. Average bindings scores to LILRB2 
were calculated for HLA-B allotypes sharing identical amino acid 
residues at position 67, 70 and 97. For comparison purposes, 
binding scores to LILRB1 were similarly determined. The average 
binding scores were then correlated to odds ratios reflecting the 
impact of the respective amino acids residues at position 67, 70 
and 97 on HIV-1 disease progression.
Results: Six amino acid variants at position 97, four amino acid 
variants at position 70, and five amino acid variants at position 67 
were included into the analysis. Overall, we observed an almost 
perfect inverse correlation between the odds ratios of each 
amino acid variant at position 97 on HIV-1 control and LILRB2 
binding scores of class I alleles carrying the respective amino acid 
variant (R=0.88, p=0.02). Similar findings were made for amino 
acid variants at position 70 (R=0.993, p=0.007) and position 67 
(R=0.95, p=0.005). No significant correlations were observed 
when HLA-LILRB1 binding scores were used instead of LILRB2.
Conclusion: These data suggest that amino acid polymorphisms 
at position 67, 70 and 97 of the HLA-B binding groove influence 
HIV-1 immune control through altered interactions with the 
immunomodulatory LILRB2 receptor.
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Association of Interleukin-10 Promoter Genetic 
Variants with T-Cell and B-Cell Activation in HIV-1 
Infection 
D. Naicker1, B. Julg2, C. McClurg2, M. Ghebremichael2,  
F. Porichis2, J. Zupkosky2, M. Jaggernath1, M. Mokgoro1,  
P. Goulder3, B. Walker2, D. Kaufmann2, T. Ndung’u1
1HIV Pathogenesis Programme, Durban, South Africa; 2Ragon 
Institute of MGH, MIT and Harvard, Boston, MA, USA; 
3University of Oxford, Department of Paediatrics, United 
Kingdom, United Kingdom (Great Britain)
Background: Interleukin-10 (IL-10) is a potent immunoregulatory 
cytokine, with promoter polymorphisms that have previously 
been associated with HIV-1 susceptibility and pathogenesis. 
Association of IL-10 SNPs with markers of CD4, CD8 and B cell 
activation has not previously been investigated.
Methods: Two IL-10 polymorphisms were genotyped by TaqMan 
allelic discrimination and markers of activation of CD4, CD8 and 
B cells were measured in 63 individuals using flow cytometry. 
The following monoclonal antibody combinations were used: 
anti-CD3 Pac-blue, anti-CD38 PE-Cy7, anti-HLA-DR ACP-Cy7, anti-
CD95 PE, anti-CD19 Alexa-700, anti-IgG PE-Cy5, anti-PD-1 APC, 
anti-Ki67 FITC, anti-CD4 Qdot605 and anti-CD8 Qdot655.
Results: Previous studies on this cohort showed a significant 
association between -1082GG and higher median IL-10 expression, 
compared to the -1082AA/AG (p= 0.0006). The -592AA and 
-1082AA (both previously shown to be associated with low-IL-10 
production) had significantly higher median expression of HLA-
DR on CD4 and CD8 cells respectively, compared to the other 
genotypes (-592AA vs. -592CA p= 0.005, -592AA vs. -592CC p= 
0.03 and -1082AA vs. -1082AG p= 0.02). The -592AA genotype also 
had a higher median expression of CD95 and PD-1 on CD4 cells 
(-592AA vs. -592CA p= 0.0227, -592AA vs. -592CC p= 0.0270 and 
-592AA vs. -592CA p= 0.01 respectively). The -592CC and -1082GG 
genotypes associated with higher median expression of IgG on the 
surface of B cells (-592CC vs. -592AA p= 0.0207 and -1082GG vs. 
-1082AG p= 0.0392, -1082GG vs. -1082AA p= 0.0051).
Conclusion: These data suggest that IL-10 polymorphisms that 
affect cytokine production and HIV pathogenesis may affect 
markers of immune activation and exhaustion in response to 
antigen, and suggest a beneficial role for IL-10 in chronic HIV 
infection. Further studies on association between IL-10 and the 
quality and magnitude of immune responses in HIV infection 
are needed.
P06.05
Human Leukocyte Antigen Class I Supertypes and 
Viral Control in HIV-1 Infected Former Plasma Donors 
from China
J. Hao1, K. Hong1, J. Chen1, M. Jia1, Y. Ruan1, Y. Shao1
1National Center for AIDS/STD Control and Prevention, Beijing, 
China
Background: The role of human leukocyte antigen (HLA) class I 
supertypes in controlling human immunodeficiency virus type 1 
(HIV-1) infection in Chinese has not been established. The aim 
of this study is to examine the frequency of HLA-A and HLA-B 
alleles and supertypes of 222 HIV-1 infected former plasma 
donors in central China and to investigate their impact on HIV-1 
viral control.
Methods: HLA-A and HLA-B alleles were genotyped with PCR-SSP 
and sequence-based typing assay to four-digit resolution. The 
HLA alleles were classified functionally to 4 HLA-A supertypes 
and 6 HLA-B supertypes according to their shared peptide 
binding properties. Plasma viral load was determined using the 
Roche Amplicor ultrasensitive assay which has a lower detection 
limit of 50 copies HIV-1 RNA per ml.
Results: HLA-A03 supertypes(A03s) and HLA-B62 supertypes(B62s) 
were associated with lower viral load (P=0.0206, P=0.0483), 
whereas HLA- A24 supertypes(A24s) appeared to have an 
association with higher viral load (P=0.0483). There was a highly 
significant correlation between the genotypic supertypes(GS) 
and viral load (Kendall’s tau b = 0.180, P=0.000). The median viral 
load was lower among A*3001(P=0.0139)、A*1101(P=0.0096)
、B*5101(P=0.0025)、B*3501(P=0.0091) or B*4601(P=0.001) 
carriers and higher in A*2301(P=0.0106) carriers.
Conclusion: HLA-A03s and -B62s may be associated with 
favorable HIV-1 viral control, A24s associated with unfavorable 
viral control; HLA-B*4601 within B62s and HLA-A*2301 within 
A24s might contribute to the outcomes of HIV-1 viral control.
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KIR-HLA Footprints and NK Cell-Mediated 
Recognition of HIV-1
C.F. Thobakgale1, J. Carlson2, J. Wright1, N. van Teijlingen3,  
M. Jaggernath1, P. Goulder4, B.D. Walker3, M. Carrington5,  
D. Heckerman2, M. Altfeld3, T. Ndung’u1
1University of KwaZulu-Natal, Durban, South Africa; 2Microsoft 
Research, Redmond, WA, USA; 3Ragon Institute of MIT, MGH 
and Harvard, Boston, MA, USA; 4University of Oxford, Oxford, 
United Kingdom (Great Britain); 5Cancer and Inflammation 
Program, Laboratory of Experimental Immunology, Frederick, 
MD, USA
Background: Increasing data suggest an important role of KIR+ 
NK cells in the control of HIV-1, however the precise mechanisms 
on how NK cells recognize HIV-1-infected cells remain poorly 
understood. KIRs can bind to HLA class I molecules, but the 
binding affinity of these interactions is dependent on the HLA 
class I presented epitope. Recent reports have suggested that 
sequence variations within HIV-1 epitopes presented by HLA class 
I can affect the binding of inhibitory KIRs expressed on NK cells, 
potentially modulating NK cell responses to infected cells. Here 
we investigated whether HIV-1 might adapt to the combined KIR/
HLA genotypes on a population level to identify areas within HIV-
1 that might be targeted by KIR+ NK cells. 
Methods: HIV-1 Gag was sequenced in 390 untreated chronically 
clade C infected individuals from KwaZulu-Natal, South Africa. All 
study subjects were HLA class I and KIR typed. Phylogenetically-
corrected logistic regression analysis of KIR/HLA associated Gag 
sequence polymorphisms was performed and q-values were 
used for multiple test correction.
Results: A total of 93 sequence polymorphisms significantly 
associated with the combined HLA/KIR genotypes were identified 
(p<0.05), 6 of them with a false-positive rate of less than 20% 
(q<0.2). These significant associations were independent of 
previously identified KIR or HLA-linked polymorphisms. 
Conclusion: This study identified several sequence 
polymorphisms within HIV-1 Gag that were significantly 
associated with the expression of combined KIR/HLA genotypes 
at the population level, indicating adaptation of HIV-1 to NK cell 
mediated immune pressure. KIR/HLA class I binding studies in 
the context of the sequence polymorphisms and studies for NK 
cell function are ongoing to determine the consequence of these 
sequence changes for NK cell-mediated recognition of HIV-1-
infected cells.
P07.01
Two Independent Functions of Vγ2Vδ2 T Cells 
Discriminated by CD16 During HIV-1 Infection
X. He1, H. Liang1, Y. Zhao1, H. Peng1, D. Liu1, Y. Shao1
1National Center for AIDS/STD Control and Prevention, China 
CDC, Beijing, China
Background: Vγ2Vδ2 (Vδ2) T cells play a vital role in the control 
of HIV infection. Vδ2 T cells recognize phosphoantigens such as 
IPP, and they mediate ADCC through FcγRIIIa (CD16). Our goal is to 
understand how the heterogeneous repertoires of Vδ2 T cells are 
involved in both phosphoantigen -induced response and ADCC in 
HIV infection, especially in the early stage of HIV infection.
Methods: PBMCs were obtained from a total of 81 subjects, 
including 18 early, 42 chronic HIV-1 infected subjects (all 
treatment-naive) and 21 healthy subjects. Cellular immune 
functions of Vδ2 T cells were analyzed by flow cytometry.
Results: Circulating Vδ2 T cells comprised two functionally 
diverse subsets which were discriminated by the CD16 
expression. Most cytotoxic molecules and IFN-γ were released 
by CD16- subset (98% in average) after IPP stimulation, while 
the CD16+ subset was in charge of triggering ADCC via CD16 
that was closely related to HIV-associated changes in Vδ2 T 
cell-mediated ADCC (p< 0.001). In early HIV infection, the CD16- 
Vδ2 T cells dramatically decreased in comparison with healthy 
controls (p=0.02), accompanied by the decline of IPP-responsive 
Vδ2 T cells (p=0.01). Interestingly, a dramatic functional switch 
of Vδ2 T cell-mediated ADCC with almost reverse profile of the 
CD107a and IFN-γ expression compared to uninfected group was 
observed since early HIV infection. Frequency of CD107a+ Vδ2 
T cells from early-infected group was significantly higher than 
that from healthy controls (p<0.05). Although the IPP-activated 
Vδ2 T cells declined notably in chronic-infected individuals with 
CD4>500 (cells/μl), the percentage of antibody-dependent 
cytotoxic Vδ2 T cells was over threefold as high in CD4>500 
individuals as in healthy controls (p<0.05 for both).
Conclusion: These data revealed the involvement of two 
Vδ2 T subsets with different functions during HIV infection 
and highlighted the plasticity of Vδ2 T cell-mediated ADCC in 
controlling HIV infection. 
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TLR7/9 Antagonist Reduces HIV-1-Induced Immune 
Activation
J. Chang1, R.J. Lindsay1, E.H. Doyle1, V. Vrbanac2, E.N. Seung2,  
T. Dudek1, R.J. Bosch3, M. Precopio4, E. Kandimalla4, A. Tager2, 
M. Altfeld1
1Ragon Institute of MGH, MIT and Harvard, Boston, MA, 
USA; 2Massachusetts General Hospital, Boston, MA, USA; 
3Harvard School of Public Health, Boston, MA, USA; 4Idera 
Pharmaceuticals Inc., Cambridge, MA, USA
Background: T cell immune activation is a strong predictor of 
HIV-1 disease progression and HIV-1 transmission, and IFN-
alpha production following TLR7 stimulation has been associated 
with elevated CD8+ T cell activation (Meier et al., Nat Med 
2009). We therefore hypothesized that modulation of TLR7 
stimulation could be used to manipulate IFN-alpha production 
and subsequently reduce HIV-1-associated immune activation. 
TLR7/9-specific antagonists developed for treatment of auto-
immune diseases were used in vitro and in vivo in a humanized 
mouse model.
Methods: Humanized BLT mice were generated by transplanting 
irradiated NOD/SCID/γc-/- mice with human fetal thymus and 
injected with human hematopoietic stem cells isolated from 
matching liver tissue. Following reconstitution, cells were 
harvested from the mice to examine the effects of the antagonist 
in vitro. Humanized mice were also infected with HIV-1 and then 
either treated or untreated with TLR7/9 antagonist from Idera. 
T cell activation markers were examined pre-infection, following 
infection and during treatment with the antagonist. Additionally, 
responsiveness of DCs to TLR7/8 stimulation ex vivo following in 
vivo TLR7/9 antagonist treatment was assessed by intracellular 
cytokine staining. 
Results: 16-20 weeks after transplant, human DC, monocyte and 
T cell populations were detectable in the mice. Ex vivo stimulation 
with TLR7/8 induced cytokine production by humanized mice DCs 
and monocytes similar to those observed from human PBMCs 
and this was significantly blocked by in vitro treatment with the 
TLR7/9 antagonist (P<0.05). HIV-1 infection of humanized mice 
led to increased T cell immune activation marker CD38 on human 
T cells in vivo, and treatment of infected mice with the TLR7/9 
antagonist led to a significant reduction in CD38 expression. 
Conclusion: Treatment of HIV-1-infected humanized BLT mice 
with a TLR7/9 antagonist resulted in a significant reduction of 
HIV-1-associated immune activation. This may have important 
implications in reducing viral transmission associated with higher 
immune activation in HIV-1.
P07.03
Frequent and Strong Antibody-Mediated NK Cell 
Activation to HIV-1 Env in Individuals with Chronic 
HIV-1 Infection
C. Thobakgale1, L. Fadda2, K. Lane2, I. Toth2, F. Pereyra2,  
S. Bazner2, T. Ndung’u1, B.D. Walker2, E. Rosenberg2, G. Alter2, 
M. Carrington3, T. Allen2, M. Altfeld2
1University of KwaZulu-Natal, Durban, South Africa; 2Ragon 
Institute of MIT, MGH and Harvard, Boston, MA, USA; 3Cancer 
and Inflammation Program, Laboratory of Experimental 
Immunology, Frederick, MD, USA
Background: Natural killer (NK) cells are critical in viral control 
and NK cells that respond to HIV-1 peptides have been described. 
However, it is unclear how NK cells recognize HIV-1 antigen. We 
investigated NK cell responses to HIV-1 peptides during early and 
chronic HIV-1 clade B infection.
Methods: NK cells responding to HIV-1 peptides were assessed 
by multiparameter flow cytometry using whole blood from 74 
individuals with treated or untreated early or chronic HIV-1 infection. 
In addition, 15 HIV uninfected individuals were also studied.
Results: No NK cell responses to HIV-1 peptides were detected in 
HIV-1 uninfected individuals. The HIV-1 NK cell specific responses 
to peptide were less frequent during the first year of infection 
but were of high magnitude and frequent in individuals with 
controlled or progressive infection (22% vs 79%; P<0.00001). 
The activation of NK cells to peptide pools required the presence 
of plasma IgG and the responding NK cells had a low CD16 
expression and high CD57 expression. Furthermore, plasma 
derived from HIV-1 infected individuals was sufficient to trigger 
a response to HIV-1 Env peptide pool by NK cells from healthy 
donors suggesting the role of antibodies in mediating this activity. 
Conclusion: NK cell responses to specific antigens can be 
induced in HIV-1 infection. Large cohorts are needed to assess 
the consequences of these NK cells against HIV-1 control or 
protection from infection.
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Toll Like Receptor 7 Regulates Viral Loads and 
Cytokine Secretion During Acute Retroviral Infection
E. Browne1
1Massachusetts Institute of Technology, Cambridge, MA, USA
Background: Acute HIV infection is characterized by a high 
viremia accompanied by a powerful wave of pro-inflammatory 
cytokines that affects the subsequent course of infection 
and pathogenesis. Thus, understanding the mechanisms that 
regulate cytokine secretion and viremia is a key priority. The 
innate immune receptor TLR7 has been identified a retrovirus-
sensing protein, and is expressed in several key immune lineages. 
In vitro data suggests that HIV can trigger TLR7-dependent innate 
immune responses, but TLR7s role in vivo is unclear.
Methods: To determine whether TLR7 affects viremia or cytokine 
secretion during acute retroviral infection, we analyzed the 
plasma of wild type and TLR7 deficient mice infected with the 
model retrovirus, Friend virus (FV). 
Results: We identified 16 cytokines that are significantly 
upregulated in the plasma of wild-type mice infected with FV, 
the majority of which are also upregulated during HIV infection. 
Individual cytokines have distinct kinetic profiles and intensities, 
with peak levels ranging from 5dpi to 14dpi. To examine the 
contribution of TLR7 to this response, we compared viral 
loads and cytokine levels of wild-type or TLR7 deficient mice. 
Surprisingly, we found that majority of the pro-inflammatory 
cytokines exhibited exacerbated secretion in the absence of 
TLR7, while only an early wave of the anti-inflammatory cytokine 
IL-10 was attenuated. This exacerbated cytokine storm was 
accompanied by an elevated viremia. Significantly, IL-10 deficient 
mice also exhibited elevated viremia and cytokine secretion 
during acute infection. By contrast, TLR7deficient mice exhibit an 
attenuated antibody response, while anti-viral antibody levels in 
IL-10 deficient mice were normal. 
Conclusion: Our results demonstrate that TLR7 negatively 
regulates viral loads and cytokine secretion during acute retroviral 
infection by promoting an early wave of IL-10, and that TLR7 
regulates the development of anti-viral antibodies independently 
of IL-10. These results reveal that TLR7 plays multiple roles in 
regulating the immune response to retroviral infection. 
P07.05
Tim-3-Mediated Signaling in NK Cells May Be 
Modulated by Increased Galectin-9 Expression in 
HIV-1 Infection
S. Jost1, U.Y. Moreno-Nieves1, W.F. Garcia Beltran1, K. Rands1,  
J. Reardon1, I. Toth1, A. Piechocka-Trocha1, B.D. Walker1,  
M. Altfeld1, M.M. Addo1
1Ragon Institute of MGH, MIT and Harvard, Boston, MA, USA
Background: Natural Killer (NK) cells constitutively express 
high levels of Tim-3, an immunoregulatory molecule recently 
proposed to be a marker for mature and fully functional NK cells 
(Ndhlovu et al., 2012). Cytokines can induce Tim-3 expression on 
NK cells, and IFN-gamma production by Tim-3+ NK cells can be 
enhanced by exposure to Galectin-9 (Gleason et al. 2012), yet 
their ability to kill target cells is lost upon Tim-3 cross-linking. 
Moreover, up-regulation of Tim-3 on NK cells has been associated 
with reduced anti-viral properties in chronic hepatitis B infection 
(Ju et al., 2010). However, the impact of HIV-1 infection on Tim-3 
expression on NK cells and on Tim-3-mediated NK cell function 
has not been studied yet.
Methods: Flow cytometry was used to analyze Tim-3 and 
intracellular galectin-9 expression in subjects with acute and 
chronic HIV-1 infection, in HIV-1 elite (VL <50 copies/ml) and 
viremic controllers (VL <2000 copies/ml), and in HIV-1 negative 
subjects. Plasma levels of Galectin-9 were quantified by ELISA. 
Results: HIV-1 infection was associated with reduced expression 
of Tim-3 on NK cells, as early as in acute infection, and could 
be normalized by HAART. Importantly, percentages of Tim-3+ 
CD56dim NK cells correlated with CD4+ cell counts in untreated 
patients. Plasma concentrations of Galectin-9 were higher 
in HIV-1-infected individuals than in controls. Interestingly, 
Galectin-9 expression in immune cells was significantly elevated 
in acute infection, with monocytes and dendritic cells displaying 
the highest levels, which correlated with viral loads. In vitro, 
Galectin-9 triggered NK cell activation and Tim-3 down-regulation 
on NK cells. 
Conclusion: Further investigations are warranted to determine 
whether increased Galectin-9 production alters Tim-3 function 
and contributes to NK cell impaired activity in chronic HIV-1 
infection. Defining the role of NK cell receptors in the control 
of HIV-1 will offer novel therapeutic targets to manipulate and 
improve future HIV-1 vaccine strategies. 
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Implications of Post-translational Modifications of 
IRF7 on pDC IFN-Alpha Response
M. Griesbeck1, E. Doyle1, R.J. Lindsay1, J. Boucau1, S. LeGall1,  
M. Altfeld1, J.J. Chang1
1Ragon Institute of MGH, MIT and Harvard, Charlestown, MA, 
USA
Background: We previously showed that plasmacytoid dendritic 
cells (pDCs) derived from females can produce significantly more 
IFN-alpha in response to HIV-1 and HIV-1-encoded TLR7/8 ligands 
than pDCs derived from males, resulting in stronger secondary 
activation of CD8+ T cells (Meier et al., Nat Med 2009). Given the 
crucial role of interferon regulatory factor 7 (IRF7) in the regulation 
of type I IFN production by pDCs, the goal of the current study was 
to investigate its impact on the observed differences. 
Methods: Fresh PBMC were isolated from HIV-1-negative subjects 
enrolled at Massachusetts General Hospital and stimulated by 
either CL097 (synthetic TLR7 ligand) or AT-2 inactivated HIV-1. 
Phosphorylation levels of proteins involved in the TLR7 pathway 
including IRF7 were measured in pDCs by phospho-flow cytometry 
at baseline and at different time-points after TLR7 stimulation. The 
kinetics of IRF7 modifications in the TLR7 pathway were confirmed 
using mRNA expression of IFN-alpha 
Results: Baseline levels of phosphorylated IRF7 were found to be 
similar between males and females. However we observed faster 
phosphorylation kinetics of IRF7 in females than in males using 
flow cytometry with phospho-IRF7 peaking in females at 20min 
post-stimulation and males at 30min. 
Conclusion: These data indicate that sex differences in the 
kinetics of IRF7 phosphorylation might account for described 
higher IFN-alpha production upon TLR7 stimulation in females, 
providing new insights into the mechanisms underlying faster 
HIV-1 disease progression in females compared to males after 
controlling for viral load (Farzadegan et al., Lancet 1998). 
P07.07
Developing a Quantitative Model of Antibody 
Effector Function
A.W. Boesch1, M. Ackerman1
1Thayer School of Engineering at Dartmouth, Hanover, NH, USA
Background: While the induction of neutralizing antibodies 
remains a cornerstone of HIV vaccine development, the success 
of the Thai trail and evidence from non-human primate (NHP) 
studies has indicated that non-neutralizing antibodies may 
provide protection from infection. These non-neutralizing 
antibodies can act as molecular beacons to recruit innate immune 
cells to recognize infected CD4T cells or free virus as pathogenic. 
The ability of an antibody to efficiently recruit innate immune 
cells depends on complex interactions between the pathogenic 
target, the antibody, and an effector cell. 
Methods: Here we present a quantitative model of natural killer 
cell mediated antibody dependent cellular cytotoxicity (ADCC), 
and examine the impact of core fucosylation, FcgR3a expression/
occupancy, serum IgG competition and mutations in the Fc 
binding domain. 
Results: The results indicate that FcgR3a site occupancy can 
predict the percentage of cells killed on an ADCC dose response 
curve. In addition, it appears ADCC is initiated past a threshold of 
FgR3a site occupancy on the natural killer cell. 
Conclusion: This provides key insight into the mechanism of the 
innate immune response and provides powerful evidence that 
the effector function of antibodies should be a key consideration 
in the development of HIV vaccines. 
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Dendritic Cell Mediated Inhibition of Lentiviral 
Infection
A. Drake1, E. Browne1, R. Phennicie1, J. Chen1
1MIT Koch Institute for Integrative Cancer Research, 
Cambridge, MA, USA
Background: Lentiviral entry to quiescent lymphocytes 
represents a ‘time bomb’ waiting for cellular activation to 
spread infection. In order to undergo immune activation T cells 
interact with dendritic cells presenting peptide:MHC complexes 
‘sampling’ them to look for agonist peptides and receiving 
survival signals from self peptides. This makes the dendritic 
cell:T cell interaction an ideal checkpoint to contain lentiviral 
infection of quiescent lypmhocytes.
Methods: We have used replication defective lentiviral vectors 
expressing reporter genes and/or HIV proteins to study the innate 
immune response to lentiviral infection in vitro using primary 
mouse and human cells and in vivo in B6 mice. We have used 
flow cytometry and PCR to quantify the infection rates in various 
culture and adoptive transfer conditions to identify conditions 
where successful viral infection is inhibited.
Results: Activating T cells exposed to dendritic cells display 
inhibited lentiviral vector infection compared to activated 
control cells. This infection reduction is mediated by dendritic 
cell:T cell contact. Dendritic cell mediated inhibition of infection 
reduces over time as cells become fully activated and proliferate. 
When using lentiviral vectors similar results are seen in primary 
human T cells in culture. However when replication defective 
vectors expressing HIV proteins are used to infect T cells de novo 
expression of HIV proteins in the host cell prevents DC mediated 
inhibition. We have gone on to use knockout mice to assess 
the role of established innate immune sensing pathways in DC 
mediated inhibition but have not yet identified the molecular 
sensor mediating this phenomenon.
Conclusion: The inhibition of productive T cell infection by 
lentiviral vectors caused by contact with dendritic cells represents 
a previously undescribed innate immune response which we 
have called DC mediated inhibition. The successful lentiviral 
pathogen HIV overcomes DC mediated inhibition enhancing its 
replication and obscuring this immune response. 
P07.09
HLA-Cw*0102-Restricted HIV-1 p24 Epitope Variants 
Can Modulate the Binding of the Inhibitory KIR2DL2 
Receptor and Primary NK Cell Function
C. Koerner1, L. Fadda1, S. Kumar1, N. van Teijlingen1,  
A. Piechocka-Trocha1, M. Carrington2, M. Altfeld1
1Ragon Institute of MGH, MIT and Harvard, Charlestown, MA, 
USA; 2National Cancer Institute at Frederick, Frederick, MD, 
USA
Background: Recently, it was shown that Natural Killer (NK) 
cell-mediated immune pressure can result in the selection of 
HIV-1 escape mutations contributing to accumulating evidence 
suggesting that NK cells play an important role in the control 
of HIV-1 infection. Selection of HLA class I-presented HIV-1 
epitopes that allow for engagement of inhibitory killer cell Ig-
like receptors (KIRs) might serve as a potential mechanism for 
NK cell escape. We therefore investigated the consequences of 
sequence variations within HLA-Cw*0102-restricted epitopes 
on the interaction with KIR2DL2 using a large panel of HIV-1 
p24 Gag peptides.
Methods: A total of 217 decameric peptides spanning HIV-1 p24 
Gag and overlapping by 9aa were screened for HLA-Cw*0102 
stabilization by co-incubation with Cw*0102(+) TAP-deficient T2 
cells using a flow cytometry-based assay. KIR2DL2 binding was 
assessed using KIR2DL2-Fc. Function of KIR2DL2(+) NK cells was 
flow cytometrically analyzed by measuring degranulation of 
primary NK cells after co-incubation with peptide-pulsed T2 cells.
Results: We identified 11 peptides stabilizing HLA-Cw*0102 on 
the surface of T2 cells. However, only one peptide (p24 Gag209-
218) also allowed for binding of KIR2DL2. Notably, functional 
analysis showed significant inhibition of KIR2DL2(+) NK cell 
function in the presence of p24 Gag209-218-pulsed T2 cells, 
while degranulation of KIR2DL2(-) NK cells was not affected. 
Moreover, we demonstrated that sequence variations in position 
7 of this epitope observed frequently in naturally occurring HIV-1 
sequences can modulate binding to KIR2DL2.
Conclusion: Our results show that variations in HIV-1 peptides 
presented by HLA can modulate target cell recognition by NK 
cells. Understanding the mechanisms that determine NK cell-
mediated recognition of HIV-1-infected cells will be a critical step 
for harnessing NK cell immunity for vaccine design, in particular 
given the recent discovery of virus-specific memory NK cells in 
mice (Paust et al., Nat Imm 2009). This study was supported by 
the NIH, Ragon Institute and HU CFAR.
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HIV-1 p24 Derived Epitopes Modulate KIR2DL2-
Binding to HLA-Cw03
N.H. van Teijlingen1, C. Körner2, L. Fadda2, C. Brander3,  
M.N. Carrington4, D. van Baarle1, M. Altfeld2
1UMC Utrecht, Utrecht, Netherlands; 2Ragon Institute of 
MGH, MIT and Harvard, Boston, MA, USA; 3IrsiCaixa (Institut 
de Recerca de la Sida), Barcelona, Spain; 4National Cancer 
Institute at Frederick, Frederick, MD, USA
Background: Recent studies have suggested that HIV-1 can 
evade Natural Killer (NK)-cell-mediated immunity by mutating 
viral epitopes to enhance engagement of inhibitory Killer Ig-like 
receptors (KIRs) expressed on NK cells. However, the precise 
mechanisms modulating the interaction of inhibitory KIRs and 
their HLA class I ligands, and the role that HIV-1 epitopes might 
play in this interaction are not well understood. In this study 
we investigated whether HLA-Cw3-presented epitopes within 
HIV-1 p24 Gag can modulate binding of KIR2DL2, an inhibitory 
KIR, to HLA-Cw03. 
Methods: Using tapasin-deficient 721.220 cell line expressing 
HLA-Cw*0304 we initially screened for HIV-1 peptides that 
stabilized HLA-Cw*0304 expression using 222 10-mer peptides 
overlapping by 9 amino acids spanning the entire HIV-1 p24 Gag 
sequence. Peptides stabalizing HLA-Cw*0304 expression were 
thereafter investigated for their ability to facilitate binding of a 
KIR2DL2-IgG fusion construct.
Results: We identified several HIV-1 p24 epitopes that were 
able to stabilize HLA–Cw*0304 expression. A subset of these 
epitopes also allowed for binding of KIR2DL2. Currently we are 
investigating the consequences of KIR2DL2-binding to HLA class I 
presented HIV-1 epitopes for the antiviral function of primary NK 
cells from KIR2DL2+ individuals.
Conclusion: Taken together, these studies have identified 
epitopes within HIV-1 that enhance the binding of the inhibitory 
NK cell receptor KIR2DL2 to its ligand HLA-Cw3, and are in line 
with recent data suggesting that the sequence of the HLA class 
I presented epitope has an important impact on the interaction 
between KIR and HLA class I (Boyington et al. Nature 2000, Vivian 
et al. Nature 2011).
P07.11
Chronic SIV Infection Induces Differentiation and 
Accumulation of Cytotoxic CD16+ NK Cells in Lymph 
Nodes Followed by Transmigration to the Mucosae
H. Li1, T. Evans1, J. Gillis1, R. Reeves1
1NEPRC, Harvard Medical School, Southborough, MA, USA
Background: Natural killer (NK) cells inhibit lentiviral replication 
both directly and indirectly, but substantial evidence also 
indicates HIV/SIV can induce NK cell dysfunction. NK cells can 
be subdivided based on expression of CD56 and CD16. In blood, 
cytotoxic CD16+ NK cells are the dominant subpopulation, while 
cytokine-secreting CD56+ and double-negative (DN) NK cells are 
the primary NK cells found in lymph nodes (LN). Furthermore, 
CD56+ and DN NK are thought to be precursor populations, 
whereas CD16+ NK cells are terminally differentiated. The effects 
of HIV/SIV infection on NK cell distribution, trafficking, and 
development are unclear. 
Methods: Macaque NK cells were isolated from blood, LN, and 
mucosal tissues of naive and chronically SIV-infected animals and 
then analyzed phenotypically by surface and intracellular flow 
cytometry, evaluated functionally by ICS and in a direct killing 
assay against MHC-devoid 721.221 cells. In situ analyses were 
performed by immunohistochemistry.
Results: In peripheral blood of chronically infected animals, 
we found a specific expansion of CD16+ NK cells, coupled 
with high frequencies of cytotoxic perforin+ CD16+ NK cells in 
LN, where they are normally absent. Interestingly, classic LN-
trafficking molecules, CD62L and CCR7, were downregulated to 
undetectable levels on blood and LN CD16+ NK cells, suggesting 
they did not migrate from extralymphoid tissues. Furthermore, 
the putative NK cell precursors, CD56+ and DN NK cells, exhibited 
increased proliferation and activation, providing a potential 
source of differentiated CD16+ NK cells. CD16+ NK cells in LN also 
upregulated the mucosa-trafficking marker, α4β7, correlating 
with increased frequencies of cytotoxic CD16+ NK cells in 
colorectal and jejunum tissues of infected animals.
Conclusion: Our data suggest a novel mechanism whereby 
lentivirus infection induces differentiation of cytotoxic CD16+ 
NK cells, which are normally absent in LN, to differentiate in 
situ and then transmigrate to the gut mucosa, the primary site 
of virus replication. 
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Modulation of HIV-1 Replication In Primary Dendritic 
Cells In Contact With Autologous CD4 T-Lymphocytes
B. Su1, M.E. Biedma1, A. Lederle1, M. Lambotin1, C. Moog1
1INSERM U748, Université de Strasbourg, Strasbourg, France
Background: Immature dendritic cells (DCs), which reside in 
genital mucosal surfaces, are among the first cells that encounter 
HIV-1. These cells poorly replicate R5-tropic HIV-1, but have 
been shown to efficiently transfer the virus to autologous CD4 
T-lymphocytes. We have shown that HIV-1 replication was 
enhanced in primary HIV-1-loaded DCs when they are in close 
contact with autologous CD4 T-lymphocytes. Recently, SAMHD1 
has been proposed to restrict HIV-1 replication in myeloid cells by 
decreasing deoxynucleoside triphosphate (dNTP) pools. We aimed 
to decipher whether SAMHD1 was involved in the increased HIV-
1 replication observed in DCs coculture with CD4 T-lymphocytes.
Methods: DCs were generated from human blood CD14+ 
monocytes. After 2 hours of incubation with HIV-1, DCs were 
added to autologous primary CD4 T-lymphocytes. The percentage 
of infection was quantified by flow cytometry (intracellular p24 
staining). The expression of intracellular SAMHD1 was measured 
by flow cytometry and by western blot. Virus-like particles 
containing Vpx (VLP-Vpx) was used as control to decrease 
SAMHD1 expression.
Results: HIV-1 replication was enhanced in DCs cocultured 
with autologous CD4 T-lymphocytes compared to DCs alone. 
Slightly lower levels of SAMHD1 expression were detected in 
infected cocultured DCs by flow cytometry. Moreover, addition 
of exogenous dNTPs to the culture significantly increased HIV-1 
replication in DCs. As control, VLP-Vpx enhanced viral replication 
and decreased SAMHD1 expression in DCs.
Conclusion: Preliminary results suggest that the stimulation of 
HIV-1 replication in DCs observed in coculture conditions was 
partially associated to the concomitant decrease of SAMHD1 
expression in DCs. As HIV-1 replication was inhibited by Abs 
in DCs, further investigations are required to determine if 
SAMHD1 modulates HIV-1 replication in the presence of these 
Abs. Cross-links between the restriction factors and humoral 
immune response should be considered in the development of 
an effective anti-HIV-1 vaccine.
P07.13
Early Immune Events During Acute HIV Infection
B.M. Slike7, B. Tassaneetrithep1, S. Nitayaphan2, K. Rono3,  
E. Sanga4, A. Sekiziyivu5, D. Stablein6, L. Eller7, M.A. Eller7,  
J. Kim7, N. Michael7, M. Robb7, M. Marovich7
1Siriraj Hospital, Mahidol University, Bankok, Thailand; 2Armed 
Forces Research Institute of Medical Sciences, Bankok, 
Thailand; 3Walter Reed Program, Kericho, Kenya; 4Mbeya 
Medical Research Programme, Mbeya, United Republic of 
Tanzania; 5Makerere University Walter Reed Project, Kampala, 
Uganda; 6Emmes Corporation, Rockville, MD, USA; 7US Military 
HIV Research Program, Silver Spring, MD, USA
Background: We characterized plasma cytokine and chemokine 
profiles at baseline and during acute infection in a prospective 
high-risk cohort (RV217). PBMC collected in parallel allow for the 
longitudinal analysis of changes in immune cell populations during 
acute infection. These data can provide insight into the earliest 
events in host-HIV interaction and inform HIV vaccine development.
Methods: Semiweekly viral load (VL) testing in individuals at high-
risk for HIV acquisition was performed to prospectively identify 
very early acute HIV infections (Fiebig stage I/II, NAT+/Ab-). 
Cytokines were assayed in plasma from pre-infection through 
early plasma viral load set point using the Q-Plex Multiplex Array 
or by traditional ELISA. Peripheral blood cells were longitudinally 
analyzed with multiparameter flow cytometry.
Results: African participants were all female and acquired subtype 
A, C and D recombinant HIV while participants in Thailand were 
male and acquired HIV subtype E predominantly. Longitudinal 
plasma samples from acutely infected individuals (n=24) showed 
similar trends in cytokine profiles with statistically significant 
increases in expression over time. VL setpoint, IL-10 and MCP-1 
expression differed by region. Preliminary PBMC analysis revealed 
frequency and phenotypic changes in all antigen presenting cell 
populations. Significant decreases in plasmacytoid dendritic cells 
were observed at peak VL, which preceded a sharp decline in 
plasma IFN-α to near baseline values. MCP-1 and IP-10 also rose 
sharply in conjunction with fluctuations in T cell subsets and 
APCs. These early changes could impact adaptive cellular and 
humoral immune responses.
Conclusion: Understanding cytokine kinetics and VL dynamics 
during acute HIV infection may help identify key controls 
of early viral set point. Regional differences may reflect HIV 
subtype, gender, background cytokine expression levels and 
co-morbidities as these covaried. Analyses of correlations 
with immune cell phenotype/function and viral set point are 
underway. Efforts focus on examination of the evolution of the 
innate response after infection, prior to peak viremia.
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HIV Triggers Immunoregulatory Dendritic Cells And 
Regulatory T Cells Through The Non-Canonical NF-kB 
Pathway
O. Manches1, M.V. Fernandez1, J. Plumas2, L. Chaperot2,  
N. Bhardwaj1
1NYU Cancer Institute, New York City, NY, USA; 2Inserm, U823, 
Immunobiologie et Immunotherapie des cancers, La Tronche, 
France
Background: HIV stimulates plasmacytoid dendritic cell (pDC) 
through TLR7 and induce the secretion of high levels of IFNα. 
pDC stimulated by HIV also upregulate the expression of the 
enzyme indoleamine 2,3 dioxygenase (IDO). IDO is critical for the 
induction of regulatory T cells (Treg) by HIV-activated pDC. We 
investigated the molecular mechanisms of IDO induction and its 
consequences for Treg function.
Methods: The cells used were purified primary pDC and 
the GEN pDC cell line. A combination of siRNA knock-down, 
immunoprecipitation of TLR signaling pathway molecules, IDO 
promoter engineering and chromatin immunoprecipitation was 
used to determine the molecular mechanisms of IDO induction in 
pDC. To analyze Treg function and interaction with conventional 
DC (cDC), blocking antibodies to CTLA- 4 and CTLA-4-Ig were used.
Results: We demonstrate that HIV induces activation of the 
non-canonical NF-kB pathway in pDC, and is essential for 
IDO induction. TLR7 triggering induces recruitment of TRAF3 
to the TLR-MyD88 complex, followed by release of NIK and 
phosphorylation of IKKα. Activation of the non-canonical NF-
κB pathway culminates in p52/RelB nuclear translocation and 
binding to the IDO promoter.
Furthermore, IDO-expressing pDC trigger the generation of 
Treg, which dampen cDC activation through CTLA-4. CTLA-4 
also induces IDO expression in cDC in a NIK-dependent fashion, 
allowing cDC to induce Treg from naïve CD4+ T cells.
Conclusion: The non-canonical NF-kB pathway plays a central 
role in regulating IDO expression in pDC and cDC upon HIV 
infection, and may be a potential target for regulating Treg 
activity in chronic or acute HIV infection.
P07.15 LB 
Apoptotic Microparticles Generated During Acute 
HIV-1 Infection Inhibit Human Dendritic Cells Via CD44
D. Frleta1, C.E. Ochoa1, H.B. Kramer2, S.A. Khan1, A.R. Stacey2, 
P. Borrow2, B.M. Kessler2, B.F. Haynes3, N. Bhardwaj1
1New York University Langone Medical Center, New York, NY, 
USA; 2University of Oxford, Oxford, United Kingdom (Great 
Britain); 3Duke University Medical Center, Durham, NC, USA
Background: Acute human immunodeficiency virus type 1 (HIV-
1) infection results in dysregulated immunity which contributes 
to poor control of viral infection. Dendritic cells (DCs) are key 
regulators of both adaptive and innate immune responses 
needed for controlling HIV-1 and we surmised that plasma 
factors elicited during acute HIV-1 infection (AHI) may impede DC 
function. Such inhibitory factors present in AHI plasma include 
apoptotic microparticles (MPs), small membranous blebs derived 
from dying cells.
Methods: Plasma samples over sequential time points were 
obtained from AHI patients or healthy controls. Apoptotic MPs 
were isolated from supernatant of UV-irradiated PBMCs, AHI 
patient plasma or control plasma. Human DCs were treated with 
MPs or 10% plasma (control or AHI) and subsequently stimulated 
with various TLR agonists. DC activation was then assessed. 
MP-specific receptors were isolated from the DC surface and 
sequenced by mass spectrometry. 
Results: AHI plasma inhibited TLR-stimulated DC cytokine 
production. The inhibitory capacity of AHI plasma occurs at 
time of viral ramp-up, whereas plasma at times before plasma 
viremia is not inhibitory. We determined this inhibition was not 
mediated by virus. Because apoptotic MPs are elevated in AHI 
plasma, we treated DCs with experimental and AHI plasma-
derived MPs, both of which reduced DC activation. The inhibition 
of DCs by AHI plasma or MPs blocked DC capacity to prime IFNg-
producing T helper 1 CD4+ T cells as well as NK cell activation. 
Mass spectrometric analysis revealed CD44 a MP receptor, and 
blocking CD44 on DCs relieves MP-mediated suppression. Direct 
ligation of CD44 also inhibits DC activation. MP-CD44 interaction 
activates Rac1, c-Abl, and AKt signaling.
Conclusion: Determining the factors in AHI which block DC 
function will provide potential targets to stimulate HIV-specific 
immunity. We are currently investigating molecular mechanisms 
of CD44-mediated DC inhibition and downstream signaling 
events that can be targeted to alleviate DC inhibition.
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Are the KIR3DS1homozygous and 
KIR3DL1*h/*y+HLA-B*57 Genotypes Associated 
Protection From HIV by Different Routes of 
Exposure?
B. Tallon2, J. Bruneau1, C.M. Tsoukas2, J. Routy2, N.F. Bernard2
1Centre de Recherche du Centre Hospitalier de l’Université de 
Montréal, Canada; 2Research Institute McGill University Health 
Center, Montreal, Canada
Background: We previously reported that HIV Exposed 
Seronegative (HESN) individuals have a higher frequency than 
HIV infected subjects of 2 genotypes: homozygosity for Killer 
Immunoglobulin-like Receptor (KIR) 3DS1 (KIR3DS1hmz) and 
homozygosity for high expression KIR3DL1 genotypes co-expressed 
with HLA-B*57 (*h/*y+B*57). KIR3DL1/S1 are Natural Killer (NK) 
cell receptors that influence NK functionality. Here, we assessed 
whether these genotypes were associated with protection by 
parenteral and mucosal routes of HIV exposure.
Methods: 473 Caucasian individuals were typed for HLA, KIR3DL1/
S1 generic genotypes and KIR3DL1 allotypes. Of 88 HESN, n=69 
were injection drug users (IDU) and 19 were sexually exposed 
(sHESN). Of 385 HIV seropositive subjects n=108 were IDU and 
n=277 were infected through sexual exposure. The frequency of 
KIR3DS1hmz and *h/*y+B*57 carriers was compared in HESN 
versus HIV susceptible subjects exposed through parenteral 
versus mucosal routes.
Results: KIR3DS1hmz were more frequent among HESN than 
HIV positive IDU (10% versus 2.7%, respectively, p=0.05). This 
genotype was also more frequent among HESN than HIV infected 
individuals exposed sexually (25% versus 5.7%, respectively, 
p<0.01). The *h/*y+B*57 genotype was more frequent among 
HESN than HIV positive IDU (7.2 vs. 0%, respectively, p<0.01). This 
genotype was not observed among any sHESN and was detected 
in 1.8% of mucosally HIV infected individuals (p=not significant).
Conclusion: The protective HESN KIR3DS1hmz genotype is 
associated with protection from HIV infection by both mucosal 
and parenteral routes. *h/*y+B*57 carriers are more frequent 
among IDU HESN than HIV susceptible subjects suggesting a 
protective effect via exposure by this route. Although there is no 
evidence that the *h/*y+B*57 genotype is protective at the level 
of sexual exposure the small number of sHESN precludes making 
firm conclusions on this point. Carriage of both these genotypes 
is linked to potency of NK cell function, which may influence 
early innate responses to HIV.
P07.17 LB 
S100A9 Protein is a Novel Ligand for the Receptor 
CD85j and Their Interaction is Implicated in the NK 
cell-mediated control of HIV-1 Replication
U.Y. Moreno Nieves1, V. Arnold1, J.S. Cummings1, C. Didier1,  
A. Gilbert1, F. Barré-Sinoussi1, D. Scott-Algara1
1Institut Pasteur, Paris, France
Background: CD85j is a receptor expressed by different cells of 
the human immune system including Natural Killer (NK) cells. 
Previous reports have shown that CD85j interacts with several 
MHC-I molecules, as well as with some viral proteins (Cosman 
D et al., 1997). We have also demonstrated that CD85j+ NK 
cells efficiently control HIV-1 replication in monocyte-derived 
dendritic cells (MDDC) in vitro (Scott-Algara D et al., 2008). We 
hypothesize that the CD85j+ NK cell-mediated anti-HIV activity 
in MDDC is specifically dependent on the interaction between 
CD85j receptor and unknown non-HLA class I ligand(s). Therefore 
we focused on the identification CD85j ligand(s) and its(their) 
implication in the control of HIV-1 infection.
Methods: To identify the CD85j ligand(s), lysates from MDDC 
infected or not by HIV-1 were co-immunoprecipitated using 
CD85j recombinant receptor and analyzed by SELDI-TOF-MS 
protein chip arrays. The interaction between CD85j and its 
ligand(s) where then confirmed by ELISA test. Surface expression 
of the putative ligand(s) was analyzed by flow cytometry. To 
confirm the implication of the interaction receptor-ligand in the 
control of HIV replication, NK cells were pre-stimulated with 
CD85j ligands and co-cultured with HIV-infected MDDC or CD4+ 
T cells, then, intracellular and supernatant p24 were measured. 
Results: We found that the CD85j receptor interacts with the 
calcium-binding protein S100A9. We further demonstrated 
that HIV-1 infection of MDDC modulates the expression of S100 
proteins at the surface of MDDC. Pre-stimulation of NK cells 
with S100A9 monomers resulted in an increased control of HIV 
infection in MDDC and CD4+ T cells. Moreover, pre-stimulation of 
NK cells with S100A9 tetramers resulted in a better and increased 
control of HIV-1 infection in CD4+ T cells. 
Conclusion: Triggering the inhibitory receptor CD85j on NK cells 
by S100A9 may be implicated in the establishment and/or the 
regulation of the specific anti-HIV-1 NK cell response.
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KIR/HLA Genotype Combinations Are Determinants 
Of Natural Killer (NK) Cell Mediated Antibody-
Dependent Cellular Cytotoxicity (ADCC) Potency
M.S. Parsons1, P. Zanoni1, B. Tallon1, S. Miconiatis1, N. Shoukry2, 
J. Bruneau2, C.M. Tsoukas1, N.F. Bernard1
1Research Institute McGill University Health Center, Montreal, 
Canada; 2Centre de Recherche du Centre Hospitalier de 
l’Université de Montréal, Canada
Background: Several allelic variants of the killer immunoglobulin-
like receptor 3DL1 (KIR3DL1) in combination with their HLA-
Bw4 ligands, are associated with protection from HIV infection 
and/or time to AIDS. The HLA-B*57+KIR3DL1*h/*y genotype 
combination (KIR3DL1*h/*y encodes high expression receptors) 
has the most potent effect on slowing time to AIDS in HIV infected 
individuals. Although this HLA/KIR combination confers natural 
killer (NK) cells with high functional potential, the mechanism 
of the AIDS protective effect remains unknown. Indeed, NK cells 
expressing 3DL1 fail to degranulate upon exposure to autologous 
HIV-infected CD4+ T-lymphocytes. As HLA-Bw4/KIR3DL1 
combinations also endow NK cells with antibody-dependent 
cellular cytotoxicity (ADCC) functional potential, we hypothesized 
that NK cells from individuals carrying HLA-B*57+3DL1*h/*y 
mediate more potent ADCC than NK cells from individuals with 
less protective HLA/KIR combinations.
Methods: We compared the ability of NK cells from 39 HIV-
uninfected individuals carrying HLA-B*57+3DL1*h/*y (n=11), 
other HLA-Bw4+3DL1 combinations (n=18), or 3DL1 in the 
absence of HLA-Bw4 (n=10) to mediate anti-HIV ADCC. Anti-HIV 
ADCC was measured as the ability of NK cells to deliver granzyme 
B to HIV gp120-coated CEM.NKr.CCR5 cells (i.e. percent of 
granzyme B positive cells) in the presence of a common source of 
anti-HIV antibodies. This GranToxiLux assay efficiently measures 
ADCC, as target cells do not receive granzyme B in the presence 
of antibodies from seronegative individuals or F(ab’)2 fragments 
of anti-HIV antibodies. 
Results: NK cells from HLA-B*57+3DL1*h/*y carriers mediate 
more potent ADCC (13.4+/-2.61%) than those from individuals 
carrying other HLA-Bw4+3DL1 combinations (5.15+/-1.54%) 
or 3DL1 in the absence of HLA-Bw4 (2.78+/-1.48%) (p=0.002, 
Kruskal-Wallis test, p<0.05 and p<0.01 respectively, Dunn’s 
Multiple Comparisons test). 
Conclusion: Therefore, HLA/KIR dependent NK cell “education” 
is a determinant of ADCC functional potential, and should be 
taken into consideration when evaluating ADCC as a correlate of 
disease progression or vaccine efficacy.
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Mucosal Prime with a Replicating Vaccinia-Based 
Vaccine Promotes Mucosal Immunity Against SIV
X. Tang1, Y. Du1, C. Sun2, L. Chen2, L. Zhang3, Z. Chen1
1AIDS Institute, LKS Faculty of Medicine, The University of 
Hong Kong, Hong Kong, Hong Kong; 2Institute of Biomedicine 
and Health, Chinese Academy of Sciences, Guangzhou, China; 
3Comprehensive AIDS Research Center, Tsinghua University, 
Beijing, China
Background: We previously demonstrated that vaccine prime 
with a recombinant replication-competent modified vaccinia 
Tiantan (rMVTTSIVgpe) was able to enhance the boost effects of a 
rAd5SIVgpe for eliciting protective immunity against SIV mucosal 
challenge in rhesus macaques. Whether this heterologous prime 
and boost regimen is able to elicit potent mucosal immunity 
specific to SIV remains less understood.
Methods: Different groups of mice were immunized with the 
following regiments: rMVTTSIVgpe-rAd5SIVgpe, rAd5SIVgpe-
rMVTTSIVgpe and rAd5SIVgpe-rAd5SIVgpe. rMVTTSIVgpe was 
administrated through intraoral and intranasal routes (ioin) 
routes whereas rAd5SIVgpe was given through the intramuscular 
injection (im).
Results: Consistent with previous findings in macaques, 
mice immunized with the rMVTTSIVgpe-rAd5SIVgpe regimen 
generated significantly stronger systemic cellular immune 
responses as well as serum antibody responses than any other 
vaccine regimens. Furthermore, as compared with other groups, 
this rMVTTSIVgpe-rAd5SIVgpe regimen induced significantly 
higher frequencies of gut-homing CCR9+ Gag-specific CD8+ T 
cells as well as CCR6+ Gag-specific CD4+ and CD8+ T cells. This 
regimen also elicited the highest level of CD8+ T cell ELIspot 
responses against Gag, Pol and Env antigens in mesenteric 
lymph nodes (mLN). Besides, SIV-specific IgGs could be detected 
in the rectal wash of mice received rMVTTSIVgpe-rAd5SIVgpe 
immunization with detectable neutralizing activity.
Conclusion: These findings demonstrated that mucosal priming 
with rMVTTSIVgpe significantly promoted mucosal immunity 
against SIV, which may have implications to the effectiveness 
of the mucosal rMVTTSIVgpe prime-systemic rAd5SIVgpe 
boost vacciniation strategy in preventing mucosal infection of 
SIVmac239 in macaques.
P08.01
Natural Killer Cells Present in Gut Mucosa as 
Potential ADCC Effector Cells
M. Sips1, G. Sciaranghella2, N. Tong2, D. Kwon2, P. Brouckaert1, 
G. Alter2
1Ghent University, Ghent, Belgium; 2Ragon Institute, USA, 
Charlestown, MA, USA
Background: Data from the RV144 HIV vaccine trial showed 
a moderate protection from HIV infection in the absence of 
neutralizing antibodies or CTL activity. In contrast, all vaccinees 
mounted robust HIV-specific binding antibodies, that may have 
provided some level of protection through their capacity to 
recruit antibody dependent cellular cytotoxicity (ADCC). The 
capacity of an antibody to recruit ADCC relies on its ability to 
interact with the Fc-receptor, FCγRIII (CD16), expressed on 
Natural Killer (NK) cells. However, little is known about innate 
immune effector cells present within mucosa, and whether they 
have the capacity to be harnessed by ADCC inducing antibodies 
should they be elicited by a vaccine. Here we hypothesized 
that abundant numbers of CD16+ NK cells line the gut mucosa, 
providing a robust effector arm that could be harnessed by ADCC 
inducing antibodies.
Methods: The frequency and function of CD16+ cells in the colon 
was assessed by flow cytometry following enzymatic digestion of 
intestinal resections from HIV-uninfected subjects.
Results: Significantly fewer NK cells were found in colon 
resections compared to peripheral blood of healthy controls 
(median: 10.40% vs. 18.80%, p=0.0062, respectively). 
Furthermore, while both CD56bright immunoregulatory and 
CD56dim cytolytic NK cells able to mediate ADCC were present in 
the gut, the frequency of these 2 subsets was altered compared 
to the blood. Moreover, fewer NK cells expressed NKp46, 
NKG2A, KIR, CD8, perforin, and importantly CD16 in the gut 
compared to the blood. However, gut NK cells demonstrated 
similar to blood cytolytic activity upon stimulation.
Conclusion: Taken together, these data suggest that ADCC inducing 
antibodies present within the gut mucosa may likely recruit the 
antiviral activities of NK cells. Greater emphasis should be placed 
on developing innate immune recruiting antibody assays that 
measure the capacity of antibodies to recruit the antiviral activity 
of innate immune cells present within mucosal membranes where 
transmission occurs.
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Intravaginal Immunization Using a Novel Antigen 
Delivery Device Elicits Robust Baccine Antigen-
Specific Systemic and Mucosal Humoral Immune 
Responses
P.F. McKay1, J.F. Mann1, A. Pattani2, V.L. Kett2, K. Malcolm2,  
R.J. Shattock1
1Imperial College, London, United Kingdom (Great Britain); 
2School of Pharmacy, Queen’s University, Belfast, United 
Kingdom (Great Britain)
Background: While it is relatively easy to elicit antigen-specific 
serum antibody it is much more difficult to establish meaningful 
levels of specific antibody at mucosal surfaces, the major 
route of viral invasion. We sought to determine if mucosal 
vaccination using topical vaginal application could initiate local 
antigen-specific immunity, enhance previously existing systemic 
immunity or re-target responses to the mucosae.
Methods: We used a silicone elastomer ring device to deliver 
a protein vaccine formulation to the vaginal mucosal surface. 
Cylindrical rod-shaped inserts (2 x 7mm) were prepared by 
freeze-drying an aqueous hydroxypropylmethylcellulose (HPMC) 
gel containing recombinant CN54gp140 (500μg) with and 
without the TLR7/8 agonist R848 (resiquimod – 500μg). Inserts 
were loaded into cavities within each ring such that only the ends 
of the inserts were exposed. Sheep received an intramuscular 
injection of 100μg HIVgp140 + 200μg R848 followed by three 
successive ring applications of one week duration, separated by 
one month intervals. Other sheep received only the ring devices 
without priming. Serum and vaginal mucosal fluids were sampled 
every two weeks and analysed by CN54gp140 ELISA. Antigen-
specific cellular responses were determined at necropsy.
Results: Vaccine antigen-specific serum antibody responses 
were detected in both the intramuscularly primed and vaginal 
mucosally-primed groups. Those animals that received only 
vaginal vaccinations had identical IgG but superior IgA responses. 
Analysis revealed that all animals exhibited mucosal antigen-
specific IgG and IgA with the IgA responses 30-fold greater than 
systemic levels. Surprisingly, very high numbers of antigen-specific 
B cells were detected in local genital draining lymph nodes.
Conclusion: We have elicited local genital cellular and humoral 
immune responses after topical application of an adjuvanted 
antigen formulation within a novel vaginal ring vaccine delivery 
device. This regimen and delivery method elicited high levels 
of antigen-specific mucosal IgA and large numbers of local 
antigen-reactive B cells, both likely essential for effective 
mucosal protection.
P08.03
Increased Epithelial Thickness and Reduced HIV 
Receptor Expression in the Ectocervical Mucosa Is 
Associated with Relative HIV Resistance
K. Broliden1, J. Kimani1, B. Ball1, J. Cheruiyot1, N. Mugo1,  
W. Jaoko1, F. Plummer1, R. Kaul1, T. Hirbod1
1Karolinska Institutet, Stockholm, Sweden
Background: The female genital tract is an important site of HIV 
acquisition, but the epithelial and submucosal tissue factors 
associated with HIV susceptibility have not been defined. 
Methods: Ectocervical biopsies were obtained from HIV-exposed 
seronegative (HESN) women (n=20) and HIV-seronegative lower 
risk controls (n=20). Epithelial thickness and tissue distribution 
of immunological markers were assessed in situ by immunohisto-
chemistry and measurement of mRNA expression was performed 
by quantitative PCR. 
Results: The thickness of the ectocervical epithelium was 
significantly higher in HESN vs. lower risk subjects. CD4 and DC-
SIGN mRNA expression was significantly lower in HESN than 
lower risk women, and in situ immunohistochemical analysis 
confirmed the reduced CD4 expression in HESN participants. In 
addition, immunohistochemistry demonstrated lower CCR5 and 
higher Langerin expression in the HESN subjects. 
Conclusion: A thicker epithelial barrier and altered expression 
of HIV binding receptors in the ectocervix of HESN women may 
contribute to protection against HIV transmission.
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Impact of the Innate Environment on Maintaining 
Memory T-Cell Numbers in the Female Genital Tract: 
Implications for Mucosal Vaccine Efficacy?
S. Dabee1, J. Passmore1, A. Williamson1, P. Gumbi1
1University of Cape Town, Cape Town, South Africa
Background: Preventative HIV vaccines aim to elicit long-lived 
protective immune responses at the site of HIV transmission, 
capable of responding quickly to HIV challenge, but which 
remain stable at effector sites of the genital mucosa. The 
genital mucosa is, however, commonly confronted with innate 
immune modifiers and inflammatory agents including sexually-
transmitted infections, behavioural and hygiene practices. 
We investigated the impact of mucosal inflammation and 
homeostatic cytokines on local T-cell phenotype, proliferation, 
exhaustion and activation. 
Methods: Levels of activation (CD38, HLA-DR), proliferation 
(Ki67) and senescence (CD57) were measured on T-cells isolated 
from cervical cytobrushes and blood from 46 HIV-negative 
women by flow cytometry and inflammatory cytokines and IL-7 
in genital secretions were measured by ELISA. 
Results: HIV-negative women generally had higher concentrations 
of inflammatory (IL-1β, IL-6, IL-8) than homeostatic cytokines 
(IL-15, IL-7) in their genital secretions. Cervical IL-7 correlated 
positively with inflammatory cytokine concentrations, suggesting 
that inflammation and homeostatic cytokine production were 
linked. HIV-negative women with lower cervical CD4+ T-cell 
frequencies had the highest concentrations of genital IL-7 
(p=0.028; rho=-0.23) suggesting that local IL-7 production 
increased in response to elevated CD4+ T-cells. In vitro culture 
of T-cells with IL-7 caused an increase in activation of both CD4+ 
(CD38 p=0.002; HLA-DR p=0.01) and CD8+ (CD38 p=0.01; HLA-DR 
p=0.006) T-cells compared to cells not stimulated with IL-7. IL-7 
also caused an increased Ki67 expression by CD4+ T-cells (p=0.04). 
Conclusion: In conclusion, local IL-7 in the presence of genital 
inflammation may favour T-cell activation and turnover of 
vaccine-induced responses in the genital tract. 
P08.05
Role of Novel Type I Interferon Epsilon in Mucosal 
Immunity
Y. Xi1, S.L. Day1, R.J. Jackson1, C. Ranasinghe1
1John Curtin School of Medical Research, Canberra, Australia
Background: Newly discovered type I interferon-epsilon (IFN-ε) 
is found to be constitutively expressed in mucosal tissues, i.e 
lung, reproductive tissue and intestine. Our previous studies 
have postulated that IFN-ε could play a role in modulating 
mucosal immunity. As HIV is a disease of the mucosae, we 
further evaluated the immuno-biology of IFN-ε in the mucosae 
and tested whether IFN-ε could be used as a mucosal adjuvant 
to enhance HIV-specific immunity. 
Methods: Poxvirus (Vaccinia Virus and Fowl poxvirus) co-
expressing HIV-1 gag/pol and interferon epsion (VV-HIV-IFN-ε 
or FPV-HIV-IFN-ε) were used in this study to evaluate immuno-
biology and adjuvant activity of IFN-ε 
Results: Firstly, VV-HIV-IFN-ε was utilized to study the immuno-
biology of IFN-ε compared to IFN-α4 or IFN-β. Following 
intranasal (i.n.) VV-HIV-IFN-ε infection, a rapid VV clearance 
in lung was induced that correlated with 1) an elevated lung 
VV-specific CD8+CD107a+IFN-γ+, 2) up-regulated activation 
markers CD69/CD103 on CD8 T cells, 3) enhanced lymphocyte 
recruitment to lung alveoli with reduced inflammation and 
4) heightened functional/cytotoxic CD8+CD4+ T cell subset 
(CD3hiCCR7hiCD62Llo) in lung lymph nodes. These responses 
were different to that observed following i.n. VV-HA-IFN-α4 or 
VV-HA-IFN-β infections. Secondly, intranasal/intramuscular (i.n./
i.m.) heterologous prime-boost immunization (FPV-HIV-IFN-ε/
VV-HIV-IFN-ε) was used to evaluated adjuvant activity of IFN-ε. 
Data indicated that IFN-ε induced elevated HIV-specific effector 
but not memory CD8 T cells responses in spleen, genito-rectal 
nodes and Peyer’s patch compared to the control (i.n. FPV-
HIV/i.m. VV-HIV). Interestingly, unlike IFN-β and IFN-α4, IFN-ε 
uniquely induce elevated frequency of α4β7 and CCR9 expressing 
HIV-specific CD8 T cells in gut mucosae. 
Conclusion: In conclusion, our data indicated that 1) IFN-ε can 
induced excellent T cell response in the mucosae especially lung 
and gut, and 2) rather than an vaccine adjuvant IFN-ε has the 
potential to be used as an anti-microbicide to prevent or reduced 
mucosal infection such as TB or HIV.
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Anti-gp41 Antibodies Inhibit Infection and 
Transcytosis of HIV-1 Infectious Molecular Clones 
Expressing Transmitted/Founder Envelopes
S. Jain2, C. Ochsenbauer1, J.C. Kappes1, K.L. Rosenthal2
1University of Alabama at Birmingham, Birmingham, AL, USA; 
2McMaster University, Hamilton, Canada
Background: Prophylactic vaccine strategies against HIV-1 must 
effectively prevent virus transmission, infection and cell-to-cell 
spread during the earliest stages of acute infection. Since the 
genital mucosa is the primary site of entry, mucosal defense 
is critical for early control of infection. Recent identification of 
transmitted/founder (T/F) HIV-1 genomes has demonstrated a 
consistent genetic bottleneck during mucosal transmission and 
suggests that T/F viruses may exhibit distinct phenotypes. HIV-1 
Env gp41-specific responses are among the first to be generated 
in natural HIV infection.
Methods: Previously, we developed chimeric virus-like particle 
(VLP) immunogens that elicit potent systemic and mucosal 
antibodies against two highly conserved regions of gp41, by 
employing an optimized immunization strategy. The ELDKWA 
and QARVLAVERY epitopes are found with the membrane 
proximal external region (MPER) and the coiled coil region of 
gp41, respectively. Importantly, the epitope-specific IgG and 
IgA fractions derived from immunized mice were shown to be 
effective in neutralizing and preventing transcytosis of HIV in 
vitro. In particular, the QARVLAVERY epitope is remarkably 
conserved and induced unusually high and early levels of anti-
QARV IgA, making it an attractive candidate for generation of 
broadly reactive mucosal antibodies.
Results: In this study, we assessed the effectiveness of mucosal 
and systemic mouse antibodies elicited against these gp41 
epitopes to inhibit T/F Env function. For this, we employed 
recombinant infectious molecular clones (Env-IMC) of HIV-1 that 
encode mucosally transmitted/founder env genes. Our results 
show that the gp41-specific IgG and IgA fractions effectively 
prevented the infection of TZM-bl cells and inhibited HIV 
transcytosis in an assay measuring the passage of infectious 
virus across an epithelial monolayer. Interestingly, the T/F Env-
IMC tested were more sensitive to the antibodies than the R5 
lab-adapted strains included as controls.
Conclusion: These results highlight the potential of gp41-based 
immunogens to impart effective mucosal protection in the 
earliest stages of HIV transmission and infection.
P08.07
Induction of HIV Mucosal Immunity at Distal Sites 
After Encapsulation of NOD1 and NOD2 Ligands in 
Biodegradable Nanocarriers
V. Pavot1, N. Rochereau2, V. Lahaye1, C. Genin2, E. Perouzel3,  
T. Lioux3, C. Primard1, T. Delair4, S. Paul2, B. Verrier1
1IBCP-CNRS, Lyon, France; 2GIMAP, Saint Etienne, France; 
3Cayla Invivogen, Toulouse, France; 4University of Lyon - IMP, 
Lyon, France
Background: The use of TLR ligands as mucosal adjuvant for 
vaccine administration is already largely described; wherease 
the use of NOD-like receptors ligands is still investigated. As 
activation of intracytoplasmic NOD like-receptors is able to induce 
production of pro-inflammatory molecules, we have evaluated if 
their co-delivery into biodegradable nanocarriers carrying HIV-
Gag antigens could amplify the mucosal immune responses in 
mice at the vaginal and intestinal (HIV replication site) 
Methods: We used Poly(Lactic Acid) (PLA) nanoparticles (NPs) 
(~200 nm) for co-delivery of p24 and NOD ligands. As NOD like-
receptors are mainly expressed by antigen presenting cells, we 
first assessed the capacity of free or encapsulated ligands to 
induce monocyte derived dendritic cells (MoDCs) maturation. 
Then, as NOD like-receptors are principally expressed at the 
intestinal level we compared by oral immunization of BALB/c 
mice encapsulated ligands co-delivered with PLA-p24 NPs. To 
assess the adjuvant effect, p24-specific cellular and humoral 
responses were analyzed on splenocytes and in vaginal washes, 
faeces and sera.
Results: The state of MoDCs maturation was characterized 
by the expression of CD80, CD83 and CD86. We showed that 
encapsulation of NOD1 or NOD2 ligand increases significantly 
their expression, compared to the effect of free ligands, probably 
due to a better uptake of encapsulated ligands 
By analyzing humoral immune responses, we observed that co-
administration of p24 and NOD2 ligand by two different NPs was 
the most efficient formulation to induce anti-p24 IgG and IgA 
responses in faeces. By contrast co-formulation of p24 and NOD1 
ligand in the same NP induced a better CD8 IFNγ response. 
Conclusion: Encapsulation of NOD ligands into PLA nanoparticles 
seems to favour their action on DCs maturation, their co-
administration with PLA-p24 NPs inducing an adjuvant effect. 
Use of those ligands as mucosal adjuvant deserve further 
experiments and we are investigating the mechanisms involved 
and increasing delivery efficacy after co-encapsulations.
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The Humanized BLT Mouse to Study HIV 
Transmission
M. Deruaz1, T.T. Murooka1, T. Dudek2, V.D. Vrbanac1, T. Tivet1, 
K.C. Bankert1, T.M. Allen2, A.M. Tager1, A.D. Luster1
1Massachusetts General Hospital, Harvard Medical School, 
Charlestown, MA, USA; 2Ragon Institute of MGH, MIT and 
Harvard, Charlestown, MA, USA
Background: Worldwide, the majority of HIV-1 infections are 
acquired by vaginal transmission. Studies in SIV-1 infected non-
human primates have shown that SIV-1 infection takes hold 
initially in a small population of CCR5+ cells in the in female 
lower genital tract (FLGT) where the infection expands first 
locally before disseminating to the draining lymph node (LN) to 
establish a systemic infection. Our goal is to use humanized BLT 
mice to address whether the infection paradigm established for 
SIV-1 in non-human primates holds true during HIV-1 infection 
in vivo.
Methods: We studied the kinetics of infection during the first 
two weeks after intravaginal HIV-1 exposure by measuring the 
presence of virus in the FLGT, LNs and blood after 2, 6, 10 and 12 
days post infection (p.i.) by qPCR and flow cytometry. 
Results: Our results show that similar to the non-human primate 
model, the presence of virus is first detected by qRT-PCR in the 
FLGT as soon as day 2 p.i., followed by the LN at day 6 p.i. and the 
blood at day 12 p.i.. Similar but delayed kinetics were observed 
using p24 staining by flow cytometry, with positive staining of T 
cells located in the FLGT at day 6 p.i., in the draining LN between 
day 6 and day 10, and in the non draining LN at day 12 p.i.. 
Conclusion: Our data suggests that HIV-1 transmission and initial 
replication in BLT mice following intravaginal exposure occurs 
first locally in the LGT and then disseminates to the draining LN. 
The virus then spreads to the non-draining LNs and subsequently 
into the blood, suggesting that BLT mice have an “eclipse phase” 
following HIV infection similar to what have been described for 
SIV infection of macaques and HIV infection of humans.
P08.09
Systemic Administration of a Broadly-Neutralizing 
IgG Antibody to Generate HIV-Neutralization 
Responses in Breast Milk
G.G. Fouda1, J. Amos1, K. Beck1, S. Smith1, X. Wang2, K. Reimann2, 
S. Permar1
1Duke Human Vaccine Institute, Durham, NC, USA; 2Beth Israel 
Deaconess Medical Center, Boston, MA, USA
Background: Postnatal acquisition of HIV during breastfeeding is 
responsible for almost half of 350,000 pediatric HIV infections 
occurring yearly. Thus, there is an urgent need to develop 
immunologic interventions to impede breast milk transmission 
of HIV, including immunization and passive infusion strategies. 
We previously observed that functional antibody responses in 
milk of HIV- infected mothers mirror that in plasma, suggesting 
that inducing strong systemic IgG responses may lead to virus 
inhibition in milk. Therefore, we investigated the kinetics of 
binding and neutralizing antibodies in plasma and milk of 
passively- infused lactating rhesus monkeys.
Methods: The broadly neutralizing antibody b12 engineered in 
a rhesus IgG1 backbone was administered intravenously to four 
hormone-induced, lactating female rhesus monkeys at a dose 
of 5mg/kg. Milk and blood was collected frequently until 72 h 
post infusion, then weekly for 4 weeks. Levels of the infused 
antibody and the neutralizing activity in the milk and systemic 
compartments were measured at each time-point. 
Results: The b12 IgG levels peaked 1 hour post-infusion in 
plasma and 24 to 72h post-infusion in milk. The median peak b12 
antibody levels were 87,503 ng/ml (range 62,548 to 101,525 ng/
ml) in plasma and 47 ng/ml (range 16 to 202 ng/ml) in milk. The 
peak in plasma neutralization was 1 to 6 hours post-infusion and 
the neutralization titer slowly declined after 24 hours. The peak 
neutralization titer in milk (median ID50: 70, range: 50-103) was 
approximately two logs lower than in plasma (median ID50: 2313, 
range: 1875-3128) and occurred within 24 hours post-infusion 
in 3 of 4 animals. There was a significant correlation between 
neutralization titers in milk and plasma (r=0.48, p=0.01).
Conclusion: The neutralizing activity detected in milk following 
systemic administration of a broadly- neutralizing IgG antibody 
supports the induction of strong systemic anti-HIV IgG responses 
to generate HIV inhibitory antibodies in breast milk.
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Semen Modulates the Differentiation of Monocyte-
Derived Dendritic Cells Towards a Tolerogenic Profile
F. Remes Lenicov1, C. Rodríguez Rodrigues1, C. Jancic1,  
J. Sabatté1, M. Cabrini1, M. Donalson2, R. Pasqualini Jr2,  
J. Geffner1, A. Ceballos1
1Instituto de Investigaciones Biomedicas en Retrovirus y SIDA, 
Buenos Aires, Argentina; 2Instituto Médico Halitus, Buenos 
Aires, Argentina
Background: HIV vaccines have not been able to provide immune 
protection against sexually-transmitted HIV. We hypothesized 
that semen has an active role in the transmission of HIV by 
influencing the early events of the immune response. This study 
analyzed the ability of spermatozoa and seminal plasma (SP) to 
modulate in vitro the differentiation profile of human monocyte-
derived dendritic cells (DC).
Methods: Spermatozoa were purified by swim-up of semen 
samples from healthy donors, while SP was obtained by semen 
centrifugation. DC were obtained by incubating peripheral blood 
monocytes (>85% purity) with GM-CSF and IL-4 for 5 days, in 
the absence or presence of spermatozoa (Sp: monocyte ratio 
4:1) or SP (dilution 1:5000). DC phenotype was analyzed by flow 
cytometry while cytokine production was measured by ELISA.
Results: Differentiation of DC performed in the presence of 
spermatozoa or SP resulted in a marked reduction of CD1a 
expreession together with increased expression of CD14. The 
mean fluorescence intensity for CD1a was: 7464 ± 106, 210 ± 25 
and 766 ± 35 (p<0.05 for controls vs spermatozoa- or SP-treated 
cells, respectively). We also found that spermatozoa and SP 
significantly (p < 0.05) increased expression of HLA-DR, CD86 and 
CD80. However, stimulation of treated DC with LPS resulted in 
reduced production of IL-12p70 or IL-23, but increased secretion 
of IL-10 (p < 0.01). Moreover, DC differentiated in the presence 
of SP or spermatozoa induced the expansion of CD25+FOXP3+ 
T lymphocytes: 5±1% vs 12 ±4% and 9 ±2% CD25+FOXP3+ 
cells (p<0.05, control vs SP- or spermatozoa-treated cells 
respectively). Finally, the effect of SP on DC phenotype and 
IL-12p70 production was partially abrogated by antgonizing 
prostaglandin-E2 signalling, suggesting a role of prostaglandins 
as mediators of semen effects.
Conclusion: Our data support the notion that semen may alter 
the anti-HIV immune response by inducing a tolerogenic profile 
in dendritic cells.
P08.11
Strong SIV gp120-Specific IgG/IgA Responses in Milk 
of African Green Monkeys May Contribute to the 
Rarity of Postnatal Transmission in This Species
J.D. Amos1, A.B. Wilks2, G.G. Fouda1, S.D. Smith3, G.R. Overman1, 
K. Beck3, M.A. Moody1, G.D. Tomaras1, S.R. Permar1
1Duke Human Vaccine Institute, Durham, NC, USA; 2Division 
of Viral Pathogenesis, Beth Israel Deaconess Medical Center, 
Boston, MA, USA; 3Division of Laboratory Animal Resources, 
Duke University, Durham, NC, USA
Background: African green monkeys (AGMs), natural SIV hosts, 
sustain nonpathogenic infections and rarely transmit the virus to 
their suckling infants, despite exposure to high milk virus RNA 
loads. Furthermore, we previously reported strong autologous 
neutralization responses in milk of SIV-infected AGMs which could 
contribute to impediment of infant virus acquisition. Comparing 
mucosal B cell populations and responses in milk of AGMs to that 
of rhesus monkeys (RMs), symptomatic SIV hosts with high rates 
of postnatal transmission, could elucidate the protection against 
postnatal virus transmission in natural SIV hosts.
Methods: Six female AGMs and four female RMs were hormonally-
induced into lactation prior to intravenous inoculation with 
SIVsab92018 and SIVmac251, respectively. B cells in milk and 
blood were phenotypically analyzed by flow cytometry. Total and 
SIV gp120-specific IgG/IgA responses in milk and plasma were 
measured using autologous virus-specific ELISA.
Results: SIV gp120-specific IgG responses were approximately 
one log higher in milk (p=0.02) and plasma (p=0.009) of AGMs 
compared to that of RMs. Remarkably, the milk SIV gp120-specific 
IgA response of AGMs was two logs higher than that of RMs 
(p=0.009). Comparing the milk SIV gp120-specific IgA responses 
to other mucosal compartments of AGMs, milk responses were 
higher than rectal (p = 0.03), but similar to vaginal responses. 
Although there were no significant differences in the milk 
memory B cells populations of AGMs and RMs, we observed 
a reduced proportion and absolute number of naive B cells 
(CD20+, IgD+, CD27-) in milk of RMs (median = 7.9%, 0.16 cells/
µl) compared to AGMs (median = 26.5%, 4.2 cells/µl) (p = 0.009 
and 0.06, respectively) during chronic infection.
Conclusion: AGMs appear to preserve SIV-specific IgG/IgA 
responses in milk during chronic infection, potentially due to 
a lack of immune activation and B cell dysfunction, which may 
contribute to the rarity of postnatal SIV transmission in this 
natural host species.
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P08.14
Lack of IgA Envelope-Reactive Antibody Producing 
Cells in Terminal Ileum in Early and Chronic HIV-1 
Infection
A.M. Trama1, H. Liao1, A. Foulger1, D.J. Marshall1, J.F. Whitesides1, 
R. Parks1, R. Meyerhoff1, K.E. Lloyd1, M. Donathan1, J. Lucas1,  
K. Soderberg1, T.B. Kepler2, N. Vandergrift1, N. Yates1,  
G.D. Tomaras1, M.A. Moody1, B.F. Haynes1
1Duke University, Durham, NC, USA; 2Boston University, 
Boston, MA, USA
Background: HIV-1 vaccines must induce protective antibodies 
at mucosal surfaces; the role of IgA in protection remains 
unknown. The HIV-1 Env antibody response begins ~day 17 after 
transmission, and derives from a polyreactive memory B cell pool 
of gut flora-reactive IgG1 and IgA B cells. Whereas the IgG Env 
antibody response persists years after acute HIV-1 infection, the 
initial IgA response decreases over the first month. There is also 
selective destruction of terminal ileum germinal centers in early 
HIV-1 infection (EHI). To determine HIV-1 IgA responses in gut, 
we isolated Env-reactive antibodies from ileum from patients in 
EHI and chronic HIV-1 infection (CHI).
Methods: Single plasma cells (PCs) and IgD- memory B cells 
were sorted from the ileum and/or blood of 7 EHI and 3 CHI. 
Antibodies were isolated by PCR amplification of Ig heavy chain 
V(D)J and light chain VJ genes and characterized by ELISA and 
Luminex.
Results: Whereas CHI blood memory IgA+ B cells reactive with 
HIV-1 envelope ranged from 0.20-0.79%, only 0-0.07% of ileum 
IgA+ B cells were Env-reactive. Of 254 mAbs isolated from EHI 
ileum, only 3 (1.2%) were HIV-1-reactive. In CHI, 9 (5.7%) of 
158 mAb were HIV-1 reactive. None of the HIV-1 reactive ileum 
antibodies were of the IgA isotype.
Conclusion: HIV-1 envelope reactive IgA+ memory B cells and PCs 
can be found in the blood, but there is a dearth of HIV-1 reactive 
memory IgA+ B cells and PCs in ileum in EHI and CHI. Loss of IgA in 
plasma after acute HIV-1 infection is paralleled by the loss of IgA+ 
B cells in ileum, and is likely a consequence of HIV-1-induced ileum 
germinal center apoptosis. For vaccine design, it will be important 
to determine if mucosal IgA+ B cell loss is due to replicating virus 
or is triggered by soluble HIV-1 envelope.
P08.13
γδ T-Cells in HIV Infection
N.G. Holt1, J. Johnson1, S. Wilton1, E. Byrne1, A. Piechocka-
Trocha1, B.D. Walker2, D. Kwon1
1Ragon Institute of MIT, MGH and Harvard, Boston, MA, USA; 
2Howard Hughes Medical Institute, Chevy Chase, MD, USA
Background: γδ T-cells represent a first line of defense against 
pathogens in the mucosa. Despite their prevalence in gut 
associated lymphoid tissue (GALT), little is known about their role 
in HIV infection. We hypothesize that γδ T-cells are stimulated 
by viral antigen and demonstrate anti-HIV activity, comprising a 
critical component of the mucosal response to HIV.
Methods: To assess the role of γδ T-cells, we analyzed peripheral 
blood and GALT samples from HIV(-) and HIV(+) patients, 
including elite controllers. γδ T-cells were isolated and assessed 
in viral inhibition and CD4+ killing assays. The cellular pathway 
associated with cell killing was also evaluated. An HIV antigen 
screen was used to stimulate sorted γδ T-cells. Nanostring 
analysis was used to measure mRNA. High-throughput TCR 
sequencing was performed in peripheral and mucosal tissue.
Results: The mucosal subtype, Vδ1, exists at higher percentages 
in HIV(+) peripheral blood, particularly elite controllers 
(17.1±4.0), relative to HIV(-) subjects (0.3±0.2) (p=0.0001). A 
100-fold increase of the Vδ1 subtype was detected in the ileum 
of HIV controllers. Vδ1 cells in the GALT of HIV(-) patients, unlike 
those in the periphery, directly kill up to 80%±20% of HIV+CD4+ 
T-cells in culture and inhibiting virus production by 3 logs. These 
antiviral effects are expanded to the periphery in the setting of 
elite control. γδ T-cell mediated killing is correlated to perforin 
expression (R=0.8088). Nef-specific responses in Vδ1 cells were 
observed in patients with lower viral loads and higher CD4+ 
count indicating that antiviral effects may be mediated by an HIV-
specific response (p=0.01). 
Conclusion: γδ T-cells play a key role in the response to HIV 
infection. HIV specific γδ T-cells are expanded from mucosal 
tissue to the periphery where they exert anti-viral effects. 
Further study may suggest ways to harness this unique subset to 
stimulate both innate and acquired immunity in response to HIV.
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P08.16
Improved Systemic and Mucosal Antibody Responses 
with a CCR10 Ligand Adjuvant
N. Hutnick1, D.J. Myles1, A. Ginsberg1, A.S. Khan2, J. Yan2,  
Z. Moldoveanu3, J. Mestecky3, P.A. Marx4, M. Kutzler5,  
D.B. Weiner1
1University of Pennsylvania, Philadelphia, PA, USA; 2Inovio 
Pharmaceuticals, Blue Bell, PA, USA; 3University of Alabama, 
Birminham, AL, USA; 4Tulane University, Covington, LA, USA; 
5Drexel University, Philadelphia, PA, USA
Background: The induction of potent mucosal immune 
responses will be critical for an effective HIV vaccine, However, a 
major limitation of current vaccine development is the ability to 
induce mucosal antibodies by a systemic, non-replicating vector. 
To address this inadequacy, we have hypothesized that encoding 
instructions for immune cell targeting to the mucosa in the form 
of MEC, a mucosal chemokine adjuvant delivered as a plasmid 
can redirect immune responses in vivo. MEC (CCL28) is normally 
expressed by epithelium in the skin, lungs, and intestines and it 
functions to attract CCR10 expressing plasmablasts locally.
Methods: IIndian rhesus macaques were vaccinated using EP 
delivery with either a pcon SIVmac239 gag, pol, SIVsm unmatched 
E660 env vaccine delivered IM alone (n=5), with CCL28 (MEC, 
n=5) or a plasmid expressed H1 HA Influenza vaccine alone (n=4) 
or with MEC (n=4). SIV Vaccinated animals and 6 naïve controls 
were challenged vaginally twice weekly for four weeks with 
500TCID50 SIVsmE660. 
Results: The inclusion of a CCR10 ligand adjuvant enhanced 
vaginal and serum IgG and IgA titers compared with DNA alone. 
In Flu vaccinated animals functional HAI antibody titers were 
significantly elevated and above the 1:40 titer required for 
protection in humans with just a single dose of H1HA delivered 
with the MEC adjuvant. Following SIV challenge monkeys 
vaccinated with a CCR10 adjuvant showed 89% protection from 
the establishment of infection compared 40% with DNA alone 
with only 16% of the naïve animals.
Conclusion: Mucosal and systemic antibody responses were 
enhanced with the inclusion of a CCR10 ligand adjuvant. Dose 
sparing was also observed. DNA vaccination alone improved 
challenge outcome, and this was further enhanced by the 
inclusion of a CCR10 ligand adjuvant. The inclusion of mucosal 
homing chemokines represents a novel approach to induce 
improved mucosal immune responses by non-live systemic 
immunization of relevance to HIV infection. 
P08.15
Human Intestinal Beta Defensins Inhibit Viral 
Replication and Are Diminished in Chronic Untreated 
HIV Infection
B. Corleis1, W.G. Gostic1, J.A. Johnson1, D.S. Kwon1
1Massachusetts General Hospital, Boston, MA, USA
Background: One of the hallmarks of HIV infection is an early 
and dramatic depletion of CD4 T cells in the intestinal lamina 
propria. This loss of T cells is accompanied by intestinal epithelial 
cell disruption resulting in the translocation of luminal bacterial 
products, persistent systemic immune activation and resultant 
disease progression. Beta defensins are cationic antimicrobial 
polypeptides produced by intestinal epithelial cells and 
phagocytes that are a part of the innate immune response. They 
have a pivotal role in maintenance of immune homeostasis in 
the gut. Although beta defensins have been reported to inhibit 
bacterial and viral replication in vitro, their role in HIV infection 
has been incompletely characterized.
Methods: We investigated anti-viral activity and production of 
defensins in intestinal mucosal biopsies, stool and plasma from 
individuals with chronic untreated HIV (chronic progressors), 
immunologically controlled HIV (elite controllers) and HIV 
uninfected individuals using ELISA, immunohistochemistry, 
quantitative PCR and viral inhibition assays.
Results: Plasma levels of beta defensins were increased in the HIV 
controller group compared to HIV progressors, whereas levels 
of beta defensins were significantly decreased in biopsies from 
chronic progressors. Beta defensin release was induced by HIV 
in ex vivo cultured intestinal cells. Recombinant beta defensins 
inhibited HIV replication in vitro.
Conclusion: Beta defensins are upregulated by HIV and inhibit viral 
replication in vitro. Chronic progressors, however, had diminished 
levels of beta defensins in gut biopsies and in the plasma. We 
propose that beta defensins are induced in HIV infection and 
have a role in inhibiting viral replication and preventing intestinal 
epithelial cell disruption. In chronic infection, however, their 
release is diminished, likely due to epithelial damage in the 
setting of persistent viremia and mucosal inflammation.
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T cell Immune Quiescence As A Contributor To 
Resistance To Infection Among HIV Exposed 
Seronegative (HESN) Commercial Sex Workers from 
Nairobi, Kenya
K.R. Fowke1, T.B. Ball2, J. Kimani3, F.A. Plummer1
1University of Manitoba, Winnipeg, Canada; 2Public Health 
Agency of Canada, Winnipeg, Canada; 3Kenyan AIDS Control 
Program, Nairobi, Kenya
Background: Participants from the Majengo Commerical Sex 
Worker Cohort in Nairobi, Kenya have been intensely exposed 
to HIV for 7-20 years of follow-up, and yet have remained 
uninfected. Since activated CD4+ T cells are much more 
susceptible to HIV infection and have been suggested to form the 
initial focus of mucosal infection, we have conducted a number 
of studies to characterize the T cell phenotype in the mucosal 
and systemic compartments of these HIV exposed seronegative 
women (HESN). 
Methods: Representative sampling (n=~30) of HESN women 
and a similar sized control group of newly enrolled commercial 
sex workers were compared. Gene expression analysis, immune 
phenotyping, and in vitro HIV infection assays were performed 
on peripheral blood mononuclear cells. Mucosal assessment of 
the female genital tract (FGT) included proteomic analysis by 
mass spectrometry, flow cytometry and cytokine/chemokines 
determinations by bead arrays. 
Results: Gene expression analysis revealed the HESN women 
showed reduced gene levels for pathways involved in T cell 
receptor activation and HIV host dependent factors. Systemic 
CD4+ T cells showed lower levels of immune activation (CD69) and 
higher levels of regulatory T cells (T regs). Infection frequency, the 
number of infected replicate wells, was lower in the HESN women 
and correlated with ex vivo assessment of reduced T cell activation 
and elevated T reg levels. Mucosal assessment by proteomics 
showed higher levels of anti-inflammatory serine proteases and 
lower levels of the chemokines IP-10 and MIG, which functions are 
to recruit activated T cells into the mucosal environment. 
Conclusion: Together, these data suggest that the HESN women of 
the Majengo Cohort display a T cell Immune Quiescent phenotype 
that is characterized by fewer activated T cells, more regulatory T 
cells and a mucosal environment that favours quiescent cells. The 
result is an environment that is not favorable for the establishment 
of HIV infection. 
P08.17
Biodistribution of Neutralizing Monoclonal 
Antibodies IgG1 b12 and LALA in Mucosal and 
Lymphatic Tissues of Rhesus Macaques
A.J. Hessell1, E. Epson1, B. Moldt2, E. Rakasz3, S. Pandey1,  
W.F. Sutton1, Z. Brower1, V.M. Hirsch4, D.R. Burton5,  
N.L. Haigwood1
1Oregon Health & Science University, Oregon National Primate 
Res Ctr, Beaverton, OR, USA; 2The Scripps Research Institute, 
La Jolla, CA, USA; 3University of Wisconsin-Madison, Madison, 
WI, USA; 4NIAID, NIH, Bethesda, MD, USA; 5The Scripps 
Research Institute and IAVI Neutralizing Antibody Center, La 
Jolla, CA, USA
Background: HIV-1 transmission occurs predominantly through 
mucosal surfaces. In macaque models of SHIV mucosal 
transmission, passive administration of the monoclonal 
neutralizing antibody IgG1 b12 (b12) can protect against virus 
infection. However, an Fc variant of b12, deficient in FcγR and 
complement binding, (LALA) had diminished protective capacity. 
Concentrations and kinetics of b12 and LALA in serum and in 
mucosal secretions were determined in the protection studies, 
but the biodistribution and kinetics of the antibodies in mucosal 
and lymphatic tissues and around the site of viral challenge have 
not been assessed. 
Methods: We conducted a pilot study to develop protocols to 
process macaque tissue specimens and to detect and quantify 
passively transferred neutralizing antibodies (NAbs) in tissue 
homogenates. To confirm that transport of LALA to the site 
of challenge was not altered from that of b12, we obtained 
secretions and tissue specimens from rhesus macaques that had 
been passively infused with either b12 or LALA at 24 hours prior to 
necropsy, matching the time of challenge in the protection study. 
Results: We quantified passively administered b12 and LALA in a 
variety of macaque mucosal and lymphoid tissues and assessed 
the neutralization capacity of the NAbs localized in vaginal and 
rectal sites typically exposed to virus in challenge studies. We 
demonstrated that the rapid distribution and broad delivery to 
lymphoid and mucosal tissues of both b12 and LALA are equivalent. 
Conclusion: We developed and utilized a methodology 
to evaluate the transudation of transferred antibody into 
mucosal and lymphatic tissues and showed that the reduction 
in the protective capacity of LALA compared to b12 cannot 
be attributed to a differential effect of biodistribution. This 
methodology will be useful to describe the pharmacokinetics 
of newly discovered MAbs and may inform about the 
characteristics of therapeutic antibodies or antibodies to elicit 
by vaccination. 
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P08.20 LB 
Influence of Hormones and HIV Infection on Viral 
Transport
D.J. Stieh1, S.A. Allan1, S.A. Shukair1, G.C. Cianci1, A.J. Fought1, 
A. French2, T.J. Hope1
1Northwestern University, Chicago, IL, USA; 2Ruth M. Rothstein 
CORE Center, Chicago, IL, USA
Background: Inhibiting transport of virions within the female 
reproductive tract is an attractive mechanism for transmission 
prevention. The mucosal environment varies with menstrual 
cycle and concurrent bacterial vaginosis (BV). Previous studies 
of transport within mucosal samples have focused on cervico-
vaginal samples in exclusion. Severe BV corresponds to increased 
incidence of female-to-male HIV-1 transmission although the 
mechanism remains unclear.
Methods: We have established a cohort of HIV +ve and –ve women 
to be longitudinally studied for correlates of inhibited transport 
phenotypes. Cervical and cervico-vaginal mucus samples (CM and 
CVM, respectively) are collected, along with mucosal antibodies, 
vaginal smears, hormone levels, viral load, T cell monitoring panels 
as well as medical and behavioral history. Viral transport assays 
employ a diverse panel of viral isolates, testing clade specific 
effects. As of this interim analysis, over 60 study subjects have 
been recruited and repeat sampling is beginning.
Results: The hormone profile demarcating menstrual cycle 
phase correlates strongly with particle movement. In CVM, the 
nature of viral interactions with their environment changes; 
lowest progesterone to estradiol ratio corresponds with 
hindered diffusion. Non-reactive similarly sized PEGylated beads 
have freely diffusive behavior throughout the menstrual cycle. 
Cycle classification into follicular, mid-cycle and luteal periods 
demonstrates that CVM in the luteal phase is, unexpectedly, most 
permissive to viral transport. Severe BV has modest effects on pH 
of CVM and no effect on CM. This is reflected in viral transport 
characteristics whereby the magnitude and nature of movement 
is invariant during severe BV relative to healthy flora.
Conclusion: It is unlikely that the mechanisms of increased 
transmission with BV are related to virus diffusing more freely 
within mucus. Correlates of hindered diffusion are not restricted 
to adaptive immune responses. This study begins to reveal the 
significance of immune correlates and hormone profiles on 
HIV-1 transmission mechanisms and transport in the female 
reproductive tract.
P08.19 LB 
A Novel Mechanism of HIV Transcytosis and Infection
S. Gupta1, J.C. Becerra1, D.N. Forthal1
1University of California Irvine, Irvine, CA, USA
Background: Female genital tract mucosae are bathed in acidic 
secretions, which, in the case of HIV-1 infected women, likely 
contain virus coated with antibody. Thus, uninfected male sexual 
partners are often exposed to an acidic milieu containing virus in 
the form of immune complexes. We investigated the impact of low 
pH and antibody on transcytosis, a potentially critical mechanism 
by which HIV-1 passes through genital tract epithelia to infect 
susceptible target cells.
Methods: HIV-1 was incubated with Env-specific monoclonal 
and polyclonal antibodies at pH 6.0 or pH 7.4 and exposed to 
the apical surface of tight junction-forming human endometrial 
carcinoma (HEC-1) cells in transwell plates. The quantity and 
infectivity of transcytosed virus was measured by RT-PCR and 
infection of TZMbl cells, respectively.
Results: We found that the combination of acidic pH and Env-
specific antibody augmented transcytosis as much as 30-fold 
compared with Env-specific antibody at neutral pH or compared 
with non-specific antibody or no antibody at neutral or acidic pH. 
The pH and antibody dependence of enhanced transcytosis was 
blocked by antibody specific for the Fc neonatal receptor (FcRn) 
or by treatment with bafilomycin A1 (which inhibits acidification 
of endosomes). Non-neutralizing antibodies resulted in a lower 
quantity of total transcytosed virus, measured by RT-PCR, than did 
neutralizing antibodies. However, the ratio of total to infectious 
virus was much higher for neutralizing antibodies, indicating 
that neutralizing antibodies efficiently allow transcytosis while 
blocking infectivity of the transcytosed virus; the non-neutralizing 
antibodies facilitate transcytosis (although to a lesser degree 
than the neutralizing antibodies) without blocking infectivity.
Conclusion: These results demonstrate that acidity and Env-
specific antibody greatly enhance transcytosis of virus across 
mucosal epithelial cells via FcRn. Since male penile and urethral 
tissues express FcRn, our results suggest a novel mechanism by 
which antibody, and in particular, non-neutralizing antibody, might 
facilitate female-to-male transmission following sexual exposure.
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Prior Individual and Couples’ Voluntary HIV 
Counseling and Testing (CVCT) in Couples Seeking 
CVCT in Lusaka, Zambia
A. Appiagyei1, L. Banda1, A. Mwaanga1, E. Gudo1, J. Mubonde1, 
W. Kilembe1, S. Allen2
1Zambia Emory HIV Research Project, Lusaka, Zambia; 2Emory 
University School of Medicine, Atlanta, GA, USA
Background: The majority of new HIV infections in Africa are 
acquired in marriage, and heterosexual couples represent the 
largest HIV risk group in sub-Saharan Africa. However, only 
15% of Zambians report ever testing for HIV. This study aims to 
investigate trends in prior individual and couples HIV testing in a 
cohort of clients who sought couples HIV counseling and testing 
(CVCT) in Lusaka, Zambia. 
Methods: Couples who sought first-time CVCT at Lusaka district 
government clinics through the Zambia Emory HIV Research 
Project (ZEHRP) provided information on prior HIV testing. 
Clients were grouped based on whether: only one of the partners 
had ever tested (further disaggregated by sex), both had tested 
individually but never as a couple, or both had tested as a couple. 
Results: In a sample of 7,582 discordant and concordant negative 
couples tested from October 2009 to December 2011, prior 
testing in the male partner alone was seen in 7%. In 33%, the 
woman alone had tested previously. In 25%, both partners had 
tested individually but never as couple, while in another 25% 
neither partner had ever tested prior to CVCT. Ten percent of 
couples reported prior testing as a couple.
When disaggregated by sex, woman-only previous testing was 
predominant throughout the study period, while men-only 
previous testing, though relatively low, increased by 2.5%. From 
the beginning of the study period to the end, couples reporting 
having previously tested together increased by 2%. Couples 
where both had tested individually but never as a couple 
increased steadily over the study period.
Conclusion: Both prior individual and couples testing increased 
over the study period, though this increase was more obvious for 
individual testing. Despite endorsement of CVCT by the Zambian 
Ministry of Health since 2008, to date few couples have been 
jointly tested and counseled in the capital city. 
P09.01
Trends in Uptake of Couples Voluntary HIV 
Counseling and Testing (CVCT) in Lusaka and 
Southern Province, Zambia
A. Appiagyei1, M. Tufton1, A. Mwaanga1, E. Gudo1, J. Mubonde1, 
W. Kilembe1, S. Allen2
1Zambia Emory HIV Research Project, Lusaka, Zambia; 2Emory 
University School of Medicine, Atlanta, GA, USA
Background: Couples HIV testing and counseling (CVCT) has been 
proven to decrease transmission of HIV in discordant couples by 
two-thirds. In order to achieve a snowball effect and establish 
CVCT as a social norm, the intervention must reach 15-20% of 
the target population. Considering demographics in Lusaka, 
Zambia, approximately 40,000 - 50,000 couples must be tested 
together within a few years to establish norms and set the stage 
for social diffusion. 
Methods: The authors investigated trends in couples seeking 
first time ZEHRP CVCT services in Lusaka and Southern Province 
government district clinics from January 2008 – December 2011. 
Trends in increases or decreases in uptake were compared to 
historical data such as changes in incentives for couples and CVCT 
promoters, as well as external events such as couples testing 
campaigns and government policies. 
Results: Over the study period, ZEHRP tested 37,859 couples. 
Declines in number of couples tested coincided with a 
discontinuation of performance based pay for District Clinic 
Promoters (DCPs) and a reduction in couples transport 
reimbursement. Though six new government clinics began offering 
ZEHRP CVCT in quarter four of 2008, no performance based pay 
or transport reimbursement were provided, and numbers were 
lowest at this time than at any point in the study period. 
A sharp increase in CVCT uptake was seen in quarter one of 
2010, which coincided with a mass media campaign for CVCT 
by another Zambian non-governmental organization, though 
uptake gradually declined once the campaign ended. 
Number of couples seen in Southern Province remained stable 
throughout the study period, while most fluctuations were seen 
in Lusaka. 
Conclusion: Client and promoter incentives as well as mass 
media have been shown to influence uptake of CVCT. In urban 
areas where cost of living is high, CVCT programs must consider 
opportunity costs to encourage uptake. 
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P09.04
Effect of an Intervention to Promote Contraceptive 
Uptake on Incident Pregnancy: A Randomized 
Controlled Trial Among HIV Positive Couples in 
Zambia
K. Wall1, B. Vwalika2, L. Haddad2, N. Htee Khu2, C. Vwalika2,  
W. Kilembe2, E. Chomba2, R. Stephenson1, D. Kleinbaum1,  
A. Nizam1, I. Brill3, A. Tichacek2, S. Allen2
1Emory University, Atlanta, GA, USA; 2Rwanda Zambia HIV 
Research Group, Atlanta, GA, USA; 3University of Alabama at 
Birmingham, Birmingham, AL, USA
Background: Prevention of unintended pregnancy, especially 
among HIV positive couples and in settings where both HIV and 
total fertility rates are high, is a critical public health initiative.
Methods: A factorial randomized controlled trial evaluated the 
effect on incident pregnancy of two interventions (a “Methods” 
and “Motivational” intervention) to promote long-term 
contraceptive use among HIV serodiscordant and concordant 
positive couples (N = 1060) identified from CVCT clinics in 
Lusaka, Zambia. 
Results: Couple baseline serostatus and contraception usage 
were both individual effect measure modifiers (p<0.0001). 
Among couples in which the woman was not using a contraceptive 
method at baseline (N=782), there was no significant effect of 
the interventions overall or when stratifying by couple serostatus 
on incident pregnancy. Among couples in which the woman was 
using a contraceptive method at baseline, concordant positive 
couples (HR = 0.20; 95%CI: 0.08-0.53), and couples in which 
the woman was HIV positive at baseline (HR = 0.21; 95%CI: 
0.09-0.51) who received “Methods + Both” interventions - 
which combined information on contraceptive methods and 
motivational messages for future planning behaviors - were 
at significantly decreased hazard for pregnancy relative to 
those receiving “Motivational + Control” interventions -- which 
provided motivational messages for future planning but not 
information on contraceptive methods.
Conclusion: An educational intervention promoting long-term 
contraceptive method uptake among HIV positive couples is 
successful at decreasing time to pregnancy in the context of 
couples’ HIV testing, particularly among women who are HIV+ 
and already using a contraceptive method. A combination 
of motivational messages for future planning behaviors and 
information on long-term contraceptive methods appears to be 
the best intervention for reducing incident pregnancy among 
concordant positive and serodiscordant couples. Further work is 
needed to understand the interventions appropriate for women 
who are currently not contraceptive users.
P09.03
Promotion of Couples’ Voluntary HIV Counseling 
and Testing in Lusaka, Zambia by Influence Network 
Leaders and Agents
K. Wall1, W. Kilembe2, A. Nizam1, C. Vwalika2, M. Kautzman2,  
E. Chomba2, A. Tichacek2, G. Sardar2, D. Casanova2,  
F. Henderson2, J. Mulenga2, D. Kleinbaum1, S. Allen2
1Emory University, Atlanta, GA, USA; 2Rwanda Zambia HIV 
Research Group, Atlanta, GA, USA
Background: In sub-Saharan Africa, most HIV transmissions occur 
in stable
heterosexual relationships. Couples’ voluntary HIV counseling and 
testing [CVCT] is an effective strategy targeting this at-risk group. 
This study identified predictors of successful CVCT promotion in 
Lusaka, Zambia.
Methods: CVCT promotions were conducted by influential 
network leaders [INLs] who identified agents [INAs], who in turn 
delivered CVCT invitations from over an 18-month period, with a 
mobile unit crossing over from one intervention neighborhood to 
another at 9 months. INA, couple, and invitation characteristics 
predictive of couples’ testing were evaluated accounting for two-
level clustering. 
Results: 320 INAs delivered 29,119 invitations resulting in 1727 
couples testing (6% success rate). In multivariate analyses, INA 
characteristics significantly predictive of CVCT uptake included 
promoting in community-based (adjusted odds ratio [aOR]=1.3) 
or health (aOR=1.5) networks versus private networks, being 
employed in the sales/service industry (aOR=1.5) versus unskilled 
manual labor, owning a home
(aOR=0.7) versus not, and testing for HIV with a partner (aOR=1.4) 
or alone (aOR=1.3) versus never testing. Cohabiting couples 
were more likely to test (aOR=1.4) than non-cohabiting couples. 
Context characteristics predictive of CVCT uptake included 
inviting couples (aOR=1.2) versus individuals, the woman 
(aOR=1.6) or couple (aOR=1.4) initiating contact versus the INA, 
the couple being socially acquainted with the INA (aOR=1.6) 
versus having just met, home invitation delivery (aOR=1.3) versus 
elsewhere, and easy invitation delivery (aOR=1.8) versus difficult 
as reported by the INA. Use of mobile units was very low and did 
not substantially contribute to CVCT service delivery. 
Conclusion: This study demonstrated the ability of influential 
people to promote CVCT and identified agent, couple, and context-
level predictors of CVCT uptake in Lusaka, Zambia. We encourage 
the development of CVCT promotions in other sub-Saharan African 
countries to support sustained CVCT dissemination.
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Performance of Self-Reported Adherence to Oral 
Pre-Exposure Prophylaxis (PrEP) Among HIV 
Heterosexual Serodiscordant Couples in Rural 
Uganda
F.M. Kibengo1, E. Ruzagira1, U.M. Bahemuka1, D. Katende1,  
A. Abaasa1, B. Barin2, F. Priddy3, J. Haberer4, A. Kampala1
1Medical Research Council/Uganda Virus Research Institute, 
Entebbe, Uganda; 2The EMMES Corporation, New York, NY, 
USA; 3International AIDS Vaccine Initiative, New York, USA; 
4Massachusetts General Hospital Center for Global Health, 
Boston, MA, USA
Background: Adherence is one of the main determinants of 
PrEP efficacy. Most PrEP studies applied subjective adherence 
measures, which often produce overestimates and problematic 
efficacy data interpretation; creating a need for more objective 
measures. This study examines self-reported adherence to oral 
PrEP compared to Medical Events Monitoring System (MEMS). 
Methods: Seventy-two HIV-uninfected partners (50% women) 
in Uganda were randomized to daily or intermittent (Monday, 
Friday and within 2 hours after sex, not exceeding 1 dose/day) 
oral emtricitabine/tenofovir or placebo in a 2:1:2:1 ratio for four 
months. Adherence was assessed monthly by MEMS and self-
reported taken or missed doses by timeline follow-back calendar. 
MEMS data was adjusted for extra openings without pill removal 
and removal of multiple pills. Non-fixed days within intermittent 
regimen were classified as adherent/non-adherent based on self-
reported sex by SMS. Adherence rates by taken/missed doses 
were compared to raw MEMS data using Spearman correlation. 
Results: Treatment and placebo groups were combined since 
adherence rates were similar. Daily raw MEMS adherence rate 
was significantly higher than fixed Intermittent rate (p=0.04) and 
post-coital dosing rate (p<0.0001). Raw MEMS data for daily and 
fixed intermittent dosing, poorly correlated with self-reported 
taken doses (r=0.14, p=0.42 and r=0.01, p=0.94, respectively) and 
missed doses (r=0.30, p=0.08 and r=0.07, p=0.69, respectively). 
Self-reported daily adherence had high sensitivity but only 
fair positive predictive value (PPV) and very poor specificity. 
Self-reported adherence to intermittent fixed dosing had fair 
sensitivity, PPV and negative predictive value (NPV), but poor 
specificity. Self-reported adherence to post-coital dosing had 
very good sensitivity and NPV but poor specificity. 
Conclusion: Median adherence for daily and intermittent fixed 
PrEP was high by objective and subjective measures, but poorly 
correlated. Adherence to post-coital dosing was poor and likely 
overestimated by self-report (possibly reflecting technical 
challenges of SMS). Self-reported adherence measures were 
highly sensitive but poorly specific. 
P09.05
HIV-Free Children Born to HIV-Seropositive Mothers 
in Bamako, Mali:A Six-Year Perspective on Providing 
MTCTP at the Front Line of AIDS
Y. Koné1, B. Aboubacar2, L. Levitz2, C. Gomez Mira2, J. Toffoli2, 
N. Ryback2, E. Kossow2, T. Huang2, A. Bicki2, K. Tounkara2,  
Y. Traoré3, F. Siby Diallo4, M. Rochas2, A.S. De Groot5
1Community Health Center, ASACOMSI / GAIA Vaccine 
Foundation, Mékin-Sikoro/ Bamoko, Mali; 2GAIA Vaccine 
Foundation, Bamako, Mali; 3Department of Obstetrics 
and Gynecology, Hôpital Touré, Bamako, Mali; 4Regional 
Department of Health, Bamako, Mali; 5GAIA Vaccine 
Foundation, Institute for Immunology and Informatics, 
Providence, RI, USA
Background: GAIA Vaccine Foundation (GAIA VF) conducted 
a six-year retrospective assessment of its Mother To Child 
Transmission Prevention (MTCTP) program for effectiveness as a 
non-vaccine HIV prevention tool.
Methods: The MTCTP program at the Sikoro prenatal care center 
(Chez Rosalie) opened in 2005. We evaluated MTCTP acceptance 
and HIV test results of babies born in the MTCTP program from 
2005-2011. We also surveyed HIV+ mothers at the clinic about 
MTCTP risk in July 2011.
Results: 10,471 women were counseled about HIV infection 
during the study period (average 145/month). An overwhelming 
majority (99.1%) agreed to HIV testing: 202 (2.15%) were HIV+, of 
whom 125 (61.9%) accepted MTCTP treatment. Ninety-two HIV+ 
women delivered at Chez Rosalie. Most used the baby formula 
provided at the clinic, and a minority chose breastfeeding (as 
per national policy since 2010). Notably, 100% of babies born 
to MTCTP-adherent mothers were HIV-seronegative. Thirty-
five HIV+ mothers were interviewed about MTCTP for their 
150 children. Of the seven polygamous women interviewed, 
none informed their husbands about their HIV+ status; single 
and monogamous mothers were significantly more likely to 
communicate their status.
Conclusion: The number of women accepting treatment and 
remaining in care decreased over the 6-year period. Women 
moved to another clinic after testing positive and also returned 
to their home villages to deliver, despite having been educated 
about risks. Two children of mothers who were followed at Chez 
Rosalie but not enrolled in MTCTP were born HIV+; risk factors 
for transmitting HIV included late diagnosis (during pregnancy), 
breast feeding without concomitant ARV treatment, and single 
parent status. Lack of disclosure was worrisome, considering 
the number of polygamous relationships. GAIA is working on 
improving methods to reduce new HIV infections in Sikoro by 
destigmatizing HIV and MTCTP, and by scaling-up existing peer-
education programs to improve willingness to participate in and 
adhere to MTCTP.
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HIV-1 Subtype C Primary Isolates Exhibit High 
Sensitivity to an Anti-gp120 RNA Aptamer 
H.T. Mufhandu1, K.B. Alexandre2, E.S. Gray2, L. Morris2, M. Khati1
1Council for Scientific and Industrial Research (CSIR), Pretoria, 
South Africa; 2National Institute for Communicable Diseases 
(NICD), Johannesburg, South Africa
Background: Globally, HIV-1 subtype C is the most prevalent 
subtype, yet most antiretroviral drugs are developed against 
subtype B. UCLA1 RNA aptamer, which we previously showed 
neutralizes HIV-1 subtype C Env-pseudotyped viruses was 
examined for neutralization of subtype C primary isolates 
in PBMC and monocyte-derived macrophages (MDM). We 
also assessed the ability of subtype C to develop resistance 
to UCLA1 inhibition by propagating the isolates in increasing 
concentrations of the aptamer. 
Methods: UCLA1 was tested against clinical isolates in PBMC 
(6 isolates) and MDM (4 isolates) using a p24 antigen read-out. 
Three viruses were grown in the presence of increasing aptamer 
concentrations to select for resistance. The viruses were passaged 
every 7 days up to 12 weeks in CD8 depleted PBMC. The gp160 
was sequenced, analyzed and compared with wildtype viruses.
Results: UCLA1 neutralized 67% and 75% of viruses tested in 
PBMC and MDM, respectively. Overall, the aptamer neutralized 
one X4 and six R5 tropic viruses with IC80 values in the nanomolar 
range. Two viruses remained sensitive to the aptamer even in 
the presence of 4- and 12-fold increased UCLA1 concentrations. 
One isolate exhibited resistance after 12 weeks of propagation 
tolerating 12-fold the starting IC70. Fifty-eight amino acid changes 
and two insertions along the gp160 were observed. The changes 
observed within the V1/V2 and V3 loops confirmed our previous 
data shown by truncation and single point mutational analyses 
to confer resistance to UCLA1.
Conclusion: UCLA1 was able to neutralize infection of primary 
isolates in PBMC and MDM without tropism restriction. The 
extensive amino acid sequence changes associated with UCLA1 
resistance may indicate a high genetic barrier needed for resistance 
to UCLA1. This was also suggested by the low rate of resistance 
(only 1 of 3 isolates) observed in the study suggesting that UCLA1 
is a potential anti-HIV-1 subtype C entry inhibitor drug. 
P09.07
Straightforward Selection of Broadly Neutralizing 
Single-Domain Antibodies Targeting the Conserved 
CD4 and Co-receptor Binding Sites of HIV-1 gp120
J. Matz1, P. Kessler1, J. Bouchet1, O. Combes1, D. Baty1, L. Martin1, 
S. Benichou1, P. Chames1
1INSERM, Marseille, France
Background: The interaction of gp120 with CD4 is the first step 
of HIV cycle. It is the pivotal event allowing the entry of HIV into 
CD4+ cells. gp120 is the main target for neutralizing antibodies 
(nAb) but most of its accessible epitopes are highly variable and 
thus, HIV can bypass these nAbs.
Single domain antibodies (sdAb) derived from llama antibodies 
bind their antigen without requiring variable domains pairing. 
They are able to bind unconventional epitopes, like those 
present in protein cavities. Their small size (13 kDa) allows them 
to accede to very narrow space, such as the space between virus 
and cell membranes during infection. SdAbs are highly stable, 
easy to clone and produce in large amounts.
Methods: Using trimeric gp140, free or bound to a CD4 mimic, as 
immunogens in llamas, we selected a panel of broadly neutralizing 
single-domain antibodies that bind either to the CD4 or to the co-
receptor binding sites (CD4BS and CoRBS, respectively).
Results: When analyzed as monomers or as homo- or hetero-
multimers, the best sdAb candidates could not only neutralize 
viruses carrying subtype B envelopes, corresponding to the 
Env molecule used for immunization and selection, but were 
also efficient in neutralizing a broad panel of envelopes from 
subtypes A, C, G and CRF01_AE. Interestingly, sdAb multimers 
exhibited a broader spectrum of neutralizing activity than the 
parental sdAb monomers.
Conclusion: The extreme stability and high recombinant 
production yield combined to their broad neutralization capacity 
make these sdAbs new potential microbicide candidates for HIV-1 
transmission prevention.
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Progress and Challenges in Integrating CVCT into 
Routine Antenatal Services in Government Clinics in 
Ndola, Zambia
N. Czaicki1, J. Davitte2, B. Siangonya2, I. Thior3, J. Pulerwitz3,  
M. Inambao2, S. Allen1
1Emory University, Atlanta, GA, USA; 2Rwanda Zambia HIV 
Research Group, Ndola, Zambia; 3PATH, Washington, DC, USA
Background: In 2008, the Ministry of Health in Zambia 
recommended that HIV testing be provided to partners of 
antenatal clients. Herein the Zambia Emory HIV Research Project 
(ZEHRP) in collaboration with the Arise Program/PATH funded 
by CIDA examines the transition of Couples’ Voluntary HIV 
Counseling and Testing (CVCT) from NGO-sponsored weekend 
services to integrated weekday services in government clinics in 
Ndola, the second largest city in Zambia. We also describe how 
CVCT data are being recorded and reported. 
Methods: Data were extracted from government-issued logbooks 
in antenatal clinic (ANC), prevention of mother to child (PMTCT), 
and voluntary counseling and testing (VCT) services in the six 
largest government clinics for the year 2010, and in15 clinics in 
the first half of 2011. CVCT procedures and record-keeping were 
documented through observation and counselor interviews. 
Results: In 2010, only one of the six largest clinics tested more 
than four couples/week. In this clinic, a community promotions 
campaign in Q2 resulted in an average of 5 couples/day seeking 
testing, though numbers tapered off over time to 2 couples/day 
by Q4. In March-May of 2011, 11 of 15 clinics averaged less than 
10 couples per month. Four clinics recorded 20 to 60 couples/
month: 77% of couples were seen in ANC with the remainder 
tested in VCT. Obstacles included low participation of men, lack of 
staff trained to counsel couples jointly, procurement challenges 
for HIV tests for men in ANC, and non-uniform recording of CVCT 
in ANC and VCT logbooks. 
Conclusion: This study identified several challenges for integrating 
CVCT into regular clinic services. To address these challenges, 
we recommend implementing new data recording instruments, 
increasing training of counselors and nurses in CVCT, prioritizing 
ANC clients attending with partners and expanding of community 
sensitization using proven models. 
P09.09
Are Fishing Communities Another Most-at-Risk-
Population? Results of a Community-Based Study 
Along Lake Victoria, Uganda
A. Ssetaala1, J. Mpendo1, A. Nanvubya1, S. Sigirenda1,  
L. Nielsen2, N. Kiwanuka3
1UVRI-IAVI HIV Vaccine Program, Entebbe, Uganda; 
2International AIDS Vaccine Initiative(IAVI), New York, USA; 
3Makerere University College of Health Sciences School of 
Public Health, Kampala, Uganda
Background: A recent study reported HIV prevalence of 28.8% 
among high risk persons in fishing communities (FC) of Uganda, 
indicating that FC may be another most-at-risk-population 
(MARP). However, these findings do not reflect the population-
based HIV prevalence in FC. We conducted a community-based 
study to determine the population representative HIV prevalence 
and incidence among FC along Lake Victoria shores, Uganda.
Methods: Community-wide mapping and census of households 
in 8 fishing communities was conducted. A computer-based 
random sample of 2200 participants aged 18-49 years was 
selected for interviewing by same-sex interviewers using a semi-
structured questionnaire. Blood was collected for HIV serology 
using rapid HIV tests as per the national algorithm.
Results: We interviewed 2,192 (99.6%) participants, of whom 
fifty percent were females, median age 29 years, IQR 24-35 years 
and 82% had stayed in the communities for at least a year. 
HIV prevalence was 26.7%, higher among females than males 
[32.6% vs. 20.8%, p<0.01,OR=0.5], those who were single [34.7% 
vs. 27.8%, p<0.01, OR=1.4], those with >5 lifetime sexual partners 
[32% vs. 21%, p<0.01,OR=1.7], with no formal education [39.2% 
vs. 25.5%, p<0.01,.OR=0.5], reported alcohol use in previous 3 
months [32% vs. 20.8%, p<0.01, OR=1.8], alcohol use before sex 
[34% vs. 21%, p<0.01, OR=0.5] and used illicit drugs [33% vs. 
25.6%, p<0.01, OR=0.7]. 
HIV prevalence varied by occupation, highest among sex workers 
(66.7%), boat makers (50%), government employees (43%), bar 
owners (37.6%) and bar attendants (36.4%), [p<0.01]. Prevalence 
increased with age [p<0.01] and was not associated with 
consistent condom use [26.8% vs. 26.4%, p=0.45].
Conclusion: FC in Uganda have a disproportionately high HIV 
prevalence compared to the national average of 6.7%. Our 
prevalence estimate was comparable to that reported among 
high risk FC. Prevention efforts towards reducing HIV prevalence 
in these communities are needed, and such populations may be 
considered for future HIV prevention trials. 
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Alcohol and Illicit Drug Use Among Potential HIV 
Vaccine Efficacy Trial Volunteers Along Lake Victoria, 
Uganda
I. Ssekandi1, A. Ssetaala1, J. Mpendo1, A. Nanvubya1,  
L. Nielsen2, N. Kiwanuka3
1UVRI-IAVI HIV Vaccine Program, Kampala, Uganda; 
2International AIDS Vaccine Initiative, New York, USA; 
3Makerere College of Health Sciences School of Public Health, 
Kampala, Uganda
Background: HIV has adversely affected fishing communities 
(FC), with prevalence ranging between 25-30% on Lake Victoria. 
To better characterize the HIV prevalence among FC and explore 
potential for HIV vaccine efficacy trials, we conducted a pilot 
study on HIV prevalence, sexual risk behavior, alcohol and drug 
use in these communities. 
Methods: A cross-sectional HIV prevalence survey was conducted 
in 8 FC over 3 months. Census and mapping to determine the 
average population size in each community were conducted 
prior to the study. After obtaining informed consent, 2,200 
individuals aged 18-49 years from randomly selected households 
were tested for HIV and responded to questionnaires on sexual 
behavior, alcohol consumption and drug use.
Results: Fifty three percent (53.0%) had consumed alcohol 
in the past three months with males consuming more alcohol 
than females [59.0% vs. 46.8%, p<0.01].19.2% of alcohol 
consumers also used illicit drugs [p<0.01]. Alcohol consumption 
in the previous 3 months was highest among Catholics [p<0.01], 
those with no formal education [p=0.01], sex workers (100%), 
loaders/off loaders (79%), bar owners (69.7%), construction 
workers (66.7%), bar attendants (66.1%) and fishermen [(61.0%), 
p<0.01]. Daily alcohol consumption was highest among older 
participants (35-49years) and sex workers [p<0.01]. Alcohol 
consumption before sex (43.0%) was highest among youths (25-
34 years), sex workers, bar owners and attendants [p<0.01]. HIV 
prevalence was higher amongst alcohol consumers [63.4% vs. 
36.6%, p<0.01], with daily and weekly consumers having a higher 
prevalence [73.0% vs. 27.0%, p=0.05].
Illicit drugs like cocaine, Miraa/Khat were used by 13.8% of 
participants, mostly amongst sex workers [(33%), p<0.01]. Illicit 
drugs were used mainly on a daily basis [(44.6%), p<0.01]. 
Conclusion: Alcohol and illicit drug use is prevalent in FC and 
associated with higher prevalence of HIV infection. Efforts towards 
controlling alcohol and illicit drug use might help control HIV in 
these communities 
P09.11
Conformation-Dependent Recognition of HIV Gp120 
by DARPins Provides Novel Possibilities to Develop 
Distinct HIV Entry Inhibitors
A.M. Mann1, N. Friedrich1, A. Krarup1, P. Rusert1, J. Weber1,  
B. Dreier2, P. Pugach3, M. Robbiani3, J.A. Robinson4,  
A. Pluckthun2, A. Trkola1
1University of Zurich, Zurich, Switzerland; 2Institute of 
Biochemistry, University of Zurich, Zurich, Switzerland; 3Center 
for Biomedical Research, Population Council, New York, NY, 
USA; 4Institute of Organic Chemistry, University of Zurich, 
Zurich, Switzerland
Background: Designed Ankyrin Repeat proteins (DARPins) are 
a novel type of binding protein scaffold designed as antibody 
alternative for biomedical applications. DARPins share many 
properties with antibodies, most noteworthy a high target 
specificity and affinity, but they differ from antibodies in size, 
structure and binding pattern and, importantly, favorable 
biophysical properties such as exceptional stability. This 
together with high-yield prokaryotic production renders DARPins 
promising candidates for microbicide development.
Methods: DARPin DNA libraries encoding either two or three 
internal ankyrin repeats were subjected to ribosome display 
selections and panned against recombinant gp120 proteins. 
Wild type, CD4 induced, V1V2 truncated and deglycosylated JR-
FL gp120, as well as structural V3 loop mimetics were probed 
as target. Obtained DARPin clones were sequenced, mapped 
for reactivity with HIV gp120 by ELISA and probed for inhibitory 
activity using the TZM-bl pseudotype virus inhibition assay.
Results: DARPin selection proved more successful when 
conformationally arrested targets were used for panning. 
Overall, gp120-specific DARPins recognizing a variety of epitopes 
including the CD4bs, CD4i and the V3 loop were obtained. 
Gp120 mutant binding analysis revealed that DARPin molecules 
depended to a higher degree on a structural conservation of 
the envelope protein than gp120 specific antibodies recognizing 
overlapping domains. Most noteworthy, V3 loop specific clones 
were selected, which unlike V3 loop antibodies, recognized 
the V3 loop in a conformation-dependent manner and thus do 
not efficiently bind linear V3 loop peptides. In contrast to V3-
loop directed antibodies these DARPins proved to bypass the 
envelope shielding by the V1V2 domain and thus were capable 
of neutralizing TIER-2 viruses.
Conclusion: Gp120 proved a challenging target for selection 
of DARPin binders against gp120. Nonetheless, by combining 
different selection strategies we were able to derive a variety of 
gp120-specific DARPin molecules, including some with unique 
HIV entry blocking activity.
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Heme Oxygenase-1 Reverses HIV-1 Tat Activity: 
Prospects for AIDS Prevention
M.E. Cueno1, K. Imai1, K. Ochiai1
1Nihon University School of Dentistry, Tokyo, Japan
Background: Heme oxygenase-1 (HO-1) is a HEME regulator 
and plays a role in ameliorating HIV-1 infection. In particular, 
HO-1 inhibits Tat-dependent activation of HIV-1 LTR promoter 
inhibiting viral gene expression. This suggests that increasing 
HO-1 activity in HIV-infected cells can reverse Tat action which 
may contribute to AIDS prevention. However, the correlation 
between HO-1 and HIV-1 Tat has not been fully elucidated. In 
order to fully understand how increasing HO-1 activity reverses 
Tat action and result into the prevention of HIV infection, the 
mechanism behind the correlation between HIV-1 Tat and HO-1 
should first be established.
Methods: Throughout the study we made use of Jurkat T cells 
(control) and Jurkat-Tat T cells. Whole cell extracts were obtained 
and mitochondrial extracts were isolated separately. HO-1, 
HEME, superoxide dismutase (SOD), catalase and hydrogen 
peroxide (H2O2) levels were measured using commercially 
available assays. Immunoassays confirmed both the presence of 
Tat and NADPH oxidase activity via the HEME-activated gp91phox 
Results: We found that in Tat-expressing cells, HO-1 and SOD 
amounts were decreased, HEME and H2O2 levels were increased 
and catalase concentration was unchanged. In addition, we 
observed an accumulation of gp91phox and H2O2 amounts. We 
suspect that Tat activity in Jurkat T cells lead to the following 
sequence of events: (1) decrease in HO-1 and SOD activities; 
(2) low SOD amounts leaves catalase amounts unchanged; (3) 
low HO-1 levels allows HEME to accumulate; (4) high amounts 
of HEME favors the accumulation of the gp91phox subunit 
which subseuqently increases NADPH oxidase activity; and (5) 
ultimately leads to H2O2 accumulation. We hypothesize that 
by increasing HO-1, as previously reported, HIV-1 infection was 
ameliorated ascribable to a reversal in Tat activity.
Conclusion: HIV-1 Tat lowers HO-1 activity which consequentially 
leads to H2O2 accumulation. We suspect, based on a previous 
report, that increasing HO-1 ameliorated HIV-1 infection by 
reversing Tat activity.
P09.13
Anti-HIV and Immune Modulating Activities of IND02
M.E. Biedma1, B. Connell2, S. Schmidt1, H. Lortat-Jacob2,  
C. Moog1, E. Prakash3
1Instituté de Virologie, INSERM U748, Strasbourg, France; 
2Institut de Biologie Structurale, Grenoble, France; 3Indus 
biotech Pvt Ltd, Pune, India
Background: A vaccine that prevents HIV infection should not 
only induce functional inhibitory, neutralizing antibodies, but 
also promote Fc-mediated inhibitory antibodies displaying 
ADCC or phagocytosis. The aim of this study is to analyze the 
effect of IND02, a cinnamon derived procyanidin polymer on 
the interaction of HIV-1 gp120 with its co-receptors as well as its 
adjuvant like activity along with HIV-specific antibodies.
Methods: The ability of IND02 to interact with the HIV envelope 
glycoprotein gp120 was analyzed by studying binding of IND02 
to gp120 envelopes by Biacore. The expressions of FcγRs were 
evaluated on macrophages and NK primary cells incubated 
with IND02 by flow cytometry. The inhibitory activity of IND02 
was assessed on PBMC using TZM-bl assay for neutralization, 
Fc-mediated inhibitory activity on macrophages and Antibody 
Dependant Cellular Cytotoxicity in presence or absence of anti-
HIV antibodies.
Results: Binding of IND-02 to gp120 envelopes was dose-
dependent within the μM range and was capable to inhibit gp120-
CD4 interaction. A moderate decrease in the expression of FcγR I 
and III was observed on macrophages treated with IND02, while 
FcγR II expression was unaffected. FcγRIII expression on NK cells 
was not modified. IND02 demonstrated low inhibitory activity on 
TZMbL and PBMC, but was able to efficiently inhibit HIV infection 
on macrophages. Moreover IND02 demonstrated synergistic 
effect when combined with monoclonal inhibitory antibodies. An 
enhanced ADCC was detected in presence of IND02 and anti-HIV 
specific antibodies.
Conclusion: IND02 represents an interesting class of botanical 
molecule that binds to HIV-1 envelope protein, including the co 
receptor binding site, impairing HIV interaction with co-receptors 
on target cells. This interaction could explain the decreased 
HIV replication observed after IND02 treatment. Besides, an 
augmentation in the activity of HIV-specific antibodies, involving 
ADCC and Fc-mediated phagocytosis, was observed in presence 
of IND02 supporting additional adjuvant mechanisms that could 
enhance immune responses against HIV.
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HIV Risk Among Men Who Have Sex with Men 
(MSM) in Nigeria: A Potential Population for HIV 
Vaccine Trial
A.O. Adeyemi1, K. Oyediran1, K.B. Issa2, A. Azeez2,  
A. Atobatele3, O. Fakunle4
1MEASURE, Abuja, Nigeria; 2Federal Ministry of Health, Abuja, 
Nigeria; 3USAID, Abuja, Nigeria; 4University College Hospital, 
Abuja, Nigeria
Background: MSM are at a high risk of HIV. Due to their risk, they 
are potential population for HIV vaccine trials. Nigeria conducted 
2010 Integrated Biological Behavioral Surveillance Survey (IBBSS) 
among the high risk groups. Unfortunately, MSM had the second 
highest HIV prevalence after female sex workers, and some with 
female partners. Thus, HIV prevention among MSM is of great 
national importance. This study evaluates predictors of their 
risky behavior which will be useful in enrolling them for future 
HIV vaccine trials.
Methods: Secondary analysis of 2010 IBBSS data involving 
1545MSM between 18–49years was done. IBSSS involved HIV 
testing with information collected on sexual/reproductive 
health indicators. Risky sexual behavior was defined as sex 
without condom and with more than one male partner. 
Multivariate logistic regression was used to model predictors of 
risky sexual behavior.
Results: Mean age: 25.4±6.0years; HIV prevalence: 17.2%; 12.2% 
were married to female partners; median anal sex partner was 
3. About 31.5% tested and received results for HIV; condom 
use at last anal sex: 52.1%; sex with girlfriends: 41.9%; 18.3% 
paid for sex; 12.2% used marijuana; daily alcohol use 26.6% 
and 33.1% were reached with prevention programs. About 34% 
MSM engaged in risky sexual behavior. Predictors of risky sexual 
behavior were use of alcohol OR=2.9 95%CI:1.3-6.1; being away 
from home for >1month OR=2.5 95%CI:1.3-5.7; anal sex without 
condom OR=2.9 95%CI:1.6–4.4; sex with ≥3 partners OR=5.6 
95%CI:2.1-7.3; while previous STI OR=0.6 95%CI:0.3-0.9; having 
a female marital partner OR=0.7 95%CI:0.4-0.9; known HIV result 
prior to survey OR=0.6 95%CI:0.3-0.9 were protective.
Conclusion: High number of MSM practice risky sexual behavior 
that is driven by alcohol, multiple male partners and is reduced 
by previous STI or known HIV result. Lastly, there is a need for 
innovative and result-oriented behavioral interventions among 
MSM to reduce their HIV risk.
P09.15
Inhibition of HIV-1 Subtype C by 2’F-RNA Aptamers 
Isolated Against Enveloped Pseudovirus
G.G. London1, M.M. Madiga 2, E.E. Gray2, D.D. Sok3, L.L. Morris2, 
D.D. Burton 4, M.M. Khati5
1CSIR, Biosciences, Pretoria, South Africa; 2National Institute 
for Communicable Diseases, Johannesburg, South Africa; 3The 
Scripps Research Institute, San Diego, CA, USA; 4Department 
of Immunology, The Scripps Research Institute, San diego, CA, 
USA; 5CSIR Biosciences, Pretoria, South Africa
Background: Human immunodeficiency virus type-I (HIV-1) 
envelope glycoprotein (Env) mediates the first step of entry and 
represents an attractive target . However, the genetic diversity of 
Env among HIV-1 subtypes poses a challenge. Although evidence 
suggest that entry inhibitors in clinical use have comparable 
efficacy against HIV-1 subtypes, but a subset of anti-Env are 
resistant to HIV-1 subtype C which is the most globally prevalent 
virus. In a view to prevent infection of HIV-1 subtype C, we 
isolated nucleic acids ligands aptamers against HIV-1 subtype C 
Env pseudovirion and tested their efficacy. 
Methods: We isolated 109 unique 2`F-RNA aptamer sequences 
against HIV-1 subtype C Env pseudovirus using systematic 
evolution of ligands by exponential enrichment (SELEX) process. 
After 9 selex cycles, we grouped aptamer clones by binding 
activity to gp120 then selected one of the aptamer which 
neutralized infection of parental virus with IC50 values <5 nM. 
We tested efficacy of a selected aptamer against 31-pseudovirus 
panel from subtype C using single cycle luciferase assay in TZM-
bl cells. In addition, we mapped the epitope on gp120 binding 
by competition
Results: When screened on a 31-panel of HIV-1 subtype C 
pseudoviruses, RNA aptamer CSIR 1.1, neutralized 26 /31 (84%) 
with mean IC50 of 6.7 ± 8.8 nM. Competition ELISA results 
revealed CSIR 1.1 bind to the epitope overlapping CD4 and VRC01 
on monomeric gp120 but not b12 or b6. In contrast to CD4, CSIR 
1.1 did not enhance the binding of 17 b to the co-receptor region 
on monomeric gp120 showing a different binding mode to the 
soluble CD4
Conclusion: Our data show that we have isolated new RNA 
aptamers with efficacy against diverse HIV-1 subtype C viruses. 
The immediate future research would include testing efficacy on 
primary isolates and precise mapping . 
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Infrequent, Low Magnitude HIV-Specific T Cell 
Responses In HIV-Uninfected Participants In The 1% 
Tenofovir Microbicide Gel Trial (CAPRISA004)
W.A. Burgers1, T.L. Muller1, A. Kiravu1, V. Naranbhai2,  
S. Sibeko2, L. Werner2, Q. Abdool Karim2, S.S. Abdool Karim2
1University of Cape Town, Cape Town, South Africa; 2CAPRISA, 
Nelson R Mandela School of Medicine, Durban, South Africa
Background: Macaque studies of antiretroviral-containing 
microbicide gels administered rectally or vaginally followed by SIV 
challenge have documented priming of SIV-specific T cell responses 
in the blood of protected animals. This concept has been termed 
“chemo-vaccination”, where aborted viral replication is thought 
to leave an immune footprint of exposure, which may augment 
protection provided by microbicides/PrEP. We investigated 
whether T cell responses were detectable in women participating 
in CAPRISA004 1% tenofovir microbicide trial, which showed 39% 
efficacy in reducing HIV acquisition.
Methods: Thirty-eight HIV-uninfected participants were selected 
based on consistently high gel use and a high number of recorded 
sex acts over the duration of the trial. Cryopreserved PBMC were 
stimulated with HIV-1 peptide pools based on the HIV-1 clade 
C proteome, and IFN-gamma production was measured by the 
ELISPOT assay. Positive response were defined as >55 SFU/106 
PBMC. Samples were tested at the visit at which preceding 
monthly coital activity was the participant’s highest, and at study 
exit. Assays were conducted blinded to placebo or tenofovir arm.
Results: T cell responses were detected in 1/18 tenofovir and 
2/13 placebo participants at the high gel use visit. Responses 
were of low magnitude (between 60 and 100 SFU/106 PBMC), 
and directed at peptide pools from HIV Gag, Pol, Nef and Env. 
T cell responses were not detected at the exit visit. These data 
suggest that HIV-specific responses are infrequently detected 
in blood in uninfected participants from a clinical trial of a 
vaginal microbicide, and where present, are of low magnitude 
and transient.
Conclusion: Magnitude and timing of viral exposure may account 
for differences in detecting systemic T cell responses between 
preclinical studies in non-human primates and a human clinical 
trial of a vaginal microbicide. 
P09.17
Female Sex Workers and Condom Use: Lessons for 
Future HIV Vaccine Trial in Nigeria
O. Fakunle1, A. Adeyemi2, O. Busari3, O. Adesola4
1University College Hospital, Ibadan, Nigeria; 2MEASURE, 
Abuja, Nigeria; 3Federal Medical Center, Ido-Ekiti, Nigeria; 
4Mainland Hospital, Lagos, Nigeria
Background: Condom remains one of the most effective means 
of HIV prevention in the absence of proven, safe and effective 
vaccine. Nigeria has a surveillance system that monitors HIV 
trend among most-at-risk populations. Female sex workers (FSW) 
have the highest HIV prevalence compared to other groups. Since 
the ultimate goal is to prevent new infection, there is a need to 
evaluate condom use among FSW and the lessons will be vital for 
future HIV vaccine trial.
Methods: Secondary data analysis of 2010 Integrated Bio-
Behavioral Surveillance Survey was done with 4559 brothel 
and non-brothel FSWs in 9 Nigerian states. The survey involved 
HIV testing. Administered questionnaires had information on 
socio-demographic, HIV, sexual/reproductive health variables. 
Predictors of consistent condom use were evaluated using 
multiple logistic regression models.
Results: The median age was 26years (15-49years); median age 
at first sex was 17years (11-22years); average clients/day was 
4; 38% had ever been married with 8.1% currently married and 
3.7% living with their spouse; 74.6% used condom consistently; 
47.4% completed at least secondary education; 53.6% had been 
away from home for more than 1month; 60.2% tested and 
received HIV result within the last 12months; and 91.2% knew 
that condom could protect against HIV. Significant predictors of 
consistent condom use include testing and knowing result for 
HIV OR=1.9 95%CI:1.4-2.5; being away from home for ≥1month 
OR=1.4 95%CI:1.1-1.9; engaged in sex trade for 24months or 
less OR=2.7 95%CI:2.0-3.7; those that had 4 or more clients per 
day OR=1.7 95%CI:1.3-2.3) and those aged 25years and above 
OR=1.4 95%CI:1.1-2.1.
Conclusion: Older FSW with shorter duration in sex trade, having 
more clients, aged above 25years and away from home are more 
likely to use condom consistently. Lessons from condom uptake 
among FSW may lead to targeting FSW with these features for 
inclusion criteria for HIV vaccine trial in Nigeria.
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Engineering SIV-Resistant Macaque Hematopoietic 
Stem Cells and CD4+ T Cells with CCR5-Specific Zinc-
Finger Nucleases
G. Bonello1, P. Lentz1, M. Salas1, M. Cepeda1, R. White1,  
M. Gauduin1
1Texas Biomedical Research Institute, San Antonio, TX, USA
Background: CCR5 is the major HIV co-receptor, and individuals 
homozygous for a 32-bp deletion in CCR5 are resistant to infection 
by CCR5-tropic HIV-1. Zinc finger nuclease (ZFN) technology is a 
class of engineered DNA-binding proteins facilitating targeted 
genome editing by binding to a user-specific locus and causing 
a double-strand break in the region of interest. As a result, 
the gene of interest targeted by ZFN cleavage is disrupted. We 
investigated the ability of a Ccr5 gene-specific ZFN to establish 
SIV-resistant CD4+ T cells and hematopoietic progenitor cells 
isolated from macaques. 
Methods: Bone marrow and blood samples were obtained 
from ten naïve uninfected rhesus macaques. Immunomagnetic 
enrichments were performed to isolate hematopoietic stem/
progenitor cells and CD4+ T cells using magnetic-beads. 
Purified cells were nucleofected with RNAs encoding for a 
Ccr5-specific ZFNs.
Results: We successfully engineered CCR5-modified macaque 
CD4+ T lymphocytes that were resistant to in vitro infection 
with SIVmac239, SIVmac251, and CCR5-tropism SIVagm. CD4+ 
T lymphocytes that incorporated RNAs encoding for the Ccr5-
specific set of ZFNs marked resistance to SIV infection as showed 
by lack of p27 expression in culture supernatants. Infection 
of non-modified CD4+ T lymphocytes led to significant p27 
production from day 5 post-infection with a pick at day 7 post-
infection. We developed and optimized the conditions for proper 
isolation, expansion and in vitro differentiation of macaque 
hematopoietic stem cells to be used for the generation of SIV-
resistant macaque hematopoietic stem cells using our ZFNs. We 
successfully engineered CD34+ hematopoietic stem cells using 
nucleofection of RNAs encoding for a Ccr5-specific ZFNs.
Conclusion: We demonstrated the feasibility of using ZFN 
technology to establish CD4+ and hematopoietic stem cells 
resistant to SIV infection in macaque model. The generation of 
a nonhuman primate model using this modern molecular-based 
strategy might significantly help in the design of new therapies to 
prevent viral infection in human. 
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Protection of Human Research Participants Through 
Routine Inspection of Ongoing HIV Prevention and 
Treatment Clinical Trials:Experiences from Zimbabwe
R.B. Zinyama-Gutsire1, R. Musesengwa1, S. Ruzario1, R. Gunda1
1Medical Research Council of Zimbabwe, Harare, Zimbabwe
Background: The Medical Research Council of Zimbabwe 
(MRCZ) is the National Ethics Committee in Zimbabwe. MRCZ 
was established in 1974 under the Research Act of 1959 and 
Government Notice No. 225 of 1974 to promote and co-ordinate 
health research in Zimbabwe. The main mandate of MRCZ is the 
scientific review, ethics approval and oversight of all ongoing 
medical research studies in Zimbabwe inspection of all on 
going research studies involving humans using an established 
Human Protection System. Routine inspections and ‘for cause’ 
inspections are carried out to ensure utmost protection of 
research participants and to ensure protocol adherence and ICH-
GCP compliance. HIV prevention and HIV drug treatment clinical 
trials receive more detailed attention during inspections as they 
are delicate and complicated. 
Methods: During the inspection process the following aspects 
are checked on and thoroughly reviewed: initial and continuing 
MRCZ approval letters, protocol version at study site, National 
Drug Regulatory Body approval in case of drug clinical trials, valid 
continuing review approvals, staff qualifications, staff registration 
with professional bodies and relevant experience, evidence 
of research ethics and GCP training, data storage, signed and 
dated participant consent forms, external monitors reports and 
recommendations, approved study data collection tools, procedure 
rooms and interviews study participants. MRCZ adherence to Local 
and International Research Ethics Guidelines and offers research 
ethics and GCP training courses to local researchers. 
Results: A recent development has been proactive requests from 
researchers for research ethics and GCP training, an indication of 
the increased awareness amongst researchers in Zimbabwe of 
the need for this training. 
Conclusion: There has been significant improvement in 
protection of research participants, protocol adherence and 
ICH-GCP compliance by researchers as a result of the increased 
inspection of all ongoing research studies in Zimbabwe. More 
and more researchers are now aware of international research 
P10.01
Dealing with Research Participants’ Complaints in 
HIV/ AIDS Prevention Studies: Experiences from 
Zimbabwe
R. Gunda1, S. Ruzario1, R. Chekera1, M. Phiri1, R. Gutsire1
1Medical Research Council of Zimbabwe, Harare, Zimbabwe
Background: The Medical Research Council of Zimbabwe 
(MRCZ) houses the National Ethics Committee which safeguards 
the rights, safety and well-being of all research participants. 
Research participants in AIDS Prevention Trials, including HIV/
AIDS vaccine trials, do from time to time have complaints during 
research implementation. The National Ethics Committee takes 
these complaints seriously and works tirelessly to address all 
complaints that research participants report to them in order 
to continuously improve the ethical conduct of AIDS research. 
The research community as a whole suffers when even a few 
investigators ignore the basic principles of ethics. 
Methods: We ensured that all research participants in Zimbabwe 
are well informed of the National Ethics Committee`s complaint 
procedure. Adequate information on how to lodge a complaint 
is supplied upon request. Complaints are listed with all relevant 
details and are investigated fully by the Council. Depending on 
each complaint, urgent meetings with investigators and study staff 
are done. Urgent for-cause site inspections, interviews with study 
participants, impromptu meetings with Community Advisory 
Board members and the communities are also done. Community 
Research Ethics Awareness Outreaches are conducted periodically 
and annual Research Ethics Forums are held for researchers and 
participants to bridge the gap between them
Results: The MRCZ managed to address all participants complaints 
reported in 2011. The number of for-cause site inspections for 
HIV/AIDS Prevention Trials increased from 2 in 2010 to 8 in 2011. 
Complaints included participants spending longer times at a 
research site than the time written on the informed consent, 
insufficient food given at research site, laboratory results not 
being issued on time as promised, confidentiality not being 
maintained and insufficient bus fare reimbursements being given
Conclusion: A functional system to handle complaints from 
research participants helps to improve the ethical conduct of 
research. Experiences from the Medical Research Council of 
Zimbabwe will be shared.
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Global Implementation of Good Participatory 
Practice Guidelines for Biomedical HIV Prevention 
Research: Charting Progress and Setting Milestones
S. Hannah1, M. Warren1, E. Bass1
1AVAC, New York, NY, USA
Background: In 2007, UNAIDS and AVAC developed the Good 
Participatory Practice (GPP) Guidelines with the aim of ensuring 
community and stakeholder engagement in HIV prevention 
research. The second edition, launched in 2011, provides the 
first standardized framework for GPP compliance. Five years 
after initial publication, it is possible and necessary to evaluate 
milestones in adoption of the guidelines at trial site, sponsor, 
country, and international levels in order to gauge progress and 
next steps. 
Methods: A systematic review of 1) articles citing or mentioning 
GPP; 2) GPP-specific trainings requested and/or carried out by 
AVAC partners; 3) national and international forums in which GPP 
was mentioned, adopted or presented shows that GPP is gaining 
currency and relevance as key in guiding not only prevention 
research but all research involving human subjects.
Results: Support for and awareness of GPP have increased 
dramatically over the past five years. There is, however, a continued 
need for technical support for implementation. Common gaps in 
practice included low levels of documentation of engagement 
activities, planning around possible contentious issues and trial 
results, and stakeholder input in trial protocols. National level 
implementation activities provided initial steps in requirement 
of GPP. For example, GPP was presented to US President 
Obama’s Commission for Bioethics, and subsequently cited as 
recommendation for community engagement in the Commission’s 
official report. This effort secured international recognition and 
expanded relevance beyond HIV prevention research. Additional 
action is necessary for requirement and monitoring of practices.
Conclusion: While stakeholder engagement has long been 
accepted practice in HIV prevention research, findings from 
multiple implementation processes suggest the value and power 
of applying a systematic framework to practices. Awareness of 
GPP has increased, however meaningful implementation within 
and outside of HIV prevention research necessitates sustained 
commitments, new resources and action on the part of national, 
international and community-level stakeholders.
P10.03
Meta-Analysis of Correlates of HPV Vaccine 
Acceptability Among Men: Supporting Vaccine 
Implementation Science
P.A. Newman1, C. Logie1, K. Asakura1
1University of Toronto, Toronto, Canada
Background: Understanding ubiquitous research-to-practice 
gaps in uptake of adult vaccines, particularly those for sexually 
transmitted infections (e.g., suboptimal human papillomavirus 
[HPV] vaccine uptake among men in the US), may provide evidence 
to support the successful dissemination of future HIV vaccines. 
To this end, we assessed rates of HPV vaccine acceptability and 
factors correlated with HPV vaccine acceptability among men.
Methods: We used a comprehensive search strategy across 
multiple electronic databases to locate studies that examined 
rates and/or correlates of HPV vaccine acceptability. The search 
strategy had no date or language restrictions. Search keywords 
included vaccine, acceptability and all terms for human 
papillomavirus. We calculated mean HPV vaccine acceptability 
scores across studies. We conducted meta-analysis using a 
random effects model on cross-sectional studies reporting 
correlates of HPV vaccine acceptability. All studies were assessed 
for risk of bias.
Results: Of 301 identified studies, 22 met inclusion criteria. Across 
18 studies (n=7787), weighted mean HPV vaccine acceptability = 
52.3 (SD 17.5) (100-point scale). HPV vaccine acceptability was 
significantly higher among gay/bisexual/MSM (65.1, SD 15.1) 
versus heterosexual men (47.3, SD 14.7). Among 11 studies 
(n=4064) included in meta-analyses, perceived HPV vaccine 
benefits and doctor recommendation had medium effect sizes, 
and the following factors had small effect sizes on HPV vaccine 
acceptability: anticipatory regret, perceived effectiveness, fear of 
side effects, perceived partner support for vaccination, perceived 
susceptibility to HPV, number of lifetime sexual partners, having a 
current sex partner, Hepatitis B vaccine uptake, smoking cigarettes, 
HPV awareness, knowledge and non-white ethnicity.
Conclusion: Public health campaigns tailored for men that 
promote positive HPV vaccine attitudes, HPV knowledge and risk 
awareness, and healthcare provider education, may support HPV 
vaccine acceptability for men; these factors may be instructive 
in planning for future HIV vaccine dissemination. Future 
investigations employing rigorous designs, including intervention 
studies, are needed to support effective vaccine promotion 
among men.
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A Case Study of a National Ethics Committee:-
Challenges in Regulating HIV Prevention Research in 
Zimbabwe
M.E. Phiri-Shana1, R. Musesengwa1, S. Ruzario1, R.B. Gutsire-
Zinyama1, R. Gunda1
1Medical Research Council of Zimbabwe, Harare, Zimbabwe
Background: As efforts in search of effective HIV prevention 
strategies intensify, studies have become exceedingly complex, 
posing several regulatory challenges to most African Ethics 
Committees, the MRCZ included. Challenges faced include: 
Researchers not being clear on how to operate in compliance to 
local and sponsor country regulations; i.e. when a host country 
ethics committee has issued a decision on an issue concerning 
rights, safety and well being of participants while an overseas 
ethics committee has not. Prevention studies require frequent 
assessment, at MRCZ this has been hampered by limited 
resources. Ascertaining comprehension of these complex studies 
by participants and ensuring they receive new information 
promptly has also been a challenge. MRCZ has taken several 
measures to address regulatory challenges faced. 
Methods: Routine, for- cause and passive inspections of ongoing 
approved research studies have been done. During these, 
participant comprehension checklists used at enrollment were 
audited and interviews with participants held to assess study 
knowledge levels. MRCZ has also set up a database to record 
types of inspections, number of Serious Adverse Events and 
protocol deviations
Results: From year 2000, MRCZ has actively and passively 
inspected about 1000 studies of these 5 were for- cause. MRCZ 
has also trained 340 research staff and 15 members of Council in 
Research Ethics, GCP and National Research Guidelines to build 
capacity. Due to this there has been: - Adoption of a harmonized 
review process; A decrease in for- cause inspections and an 
improvement in study documentation. All initial and continuing 
review submissions now include GCP certificates of study staff as 
well as participant comprehension checklists. 90% of interviewed 
participants show understanding of research studies they are 
involved in.
Conclusion: Regulatory bodies should consolidate efforts in 
understanding the complex and dynamic HIV research arena and 
in ensuring that research is carried out in a well regulated arena.
P10.05
Willingness to Participate in Vaccine Trials Among 
MSM in São Paulo, Brazil
G. Calazans1, R. Gamboa1, A. Kalichman1, M. Ribeiro2,  
M. Veras2
1Sao Paulo HVTU - CRT-DST/AIDS, São Paulo, Brazil; 2School of 
Medical Sciences, Santa Casa de São Paulo, Brazil
Background: An effective HIV vaccine still poses a great challenge 
to research scientists. Among the most vulnerable populations 
to HIV infection in Europe, United States and Latin America are 
men who have sex with men (MSM), potential volunteers for HIV 
vaccine research. We have asked MSM from a large LA city about 
their willingness to participate (WTP) in HIV vaccine trials. 
Methods: A survey of men who attend MSM-identified venues in 
downtown São Paulo was carried out between November 2011 
and January 2012. Time-location sampling approach was used. 
During sampling events, interviewers approached and asked 
men to respond a brief eligibility interview and consecutively 
applied a questionnaire to men who referred having ever anal 
or oral sex with men or transvestite. Here we analyze WTP in 
hypothetical HIV preventative vaccine trials.
Results: 1217 MSM were interviewed (missing data=3), 54,6% 
would accept participating, 35,3% would deny, and 9,9% stated 
they were unsure/maybe/depending on more information or 
assurances before deciding whether to participate in vaccine trials. 
WTP in HIV vaccine trial was similar across age groups (p=.450) and 
race/ethnicity (p=.534). There was no patterned difference among 
those who self-identified as homosexual, bisexual or transgender 
(p=.542) as well as among those who would have sex with an HIV-
infected person, the size of their HIV-infected network (p=.251). 
Although not significant (p=0.06) a trend was suggested with WTP 
and the level of education of the head of the household, as years 
of education increased greater WTP. 
Conclusion: Findings indicate that, despite the lack of success in 
recent phase II/III trials, there is substantial WTP in HIV vaccine 
studies, expressing the hope for an effective vaccine retain a pool 
of potential volunteers among the most vulnerable population. 
Subsequent analysis should focus on association with behavioral 
aspects, as risk behaviors, experience of discrimination due to 
sexuality and WTP.
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Knowledge, Attitude and Practice of Safe Sex Among 
Men Who Have Sex with Men (MSM) in Nigeria
R.G. Ezomoh1
1The Initiative for Equal Rights, Lagos, Nigeria
Background: The success of the antiretroviral drugs in the late 
90s resulted in increase sexual risk-taking behaviors among MSM 
and “business as usual” attitude to sex which has resulted in 
the high prevalence of HIV infection. We therefore studied the 
knowledge, Attitude and Practice of safe sexual practices among 
Men who have sex with men (MSM)
Methods: Self administered open ended questionnaire with 
four sections: Biodata, knowledge, Attitude and practice of safe 
sexual practices were administered. 8 MSM communities were 
selected using stratified sampling method and a key opinion 
leader was selected per community; the KOLs administered the 
questionnaire to a total of 1600 MSM (200) per community
Results: 1600 participants were recruited into this survey and 
all were MSM (100%). 17% were aged 18-20years, 65% were 
between the age 21-29years while 10% were aged 30-40 years 
and 8% were over 40years of age. 96% of our respondents 
had good knowledge of condom use while 39% were informed 
about the advantage of lubricants for anal sex. 67% admitted 
to inconsistent use of condom. All our participants have been 
involved in 3 casual relationships in the last 12months. 78% had 
unprotected anal sex in the last 3 months with and 88% of them 
were between the 18-29 years of age. 64% had oral sex in the last 
3 months and 36% of them were between 30-40 years. 
43% of our participants take alcoholic beverages. 11% smoke 
cigarette.Only 38% of our participants knew their H.I.V status
Conclusion: MSM have good knowledge of condom use but 
behavioral change is low. These findings show that more HIV 
counseling/testing centers need to be created for MSM. Lots 
of MSM need to be reached with intervention to improve 
knowledge of risky practices associated with high risk men, 
reduce high-risk sexual practices, reduce barriers to HIV/STI 
detection and treatment
P10.07
Human Subject Protection and Ethical Review of 
Research Protocol
N.M. Otuonye1, F.O. Nwaokorie2, D. Suprumont 3, T. Halidoub4, 
E.I. Otuonye5
1Nigerian Institute of Medical Research, Yaba, Nigeria; 
2Nigerian Institue of Medical Resaerch, Yaba, Nigeria; 3Institute 
de droit de la Santé, Faculty de droit Neuchâtel, Neuchatel, 
Switzerland; 4IRSS-DRO/Centre Muraz 01, Bobo Dioulass, 
Burkina Faso; 5Evergreen Chambers Off Ojuelebga, Surulere 
Lagos, Nigeria
Background: The purpose of this project was to train health 
personnel, researchers and IRB members to design protocols 
with ethical integrity and to approve the conduct of protocols 
with scientific merit. The burden of TB, HIV and Malaria is heavier 
in sub - Saharan Africa; hence there are calls for competent 
review of ethical processes to ensure that research proposals 
and protocols comply with international standards
Methods: Sixty nine medical personnel including Doctors, Nurses, 
Biomedical Scientists, and Pharmacists, legal officer, clergy, 
community representative and Researchers were trained on 
Human subject protection. Participants were trained on Basic 
principles and international guidelines on bioethics, Basics of 
research and clinical trials, Ethical review of research protocols, 
Risk, benefit and inducement. Other slides that were presented 
included: Standard of care and prevention, research protocol, 
standard of care, Good participatory practices, Informed consent, 
HIV treatment, prevention research and monitoring of research. 
Pre and Post test was used to evaluation participants’ performance. 
Results: The 4 day workshop conducted at Mainland Hospital 
Yaba, Lagos, Nigeria, from 28th June to 1st July, 2011, adopted 
a participatory approach including brainstorming, group 
discussion, slide presentations and case studies. The pre and 
post-test evaluation indicated that participants’ knowledge 
improved significantly in conduct of ethically sound research 
(45.3% vs 65.0%; P=0.001). 
Conclusion: From our experience training and retraining of health 
personnel and researchers would increase their knowledge 
and skill to conduct research that is ethically regulated and of 
international standard. IRB members would improve their ability 
to understand the operations of research ethics and develop 
adequate confidence in reviewing research protocols and 
monitor research activities
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Funding the Critical Path from Research to Reality: 
Sustaining HIV Vaccine R&D Amidst Economic 
Uncertainty
K. Fisher1, E.D. Donaldson1, B. Gobet2, L. Green3, T. Harmon4,  
P. Harrison1, R. Lande3, M. Warren1
1AVAC, New York, NY, USA; 2UNAIDS, The Joint United Nations 
Programme on HIV/AIDS, Geneva, Switzerland; 3International 
Partnership for Microbicides, Silver Spring, MD, USA; 
4International AIDS Vaccine Initiative, New York, NY, USA
Background: Since 2004, the HIV Vaccines and Microbicides 
Resource Tracking Working Group has employed a 
comprehensive methodology to track trends in R&D investments 
and expenditures for biomedical HIV prevention options, 
including HIV vaccines, microbicides, pre-exposure prophylaxis 
(PrEP), treatment as prevention, adult voluntary medical male 
circumcision, female condoms, HSV-2 prevention and vertical 
transmission prevention. Such monitoring is critical to identifying 
trends in investment and providing a fact base for policy advocacy 
on R&D spending levels and allocations.
Methods: To estimate annual investment in HIV vaccine R&D, data 
were collected from government agencies, nonprofit research 
organizations, foundations and pharmaceutical/biotechnology 
companies on annual disbursements for product development, 
clinical trials and trial preparation, community education and 
policy advocacy efforts. 
Results: Preliminary estimates suggest that public and 
philanthropic funding for HIV vaccine research has been 
experiencing increased stress. As funding priorities shifted 
within governments and major donors revised their R&D grant 
strategies, disbursements for research in 2011 were often flat-
lined or decreased. While the biotechnology industry continued 
their R&D efforts, companies increasingly focused on forming 
product development partnerships to ensure future funding 
and relied on grants from public sector sources to continue their 
clinical trials. 
Conclusion: 2011 saw continued progress toward the 
development of a safe and effective HIV vaccine. With the 
discovery of antibodies predicting the risk of HIV infection, the 
start of large-scale follow-on trials and the initiation of HIV 
vaccine R&D programs in more countries around the world, 
there has been real progress on the path from research to reality. 
However, funding to pursue all this promise is highly uncertain. 
Sustained resources will be essential to assure that trials now 
underway can proceed, and increased expenditures will be 
similarly essential for the successive clinical phases of the most 
promising vaccine candidates.
P10.09
Willingness to Participate in HIV Vaccine Efficacy 
Trials in a Population of Fishing Communities, 
Uganda
A. Nanvubya1, J. Mpendo1, A. Ssetaala1, W. Kidega2,  
S. Sigirenda1, L. Nielsen1, N. Kiwanuka1
1UVRI-IAVI HIV Vaccine Program, Kampala, Uganda; 
2International HIV/AIDS Alliance in Uganda, Kampala, Uganda
Background: With a number of preventive HIV vaccine 
candidates under pre-clinical and early-phase human studies, it 
is critical to intensify efforts to identify and prepare populations 
for potential efficacy trials. Willingness to participate (WTP) in 
HIV vaccine trials in most at risk populations for HIV infection 
is unknown especially in Sub-Saharan Africa. We assessed WTP 
in a potential HIV-1 vaccine efficacy trial population of fishing 
communities in Uganda. 
Methods: A community-representative random sample of 
2,200 individuals, 18-49 years was selected at baseline from 8 
fishing communities around Lake Victoria. After consent, data 
on HIV risk behaviors and WTP in future HIV vaccine trials were 
collected using a semi-structured questionnaire; venous blood 
was collected for HIV serology using rapid HIV tests as per the 
Uganda National algorithm. 
Results: Fifty percent of respondents were females and a 
majority (91%) had attained some level of education. Almost 
all respondents, 89% (1,953/2,192) expressed WTP in future 
HIV vaccine trials. Males were more willing to participate than 
females (p<0.01). WTP was associated with awareness of ongoing 
HIV vaccine research (p<0.01). Unwillingness to participate was 
attributed mainly to perceived fear of side effects (42%) and fear 
that the study vaccine may cause HIV/AIDS (26.3%). The overall 
HIV prevalence was 26.7%, lower among those who responded 
positively to WTP (26.8%) than those who did not (27.7%). 
Conclusion: WTP in HIV vaccine trials in this population is high 
but extensive education on HIV vaccine safety particularly on 
vaccine induced side effects and false positivity will be required in 
preparation for these trials. Because of the high HIV prevalence, 
this population should be targeted for future HIV vaccine trials. 
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Exploring Research Participants’ Perceptions and 
Comprehension of the Informed Consent Process in a 
Pre-exposure HIV Prevention Study: A Case Study
S. Ruzario1, W. Mavhu2, R. Musesenngwa1, R. Zinyama-
Gutsire1, R. Gunda1, M. Phiri1, T. Rossouw3
1Medical Research Council of Zimbabwe, Harare, Zimbabwe; 
2ZAPP University of Zimbabwe, Harare, Zimbabwe; 3University 
of Pretoria, Pretoria, South Africa
Background: Ensuring informed consent is a complicated 
component of clinical trials particularly with HIV prevention trials 
conducted in resource-limited settings. An inherent challenge of 
the informed consent process for HIV prevention studies is making 
sure trial participants understand that their participation does not 
increase exposure to HIV. Participants need to comprehend that 
partaking in such trials does not necessarily protect them from 
HIV. It is important to continuously monitor the informed consent 
process for clinical trials with view to improving the procedure.
Methods: Between June and September 2011, gender-specific 
in-depth interviews were held with interviewees who had been 
purposively selected from female participants who had exited 
a vaginal HIV prevention study. An interview guide was used to 
elicit views around the informed consent process. Discussions 
were conducted and audio-recorded. Audio-recorded data were 
transcribed, translated verbatim into English, coded using NVivo 
8 and analysed using grounded theory principles. 
Results: Twenty interviewees were held. Key information about 
the study was given as participants articulated study aims well. 
The informed consent process had been rushed and participants 
had not had enough time to decide and consult. Due to both 
excitement and anxiety, participants felt pressured to sign 
consent forms before comprehending some aspects of the study. 
Some found it difficult to ask questions. Data suggested that both 
the study procedure and duration had not been fully explained. 
Mixed feelings on male partner involvement in decision-making 
around study participation existed, with some feeling that 
spouses should have been involved and others stating that 
partner consultation did not matter.
Conclusion: This study elicited some of the issues that 
characterise the informed consent process for clinical trials 
conducted in resource-limited settings. It highlighted the need 
for researchers’ ingenuity in order to come up with strategies 
that tailor the informed process to suit specific needs and 
circumstances of individual participants.
P10.11
Training Trial Staff in the Use of a Mixed Method 
Assessment of Understanding Tool in HIV Vaccine 
Trials
J. Mbogua1, T. Mebrahtu1, G. Lindegger2, W. Sabrina1,  
O. Anzala3, G. Mutua3, J. Mpendo4, E. Karita5, S. Singh1
1International AIDS Vaccine Initiative, Nairobi, Kenya; 2HIV 
AIDS Vaccine Ethics Group (HAVEG), KwaZulu Natal, South 
Africa; 3Kenya AIDS Vaccine Initiative (KAVI), Nairobi, Kenya; 
4Uganda Virus Research Institute (UVRI), Entebbe, Uganda; 
5Projet San Francisco, Kigali, Rwanda
Background: Volunteer understanding of trial concepts is a critical 
part of informed consent in clinical trials. Standard practice is 
to use closed-ended true/false forms to assess understanding; 
however such tools may overestimate understanding and 
most likely measure memory only. Open ended tools, such 
as scenarios, may be preferable. Following pilot studies that 
compared various methods of assessing understanding, a mixed 
method tool was developed by HAVEG, IAVI and partners. The 
tool employs both True/False questions for simpler concepts and 
open-ended scenarios for complex concepts. 
Methods: Trainings on use and implementation of the mixed 
method tool were conducted with doctors and counselors from 
IAVI partner research centers in Kenya, Uganda and Rwanda. 
Their understanding of all informed consent concepts was 
assessed, and practice sessions with past volunteers and other 
community staff with similar profiles to actual trial volunteers 
were conducted. 
Results: Initially the training participants did not see the benefit 
of the new tool, and expressed reservations about cost, skill, 
screen outs and time required to implement it.
However, following exposure to the tool, the participants felt 
the tool improves interaction between staff and volunteers, 
better evaluates understanding and identifies challenging 
concepts. They reported that scenarios bring to light unfounded 
assumptions about volunteer understanding or lack thereof. 
It also became apparent that the mixed methods tool requires staff 
to have much better understanding of trial concepts themselves. 
“Volunteers” also seemed to prefer the tool as it offered them an 
opportunity to demonstrate their understanding.
Conclusion: Training significantly increases support for the 
mixed method tool reflecting the importance capacity building. 
Further, staff responses suggest mixed method tools of assessing 
understanding, not only provide better assessment of concepts, 
but may be preferred by trial staff and volunteers. 
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Does AID Vaccine Research Offer Fresh Messages for 
Public Health Campaigns? A Review of Public Health 
Communication Related to HIV AIDS In Uganda 
J. Nam1
1Olive Branch Media, Kampala, Uganda
Background: HIV AIDS is a complex scientific phenomenon 
of our time. Ultimately however, HIV AIDS is a public health 
matter of unparalleled concern . This is due to the social and 
economic dimension of the HIV AIDS epidemic in the public 
domain. Public health communication is an integral part and key 
instrument employed by national health systems worldwide, in 
the management of public health. 
Methods: By quantitative and qualitative method of data 
analysis. This paper investigates t he evolution of public health 
communication in Uganda related to HIV AIDS in a period 
covering over two decades. A period that initially placed Uganda 
as model country in the fight against HIV AIDS globally, as result 
of the country’s success in decreasing HIV AIDS prevalence rates 
at national level. It also examines the likely factors behind the 
recent resurgence in new infections and prevalence rates. 
Results: This paper postulate, giving empirical evidence, that 
key to the initial success of the fight against HIV AIDS in Uganda 
were the novelty of public health messages in the face of a fatal 
disease hitherto unknown by the public, and the means of their 
delivery. It argues that with the passage of time and reduction in 
stigma associated with being an HIV AIDS patient, public health 
messages became over used and ineffective. 
Conclusion: The paper explores possible sources of new 
public health messages and techniques of dissemination using 
traditional and new media. It probes whether the on-going 
research on AIDS Vaccine could generate new messages vital 
for public health campaigns, without giving a false impression 
of cure, a tendency that experts concur could lead to the rise in 
risky behavior in the public in some countries, as has been the 
case with the introduction of antiretroviral drugs and medical 
male circumcision. 
P10.13 LB 
Update on Policy Change Proposal to End 
Institutional Biosafety Committee (IBC) Review of 
rDNA Vaccine Clinical Trials
M.E. Enama1, N. Jones2, B.S. Graham1, H.C. Lane3
1VRC/NIAID/NIH, Bethesda, MD, USA; 2OSPFM/NIAID/NIH, 
Bethesda, MD, USA; 3DCR/NIAID/NIH, Bethesda, MD, USA
Background: The HIV vaccine regimen showing partial efficacy 
in the RV 144 study included a canarypox-vectored vaccine 
(ALVAC). The ongoing HIV vaccine efficacy trial, HVTN 505, 
involves two gene-based vaccines developed by VRC/NIAID/
NIH: plasmid DNA and adenoviral-vectored vaccines. The “NIH 
Guidelines for Research Involving Recombinant DNA Molecules,” 
established in 1976, have evolved over time. Current NIH policy 
is that every clinical trial of rDNA vaccines must have IBC reviews. 
The primary role of the IBC is to assess risk to public health and 
the environment. 
Methods: The NIAID Barriers to Clinical Research project identified 
repetitive IBC review of gene-based vaccines as a barrier. For 
example, in the last 10 years >100 local IBC reviews have been 
conducted for the VRC HIV vaccines. IBC reviews for ALVAC 
vaccines remain a requirement for NIH funding despite completion 
of a Phase III clinical trial, >20 years of human experience with 
ALVAC vaccines and widespread community-based use of USDA-
approved canarypox-vectored veterinary vaccines, which have not 
indicated a risk to public health or the environment.
Results: The NIAID policy change proposal has been considered 
by a Recombinant DNA Advisory Committee (RAC) working group. 
Policy change options were discussed at the September 2011, 
December 2011 and March 2012 RAC meetings. The RAC proposal 
will be published in the Federal Register for public comments.
Conclusion: Repetitive IBC reviews of rDNA vaccine clinical 
trials divert time and attention of IBC expertise from truly novel 
agents and incur a cost to NIH with no added safety benefit. 
NIAID proposes that IBC review is no longer needed for clinical 
trials of non-transmissible rDNA vaccines because there are no 
unique biosafety concerns for this class of vaccines based on 
their recombinant DNA nature. The IBC specific roles are not 
applicable for rDNA vaccine protocols and are fulfilled through 
other regulatory oversight including the FDA.
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P11.02
Early Changes in the CD8 T Cell Immunodominance 
Hierarchy in Primary HIV Infection Prior to 
Seroconversion 
N. Keane1, C. Almeida1, A. Chopra1, D. Cooper1, E. Demaine1,  
S. Mallal1, M. John1
1Murdoch University, Perth, Australia
Background: Identification of the earliest CD8 T-cell responses 
against HIV may help select critical viral targets for inclusion in 
an HIV vaccine. We describe changes to the earliest detected 
CD8 T-cell responses and changes in genetic sequence encoding 
targeted epitopes in an individual who presented with Fiebig stage 
II, clade C acute HIV-infection, 27 days after sexual transmission.
Methods: We examined HLA-restricted CD8 T-cell responses by 
IFNγ ELISpot and HIV Gag, Pol, Nef and Env sequence by 454 
deep sequencing over 6 timepoints, from days 27-118 after 
HIV-transmission. HIV-specific IFNγ responses were detected 
against ten HIV epitopes in Gag, Nef and Env at day 27 post HIV-
transmission when the patient’s CD4 T-cell count was at a nadir 
of 224 cells/_l, the plasma HIV RNA >106 copies/ml and prior to 
any detectable p24 antibody. 
Results: Immunodominant responses were detected to the 
HLA-B*07:02 restricted Env IIRRIRQGL (IL9) epitope and 
the B*07:02 Gag GPGHKARVL (GL9) epitope (>4000SFU). A 
detectable but weaker response was observed to HLA-B*08 Nef 
FLKEKGGL (FL8) epitope (1010SFU). These responses declined 
over subsequent timepoints to 470 and 1630SFU on day 118 
coincident with a 2 log fall in the plasma viral load, a rise in the 
CD4 T cell count to 533 cells/µL and antibody seroconversion. 
The Nef FL8 became the immunodominant response after day 
34. IFN_ responses broadened from 10 responses at day 27 to 
23 responses by day 118. Analysis of Gag, Nef and Pol genes by 
454 deep sequencing showed no evidence of escape within the 
targeted epitopes as a cause of their decline over time. 
Conclusion: Early changes in the CD8 T-cell immunodominance 
hierarchy are apparent in acute HIV-infection prior to 
seroconversion, including early immunodominant targeting of 
Env epitopes. Subsequent broadening of the CD8 T-cell response 
was not associated with CD8 T-cell escape in this case. 
P11.01
Evaluation of the Dual IFNγ/IL-2 Fluorospot-Assay 
with Flow Cytometry For Detection of HLA-Restricted 
HIV-Specific T-Cell Responses in HIV Controllers
N. Keane1, C. Almeida1, S. Roberts1, I. Ahmad1, S. Mallal1,  
M. John1
1Murdoch University, Perth, Australia
Background: The IFNγ ELISpot assay is used widely for high 
through-put screening of HIV-specific responses in studies of 
HIV infection and vaccine studies. However, dual production of 
IFN/IL-2 and increased proliferative capacity may be associated 
with better natural control of HIV infection. We evaluated a 
novel fluorospot assay enabling the identification of dual IFNγ/
IL-2 producing antigen-specific cells and compared it with 
intracellular cytokine staining by standard flow cytometry in 
individuals with natural control of HIV-infection.
Methods: PBMC from five untreated HIV-infected individuals 
were stimulated overnight with HIV peptides or controls in 
dual IFN/IL-2 pre-coated plates. Peptide arrays were specifically 
selected based on the individual HLA type. Secreted IFNγ and 
IL-2 were detected using fluorescent-conjugated antibodies. 
Fluorescent spots were enumerated on the iSpot AID reader. 
Responses were considered positive if >50 spots/million cells 
SFU after background subtraction.Positive responses were then 
evaluated by flow cytometry using the Gallios flow cytometer. 
Results: Dual IL-2/IFNγ producing cells were detected to anti-CD3-
stimulated PBMC from all patients. IFNγ responses alone were 
detected to 35 of 136 HLA-restricted peptides tested (median 
=73, 52-4190 SFU) across the 5 patients (1/19, 5/19, 7/28, 9/15 
and 13/55 for each patient), while IL-2 responses were either low 
grade or undetectable for the majority of HIV peptides tested. 
Dual IFNγ/IL-2 producing HIV-specific T cells were not detected 
using the fluorospot assay. 24/35 peptides induced CD8 T cell-
IFNγ production by flow cytometry. 
Conclusion: HIV-specific mono-IFNγ responses were detected 
using the novel fluorospot assay. However limited HIV-specific dual 
IFNγ/IL-2 responses were detected in this patient group. A greater 
number of epitope-specific positive responses were detected 
in the fluorospot compared with flow cytometry suggesting the 
fluorospot may be more sensitive in detecting a greater breadth 
of epitope-specific T cell responses, and therefore better for 
screening purposes than flow cytometric methods. 
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Different Memory T Cell Phenotypes Are Elicited by 
Ad5 and Rare Adenoviruses
P. Penaloza1, E. Borducchi1, A. McNally1, N. Simmons1,  
J. Teigler1, N. Provine1, W. Tan2, R. Ahmed2, D.H. Barouch1
1Beth Israel Deaconess Medical Center, Boston, MA, USA; 
2Emory University, Atlanta, GA, USA
Background: The anamnestic potential of memory T cells are 
pivotal components of the adaptive immune response. Analyzing 
memory T cells elicited by different vaccine vectors is crucial for 
the identification of novel vaccine modalities against HIV.
Methods: 6-8 week old C57BL6 mice were used for these 
experiments. Mice were immunized intramuscularly with 10^10 
VP in PBS. The different adenoviral vaccines (Ad5, Ad26, Ad35, 
Ad48) expressed the glycoprotein (GP) derived from lymphocytic 
choriomeningitis virus (LCMV). For challenge studies, the mice 
were infected with 2x10^6 PFU of LCMV Cl-13 intravenously. 
Early and late CD4 and CD8 T cell recall was measured by flow 
cytometry. Viral control was assessed by standard plaque assay 
on VERO cells. 
Results: We have compared T cell memory phenotypes and 
immune protection elicited by common adenoviruses serotype 
5 (Ad5) versus rare adenoviruses serotypes (Ad26, Ad35, and 
Ad48). For these comparative studies, we immunized mice with 
non-replicating adenovirus vectors expressing the lymphocytic 
choriomeningitis virus (LCMV) GP, and challenged with chronic 
LCMV Cl-13. Our comparative data show that Ad5-GP generates 
an increased magnitude of LCMV GP-specific CD8 T cell responses 
(compared to that generated by rare adenoviruses). However, 
GP-specific CD8 T cells elicited by Ad5-GP immunization express 
inhibitory PD-1, and produce reduced amounts of cytokines, 
suggesting qualitative defects in memory CD8 T cells. This 
unexpected expression of PD-1 may also reflect antigen-
persistence of Ad5.
Conclusion: Memory T cells elicited by rare adenovirus-based 
vaccines results in greater T cell recall potential after viral 
challenge, and higher functionality compared to vaccination with 
Ad5. These data suggest that alternative serotype Ad vectors 
may offer substantial benefits over Ad5 as vaccine vectors in 
eliciting optimal T cell memory to chronic viruses such as HIV, 
HBV or HCV.
P11.03
Gag-Specific Cellular Immunity Determines In 
Vitro Viral Inhibition and In Vivo Virologic Control 
Following SIV Challenges of Vaccinated Monkeys
K.E. Stephenson1, H. Li1, B.D. Walker2, N.L. Michael3,  
D.H. Barouch1
1Beth Israel Deaconess Medical Center and Harvard University, 
Boston, MA, USA; 2Ragon Institute of MGH, MIT, and Harvard, 
Charlestown, MA, USA; 3US Military HIV Research Program, 
Walter Reed Army Inst. of Research, Silver Spring, MD, USA
Background: A vaccine for HIV-1 would ideally block HIV-
1 acquisition as well as durably control viral replication in 
breakthrough infections. A recently published study showed that 
optimal SIV vaccines can reduce SIV infection risk and setpoint 
viral loads following SIV challenges in rhesus monkeys, and that 
immunization with SIV Env was required for blocking acquisition 
of infection (Nature 2012 482:89-93). Here we investigate 
whether CD8+ T lymphocytes from these vaccinated rhesus 
monkeys mediate viral inhibition in vitro and whether these 
responses predict virologic control following SIV challenge.
Methods: PBMC from 23 monkeys that received DNA/MVA, 
MVA/MVA, Ad26/MVA, or MVA/Ad26 vaccines expressing 
SIVsmE543 Gag/Pol/Env were used in CD8+ T-cell-mediated in 
vitro viral inhibition assays. CD8-depleted PBMC were infected 
with SIVmac251, and viral inhibition was defined as the log 
reduction in p27 of cultures of CD8-depleted PBMC with and 
without CD8+ T lymphocytes. Viral inhibition was correlated 
with cellular immune responses and setpoint viral loads using 
Spearman rank-correlation tests.
Results: In vitro CD8+ T-cell-mediated viral inhibition prior to 
challenge correlated with Gag-specific ELISPOT (P=.002), total 
and central memory CD8+ (P<.001 for both), and total and central 
memory CD4+ responses (P=.002 and P=.001, respectively). A 
trend was observed with Gag-specific effector memory CD8+ T-cell 
responses (P=.014; P<.006 required for significance after multiple 
comparison adjustments). Viral inhibition did not correlate with 
Pol- or Env-specific cellular immune responses. Moreover, in vitro 
viral inhibition prior to challenge inversely correlated with in vivo 
setpoint viral loads following challenge (P=.014).
Conclusion: These data demonstrate for the first time that the 
in vitro viral inhibition assay following vaccination is a predictor 
of in vivo virologic control following infection. Furthermore, in 
vitro viral inhibition correlated with Gag-specific, but not Pol- 
or Env-specific, cellular immune responses. These data suggest 
the importance of including Gag in an HIV-1 vaccine in which 
virologic control is desired.
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The Roles of HIV-1 Specific CD8+ T Cell Responses 
and HLA Class I Alleles on Viral Control and Viral 
Escape in HIV-1 Infected Thai Individuals
S. Buranapraditkun1, U. Hempel2, W.H. Hildebrand3,  
T.M. Allen2, K. Ruxrungtham1
1Chulalongkorn University, Bangkok, Thailand; 2Ragon Institute 
of MGH, MIT and Harvard, Boston, MA, USA; 3Department of 
Microbiology and Immunology, Univ. of Oklahoma, Oklahoma 
City, OK, USA
Background: Knowledge about the role of specific HLA class I 
alleles, CD8+ T cell responses, and viral escape on viral control have 
not been well characterized in clade CRF01_AE and Asian ethnics. 
Methods: 195 naïve HIV-1 CRF01_AE infected Thai individuals 
were screened for HIV-1 specific CD8+ T cell responses with a set 
of 413 OLPs of the HIV-1 proteome by IFN-gamma ELISpot assay. 
Novel epitopes were characterized by HLA restriction and fine 
epitope mapping. The association of epitopes and/or HLA alleles 
with low VL level and/or viral escape was analyzed. 
Results: Thirty-three OLPs were identified as potential novel 
epitopes. A viral control epitope, RI10 (HIV-protease, previously 
described in HIV-1 B clade as -B*13 restricted) was found 
restricted by HLA-A*0203 in Thais. Interestingly, HLA-A*0203+ve 
patients with RI10 responders had a significantly lower VL than 
non-responders (p = 0.0167). This data may support the low VL 
from loss of viral fitness of RI10. Moreover, the patients exhibiting 
mutations in RI10 showed no ELISpot responses. Another known 
HLA-A*1101 epitope, AK11 (in Gag-p24) was also identified as a 
viral control epitope in this study. Of note, there was no significant 
mutation found in patients expressing A*1101. We also found a 
novel immunodominant epitope (29% response rate) restricted 
by HLA-Cw*0102: YI9 (in Gag-p24) which was associated with 
viral escape. Mutations at P2 (S278X), P4 (V280X) and P5 (S281G) 
impaired the Elispot responses, however the P2 anchor S278K 
mutation had the highest negative impact (p = 0.0002). 
Conclusion: In HIV-1 CRF01_AE infected Thais we characterized 
three CD8 epitopes (RI10, AK11 and YI9) restricted by 
HLA-A*0203, -A*1101 and -Cw*0102, respectively. RI10 and 
AK11, but not YI9, were associated with lower VL and possible 
control of HIV. Further characterization of those possible novel 
epitopes is warranted.
P11.05
Loading Dendritic Cells from HIV-1 Infected Patients 
with PLA-p24 Nanoparticles or MVA Expressing HIV 
Genes Induces HIV-1-Specific T Cell Responses 
N. Climent1, S. Munier2, N. Piqué3, F. García1, V. Pavot2,  
A. León1, C. Primard2, L. Miralles1, C. Rovira1, V. Casanova4,  
P. McCormick5, J.M. Gatell1, B. Verrier2, T. Gallart1
1Hospital Clinic, Barcelona, Spain; 2Institut de Biology et 
Chimie des Protéines, FRE3310 CNRS/UCBL, Lyon, France; 
3Dept. Microbiology and Parasitology, Pharmacy Faculty, U 
of Barcelona, Barcelona, Spain; 4Department of Biochemistry 
and Molecular Biology, Faculty of Biology, Barcelona, Spain; 
5Dept. Biochemistry and Molecular Biology, Faculty of Biology, 
Barcelona, Spain
Background: The evaluation of the interaction of new 
immunogens with dendritic cells is important for new vaccine 
strategies. We used polylactic acid (PLA) colloidal biodegradable 
particles, coated with HIV Gag antigens (p24), and Modified 
Vaccinia Ankara (MVA) expressing Gag or Tat, Nef and Rev in 
an ex vivo model of human monocyte-derived dendritic cells 
(MDDC) to compare two different loading strategies,either viral 
or synthetic derived.
Methods: We have assessed the interaction of PLA nanoparticles 
bearing p24 (PLA-p24) or MVA expressing Gag or Tat, Nef and Rev 
with MDDC of HIV-1 infected patients and the capacity of these 
cells to process and present the HIV-1 antigens to autologous 
human T cells from HIV-1-infected patients. 
Results: PLA-nanoparticles were captured by 98% of MDDC from 
HIV-1 infected patients, without deleterious effects for the cells. 
Capture of PLA-p24 induced a slight degree of MDDC maturation, 
cytokine and chemokine secretion and migration towards 
a gradient of CCL19 chemokine. After complete maturation 
induction of PLA-p24-pulsed MDDC, maximal expression of 
maturation markers was observed, together with a strong 
migration towards a gradient of CCL19 chemokine. PLA-p24-
loaded MDDC were able to induce HIV-specific T cell proliferation 
(two-fold higher for CD4+ than CD8+) and cytokine secretion 
(IFN-γ and IL-2). Upon exposure to MVA-gag, MDDC produced 
cytokines and chemokines and maintained their capacity to 
migrate to a gradient of CCL19. MDDC infected with MVA-gag, 
MVA-gag trans-membrane and MVA-nef were able to induce 
HIV-specific CD8+ proliferation and secretion of IFN-γ, IL-2, IL-6 
and TNF-α. 
Conclusion: These findings support the use of both HIV antigens 
(PLA particles carrying HIV antigens or MVA expressing HIV 
genes) as anti-HIV vaccines. 
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Increased Differentiation Associates with Decreased 
Polyfunctionality for HIV but Not CMV-Specific CD8+ 
T Cell Responses
C. Riou1, M. Abrahams2, K. Mlisana3, R. Koup4, M. Roederer4,  
S. Abdool Karim5, G. de Bruyn6, C. Williamson2, C.M. Gray1, 
W.A. Burgers2
1University of Cape town, Cape Town, South Africa; 2Division 
of Virology, University of Cape Town, Cape Town, South 
Africa; 3CAPRISA and Medical Microbiology Dept, University 
of KwaZulu Natal, Durban, South Africa; 4Vaccine Research 
Center, NIH, Bethesda, MD, USA; 5CAPRISA, University of 
KwaZulu Natal, Durban, South Africa; 6Perinatal HIV Research 
Unit, Chris Hani Baragwanath Hospital, Johannesburg, South 
Africa
Background: The generation of polyfunctional CD8+ T cells, in 
response to vaccination or natural infection, has been associated 
with improved protective immunity. However, it remains 
unclear whether the maintenance of polyfunctionality is linked 
to particular phenotypic characteristics of the cell, such as the 
differentiation stage of memory T cells. The goal of this study was 
to investigate the relationship between the memory maturation 
stage and polyfunctional profiles of antigen-specific CD8+ T cells.
Methods: We analyzed the polyfunctionality of HIV-specific 
CD8+ T cells within different memory subpopulations in 20 
ART-naïve HIV-1 infected individuals at approximately 34 weeks 
post-infection and compared them to CMV-specific CD8+ T 
cell responses. Memory subsets were distinguished based on 
CD45RO and CD27 expression levels, and four functions were 
assessed (CD107a, MIP-1β, TNFα and IFNγ).
Results: Our results show that polyfunctional abilities of 
HIV-specific CD8+ T cells differ according to their memory 
phenotype, where terminally-differentiated HIV-specific CD8+ 
T cells (CD45RO-CD27-) were mostly mono-functional (median 
69% [IQR: 57-83]), producing predominantly CD107a or MIP-1β. 
Moreover, the proportion of HIV-specific mono-functional CD8+ 
T cells associated positively with the proportion of terminally-
differentiated HIV-specific CD8+ T cells (p=0.019, r=0.54). On the 
other hand, HIV-specific early-differentiated cells of a central 
memory-like phenotype (CD45RO+CD27+) exhibited a higher 
proportion of cells positive for three or four functions (p<0.001) 
and a lower proportion of mono-functional cells (median 27% 
[IQR: 16-38], p<0.001) compared to terminally-differentiated 
cells. In contrast, CMV-specific CD8+ T cell polyfunctional 
capacities were similar across all memory subpopulations, 
with terminally and early-differentiated cells endowed with 
comparable polyfunctionality.
Conclusion: Overall, these data show that for HIV-specific 
responses, the memory differentiation stage can influence 
the polyfunctional properties of CD8+ T cells, suggesting that 
terminal differentiation of HIV-specific CD8+ T cells might 
be detrimental for viral control. These results may help in 
understanding phenotypic attributes related to effective T cell 
responses against HIV-1.
P11.07
Rapid Evolution of HIV-1 to Functional CD8+ T-Cell 
Responses in Humanized BLT Mice
T.E. Dudek1, D.C. No1, E. Seung2, V. Vrbanac2, L. Fadda1,  
K.F. Bryant3, M. Altfeld1, A.D. Luster2, D.M. Knipe3, A.M. Tager2, 
T.M. Allen1
1Ragon Institute of MGH, MIT and Harvard, Charlestown, MA, 
USA; 2Center for Immunology and Inflammatory Diseases, 
MGH, Boston, MA, USA; 3Harvard Medical School, Boston, MA, 
USA
Background: The newly developed humanized BLT (bone marrow, 
liver, thymus) mouse model holds great promise to facilitate the 
in vivo study of human immune responses. However, little data 
exists regarding the extent to which cellular immune responses 
in humanized BLT mice accurately reflect those seen in humans.
Methods: Multiple sets of humanized BLT mice reconstituted 
with distinct human tissues were infected with the HIV-1 
molecular clone JR-CSF. Mice were then bled every two weeks 
to measure plasma viral loads, sequence evolution and cellular 
immune responses.
Results: During the acute phase of infection BLT mice rapidly 
mounted multiple HIV-1-specific CD8+ cellular immune responses 
against normally immunodominant human CD8 epitopes, 
with rapid and reproducible viral escape observed within 
epitopes that similarly tend to escape early in humans. CD8+ 
T cell responses and viral escape to these same epitopes was 
confirmed in mice reconstituted with distinct human tissue but 
expressing the same restricting HLA alleles. Importantly, in two 
independent groups of mice expressing HLA-B*57 we observed 
the rapid induction of CD8+ T-cell responses against a number of 
B*57-restricted responses at frequencies similar to those seen 
in humans, including the normally immunodominant B*57-IW9, 
-KF11 and -TW10 epitopes in Gag from which the virus failed to 
rapidly escape. As in humans, the presence of these conserved 
responses correlated with significantly greater control over early 
viral replication. Preliminary vaccine studies in BLT mice support 
the ability of conventional approaches to induce CD8+ T cell 
responses and suppress viral loads. 
Conclusion: These studies indicate that the specificity, 
magnitude, and immunodominance patterns of human CD8+ 
T-cell responses in humanized BLT mice appear to closely reflect 
those of humans. These data support the potential of humanized 
BLT mice to significantly advance HIV-1 vaccine development, 
providing a critical new tool to complement the SIV infected 
macaque model.
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P11.10
The Increased Sensitivity of CTLs Induced by Vaccinia 
Vector Is Developed as Intrinsic Feature In Vivo and 
Independent of Microenvironment In Vitro
Z. Hu1, C. Qiu2, Y. Wan1, J. Xu1
1Shanghai Public Health Clinical Center, Fudan University, 
Shanghai, China; 2Institutes of Biomedical Sciences, Fudan 
University, Shanghai, China
Background: DNA prime-vaccinia viral vector (rVV) boost has 
been widely used as an effective regimen for T cell vaccine. This 
regimen could efficiently enhance the potency of immunogen-
specific T cell responses with minimizing responses to vectors. 
In addition, we and others found that the sensitivity for T 
cells responding to antigenic stimulation is elevated by this 
vaccination regimen. However, it remains unknown whether 
the increased sensitivity of CD8+ T cells is gained during the 
activation and differentiation as intrinsic property or is resulted 
from the influence of microenvironment
Methods: The magnitude, potency and sensitivity of T cell 
responses induced by different vaccine regimens were compared 
by using ELISpot and ICS. Purified CD8+ T cells from each 
vaccination regimen were mixed with splenocytes from naïve or 
mock rVV immunized mouse and determined for their sensitivities. 
Statistical analysis was performed by using Prism5.0 software
Results: As expected, the magnitude, potency and sensitivity of 
T cell responses induced by DNA prime-rVV boost is 20-, 15- and 
100- fold higher than that in group with repeated DNA boost, 
respectively. Interestingly, the sensitivity of CD8+ T cells purified 
from each vaccination regimen group is comparable before and 
after the mixture with splenocytes from either naïve or mock rVV 
immunized mouse, suggesting that the removal of inflammatory 
microenvironment did not decrease the sensitivity of CD8+ T 
cell responses. Accordingly, the addition of vaccinia induced 
microenvironment to CD8+ T cells purified from DNA group does 
not enhance their sensitivity
Conclusion: Our results demonstrated that the increased 
sensitivity of CD8+ T cells by DNA prime-rVV boost regimen is 
intrinsic property and likely to be developed and gained during 
the activation and differentiation in vivo by vaccine, this effect 
is independent with inflammatory microenvironment in memory 
status. These findings have important implications for the design 
of new vaccine and immunization strategies
P11.09
Cross-Clade CTL Recognitions for Clade B and A/E 
Viruses in A/E Virus-Infected Japanese Individuals
K. Watanabe1, H. Murakoshi1, M. Koyanagi1, Y. Tamura1,  
R. Maruyama1, T. Chikata1, H. Gatanaga2, S. Oka2, M. Takiguchi1
1Kumamoto University, Tokyo, Japan; 2AIDS Clinical Center, 
National Center for Global Health and Medicine, Tokyo, Japan
Background: Cytotoxic T lymphocytes (CTLs) play an important 
role in the control of HIV-1. CTL responses to HIV-1 have been 
well studied in HIV-1 clade B-infected and clade C-infected 
individuals. However cross-clade CTL recognitions have not 
been well analyzed. In this study, we analyzed cross-clade CTL 
recognition for clade B and A/E viruses in A/E virus-infected 
Japanese individuals
Methods: PBMC samples were collected from chronically HIV-
1 infected Japanese cohort in NCGM. Twenty-six clade A/E-
infected individuals were analyzed by ELISPOT assay using the 
11-mer overlapping peptides and then the responses of CTLs to 
these peptides was compared to those from 402 clade B-infected 
Japanese individuals. Thereafter CTL responses to each single 
peptide and to truncated peptides were evaluated by ELISPOT 
assay and intracellular cytokine staining (ICC) assay, respectively.
Results: Similar level of CTL responses to Gag, Pol and Nef 
were found in clade A/E-infected individuals as compared to 
that in clade B-infected ones. We identified 15 cross-clade CTL 
epitopes from 14 cocktails where the frequency of responders 
was high in clade A/E infected samples. The sequences of 
7 epitopes were conserved between clade B and clade A/E 
viruses, whereas 8 epitopes showed different amino acid 
sequences between two viruses. In these 8 epitope regions, we 
confirmed cross-clade CTL recognition by ICC assay using clade 
A/E consensus sequence peptide.
Conclusion: Cross-clade CTLs were predominantly induced in clade 
A/E-infected individuals by clade B consensus sequence peptides 
in this study. Moreover, CTL responses were induced not only in 
conserved region but also in different sequence region between 
the 2 viruses, indicating that polymorphic sequence epitopes 
among clades can be also candidate for the target of CTL-based 
vaccines. Further analysis of cross-clade CTL recognition is needed 
for the widely applicable vaccine development.
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Programmed Death-1(PD-1), a Correlate of 
Protection Against Disease Progression in HIV-1 
Infected Long-Term Non-Progressors 
J. Kyosiimire-Lugemwa1
1MRC/UVRI Uganda Research Unit on AIDS, Kampala, Uganda
Background: Long-Term Non-Progressors (LTNP) control HIV-
1 disease progression but correlates of control are not clear. 
T-cell activation and expression of Programmed Death-1 (PD-1), 
a marker of T-cell inhibition/exhaustion, have been suggested 
as markers of progression to AIDS. We assessed levels of T-cell 
activation and PD-1 in LTNP and Rapid progressors (RP).
Methods: We recruited 15 LTNP and 15 RP originally enrolled in 
the Entebbe Cohort in Uganda. All were ART naïve and 29 were 
women. HLADR, CD38 and PD-1 levels were assessed in CD4, CD8 
and CD45RA T-cells by flow cytometry. HIV-1 disease progression 
markers: plasma lipopolysaccharide (LPS) levels, HIV-1 RNA viral 
load (VL), HIV-1 pro-viral DNA load (PVL) and CD4 counts at 
enrollment were quantified. Comparisons between groups were 
performed using the Mann-Whitney U test and correlations by 
Spearman’s linear correlation coefficients.
Results: Activated (HLADR+CD38+) CD4+CD45RA+ were higher 
in the LTNP (median 0.64% for LTNP and 0.18% for RP, p=0.03). 
PD-1 expression in the CD4 and CD8 T-cell subsets was higher in 
the LTNP (CD4+PD-1+ median 39.6% for LTNP and 1.0% for RP, 
p=0.001; CD8+PD-1+ median 60.8% for LTNP and 13.5% for RP, 
p=0.003). VL (p=0.05), PVL (p=0.03), LPS (p=0.005) were higher 
in the RP and enrollment CD4 count (p=0.0002) was higher 
in the LTNP. VL, PVL and LPS positively associated with each 
other and all negatively associated with enrollment CD4 count. 
CD4+PD-1+ correlated negatively with VL (rs=-0.40, p=0.03), 
LPS (rs=-0.38, p=0.04) and positively with enrollment CD4 count 
(rs=0.36, p=0.05). CD4+CD45RA+HLADR+CD38+ correlated 
positively with enrollment CD4 counts (rs=0.38, p=0.04). 
Positive correlations were observed between CD4+CD45RA+/-
HLADR+CD38+, CD8+CD45RA+HLADR+CD38+ and CD4+PD-1+ 
and CD8+PD-1+ T-cells. 
Conclusion: Co-expression of PD-1 and activation markers was 
higher in the LTNP compared to the RP, contrary to other studies. 
PD-1 correlated with markers of protection against HIV-1 disease 
progression, suggesting a beneficial role for PD-1. 
P11.11
The Recognition of HIV-1 Consensus Group M Gag 
and Nef Peptide Reagents in Mono- and Multi-clade 
Epidemics: Implications for HIV Vaccine Design
L. Zembe1, M. Tongo2, E. Ebong3, E.M. Ngobe3, C. Williamson2, 
W. Burgers2
1University of Cape Town, Cape Town, South Africa; 2Division 
of Virology, University of Cape Town, Cape Town, South Africa; 
3Institute of Medical Research and Study of Medicinal Plants, 
Younde, Cameroon
Background: The high level of genetic diversity of HIV-1 poses a 
major challenge for global vaccine development. Vaccines based 
on centralized sequences would minimize genetic distances 
to multiple clades and potentially maximize cross-reactivity. 
Whether reactivity of these centralized peptide reagents differs 
in mono- and multi-clade epidemic is unknown.
Methods: In this study, full-length gag and nef gene sequences 
(from Cameroon, 50 and 54, respectively and South Africa, 23 and 
19, respectively) were characterized. HIV-specific T-cell responses 
to group M consensus Gag and Nef peptide reagents were 
characterized at the peptide level using the IFN-γ ELISpot assay.
Results: Viruses from Cameron exhibited a large degree of 
genetic diversity; all subtypes were present excluding subtype 
C, with CRF02_AG being dominating (49%). Contrary, sequenced 
viruses from South Africa were all pure subtype C viruses. 
Despite the greater diversity of viral clades in the Cameroonian 
cohort, the genetic distances to the consensus M reagents 
was similar for both cohorts (11% and 15% for Gag and Nef, 
respectively). Whilst the magnitude and breadth of responses 
to Con M Gag and Nef did not differ significantly between the 
two cohorts, there was a greater frequency of responders in the 
Cameroonian cohort compared to South Africans (95% versus 
82%, respectively). For the Cameroonian cohort, 75/182 (41%) 
of the consensus M peptides were targeted, while for the South 
African cohort 66/182 (36%) of the peptides were targeted, with 
the majority being recognized in only 1-2 participants (69% and 
76%, respectively). Patterns of immunodominance and targeting, 
however, differed dramatically between the two cohorts, with 
only 36% and 39% of Gag and Nef peptides commonly recognized 
between the two cohorts. 
Conclusion: Although similarities in total magnitude and breadth 
may be observed between different epidemics, patterns of 
immunodominance of centralized immunogens may be different 
which may have implications for vaccine development.
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Control of HIV-1 by Multiple Immunodominant HIV-
1-Specific CD8+ T Cells in HIV-1-Infected Japanese 
Individuals
H. Murakoshi1, M. Koyanagi1, H. Gatanaga2, T. Naruto1,  
S. Oka2, M. Takiguchi1
1Center for AIDS Research, Kumamoto University, Kumamoto, 
Japan; 2AIDS Clinical Center, National Center for Global Health 
and Medicine, Tokyo, Japan
Background: Previous studies of the comprehensive analysis of 
HIV-1-specific CTL responses in Caucasian and African cohorts 
demonstrated the association of the CTL responses to HIV-1 
Gag protein with the control of HIV-1 replication. However, such 
analysis in Asian cohorts has not been reported. In the present 
study, we performed the comprehensive analysis of CD8+ T cell 
responses against 11-mer overlapping HIV-1 Nef, Gag, and Pol 
peptides in 401 chronically HIV-1 clade B-infected treatment-
naive Japanese individuals.
Methods: The CD8+ T cell responses to cocktails of the peptides 
were evaluated by measuring IFN-g-producing CD8+T cells by 
using ELISPOT assay.
Results: To clarify CTLs which control HIV-1 infection in this 
cohort, we statistically analyzed differences of viral load and 
CD4 counts between responders to each peptide cocktail in 
each HLA+ individuals and non-responders using two-tailed 
Mann-Whitney’s test. We found that several HLA alleles were 
significantly correlated with low viral load and high CD4 counts 
in the responses to 5 Nef, 10 Gag, or 16 Pol cocktails. In these 
cocktails, we identified 2 Nef, 12 Gag and 7 Pol CTL epitopes 
restricted by 9 HLA alleles. The breadth of CTL responses to 
these epitopes was significantly associated with low viral load 
(p=1.7x10-10) and high CD4 counts (p=4.1x10-13). The total 
magnitude of responses to the epitopes was also significantly 
correlated with low viral load (r=-0.30, p=1.8x10-9) and high CD4 
counts (r=0.37, p=5.0x10-14).
Conclusion: These results suggest that the CTL responses to 
these epitopes play an important role in the control of HIV-1 
infection in chronically HIV-1-infected Japanese individuals.
P11.13
Early Presentation of HIV-1 KF11Gag and KK10Gag 
Protective Epitopes Facilitate Rapid CD8+ T Cell 
Activation and Killing of Virus Infected Cells
H. N. Kløverpris1, R. Payne1, J.B. Sacha2, F. Chen3, J. Rasaiyaah4, 
G. Towers4, P. Goulder1, J. G Prado5
1University of Oxford, Oxford, United Kingdom (Great Britain); 
2Oregon Health & Science University, Portland, OR, USA; 3Royal 
Berkshire Hospital, Reading, United Kingdom (Great Britain); 
4University College London, London, United Kingdom (Great 
Britain); 5AIDS Research Institute IrsiCaixa, Barcelona, Spain
Background: CD8+ T cells are major players for the antiviral 
immunity against HIV-1 through recognition of viral epitopes 
presented on the surface of infected cells. However, the kinetics 
and timing of HIV-1 epitope presentation remains poorly 
understood but nonetheless crucial for development of a 
successful CD8+ T cell based vaccine. 
Methods: Epitope presentation and killing of virus infected cells 
was assessed in HIV-1 susceptible T cell lines, H9, U937, primary 
CD4+, and B cell lines expressing HLA-B*5701 or B*2705 by 
synchronized infection with HIV-1 or VSV-HIV-1 to determined 
the contribution of incoming particles to epitope presentation. 
Infected cells were co-cultured with CD8+ T cell lines specific for 
the epitopes KF11Gag, KK10Gag, KY9Pol and VL9Vpr. Kinetics 
of epitope presentation were monitored by the production of 
CD107b and MiP1ß in the co-culture at 0, 3, 6, 18 and 24 hours 
post-infection. In addition, killing of infected cells was determined 
in paralleled by the decrease of CD4+/p24 Gag+ cells
Results: We comprehensively studied the kinetics of antigen 
presentation of the KF11Gag and KK10Gag epitopes, restricted 
by protective HLA alleles B*5701 and B*2705, and compared 
these to KY9Pol and VL9Vpr epitopes, in a single cycle of virus 
replication. We observed differences in epitope presentation 
kinetics with early presentation within 3 hours post-infection, 
for KF11Gag, KK10Gag and KY9Pol epitopes, but only late 
presentation for VL9Vpr. In addition, we illustrate how early 
presentation relies on antigen processing from incoming virus, 
which correlates with rapid CD8+ T cell activation and clearance 
of virus-infected cells. 
Conclusion: Our data strongly support the importance of 
identifying early-presented HIV-1 epitopes to eliminate infected 
cells before the release of new infectious viral particles.
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Detection of HIV T-Cell Responses with 
Polifunctionality and High Plasma Levels of the 
B-Chemokine MDC in Exposed HIV-Seronegative 
Individuals (ESN)
G. Turk3, L. Abusamra1, N. Laufer3, A.M. Rodríguez3,  
J. Falivene3, Y. Ghiglione3, A. Mangano1, L. Giavedoni2,  
M.M. Gherardi3
1Hospital de Pediatría Juan P Garrahan, Buenos Aires, 
Argentina; 2Southwest National Primate Research Center, San 
Antonio, TX, USA; 3Instituto de Investigaciones Biomédicas en 
Retrovirus y Sida, Universi, Buenos Aires, Argentina
Background: The mechanisms of protection from infection in 
ESN individuals are largely undefined and likely multifactorial. 
Our aim was to analyze HIV-specific T-cell responses and plasma 
cytokine levels in ESN and their respective HIV partners (HIV-P) 
in comparison with HIV chronically infected subjects (C) and 
healthy donors (HD). 
Methods: Plasma levels of 37 cytokines were measured by 
Luminex technology in: 10 HD, 9 ESN and their HIV-P, and 12 C. 
All HIV patients were off-HAART. Frozen PBMCs from the same 
individuals were used to determine HIV-specific T-cell responses 
by IFN-g ELISPOT. Also, production of different cytokines was 
evaluated in certain samples by intracellular staining (ICS). Data 
was compared inter- and intra-groups and correlated to viral 
load (VL) and CD4 T cell counts, using parametric and non-
parametric statistics.
Results: Elispot responses were evaluated in 6 of the 
serodiscordant couples. Two ESN showed T-cell responses 
against Env or Gag. ESN had a higher proportion of HIV-specific 
bifunctional and trifunctional cells in comparison with their HIV-P 
partners. HIV-P had Nef and Env T-cell responses of significant 
higher magnitudes compared to C. Macrophage-derived 
chemokine (MDC), characterized to have HIV-suppressive 
activities, was the only soluble marker significantly elevated 
in plasma of ESN in comparison with HD. Interestingly, MDC 
showed a positive correlation with CD4 T-cell count among HIV-P. 
HIV-P compared to C showed minor levels of the inflammation 
biomarker sCD40L associated with AIDS defining illness, and 
in this group VL was positively correlated with IP-10 and IL-10, 
whereas TNF-a correlated with VL in C. 
Conclusion: Both innate and specific immune components may 
be acting in the resistance to HIV infection in ESN. On the other 
hand, the characteristics of the immune response generated in 
their partners can also play a role in the viral pressure generated 
affecting the viral population to be transmitted. 
P11.15
The Impact of HLA-Cw*12:02 on Control of HIV-1 
Infection
M. Koyanagi1, K. Honda1, T. Chikata1, T. Akahoshi1,  
H. Murakoshi1, H. Gatanaga2, S. Oka2, M. Takiguchi1
1Center for AIDS Research, Kumamoto University, Kumamoto, 
Japan; 2AIDS Clinical Center, National Center for Global Health 
and Medicine, Tokyo, Japan
Background: Previous studies have demonstrated that higher 
HLA-C expression, which is determined through a single 
nucleotide polymorphism 35 kb upstream and the variation 
within the 3’ untranslated region of the HLA-C locus, associate 
with slow progression of HIV-1-infected disease. Although 
HLA-C plays important roles in presenting antigens to CTLs or a 
ligand for inhibitory killer cell Ig-like receptors (KIR), the role of 
HLA-C-restricted CTL and NK cells in the control of HIV-1 is still 
unclear. Our recent study of chronically HIV-1 infected Japanese 
cohort showed that the HLA-B*52:01-Cw*12:02 haplotype was 
significantly associated with lower viral load. In this study, we 
investigated whether HLA-Cw*12:02-restricted CTLs or NK cells 
via KIR have a significant impact on viraemic control. 
Methods: We sequenced Pol, Gag and Nef from 400 chronically HIV-
1 clade B-infected treatment-naïve Japanese individuals and then 
analyzed amino acid polymorphisms associated with HLA-B*52:01-
Cw*12:02 haplotype using Fisher’s exact test. Next we performed 
intracellular IFNg staining or IFNg ELISPOT assay to detect CTL 
responses to the peptides including those polymorphisms.
Results: We found 9 amino acid polymorphisms significantly 
associated with HLA-B*52:01-Cw*12:02 haplotype (p<0.002 
q<0.2). By using ICC assay, we identified 2 Cw*12:02-restricted 
CTL epitopes and 4 B*52:01-restricted ones. Four Cw*12:02-
restricted CTL epitopes including previously reported ones 
were analyzed to investigate the effect of Cw*12:02-restricted 
CTLs on control of HIV-1. No significant correlation between 
the responses to these Cw*12:02-restricted epitopes and viral 
load was found in chronically HIV-1 infected Cw*12:02 positive 
Japanese individuals.
Conclusion: Those results showed that HLA-Cw*12:02-restrected 
CTLs have no effect on control of HIV-1 and suggested that HLA-
B*52:01-restrected CTLs or Cw*12:02-resticted NK cells control 
HIV-1 viraemia in Japanese cohort.
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Breadth or Conservation Score (CS): Which Is More 
Important for HIV-1 T Cell Based Vaccine Immunogen 
Design?
P. Kunwar1, N.R. Hawkins2, X. Yu2, Y. Liu3, A. Collier4,  
E.E. Gabriel2, T. Hertz2, H. Horton5
1University of Washington / Seattle Biomedical Research 
Institute, Seattle, WA, USA; 2Statistical Center for HIV/
AIDS Research & Prevention (SCHARP), Seattle, WA, USA; 
3Department of Microbiology, University of Washington, 
Seattle, WA, USA; 4Department of Medicine, University of 
Washington, Seattle, WA, USA; 5Seattle Biomedical Research 
Institute, Seattle, WA, USA
Background: One of the greatest challenges to develop an 
efficacious HIV vaccine is the enormous diversity of HIV-1. To 
tackle this problem, T cells based vaccine approaches have 
come up with two main camps: the mosaic immunogen camp: 
increasing the breadth of vaccine-induced responses, and the 
conserved immunogen camp: targeting vaccine-induced T-cell 
responses only to highly conserved viral regions. While both 
approaches are theoretically sound, there is no current data 
suggesting that either approach will be successful in inducing 
T cells with superior antiviral efficacy. Here we analyzed T cell 
responses elicited during early HIV-1 infection, to address the 
question whether CS of targeted epitopes and breadth of T cell 
responses play an important role in viral control. 
Methods: Using IFN-γ ELISpot, we comprehensively mapped T 
cell epitope specificities recognized by 24 ART-naïve individuals 
during early infection. We identified CS of targeted epitopes, 
where the CS is defined as the proportion of random HIV-1 group 
M amino acid sequences in the LANL database that include the 
epitope. We used a prediction model to impute the viral load (VL) 
set-point using the first available VL as a predictor for subjects 
lacking VL set-point. We further evaluated the association 
between the CS of the targeted epitopes and breadth of T cell 
responses to the individuals’ VL set-point.
Results: The breadth of CD8+ T cell responses inversely correlated 
with VL set-point (r=-0.46, p=0.025). Subjects possessing CD8+ T 
cells recognizing at least one conserved epitope had a lower VL 
set-point compared to those recognizing only variable epitopes 
(p=0.093). 
Conclusion: Breadth and CS of HIV-specific CD8+ T cells elicited 
during early infection are both important for controlling viral 
replication in vivo. Rationale design of immunization approaches 
should aim at eliciting a greater breadth of CD8+ T cell to 
conserved epitopes. 
This project is funded by NIH grant#R01AI090783
P11.17
Recombinant DNA/MVA/ChAdV-63-Elicited T 
Cells Specific for Conserved Regions of the HIV-
1 Proteome Recognize HIV-1 Infected Cells and 
Suppress HIV-1
T. Ahmed1, N. Borthwick1, H. Yang1, G. Hancock1, L. Yorke1,  
U. Ebrahimsa1, A. Rose1, A. Black1, E. Hayton1, A. McMichael1, 
L. Dorrell1, T. Hanke1
1Oxford University, Oxford, United Kingdom (Great Britain)
Background: Currently, immunogenicity assessments of 
candidate HIV-1 vaccines in human clinical trials rely on the use of 
peptides for sensitization of target cells. However, employment 
of HIV-1-infected cells provides more informative and relevant in 
vitro readouts of HIV-1 recognition.
Methods: A viral suppression assay (VSA) was developed to 
assess CD8+ T cell responses to infected autologous CD4+ targets 
using HIV-1 p24 levels as measured by flow cytometry and ELISA. 
In parallel, we also investigated live virus infected cells for re-
stimulation of vaccine elicited T cells in an IFN-γ ELISpot assay.
Results: HIV-1 infection kinetics is influenced by the multiplicity 
of infection (MOI) used to infect autologous CD4+ cells, with 
rapid kinetics observed at higher MOIs. For HIV-1 BaL optimal 
infection of autologous CD4+ cells was achieved at MOI of 0.05. 
In the VSA, HIV-1 BaL virus replication was shown to be sensitive 
to the chemokines MIP-1α and RANTES added in the absence 
of effector cells. Pre-activated effector cells indicated increased 
non-specific background suppression in healthy controls, which 
was reduced following a prolonged rest before co-culture with 
autologous CD4+ targets, but led to marked proliferation of the 
CD8+ T cell effectors. Preliminary investigations in vaccinees 
show that HIV-1 suppression mediated by CD8+ T cells can be 
detected in vitro following vaccination and that P24 ELISA has 
higher sensitivity than flow cytometry. As an alternative to the 
VSA, an IFN-γ ELISpot assay has also been optimized for the use 
of autologous HIV-1-infected CD4+ cells. Using both of the above 
assays, preliminary characterization of T cell responses induced 
in volunteers receiving pSG2.HIVconsv DNA, MVA.HIVconsv and 
ChAdV63.HIVconsv vaccines will be shown.
Conclusion: Two assays employing HIV-1 infected target cells 
were standardised and employed to characterize responses 
elicited in participants of the HIV-1 vaccine trial HIVCORE002 in 
Oxford, UK.
Topic 11:  T Cell Immunity
226
Posters
PO
STERS
AIDS Vaccine 2012
P11.20
Effect of HIV Infection on the Expression and the 
Activity of the Proteasome in Primary CD4 T Cells 
J. Boucau1, C.S. Carlin1, J. Madouasse1, M. Shimada1, S. Le Gall1
1Ragon Institute of MGH, MIT and Harvard, Charlestown, MA, 
USA
Background: HIV-specific CD8 T cells responses rely on 
the recognition of peptide-MHC-I complexes by cognate T 
cell receptors. HIV-derived MHC-I epitopes result from the 
degradation of viral proteins by the cellular processing machinery 
including proteasomes and aminopeptidases. Interferon gamma 
changes proteasome composition and peptidase activities. We 
hypothesize that HIV infection might affect the expression or 
activities of the antigen processing machinery, either through a 
direct effect of the virus or indirectly through cellular activation 
or from the release of cytokines by surrounding infected cells.
Methods: Primary CD4 T cells were selected from peripheral 
blood mononuclear cells of HIV seronegative individuals, and 
then activated with phytohemagglutinin or anti-CD3/CD28 beads 
prior to infection with HIV NL4-3. Cell activation was assessed 
by flow cytometry. The expression of proteasomal subunits was 
quantified by western blot at 4 days post activation or at 12 to 
18 days post infection. Peptidase activities of CD4 T cells were 
characterized using a fluorescence-based assay.
Results: In CD4 T cells isolated from 15 donors, the expression 
of 2 proteasome catalytic, 2 non-catalytic and 2 19S lid subunits 
significantly decreased with increasing percentage of HIV-
infected cells (p<0.05). Accordingly, the chymotryptic activity 
of the proteasome decreased upon HIV-infection (p=0.027). 
After PHA activation, peptidase activities increased and the fold 
change in aminopeptidase and caspase-like peptidase activities 
between PHA-activated and non-activated samples correlated 
with the percentage of CD25-positive cells (p<0.01). The in vitro 
degradation of HIV peptide in extracts from T cells analyzed by 
mass spectrometry shows differences in epitope production 
between non-activated and PHA-activated cells.
Conclusion: Both HIV infection and cellular activation affect the 
expression and peptidase activities of the antigen processing 
machinery of primary CD4 T cells which may impact the 
presentation of epitopes by both uninfected and infected cells 
during HIV infection.
This project was supported by NIH-NIAID grants R01 A1084106 
and P01 A1074415. 
P11.19
Downregulation of the 5’-Ectonucleotidase CD73 of 
CD8+ CTL of HIV Infected Patients Correlates with 
Immune Activation and Diminished IL-2 Production
I. Toth2, J. Hauber1, P. Hartjen2, J. van Lunzen2,  
J. Schulze zur Wiesch2
1Heinrich Pette Institute, Germany; 2University of Hamburg, 
Hamburg, Germany
Background: Chronic untreated HIV infection is immunologically 
characterized by irreversible loss of CD4+ T cells, general 
immune activation and CD4+ and CD8+ T cell dysfunction 
with diminished proliferative capacity. CD73 is an ectoenzyme 
(5’-ectonucleotidase) expressed on T cells converting 5’-AMP to 
adenosine, but there is additional evidence of ectonucleotidase-
independent CD73 function. Altogether CD73 seems to play a 
role as a co-stimulatory molecule for T cell differentiation. 
Methods: Peripheral blood of a large cohort of 103 HIV infected 
patients at different stages of HIV disease, including long-term 
nonprogressors and elite controllers, was analyzed by multicolour 
flow cytometry to determine the expression of CD73+ on CD8+ 
CTL, CD4+ T effector cells and Tregs.
Results: Surprisingly CD73 was not expressed on human 
regulatory T cells regardless of the infection status. However 
we find high expression of CD8+ in healthy controls. In HIV 
infection, CD73 seems to be generally suppressed on CD8+ T 
cells, independent of their naive or memory subtype. We find 
significant correlation between downregulation of CD73 and 
viremia, and there is an inverse correlation with CD8+ immune 
activation. Elite controllers show comparable CD73 expression to 
healthy controls. First proliferation studies show that that HIV-
specific CD8+ CD73- T cell population produces less IL-2 than 
their CD73+ counterparts. 
Conclusion: CD73 is not expressed on human Tregs. CD73 
downregulation of CD8+ T cells correlates with HIV disease 
progression. Further functional studies should look into the exact 
role of CD73 in HIV.
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T Cell Receptor Clonotypes Modulate the Protective 
Effect of Human Leukocyte Antigen Class I Alleles in 
HIV-1 Infection
H. Chen1, Z.M. Ndhlovu1, D. Liu1, L.C. Porter1, J.W. Fang1,  
S. Darko2, M.A. Brockman1, T. Miura1, Z.L. Brumme1,  
A. Schneidewind1, A. Piechocka-Trocha1, K.T. Cesa1, J. Sela1,  
T.D. Cung1, I. Toth1, F. Pereyra1, X.G. Yu1, D.C. Douek2,  
D.E. Kaufmann1, T.M. Allen1, B.D. Walker1
1Ragon Institute of MGH, MIT and Harvard, Charlestown, MA, 
USA; 2Vaccine Research Center, NIH, Chevy Chase, MD, USA
Background: Human leukocyte antigen (HLA) class I alleles B*27 
and B*57 are associated with protection against HIV-1 disease 
progression, but factors modulating the HLA protective effect 
remain unclear.
Methods: Clonality of tetramer-sorted HIV-1 epitope-specific 
CD8 T cells from HIV-1 elite controllers and chronic progressors 
expressing HLA B*27 or B*57 were determined by T cell receptor 
(TCR) gene sequencing. Polyfunctionality, proliferation, avidity 
and differentiation phenotypes were analyzed by flow cytometry. 
Recognition of a GFP reporter cell line or autologous CD4 T 
cells infected with HIV-1 containing known mutations by HIV-1 
epitope-specific bulk CD8 T cells or clonotypic CD8 T cell clones 
was analyzed by flow cytometry or analysis of p24 production. 
Immunological synapses between different CD8 T cell clones and 
infected target cells and lytic granule loading and delivery on a 
per cell basis were examined using three-dimensional confocal 
microscopy.
Results: HLA-B*27-restricted CD8 T cells in controllers and 
progressors are quantitatively similar but clearly differentiate 
based on the ability to inhibit virus replication through targeting 
of the immunodominant Gag epitope. This in turn is associated 
with distinct TCR clonotypes, which are characterized by superior 
control of HIV-1 replication in vitro, greater cross-reactivity against 
epitope variants, and enhanced perforin expression and delivery 
at the immunological synapse. Clonotype-specific differences in 
antiviral efficacy were also observed for an immunodominant 
HLA-B*57 restricted response in controllers and progressors.
Conclusion: These data indicate that the efficacy of protective 
alleles is modulated by specific TCR clonotypes that are selected 
in natural infection, and provide a functional explanation for 
divergent HIV-1 outcomes in persons with protective HLA 
alleles. Efforts to define the factors that contribute to junctional 
rearrangement of more effective TCR may be of critical 
importance for T cell vaccine design and therapeutic strategies 
for highly variable pathogens like HIV-1.
P11.21
Recombinant Attenuated M.Tuberculosis-
SIVgag(rAMtb-gag) Vaccination Primes for SIV-
Specific CD8 T Cell Response That Are Boosted by 
Ad5-SIVgag in Mice
U. Kadayam Ranganathan1, M. Larsen1, K. Abel2, W. R Jacobs 
Jr3, G. Fennelly1
1Albert Einstein College of Medicine, Bronx, NY, USA; 2Dept 
of Microbiology and Immunology, UNC School of Medicine, 
Chapel Hill, NC, USA; 3Howard Hughes Medical Institute, 
Albert Einstein College of Medicine, USA
Background: BCG vaccination is no longer advised in children 
with HIV infection due to the risk of disseminated disease. As 
a safer alternative to BCG and as a vector for HIV vaccination, 
we developed a novel vaccine based on an M. tb mutant that 
contains genetic deletions in essential nutrients (pantothenate 
and Leucine) and immune modulating pathways (ΔSecA2)
Methods: To optimize T cell responses against SIV after vaccine 
priming with a candidate ΔPanCD ΔLeuCD ΔSecA2 M. tuberculosis 
(mc26208) strain expressing the codon optimized SIVmac239 gag 
(designated mc26435), we boosted with Adenovirus 5 expressing 
SIV gag in 5-6 week old C57/BL6 mice. Lymphocytes from blood, 
lung and spleen cells were collected 2 and 6 weeks after boosting 
to detect SIV gag-specific CD8 T cells by tetrameric staining for 
the H-2Db haplotype AL11 tetramer (AAVKNWMTQTL) and flow 
cytometric analysis. 
Results: To determine the relative priming ability of rAMtb, rBCG, 
DNA vaccine, and rAd expressing the relevant Gag sequence, 
several groups of mice (5 per group) were immunized according 
to various prime/boost schedules. In general, Ad5gag boosting 
enhanced T cell responses after either mc26435 or BCG-SIV 
priming compare to mycobacterial priming alone.
Conclusion: mc26435, mc26206 (ΔPanCD ΔLeuCD) expressing SIV 
gag and rBCG boosted with Ad5gag had comparable response in 
the lung at 2 wks (2-6%). Although the most frequent SIV-specific 
CD8+ T cell responses were observed after Ad5gag boosting 
among splenocytes (7%) in BCG primed mice, significant 
responses (3-6% of all CD8+ T cells) were observed after Ad5gag 
boosting in mice primed with either rAMtb-gag strain mc26435 or 
mc26206. These results suggest that SIV-specific T cell responses 
after rAMtb-gag priming can be boosted by the Ad5gag. rAMtb-
HIV is a safe candidate vaccine for infants that is likely to prime 
for T cell responses against both HIV and TB. 
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Variable Processing and Presentation of HIV Epitopes 
in Dendritic Cells and Macrophages to CD8 T Cells
P. Gourdain1, J. Dinter1, N. Lai1, M. Shimada1, E. Duong1,  
T. Zhu1, E. Bracho-Sanchez1, P. Liebesny1, S. Le Gall1
1The Ragon Institute of MGH, MIT and Harvard, Charlestown, 
MA, USA
Background: Whether HIV-infectable subsets, such as CD4 T 
cells, monocytes, macrophages and dendritic cells (DCs), have 
equivalent capacity to produce and present MHC-I restricted 
epitopes to HIV-specific CD8 T cells is unknown. MHC-I epitopes 
are processed by an intracellular degradation pathway involving 
multiple proteases. In this study we analyzed the effect of 
toll-like receptor (TLR) agonist-mediated maturation on the 
processing and presentation of HIV antigens in monocyte-
derived DCs and macrophages.
Methods: Proteolytic activities were measured with a 
fluorescence-based activity assay. Cytosolic extracts were used 
as a source of peptidases to degrade extended epitopes in vitro. 
Degradation products were then analyzed by mass spectrometry 
and antigenicity was tested by a 51Cr release assay and a real-
time killing assay. 
Results: Upon maturation with LPS or R848, the proteasomal and 
lysosomal activities in matured macrophages are significantly 
higher compared to matured DCs. The proteasomal tryptic and 
caspase-like activities as well as the lysosomal activities decreased 
approximately 1.5-fold in matured DCs. The degradation of 
the N-terminal extended epitope 3-ISW9 in LPS-matured DCs 
yielded 2-fold more optimal epitope ISW9 than in immature 
DCs, which resulted in a 3-fold higher cell lysis in a 51Cr release 
assay. In addition, the cross-presentation of exogenously added 
p24 protein by DCs or macrophages showed reduced killing of 
APCs by ISW9-specific CTLs compared to CTLs specific for TW10 
or KF11. This lower ISW9-specific killing was partly rescued by 
preincubation with protease inhibitor.
Conclusion: We showed that differences in antigen processing 
activities in DCs and macrophages upon maturation, and 
differences in HIV sequences sensitivity to intracellular 
degradation may affect the production and presentation of 
epitopes and thus the capacity of HIV-specific CTLs to recognize 
and kill infected cells. For the design of a vaccine immunogen 
it is critical to identify factors regulating the processing and 
presentation of epitopes.
Supported by NIH NIAID R01 A1084753
P11.23
Plasma Cytokine Levels and HIV-Specific Immune 
Responses During Acute/Early HIV Infection
G. Turk1, N. Laufer2, A.M. Rodriguez1, Y. Ghiglione1, J. Favilene1, 
M.J. Ruiz1, O. Sued3, L. Giavedoni4, P. Cahn5, H. Salomon1,  
M.M. Gherardi1
1Instituto de Investigaciones Biomédicas en Retrovirus y SIDA 
INBIRS, Buenos Aires, Argentina; 2Instituto de Investigaciones 
Biomédicas en Retrovirus y SIDA INBIRS., Argentina; 3Fundacion 
Huesped, Buenos Aires, Argentina; 4Southwest National 
Primate Research Center, San Antonio, TX, USA; 5Fundacion 
Huesped/Hospital Juan A Fernandez, Buenos Aires, Argentina
Background: It is believed that initial encounter between HIV and 
the human host triggers a complex series of events that dictate 
future disease course. Inter-individual differences among the 
host-players involved in these processes seem to early determine 
different rates of disease progression. Here we were aimed at 
studying the relationship between innate and adaptive soluble 
immune mediators, HIV-specific T-cell response and the course 
of acute infection.
Methods: Plasma levels of 37 cytokines were measured by 
Luminex technology in different groups of volunteers: 10 healthy 
donors (HD) and 50 HIV infected-subjects: 10 chronics, 12 aviremic 
controllers (EC) and 28 subjects enrolled during acute infection 
(AI). All HIV patients were off-HAART. Frozen PBMCs from the 
same individuals were used to determine HIV-specific T-cell 
responses by IFN-gamma ELISPOT. Data was compared inter- and 
intra-groups and correlated to viral load (VL), CD4 T cell counts and 
both virological (VL) and immunological (CD4 count) set-points (in 
AI), using parametric and non-parametric statistics. 
Results: Compared to HD, cytokines significantly elevated during 
acute and chronic infection included IL-1alfa, IL-10, IP-10 and 
TNF-alfa. Conversely, IL-12p40 and the macrophage-derived 
chemokine (MDC) were only significantly elevated in chronics 
and not in AI subjects who showed similar levels to HD and even 
EC. Moreover, levels of IL-12p40, IL-12p70 and MDC directly 
correlated with CD4 T-cell count among chronics and both CD4 
T-cell count and immunological set point in AI. Regarding HIV-
specific T-cell response during AI, proportion of Gag-specific and 
Nef-specific cells significantly correlated (directly and inversely, 
respectively) with immunological set point
Conclusion: Both early and late components of the immune 
system help preserve CD4 T-cell subset in HIV+ subjects: key 
cytokines involved in the initiation and regulation of cellular 
immune response and anti-Gag specificity of effector T-cells. 
These features should be taken into account during vaccine 
formulation design to boost favorable results.
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Different Abilities of CTL Specific for Two HLA-
A*24:02-Restricted Overlapping Optimal Epitopes to 
Select Same HIV-1 Escape Mutant Virus 
X. Sun1, M. Fujiwara1, N. Kuse1, S. Oka2, M. Takiguchi1
1Center for AIDS Research, Kumamoto University, Kumamoto, 
Japan; 2AIDS Clinical Center, National Center for Global Health 
and Medicine, Tokyo, Japan
Background: Cytotoxic T lymphocytes (CTLs) are thought to 
exert immunologic selection pressure of escape mutation. 
Previous reports have showen that some overlapping peptide 
epitopes were presented by same HLA molecules. However, the 
abilities and properties of those CTLs to selection of same escape 
mutation are not well studied.
Methods: CTL clones were established by stimulation of PBMC 
with a synthetic peptide (Nef138-8: RYPLTFGW or Nef138-10: 
RYPLTFGWCF) by limiting dilution method. Cytotoxic activity 
toward peptide-loaded cells was performed by 51Cr releasing 
assay. CTL suppression ability was tested by HIV-1 replication 
assay toward primary CD4+ cell. In vitro selection of escape 
mutation was performed by competitive HIV-1 replication assay. 
The frequency of tetramer positive cells in PBMC of HLA-A*24:02+ 
patients was detected by flow cytometry analysis.
Results: Both 8-mer and 10-mer epitopes specific CTLs were 
established from PBMC of the patients. The ability of Nef138-
10-specific CTLs to suppression HIV-1 replication in vitro was 
much higher than that of Nef138-8-specific CTLs. In addition, 
at the early stage of infection, Nef138-10-specific CTLs was 
predominantly elicited in the patients more than the latter ones. 
Cross-reactive Nef138-8-specific CTLs recognizing both WT and 
2F epitopes were detected in some patients. Moreover, in vitro 
competitive HIV-1 assay showed that both CTLs can select escape 
mutants, though the ability of Nef138-10-specific CTLs was 
stronger than that of Nef138-8-specific ones.
Conclusion: The present study demonstrated that Nef138-10-
specific CTLs play a major role in the selection of the escape 
mutation, and that Nef138-8-specific CTLs also have ability to 
select it. We showed selection of the same escape mutants by 
CTL specific for same HLA-restricted overlapping epitopes.
P11.25
Increased Mucosal CD4+ T-Cell Activation Following 
Vaccination with an Adenoviral Vector in Rhesus 
Macaques
I. Bukh1, R. Calcedo1, S. Roy1, D.G. Carnathan1, R. Grant1,  
S.J. Ratcliffe1, J.M. Wilson1, M.R. Betts1
1University of Pennsylvania, Philadelphia, PA, USA
Background: The possibility that vaccination with Adenoviral 
vectors increased mucosal T-cell activation remains a central 
hypothesis to explain the potential enhancement of HIV 
acquisition within the STEP trial. Modeling this within rhesus 
macaques is complicated because human Adenoviruses, 
including Adenovirus type 5 (HAd5), do not productively infect 
macaques. We created a vector based upon a naturally occurring 
rhesus macaque Adenovirus (SAdV7) to test whether vaccination 
with a species-specific Adenoviral vector enhances mucosal 
T-cell activation within the natural host. 
Methods: Twelve rhesus macaques were vaccinated 3x 
intramuscularly with SAdV7 vector. Five HAd5-vaccinated 
animals were included as controls. PBMC and rectal biopsies 
were obtained at baseline, multiple times post-prime and post-
17 week boost (8x/animal), and post-31 week second boost (1x/
animal). We assessed rectal mucosal lamina propria and blood 
for frequency changes of Ad-specific T-cell responses and T-cell 
activation levels by measuring IFNg, TNFa, IL2, CD25, Ki67, CD69, 
and HLA-DR.
Results: Naturally acquired pre-existing SAdV7-specific CD4+ 
T-cells were identified in 10/13 macaques within blood and/
or rectal mucosa. Following intramuscular SAdV7 vaccination, 
rectal SAdV7-specific CD4+ T-cell responses increased above 
baseline in 9/9 animals 2-5 weeks post-prime, and subsequently 
contracted. Five weeks post-prime, 10/12 animals had rectal 
SAdV7-specific CD4+ T-cell responses ranging from 0.1-16.84%. 
As expected, SAdV7-specific CD4+ T-cells expressed CD69 and 
other activation markers (but not Ki67). Heightened expression 
of CD25, CD69, and HLA-DR was observed on total rectal memory 
CD4+ T-cells in SAdV7-vaccinated animals, and maintained 15 
weeks after the prime. Interestingly, upregulation of activation 
markers in rectal mucosa also occurred in HAd5-vaccinated 
animals. No change in activation was observed in the blood 
throughout the entire study.
Conclusion: These results indicate that peripheral vaccination 
with an Adenovirus vector can increase the activation of mucosal 
CD4+ T-cells providing an experimental model to further evaluate 
the role of host-vector interactions on increased HIV acquisition. 
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Highly Expression of Tim-3 on HIV-Specific T Cells 
Associated with Disease Progression and T-Cell 
Exhaustion in HIV-1 Infected Chinese
Z. Liu1, K. Hong1, M. Jia1, J. Hao1, Z. Gao1, S. Liu1, Y. Ruan1,  
H. Xing1, Y. Shao1
1National Center for AIDS Control and Prevention, China CDC, 
Beijing, China
Background: The exact mechanism of T-cell exhaustion remains 
to be defined during HIV-1 infection. Recent studies suggest that 
the inhibitory receptor T-cell immunoglobulin domain and mucin 
domain 3(Tim-3) may play an important role in the exhaustion of 
HIV-specific T cells.
Methods: 72 HIV-1 infected individuals with different disease 
outcomes were recruited in this study. Tim-3 expression and 
the profile of cellular immune response were measured by 
using Multicolor Intracellular Cytokine Staining (ICS) assay. 
Association between Tim-3 expression levels and disease 
progression was analyzed. And the potential role of Tim-3 on 
immune regulation during HIV-1 infection was investigated 
through assessment of CTL response with frequencies of Tim-3 
expression and blocking effect.
Results: Tim-3 was found to be highly expressed on HIV-specific 
CD4+ T cells and CD8+ T cells, especially in primary infectors and 
AIDS patients. The frequencies of Tim-3 expression correlate 
with disease progression. The level of Tim-3 expression was 
related with cytokines production and blockade of Gal-9/TIM-
3 signaling partially restored the ability of HIV-specific T cells to 
secrete cytokines in vitro.
Conclusion: The frequencies of Tim-3 expression correlate 
with disease progression in HIV-1 infected individuals and 
manipulating Gal-9/TIM-3 signaling pathway may provide a 
novel therapeutic measure to control HIV-1 replication.
P11.27
HLA-Associated Viral Polymorphism in Chronically 
HIV-1-Infected Japanese Cohort: Analysis of Four-
Digit HLA Allele Level
T. Chikata1, J.M. Carlson2, Y. Tamura1, Z.L. Brumme3, T. Naruto1, 
M. Hashimoto1, M.A. Borghan4, M. John5, S. Mallal5,  
H. Gatanaga6, S. Oka6, M. Takiguchi1
1Center for AIDS Research, Kumamoto University, Kumamoto, 
Japan; 2eScience Group, Microsoft Research, Redmond, WA, 
USA; 3Faculty of Health Sciences, Simon Fraser University, 
Burnaby, British Columbia, Canada; 4College of Arts and 
Sciences, University of Nizwa, Oman; 5Royal Perth Hospital, 
Murdoch University, Perth, Australia; 6AIDS Clinical Center, 
National Center for Global Health and Medicine, Tokyo, Japan
Background: It is assumed that the difference of HLA class 
I distribution among ethnic populations influences HIV 
evolution because HLA-restricted immune pressure selects 
escape mutations. Approximately 50% of HLA class I alleles 
are shared between Japanese and Caucasians. The analysis of 
HLA-associated polymorphism (HLA-AP) in both Japanese and 
Caucasian infected with clade B virus is expected to clarify the 
difference of HIV-1 evolution between both populations.
Methods: We sequenced Gag, Pol, and Nef genes in 430 
treatment-naïve Japanese chronically infected with HIV-1 clade 
B and then identified HLA-associated amino acids at each codon 
using a phylogenetically corrected logistic regression model and 
false discovery rates to correct for multiple tests.
Results: We completely determined 400, 366, and 309 
sequences of Gag, Pol, and Nef, respectively, and then analyzed 
polymorphisms associated with 78 four-digit HLA alleles (21 
HLA-A, 38 HLA-B, and 19 HLA-C alleles). At the threshold of 
q<0.2, we found 195 HLA-APs (67 in Gag, 61 in Pol, and 67 
in Nef). These polymorphisms were observed at 39 of 501 
(7.8%) Gag, 42 of 1004 (4.2%) Pol, and 33 of 207 (16.0%) Nef 
codons. Ninety-six HLA-APs associated with more than one HLA 
subtype allele were detected in 4-digital HLA allele analysis. 
Approximately 40% of HLA-APs were associated with HLA 
alleles predominantly found in Asia. Out of HLA-APs associated 
with common HLA alleles, approximately 50% were found in 
Caucasian population (IHAC cohort).
Conclusion: This study demonstrated that only 30% of HLA-APs 
were shared between Caucasians and Japanese, indicating that 
the difference in HLA allele distributions resulted in distinct 
HIV-1 evolution.
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Longitudinal Assessment of HIV-1-Specific T-Cell 
Responses Generated During Acute Subtype C HIV-1 
Infection and Associations with Viral Set Point
M. Radebe1, Z. Ndhlovu2, M. Mokgoro1, L. Maphumulo1,  
M. Jaggernath1, F. Chonco1, T. Ndung’u1, B.D. Walker2
1University of Kwazulu-Natal, Durban, South Africa; 2Ragon 
Institute of MGH, MIT and Harvard, Boston, MA, USA
Background: HIV-1-specific CD8+ T-cell responses generated 
during acute infection play a key role in determining the course 
of disease. However, these early responses may disappear as the 
infection progresses. Tracking the phenotype, functional ability 
and fate of these early responses may help elucidate features of 
CD8+ T-cells that contribute to viral control.
Methods: We characterized the magnitude and breadth of HIV-1-
specific CD8+T-cell responses using the overnight IFN-γ ELISPOT 
assay in 20 HIV-1 subtype C acutely infected, antiretroviral naive 
individuals as early as 28 days post initial exposure and up to 12 
months post-infection. Cultured IFN-γ ELISPOT assays were used 
to assess early epitope-specific CD8+ T-cell responses that were 
below the limit of detection by overnight ELISPOT assays at 12 
months post-infection. 
Results: The initial CD8+ T-cell responses detected during the 
decline in acute phase peak viremia were narrowly directed: 
T-cell responses were directed against an average of three (range 
0-6) of the 410 peptides tested. At 12 months post-infection, 
immune responses had broadened with an average of seven 
peptides targeted (range 2-11). The majority of persistent T-cell 
responses targeted epitopes within Gag and Pol (50% and 30%, 
respectively). The breadth of persistent CD8+T-cell responses 
correlated negatively with viral set point (P=0.02). An average of 
65% of earlier CD8+ T-cell responses which where not detected 
by the overnight ELISPOT at later time points, were detected by 
the cultured ELISPOT assay. There was no correlation between 
the magnitude or breadth of responses measured using the 
cultured ELISPOT assay and viral set point.
Conclusion: These data suggest that persistent CD8+ T-cell 
responses generated during the earliest stages of HIV-1C 
infection may play a role in viral control. Furthermore, effector 
T-cell responses that disappear following acute infection are 
maintained as memory T-cell responses and our preliminary data 
suggest that they have no significant impact on viral control.
P11.29
Changes in gd T Cell Function and Gut Homing 
Receptors Following SIV Infection of Rhesus 
Macaques
I. Tuero1, M. Robert-Guroff1
1National Institutes of Health/National Cancer Institute, 
Bethesda, MD, USA
Background: During simian immunodeficiency virus (SIV) 
infection changes occur in the gd TCR T cell population. The major 
subset in mucosal tissue, Vd1, becomes prevalent in peripheral 
blood relative to the Vd2 subset. gd T cells have the ability to 
expand in vitro and in vivo making them attractive as cytotoxic 
effectors against infections like SIV and HIV. 
Methods: We studied gut homing receptors and functionality 
of Vd1 and Vd2 T cells in blood and jejunum of naïve (8 and 3 
respectively) and SIV infected (13 and 9 respectively) animals. 
Vd1+ and Vd2+ T cells were identified by flow cytometry using 
pan gd TCR-PE and Vd2-FITC mAbs. Intracellular staining for IFN-g 
and perforin was performed after Phorbol-Myristate-Acetate/
Ionomycin stimulation.
Results: Here, the Vd1 subset in SIV infected macaques was 
not significantly increased in blood, but in jejunum, Vd1 T cells 
became predominant compared to Vd2 T cells (p=0.0044) and 
to the level in blood (p=0.0014). Expansion of the Vd1 subset 
in jejunum was linked to increased expression of the a4b7 gut 
homing marker on peripheral blood Vd1 T cells (p=0.033). After 
stimulation, Vd1 and Vd2 T cells in blood produced both IFN-g 
and perforin. Higher frequencies of Vd1 T cells produced perforin 
in SIV+ animals compared to naïve (p=0.0186), while IFN-g 
producing cell frequencies decreased (p=0.0066). Most Vd1 T 
cells were CD4-CD8- (DN). Those producing perforin were also 
mainly DN compared to CD4+ and CD8+ Vd1 T cells (p=0.0156).
Conclusion: Expansion of Vd1 T cells in the jejunum is associated 
with increased trafficking from peripheral blood to the mucosal 
site. This expanded population with cytotoxic potential could 
contribute to viremia control. 
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HIV-Specific Cytolytic CD4 T-Cell Responses 
Effectively Control HIV Infection in Macrophages
D.Z. Soghoian1, M. Flanders1, K. Sierra-Davidson1,  
S. Ranasinghe1, S. Cutler1, I. Davis1, M. Lindqvist1, K. Lane1,  
B. Kuhl1, G. Kranias1, A. Piechocka-Trocha1, H. Jessen2,  
B.D. Walker1, H. Streeck1
1Ragon Institute of MGH, MIT, and Harvard, Charlestown, MA, 
USA; 2Praxis Jessen Jessen Stein, Berlin, Germany
Background: HIV-specific cytolytic CD4 T-cell responses expand 
during acute HIV infection in individuals who control viremia 
and are associated with better disease outcome. Up to 75% of 
the HIV-specific CD4 T-cells exhibit a cytolytic phenotype during 
acute infection, but it is not understood how cytolytic CD4 T-cells 
contribute to viral control or what their primary target cells are.
Methods: Using a novel, fluorescence-based single-round viral 
suppression assay, we assessed the ability of CD4 T-cells from 
HIV infected subjects to lyse infected macrophages. Elimination 
of infected macrophages and CD4 cytolytic phenotype were 
determined by flow cytometry. In addition, HIV-specific CD4 
T-cell clones were generated and their cytolytic ability examined 
by Cr51-release and viral inhibition assays.
Results: We observed significantly higher degranulatory HIV-
specific CD4 T-cell responses in HIV controllers compared to 
progressors (p=0.015). Moreover, about 1/4 of all HIV-specific 
CD4 T-cell clones showed cytolytic activity by Cr51-release. 
Using a single-round viral suppression assay, we additionally 
observed that HIV-specific CD4 T-cells from chronically infected 
subjects were able to significantly lyse HIV infected macrophages 
(p=0.004). Elimination of HIV-infected macrophages was dose-
dependent, up to 37% at E:T=5:1. Lytic ability could be observed ex 
vivo, and was enhanced after short term Gag-specific expansion 
in culture (11% to 32%, p=0.014). Furthermore, we observed that 
the inhibitory capacity of CD4 T cells could be abrogated using 
an HLA-DR blocking antibody. CD4 T-cell-mediated macrophage 
lysis was associated with strong HIV-specific cytolytic activity by 
intracellular cytokine staining and high expression of granzymes/
perforin within HIV-specific CD4 T-cells.
Conclusion: Our data demonstrate that HIV-specific CD4 
T-cells derived from infected individuals have the ability to 
eliminate infected macrophages. These data suggest a role for 
HIV-specific cytolytic CD4 T-cell responses, in the absence of 
CD8 T cell responses, in the lysis of HIV-infected macrophages, 
which represent important reservoirs for viral infection and 
viral dissemination.
P11.31
Breadth, Phenotype and Functionality of Gag-
Specific T Cell Responses Induced by a Heterologous 
DNA/MVA Prime-Boost HIV-1 Vaccine Regimen
L. Podola1, A. Bauer1, A. Haule2, L. Sudi2, C. Nilsson3, K. Godoy-
Ramirez3, P. Mann1, M. Missanga2, B. Kaluwa2, L. Maboko2,  
C. Lueer1, M. Mwakatima2, S. Aboud4, M. Bakari4, J. Currier5, 
M. Robb5, S. McCormack6, S. Joseph6, E. Lyamuya4,  
M. Hoelscher1, B. Wahren3, E. Sandström3, G. Biberfeld3,  
C. Geldmacher1, A. Kroidl1
1Ludwig-Maximilians University of Munich, Mbeya, United 
Republic of Tanzania; 2Mbeya Medical Research Programme, 
Mbeya, United Republic of Tanzania; 3Karolinska Institute and 
Swedish Institute for Communicbale Disease, Solna, Sweden; 
4Muhimbili University of Health and Allied Sciences (MUHAS), 
Dar Es Salaam, United Republic of Tanzania; 5US Military HIV 
Research Program, Rockville, MD, USA; 6MRC Clinical Trials 
Unit, London, United Kingdom (Great Britain)
Background: Broad Gag recognition and polyfunctionality of 
vaccine-induced AIDS virus-specific T cell responses correlate 
with better viral control in non-human primates and also in 
chronically HIV-infected individuals.
Methods: Breadth and polyfunctionality of HIV-vaccine induced 
Gag-specific T cell responses were investigated in healthy Tanzanian 
volunteers who participated in the Tanzania Mozambique HIV 
vaccine trial (TaMoVac 01). Vaccine recipients received 3x 0.6 or 
1.0mg intradermal injections of multiclade, multigene HIV-DNA 
vaccine boosted with 2x heterologous Modified Vaccinia Ankara 
(MVA)-CMDR. Using fresh peripheral blood mononuclear cells, the 
breadth of response was determined after the first MVA-CMDR 
boost using peptide pools for 9 successive Gag regions with an IFN-
gamma ELISpot assay. Functionality (IFN-gamma, IL-2, TNF-alpha, 
Mip-1beta and the degranulation marker CD107) and phenotype 
(CD3, CD4, CD8) of HIV-specific T cells were assessed using flow 
cytometry in 52 participants after stimulation with peptide pools 
covering whole Gag-CMDR protein.
Results: Two weeks after the first MVA-CMDR boost, a median 
of 2 Gag regions were recognized (range: 0-9, Placebos 
not excluded) by 45 participants. There was a strong linear 
correlation between the magnitude and the breadth of vaccine-
induced Gag recognition (p<0.0001, r2=0.44). 13 (25%), 13 
(25%), 3 (6%) and 29 (56%) of 52 subjects mounted IFN-gamma+ 
Gag-specific T cells that were either only CD4+, CD4+ & CD8+, 
only CD8+, or CD4+ and/or CD8+, respectively. Fifty percent 
of IFN-gamma+ Gag-specific CD4 T cells co-expressed TNF-
alpha and/or IL-2. Co-expression of Mip-1beta or CD107 was 
reduced compared to CMVpp65-specific CD4 T-cells, which were 
measured simultaneously. More than 50% of IFN-gamma+ Gag-
specific CD8 T-cells co-expressed CCR5 ligand Mip-1beta and a 
large proportion of these had degranulated.
Conclusion: The TaMoVac-01 HIV-1 vaccine regimen induces a 
relatively broad Gag-specific response frequently dominated by 
CD4 T cells, many of which co-express IL-2 and/or TNF-alpha, 
but also induces detectable Gag-specific CD8 T-cells in a third of 
vaccine recipients.
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Potent Cellular Immune Responses After Therapeutic 
Immunization of HIV-Positive Patients with the 
PENNVAX®-B DNA Vaccine in a Phase I Trial
P. Tebas1, L. Ramirez1, M.P. Morrow2, J. Yan2, D. Shah2, J. Lee2, 
D.B. Weiner1, J. Boyer1, M. Bagarazzi2, N.Y. Sardesai2
1Department of Pathology and Laboratory Medicine, U of 
Pennsylvania, Philadelphia, PA, USA; 2Inovio Pharmaceuticals, 
Blue Bell, PA, USA
Background: Although highly active antiretroviral therapy 
(HAART) regimens have dramatically transformed treatment of 
HIV infection, achieving 95% adherence to HAART regimens is 
notoriously difficult. The successful creation of an immunotherapy 
for infection could eliminate the potential pitfalls associated with 
the necessity for long-term adherence to drug therapy. To that end, 
we evaluated the safety and immunogenicity of the PENNVAX®-B 
vaccine, delivered with in vivo electroporation (EP) in HIV-infected 
volunteers on HAART in a Phase I open-label study.
Methods: Enrollment criteria included HIV RNA<75copies/
mL, CD4>400/µL with nadir >200/µL. Twelve eligible subjects 
received a 4 dose series (day 0, weeks 4, 8 and 16) of 3 mg 
PENNVAX®-B (consisting of SynCon® HIV Gag, Pol, and Env 
immunogens) intramuscularly followed by in vivo EP with the 
CELLECTRA®-5P device.
Results: All the enrolled subjects completed the immunization 
schedule. The vaccine demonstrated an acceptable safety profile 
and was generally well tolerated. Overall, 9 out of 12 subjects 
(75%) showed significant vaccine-specific T-cell responses in the 
form of IFN-γ ELISpot against at least one of the three vaccine 
antigens (Gag, Pol, or Env) following vaccination. Furthermore, 
responses were not dominated by a single antigen, as 50% of 
subjects had strong vaccine induced responses to at least 2 
of the 3 antigens and 3 showed vaccine-induced responses 
to all 3 antigens. Importantly, the ELISpot responses induced 
by vaccination were predominantly CD8+T-cells, which are 
considered to be paramount in clearing chronic viral infections 
and an important measure of the performance of a therapeutic 
vaccine. Additionally, HIV-specific immune responses were 
assayed by flow cytometry to measure IFN-γ production by both 
CD4+ and CD8+T cells as well as co-expression of the CTL-related 
markers CD107a, GranzymeB and Perforin.
Conclusion: Analysis of these data should provide more definitive 
evidence of HIV-specific CTL function, which has been implicated 
in control of viral replication in HIV-infected patients. 
P11.33
Alteration of HIV Epitope Processing and 
Presentation by HIV Protease Inhibitors
G. Kourjian1, J. Boucau1, M. Shimada1, N.Y. Lai1, S. Le Gall1
1Ragon Institute of MGH, MIT and Harvard, Boston, MA, USA
Background: Epitopes displayed by MHC-I come from the 
multistep degradation of proteins by intracellular peptidases 
such as proteasome and aminopeptidases or cathepsins in the 
exogenous pathway. We hypothesize that due to structural 
homologies HIV protease inhibitors (PIs) used in antiretroviral 
therapies may affect activities of cellular peptidases involved 
in epitope processing and may affect epitope presentation to 
immune cells. 
Methods: Using a fluorogenic assay the effect of 5 HIV-1 PIs 
(Ritonavir, Saquinavir, Nelfinavir, Indinavir, Atazanavir) on 
proteasome, aminopeptidase and cathepsin activities was tested 
in PBMCs from at least 6 healthy donors. Using PBMC cytosol 
as a source of peptidases and HPLC and mass spectrometry to 
define and quantify the degradation products, the effect of HIV 
PIs on HIV peptide processing kinetics and HIV epitope half-
life was assessed. Finally we assessed the impact of PIs on the 
endogenous processing and presentation of epitopes by infected 
cells to CD8 T cells using a fluorescence-based cytotoxicity assay.
Results: HIV PIs variably altered proteasome, post-proteasomal 
aminopeptidases and cathepsin activities. Depending on the PI, 
some activities were inhibited (from 1.1 to 5 folds, p<0.001), 
enhanced (1.2 to 9 folds, p<0.001), and others not changed. 
These PI-induced changes in protease activities modified HIV 
peptide processing patterns and HIV epitope intracellular half-
life prior to MHC-I loading. Depending on the PI and the epitope 
the half-life was increased 1.5 fold (p<0.01) or decreased 1.3 fold 
(p<0.05). Furthermore HIV PI altered (from 2.2 fold decrease to 
1.3 fold increase, p<0.01) the presentation of HIV epitopes and 
recognition by epitope-specific CD8 T cells.
Conclusion: These findings suggest that in HIV-infected patients 
an antiretroviral therapy including PIs might -by altering host 
proteases function- modify the pattern of epitope presentation, 
leading to the elicitation of additional CTL responses against HIV 
and potentially against other pathogens co-infecting HIV+ persons.
This project was supported by NIH-NIAID grant R01-A1084106.
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Preferential Targeting Of Co-evolving Gag Residues in 
Long-Term Non Progressors 
J. Sunshine1, K. Shekhar2, D. Heckerman3, A.K. Chakraborty2,  
N. Frahm 4
1University of Washington, Seattle, WA, USA; 2Massachusetts 
Institute of Technology, Cambridge, MA, USA; 3Microsoft 
Research, Los Angeles, CA, USA; 4Fred Hutchinson Cancer 
Research Center, Seattle, WA, USA
Background: A recent analysis of mutational patterns within 
Gag revealed independently evolving groups of residues 
(termed sectors) whose mutations are collectively coordinated. 
Of these sectors, sector 3 is the least tolerant of multiple 
simultaneous mutations and therefore is proposed to be the 
most vulnerable to a targeted immune attack. We hypothesized 
that coordinated CTL targeting of sector 3 residues is associated 
with immune control. 
Methods: We completed a comprehensive evaluation of Gag-
specific responses in a cohort of 9 Long-term non-progressors 
(LTNPs, VL <2000 RNA copies/ml, untreated) and 9 HIV 
progressors (VL>10,000 RNA copies/ml, untreated). A Gag 
peptide set of 11-mer peptides overlapping by 10 amino acids 
was generated to reflect all variants found in at least 5% of clade 
B sequences in the LANL HIV Sequence Database. This peptide 
set includes 1300 peptides and covers all 500 amino acids of Gag. 
All study subjects were screened for responses to all peptides by 
IFN-γ/IL-2 FluoroSpot.
Results: We observed a trend in the preferential targeting of 
sector 3 residues by LTNPs (p=0.07). This trend was not observed 
for any other sector or in total breadth of responses. Supporting 
the importance of sector 3 targeting, we found a significant 
positive correlation in our cohort between the relative proportion 
of sector 3 responses and CD4 count (r=0.49, p=0.04). We found 
no significant differences between LTNPs and HIV-Progressors 
in either the targeting of conserved 11-mers or overall Gag 
epitope variant recognition. Interestingly, LTNPs demonstrated 
higher levels of variant recognition than HIV-progressors when 
considering only the variable regions containing sector 3 residues.
Conclusion: We found that preferential targeting of sector 3 
residues distinguished Gag-specific responses between LTNPs 
and HIV-progressors, and that coordinated targeting of sector 
3 residues may require cross-reactive responses. Additional 
investigations are ongoing to elucidate the role of sector 3 
targeting in immune control of HIV. 
P11.35
Peripheral T Follicular Helper Cells from H1N1/09 
Vaccine Nonresponders Fail to Induce Antigen-
Specific Antibody Production In Vitro
A. Parmigiani1, S. Pallikkuth1, S.Y. Silva1, M. Fischl1, R. Pahwa1, 
S. Pahwa1
1University of Miami, Miami, FL, USA
Background: Mechanisms underlying poor Ab responses to 
vaccines in well controlled HIV infected patients are not fully 
understood. In this study we have examined the role of a 
novel subset, the peripheral T follicular helper cells (pTFH) in 
Ab production.
Methods: The study was conducted in cryopreserved cells of 
16 HIV-infected, ART-treated individuals and 8 healthy donors 
(HD) who had been given a single dose of H1N1/09 influenza 
vaccine in 2009. Only 8 of the 16 patients and all HD had a flu-
Ab response at 4 wks post vaccination. Vaccine responder (VR) 
and non responder (VNR) patients were equivalent in mean age, 
viral load, CD4 and CD8 T and B cells. B (CD20+) and TFH (CD3+ 
CD4+ CD45RA– CXCR5+) cells were purified by cell sorting on a 
FACS ARIA and co-cultured. IgG levels in culture supernatants 
were determined by ELISA. B and T cell phenotypic analysis was 
performed by multicolor flow cytometry. Differences between 
groups were analyzed by Student t-test or the 2-sample Wilcoxon 
rank-sum (Mann-Whitney) test.
Results: Frequency of pTFH was equivalent in HIV+ patients 
and HD before vaccination. pTFH cells underwent significant 
expansion at wk4 compared to baseline in VR patients (p= 0.003) 
and HD (p= 0.001) with increased frequency of Ki67+ cells. In VR, 
H1N1-specific IgG production was evident in CD4+ CXCR5+/B cell 
co-cultures but not in CD4+ CXCR5–/B cell co-cultures [HIV+ n = 
3; p = 0.043] and [HD n=3; p = 0.014], concurrently with increase 
in frequencies of plasmablasts. These changes were not seen in 
vaccine nonresponders.
Conclusion: pTFH cells promote antigen-specific Ab production 
by B cells in vitro. Although their relationship to lymph node 
germinal center TFH has not been clarified, analysis of pTFH 
function represents a novel and easily accessible surrogate 
marker for vaccine responsiveness in stable HIV infected patients 
with equivalent CD4 T cells.
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A High-Dimensional Immune Monitoring Model 
of HIV-1-Specific CD8 T Cell Responses Accurately 
Identifies Subjects Achieving Spontaneous Viral 
Control
Z.M. Ndhlovu1, L. Chibnik2, J. Proudfoot1, S. Vine1, A. McMullen1, 
K. Cesa1, F. Porichis1, D. Alvino1, A. Piechocka-Trocha1,  
P. De Jager3, B.D. Walker1, D. Kaufmann1
1Ragon Institute of MGH, MIT and Harvard, Charlestown, MA, 
USA; 2Brigham and Women’s Hospital & Harvard Medical 
school, Boston, MA, USA; 3Brigham and Women’s Hospital & 
Harvard Medical School, Boston, MA, USA
Background: The development of immune monitoring models 
to determine HIV-1 vaccine efficacy is a major challenge. HIV-
1-specific CD8 T cells likely play a critical role in individuals 
achieving spontaneous viral control (HIV-1 controllers) and will 
be important in immune interventions. However, no single CD8 T 
cell function is uniquely associated with controller status. 
Methods: Here we describe the building of immune monitoring 
models based on inter- and intra-donor analysis of HIV-1-specific 
CD8 T cell proliferation and cytokine secretion assessed at 
different time points after antigen stimulation. The discovery 
data set used to build a palette of immune monitoring models 
of HIV-1-specific CD8 T cell functions was generated on 26 
controllers, 15 progressors and 23 ART-treated subjects. An 
independent cohort of 10 controllers and 10 progressors was 
investigated to validate our results. We used Area Under the 
Receiving Operating Characteristic curves (AUC) to assess the 
ability of individual variables to differentiate between controllers 
and non-controllers. 
Results: Our analyses identified links between HIV-1-specific 
CD8 T functions, HLA-I alleles, and disease stage. The best 
accuracy (AUC) values were observed for proliferation. 
Early (6h) IL-2 secretion and slopes of TNF-α, IL-2 and IFN-γ 
production also contributed to the models whereas gender and 
age had no discriminatory value. A model incorporating five 
HIV-1-specific CD8 T cell functions achieved 90% accuracy in 
the discovery cohort on which it was trained, and was able to 
accurately discriminate controllers from non-controllers in the 
validation cohort.
Conclusion: Our multidimensional modeling approach shows 
that integration of different dimensions of data leverages 
independent associations and discriminates much better than 
any one measure. This modeling approach is amenable to 
incremental incorporation of new knowledge to build evolving 
flexible tools that are usable in translational clinical research 
and thus, has important applications in predictive model 
development and immune monitoring of HIV-1 vaccine trials.
P11.37
Identification of HIV-1-Specific Regulatory T Cells 
Using HLA-Class-II Tetramers
M. Angin1, P.L. Klarenbeek2, M. King1, K.W. Wucherpfennig3, 
M.M. Addo1
1Ragon Institute of MGH, MIT and Harvard, Boston, MA, USA; 
2Brigham and Women’s Hospital, Boston, MA, USA; 3Dana-
Farber Cancer Institute, Boston, MA, USA
Background: Regulatory T cells (Tregs) are potent immune 
modulators whose role in HIV-1 immuno-pathogenesis remains 
inadequately understood. While “bulk” Treg populations have 
been studied extensively in the context of HIV-1 infection, no 
reliable data is available on HIV-1 specificity of Tregs and induction 
of these cells in infected individuals or vaccine recipients.
Part of the challenge in detecting antigen-specific Treg 
populations relates to the limited availability of visualization 
tools and the scarcity of the overall human Treg population 
-representing roughly 5% of CD4+ T cells with absolute Treg 
numbers further decreasing during HIV-1 disease progression.
Methods: In order to screen for HIV-1 specific regulatory 
T cell populations, we first flow-sorted and expanded 
CD4+CD25+CD127low Tregs ex vivo from HLA DRB1*0401 
expressing HIV-1 infected individuals. Expanded Tregs underwent 
analysis of function, phenotype, deep TCR sequencing and 
epigenetic analysis. Treg lines were then stained with HLA class II 
tetramers specific for HIV-p24-gag and appropriate controls.
Results: Expanded Tregs were highly suppressive and displayed 
the phenotype of “activated” Tregs. Tregs were highly 
demethylated at the TSDR as shown by epigenetic analysis 
of the FOXP3 gene and showed an unskewed TCR repertoire 
compared to unexpanded ex vivo-sorted Tregs. Staining with 
HLA-class-II-tetramers specific for the HIV-p24-Gag epitope 
DRFYKTLRAEQASQ revealed a detectable response in one 
subject (an individual with chronic untreated progressive HIV-1 
infection), at a frequency of 0.19% of CD4+ T cells in the non-
enriched Treg culture. After tetramer-positive T cell enrichment, 
this frequency was increased to 6.14%.
Conclusion: Our data represent the first identification of HIV-1-
epitope-specific Tregs in HIV-1 infected individuals. Identification 
and further functional characterization of HIV-1 specific Tregs will 
provide important insight for the evaluation of vaccine strategies 
as these may lead to induction of not only HIV-1-specific effector 
populations but also HIV-1-specific regulatory T cells, which may 
negatively impact vaccine immunogenicity.
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P11.39
The HIV-1 Protective -35SNP Effect in Caucasians Is 
CD8 T Cell Mediated
T. Corrah1, S. Brackenridge2, N. Goonetilleke2, H. Yang2, S. Deeks3, 
L. Dorrell2, M. Cohen4, A. McMichael2
1Addenbrooks Hospital, University of Cambridge, Cambridge, 
United Kingdom (Great Britain); 2Weatherall Institute of 
Molecular Medicine, University of Oxford, Oxford, United 
Kingdom (Great Britain); 3University of California San 
Francisco, San Francisco, CA, USA; 4University of North 
Carolina School of Medicine, NC, USA
Background: Previous studies in Caucasians have observed that 
a single nucleotide polymorphism 35kb upstream of the HLA-C 
gene (-35SNP) associates with control of HIV-1 viral load set-
point and cell surface expression of HLA-C. HIV-1 selectively 
downregulates HLA-A and HLA-B but not HLA-C, via the action 
of the Nef protein. Thus it has been speculated that higher cell 
surface HLA-C expression results in a stronger HLA-C-restricted 
T cell response which might play a role in the control of HIV-
1 replication in individuals with the protective -35C variant. 
However, HLA-C-restricted CD8 T cell responses are relatively 
weak and we could find no difference in functional HLA-C-
restricted CD8 T cell activity measured by IFN-γ ELISPOT assay, 
according to -35SNP genotype. Therefore, we aimed to examine 
if there is any correlation between total CD8 T cell function and 
the -35SNP.
Methods: The viral suppression assay, which involves directly 
infecting autologous CD4 T cells with primary HIV-1 strains 
and co-culturing with autologous CD8 T cells, was used as a 
surrogate for immune control in vivo. The CD8 T cells from 46 
antiretroviral therapy naïve HIV-1 infected Caucasians were 
assessed using this assay.
Results: When CD8 T cell antiviral activity was grouped 
according to -35SNP genotype, the -35CC group possessed 
significantly higher CD8 T cell antiviral activity than the -35TT 
group (p=0.0151; Mann-Whitney). Protective HLA-B alleles were 
always in linkage disequilibrium with HLA-C alleles that are in 
linkage disequilibrium with the -35C allele. Similarly risk HLA-B 
alleles were in linkage disequilibrium with HLA-C alleles that are 
in linkage disequilibrium with the -35T allele.
Conclusion: In conclusion, the protective -35SNP effect in HIV-1 
disease is mediated through CD8 T cells. However, the -35SNP 
may simply be a marker for protective and risk HLA-B alleles.
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Plasticity of HIV-Specific CD8 T Cell Responses 
In Untreated HIV-1 Infection- A Step Towards 
A Therapeutic Vaccine Against Drug Resistance 
Mutations
J. Roider1, A. Kalteis1, T. Vollbrecht1, L. Gloning1, R. Stirner1,  
N. Henrich1, J.R. Bogner1, R. Draenert1
1University of Munich, Munich, Germany
Background: For a therapeutic HIV-1 vaccine, it should be 
considered that the immune system has been confronted with 
a certain viral sequence and mounted CD8 T cell responses 
specifically towards the infecting virus. One question is whether 
the immune system of HIV-infected individuals can create a new 
response towards a variant epitope in the case of vaccination. To 
study this in a comparable setting, we addressed the question 
how frequently a new CD8 T cell response can be generated 
after the occurrence of a viral escape mutation in its recognized 
epitope in a population not selected for a certain HLA allele. 
Methods: 19 HIV-infected untreated subjects were sampled 
longitudinally (>6 months. We searched for CD8 T cell responses 
that declined over the course of untreated infection and 
sequenced the autologous virus of the early and late time point 
by RT-PCR. Recognition of wildtype and newly arising sequences 
was compared in peptide titration assays.
Results: A total of 30 declining CD8 T cell responses were studied 
in detail and viral sequence analyses showed amino acid changes 
in 25 (83%) of these. Peptide titration assays revealed 12 (48%) 
viral escape mutations with 2 de-novo responses (17%). Here the 
de-novo response showed less effector functions than the original 
CD8 T cell response. In addition we identified 5 (20%) shifts in 
immunodominance. None of the subjects with adaptation to the 
changing virus carried the HLA alleles B27, B57 or B*5801.
Conclusion: Our results show that CD8 T cell responses can 
adapt to the mutations of HIV. However it was limited to only 
28% (7 out of 25) of cases in a cohort not expressing protective 
HLA alleles.
P11.41 LB 
Chronic Progressive HIV-1 Infection Is Associated With 
Elevated Levels Of Myeloid-Derived Suppressor Cells
T. Vollbrecht1, J. Roider1, R. Stirner1, A. Tufman1, R.M. Huber1, 
J.R. Bogner1, A. Lechner1, C. Bourquin2, R. Draenert1
1Ludwig-Maximilians-University, Munich, Germany; 2University 
of Fribourg, Fribourg, Switzerland
Background: Myeloid-derived suppressor cells (MDSC) have 
been described as suppressors of T cell functions in many tumor 
models. However MDSC in HIV-1 infection have not been studied 
to date. As impaired T cell function is a hallmark of chronic 
progressive HIV-1 infection, we hypothesized that MDSC also 
play a role here. 
Methods: Surface staining and FACS analysis were performed on 
freshly isolated PBMC of HIV-infected individuals and compared 
to healthy controls and individuals with lung carcinoma. MDSC 
of late-stage HIV-infected subjects were isolated using magnetic 
beads and co-cultured with the respective CD8 T cells for 
evaluation of proliferative capacity.
Results: We found that chronically HIV-infected HAART-naïve 
individuals had significantly higher CD11b+CD14-CD33+CD15+ 
MDSC levels than healthy controls (p=0.01). MDSC frequencies 
showed a positive correlation with viral load (r2=0.24, p=0.0002) 
and a negative correlation with CD4 count (r2=0.29, p<0.0001). 
Initiation of HAART led to a rapid drop in MDSC levels. MDSC from 
HIV-infected progressors restricted the proliferative capacity of 
CD8 T cells from healthy donors and of Gag/Nef-specific CD8 T 
cells from HIV-controllers in vitro. Furthermore CD11b+CD14-
CD33+CD15+ MDSC induced the expansion of CD4+CD25+FoxP3+ 
regulatory T cells when co-incubated with PBMC from controllers 
in vitro.
Conclusion: We conclude that chronic uncontrolled HIV-infection 
is associated with elevated levels of MDSC which potentially 
contribute to the impaired T cell responses characteristic for the 
progressive disease stage.
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Comparable Antiviral Capacity but Favorable In Vitro 
Survival of CD8s from Elite Controllers Compared to 
Untreated Progressors
D. Shasha1, F. Porichis1, K. Daniel1, O. Angiuli1, D.E. Kaufmann1, 
B. Walker11
1The Ragon Institute of MGH, MIT and Harvard, Boston, MA, 
USA
Background: CD8s inhibition of viral replication in vitro was 
demonstrated as one of the best laboratory correlates to HIV 
control. However, past studies invariably used CD8s which were 
rested in vitro for few days before antiviral capacity examined. 
This might suggest that the difference between CD8s from elite 
controllers (EC) and chronic progressors (CP) is not in their 
inhibition capacity but in their ability to retain cytotoxicity during 
prolonged incubation. Here we compared cytotoxicity and 
apoptosis of CD8s immediately after their purification (“fresh 
CD8s”) or 3 days after in vitro rest (“old CD8s”)
Methods: Samples from 10 EC, 10 CP, 5 HAART treated and 5 HIV 
negative patients were examined. “Fresh” and “old” CD8s were 
used as effectors in viral inhibition assays. HIV-specific CD8s were 
quantified using tetramer staining. Annexin V binding was used 
to evaluate apoptosis.
Results: Using “old” CD8s inhibition capacity was higher among 
EC compared to CP (logP24 reduction 1.225 vs 0.238, p=0.044). 
For both EC and CP inhibition was much stronger using “fresh” 
CD8s, but no significant difference was found between EC and CP 
(logP24 reduction: 3.13 vs 3.85, p=0.29). HIV negative subjects 
showed no inhibition using “fresh” or “old” CD8s. IL-2 partially 
rescued antiviral capacity of rested CD8s. Loss of HIV-specific 
CD8s measured by tetramer staining was higher in CP compared 
to EC with up to 10-fold increase in Annexin V binding
Conclusion: HIV-specific CD8s from CP are endowed with an 
unexpectedly strong viral inhibition capacity when examined 
directly ex vivo. CD8s from EC and CP mediated similar HIV 
suppression directly ex vivo, while the superior antiviral activity 
of CD8s from EC after a 3d incubation was associated with better 
survival of HIV-specific CD8s. The capacity to survive and exert 
effector functions over extended periods, rather than the intrinsic 
antiviral capacity, best distinguishes CD8s from EC and CP.
P11.43 LB 
The Early Th17/Treg Ratio Predicts The Immune 
Activation Set Point In Patients With Primary HIV 
Infection
M.F. Chevalier1, G. Petitjean2, C. Didier2, P. Girard3, L. Meyer4,  
F. Barré-Sinoussi2, D. Scott-Algara2, L. Weiss5
1Institut Pasteur; Université Paris Diderot, Paris, France; 
2Institut Pasteur, Paris, France; 3AP-HP Hôpital Saint-Antoine, 
Paris, France; 4INSERM U1018, Paris, France; 5Université Paris 
Descartes; AP-HP; Institut Pasteur, Paris, France
Background: Persistent systemic immune activation plays a 
central role in the pathogenesis of HIV disease. Impairment of 
the intestinal barrier and subsequent microbial translocation 
might be involved in chronic immune activation. Th17 cells are 
important in the maintenance of intact epithelium and host 
defense against extracellular pathogens. The ratio between the 
two closely related CD4 subsets Th17 and Tregs has been recently 
found to shrink with HIV/SIV disease progression. The aim of the 
study was to analyze, in patients with early primary HIV infection 
(PHI), the relationship between Th17/Treg ratio and the immune 
activation set point, known to predict disease progression.
Methods: 27 patients with early PHI were included in a 
prospective longitudinal study and followed-up for 6 months. 
T-cell activation and CD4+CD25+CD127lowFoxp3+ Treg frequency 
were assessed on fresh PBMC. Th17 cells were quantified by 
intracellular cytokine staining on sorted peripheral CD4 T cells 
stimulated with PMA/ionomycin for 5h. Correlations were 
assessed using spearman non-parametric tests. Plasma I-FABP, 
a marker of mucosal damages and soluble CD14 (sCD14) were 
measured by ELISA.
Results: A strong negative relationship was found at baseline 
between the Th17/Treg ratio and the proportion of activated CD8 
T cells expressing CD38/HLA-DR (p=0.008) or Ki-67 (P=0.001). At 
baseline, Th17/Treg ratios also negatively correlated with sCD14 
plasma levels (p=0.003). I-FABP levels, which were similar to 
controls at baseline, increased at month 6. The Th17/Treg ratio 
at baseline (but not the proportion of Th17 cells) negatively 
correlated with the frequency of HLA-DR+CD38+ or Ki-67+ CD8 
T cells at month 6, defining the immune activation set point 
(p=0.02 and p=0.0005 respectively). sCD14 plasma levels were 
also found to predict the immune set point (p=0.02).
Conclusion: Our data do not support early mucosal damages in 
PHI. However, the early Th17/Treg balance correlates with sCD14 
levels and predicts the immune activation set point.
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Comparison of the Depth of Vaccine-Elicited HIV-1 
Env Epitope-Specific CD8+ T Lymphocyte Responses
S.L. Hulot1, B.T. Korber2, G. Pantaleo3, J. Tartaglia4, B. Jacobs5, 
B. Perdiguero6, C.E. Gomez6, M. Esteban6, N. . Letvin1,  
M.S. Seaman1, B. . Haynes7, S. Santra1
1Beth Israel Deaconess Medical Center, Boston, MA, USA; 
2Los Alamos National Laboratory, Los Alamos, NM, USA; 
3Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, 
Switzerland; 4Sanofi Pasteur, Toronto, Canada; 5Center for 
Infectious Diseases and Vaccinology, Tempe, AZ, USA; 6Centro 
Nacional de Biotecnologia, Madrid, Spain; 7Duke University 
Medical Center / Duke Human Vaccine Institute, Durham, NC, 
USA
Background: One of the major challenges in the development of 
an effective HIV-1 vaccine is the extraordinary genetic diversity of 
the virus. Immunizations of nonhuman primates using consensus 
and mosaic immunogens have been shown to elicit cross-reactive 
CD8+T lymphocyte responses that increase the depth of epitope 
recognition. However, one of the limitations of vaccine-induced 
epitope-specific CD8+T lymphocytes includes lack of protection 
against diverse strains and emergent forms of HIV-1 due to 
altered T cell receptor (TCR) affinity for variant peptide:MHC 
class I complexes.
Methods: In this study, we immunized a cohort of fifteen 
Mamu-A*01+ rhesus monkeys with either a 3-valent mosaic 
Env, group M consensus Env, or single clade B Env vaccine and 
compared the ability of the CD8+T lymphocyte populations 
elicited by each immunogen to recognize variants of an HIV-1 
envelope epitope sequence p41A (YI9). We identified vaccine-
induced CD8+T lymphocytes populations using tetramers 
constructed with 9 variants of p41A epitope. We assessed the 
ability of those variant peptides to activate CTL by measuring 
cytokine production and CD107a expression. We evaluated 
proliferation using carboxyfluorescein succinimidyl ester. 
Finally, we investigated the functional avidity of these CD8+T 
lymphocytes for the variant peptide:Mamu-A*01 complexes 
using surface plasmon resonance technology.
Results: Our data show that Env immunizations can generate 
cross-reactive CD8+T lymphocytes that recognize 2 of 9 (22%) 
of the variants of p41A epitope, with higher responses induced 
by the consensus and the 3-valent mosaic immunogens (variant 
from clade C and variant from clade A/E) compared to the single 
clade Env immunogen. Tetramer-binding data also show that 
CD8+ T lymphocytes from monkeys immunized with mosaic 
immunogen have a trend of higher binding to majority of the 
variant peptides tested. 
Conclusion: This underscores the potential of mosaic 
immunogens for generating cellular immune responses with 
greater depth. 
P11.45 LB 
Loss and Regain of SIV Control Upon CD8+ Cell 
Depletion In Vivo In SIV-Controller Macaques Is Not 
Associated With Efficient SIV Specific CD8+ T-Cells
C. Hamimi1, T. Bruel2, N. Dereuddre-Bosquet2, A. Cosma2,  
S. Shin1, A. Corneau3, P. Versmisse1, C. Torres3, B. Delache3,  
S. Even3, S. Guenounou3, B. Targat3, B. Malleret3, I. Karlsson3,  
F. Barré-Sinoussi1, R. Le-Grand3, G. Pancino1, A. Saez-Cirion1,  
B. Vaslin3
1Institut pasteur, Paris, France; 2CEA, Division of Immuno-
Virology, Institute of Emerging Diseases, Paris, France; 3CEA, 
Division of Immuno-Virology, Institute of Emerging Diseases 
and I, Paris, France
Background: Spontaneous long-term HIV/SIV control in HIV-
controller patients and SIV-controller macaques (SIC) is usually 
associated to protective MHC-class-I alleles and efficient CD8 
T-cell responses. However, many HIV-controllers efficiently 
control HIV-infection despite of non-protective MHC background 
and weak CD8 T-cell responses, raising the question of real 
contribution of this response in maintaining viral control. We 
addressed this question by depleting in vivo CD8+ cells in SIC 
bearing or not protective MHC and weak CD8 T-cell responses.
Methods: We studied five SIVmac251</sub>-infected cynomolgous 
macaques which maintained viremia <400 RNA copies/ml during 
5 years. We transiently depleted CD8+ cells in vivo in these 
animals by injection of anti-CD8 mAb. We analysed, in blood and 
tissues, the viral load evolution, T-cell frequency and activation, 
SIV-specific T-cell functionality and plasma cytokine levels.
Results: CD8+ -depletion in blood and tissues lasted between 
10-21 days. One SIC kept undetectable viremia during depletion 
despite carrying infectious and in vitro inducible SIVmac251 in CD4 
T-cells. Four SIC experienced a viral rebound (3.103 -7.104 RNA 
copies/ml) but were able to subsequently re-control viremia to 
baseline levels (17-21 days post-depletion). In two SIC, regain of 
viral control started despite CD8+ T-cells being still undetectable. 
In the two other SIC, regain of viral control coincided temporally 
with the recovery of CD8 T-cells. However, CD8 T-cell recovery 
was accompanied by relatively weak expansion of SIV-specific 
CD8 T-cells with no acquisition of effector antiviral functions. 
Depletion provoked induction of pro-inflammatory cytokines 
and homeostatic activation/expansion of CD4+ T-cells, which 
correlated with plasma viremia (p=0.0006).
Conclusion: Our results suggest that SIV-specific CD8 T-cell 
responses are likely not the major contributor for the long-
term maintainance of SIV-control in this SIC model. Other 
mechanisms, including weak viral reservoirs and control of 
activation, may contribute to viral control. Our SIC model will 
be useful to investigate mechanisms contributing to natural 
HIV-control in humans.
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IL-7 Abrogates Memory T Regulatory Cell Functions 
By Modulation of CD39/ATP Axis In Vitro And In Vivo 
In HIV Infected And Non-Infected Patients
M. Younas1, S. Hue1, M. Surenaud1, C. Lacabaratz1, A. Guiguin1, 
A. Wiedman1, S. Becq2, T. Croughs2, J. Lelievre1, Y. Levy1
1Faculté de médecine, Université Paris-Est, Créteil, Créteil, 
France; 2Cytheris, France
Background: IL-7 cytokine regulate the expansion and 
maturation of T cells. The good safety profile of IL-7 raises the 
opportunity of its use as a vaccine adjuvant. However, its role 
on the regulation of T cell responses has not been explored. 
We investigated the effects of IL-7 on regulatory T cell (Treg) 
functions invitro and invivo.
Methods: Treg and CD8+ T cells were isolated from healthy 
donors (n=10) (HD) and chronically HAART treated HIV+ pt 
enrolled in a phase I/II IL-7 INSPIRE study (n=6X) (Levy et al, 
CID, in press). Treg subpopulations (naïve CD45RA+FoxP3++CD
45RA+CD25++CD127+/-, memory (mTreg) Foxp3highCD45RA-
CD25highCD127low, FoxP3++CD45RA-CD25++CD127+/-) were 
cultured with IL-7 (10 ng/ml). Phenotype (CD39, Bcl-2, Stat5P, 
purinergic receptor P2X7R), suppression of the proliferation of 
autologous antiCD3 activated CD8+ T cells (CFSE stained) and 
cytokine profile (IL-17 production) of Treg were analyzed.
Results: In HD, IL-7 induces expression of STAT5 and BCL-2 on all 
Treg populations. IL-7 reduces the suppressive effects of mTreg 
on CD8+ proliferation (% CFSE low w/wo IL7 was 15% and 40%, 
respectively, n=4, P=0.01). This effect was associated with a down-
modulation of CD39 enzyme (MFI 65 vs 90 w/wo IL7, P=0.01) 
and an increase of P2X7R expression. IL-7 effect was reproduced 
using anti-CD39 blocking antibody and PPAD (inhibitor of P2X7R). 
IL-7 incubated Treg switched to a Th17 phenotype as assessed 
by the increase of Th17 production and RORgC expression. IL-7 
treated patients exhibited a decrease of the frequency of Treg/
CD39+ and an increase of RORgC mRNA in PBMCs as compared 
to pre-IL-7 therapy.
Conclusion: IL-7 relieves the suppressive effect of mTreg 
through a modulation of the CD39/ATP axis. By increasing P2X7R 
expression, IL-7 increases the susceptibility of these cells to ATP, 
a trigger of Th17 differentiation. An effect also observed in IL-7 
treated patients. These results suggest that IL-7 could be used as 
adjuvant to reinforce T cell responses.
P11.47 LB 
Understanding The Precursor Frequencies of HIV-1 
Specific CD4+ T Cells In Seronegative Donors
S.L. Campion1, T. Brodie2, A. Rossetti2, N. Goonetilleke1,  
F. Sallusto2, A. McMichael1
1University Of Oxford, Oxford, United Kingdom (Great Britain); 
2IRB, Bellinzona, Switzerland
Background: HIV-1 specific T cell responses are detectable 
amongst a proportion of HIV-1 exposed, seronegative 
individuals. Previous studies from our group have demonstrated 
these responses are predominately mediated by CD4+ T cells 
and can be mapped and titrated at the peptide level. Curiously, 
approximately 1 in 4 HIV-1 un-exposed seronegative donors 
also have demonstrable HIV-1 specific T cell responses. This 
observation raises a number of questions regarding the ontogeny 
of pre-existing HIV-1 specific T cells and their potential role in the 
acquisition of HIV-1 
Methods: A highly sensitive T cell library method was used 
to screen the naïve, central and effector memory CD4+ T cell 
subsets from 10 healthy, HIV-1 seronegative, leukapharesis 
donors. 192 cell lines per subset were screened against pools 
of overlapping 18mer peptides, spanning the entire HIV-1 
proteome and proliferative responses quantified using tritiated 
thymidine incorporation.
Results: HIV-1 specific CD4+ T cell response were detectable 
within the CD4+ T cell memory compartments of all 10 subjects 
tested, albeit at low frequency. HIV-1 specific CD4+ T cell 
responses spanned the entire HIV-1 proteome and were typically 
of low avidity. There was considerable variability between donors 
both in the proteins recognized and precursor frequencies of 
HIV-1 specific T cell responses. However, across all subsets tested 
CD4+ T cells specific for HIV-1 envelope appeared to exist at 
the highest precursor frequency, with Pol seemingly the least 
frequently targeted.
Conclusion: We show HIV-1 specific CD4+ T cells to be 
detectable within the memory compartment of all 10 donors 
tested. In the absence of known prior exposure to HIV-1 these 
observations are indicative of low level cross reactivity within 
the immune system. The use of the T cell library technique to 
interrogate the naïve and memory precursor frequencies of 
HIV-1 specific T cells should prove beneficial in the design of 
novel therapeutic vaccines.
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Improving Immunogenicity of HIV-1 Envelope gp120 
by Glycan Removal and Immune Complex Formation
R. Kumar1, M. Tuen1, H. Li1, D.B. Tse2, C.E. Hioe1
1New York University School of Medicine, New York, NY, USA; 
2NYU School of Medicine, Department of Medicine, NY, NY, 
USA
Background: HIV-1 envelope (Env) gp120 is an important target 
for neutralizing antibody (Ab) responses against the virus. 
However, developing gp120 vaccines that elicit potent and broad 
neutralizing Abs has proven to be a formidable challenge. The 
envelope gp120 is highly glycosylated and carbohydrate moieties 
play an important role in modulation of immunobiological 
property of HIV-1 Env gp120. Previously, removal of a specific 
N-linked glycan at residue 448 by N to Q mutation (N448Q) 
has been found to enhance in vitro antigenicity of neutralizing 
epitopes in the V3 loop. In the present study we examined 
immunogenicity of mutant gp120 in mice.
Methods: Two immunization protocols were tested. First, using 
plasmid DNA expressing gp120BH10 followed by protein boost 
with QS-21 adjuvant. Second, gp120 was administered as an 
immune complex with antibody in DDA/MPL adjuvant. Cellular 
responses were measured using spleen cell proliferation and 
cytokine production by Bio-Plex multiplex assay. Sera were 
evaluated for antibody binding via ELISA and neutralization 
activity via TZM-bl assay
Results: With the DNA prime/protein boost protocol, N448Q 
gp120 mutant induced higher levels of gp120 specific 
lymphoproliferation and cytokine production as compared to 
wild type. However, both mutant and wild type gp120s failed 
to generate anti-V3 Abs and virus-neutralizing Ab response. 
In contrast, immunization with mutant gp120 in complex with 
mAb 654 elicited higher titers of neutralizing Abs activity than 
the wild type counterpart. Neutralizing activity was directed 
to V3 and other undefined neutralizing epitopes. Improved 
immunogenicity of immune complexes correlated with increased 
reactivity and proteolytic resistance of V3 and other Ab epitopes
Conclusion: These data demonstrate the advantage of combining 
site-specific N-glycan removal and immune complex formation 
as a novel vaccine strategy to improve immunogenicity of Ab 
epitopes on critical regions of HIV-1 gp120. Importantly, epitope 
immunogenicity is governed not only by its antigenicity but also 
by its stability against proteolytic degradation
P12.01
Construction of Site Selected Phage Library and 
Characterization of Anti-V3 scFvs from Indian Clade C 
HIV-1 Infected Patient
R. Kumar1, R. Andrabi1, A. Tiwari1, P. Somi Sankaran1, N. Wig1, 
D. Dutta1, A. Sankhyan1, L. Khan1, S. Sinha1, K. Luthra1
1All India Institute of Medical Sciences (AIIMS), New Delhi, 
India
Background: Till date, few broadly neutralizing antibodies 
are generated against HIV-1 and they have limited breadth 
and potency against clade C viruses, which are predominant 
worldwide and in India. Here we have produced nine different 
human scFvs against the V3 region of HIV-1 envelope.
Methods: A V3 specific phage library was constructed from EBV 
transformed B cells of a clade C HIV-1 infected Indian patient, 
whose plasma exhibited good neutralization potential against 
a panel of viruses. Diversity of the constructed phage library 
was analysed by DNA fingerprinting of 10 randomly selected 
clones from the unselected library using BstN1 enzyme. One 
round of biopanning was done against HIV-1 consensus V3C and 
V3B peptides. scFvs were than characterised for their binding, 
specifity and expression profile. VH and VL genes of anti-V3 scFvs 
were sequenced for their preferential gene usage. 
Results: DNA fingerprinting analysis of clones from unselected 
library showed that 90% of clones in the library were distinct. 
Thirty clones were randomly selected after biopanning. Nine 
clones showed binding in phage ELISA and exhibited a unique 
DNA fingerprint. Soluble expression of the selected scFvs was 
checked by SDS-PAGE and confirmed by Western blot. All the 
nine anti-V3 scFvs showed cross-reactivity against both the V3 
peptides and did not bind to unrelated peptides. Distribution of 
VH gene segments of these anti-V3 scFvs were different, 56% 
(5/9) of scFvs used VH4, thirty 33% (3/9) VH5 and 11% (1/9) 
showed VH3 gene usage. Among the light chains, IGKV1 and 
IGKV3 were most preferentially used gene segments. Further 
these scFvs displayed a stable binding to V3 peptides in different 
denaturing agents.
Conclusion: This is the first study to generate human anti-V3 
scFvs against HIV-1 clade C. Further characterization of these 
scFvs for their neutralization potential and epitope mapping will 
provide useful information for immunogen design. 
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Simian Immunodeficiency Virus-Vpx as an Adjuvant 
for Integrase Defective Lentiviral Vector-Based 
Vaccines
M. Blasi1, A. Rossi2, Z. Michelini2, P. Leone2, G. Perretta3,  
A. Cimarelli4, M.E. Klotman1, D. Negri2, A. Cara2
1Duke University School of Medicine, Durham, NC, USA; 
2Istituto Superiore di Sanita’, Roma, Italy; 3Istituto di Biologia 
Cellulare e Neurobiologia-CNR ENEA-Casaccia, Roma, Italy; 
4Ecole Normale Superieure de Lyon, Lyon, FL, France
Background: Integrase defective lentiviral vectors (IDLV) 
represent a promising delivery system for immunization 
purposes. Human dendritic cells (DC) are the main cell types 
mediating the immune response and are readily transduced 
by IDLV, allowing effective triggering of in vitro expansion of 
antigen-specific primed CD8+ T cells. However, DC transduction 
efficiency is hindered by the presence of SAMHD1 restriction 
factor, which inhibits viral DNA synthesis.
Methods: IDLV expressing Flu-M1 containing simian 
immunodeficiency virus (SIV)-Vpx was produced and titred 
on 293T by standard methods. Monocytes from HLA-A*0201 
and M1-positive selected donors were differentiated into 
DC and transduced with IDLV-M1/Vpx and control IDLV/M1 
or left untreated. IDLV-transduced DC were co-cultured with 
autologous PBMC and the expansion of M1-specific CD8+ T cells 
was analysed by pentamer staining and IFN_ ELISPOT
Results: The addition of the SIV-Vpx protein during IDLV 
preparation resulted in a striking improvement of IDLV 
transduction of human DC, thus increasing the ability of IDLV-
transduced DC to act as functional antigen presenting cells, as 
evaluated by pentamer staining and IFN_ ELISPOT, in the absence 
of vector integration. Importantly, the presence of SIV-Vpx allows 
for the use of lower amount of input vector preparation, further 
improving the safety profile of IDLV.
Conclusion: These results have important implications for the 
development of vaccine strategies based on the use of IDLV as a 
novel, safe and efficient delivery system.
P12.03
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Further Confirmation of Broadly Conserved, Highly 
Immunogenic Cross-Clade HIV CTL Epitopes for 
Inclusion in the GAIA HIV Vaccine
A.S. De Groot1, L. Moise1, O. Koita2, K. Sangare2, L. Levitz1,  
J. Rozenhal3, Z. Koty4, K. Tounkara4, M. Ardito1, C.M. Boyle1,  
M. Rochas4, W. Martin1
1EpiVax, Inc, Providence, RI, USA; 2University of Bamako, 
Bamako, Mali; 3Institute of Immunology and Informatics 
University of Rhode Island, Providence, RI, USA; 4GAIA Vaccine 
Foundation, Bamako, Mali
Background: One of the biggest challenges for HIV vaccine 
design is identifying conserved HLA Class I- and Class II-restricted 
epitopes that would impart substantial fitness cost to the virus, 
thereby controlling or preventing infection. Here, we set out to 
develop an epitope-driven, DNA-prime/pseudoprotein-boost 
HIV vaccine (GAIA vaccine) composed of such epitopes.
Methods: Analysis was performed in 2003 on 10,803 HIV-1 
sequences, and again in 2009, on an expanded set of 43,822 
sequences. These were searched for conserved 9-10-mer 
segments with the EpiMatrix suite of immunoinformatic 
algorithms. From the most highly conserved (>5% isolates) or 
top 1,000 scoring 9-mers, HLA Class I binding sequences and 
Class II immunogenic consensus sequences (ICS) were identified 
for vaccine design. Validation was performed in Thailand, the 
USA, and Mali via in vitro binding and IFN-γ ELISpot assays, 
using HIV-infected donor peripheral blood. HLA transgenic mice 
were immunized in DNA-prime/peptide-boost vaccine studies 
including these epitopes.
Results: Epitopes selected as described are more broadly 
conserved than those selected for other epitope-based vaccines 
(>70%, compared to Epimmune’s 40%). Antigenicity of 98% of 
ICS epitopes and Class I epitopes (87% A2, 29% A3, 67% B7, 20% 
A24) was confirmed in HIV-infected subjects. Fifteen ICS peptides 
and 12 A2 peptides were confirmed in both Mali and the USA. 
Sixteen A3 peptides were confirmed weighting sequences for 
conservation and immunogenicity (as determined by EpiMatrix 
score), in vitro binding, and positive ELISpot responses. Epitope 
immunogenicity was validated in HLA transgenic mouse 
immunization studies.
Conclusion: The GAIA vaccine approach is an effective means of 
triaging HIV epitope sequences to identify the most immunogenic 
and conserved epitope candidates across HLA allotypes. HLA 
transgenic mouse studies showed prototype DNA vaccines 
including these epitopes to be immunogenic, suggesting the 
epitope-rich GAIA vaccine would induce greater immunogenicity 
than other DNA/viral vector prime-boost vaccines in humans.
P12.05
Conservation of HIV-1 T Cell Epitopes Across Time 
and Clades: Validation of Immunogenic HLA-A2 
Epitopes Selected for the GAIA HIV Vaccine
A.S. De Groot1, K. Sangare2, O. Koita2, M. Ardito1, C. Boyle1,  
L. Levitz1, J. Rozenhal3, K. Tounkara4, S. Dao5, Y. Kone3, Z. Koty3, 
L. Moise1, W. Martin1
1EpiVax, Inc, Providence, RI, USA; 2University of Bamako, 
Bamako, Mali; 3GAIA Vaccine Foundation, Providence, RI, 
USA; 4GAIA Foundation, Bamako, Mali; 5Infectious Disease and 
Tropical Medicine Unit Point G, Bamako, Mali
Background: HIV genomic sequence variability has complicated 
efforts to generate an effective globally relevant vaccine. Our 
strategy for HIV-1 vaccine design is to select epitopes that can 
induce broad and dominant HLA-restricted immune responses 
targeted to the regions of the viral genome conserved in sequence, 
three-dimensional configuration, and across time which may 
represent regions that are constrained due to functional or 
structural limitations. These “Achilles’ Heel” epitopes would be 
ideal candidates for inclusion in an epitope-based HIV vaccine. 
Methods: Highly conserved T-cell epitopes were selected using 
the EpiMatrix suite of immunoinformatic tools. This analysis was 
first performed in 2002 on 10,803 HIV-1 sequences available at 
that time and again in 2009 on an expanded 43,822 sequences. 
Selected epitopes were validated for binding and immunogenicity 
with PBMCs from HIV-infected donors in Providence, RI and 
Bamako, Mali. 
Results: 38 highly conserved HLA-A2 candidate epitopes were 
selected. Analysis done in 2009 revealed surprising stability of 
25 of the epitopes selected in 2002 and identified an additional 
13 highly conserved HLA-A2 candidates. Thirty-five (92%) of the 
38 selected epitopes stimulated IFNg response in PBMC from 
at least one subject. Twenty-one of 25 peptides selected in 
2002 were validated in assays performed in Providence. Eleven 
(85%) of the 13 peptides selected in 2009 were confirmed in 
assays performed in Mali. Twelve of 18 peptides assayed in both 
Providence and Mali were confirmed in both locations.
Conclusion: The validation of these selected HLA-A2 epitopes 
conserved across time (2002-to-2009), geography (Providence 
and Mali) and clades supports the hypothesis that these 
epitopes could provide effective coverage of virus diversity 
and would be appropriate candidates for inclusion in a globally 
relevant HIV vaccine.
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Antigen Processing Sites in gp120 Are Conserved 
Across HIV Virus Clades
B. Yu1, S.M. O’Rourke1, J.F. Morales1, G.P. Tatsuno1, K.A. Mesa1, 
P.W. Berman1
1University of California, Santa Cruz, Santa Cruz, CA, USA
Background: A puzzling observation in HIV vaccine research is the 
fact that recombinant gp120 is able to adsorb bNAbs from HIV+ 
patient sera, but unable to elicit such bNAbs. To account for its 
poor immunogenicity, we wondered if the epitopes recognized 
by bNAbs might be proteolyzed in vivo. Cathepsins L, S, and D 
are the major proteases responsible for antigen processing and 
presentation. Previously, we defined the cathepsin cleavage sites 
on MN rgp120 and found that they co-localized with epitopes 
recognized by bNAbs. Although examination of gp120 sequences 
suggested that these sites were conserved, the recognition 
motifs for cathepsins are poorly defined and it was important to 
verify their presence by protease digestion studies.
Methods: Purified gp120s from three clades of HIV were digested 
with cathepsins L, S, and D. These included envelope proteins 
from the from the 108060 (clade B), A244 (CRF01_AE) and 97001 
(clade C) isolates. N-terminal sequencing was used to identify 
the cathepsin cleavage sites. 
Results: When combined with the previous MN-rgp120 results, 
we found that 6 out of 10 cathepsin cleavage sites were conserved 
in four viruses from three different clades of HIV. We found that 
polymorphisms that inactivate cleavage sites often result in the 
formation of an alternate nearby site. Although cleavage is an 
ordered processing beginning in the V3 domain, the cleavage 
sites in this domain are more polymorphic than other sites. 
Conclusion: Our results suggest that cathepsin cleavage sites are 
highly conserved in gp120 and co-localize to regions recognized 
by bNAbs. These results are consistent with our hypothesis 
that the poor immunogenicity of gp120 epitopes results from 
protease digestion in vivo. Current studies are in progress to 
determine whether inactivation of these sites or enzymes may 
provide a new approach to improving the immunogenicity of 
epitopes recognized by bNAbs. 
P12.07
Extensive Glycoform Heterogeneity in the gp120 
Envelope Proteins Used in the RV144 Trial 
B. Yu1, J.F. Morales1, S.M. O’Rourke1, G.P. Tatsuno1, P.W. Berman1
1University of California,Santa Cruz, Santa Cruz, CA, USA
Background: The AIDSVAX B/E vaccine used in the RV144 trial 
consisted of recombinant gp120s derived from the MN and 
A244 strains of HIV-1, both produced in CHO cells. In order 
to understand the correlates of protection and to design 
RV144 follow-up studies, it is important to characterize the 
vaccine immunogens and to know the extent to which newly 
manufactured gp120 subunit vaccines replicate the glycosylation 
of the AIDSVAX B/E vaccine immunogens. It has long been known 
that glycosylation affects antigenicity and immunogenicity. 
Recent data suggest that several epitopes recognized by broadly 
neutralizing antibodies are critically dependent on glycosylation 
in the gp120 V2 domain. In these studies we investigate the 
heterogeneity in net charge attributed to glycoform variation.
Methods: Isoelectric focusing was used to analyze recombinant 
MN and A244 rgp120 proteins from the unformulated bulk used 
to manufacture the AIDSVAX B/E vaccine. We compared these 
proteins with MN and A244 rgp120 proteins freshly produced in 
293 cells. Differences in the binding of monoclonal antibodies 
and soluble CD4 were measured by ELISA.
Results: MN and A244 rgp120 proteins produced in CHO cells 
and 293 cells exhibit extensive heterogeneity in net charge due 
to glycosylation. More than 16 species of MN-rgp120 and 24 
species of A244-rgp120 were identified. Proteins produced in 
CHO cells were distinctly more acidic than proteins produced in 
293 cells. These differences affected the binding of ligands that 
targeted the CD4 binding site but not other regions of gp120. 
Conclusion: The rgp120 proteins used in the RV144 trial exhibited 
remarkable variation in net charge attributable to differences 
in glycosylation. The extent of gp120 glycosylation is cell-line 
dependent. Differences in glycosylation affect antibody binding 
and may represent a significant variable in the development of 
new antigens for RV144 follow-up studies and in neutralization 
assays that depend on pseudoviruses produced in 293 cells.
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Stability and Neutralization Capacity of a Novel 
Mosaic HIV-1 gp140 Trimer in a Guinea Pig Model
J.P. Nkolola1, J.M. Kovacs2, B. Korber3, B. Chen2, M. Seaman4,  
D. Barouch1
1BIDMC / Ragon Institute of MGH, MIT and Harvard, Boston, 
MA, USA; 2Children’s Hospital Boston, Boston, MA, USA; 3Los 
Alamos National Laboratory, Los Alamos, NM, USA; 4Beth 
Israel Deaconess Medical Center, Boston, MA, USA
Background: The generation of globally relevant HIV-1 
immunogens mimicking native, trimeric Envelope (Env) structure, 
remains a major challenge for HIV-1 vaccine development. We 
identified a mosaic Env sequence, originally designed to optimize 
cellular immunologic coverage of global HIV-1 sequence 
diversity, which was capable of forming biochemically stable 
trimers. We assessed this mosaic Env gp140 trimer in guinea pig 
immunogenicity studies compared to our previously reported 
biochemically stable C97ZA012 (clade C) trimer.
Methods: Stable Env gp140 trimer derived from a synthetic 
mosaic sequence was stabilized with the T4-fibritin C-terminal 
trimerization tag and produced in 293T cells via PEI transfection. 
Characterization was performed by Western blotting, size-
exclusion chromatography and surface plasmon resonance 
(SPR). Guinea pigs were immunized three times with 100 µg 
of mosaic or clade C gp140 protein trimer in CpG/Emulsigen 
adjuvants. Antibody responses were determined by ELISA and 
TZM.bl neutralizing antibody assays.
Results: Stabilized mosaic gp140 trimer exhibited a single 
band by Western blotting, single peak by size-exclusion 
chromatography both after production, a freeze-thaw cycle 
and 7-day incubation at 4ºC. SPR analyses revealed mosaic 
gp140 binding with bNAb VRC01. The trimeric mosaic gp140 
immunogen elicited high-titer antibodies in guinea pigs by 
ELISA and high-titer, cross-clade neutralization activity against 
tier 1 viruses. When compared to clade C gp140 trimer, NAb 
responses generated by mosaic gp140 trimer were 8.2- and 
3.7-fold higher against clade B viruses (SF162.LS and Bal.26, 
respectively) but were 10.3- and 46.7-fold lower against clade 
A and C viruses (DJ263.8 and MW965.26, respectively).
Conclusion: A novel, foldon-stabilized mosaic gp140 trimer 
elicits high-titer binding antibodies as well as high-titer, cross-
clade neutralization of tier 1 viruses. The profile of the NAbs 
elicited by the mosaic trimer differed from that elicited by 
the clade C trimer. Further exploration and refinement of 
this concept may contribute to the development of a globally 
relevant Env immunogen. 
P12.09
Development of Chimeric HIV Env Immunogens for 
Mucosal Delivery with Attenuated Canine Distemper 
Virus (CDV) Vaccine Vectors
X. Zhang1, S. Richlak1, H.T. Nguyen1, O. Wallace1, G. Morrow1, 
M. Caulfield1, C. Parks1
1International AIDS Vaccine Initiative, Brooklyn, NY, USA
Background: Our aim is to develop replication-competent viral 
vectors for mucosal delivery, which express HIV-Env immunogens 
that closely mimic the trimeric glycoprotein spike found on HIV 
particles. We have developed attenuated recombinant CDV 
(rCDV) expressing SIVmac239-Env and shown that this vector can 
be used safely to elicit Env-specific immune responses in ferrets 
and non-human primates through intranasal administration. 
Methods: To augment the cell surface expression of trimeric 
HIV-Env and increase the replicative capacity of rCDV vectors 
encoding the HIV glycoprotein, we have constructed chimeric 
immunogens in which signal peptide (SP), transmembrane 
domain (TM), or cytoplasmic tail (CT) domains in HIV-Env have 
been replaced with analogous sequences from the vesicular 
stomatitis virus (VSV)-G or CDV-F glycoproteins and compared 
cell surface protein expression, antibody binding profiles and Env 
function in transient expression assays.
Results: Chimeric glycoprotein based on subtype C Env 
proteins were expressed on the surface of transfected cells 
in conformations recognized by various broadly neutralizing 
antibodies (bnAb) targeting distinct Env regions including VRC01, 
b12, and b6 specific for the CD4 binding site, PG9 and PG16 (V1/
V2), 4e10 (gp41) but not by PGT-126 (V3) and 2G12 (glycans). 
Moreover, treatment of transfected cells with soluble CD4 
induced conformational changes needed to expose epitopes for 
CD4 binding-dependent antibodies (17b, 48d and F425-A1g8). 
Recombinant CDV vectors encoding two chimeric Envs have 
been created. One is expressed most abundantly in transfected 
cells and contained the VSV SP and CDV TM-CT. The second is 
a highly fusogenic Env that contained the CDV SP and CDV CT. 
Both vectors expressed Env and are being further characterized 
in vitro and in vivo. 
Conclusion: Collectively, we have shown CDV can be used 
as a mucosal delivery vector for SIV-Env and that HIV-Env 
modifications can be made that improve cell surface expression 
of the trimeric glycoprotein containing structural determinants 
recognized by bnAbs.
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The Viral Vector Vaccine VSV-GP Boosts Immune 
Response upon Repeated Applications
R. Tober2, Z. Banki2, A. Ejaz2, A. Muik1, L. Egerer2, D. von Laer2, 
J. Kimpel2
1Applied Virology and Gene Therapy Unit, Georg-Speyer-Haus, 
Frankfurt, Germany; 2Innsbruck Medical University, Innsbruck, 
Austria
Background: Vesicular stomatitis virus (VSV) is a potent candidate 
vaccine vector for various viral diseases (e.g. HIV, HCV, RSV). The 
biggest limitation of VSV, however, is its neurotoxicity, which 
limits application in humans. The second drawback is that VSV 
induces neutralizing antibodies rapidly and is thus ineffective 
as a vaccine vector upon repeated applications. Our group has 
recently shown that VSV pseudotyped with the glycoprotein (GP) 
of the lymphocytic choriomeningitis virus (LCMV), VSV-GP, is not 
neurotoxic. The aim of this project was to evaluate the potential 
of VSV-GP as a vaccine vector. 
Methods: For this purpose, we used Ovalbumin (OVA) as a 
model antigen and analyzed immunogenicity of GP-pseudotyped 
and wildtype VSV containing OVA (VSV-GP-OVA and VSV-OVA) in 
vitro and in vivo in mouse models.
Results: We showed that both vectors infected murine bone 
marrow-derived dendritic cells (bmDCs) in vitro. These bmDCs 
were able to activate OVA specific CD8+ and CD4+ T cells. 
Immunization experiments in mice revealed that both VSV-OVA 
and VSV-GP-OVA induced functional OVA-specific cytotoxic T 
cells (CTLs) after a single immunization. In addition, with both 
viruses, mice generated antibodies against OVA. However, 
boosting with the same virus was only possible for the GP-
pseudotyped virus but not for wild type VSV. The efficacy of 
repeated immunization with VSV-OVA was most likely limited by 
high levels of neutralizing antibodies, which we detected after 
the first immunization. In contrast, no neutralizing antibodies 
against VSV-GP were induced even after boosting.
Conclusion: Taken together, we showed that the non-neurotoxic 
VSV-GP is able to induce specific T cell and B cell responses 
against the model antigen OVA to the same level as the wild 
type VSV vector. However, in contrast to wild type VSV, VSV-GP-
OVA boosted the immune response upon repeated applications. 
Thus, VSV-GP is a promising novel vaccine vector.
P12.11
Targeting HIV-1 Envelope Glycoprotein Trimers to B 
Cells Using APRIL Improves Antibody Responses
M. Melchers1, I. Bontjer1, T. Tong1, N. Chung1, P. Klasse1,  
D. Eggink1, M. Gentile1, A. Cerutti1, D. Montefiori1, W. Olson1,  
B. Berkhout1, J. Binley1, J. Moore1, R. Sanders1
1Weill Medical College of Cornell University, New York, NY, USA
Background: An HIV-1 vaccine remains elusive, in part because 
various factors limit the quantity and quality of the antibodies 
raised against the viral envelope glycoprotein complex (Env). 
We hypothesized that targeting Env vaccines directly to B cells, 
by fusing them to molecules that bind and activate these cells, 
would improve Env-specific antibody responses. 
Methods: We fused trimeric Env gp140 to A PRoliferation-
Inducing Ligand (APRIL), B-cell Activating Factor (BAFF), and 
CD40 Ligand (CD40L). 
Results: The Env-APRIL, Env-BAFF and Env-CD40L gp140 trimers 
all enhanced the expression of activation-induced cytidine 
deaminase (AID) expression, the enzyme responsible for 
inducing somatic hypermutation, antibody affinity maturation 
and antibody class-switching. They also triggered IgM, IgG and 
IgA secretion from human B cells in vitro. The Env-APRIL trimers 
induced higher anti-Env antibody responses in rabbits, including 
neutralizing antibodies against Tier 1 viruses. The enhanced Env-
specific responses were not associated with a general increase in 
total plasma antibody concentrations, indicating that the effect 
of APRIL was Env-specific. All the rabbit sera raised against gp140 
trimers, irrespective of the presence of CD40L, BAFF or APRIL, 
recognized trimeric Env efficiently, while sera raised against 
gp120 monomers did not. The levels of trimer-binding and virus-
neutralizing antibodies were strongly correlated, suggesting that 
gp140 trimers are superior immunogens to gp120 monomers. 
Conclusion: Targeting and activating B cells with a trimeric HIV-1 
Env-APRIL fusion protein may improve the induction of humoral 
immunity against HIV-1. Targeting B cells directly may also be 
useful for other vaccines.
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Systems Analysis of MVA-C Induced Immune 
Response Reveals Its Significance as a Vaccine 
Candidate Against HIV/AIDS of Clade C 
C. Gómez1, B. Perdiguero1, V. Jimenez1, A. Filali-Mouhim2,  
K. Ghneim2, E. Haddad2, E. Quakkerlaar1, J. Delaloye1,  
A. Harari1, T. Roger1, T. Duhem1, R. Sekaly2, C. Melief1,  
T. Calandra1, F. Sallusto1, A. Lanzavecchia1, R. Wagner1,  
G. Pantaleo1, M. Esteban1
1Centro Nacional de Biotecnología, Madrid, Spain; 2VGTI, Port 
Saint Lucie, FL, USA
Background: Based on the partial efficacy of the HIV/AIDS Thai 
trial (RV144) with a canarypox vector prime and protein boost, 
attenuated poxvirus recombinants expressing HIV-1 antigens are 
increasingly sought as vaccine candidates against HIV/AIDS. 
Methods: Here we describe using systems analysis the biological 
and immunological characteristics of the attenuated vaccinia 
virus Ankara strain expressing the HIV-1 antigens Env/Gag-Pol-
Nef of HIV-1 of clade C (referred as MVA-C).
Results: MVA-C infection of human monocyte derived dendritic 
cells (moDCs) induced the expression of HIV-1 antigens at high 
levels from 2 to 8 hpi and triggered moDCs maturation as revealed 
by enhanced expression of HLA-DR, CD86, CD40, HLA-A2 and 
CD80 molecules. Infection ex vivo of purified mDC and pDC with 
MVA-C induced the expression of immunoregulatory pathways 
associated with antiviral responses, antigen presentation, T 
cell and B cell responses. Similarly, human whole blood or 
primary macrophages infected with MVA-C express high levels 
of proinflammatory cytokines and chemokines involved with T 
cell activation. The vector MVA-C has the ability to cross-present 
antigens to HIV-specific CD8 T cells in vitro and to increase CD8 T 
cell proliferation in a dose-dependent manner. The immunogenic 
profiling in mice after DNA-C prime/MVA-C boost combination 
revealed activation of HIV-1-specific CD4 and CD8 T cell memory 
responses, that are polyfunctional and with effector memory 
phenotype. Env-specific IgG binding antibodies were also 
produced in animals receiving DNA-C prime/MVA-C boost.
Conclusion: Our systems analysis of profiling immune response 
to MVA-C infection highlights the potential benefit of MVA-C as 
vaccine candidate against HIV/AIDS for clade C, the prevalent 
subtype virus in the most affected areas of the world. 
P12.13
Immune Responses Triggered by HIV/AIDS Vaccine 
Candidates, Derived from MVA-B, with Deletions in 
Several Immune Regulatory Genes 
J. García-Arriaza1, P. Arnáez1, C.E. Gómez1, M. Esteban1
1Centro Nacional de Biotecnología. CSIC. Madrid, Madrid, 
Spain
Background: Poxvirus vector Modified Vaccinia Virus Ankara 
(MVA) expressing HIV-1 Env, Gag, Pol and Nef antigens from clade 
B (termed MVA-B) is a promising HIV/AIDS vaccine candidate, as 
it was shown in the results obtained from a phase I clinical trial. 
Methods: To try to improve the immunogenicity elicited by 
MVA-B we have generated and characterized the innate immune 
sensing and the in vivo immunogenicity profile of new optimizing 
MVA-B vaccine candidates, which contains deletions in one, two 
or three different immunomodulatory vaccinia virus (VACV) 
genes blocking the same signaling pathway, involved in the 
induction of type I IFN. 
Results: The innate immune signals elicited by these MVA-B 
deletion mutants in human macrophages showed an up-
regulation of the expression of IFN-β and IFN-α/β-inducible 
genes. A DNA prime/MVA boost immunization protocol in mice 
revealed that these MVA-B deletion mutants were able to induce 
strong and polyfunctional HIV-1-specific CD4+ and CD8+ T-cell 
adaptive and memory immune responses, which were mostly 
mediated by CD8+ T cells with an effector phenotype. CD4+ T-cell 
responses were mainly directed against Env in MVA-B and all 
the MVA-B deletion mutants. However and interestingly, while 
MVA-B induced preferentially Env- and Gag-specific CD8+ T-cell 
responses, MVA-B deletion mutants induced more GPN-specific 
CD8+ T-cell responses. Moreover, an enhanced HIV-1-specific 
lymphoproliferative response was observed with the MVA-B 
deletion mutants. Furthermore, MVA-B and MVA-B deletion 
mutants were also able to induce antibodies against Env. 
Conclusion: These findings revealed that deletion in MVA-B of 
VACV genes that act blocking the same signaling pathway confers 
an immunological benefit by inducing innate immune responses 
and increasing the magnitude, quality and durability of the HIV-
1-specific T-cell immune responses. Our observations focused 
the use of highly optimizing MVA-based vectors as more potent 
HIV-1 vaccines. 
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A Minimal T-Cell Immunogen Designed to 
Cover HIV-1 Specificities Associated with 
Control Is Immunogenic in Mice and Breaks CTL 
Immunodominance
B. Mothe1, A. Llano1, M. Rosati2, S. Perez-Alvarez1, V. Kulkarni2, 
B. Chowdhury2, C. Alicea2, R.K. Beach2, N.Y. Sardesai3,  
G.N. Pavlakis2, B.K. Felber2, C. Brander4
1IrsiCaixa AIDS Research Institute-HIVACAT, Barcelona, Spain; 
2NCI-Frederick, Frederick, MD, USA; 3Inovio Biomedical Corp., 
Blue Bell, PA, USA; 4IrsiCaixa AIDS Research Institute-HIVACAT, 
ICREA, Barcelona, Spain
Background: Few T-cell immunogen vaccine designs exist that 
are based on large human immunogenicity data and which 
avoid inducing responses to mutable epitopes that may serve 
as immunodominant decoys. We have developed and tested 
a rationally designed T cell immunogen sequence which 
overcomes these limitations and which is currently undergoing 
pre-clinical testing.
Methods: 250 HIV-1 clade B infected individuals were screened 
for T cell responses to the entire HIV proteome. This yielded 
26 regions in HIV-1 Gag, Pol, Vif and Nef proteins that were i) 
preferentially targeted by individuals with low viral loads, ii) 
more conserved and iii) elicited responses of higher functional 
avidity and broader cross-reactivity than responses to other, less-
beneficial regions. The ‘beneficial’ segments were linked by triple 
alanines, translated into an expression-optimized nucleotide 
sequence and cloned into a CMV plasmid harboring a GM-CSF 
signal peptide. Immunogenicity was evaluated in C57BL/6 mice 
two weeks after a second DNA vaccination. Cellular immune 
responses were characterized using intracellular cytokine staining 
and IFN-γ ELISPOT using overlapping peptide pools covering the 
segments included in the T-cell immunogen.
Results: Vaccination with 20 μg of DNA generated both CD4 and 
CD8 IFN-γ+ responses to the immunogen sequence. The T-cell 
immunogen elicited a more balanced, broad T cell response to 
all protein components (Gag, Pol, Vif and Nef) contained in the 
immunogen than immunizations using plasmids encoding for the 
entire Gag, Pol, Nef, Tat and Vif proteins, which induced a strong 
Gag dominance. 
Conclusion: Despite lower in vitro expression, the DNA vaccine 
was strongly immunogenic in C57BL/6 mice, induced broad 
CD4 and CD8 T cell responses and was able to break the 
immunodominance of responses to targets that do not emerge 
as particularly beneficial in large cohort screenings. Experiments 
in humanized BLT mice are currently ongoing to map induced 
responses in the context of different HLA genotypes.
P12.15
A Novel HIV Vaccine Targets the 12 Protease 
Cleavage Sites
M. Luo1, D. Tang1, R. Capina1, X. Yuan1, C. Prego2, J.C. Pinto2,  
M. Alonso2, C. Barry1, R. Pilon1, C. Daniuk1, J. Tuff1, S. Pillet1,  
D. La1, T. Bielawny1, C. Czarnecki1, P. Lacap1, H. Peters1,  
G. Wong1, M. Kimani3, C. Wachihi3, J. Kimani3, T.B. Ball1,  
P. Sandstrom1, G. Kobinger1, F.A. Plummer1
1National Microbiology Laboratory, Winnipeg, Canada; 
2University of Santiago de Compostela, Santiago de 
Compostela, Spain; 3University of Nairobi, Nairobi, Kenya
Background: The protease of HIV-1 is a small 99-amino acid 
aspartic enzyme mediating the cleavage of Gag, Gag-Pol and 
Nef precursor polyproteins. The process is highly specific, 
temporally regulated and essential for the production of 
infectious virions. A total of 12 proteolytic reactions are required 
to generate a viable virion. Therefore, a vaccine targeting the 12 
protease cleavage sites(PCS) could be effective. The PCS of HIV-
1 are highly conserved among major subtypes, direct immune 
responses against these sites would yield several advantages. 
First, the immune response could destroy the virus before its 
establishment in the host. Second, the vaccine could force the 
virus to accumulate mutations eliminating the normal function 
of the HIV protease. Third, restricting the immune responses to 
these sites can avoid distracting immune responses that often 
generate unwanted inflammatory responses, induce excess 
immune activation, and attract more targets for HIV-1 infection, 
establishment and spread.
Methods: We have conducted a pilot study to investigate the 
feasibility and effectiveness of this approach. The recombinant 
VSV-peptides were used to immunize cynomolgus macaques 
and nanopackaged peptides were used to boost the immune 
response to the 12 PCS of SIVmac239. The controls and 
immunized macaques were repeatedly challenged intrarectally 
with an increased dosage of SIVmac239.
Results: Results showed that antibody and T cell responses 
to the 12 PCS can protect macaques against higher dosage of 
SIVmac239 challenge (p=0.0005, R=0.8005) and the vaccine 
group maintains significantly higher CD4+ counts (p=0.0002) 
than the controls weeks after being infected. Population 
coverage analysis showed that this approach can be applied to 
>95% populations in the world.
Conclusion: A vaccine targets the 12 protease cleavage sites is a 
viable approach for HIV prevention and treatment.
Topic 12:  Vaccine Concepts and Design
PO
ST
ER
S
249
Posters
AIDS Vaccine 2012
P12.18
Conformational Heterogeneity in V1/V2 Domain 
Affects the Immunological Properties of This Region
A. Pinter1, A.Z. Wu2, T. Neubert3, M.D. Burkhart1, W.J. Honnen1
1University of Medicine and Dentistry of New Jersey, Newark, 
NJ, USA; 2Nanjing University, Nanjing, China; 3NYU Medical 
Center, New York, NY, USA
Background: Recent information has shown the importance of 
the V1/V2 domain as a target in HIV-1 vaccines. This includes the 
localization of epitopes to potently neutralizing antibodies to this 
region, the demonstration that binding between a site in V1/V2 
and α4β7 receptors facilitates infection in primary CD4-positive 
T cells, and the demonstration that the presence of antibodies 
binding to the native form of the V1/V2 domain of HIV-1 gp120 
correlated with protection in the RV144 vaccine trial. These 
results highlight the need to better understand the structure and 
immunological properties of this region, in order to optimally 
express the relevant targets in HIV-1 vaccines.
Methods: The native V1/V2 domain of a clade B sequence 
(CaseA2) was expressed by fusion to the C-terminus of a 273 
aa fragment of the MuLV gp70 domain. This fusion glycoprotein 
was characterized by SDS-PAGE under various conditions, by 
radioimmunoprecipitation experiments with a panel of mAbs 
directed against V1/V2-specific epitopes, and by MALDI-TOF 
analysis of immunologically fractionated forms. 
Results: SDS-PAGE analysis of this protein after deglycosylation 
under non-reducing conditions revealed the presence of a closely 
migrating doublet, and mass-spec analysis of the immunologically 
fractionated forms suggested that these consisted of different 
disulfide-linked conformers. The two forms reacted differentially 
with a panel of V1/V2-specific antibodies and possessed variable 
reactivity with different polyclonal sera. 
Conclusion: These studies identify a conformational 
heterogeneity in the V1/V2 domain that is due to alternative 
disulfide bonding patterns. These conformations profoundly 
affect the immunoreactivity of this region, and will presumably 
influence their immunogenicity as well. Due to the importance of 
this region as a target for neutralizing and otherwise protective 
antibodies, it is likely that methods for resolving this heterogeneity 
would improve the efficacy of induction of relevant antibodies to 
this region by HIV Env vaccines.
P12.17
Control of HIV Replication By a Novel Constitutively 
Active ‘Super-PRR’
S. Gupta1, J. Termini1, G. Stone1
1University of Miami, Miami, FL, USA
Background: Innate responses are key determinants of the 
outcome of HIV infection, influencing critical events in the 
earliest stages of infection. Innate antiviral immune defenses 
are triggered through the recognition of conserved pathogen 
associated molecular pattern (PAMP) motifs within viral products 
by intracellular pattern recognition receptor (PRR) proteins in 
infected cells. Type I interferons (IFN α and beta) are induced 
directly in response to viral infection, resulting in an antiviral 
state for the cell. 
Methods: A ligand independent constitutively active form of 
PRR adaptor protein (‘super-PRR’) was constructed and tested 
for antiviral properties. NF-kb and IFN production by construct 
was tested by Luciferase reporter assays. The construct was 
transfected into RAW 264.7 cells, analyzed for surface markers 
and inflammatory cytokines. RT-PCR was performed to analyze 
the expression of cytokine/chemokine genes. TZM-bl cells were 
transfected with plasmid expressing ‘super-PRR’, infected with 
HIV-BaL virus and beta-galactosidase activity was measured.
Results: The constitutively active ‘super-PRR’ generated 50-
fold and 10-fold increase in NF-kb and IFN-beta production 
respectively as compared to vector alone. There was significant 
increased expression of CD80, CD86, CD40, CCR7, HLA-DR, 
secretion of IL-1beta, IL-6, TNF-α and expression of RANTES, 
MIP-1beta, IP-10 on transfected RAW cells. TZM-bl cells 
transfected with ‘super-PRR’ after infection with HIV-Bal virus 
showed significantly reduced replication of virus. In a transwell 
experiment, 293T cells transfected with the ‘super-PRR’ was 
sufficient to significantly reduce HIV-1 infection of TZM-bl cells, 
suggesting soluble factors are involved.
Conclusion: This constitutively active form of PRR adapter 
protein induced potent anti-viral innate immune response and 
prevented infection with HIV. The modulation of innate immunity 
has potential as a powerful strategy to complement traditional 
approaches to HIV therapy by protecting cells from viral infection. 
We are currently constructing lentiviral vector vaccines encoding 
this ‘super-PRR’ as a method to target this anti-viral response to 
the site of HIV-1 Infection.
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Development of a Novel Simian Adenovirus 24 Based 
Vaccine Vector
P. Abbink1, R.R. Bradley1, F. Ball1, D. Ng’ang’a1, E. Borducchi1, 
D.H. Barouch1
1Beth Israel Deaconess Medical Center, Boston, MA, USA
Background: Human adenovirus serotype 5 is a potent vaccine 
vector, but its use has been hampered by high seroprevalence 
amongst people in sub-Sahara Africa. Novel adenoviral vaccine 
vectors from strains with lower seroprevalence worldwide are 
being developed that can evade pre-existing immunity. Here 
we describe the development of a simian Ad24 (sAd24)-based 
vaccine vector.
Methods: Neutralizing antibodies against sAd24 were 
determined using a panel of 106 rhesus macaque sera and 128 
human sera from Rwanda and South Africa using a luciferase-
based adenovirus neutralization assay. 
The immunogenicity of a single dose of 10E7, 10E8 or 10E9 
virus particles of sAd24-SIV Gag based vector was determined 
in C57BL/6 mice. SIV-Gag-specific immune responses were 
assessed by Db/AL11 tetramer binding assays, IFN-γ ELISPOT 
assays and ICS assays.
Results: Neutralizing antibodies were found in 7% of monkeys, 
all with titers <200. In humans from sub-Saharan Africa, 45% was 
positive for sAd24 neutralizing antibodies, but titers remained 
low and 90% had titers <200. In comparison, seroprevalence of 
Ad5 in sub-Saharan Africa is 86.4-89.5% with 61.1-78.7% of this 
population showing titers >200 and 25.1-46.8% showing titers 
>1000. Gag specific cellular immune responses elicited by sAd24-
SIV Gag in mice are comparable to those seen with the human 
Ad26 and Ad28 vectors currently in development.
Conclusion: These data suggest that sAd24 is promising for 
further studies as a candidate vaccine vector.
P12.19
Immunisation with the Membrane Proximal 
External Region of gp41 of HIV-1 Grafted into 
the Transmembrane Envelope Protein of a 
Gammaretrovirus
N. Strasz1, V. Morozov1, J. Kreutzberger1, M. Lau1, J. Denner1
1Robert Koch Institute, Berlin, Germany
Background: Immunisation with the transmembrane envelope 
(TM) proteins p15E of different gammaretroviruses (e.g., porcine 
endogenous retrovirus, feline leukaemia virus, Koala retrovirus) 
resulted in strong neutralising activity, the antibodies recognised 
epitopes in the fusion peptide proximal region (FPPR) and in 
the membrane proximal external region (MPER). The MPER 
epitopes were localised similarly as the epitopes recognised by 
the broadly neutralising antibodies 2F5 and 4E10 in gp41 of HIV-
1. Despite the evolutionary difference between HIV-1 and the 
gammaretroviruses, the MPER epitope of antibodies neutralising 
PERV (FEGWFN) showed partial homology to the epitope of the 
4E10 (NWFNIT, note three identical amino acids). To generate 
hybrid antigens able to induce 2F5/4E10-like antibodies, 
sequences of the MPER and FPPR of gp41 were grafted into the 
p15E backbone of a gammaretrovirus.
Methods: Different hybrid antigens were cloned, expressed in E. 
coli and purified. Immunisation studies in rats and guinea pigs 
were performed and the antisera were characterised by ELISA, 
Western blot analysis, epitope mapping using microarray chips 
with overlapping peptides and a neutralisation assay based on 
TZM-bl cells.
Results: Antibodies against gp41 of HIV-1 were induced, 
recognising epitopes in the FPPR, but also the 2F5 epitope 
(ELDKWA) in the MPER. Step by step changes in the sequence 
of the hybrids resulted in improved binding of the antibodies to 
this epitope. However, none of the immune sera or purified IgG 
neutralised HIV-1 more that 50%. 
Conclusion: Since modifications in the hybrid proteins led to an 
increased anti-MPER response, it may be expected that further 
modifications increase neutralisation efficacy and that these 
hybrids may be the basis for candidate vaccines against HIV-1. 
Performed in the frame of the EuroNeut-41 project in the 
Seventh Framework Program.
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IFN-γ Secreting Capacity of CD8+T Cell Is 
Compromised with the Increased Copies of Epitope 
Encoding Sequences in DNA Vaccine Design
J. Wang1, Y. Wan2, J. Xu1
1Fudan University, Shanghai, China; 2Shanghai Public Health 
Clinical Center, Shanghai, China
Background: Epitope based vaccines are widely used in vaccine 
development against HIV-1, cancer and other diseases. One of the 
key components is how to enhance its immunogenicity. Previous 
studies suggested that the magnitudes of both T cell and antibody 
responses could be improved through repeating epitope in 
design, however, it remains unknown how this could influence the 
functional features of T cell responses and its optimization.
Methods: A previously indentified HIV-1RL42 envelope T cell 
epitope GIRKNYQHLWRWGTM (Env2) was employed, mini-
genes encoding a single, triplicated or sextuplicated copies of 
this epitope were synthesized and inserted into a DNA vector. 
To enhance their expression efficiency and immunogenicity, 
Kozak sequence, ER signal sequence and an universal Th2 
epitope were introduced, His tag was added to detect its 
expression. In vitro expression was confirmed by transfection 
and immunoprecipitation. C57B/C mice were inoculated i.m. and 
sacrificed to do in vivo assessment. ICS assays were used to read 
out Env2-specific immune responses. Statistical analysis was 
done with Prism5.0 software.
Results: It’s showed that all three mini-gene DNA vaccines could 
elicited appreciable IFN-γresponses in CD8+ T cells, no significant 
IL-2 secretion was observed. One way ANOVA analysis showed 
that the frequencies of IFN-γ+CD8+T cells induced ranked as 
single copy of Env2< triplicated < sextuplicated (P=0.02). Further 
analysis indicated that MFI of IFN-γ+CD8+T cells decreased 
along with the increasing of epitope copy number, which was 
single-Env2 group＞triplicated＞sextuplicated (p=0.09). When a 
single copy Env2 and the combined data from triplicated- and 
sextuplicated-Env2 were compared, we observed MFI in single 
copy Env2＞multiple copy (p=0.004).
Conclusion: Our data confirmed previous observation that 
repeated epitope design could improve the frequencies of 
specific T cells. Interestingly, we demonstrated that the IFN-γ 
secreting capacity for individual T cell might be compromised 
along with the increased responding frequencies, which should 
be taken into consideration in vaccine design.
P12.21
Development of Replication-Competent Adenovirus 
Based Vaccine Vectors
P. Abbink1, L.F. Maxfield1, D.H. Barouch1
1Beth Israel Deaconess Medical Center, Boston, MA, USA
Background: Replication-incompetent adenovirus vectors 
have shown promise as vaccine candidates. We are developing 
replication-competent adenovirus vectors to increase antigen 
expression and duration and to facilitate mucosal routes of 
vaccine delivery. We have developed replication-competent Ad5 
(rcAd5) and Ad26 (rcAd26) based vectors, tested their growth in 
human and simian cell lines, and determined the dynamics of 
virus shedding after inoculation of rhesus monkeys.
Methods: Replication-competent Ad5 and Ad26 vectors were 
produced by adding the E1 region back into the vector. To 
facilitate rcAd5 growth in rhesus monkey cells, 2 host range 
mutations were also introduced into the DNA binding protein. 
The growth of rcAd5 and rcAd26 was tested in human (Per55K, 
293, and A549) and simian (CV-1 and Cos7) cell lines. In addition, 
rcAd5 was administered intranasally to rhesus monkeys, and the 
kinetics of viral shedding was determined by qPCR on nasal, oral, 
and rectal swabs, and serum.
Results: As expected, replication-incompetent Ad5 and Ad26 
grew in the E1-complementing cell lines Per55K and 293, but not 
in A549 or CV-1 cells. In contrast, rcAd5 and rcAd26 grew in all 
human and simian cell lines tested, although rcAd26 growth was 
suboptimal in simian cells. After intranasal inoculation of rhesus 
monkeys, rcAd5 viral sequences could be detected by qPCR in 
nasal swabs for 5 weeks post-inoculation. 
Conclusion: Replication-competent Ad vectors can be produced 
efficiently by the re-introduction of E1 into standard replication-
incompetent vector backbones. However, the extent of 
replication in simian cells appears to vary based on Ad serotype. 
Future studies will compare the immunogenicity of replication-
competent vs. replication-incompetent Ad vectors.
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Antigenicity of Soluble HIV gp140 Trimers Reveals 
Differences in Solution Conformation for Differing 
HIV Strains
T.L. Gearhart1, J.D. Steckbeck1, R.C. Montelaro1, J.K. Craigo1
1University of Pittsburgh School of Medicine, Pittsburgh, PA, 
USA
Background: Eliciting effective antibody responses are key to the 
design of HIV vaccines. While the HIV envelope protein is highly 
immunogenic and provokes a high-titer antibody response during 
viral infection and experimental immunization, affinity-matured 
antibodies capable of neutralizing diverse HIV isolates are rarely 
elicited. While recent vaccine regimens have focused on DNA, viral 
vector, VLP, or attenuated virus vaccines, of increasing interest 
are improved recombinant envelope protein immunogens. 
Immunizations with trimeric gp140 proteins induce higher-titer 
neutralizing antibody responses and have structural benefits 
over monomeric gp120 immunizations. Novel approaches being 
taken for recombinant trimeric gp140 immunogens include the 
use of consensus and multi-clade gp140 trimers. A consideration 
for these synthetic proteins that is key to vaccine efficacy: do 
these proteins structurally represent a native trimeric envelope? 
Methods: To address potential differences in the functional 
conformation of gp140 trimers, we evaluated the conformational 
characteristics of trimeric gp140 proteins from varying HIV-
1 strains as well as engineered consensus gp140s via binding 
studies using surface plasmon resonance with a panel of well-
characterized monoclonal antibodies (MAbs). 
Results: Consensus trimers were recognized by more monoclonal 
antibodies than the primary strain gp140s, suggestive of the 
benefits of engineered trimers. However, analysis revealed a low 
trimer concentration that is competent to bind the quaternary-
recognizing MAb PG9. Considering the binding to other 
conformational MAbs, this suggests that while the consensus 
gp140s contain appropriately conformational monomers and 
are trimeric, the vast majority of the protein is not in a proper 
quaternary structure. 
Conclusion: These data suggest that it is important to fully assess 
structural differences of immunogens even though obvious 
phenotypic differences may not be present. Taken together, these 
observations demonstrate the need to evaluate immunogens in 
a manner that allows the measurement of functional epitope 
exposure and solution conformation to assess the potential to 
elicit a potent, broadly-neutralizing antibody response.
P12.23
Potency Of An HIV-SAM™ Vaccine In A Heterologous 
Prime-Boost Vaccination Regimen
K. Banerjee1, Y. Cu1, Y. Sun1, K. Hartog1, A. Dey1, L. Brito1,  
A. Verma1, A. Nandi1, P. Sarkar1, N.M. Valiante1, A.J. Geall1, 
S.W. Barnett1, G.R. Otten1
1Novartis Vaccines and Diagnostics, Cambridge, MA, USA
Background: Recombinant alphavirus replicon particles (VRP), 
carrying self-amplifying RNA, protects rhesus macaques against 
SHIVSF162P4 challenge when used in prime-boost regimen.
Methods: Novartis has developed a synthetic self-amplifying 
mRNA (SAM™) vaccine platform that avoids limitations of cell 
culture production and employs synthetic non-viral vaccine 
delivery systems.
Results: We evaluated systemic and mucosal immune responses 
in mice and rabbits using the SAM™ platform expressing HIV-1 
gp140 (HIV-SAM™ vaccine) prime, protein/MF59 vaccine boost 
regimen for both HIV-1 Clade B and C Env antigens. In mice, the 
primed Env-specific IgG response to 1 µg of the HIV-SAM™ vaccine 
was comparable to a 10 µg dose of an identically formulated 
DNA vaccine, 10(7) IU of VRP, and 10 µg protein/MF59 vaccines. 
The HIV-SAM™ vaccine primed response could be boosted 
robustly by a protein/MF59 vaccine and resulted in a balanced 
IgG1, IgG2a subclass response, similar to that seen with the 
VRP vaccine, but unlike the dominant IgG1 response to protein/
MF59 only vaccinations. Both Env-specific CD4+ and CD8+ T-cell 
responses were detectable after two HIV-SAM™ vaccinations. 
A TH1 type (IFNγ+, IL-5-) profile was demonstrable for the HIV-
SAM™ vaccine primed, protein boosted CD4+ T-cell response, 
similar to that seen with the DNA or VRP primed protein boosted 
responses, in contrast to a TH2 type (IFNγlow, IL-5+) response 
seen with protein/MF59 vaccination. In rabbits, priming with 
the 25 or 50 µg of the formulated HIV-SAM™ vaccine induced 
robust and avid Env-binding IgG and HIV neutralizing antibodies 
that were superior to 500 µg of an unformulated DNA vaccine 
and comparable to VRP and protein/MF59 vaccines. In addition, 
protein/MF59 boostable Env-specific vaginal wash Ig was 
consistently demonstrable in both mice and rabbits immunized 
with the HIV-SAM™
Conclusion: Together, these results suggest that HIV-SAM™ 
vaccine is potent and versatile and offers potential as a novel 
immune priming strategy. NIAID-NIH Grant 5P01AI066287.
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A Pantothenate Auxotroph of BCG Expressing Gag 
Confers Enhanced HIV-Specific Immunogenicity 
Compared to Wildtype and Perfingolysin Expressing 
Strains
S. Chetty1, E. Shephard2, D. Bowers1, M. Darby1, W. Horsnell1,  
R. Chapman1, A. Williamson1
1IIDMM, University of Cape Town, Cape Town, South Africa; 
2Department of Medicine,University of Cape Town, Cape 
Town, South Africa
Background: In tuberculosis vaccine studies, perfingolysin 
expressing strains (pfo) of recombinant Mycobacterium bovis 
(rBCG) have been shown to enhance immunogenicity as 
compared to wildtype strains whilst pantothenate auxotrophic 
strains (ΔpanCD) have been shown to be safer and more 
immunogenic. Our group has recently shown that rBCGΔpanCD 
expressing HIV-1 Gag is more immunogenic than the wildtype 
Pasteur strain of BCG in the murine model. In this study, a wild 
type strain, a ΔpanCDstrain, a pfo strain and a ΔpanCD strain 
expressing perfringolysin (ΔpanCDpfo) of Danish BCG were used 
as vectors to express HIV-1 subtype C Gag. Gag specific immune 
responses induced by a prime with each rBCG-Gag vaccine and 
boost with modified vaccinia Ankara (MVA) were compared.
Methods: rBCG vaccines were given intraperitoneally to BALB/c 
mice followed by an intramuscular MVA boost after 28 days. 
Twelve days after the boost, mice were sacrificed and single cell 
suspensions of splenocytes were stimulated with HIV peptides. 
Immunogenicity was assessed using an IFN-γ ELISPOT assay, 
cytokine bead array and multi-parameter flow cytometry. 
Results: All the rBCG-Gag vaccines primed the immune response 
to a boost with MVA. Cytokine kinetic measurements and flow 
cytometry indicated a more rapid and robust release of pro-
inflammatory cytokines, in response to ex vivo HIV peptides, 
from the splenocytes of mice vaccinated with rBCGΔpanCD(gag) 
as compared to rBCGpfo(gag)(p<0.001- p<0.05) and rBCG(gag)
(p<0.01- p<0.05). A rBCGΔpanCD(gag) prime induced increased 
polyfunctional HIV specific CD4+ and CD8+ T cells as compared 
to the other strains of BCG. We observed no enhancement of 
immunogenicity in the rBCGΔpanCDpfo(gag) group as compared 
to the rBCGΔpanCD(gag) group. 
Conclusion: As this study indicated the Danish ΔpanCD vector 
induced a more robust and rapid Gag-specific immune response 
than the wild type and perfringolysin expressing BCG Danish 
vectors, the Danish ΔpanCD vector maybe an attractive option 
for HIV vaccines. 
P12.25
Priming with DNA Encoding Functional Trimers and 
Boosting with Soluble Trimeric Protein Elicited Tier 2 
Neutralizing Antibodies in Non-human Primates
B.K. Chakrabarti1, F. Yu1, K. McKee2, C. Labranche3,  
D. Montefiori3, J.R. Mascola2, R.T. Wyatt1
1International AIDS Vaccine Initiative/The Scripps Research 
Institute, La Jolla, CA, USA; 2Vaccine Research Center/NIAID/
NIH, Bethesda, MD, USA; 3Duke University, Durham, NC, USA
Background: All known HIV-1 gp120-directed broadly 
neutralizing antibodies efficiently recognize fully cleaved JR-FL 
spikes, however, the non-neutralizing gp120-directed antibodies 
only recognize the uncleaved JR-FL spikes. Therefore, as an 
immunogen, cleaved, functional spikes may selectively present 
neutralizing epitopes to B cells, perhaps more efficiently eliciting 
neutralizing antibodies. However, attempts to make soluble 
versions of Env that fully mimic the viral spike are yet to be 
successful. In vitro, this plasmid encodes for fully cleaved, cell-
surface, trimeric JR-FL Env spikes, but only when expressed 
from a mini-LTR in a non-codon optimized state. In vivo, the LTR-
driven, non-codon-optimized Env plasmid DNA, likely requires 
tat co-transfection in trans, and rev expression in cis, for efficient 
Env expression. 
Methods: To present functional, cleaved spikes to the immune 
system, we inoculated non-human primates (NHPs) with non-
codon optimized JR-FL Env expressing plasmid DNA along with 
plasmid expressing Tat protein by electroporation. DNA priming 
was followed by boosts with soluble JR-FL gp140 trimers in 
adjuvant. As controls codon-optimized and CMV-driven Env 
plasmids were used to prime and three animals received protein 
in adjuvant only.
Results: We report that the DNA priming elicited reasonable 
ELISA binding titers in NHPs and that the elicitation of neutralizing 
antibodies against Tier 1 viruses. Following trimer protein 
boosting of the DNA-primed animals, reasonable titers of Tier 2 
neutralizing antibodies in the A3R5 assay were elicited. For the 
Tier 2 isolates tested to date, much of the neutralizing activity in 
sera maps to the CD4 binding site.
Conclusion: We conclude that DNA priming by electroporation 
is an interesting and means to present functional, cleaved HIV-
1 Env spikes to the B cell immune system to prime or initiate 
functional trimer-elicited neutralizing antibodies in primates.
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A gp41 MPER-Specific llama VHH Requires a 
Hydrophobic CDR3 Determinant for Neutralization 
but Not for Antigen Recognition
W. Weissenhorn1, D. Lutje Hulsik1, M. Hock1, Y.Y. Liu2,  
N.M. Strokappe2, M.E. Khattabi2, J.P. Langedijk3, L.E. McCoy4, 
A. Forsman-Quigley4, M.M. Aasa-Chapman4, R.A. Weiss4,  
T.C. Verrips2, L. Rutten2
1Grenoble University, Grenoble, France; 2Biomolecular 
Imaging (BMI), Faculty of Science, Utrecht University, Utrecht, 
Netherlands; 3Pepscan Systems BV, Lelystad, Netherlands; 
4MRC Centre for Medical Molecular Virology, University 
College London, London, United Kingdom (Great Britain)
Background: The membrane proximal external region (MPER) of 
the HIV-1 glycoprotein gp41 is targeted by broadly neutralizing 
antibodies such as 2F5, 4E10 and Z13, which recognize antigen 
and membrane components. 
Methods: In this study, we immunized llamas with gp41 
proteoliposomes and selected a MPER-specific single chain 
antibody (VHH), 2H10, whose gp41 epitope overlaps with that 
of mAb 2F5. 
Results: 2H10 binds to the intermediate conformation of gp41 
with medium nanomolar affinity. Construction of 2H10 biheads 
(bi-2H10) increases the binding affinity by a factor of 20. Bi-2H10 
neutralizes various sensitive and resistant HIV-1 strains, as well as 
SHIV strains in a TZM-bl cell assay. We further present structural 
data from crystallographic and NMR analyses together with 
mutagenesis data that allowed to map the interaction site on 
gp41. This revealed that 2H10 has a long CDR3 whose tip exposes 
a tryptophan residue that is not required for gp41 interaction, 
but crucial for neutralization. 
Conclusion: Our data indicate that 2H10 induced by 
immunization classifies as a functional MPER antibody as a 
bihead that requires both antigen recognition and membrane 
interaction for neutralization. 
P12.27
Optimising CN54gp140 Plasmid Delivery by 
Comparing Intramuscular and Intradermal 
Vaccination Combinations With and Without 
Electroporation
J.F. Mann1, P.F. McKay1, J. Swales1, K. Klein1, A. Fiserova1,  
A. Cope1, R.J. Shattock1
1Imperial College, London, United Kingdom (Great Britain)
Background: Prime boost vaccination studies employing plasmid 
DNA have been shown to significantly increase vaccine-induced 
immune responses with the added advantage of increasing 
vaccine-induced immune breadth. Furthermore, recent studies 
have shown that prevailing immune responses to DNA based 
vaccines can be substantially augmented by the immediate 
application of short pulses of electric current (electroporation) 
at the DNA injection site. 
Methods: We vaccinated mice with DNA via the intradermal (ID), 
intramuscular (IM) or combined (ID + IM) routes with and without 
electroporation (EP), using a Gene Transfer Unit (GTU®) plasmid 
expressing CN54gp140. Some mice were further boosted with 
recombinant trimeric CN54gp140. Female BALB/c mice (n=8) 
were vaccinated every three weeks. Serum and vaginal lavage 
samples were collected 1 week post each vaccination and tested 
by ELISA for anti-HIV-gp140 specific IgG and IgA. Spleen derived T 
cells were evaluated for antigen reactivity by IFN-g ELISpot using 
2 peptide pools of 15mers overlapping by 11, spanning the full 
length of the gp140 molecule.
Results: Antigen-specific T lymphocyte IFN-g cytokine 
expression and humoral antibody profiles were different 
after either ID or IM immunization or the combined route 
vaccinations. Moreover, we found that EP added an additional 
level of complexity by influencing T and B cell responses both 
quantitatively and qualitatively. As expected, these vaccinations 
did not elicit biologically significant levels of mucosal antigen-
specific antibody responses.
Conclusion: Multi-route vaccinations can enhance and subtly 
alter vaccine-induced B and T lymphocyte immunity. All of 
the vaccine routes benefited from enhancement to the DNA 
immunization using in vivo EP and the elicited immunity was 
again influenced by the enhanced transfection efficiency. These 
strategies are likely to be useful in the future design of vaccine 
modalities that seek to generate specific immune responses.
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Development of an Imaging Based Virus Aggregation 
Assay for Vaccine Development
D. Stieh1, C. Gioia1, M. McRaven1, G. Cianci1, P. Kiser2, T. Hope1
1Northwestern University, Chicago, IL, USA; 2University of 
Utah, Salt Lake City, UT, USA
Background: Vaccination strategies capable of eliciting 
neutralizing antibody responses to HIV remain elusive 
despite extensive efforts. Alternative antibody functions offer 
opportunities for protection without necessarily achieving 
broad neutralization breadth. Viral immune exclusion through 
aggregation has been proposed as an alternative protection 
pathway, but mechanisms for studying this phenomenon at the 
scale necessary for clinical trials have not been explored. 
Methods: Concentrated fluorescent virions of two colors, 
suspended in hydroxyethylcellulose (HEC) gel, which has been 
formulated to simulate the diffusion characteristics of cervical 
mucus, are imaged over time. Mean squared displacement and 
incidence of colocalized viral particles are determined. The 
addition of monoclonal antibodies of various specificities and 
isotypes affects these parameters is explored. Immunoglobulin 
isolated from HIV-1 positive individuals was examined as 
well. Correlative scanning electron micrographs of the 
same preparations were performed to confirm the nature of 
suspected aggregates.
Results: Multimeric antibodies, rather than monomeric isoforms, 
selectively hinder the diffusion characteristics of colocalized 
virions, more so than non-aggregated virions. The incidence of 
colocalized virions is also increased in a concentration dependent 
manner. Excessive antibody or virus concentration is seen to 
obviate aggregate formation. These results are seen in both 
monoclonal antibody experiments alongside polyclonal patient 
IgA isolated from breast milk and IgM from serum. 
Conclusion: Virus aggregation has been demonstrated 
as a feasible effector function of HIV-1 specific antibody 
preparations. This assay platform is amenable to adaptation for 
medium to high throughput sample screening and low sample 
size. Monoclonal antibodies as well as patient samples are able 
to induce similar behaviors. Measurement of viral aggregation 
as a corollary of vaccine efficacy is deserving of further 
exploration in a clinical setting. 
P12.29
Transforming Epitope-Specific gp120 Monomer-
Based Probes into Immunogens with N-linked Glycan 
Masking
G. Chuang1, J.C. Boyington1, G.J. Nabel1, P.D. Kwong1,  
I. Georgiev1
1National Institutes of Health/NIAID, Bethesda, MD, USA
Background: HIV-1 gp120 monomer-based probes have been 
used for the identification of broadly neutralizing antibodies. 
Such probes could represent starting points in the design of 
HIV-1 immunogens, though efforts must be made to silence 
immune responses directed toward non-neutralizing epitopes. 
One possible approach would be to mask these epitopes by 
introducing N-linked glycan. A potential complication to such an 
approach is glycan occupancy: although N-linked glycosylation 
generally occurs at N-X-T/S sequons, many such sequons are 
not occupied.
Methods: A computational protocol was developed to identify 
the putative positions for insertion of N-linked glycan on the 
gp120 surface. The first step involves the identification of 
residue positions on the gp120 surface where the insertion of 
the N-X-T/S sequon is predicted as energetically-tolerable. The 
second step involves the application of NGlycPred, a Random 
Forest-based predictor, to predict the glycan occupancy at the 
inserted sequons.
Results: The glycan occupancy prediction of the protocol is 
highly correlated to validated N-X-T sequon insertion designs. 
Multiple sequon insertions to gp120 monomer-based probes 
were generated based on the protocol.
Conclusion: A computational protocol was implemented to 
identify putative sites for insertion of N-X-T/S sequons with 
improved likelihood of glycan occupancy. The protocol is 
applicable to the design of N-linked glycans for masking non-
neutralizing antibody epitopes on gp120-based probes as well as 
other immunogen candidates.
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Novel Strategies for HIV-1 Epitope Delivery Using 
Foamy Viral Hybrid Proteins and Vectors
M. Mühle1, A. Bleiholder2, K. Hoffmann1, M. Löchelt2,  
J. Denner1
1Robert Koch Institute, Berlin, Germany; 2German Cancer 
Research Center, Heidelberg, Germany
Background: To prevent HIV-1 infection induction of broadly 
neutralising antibodies (bnAb) like 2F5 and 4E10 reacting 
with the membrane proximal external region (MPER) of the 
transmembrane envelope (TM) protein gp41 of HIV-1 may be 
essential. Since these antibodies appear late after infection, it is 
thought that they require a prolonged maturation time. Using 
apathogenic foamy virus (FV) as replicating gene delivery vector 
may allow antibody maturation through persistent antigen 
presentation. Based on studies showing an interaction of the 
MPER with the fusion peptide proximal region (FPPR) in gp41, 
strategies to graft these regions into backbone proteins of FV 
were examined and two, comprising the FV TM protein and the 
accessory Bet protein were tested here.
Methods: The feline foamy virus (FFV) TM protein and Bet hybrid 
proteins comprising the MPER and FPPR of HIV-1 gp41 were 
produced and antibody responses were studied in immunized 
and FFV infected animals by ELISA, Western blot and microarray-
based epitope mapping. Also, constructs for stable, high level 
expression of full length FFV Env were developed.
Results: Mapping sera from animals immunized with the FFV 
TM protein and infected cats revealed immunogenic epitopes 
in the FV FPPR and MPER. These were exchanged against their 
HIV-1 homologues in optimized FV Env. Upon transfection, these 
constructs allowed production of chimeric virus-like-particles 
(VLPs) currently used for immunization studies. By immunizing 
with the Bet fusion proteins containing the gp41 MPER, FPPR 
or MPER-FPPR, strong responses were induced against gp41 
and the 2F5 epitope ELDKWAS, demonstrating the feasibility 
of this approach. The hybrid sequences are now transferred to 
infectious FFV clones.
Conclusion: To induce bnAb of the type 2F5 and 4E10, the 
developed vaccine systems provide two new high safety strategies 
for HIV epitope delivery by either VLPs or replicating vectors. This 
work was supported by the Volkswagen Foundation.
P12.31
Molecular Epidemiology of the Protective RV144 V2 
Loop Epitope
T. Cardozo1
1NYU School of Medicine, New York, NY, USA
Background: The immune correlate analysis of the RV144 trial 
identified antibodies (Abs) targeted at the V1-V2 domain as 
potentially protective vaccine responses. Reactivity of vaccinee 
serum Abs with a glycosylated gp70-V1-V2 fusion protein or 
with certain V2 loop peptides was significantly associated with 
a lower risk of viral infection. A V2 loop segment approximately 
comprising amino acid residues 165-178 of gp120 was also 
identified by pilot vaccinee studies as a key immunogenic region. 
Methods: To identify whether the segment identified by pilot 
studies coincides with the reagents reactive in the case control 
study, I mapped the locations of the reagents associated with 
lower risk of viral infection onto the V1-V2 domain structure. 
With a single segment identified as associated both with 
immunogenicity in the pilot studies and protection in the case 
control study, I calculated the Dayhoff evolutionary sequence 
distance between the the sequences of this segment in the 
immunogens and in a panel of V2 loop based reagents used in 
the case control study, each with associated odds ratios (OR) for 
risk. OR was then plotted against distance.
Results: The same V2 loop segment from positions 165-178 that 
was specifically most immunogenic in the pilot studies appears 
to have been associated with protection in the immune correlate 
analysis. This segment corresponds to the “C” strand of the V1-V2 
domain beta-sheet fold, exactly where the broadly neutralizing 
antibody PG9 binds. Plotting the evolutionary distance between 
this segment in the RV144 immunogens and synthetic V2 loop 
based antigens used in the case control study shows that lower 
risk (lower OR) correlates with greater evolutionary distance. 
Conclusion: A V2 loop segment from positions 165-178 of gp120 
was highly immunogenic in humans. Abs elicited by the RV144 
subtype E immunogen displaying segment may have been 
protective only if they cross-reacted distantly with subtype B. 
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Antigenicity and Immunogenicity of a Novel, Acute 
HIV-1 Tanzanian Subtype C gp145 Envelope Protein 
for Clinical Development 
V. Polonis1, L. Wieczorek2, V. Kalyanaraman3, G. Matyas1,  
S. Whitney3, C. Williams4, S. Tovanabutra2, E. Sanders-Buell2, 
M. Wesberry2, C. Ochsenbauer5, A. Chenine2, M. Rao1, T. Tong2, 
C. Alving1, H. Cheng6, S. Zolla-Pazner4, N. Michael1, T. VanCott3, 
M. Marovich1
1Walter Reed Institute of Research, DIV Retrovirology, Silver 
Spring, MD, USA; 2Henry M. Jackson Foundation, Silver Spring, 
MD, USA; 3Advanced Biosciences Laboratories, Inc, Rockville, 
MD, USA; 4New York University School of Medicine, New 
York, NY, USA; 5University of Alabama, Birmingham, AL, USA; 
6University of California, Davis, CA, USA
Background: Eliciting broadly reactive neutralizing antibodies 
remains a challenge in HIV-1 vaccine development, complicated 
by variations in envelope (Env) subtype and structure, and by 
the assays used for product down-selection. Since a majority of 
new HIV-1 infections are subtype C and considering the novel 
properties of C Envs, a C Env (CO6980v0c22) from an acutely 
infected Tanzanian was developed as a candidate HIV vaccine.
Methods: The CO6980v0c22 Env sequence was codon optimized 
and a stable CHO cell line expressing gp145 was established. 
Purified gp145 was adjuvanted in alum or lipid A-liposomes, 
injected into New Zealand white rabbits (4/group; 25 ug at 
weeks 0, 4, and 8), or BALB/c mice (5/group; 10 ug in liposomes 
at weeks 0, 3, 6, 8). Antibody titers were assessed by ELISA and 
neutralizing antibodies were measured against pseudoviruses 
in TZM-bl cells or against infectious molecular clones (IMC) in a 
PBMC assay. 
Results: Secreted gp145 is a novel subunit with the full MPER 
extended by three lysines. Unlike some gp140 subunits, the 
4E10 neutralizing monoclonal antibody (mAb) binds to gp145. 
IgG1b12 binds weakly, VRC01 binds potently, as does the 
V2-specific 697D mAb; the gp145 also binds to alpha4beta7 
receptor, as demonstrated by flow cytometry. At week 10 post-
immunization, rabbit sera showed strong binding antibody 
titers to several Env antigens, including the clade B V1V2gp70 
scaffold protein. While neutralization of the HIV-2 MPER-
scaffold pseudovirus was negative, cross-clade neutralization 
was observed in both rabbits and mice, against Tier 1 subtype 
B and C pseudoviruses, and against Tier 1 and Tier 2 IMC. Using 
EGS cross-linking, it appears that the majority of the gp145 
multimers are trimeric; this is currently under investigation 
using electron microscopy techniques.
Conclusion: These data indicate essential immunogenic features 
of a novel acute C HIV-1 Env that warrants further testing for 
potential clinical development.
P12.33
Immunogenic Selection of HIV-1 MPER Epitopes for 
Improved Vaccine Design
L. Wieczorek1, M. Rao2, K. Peachman1, N. Steers1, M. Marovich2, 
N. Michael2, V. Polonis2, V. Rao3
1Henry M. Jackson Foundation, Silver Spring, MD, USA; 2Walter 
Reed Army Institute of Research, Silver Spring, MD, USA; 
3Catholic University of America, Washington, DC, USA
Background: The goal of this study was to design structural 
mimics of HIV-1 epitopes that have the potential to induce 
broadly neutralizing antibodies (bnAbs). The structure of the 
gp41 membrane proximal external region (MPER), targeted 
by three bnAbs, requires further definition. Experiments were 
designed to select epitopes with enhanced binding to MPER 
bnAbs, to identify neutralization-competent MPER structures, 
and to determine if selected MPER epitopes can broaden the 
immune response as potential vaccines.
Methods: MPER epitopes were selected by biopanning with 
phage-displayed peptide libraries against bnAbs 4E10, 2F5 and 
Z13. Epitopes were screened in competition binding assays 
where M13-displayed epitopes competed with envelope 
peptides or infectious HIV-1 for antibody binding. In vivo 
response to MPER was assessed by M13 immunoprecipitation 
and neutralization competition assays using HIV-positive 
plasma, and immunogenicity of select epitopes was assessed 
in BALB/c mice. 
Results: Forty-six unique 4E10 epitopes were identified, 
representing both MPER homologous and non-homologous 
sequences. Fourteen epitopes, capable of competing with MPER 
peptide and HIV-1 for 4E10 binding, bound HIV-positive IgG. Of 
these, five epitopes absorbed MPER-specific neutralizing activity 
in HIV-positive patient plasma. Mouse immunization with the 
selected neutralization-competent MPER epitopes elicited HIV-1 
specific cellular and humoral immune responses and boosted the 
neutralizing activity of a gp145 Env subunit vaccine.
Conclusion: This study demonstrates the diversity of epitope 
recognition by 4E10 and the unique response to MPER in vivo. 
The M13-displayed, neutralization-competent structures of 
the 4E10 epitopes have the potential to elicit and boost HIV-
1 neutralizing antibody production in mice. Phage-displayed 
epitopes can rapidly and inexpensively be selected to provide 
epitope-specific depth and variation to HIV-1 vaccine designs 
without requiring modification to major vaccine components.
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The C-Terminal Tail of HIV-1 Envelope: A Unique 
Role for Conserved LLP Arginines in Env Functional 
Properties
A. Kuhlmann1, J.D. Steckbeck1, T.J. Sturgeon1, J.K. Craigo1,  
R.C. Montelaro1
1Center for Vaccine Research, Pittsburgh, PA, USA
Background: The C-terminal tail (CTT) of HIV-1 envelope 
transmembrane protein has recently been the subject of 
an increasing number of studies to determine its role in the 
architecture of the HIV virion and in virus replication. Published 
studies from our lab have previously demonstrated that the 
lentivirus lytic peptides (LLP) domains contained in the CTT 
present highly characteristic and conserved physicochemical and 
structural properties, including a highly preferential incorporation 
of arginine over lysine at conserved sites. 
Methods: We previously reported that nonconservative 
substitution of selected LLP arginines to glutamate residues 
in a reference provirus resulted in substantial changes in Env 
structure and function, reflecting an important role of the LLP 
arginines in overall Env phenotypes. To further evaluate the role 
of LLP arginines in Env properties, we have now evaluated the 
effects of conservative substitutions of selected LLP arginines 
by lysines in the context of the HIV 89.6 provirus. The various 
lysine substitution mutants are being characterized for Env 
incorporation, fusogenicity, infectivity, and antigenicity. 
Results: To date, the results of these studies clearly indicate 
marked changes in Env functional properties as a result of the 
lysine substitutions for native arginine residues. Thus, these data 
demonstrate for the first time unique functional properties that 
are intrinsic to arginine in the LLP domains and that cannot be 
replaced by the closely related lysine. 
Conclusion: Taken together, these observations reveal the 
critical role of conserved LLP arginine residues in affecting viral 
envelope phenotypes and further highlight the role of the CTT as 
a major determinant of overall HIV Env structural and functional 
properties. As such, their role as determinants of Env antigenicity, 
immunogenicity and as conserved epitopes is also investigated in 
experimental immunizations, and will be informative for future 
vaccine design.
P12.35
The Emptied Bacteriophage T4 Head: A Novel 
Nanoparticle Vehicle to Simultaneously Deliver HIV-1 
Antigens and Genes into Dendritic Cells
V. Rao1
1The Catholic University of America, Washington, DC, USA
Background: Simultaneous delivery of HIV-1 antigens and genes 
by a single nanoparticle will greatly aid in the development of 
effective HIV-1 vaccines. We have created a highly stable, empty 
bacteriophage T4 capsid shell which can be engineered both 
inside and out. The empty head can be filled with foreign DNA 
using a powerful DNA packaging machine. Its surface can be 
arrayed with proteins as fusions of the outer capsid proteins, Hoc 
(highly antigenic outer capsid protein) and Soc (small outer capsid 
protein). The 120 x 86 nm head has a capacity to accommodate 
170-kb foreign DNA and 1025 molecules of proteins. 
Methods: A “neck” mutant fails to seal the packaged head of 
phage T4. The packaged viral genome is spontaneously emptied 
to create empty space inside. The pentameric packaging motor 
is assembled at the portal vertex. A variety of genes; reporter 
genes luciferase and GFP, HIV-1 envelope genes gp41, gp145, and 
gp160, and/or molecular adjuvant gene GMCSF are packaged 
inside the head. The surface is arrayed with enzymes such as the 
tetrameric β-galactosidase or trimers of HIV-1 gp145 as fusions 
of Soc, and dendritic cell targeting ligands such as Dec205 mAb 
or CD40L as fusions of Hoc. 
Results: The emptied phage T4 head efficiently packaged foreign 
DNA. Packaging is highly promiscuous requiring no specific 
sequence. Long concatemers, plasmid DNAs, or short PCR-
amplified DNAs are packaged efficiently. Multiple genes and 
multiple copies of each gene are packaged into the same head. 
The surface is decorated with HIV-1 gp145 trimers and dendritic 
cell targeting ligands Dec205 mAb or CD40 ligand. The engineered 
head delivered the massive “payload” into dendritic cells to near 
100% efficiency. The delivered genes were abundantly expressed 
as analyzed by immunoelectron microscopy. 
Conclusion: A novel bacteriophage T4 nanoparticle efficiently 
delivers DNA-inside, protein-outside, prime-boost HIV-1 vaccines 
to dendritic cells.
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Development of Candidate HIV Vaccines Using VSV 
Vectors to Express Membrane-Anchored MPER 
Immunogen
M. Yuan1, A. Wilson1, M. Kemelman1, M. Panis1, I. Lorenz1,  
C. Jurgens1, M.J. Chiuchiolo1, R. King1, M. Caulfield1, C.L. Parks1
1International AIDS Vaccine Initiative, Brooklyn, NY, USA
Background: The HIV-neutralizing activity of monoclonal 
antibodies 2F5, 4E10, and Z13 have shown that the membrane-
proximal external region (MPER) of HIV Env is an important 
vaccine target, but development of an immunogen that elicits 
similar virus-neutralizing antibody responses against the MPER 
from a wide range of subtypes has been difficult to achieve. It has 
been proposed that a MPER immunogen must be membrane-
associated to adopt the conformation needed to elicit broadly 
neutralizing antibodies, and accordingly, we have developed 
Vesicular Stomatitis Virus(VSV) Vectors that express membrane-
anchored MPER epitopes. 
Methods: Replication-competent and single-cycle VSV vectors 
have been developed that express a truncated VSV G protein 
(G-Stem) in which the natural G ectodomain is replaced with 
MPER sequence (GStemMPER). The nucleotide sequence of 
GStemMPER has been optimized by computer based algorithms 
to ensure genetic stability. Several VSV vector modifications are 
also introduced for directing immune responses towards MPER 
rather than G. Those strategies include relocation of GStemMPER 
and VSV G glycoprotein to achieve maximal MPER expression 
while minimize the anti-vector immunity, incorporation of 
different VSV G serotypes and pseudotyping single- cycle VSV 
vectors with various types of glycoproteins. 
Results: Western blot analysis confirmed expression of MPER 
epitopes. Assessment by FACS showed the cell surface MPER 
being recognized by 2F5 and 4E10 monoclonal antibodies. 
Immunoprecipitation study further proved incorporation of 
MPER into viral particles. 
Conclusion: Multiple VSV-GStemMPER vectors are being 
evaluated in small animal studies to compare their 
immunogenicity and whether the membrane-anchored form of 
the MPER immunogen elicits humoral responses with a broad 
range of HIV neutralizing activity.
P12.37
Yeast Surface Display of HIV Env Protein Variants for 
the Discovery of Novel Vaccine Immunogens
S. Grimm1, M. Ackerman1
1Dartmouth College, Lebanon, NH, USA
Background: The discovery of broadly neutralizing antibodies 
(bnAbs) such as 4E10, pg9 and VRC01 binding to the HIV env spike 
has electrified the field and shows that, in principle, the human 
immune system is capable of producing protective antibodies 
against HIV. All current vaccination strategies have however 
failed to elicit such bnAbs, leaving room for novel approaches to 
address this problem.
Protein engineering techniques such as yeast surface display 
have proven potential for the discovery and affinity maturation 
of monoclonal antibodies. Antibody libraries are presented 
on yeast cells and flow cytometric sorting is used to identify 
antibody variants with improved properties. As antibodies, 
also HIV env spikes are posttranslationally modified in the 
secretory pathway and composed of disulphide bond-containing 
glycoproteins. We here investigated whether HIV spike protein 
variants can be displayed or secreted from surface of the yeast 
strain S. cerevisiae. 
Methods: A panel of HIV env spike protein-encoding genes 
was inserted in vectors allowing for the display or secretion of 
the encoded proteins in S. cerevisiae. The displayed protein 
variants were analyzed for binding to either bnAbs or pooled HIV 
immunoglobulin from the serum of infected individuals (HIVIg) 
using flow cytometry. The secreted protein variants were tested 
for binding activities on an Octet biosensor.
Results: We found that HIV env spike protein variants can be 
displayed or secreted from the yeast strain S. cerevisiae. Both 
displayed and secreted variants showed binding to bnAbs and HIVIg.
Conclusion: This study suggests that yeast surface display is 
as a viable option for the engineering of HIV env spike protein 
variants and may become a valuable tool for the discovery of 
novel vaccine immunogens.
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Evaluation of a Replication-Competent VSV-SIV 
Vaccine Candidate
C.K. Jurgens1, G. Morrow1, C. Boggiano1, M. Panis1,  
J. Coleman1, R. Powell1, M. Yuan1, M. Kemelman1, N. Tamot1, 
M. Lopez1, A. Ouattara1, S. Iyer1, M. Backer1, K. Wright1,  
A. Domi1, M. Chiuchiolo1, C.R. King1, M. Caulfield1, C. Parks1
1International AIDS Vaccine Initiative, Brooklyn, NY, USA
Background: Immunity elicited by live attenuated vaccines 
confers protection against viral pathogens causing measles, 
yellow fever, smallpox and others, but this approach is not well 
suited to HIV vaccine development. Accordingly, to develop a 
vaccine that incorporates features of a live virus that make it 
immunogenic without the inherent safety issues associated 
with attenuated lentiviruses, we are developing replication-
competent, recombinant vesicular stomatitis virus (rVSV) vectors 
for delivery of SIV and HIV vaccines.
Methods: An rVSV vector was constructed in which the 
natural glycoprotein (G) was replaced with SIVmac239 Env, 
and an additional transcription unit was introduced to encode 
SIVmac239 Gag. The chimeric VSV deltaG-SIV virus vaccine was 
rescued and evaluated in vitro and in vivo. 
Results: Infection of susceptible cells with this chimeric rVSV-
SIV GagEnv virus produced infectious VSV particles containing 
functional SIV Env, and lentivirus-like particles containing Gag 
and Env. Serial passage of rVSV-SIV GagEnv vector in CD4+/CCR5+ 
cells resulted in improved replicative fitness evident by a 2-log 
increase in infectious virus titers. This adapted virus retained 
CD4/CCR5 dependence, infected primary rhesus PBMCs and 
cells isolated from lymph node and duodenum tissues ex vivo. 
Primary human monocyte-derived dendritic cells (MDDCs) also 
were susceptible to infection with the rVSV-SIV GagEnv vector. 
Indian rhesus macaques were immunized with increasing doses 
of rVSV-SIV GagEnv intramuscularly (IM) to observe reactions 
to vaccination with this new vector and to quantify immune 
responses. At the highest dose of 1x108 PFU, no adverse reactions 
were observed and serum antibody responses against Gag and 
Env were elicited, which were boosted by IM immunization with 
Ad5-SIV Gag and Ad5-SIV Env vectors. 
Conclusion: A prototype chimeric VSV-SIV live virus vaccine 
was developed and evaluated in the NHP model. Chimeric VSV-
SIV and VSV-HIV vaccine candidates designed for improved 
replication and immunogenicity currently are being evaluated in 
vitro and in vivo. 
P12.39
Vaccination with Dendritic Cells Loaded with HIV-
1 Lipopeptides Elicits Broad T Cell Immunity and 
Control of Viral Load in HIV Infected Patients
Y. Levy1, R. Thiébaut2, M. Montes3, C. Lacabaratz1, L. Sloan4,  
S. Perusat2, C. Harrod3, C. Boucherie5, S. Zurawski 3, L. Richert2, 
G. Chêne2, J. Banchereau3, K. Palucka3
1INSERM U955-Université Paris Est, Créteil, France; 2INSERM, 
U897, France Univ Bordeaux Segalen, Bordeaux, France; 
3INSERM U899-Baylor Institute for Immunology Research, 
Dallas, TX, USA; 4Baylor Institute for Immunology Research, 
Dallas, TX, USA; 5INSERM U897, Bordeaux, France
Background: The DALIA trial tested the hypothesis that 
immunization with HIV peptide loaded Dendritic Cells (DC) 
may improve HIV immune responses and help to contain 
viral replication.
Methods: 19 pts with CD4 >500 cells/m3 and HIV RNA <50 cp/
ml under HAART received at W0, 4, 8 and 12 ex-vivo generated 
IFN-α DC loaded with HIV-1 lipopeptides. Analytical treatment 
interruption (ATI) was conducted from W24. HAART resumption 
regardless of the reason and CD4 <350 cells/mm3 (or <25%) were 
considered as end points. HIV-specific immunity was evaluated 
at baseline, W16, and W48 using: i) ex vivo IFN-γ ELISPOT; ii) intra 
cellular staining; iii) multiplex analysis. PBMCs were stimulated 
with HIV peptide pools. Student t-test and Wilcoxon signed-rank 
tests were used with estimation of the False Discovery Rates 
(FDR) for controlling test multiplicity.
Results: Vaccine regimen was well tolerated. Following ATI, all 
pts experienced a viral rebound in 14 days in median (IQR 8-27). 
Median highest observed VL (peak) was 5 (4.28-5.23) log10 cp/
ml. Three patients resumed HAART and eight had CD4 <350 
cells/mm3. Median (IQR) SFU/106 PBMC rose from 186 (140-
670) at baseline to 761 (470-1154) and 1878 (1102-4443) at W16 
and 48, respectively. At the same time points the breadth of the 
response (nb of peptide pools) increased from 1 (1-3) to 4 (2-
5) (P=.009) and 6 (3-7) (P=.008). % of polyfunctional CD4+ (> 2 
cytokines among: IFN-γ,TNF-α,IL-2) increased from 0.026% (w-
4) to 0.32% (w16) (P=.002). Respective % of CD8+ were 0.26% 
and 0.35% (P=.005). Production of IL-2, IFN-g, IL-21, IL-13, IL-17 
increased significantly at W16 (FDR<.05). An inverse correlation 
was found between the peak of VL and % of polyfunctional CD4+ 
(r=-0.63, FDR=.007), production of IL-2 (r=-0.67, FDR=.006), IFN-g 
(r=-0.58, FDR=.01), IL-21 (r=-0.66, FDR=0.006) and IL-13 (r=-0.78, 
FDR=.001).
Conclusion: DC vaccination elicited polyfunctional HIV-
specific responses associated with a reduced peak viral load 
following ATI.
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From HIV Protein Sequences to Viral Fitness 
Landscapes: A New Paradigm for In Silico Vaccine 
Design
A.L. Ferguson1, A.K. Chakraborty2
1University of Illinois at Urbana-Champaign, Urbana, IL, USA; 
2MIT, Cambridge, MA, USA
Background: An inexpensive prophylactic vaccine offers the best 
hope to curb the HIV/AIDS epidemic gripping sub-Saharan Africa. 
Systematic means to guide the design of an effective immunogen 
for this, and other, infectious diseases are not available. What 
is required is a method to chart the peaks and valleys of viral 
fitness as a function of amino acid sequence. An efficacious 
vaccine would eject the virus from the high fitness peaks, and 
drive it into the valleys where its compromised fitness impairs its 
ability to replicate and inflict damage to the host.
Methods: Appealing to spin glass models in statistical physics, we 
present a novel approach to translate viral sequence databases 
into landscapes of viral fitness. These inferred models furnish a 
quantitative description of viral replicative capacity as a function 
of amino acid sequence. We illustrate this approach in the 
development of landscapes for the proteins of HIV-1 clade B Gag.
Results: In comparisons to experimental and clinical data, our 
inferred landscapes demonstrate excellent agreement with: 1) 
in vitro replicative fitness measurements, 2) clinically observed 
high-fitness circulating viral strains, 3) documented HLA 
associated CTL escape mutations, and 4) intra-host temporal 
adaptation pathways revealed by deep sequencing. These 
favorable comparisons support our landscapes as reflections of 
intrinsic viral fitness. We illustrate the value of such descriptions 
in the computational design of a CTL Gag immunogen.
Conclusion: We present a novel methodology to translate viral 
sequence data into quantitative landscapes of viral fitness. In 
an application to HIV-1 Gag, we illustrate excellent agreement 
of our model predictions with experimental and clinical data, 
and demonstrate a powerful new approach for HIV immunogen 
design. We anticipate that this approach may represent 
a heretofore unprecedented means to synthesize fitness 
landscapes for diverse pathogens, and may provide the basis for 
the design of improved prophylactic and therapeutic strategies.
P12.41
Preferential Targeting of Conserved Gag Regions 
After Vaccination with a Heterologous DNA Prime 
Modified Vaccinia Ankara Boost HIV Vaccine Regime
A. Bauer 6, L. Podola 6, A. Haule1, L. Sudi1, C. Nilsson2, P. 
Mann6, M. Missanga1, B. Kaluwa1, L. Maboko1, C. Lueer6, 
M. Mwakatima1, S. Aboud3, M. Bakari3, J. Currier4, M. 
Robb4, S. Joseph5, S. McCormack5, E. Lyamuya3, B. Wahren2, 
E. Sandström2, G. Biberfeld2, M. Hoelscher6, A. Kroidl6, C. 
Geldmacher6
1Mbeya Medical Research Programme, Mbeya, United 
Republic of Tanzania; 2Karolinska Institute and Swedish 
Institute for Communicable Disease, Solna, Sweden; 
3Muhimbili University of Health and Allied Sciences (MUHAS), 
Dar Es Salaam, United Republic of Tanzania; 4US Military 
HIV Research Program, Rockville, MD, USA; 5MRC Clinical 
Trials Unit, London, United Kingdom (Great Britain); 6Ludwig-
Maximilians University of Munich, Munich, Germany
Background: Genetic diversity is a major challenge in the design 
of vaccines against variable viruses, including HIV. Engineering 
vaccines to induce immune responses that preferentially target 
conserved antigenic regions could thus contribute to improved 
HIV vaccines.
Methods: During the Tanzania Mozambique HIV Vaccine trial 
(TaMoVac 01) phase 2a HIV vaccine trial, HIV negative Tanzanian 
volunteers received 3x 0.6 or 1mg intradermal injections with 
a multiclade, multigene DNA vaccine that included 2 plasmids 
encoding for clade B Gag-p37 (p17 & p24) and a recombinant 
Gag-p37 (clade B p17 & clade A p24). DNA vaccine recipients 
were boosted with Modified Vaccinia Ankara (MVA)-CMDR 
expressing clade A Gag that additionally covered the Gag-p15 
region. Vaccine-induced T cell responses were characterized 
using IFN-gamma ELISpot in 45 participants after stimulation of 
fresh PBMC with 9 peptide pools subdividing Gag into 9 distinct 
antigenic regions. Data were analyzed using the Mann-Whitney 
test and linear regression analysis. 
Results: Antigenic regions p17 and p24 included in the DNA 
prime and the MVA boost were recognized with higher median 
magnitude than antigenic regions within p15, which was only 
covered by the MVA boost (p<0.0001). Antigenic regions within 
p24 (clade A&B prime and clade A boost) were better recognized 
than those within p17 (clade B prime and clade A boost; p<0.0001). 
We then determined the sequence homology between the MVA 
and the DNA Gag vaccine immunogens for each of the peptide 
pools. The sequence homology ranged between 91% and 0% (for 
p15) of total amino acids within a given peptide pool and there 
was a linear correlation between the sequence homology and 
the response rate (p=0.04, r2=0.47).
Conclusion: These preliminary results support the hypothesis 
that heterologous prime-boost vaccine regimens preferentially 
induce immune responses targeting regions that are conserved 
between the priming and boosting vaccines. 
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Comparison of Cellular and Humoral Immune 
Responses Induced by Primary, Consensus or Mosaic 
HIV-1 Env DNA Vaccines 
J. Yan1, P. Pankhong2, A.S. Khan1, N.Y. Sardesai1, D.B. Weiner2
1Inovio Pharmaceuticals, Blue Bell, PA, USA; 2University of 
Pennsylvania, Philadelphia, PA, USA
Background: The genomic variability of HIV viruses has impeded 
the development of globally relevant HIV vaccines with ability 
to induce strong and broad cellular and humoral immune 
responses. Many strategies, such as codon/RNA optimization, 
addition of highly efficient leader sequences, use of consensus or 
mosaic antigens, and electroporation (EP) have all been applied 
to enhance the breadth and magnitude of immune responses 
induced by DNA vaccines. 
Methods: Highly optimized clade B and C consensus envelope 
DNA vaccines (pEY2E1-B and pEY3E1-C) were developed. Their 
immunogenicity was compared to the immune responses induced 
by an optimized mosaic gp160 envelope vaccine (pMosEnv) or 
optimized primary clade B and C envelope vaccines (pPK61-
14 and p96ZM651gp140-CD5). The immunogenicity of these 
constructs was studied in different murine models. All vaccines 
were delivered using electroporation. Antibody responses were 
determined by ELISA and cellular responses by IFN-γ ELISPOT. 
Results: Antibody analysis supported that the consensus 
immunogens induced stronger clade-specific antibody response 
than the primary immunogens, while the mosaic antigen was a 
poor inducer of antibody responses. Compared to the primary 
vaccine constructs, both consensus and mosaic constructs were 
more potent at driving diverse cellular immune responses. The 
strongest cross-reactive immune responses against various 
consensus peptides libraries were induced by pEY2E1-B and 
pEY3E-C. The consensus immunogens were up to three times 
more potent at driving subtype-specific responses that recognized 
the different cross-clade immunogens. pMosEnv exhibited robust 
cellular responses when a PTE peptide set was used. 
Conclusion: We conclude that the highly optimized consensus 
immunogens may fold into a relatively native conformation and 
exhibit improved focus on antibody and T cell conserved regions, 
while the mosaic immunogen provides important T cell responses 
but does not preserve the native structure of envelope to allow 
for similar antibody responses in their current forms. Further 
exploration of these immunogens will be interesting. 
P12.43
In Silico Prediction of the Neutralization Range of 
Human Anti-HIV Monoclonal Antibodies
E. Shmelkov1, C. Krachmarov2, A. Grigoryan1, A. Agarwal1,  
A. Statnikov3, T. Cardozo1
1New York University School of Medicine, New York, NY, 
USA; 2University of Medicine and Dentistry of New Jersey, 
Newark, NJ, USA; 3NYU Center for Health Informatics and 
Bioinformatics, New York, NY, USA
Background: Antigenic variation is a primary obstacle to HIV-
1 vaccine development since antibodies (Ab) directed against 
the viral envelope have widely variable and poorly predictable 
cross-strain reactivity. The breadth of cross-strain reactivity is 
usually estimated by in vitro neutralization of a broad panel of 
HIV-1 viral strains by a query antibody. However, this approach is 
cumbersome and cannot be scaled up to assess the more than 
60,000 circulating HIV-1 viruses.
Methods: To address this issue, we used in silico docking of a 
flexible peptide, representing the epitope-containing part of 
a viral gp120, to a static crystallographic conformation of an 
antigen-combining site of an Ab. This procedure was applied to 
predict whether neutralization would occur between the pair. To 
train the prototype method we used a panel of 59 V3 sequence 
diverse pseudoviruses (psVs) controlled for masking effects. All 
psVs had an associated experimentally derived IC50 value for 
neutralization by anti-V3 monoclonal Abs 2219 and 447-52D.
Results: We optimized the method for each of the two Abs by 
determining an optimal docking model (optimal boundaries 
of a docking peptide and an optimal Ab crystallographic 
conformation) giving the largest area under the prediction 
ROC curve (AUC) on the training set of 59 psVs. The prediction 
accuracy for the optimized method was then estimated: the AUC 
was equal to 0.96 (95% CI (0.91; 1)) for 2219, and to 0.88 (95% CI 
(0.79; 0.97)) for 447-52D.
Conclusion: The method accurately predicts the neutralization 
of any HIV-1 strain by mAbs 2219 or 447-52D based solely on 
neutralization assay independent energetics and 3D structural 
parameters. The neutralization range of these anti-V3 mAbs can 
therefore be precisely determined in silico. Furthermore, given 
the fact that mAbs 2219 and 447-52D have completely different 
binding modes, we anticipate that our approach is extensible to 
other antibody-viral complexes with known structure.
Topic 12:  Vaccine Concepts and Design
PO
ST
ER
S
263
Posters
AIDS Vaccine 2012
P12.46
A New Strategy for Repeated Application of 
Adenovirus Based Vectors: Proof-of-Concept in 
Rhesus Macaques Challenged with SIVmac239
C. Sun1, L. Feng1, L. Xiao1, P. Li1, L. Zhang2, L. Chen1
1Guangzhou Institute and Biomedicine and Health (GIBH), 
Guangzhou, China; 2Comprehensive AIDS Research Center, 
Tsinghua University, Beijing, China
Background: It is well recognized that highly active antiretroviral 
therapy (HAART) can control HIV/AIDS and prolong patient’s 
life. However, HAART is associated with drug toxicity, drug 
resistant, and patient’s affordability. Therefore, developing 
an effective therapeutic vaccine that could induce HIV-specific 
immune responses may provide a solution to reduce the need 
of antiretroviral therapy. Adenovirus based vaccines have been 
extensively evaluated as a vaccine vehicle for HIV/AIDS and a 
variety infectious diseases, however, it has been a major concern 
that anti-Ad5 neutralizing antibodies in general population or 
after the first dose of immunization can hinder the its practical 
application. The idea of using less prevalent adenovirus serotypes 
lack of long-term safety record including oncogeneicity. 
Moreover, any adenovirus serotype will inevitablely induce 
neutralizing antibodies after one single use which render the 
strategy of using more serotypes infeasible.
Methods: In this study, we explored a novel “one-size-fits-all” 
strategy, namely AVIP (Adenoviral Vector Infected PBMC), to 
circumvent the attenuated efficacy of Ad-based vaccines due to 
anti-Ad immunity. 
Results: We demonstrated that this AVIP strategy can elicit 
SIV-specific responses in both Ad5-seropositive and Ad5-
seronegative macaques. Interestingly, comparable SIV-
specific but weaker Ad5-specific responses were elicited in 
Ad5-seronegative monkeys received AVIP immunization as 
compared to direct injection of Ad5-SIV vaccines. Then a cohort 
of Ad5-seropositive SIVmac239-infected monkeys received AVIP 
immunization with Ad5 vectors expressing SIVmac239 Gag, 
Pol and Env with HAART. After therapeutic immunization, SIV-
specific response was induced in vaccinated monkeys whereas 
a slower responses were observed in non-vaccinated monkeys. 
The functional immunological profiles were also being detected, 
and we are also monitoring whether this immunological benefit 
would afford a virological benefit.
Conclusion: Our goal is to further develop the AVIP strategy as a 
simple but practically effective method for repeated delivery of 
Ad5-based vaccines in humans for HIV and other diseases.
P12.45
Engineered Microneedle Arrays for Transcutaneous 
HIV Vaccine Delivery
P. DeMuth1, B. Huang1, Y. Min1, D. Barouch2, P. Hammond1,  
D. Irvine1
1MIT, Cambridge, MA, USA; 2Harvard Medical School, Boston, 
MA, USA
Background: Needle-free delivery has the potential to enhance 
vaccine efficacy and safety, as well as facilitate cost-effective 
global vaccine distribution and storage. To this end, microneedle 
arrays provide the ability for pain-free, safe, and convenient 
materials delivery through disruption of the outer layers of 
the skin to access potent immune-competent cell populations 
residing within the epidermal/dermal tissues. 
Methods: We have employed this strategy to design a series 
of vaccine-delivery strategies based on the rapid delivery of 
dried vaccine-containing surface-coatings from biodegradable 
microneedles upon gentle application to the skin. We have 
demonstrated the utility of this approach for the rapid and 
convenient delivery of plasmid DNA as well as recombinant 
adenoviral vectors expressing model HIV antigens. 
Results: When used to deliver a plasmid expressing SIV-Gag 
together with poly(I:C) in mice, these engineered microneedles 
elicited stronger cellular and humoral immunity than traditional 
naked DNA injections and were comparable in potency to 
DNA administered with in vivo electroporation. Furthermore, 
microneedle delivery of a luciferase-expressing plasmid in 
explanted skin from Rhesus macaques showed significantly 
enhanced expression (~100-fold greater) relative to injected 
dose-matched controls. In parallel, we designed coatings to 
encapsulate replication-deficient adenoviral vectors, and dried 
microneedle-formulated Ad vaccines were observed to maintain 
biological activity at room temperature for in excess of 8 weeks, 
while control formulations rapidly lost activity within 7 days. 
Microneedle-delivery of adenoviral vectors expressing SIV-
Gag was observed to produce cellular and humoral immune 
responses comparable to traditional intramuscular/intradermal 
injection. Thus, this microneedle-based delivery strategy has the 
potential to provide enhanced vaccine stability while maintaining 
efficacy equivalent to traditional approaches. 
Conclusion: Together, these results demonstrate the promise 
of microneedles for effective and safe vaccine delivery while 
showcasing the additional potential for greater stability in 
storage and more potent immunogenicity.
Supported by: Ragon Inst. of MGH, MIT, and Harvard, NIH 
(AI095109), Dept. of Defense (W911NF-07-D-0004)
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Antigenic Mimicry of Mammalian Oligomannose by a 
Naturally Occurring Bacterial Oligosaccharide and Its 
Implications for HIV Vaccine Design
C. De Castro1, B.E. Clark3, K. Auyeung3, A. Marzaioli1,  
R.L. Stanfield2, I.A. Wilson2, R. Pantophlet3
1University of Napoli Federico II, Napoli, Italy; 2The Scripps 
Research Institute, La Jolla, CA, USA; 3Simon Fraser University, 
Burnaby, Canada
Background: Oligomannose sugars on gp120 are of significance 
to HIV vaccine design because of the description of the broadly 
neutralizing mAb 2G12 and, more recently, of the potent and 
broadly neutralizing ‘PGT’ series of mAbs, which bind with high 
affinity to clusters of oligomannose moieties on gp120. Attempts 
to elicit oligomannose-specific antibodies have focused mainly 
on immunizing with antigenic clusters of synthetic oligomannose 
or natural oligomannose. These strategies have had limited 
success, suggesting that alternative approaches are needed. 
Here, we present the surface lipo-oligosaccharide (LOS) of 
Rhizobium radiobacter Rv3 that antigenically mimics the 2G12 
epitope, as one potential new avenue of exploration.
Methods: The chemical structure of the Rv3 OS was determined 
by NMR and its antigenic similarity to the 2G12 epitope 
determined by ELISA and X-ray crystallography. Immunogenicity 
of the Rv3 OS and its ability to elicit antibodies of 2G12-like 
specificity was assessed by immunizing mice with heat-killed 
Rv3 bacteria. 
Results: The detailed chemical analysis of the Rv3 OS 
revealed that its carbohydrate backbone consists of a unique 
tetramannose backbone that is analogous to the D1 arm of 
mammalian oligomannose. 2G12 bound with at least similar 
affinity to purified Rv3 OS as reported for oligomannose. The 
2.4 Å-structure of the 2G12:Rv3 OS complex shows that 2G12 
contacts all four mannosyl moieties in the Rv3 backbone that 
mimic the D1 arm, with the majority of contacts occurring 
with the terminal mannose disaccharide. Antibodies elicited 
by immunizing with heat-killed bacteria bound a synthetic 
tetramannose epitope and monomeric gp120.
Conclusion: Although the elicited antibodies failed to exhibit the 
desired neutralizing activity, our data suggest that presentation 
of an antigenic analog of mammalian oligomannose in a bacterial 
context presents a novel avenue for pursuing immunogens 
to elicit oligomannose-specific HIV neutralizing antibodies. 
The development of Rv3-based bioconjugates using human 
carbohydrate vaccine carriers is ongoing.
P12.47
Oral Delivery of Transgenic Plant-Derived HIV-1 p24 
Antigen in Low Doses Shows a Superior Priming 
Effect in Mice Compared to Higher Doses 
I. Lindh1, A. Bråve2, D. Hallengärd2, R. Haddad3, Å. Strid1,  
S. Andersson3
1School of Science and Technology, Örebro University, Örebro, 
Sweden; 2Swedish Institute for Communicable Disease 
Control, Stockholm, Sweden; 3Örebro University Hospital, 
Sweden, Örebro, Sweden
Background: The gut associated lymphoid tissue (GALT) includes 
around two thirds of the total lymphoid system. CD4+ T-cells 
in the GALT are a main target for HIV during primary infection. 
Thus, immunization targetting GALT is likely to be of importance 
for an effective vaccine strategy. Transgenic plants expressing 
HIV antigens can reach GALT conveniently. This system allows 
multiple boosts, has simple logistics (no cold chain, no injections) 
and large production capacity. 
Methods: Three groups of mice were given extract from plant 
lines expressing HIV-1 p24 at (A) low level (20 ng/feeding); (B) 
high level (460 ng/feeding); (C) control (wild type, 0 ng). No 
adjuvant was included. The extracts were administered by 
gastric tube day 0, 14 and 28. On day 55 all mice were given an 
intramuscular (i.m.) boost with 10 micrograms of purified p24 
antigen. Immune responses were determined by measurement 
of p24-antibodies in serum by ELISA. 
Results: The mice immunized by the low dose plant line (A) 
showed a higher systemic immune response after i.m. boost 
compared to the high dose group (B). The w.t. controls (C) had 
undetectable p24-responses. The responses in group A were 3 
to 10 times higher (ELISA OD values) than in group B. Pre-boost 
antibody responses were at background levels in all groups. 
Preliminary analyses indicate a predomninant Th1-type response 
(antigen-specific IgG2a higher than IgG1). 
Conclusion: Simple and inexpensive means of vaccination 
are important in order to reach large numbers of people with 
effective vaccine regimens. The HIV-1 p24 low dose transgenic 
plant extracts given orally showed a superior priming effect in 
mice compared to the p24 high dose extracts. This could be an 
immunization method and route worth exploring further. 
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Different Biological Activity of CD154-SIVgp41 Fusion 
Protein Vaccine Component in Naïve or Pre-immune 
Individuals
L.M. Smith1, L.M. Parodi1, V.L. Hodora1, L.D. Giavedoni1
1Texas Biomedical Research Institute, San Antonio, TX, USA
Background: Trimeric gp41 might be an important target for 
neutralizing antibodies; however, the poor immunogenicity of this 
region may be due to its lack of exposure on native virus. CD154 
(CD40L) is a trimeric glycoprotein found on activated CD4 T-cells 
that binds to CD40 on APCs and leads to B-cell activation and 
differentiation to plasma cells. We designed a novel immunogen 
with the potential for inducing neutralizing antibodies to gp41 
and for stimulating activity on APC and B-cells.
Methods: A flexible (FL) and helical (HL) linkers were used to 
join CD154 and SIV gp41, which are trimeric glycoproteins 
with opposing polarities. Recombinant vaccinia viruses (VVs) 
were engineered to express CD154FLgp41 and CD154HLgp41 
glycoproteins. PBMCs from SIV naïve and immune macaques were 
exposed to wild type VV (VVwt) or to recombinant VVs expressing 
SIV Gag, gp160, and Nef (VVgen), or SIV Gag and Nef, and CD154-
gp41 fusion proteins. Cytokine production and cell activation were 
analyzed by Luminex and flow cytometry, respectively. 
Results: Both linkers allowed proper protein folding and 
CD154 biological activity. Compared to VVwt, VVgen, and 
VVCD154FLgp41, PBMCs from naïve macaques exposed to 
VVCD154HLgp41 expressed higher levels of IL-6, IL-1Rα, IL-1β, 
RANTES, GRO-α, TNF-α, IL-8, IP-10 and IL-10. In contrast, PBMCs 
from SIV-immune macaques expressed more IL-6, MIP-1α, MIP-
1β, INF-α, IL-1β, and MCP-1. Interestingly, lymphocytes from 
SIV-immune macaques were activated by VVCD154HLgp41 and 
VVCD154HLgp41 more than cells exposed to SIVgen.
Conclusion: Fusion proteins of CD154 and gp41 with either HL or 
FL assembled into trimers and activated immune cells. However, 
there was a differential cytokine expression for the fusion protein 
containing the HL, including chemokines that inhibit HIV entry. 
This increased biological activity may indicate that the helical 
linker allows for a more functional folding of the CD154 moiety. 
The CD154HLgp41 fusion protein will be tested in NHP as a novel 
vaccine component.
P12.49
Skin Tattooing as an Effective Tool for Delivering DNA 
and Protein Vaccine Immunogens
Y. Chiu1, X. Jiang1, R. Kumar2, C.E. Hioe3, S. Zolla-Pazner3,  
X. Kong1
1NYU School of Medicine, New York, NY, USA; 2Veterans Affairs 
New York Harbor Healthcare System, New York, NY, USA; 
3Departments of Pathology / NYU School of Medicine, New 
York, NY, USA
Background: Skin is an excellent site for vaccine administration 
due to the abundance of antigen presenting cells and easy 
access. When DNA or protein is delivered into the skin, uptake 
and expression of immunogens can lead to a rapid and robust 
induction of immune responses.Skin tattooing has been 
suggested as a useful tool delivering vaccines intradermally. We 
have chosen to use the skin tattooing technique to deliver both 
DNA and protein immunogens that are focusing the immune 
response on the highly immunogenic V3 region of HIV-1 gp120.
Methods: A GFP-containing plasmid was used first to optimize 
the protocol for skin tattooing on BALB/c mice. Subsequently, 
BALB/c mice were immunized using a DNA prime/Protein boost 
regimen. DNA skin tattooing was used first as the prime to 
deliver a gp120-encoding DNA plasmid intradermally at weeks 
0, 2, and 4. The animals were then given a fusion protein, V3-
bearing cholera toxin subunit B (V3-CTB), via skin tattooing 
(Group1; n=5) or intramuscular injection (Group2; n=5) at weeks 
10 and 14. Two weeks after the final immunization, the sera were 
collected and analyzed.
Results: GFP expressed in skin cells was visualized by confocal 
microscopy showing that skin tattooing can effectively 
deliver DNA into these cells. ELISA assays using sera drawn 
after the final immunization confirmed that tattoo-delivered 
DNA followed by V3-CTBelicited V3 binding antibodies, and 
these antibodies have potent neutralizing activities in an HIV 
pseudovirus neutralization assay.
Conclusion: Immunization by skin tattooing is an easy, effective, 
and economical way to administer both DNA and protein 
vaccines. Interestingly, the needle perforations may serve as a 
potent and natural adjuvant for the immunization, making skin 
tattooing a promising vaccine delivery technique.
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Viral Vector Delivery of Env Trimer Immunogens
C.L. Parks1, S. Rabinovich1, P.J. Tiberio1, K.J. Wright1, M. Yuan1, 
M.G. Delboy1, M. Kemelman1, A.J. Wilson1, R.L. Powell1,  
S. Hoffenberg1, M.J. Chiuchiolo1, C. Boggiano1, G. Morrow1,  
I.C. Lorenz1, C.K. Jurgens1, X. Zhang1, R.W. Lindsay1, W.C. Koff1,  
C.R. King1, M.J. Caulfield1
1International AIDS Vaccine Initiative, Brooklyn, NY, USA
Background: Our objective is to develop viral vaccine vectors 
that will elicit neutralizing antibodies that are specific for the 
functional attachment protein on the HIV particle. To achieve 
this goal, we are developing vectors that express membrane-
anchored Env trimers that closely mimic authentic functional 
glycoprotein spikes. 
Methods: We are using vesicular stomatitis virus (VSV) 
as a vector platform for delivery of Env immunogens as 
transmembrane glycoproteins. We have investigated a variety of 
vector designs and Env modifications to identify combinations 
that balance the practical requirement for vector genetic 
stability with factors influencing antibody responses including 
immunogen abundance, efficient post-translational processing, 
and presentation of antigenic determinants representative of a 
functional trimeric spike. 
Results: Substituting domains in Env with analogous regions 
from VSV G, we have developed a number of immunogens that 
are efficiently expressed and incorporated in the infected cell 
plasma membrane, and in most cases, progeny virus particles. 
Antigenicity was evaluated using a panel of monoclonal 
antibodies specific for various Env epitopes.
Conclusion: We identified modified Env immunogens that contain 
determinants for most classes of known broadly neutralizing 
monoclonal antibodies including those with specificity for the 
CD4 binding site (b12, PGV04), V3 and carbohydrate (PGT126), 
the MPER (2F5 and 4E10), the glycan shield (2G12), and structures 
formed by V1/V2 and carbohydrate (PG9, PG16, PGT145). Results 
from ongoing immunogenicity studies with vectors encoding SIV 
or HIV Env immunogens (subtypes A, B, or C) indicate that the 
modified trimers elicit antibody responses in small animals and 
nonhuman primates, and that some live vectors induce mucosal 
antibodies. Study sera are being analyzed for virus neutralization 
activity and fine specificity.
P12.51
Co-immunization with HIV Env DNA and Protein Elicit 
Long-Lasting Strong Cellular and Humoral Immune 
Responses
J. Li1, A. Valentin1, V. Kulkarni1, C. Alicea1, R. Kelly Beach1,  
M. Rosati1, R. Jalah1, S. Reed2, B.K. Felber1, G.N. Pavlakis1
1Frederick National Laboratory for Cancer Research, Frederick, 
MD, USA; 2Infectious Disease Research Institute, Seattle, WA, 
USA
Background: We have previously reported that potent, long-
lasting HIV-1 Env-specific cell-mediated immune responses could 
be elicited in rhesus macaques and mice using plasmids encoding 
env DNA as the immunogen. Subsequent experiments showed 
that combination of DNA and protein in the form of inactivated 
virus particles provided significant protection from infection and 
high viremia. We examine a vaccine platform combining DNA and 
recombinant Env protein co-immunization at the same time to 
generate both strong cellular and humoral immune responses.
Methods: Mice or macaques were immunized with HIV env 
gp120 DNA vaccine and/or purified gp120 protein from clade 
B or clade C isolates. Mice were immunized twice at 4 weeks 
interval with DNA only, protein only formulated in EM005 
adjuvant, or DNA&protein/EM005. Macaques were immunized 
twice at 4 weeks interval with DNA only, DNA&protein, 
DNA&protein/EM005.
Results: DNA&protein co-immunization enhances the Ab 
responses compared with DNA or protein only in mice. 
DNA&protein co-immunization generated similar levels of 
cellular immune responses compared to mice immunized 
with DNA only but those levels were significantly higher than 
those obtained in mice immunized with protein only. The 
establishment of a mouse model that gives similar results with 
the macaque model enhances our ability to test many variations 
and optimize the vaccine. Importantly, in macaques this 
strategy elicited higher binding and neutralizing Ab responses 
than DNA only and the neutralizing Abs showed broad activity. 
The presence of the EM005 adjuvant further enhanced the 
Ab responses. These responses were correlated with the up-
regulated activation of dendritic cells by EM005. The longevity 
of the Ab response was superior.
Conclusion: The strategy of DNA and protein co-immunization 
has potential for development as a prophylactic HIV-1 
vaccine. Our challenge studies show that DNA and protein 
co-immunized animals developing long-lasting Ab titers were 
protected from infection.
Topic 12:  Vaccine Concepts and Design
PO
ST
ER
S
267
Posters
AIDS Vaccine 2012
P12.54
Rational Modification of an HIV-1 gp120 Results in 
Enhanced Neutralization Breadth When Used as a 
DNA Prime
A. Wallace1, M.J. Duenas-Decamp1, M. Vaine1, P.J. Peters1,  
S. Wang1, P.R. Clapham1, S. Lu1
1University of Massachusetts Medical School, Worcester, MA, 
USA
Background: The identification of phenotypic features of the 
HIV-1 envelope glycoprotein that correlate with neutralization 
breadth is an important goal of HIV vaccine research. Recently 
we compared the immunogenic potential of two gp120s differing 
in their ability to utilize CD4; B33 (highly macrophage topic) 
and LN40 (non-macrophage tropic). Using a DNA prime protein 
boost regimen in New Zealand White Rabbits, LN40-primed 
sera displayed enhanced breadth compared to the B33-primed 
group, with differences in immunogenicity between groups 
modulated by specific residues within and flanking the V3 loop 
and the CD4bs. To better understand the role of these residues 
in eliciting breadth, we introduced reciprocal mutations between 
LN40 and B33 at these critical positions.
Methods: Three groups of four rabbits were primed with one of 
three chimeric LN40/B33 gp120 DNAs, followed by a polyvalent 
protein boost. Time course and endpoint titers were determined 
via ELISA. Neutralization breadth was analyzed by Monogram 
against a panel of sixteen viruses using a Phenosense neutralization 
assay. Anti-gp120 serum specificities were determined using a set 
of overlapping peptides spanning the entire gp120 via ELISA.
Results: We found that sera primed with a B33 chimera containing 
specific LN40 residues within the V3 loop and the CD4 binding 
loop displayed enhanced neutralization breadth against a cross-
clade panel of Tier 1 and 2 viruses compared to the B33-primed 
group. Interestingly, a second B33 chimera containing two 
additional LN40 substitutions (Stu-Bsu R373/N386) within C3/V4 
primed the broadest response, being broader than even the LN40-
primed group. Additionally, peptide ELISAs showed differences in 
reactivity between priming groups which were most pronounced 
for the C3/V4 region, suggesting an important role for these 
regions in modulating serum antibody responses against gp120. 
Conclusion: While the role of R373/N386 is still under investigation, 
these results represent potentially promising steps towards the 
rational, targeted design of a better gp120 immunogen
P12.53
Optimizing Expression of Functional HIV Envelopes in 
rVSV-ΔG Vaccine Vectors 
K.J. Wright1, M. Yuan1, A. Wilson1, C. Boggiano1, M. Kemelman1, 
P. Tiberio1, S. Phogat2, I. Lorenz3, S. Hoffenberg1, C. Jurgens1,  
C. King1, M. Caulfield1, C. Parks1
1IAVI, Brooklyn, NY, USA; 2Sanofi Pasteur, USA; 3Boehringer 
Ingelheim, USA
Background: Our objective is to develop replicating 
recombinant vesicular stomatitis virus (rVSV) vectored HIV 
vaccine candidates that deliver membrane-bound trimeric HIV 
Env in a functional conformation. 
Methods: Using a combination of nucleotide sequence 
optimization and protein domain swapping, we have generated a 
panel of novel gene inserts for VSV vectors that encode chimeric 
HIV-1 and VSV glycoprotein immunogens (EnvG). A stable VERO 
cell line engineered to express human CD4 and CCR5 was used 
to rescue rVSV vectors in which the G gene was replaced with 
coding sequence for several different EnvG proteins. 
Results: Analysis of cells transfected with plasmid DNA expressing 
EnvG constructs revealed abundant cell surface expression of 
chimeric glycoproteins. The expressed proteins retained CD4-
dependent membrane fusion activity, which is one of the main 
characteristics of functional HIV Env. The chimeric EnvG in which 
the signal peptide (SP), transmembrane (TM) and cytoplasmic tail 
(CT) domains of HIV Env were replaced with functionally related 
domains of VSV G were expressed efficiently and supported vector 
propagation to high titer specifically in CD4+CCR5+ cells. Flow 
cytometric analysis demonstrated that cell-surface expressed 
EnvG chimeras were recognized by a spectrum of HIV-1 specific 
broadly neutralizing monoclonal antibodies, including those that 
bind preferentially to the trimeric spike. Western blot analysis on 
purified viruses indicated that EnvG glycoproteins that contained 
the VSV G TM and CT were incorporated efficiently into VSV 
particles. Interestingly, an EnvG in which the Env MPER domain 
was replaced with membrane-proximal sequence from G was 
more effectively processed and incorporated into virus particles. 
Conclusion: Chimeric EnvG glycoproteins expressed efficiently 
from plasmid DNA and rVSV vectors in membrane-bound, 
fusion-competent conformation and displayed relevant HIV-
1 broadly neutralizing antibody epitopes. Small animal studies 
are underway to assess Env-specific humoral immune responses 
elicited by rVSV vectors encoding EnvG immunogens.
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Native Envelope-Based Immunogens Derived from 
Critical Timepoints in the Development of Breadth 
Elicit Rapid Neutralizing Antibodies in Rabbits
D.C. Malherbe1, A.J. Hessell1, N.D. Sather2, B. Guo1, S. Pandey1,  
F. Pissani1, H. Robins3, S. Kalams4, L. Stamatatos2, N.L. Haigwood1
1Oregon Health and Science University, Beaverton, OR, USA; 
2Seattle BioMed, Seattle, WA, USA; 3Fred Hutchinson Cancer 
Research Center, Seattle, WA, USA; 4Vanderbilt University, 
Nashville, TN, USA
Background: HIV-1 evolves rapidly within the host, resulting in 
the development of diverse variants called a viral “quasispecies” 
population. A major goal of vaccine efforts is the design of 
Envelope (Env)-based immunogens effective at eliciting broadly 
neutralizing antibodies. We hypothesize that B cells become 
programmed to develop broad NAbs by exposure to Envs 
presented by the viral quasispecies variants. We propose that 
similar programming could be achieved by a vaccine concept 
exposing the host to such Env quasispecies variants isolated from 
an individual who developed broad NAbs over time. 
Methods: Full-length functional env genes were cloned 
longitudinally from elite neutralizer CI10014 by single genome 
amplification, and a combination of in silico sequence analysis 
and in vitro neutralization was used to select vaccine candidates. 
Four immunization strategies were tested in rabbits: (1) sequential 
env evolution as it occurred in CI10014, with multiple clones per 
timepoint (Sequential); (2) sequential vaccine approach using only 
one clone per timepoint (Simplified Sequential); (3) an approach 
uniquely focused on env clones derived from timepoints where 
env evolution drove the development of breadth (Jump into 
Breadth); and (4) single env variant (Clonal). The gp160-DNA and 
gp140-trimer immunogens were co-administered. 
Results: NAbs were detected at six weeks, after only two 
immunizations and increased after additional immunizations. 
The Jump into Breadth strategy elicited significantly higher NAbs 
than the Clonal and Sequential strategies. Modest heterologous 
neutralization was obtained against Tier 1 clade A and B viruses. 
Conclusion: Exposure to env immunogens derived from 
timepoints preceding and contemporaneous with the appearance 
of neutralization breadth elicited higher NAbs than exposure to a 
single variant or a longitudinal collection of Envs. This study explores 
the use of multiple native, related HIV-1 Envs as immunogens 
and emphasizes the critical importance of understanding the 
development of breadth in an elite neutralizer subject.
P12.55
Functional Properties of an Ensemble of Candidate 
Germline-Encoded Precursors of the Anti-MPER 
Antibody 4E10
K. Finton1, B. Larmen2, K. Larimore3, A. Stuart4, D. Friend1,  
T. Vanden Bos1, P. Greenberg3, S. Elledge2, L. Stamatatos4,  
R. Strong1
1Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 
2Harvard Medical School, Boston, MA, USA; 3University of 
Washington, Seattle, WA, USA; 4Seattle Biomedical Research 
Institute, Seattle, WA, USA
Background: We have previously engineered computationally-
designed ‘epitope-scaffold’ constructs for the broadly neutralizing, 
MPER-specific antibody 4E10, consisting of the epitope grafted 
as a structural unit onto non-HIV scaffold proteins for optimal 
presentation during immunization. 4E10 epitope-scaffolds 
display dissociation constants for mature 4E10 ranging down to 
picomolar values and can elicit epitope-specific responses during 
immunization. Sera from immunized animals failed to potently 
neutralize HIV, at least partially due to differences between 
human and non-human germline repertoires. Successful 
use of epitope-scaffolds as vaccine immunogens will require 
optimizing interactions with both the mature antibody target 
and appropriate precursors, while preserving or generating 
neutralization potency during maturation.
Methods: Since a unique germline-encoded precursor sequence 
for 4E10 cannot be unambiguously assigned, we have generated 
an ensemble of the twelve likeliest candidates in order to 
study their functional and recognition properties. Interaction 
parameters between mature and candidate germline-encoded 
precursor (CGP) antibodies for engineered epitope-scaffolds, 
peptides, membrane components and HIV proteins were 
determined in surface plasmon resonance analyses and three-
dimensional structures of free and ligand-complexed forms were 
determined by x-ray crystallography. Neutralization potencies 
were determined and polyspecificity and autoreactivity were 
analyzed with large-scale peptide arrays.
Results: Unlike other anti-HIV CGPs, which display negligible 
affinities for HIV-related ligands, 4E10 CGPs display affinities 
for epitope-scaffolds which, while 1,000- to 100,000-fold 
weaker, still reach into the nanomolar range. Structural studies 
show remarkable conservation of recognition mechanisms 
while functional studies show retention of anti-HIV activity. 
Polyspecificity of both mature and CGP forms is very limited, but 
the significant autoreactivity of mature 4E10 appears directed to 
specific targets.
Conclusion: The functional gap between mature 4E10 and its 
CGPs is narrower than in other HIV-related systems. Strategies 
based on our results can be proposed to generate mature- and 
CGP-specific epitope-scaffolds for use in prime-boost vaccinations 
to target specific CGPs with desirable functional properties while 
potentially avoiding autoreactivity.
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Purification of Chemically Fixed HIV-1 Spikes for 
Oriented Display on Nanoparticles
M.B. Zwick1, D. Leaman1
1The Scripps Research Institute, La Jolla, CA, USA
Background: HIV-1 neutralizing antibodies (Abs) bind to the 
envelope glycoprotein (Env) spike, which functions as a trimer 
of gp120-gp41 heterodimers that is anchored in the viral 
membrane. However, Env trimers are low in copy number and 
coexist with irrelevant forms of Env and its byproducts, which 
typically elicit non-neutralizing Abs. 
Methods: Here, we have attempted to generate immunogens 
by fixing trimeric spikes of HIV-1JR-FL using a defined chemical 
crosslinker, purifying the crosslinked spikes from virions, and 
immunodepleting them of irrelevant Env contaminants using 
non-neutralizing Abs.
Results: Purified, crosslinked spikes were bound by a panel of 
neutralizing Abs, but not by non-neutralizing Abs, and are virtually 
devoid of non-trimeric Env. However, at least one neutralizing 
epitope on gp120, the crown of V3, appears to be occluded by 
crosslinking. An immunization was performed using the purified, 
crosslinked Env trimers as a boosting agent following a DNA prime 
using full-length env, either as soluble protein or captured onto 
small proteoliposome nanoparticles (PLNs). The binding titers 
of the Ab response to crosslinked Env spikes were quite weak, 
possibly reflecting an overall weaker immune response. Boosting 
animals with trimer-PLNs however elicited a qualitatively 
different neutralizing Ab response than uncrosslinked Env on 
virions, with sporadic activity against neutralization-resistant 
HIV-1 isolate JR-CSF, reduced neutralization of sensitive Tier 1 
isolates, and reduced antibody responses against host protein. 
Conclusion: Immunizing animals using purified, crosslinked 
Env spikes captured on PLNs elicited a qualitatively different 
and broader neutralizing Ab response than uncrosslinked, 
heterogeneous Env. We conclude that with further changes 
to the crosslinking and immunization strategy crosslinked and 
purified Env spikes hold promise as a vaccine candidate.
P12.57
Structural Definition of a Novel CD4-Induced Epitope 
That Is Targeted by a Single-Headed Immunoglobulin 
to Effect Broad and Potent HIV Meutralization
P. Acharya1, T.S. Luongo1, J. Matz2, S.D. Schmidt1, G. Chuang1,  
I. Georgiev1, P. Kessler3, Y. Yang1, P. Chames4, L. Martin3,  
J.R. Mascola1, P.D. Kwong1
1National Institutes of Health, Bethesda, MD, USA; 2Inserm, 
Marseille, France; 3CEA/iBiTecs, Gif sur Yvette, France; 
4INSERM, Marseille, France
Background: HIV-1 enters cells by sequentially binding the CD4 
receptor and a coreceptor, either CCR5 or CXCR4. Functional 
constraints result in a high degree of conservation of the receptor-
binding sites making them potential targets for intervention. The 
coreceptor-binding site on HIV-1 envelope gp120 glycoprotein is 
protected from the humoral immune system by conformational 
masking and steric occlusion. The site becomes available after 
a conformational change in gp120 following CD4 engagement, 
but at that point in the entry process, the proximity of the viral 
and cellular membranes makes the site inaccessible to bulky 
antibody molecules. Thus, in spite of being highly conserved, this 
region has not been considered a viable vaccine target.
Methods: Single domain antibody vHH120.4 was isolated 
from llama immunized with gp120 covalently linked to a CD4-
mimetic peptide. Full-length versions of this antibody (IgG2B and 
IgG3) were created and tested for neutralization. The structure 
of vHH120.4 bound to gp120 from the HIV-1 YU2 strain was 
determined at 2.1Å resolution.
Results: Both IgG2B and IgG3 versions of the vHH120.4 potently 
neutralized over 95% of a panel of circulating Tier 2 HIV-1 isolates. 
Structural analyses of vHH120.4 bound to gp120 revealed a novel 
CD4i epitope that involves antibody interactions with region on 
gp120 encompassing the bridging sheet and the base of the V3 
loop, the β19 strand, the CD4-binding loop, and the glycan at Asn 
386. This epitope overlaps the classically defined CD4-induced 
epitopes recognized by antibodies 17b and 48d, but is shifted 
towards the site of CD4 attachment.
Conclusion: The discovery of a neutralizing CD4-induced epitope 
indicates that not all CD4-induced sites are masked from 
neutralization. Whether human antibodies can also utilize the 
newly defined vHH120.4 epitope for effective neutralization 
remains to be determined; HIV-1 envelope probes designed 
to specifically select antibodies targeting this epitope are now 
being developed.
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Determination of Structural Constraint within the 
HIV Proteome through Analysis of Amino Acid 
Microenvironments
G. Gaiha1, M. Anahtar1, E. Rossin2, B. Walker1
1Ragon Institute, Charlestown, MA, USA; 2Broad Institute, 
Boston, MA, USA
Background: The design of an effective T cell based vaccine 
relies on determining the most highly constrained regions of 
the HIV proteome. 
Methods: Using publicly available crystal structures from the 
Protein Databank (PDB), we performed a systematic analysis 
of the local microenvironment of every amino acid within the 
HIV Proteome for which structural data was available (65.8%). 
Structural constraint parameters included involvement in 
protein secondary structure, relative solvent accessibility, 
and involvement of amino acid side chains in intermolecular 
interactions (Van der Waals bonds, hydrogen bonding, salt 
bridges, disulfide bridges, pi-pi bonds, and pi-cation bonds). 
Calculations of these constraints were carried out using validated 
methods of protein structure analysis and distance geometry, 
with weighted values cumulatively summed to provide a 
constraint score for every amino acid. 
Results: Amino acids with a higher constraint score were observed 
to strongly correlate with low values of entropy within viral 
sequences from every clade of HIV. Analysis of constraint score 
variation across the HIV proteome reveals that the p24 capsid 
protein to be the most highly interconnected and constrained. 
Evaluation of amino acids within known HLA-restricted epitopes 
further elucidated a preference of controller alleles for buried 
and interconnected amino acids, while progressor alleles 
predominantly targeted exposed and non-connected amino 
acids. Thermodynamic stability analysis further demonstrated 
a strong correlation with amino acid constraint and change in 
predicted Gibbs’ Free Energy. 
Conclusion: Our analyses reveal that evaluation of local amino 
acid microenvironments represents a novel method for the 
determination of constraint within the HIV proteome, setting the 
stage for more robust targeting of these constrained regions and 
enhanced immunogen design. 
P12.59 LB 
DNA Vaccines that Express the MPER of HIV-1 gp41 
Elicit Different Antibodies Depending Upon Their 
Transmembrane and Cytoplasmic Domains
J.K. Scott1, N. Gulzar1, K. Klaric1, T.M. Ross2, S. Lu3, S. Wang3
1Simon Fraser University, Burnaby, Canada; 2University of 
Pittsburgh, Pittsburgh, PA, USA; 3University of Massachusetts 
Medical School, Worcester, MA, USA
Background: 
The HIV-1 gp41 MPER contains the epitopes for 4 broadly 
neutralizing (bNt) antibodies (Abs), making it a target for vaccine 
design. We developed a panel of DNA-vaccine candidates that 
link the MPER, or larger portions of gp41’s external domain, 
to two different transmembrane (TM) and cytoplasmic (CT) 
domains. We report on the ability of DNA vaccines expressing 
these constructs to elicit MPER-specific Nt Abs in rabbits.
Methods: DNA vaccines encoding various gp41 ectodomain 
fragments, and the TM and CT of either the platelet-derived 
growth factor receptor (PGDFR-TM), or the TM and truncated 
CT of gp41 (TM1), were used to immunize rabbits; immune sera 
were tested for reactivity against the MPER displayed on the cell 
surface and for pseudovirus neutralization.
Results: Immunizations with plasmids expressing larger 
fragments of the gp41 ectodomain tethered to the PDGFR-TM 
elicited lower-titer Abs against the MPER, as compared to the 
MPER tethered to the PDGFR-TM, which elicited MPER-specific 
Abs that included those targeting the 2F5 epitope Affinity 
purification of these Abs on 2F5-epitope peptide resulted in 
Abs that bound MPER expressed on cells, but neutralized both 
pseudoviruses bearing HIV envelope and those bearing AMLV 
envelope. Immunization with DNA vaccines encoding the MPER 
fused to the gp41 TM1, elicited low-titre Abs that cross-reacted 
weakly with the MPER and strongly with regions in the CT. All 
immunization failed to produce Abs that cross-react with the 
4E10 epitope.
Conclusion: While the initial immunization studies reported here 
demonstrate that MPER reactivity is elicited by DNA immunization, 
the MPER-TM1 construct appears to elicit Abs against epitopes in 
its 27-aa CT domain. Current work is focused on replacing the gp41 
TM with an engineered TM that will optimally expose the epitopes 
for the bNt MAbs, particularly 4E10. 
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CN54gp140: Product Characteristics, Preclinical and 
Clinical Use - Recombinant Glycoprotein for HIV 
Immunization
D. Katinger1, S. Jeffs2, F. Altmann3, A. Cope2, P. McKay2,  
N. Almond4, E. Sandström5, B. Hejdeman5, G. Biberfeld5,  
C. Nilsson6, D. Hallengärd5, B. Wahren5, T. Lehner7, M. Singh8, 
D.J. Lewis9, C. Lacey10, R. Shattock2
1Polymun Scientific GmbH, Klosterneuburg, Austria; 2Imperial 
College, London, United Kingdom (Great Britain); 3Universität 
für Bodenkultur, Vienna, Austria; 4HPA-NIBSC, Potters Bar, 
United Kingdom (Great Britain); 5Karolinska Institutet, 
Stockholm, Sweden; 6Swedish Institute for Communicable 
Disease Control, Solna, Sweden; 7King’s College London at 
Guy’s Hospital, London, United Kingdom (Great Britain); 
8Lionex Diagnostics & Therapeutics GmbH, Braunschweig, 
Germany; 9University of Surry, Guildford, United Kingdom 
(Great Britain); 10University of York, York, United Kingdom 
(Great Britain)
Background: The usefulness of HIV envelope proteins for vaccine 
design is widely accepted since the RV144 HIV-1 prime-boost 
vaccine trial. It is assumed that a trimeric structure close to the 
natural form of the HIV envelope is preferable.
Methods: We have expressed the soluble form of the HIV 
envelope of the C/B’ strain 97/CN/54 in CHO cells. The production 
process consisted of a large-scale fed-batch fermentation, 
an antibody-based affinity chromatography plus additional 
purifying steps. CN54gp140 was extensively characterized for 
purity and identity. All glycosylation sites were characterized by 
mass spectrometry. Immunogenicity and safety were evaluated 
in mice, rabbits, mini-pigs, sheep as well as non-human primates. 
The antigen was formulated for clinical phase I studies in Tris 
buffer (MUCOVAC I, HIVIS07) in HEC gel (MUCOVAC I) as well as 
chemically conjugated to hsp70 (MUVAPRED).
Results: The vaccine antigen candidate CN54gp140 proved to 
be of high purity and long-term stability. The immune response 
was strongest with i.m. application whereas the mucosal routes 
(i.vag., i.n.) were less immunogenic. Safety was demonstrated in 
animal models as well as in the clinical phase I studies MUCOVAC 
I, MUVAPRED and HIVIS07.
Conclusion: CN54gp140 is a highly immunogenic trimeric 
envelope protein which can be manufactured in sufficient quality 
and quantity for clinical application. It proved to be immunogenic 
in several animal models. Finally, it is well tolerated in several 
formulations and combinations in humans.
P12.61 LB 
Design And Development of a New Lentiviral Based 
Anti-HIV Therapeutic Vaccine 
M. Rodriguez1, E. Sarry1, A. Bejanariu1, L. Casaban1, S. Abdalla1, 
E. Sabbah-Petrover1, C. Bauche1
1Theravectys, Paris, France
Background: Theravectys develops a new generation of 
prophylactic and therapeutic vaccines using optimized lentiviral 
vectors. It’s most advanced product, a therapeutic anti-HIV 
vaccinal treatment, will enter clinical Phase I/II within a few 
weeks. This vaccination will allow seropositive patients to gain 
an immunological status identical to the so-called “Functional 
Cured” patients who develop an efficient immunological 
response capable of controlling the infection without therapy
Methods: Vaccine candidates are integrative and self-
inactivated live-recombinant lentiviral vectors. They encode an 
HIV antigen, under the regulation of a patented promoter that 
is preferentially induced in APC (generating of a strong, specific 
and long lasting T-cell immune response), and showing a basal 
level expression in all cells (allowing their elimination by the 
settled immune response).
Furthermore, Theravectys developed a vaccination regimen 
based on iterative immunizations with lentivectors encoding the 
same HIV transgene, relying on different VSV-G serotypes for 
pseudotyping without generating cross-neutralizing antibodies. 
These candidates were classified as “Live recombinant vectored 
vaccines” (EMA, 2011)
Results: Theravectys set up an innovative manufacturing process 
combining high production yields, impurity profiles compatible 
with direct injections into humans and high immunogenicity.
Pilot and GMP batches have been manufactured and GLP 
preclinical studies (amongst which biodistribution, shedding and 
toxicity) performed, that showed the restricted diffusion of the 
vaccine candidates after injection and their fast disappearance 
within few weeks, correlated with an absence of macroscopic 
and microscopic toxicity
Conclusion: These data allowed the settlement of an anti-
HIV therapeutic Phase I/II clinical trial that should receive the 
authorization of the French regulatory agency before the end 
of July.
This trial will be held in France and Belgium and plans the 
enrollment of 36 HIV-1 infected patients. Theravectys’ anti-HIV 
vaccine treatment will be assessed at three doses and safety, 
tolerability and immunogenicity compared to a placebo group. 
Results are expected by September 2014 with intermediary 
analyses in September 2013
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Novel Computational Methods for Predicting 
Epitopes of Potent and Broadly Neutralizing HIV-1 
Antibodies
M.C. Evans1, A. Paquet1, P. Phung1, A. Parikh1, C. Petropoulos1, 
T. Wrin1, M. Haddad1
1Monogram Biosciences, South San Francisco, CA, USA
Background: Recent efforts in HIV-1 vaccine design have focused 
on immunogens that evoke potent neutralizing antibody 
responses to a broad spectrum of viruses circulating worldwide. 
However, the development of effective vaccines will depend 
on the identification and characterization of the neutralizing 
antibody epitopes. Consequently, we developed bioinformatics 
methods to predict epitopes using corresponding genotypes and 
phenotypes generated using a highly sensitive and reproducible 
neutralization assay.
Methods: Using 264 clonal envelope (gp120) sequences from a 
panel of multiclade HIV-1 viruses with matching neutralization 
titers to an array of neutralizing monoclonal antibodies (b12, 
PG9,16, PGT121 - 128, PGT130 - 131, PGT135 - 137, PGT141 - 145, 
and PGV04), we correlated IC50 titers with envelope mutations, 
and used this information to predict antibody epitopes. Structural 
patches were generated as amino acid groupings based on 
solvent-accessibility, diameter, atomic depth, and interaction 
networks within 3D envelope models. These patches were then 
evaluated as possible antibody targets by applying a boosted 
algorithm comprised of machine learning and statistical models. 
We identified residues with statistically significant correlation 
with IC50 titers as sites that impact neutralization sensitivity. 
Residues frequently occurring within the significant patches 
were mapped onto envelope structures as potential antibody 
binding sites.
Results: Predicted epitopes were identified based on strong 
correlations with neutralization response to each antibody. 
Residues highly associated with the IC50 titers and patch clusters 
predicting neutralization response to these antibodies were 
located within V1/V2, and V3. The predicted response by the 
algorithm was highly concordant (>80%) with the neutralization 
sensitivity of all antibodies.
Conclusion: We developed and applied computational methods 
to rapidly survey protein structures and identify epitope regions 
associated with neutralization response. This data mining 
algorithm can help identify immunological hotspots, and provide 
rapid and accurate insight into regions that are targeted by 
potent and broad neutralization responses. Studies are ongoing 
to confirm these novel epitopes.
P12.63 LB 
Pre-Clinical Development Of BCG.HIVA(CAT) Strain, 
An Antibiotic-Free Selection Strain For HIV-TB 
Pediatric Vaccine
N. Saubi1, E. Gea-Mallorquí1, A. Mbewe-Mvula2, C. Hurtado1,  
J. Gatell1, T. Hanke2, J. Joseph1
1AIDS Research Unit, Hospital Clinic/IDIBAPS-HIVACAT, 
Barcelona, Spain; 2The Jenner Institute, University of Oxford, 
Oxford, United Kingdom (Great Britain)
Background: Our starting platform was based on a heterologous 
BCG prime and MVA boost regimen delivering a common 
immunogen called HIVA. In this study, we have i) developed a 
BCG.HIVACAT strain containing an antibiotic free selection system 
(Cobra); ii) evaluated the specific HIV-1 immune responses 
induced after newborn BALB/c mice immunization with BCG.
HIVACAT prime and MVA.HIVA.85A boost; iii) evaluated the 
specific-TB immune responses induced after newborn BALB/c 
mice immunization with BCG.HIVACAT prime and MVA.HIVA.85A 
boost and iv) evaluated the influence of age on specific HIV-1 
immune responses using the same vaccination schedule.
Methods: 7-days-old newborn and 7-weeks-old adult mice 
were either left unvaccinated or vaccinated subcutaneously 
with 105 cfu of BCG.HIVACAT or BCGwt, and 16 weeks later were 
boosted intramuscularly with 106 pfu MVA.HIVA.85A. The mice 
were sacrificed 2 weeks later. The HIV-1 and TB-specific cellular 
immune responses were analyzed in spleen cells by intracellular 
cytokine staining and IFN-γ ELISPOT. 
Results: The frequencies of TB-specific CD8 + T-cells producing 
IFN-γ (P11 stimulation), and spleen cells producing IFN-γ (P11, 
P15 and PPD stimulation), were higher in BCG.HIVACAT or BCGwt 
primed and MVA.HIVA.85A boosted mice compared with mice 
vaccinated with MVA.HIVA.85A alone (i.e. 231, 108 and 24 
sfu/106 PPD stimulated splenocytes respectively). The specific 
HIV-1 immune responses (P18I10 stimulation) were lower in 
BCG.HIVACAT or BCGwt primed and MVA.HIVA.85A boosted mice 
compared with mice vaccinated with MVA.HIVA.85A alone 
(i.e. 270, 276 and 412 sfu/106 P18I10 stimulated splenocytes 
respectively). When adult and newborn mice were immunized 
using the same vaccination schedule, the HIV-1-specific immune 
responses in adult mice were higher than in newborn mice 
(0.45% vs 0.2% CD8+ T-cells producing IFN γ).
Conclusion: In conclusion we demonstrated the immunogenicity 
of BCG.HIVACAT and MVA.HIVA.85A in newborn mice but 
additional experiments should be performed in newborn mice 
testing different routes and doses that might provide different 
levels of immunogenicity. 
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Novel AIDS Vaccine Approach using Epithelial Stem 
Cells as Mucosal Antigen-Presenting Cells
G. Bonello1, N. Chenciner2, R. White1, M. Salas1, P. Blancou3,  
M. Gauduin1
1Texas Biomedical Research Institute, San Antonio, TX, USA; 
2Institut Pasteur, Paris, France; 3Universitée de Nantes, Nantes, 
France
Background: Because HIV transmission occurs predominantly 
across mucosal surfaces, the ideal vaccine strategy to prevent 
infection would be to target HIV at mucosal entry sites of 
transmission. We investigated a novel vaccine approach, which 
aim is to elicit long-term immunity against HIV infection at the 
entry site of the virus. This strategy relies on the expression of 
viral proteins from epithelial stem cells at the basal layer of the 
epithelium and using a promoter that is specific for terminally 
differentiated epithelial 
Methods: The involucrin promoter, which is exclusively 
expressed in terminally differentiated epithelial cells, was chosen 
and used as a tool. We generated a GFP-tagged replication 
competent SIVdeltaNef and a GFP-tagged replication deficient 
SIVdeltaVifdeltaNef constructs under the transcriptional control 
of the involucrin promoter (pINV). Viral stocks used to deliver 
these constructs to basal epithelial cells were obtained by their 
co-transfection with a plasmid encoding for VSV-G envelope 
proteins used as pseudotyping envelope protein of significantly 
broadened host cell range. 
Results: When administered intradermally to mice, we found 
that GFP-reporter gene under the transcriptional control of 
the involucrin promoter was expressed in the upper layers 
of the epidermis. Although transduced cells were very low in 
number, high and sustained anti-GFP antibody production was 
observed in vivo. After production of high concentrations of 
infectious viral particles, we demonstrated the integrity of our 
constructs (regions encoding for GAG, POL and GFP) in the 
VSV-G pseudotyped viral particles to be used for inoculation in 
nonhuman primate model for AIDS. 
Conclusion: After integration of pINV-driven constructs, basal 
layer cells will divide and differentiate thus triggering SIV antigens 
expression as well as both direct and cross priming. Long-term 
antigen expression in upper layers of the epithelium may occur 
even after multiple cycles of epithelia renewal, thus eliciting a 
long-term immunity against HIV/SIV infection at the site 
P12.65 LB 
Liposomal Formulation of Gp41 Derivate with 
Adjuvant MPLA: Vaccine Design, Immunogenicity in 
Animals and Safety in Humans
D. Katinger1, A. Wagner1, I. Luque2, S. Crespillo2, F. Conejero-
Lara2, M. Roger3, C. Martin3, N. Mouz3, S. Mourao4, A. Farsang5, 
F. Notka6, K. Malcolm7, N. Bosquet8, R. Le Grand8, C. Moog9,  
A. Cope10, R. Shattock10, D.J. Lewis11, R. El Habib12
1Polymun Scientific GmbH, Klosterneuburg, Austria; 
2Universidad de Granada, Granada, Spain; 3PX’Therapeutics, 
Grenoble, France; 4I.M. PROJET, Miribel, France; 5National 
Food Chain Safety Office, Budapest, Hungary; 6GeneArt AG / 
Life Technologies, Regensburg, Germany; 7Queen’s University 
of Belfast, Belfast, United Kingdom (Great Britain); 8CEA, 
Fontenay-aux-Roses, France; 9Université de Strasbourg, 
Strasbourg, France; 10Imperial College, London, United 
Kingdom (Great Britain); 11University of Surrey, Guildford, 
United Kingdom (Great Britain); 12Sanofi Pasteur, Marcy 
l’Etoile, France
Background: Gp41 of the HIV envelope, especially the MPER, 
contains highly conserved epitopes recognized by neutralizing 
monoclonal antibodies such as D5, 2F5 and 4E10. The correct 
presentation of the antigens is considered to be key for eliciting 
neutralizing immune response. The lipid bilayer of liposomes can 
mimic the virus surface and therefore provides the appropriate 
presentation of this membrane protein. In addition, liposomes 
can integrate the adjuvant monophosphoryl lipid A (MPLA).
Methods: The gp41 derivate FPA2 was mutated to increase its 
solubility and modify its structure for exposure of neutralizing 
epitopes. The protein was expressed in E. coli. The purified 
protein was solubilized with detergent. Liposomes were prepared 
containing antigen FPA2 and MPLA, a Toll-like receptor 4 agonist, 
using a continuous ethanol crossflow injection technology. 
Immunogenicity and safety was determined in rabbits and 
macaques. The liposomes formulated in HEC gel were applied 
i.n. followed by two intramuscular boosts in healthy female 
volunteers in a phase I study of safety and immunogenicity.
Results: Liposomes containing FPA2 and MPLA manufactured 
under GMP conditions were uniform and stable at 2-8°C. 
Immunogenicity was demonstrated in rabbits and monkey after 
mucosal (i.vag., i.n.) prime, followed by intramuscular boosts. 
Immune response was induced systemically and in mucosal 
surfaces. Preliminary data from the clinical phase 1 study in 
healthy volunteers demonstrated good safety with three nasal 
applications of 200 µg of the formulated protein in HEC gel and 
of two i.m. boosts.
Conclusion: The liposomal formulation of the gp41 subunit 
of HIV envelope together with MPLA as adjuvant proved to be 
well tolerated in animals and human. Liposome-formulated 
FPA2 was able to induce binding antibodies measured by ELISA 
and neutralizing activity in both blood and vaginal secretions in 
animals. Immunogenicity testing in humans is ongoing.
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2G12/PGT-Binding Yeast Glycoprotein Gp38 
Elicits Mannose-Specific HIV-1 Env Cross-Reactive 
Antibodies 
H. Zhang1, H. Fu1, B. Liu1, R.J. Luallen1, R.W. Doms2, D.F. Smith3, 
Y. Geng1
1ProSci Inc., Poway, CA, USA; 2University of Pennsylvania, 
Philadelphia, PA, USA; 3Emory University, Atlanta, GA, USA
Background: The increasing numbers of broad neutralizing 
antibodies (bNAbs) that target carbohydrates of HIV envelops 
highlight the importance of designing immunogens to elicit such 
types of bNAbs for an effective HIV vaccine.
Methods: PGT bNAbs-cross reactive proteins were detected by 
Western blots and identified by nano-LC-MS/MS. Rabbit antisera 
were raised with single PGT bNAbs-reactive yeast glycoprotein, 
and tested by ELISA, Western blots and glycan microarray. HIV-1 
pseudoviruses were generated in 293T cells, and neutralization 
assay was performed using TZM-bl cells.
Results: Using the newly identified, glycan-specific PGT bNAbs 
to search for their binders from a triple mutant(TM) strain of 
Saccharomyces cerevisiae, we found that the PGT bNAbs not only 
bind to the previously identified 2G12-reactive glycoproteins but 
also recognize several unknown proteins in TM yeast. One of 
them was identified as a short version of Gp38 with N-terminus 
truncation. Based on immunization of rabbits with various 
formulations and strategies, we found that a high titer of HIV-1 Env 
cross-reactive antibodies was induced when using a promiscuous 
T-cell epitope peptide conjugated Gp38 in a formulation with a 
Toll-like receptor 2 agonist and aluminum salts. The Gp38-elicited 
antibodies could bind to a broad range of monomeric gp120s 
from HIV and SIV. Moreover, the antibodies could also efficiently 
neutralize HIV-1 pseudoviruses when the viruses were produced 
in the presence of a mannosidase inhibitor kifunensine, which 
enriches high-mannose Man9GlcNAc2 N-linked glycans. Glycan 
microarray analysis showed that these antibodies bind to the 
synthetic Manα1,2-Manα1,2-Man containing oligosaccharides 
Conclusion: These data suggest that yeast glycoprotein Gp38, as 
well as its truncated form, is an efficient binder to the glycan-
specific HIV bNAbs, and that Gp38 is able to induce a strong glycan-
specific HIV-reactive antibody response when incorporated with 
appropriate adjuvants. These results encourage us to further 
explore the strategies to induce 2G12/PGT-like antibodies using 
Gp38 as well as its truncated form.
P12.67 LB 
Simple, Scalable And Robust Purification Of Two HIV-
1 Subtype C gp120 Monomer Subunit Antigens For 
Phase II Clinical Trial In Republic Of South Africa
Y. Wen1, S. Stephenson1, C. Zambonelli1, S. Hilt1, M. Wininger1, 
A. Dey1, S. Barnett1, A. Carfi1
1Novartis, Cambridge, MA, USA
Background: Development of an effective vaccine against HIV-
1 is challenging due to various viral evolutionary mechanisms 
to evade human immune system. The partial efficacy of the 
recent RV144 vaccine efficacy trial in Thailand provides hope for 
improvements of vaccine regimens for higher efficacy. A Phase 
IIb proof-of-concept clinical trial in the Republic of South Africa 
(RSA) is planned to confirm and extend the results of the RV144 
trial with the vaccine strategy of poxvirus vector prime plus 
envelope protein boost.
Methods: We selected two HIV subtype C gp120 vaccine 
antigens, TV1.C gp120 and 1086.C gp120, formulated with 
Novartis proprietary adjuvant, MF59 as protein boosts of the 
clinical trial. 
Results: To produce TV1.C gp120 and 1086.C gp120 monomers, 
we generated CHO stable cell lines for both gp120, which 
consistently expressed gp120 subunits with high yield. Simple, 
scalable and robust antigen purification processes were 
developed to generate both gp120 proteins. The ion-exchange 
based purification strategy enabled the separation of gp120 
monomer from dimer and produced gp120 monomer with high 
purity and homogeneity. 
Conclusion: Purified gp120 monomers were stable, either 
alone or in combination, and when formulated with adjuvant 
MF59. Finally, the early evaluations showed that both 
gp120 monomers were immunogenic and able to elicit high 
neutralizing antibody titer.
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Virus-Like Particles Highly Expressing DC-SIGN 
Concentrate Trimeric HIV-Envelope Proteins With 
Noncovalently Linked Immunoreactive Gp120  
And Gp41 
G.N. Vyas1
1UCSF School of Medicine, San Francisco, CA, USA
Background: We have hypothesized that membrane-bound 
macromolecular HIV-envelope proteins (mHIV-env) as a subunit, 
with gp120 and gp41 in their innate conformation, can be used as 
an effective immunogen to elicit broadly neutralizing antibodies 
(bnAb) against sexually or perinatally transmitted HIV-1. To test 
this hypothesis we have synthesized infection-free mHIV-env 
from the HIV-1 transmitted in humans (Vyas et al, Biologicals 
2012;40:15-20). The process has been simplified for making large 
amounts of mHIV-env coupled with DC-SIGN expressing virus-
like lipoparticles (VLP) as a candidate immunogen.
Methods: Virus isolates of plasma-derived HIV-1 (PHIV) from 
infected blood donors while negative for anti-HIV (earliest 
acute infection) were selected for expansion in an optimized 
cell substrate (OCS) prepared from lymphocytes of four donors. 
Virions in the culture supernatants were inactivated by extracting 
membrane cholesterol with 200mM cyclodextrin for 4 hours to 
maximally expel p24, RT, and viral RNA from the permeabilized 
virions. The residual host/viral DNA/RNA in the inactivated virion 
shells were hydrolyzed with protease-free Benzonase without 
loss of gp120. The mHIV-env was coupled with VLP highly 
expressing DC-SIGN (Integral Molecular, Philadelphia, PA).
Results: The inactivated virions apparently disintegrated into 
amorphous mHIV-env proteins when reacted with Benzonase. 
While the mHIV-env passed through membranes with 1,000kD cut 
off, it was retained by 30, 100, or 300kD cut off membranes as 
determined by gp120 EIA. The mHIV-env was coupled to DC-SIGN 
highly expressed on VLP. Analyses of DC-SIGN bound mHIV-env 
showed conformation-dependent immune reactivity with anti-
gp120(b12). Remarkably, the gp41 noncovalently bound to gp120 
was quantitatively detected by human monoclonal anti-gp41. 
The simplified method for preparing mHIV-env yielded trimeric 
heterodimers with an estimated molecular mass of 500kD, which 
was concentrated 10-100X with VLP expressing DC-SIGN.
Conclusion: The VLP with mHIV-env bound to DC-SIGN at 10-
100X more concentration than the 7-14 spikes per native virions 
provide a putative immunogen capable of inducing broadly 
neutralizing antibodies.
P12.69 LB 
Targeting HIV Gag p24 To DICR On Dendritic Cells 
Induces T Cell And Potent And Long-Lasting Antibody 
Responses In Non-Human Primates
A. Flamar1, R. Le Grand 2, V. Contreras2, S. Zurawski1,  
N. Dereuddre-Bosquet2, I. Mangeot2, F. Martinon2, S. Oh1,  
J. Banchereau1, G. Zurawski 1, Y. Levy3
1Baylor Institute for Immunology Research, Dallas, TX, USA; 
2CEA, Fontenay-aux-Roses, France; 3INSERM U955, Faculté de 
Médecine de Créteil, Creteil, France
Background: Targeting Dendritic Cells (DCs) with anti-DC receptor 
antibody-antigen fusion proteins is a novel approach in vaccine 
development for inducing potent humoral and cellular immune 
responses.
Methods: We engineered an anti-human DCIR recombinant 
antibody cross-reacting with the cynomolgus macaque receptor 
fused via the heavy chain C-terminus to HIV-1 Gagp24 protein 
(anti-DCIR.Gagp24). HIV patient PBMC cultures were incubated 
with anti-DCIR and control hIgG4.Gagp24 fusion proteins. After 
10 days, the total T cells were challenged with HIV Gagp24 
peptide pools, and then antigen-specific cytokine production 
was detected using intracellular staining. Macaques were also 
immunized i.d. 3 times with anti-DCIR.Gagp24 or control hIgG4.
Gagp24 with or without polyI:C. Gagp24-specific IgG titers 
from serum were measured by ELISA and the magnitude of the 
antigen-specific IFNγ responses was assessed by ELISPOT.
Results: In vitro, low doses of anti-DCIR Gagp24 prototype 
vaccine, but not the control hIgG4.Gagp24, expand of Gagp24-
specific T cells. These in vitro-expanded antigen-specific T 
cells were multifunctional, simultaneously producing multiple 
cytokines (IFNγ, TNFα and MIP-1β). In vivo, in non-adjuvanted 
naïve animals, serum anti-Gagp24 antibodies were detectable 
2 weeks after priming and titers were substantially increased 
after the 1st and the 2nd boost with anti-DCIR.Gagp24 and were 
durable, while in the control hIgG4.Gagp24 group the responses 
were minimal. Poly I:C increased the magnitude of the responses 
in the anti-DCIR.Gagp24 and hIgG4.Gagp24 groups to a similar 
level in both groups. T cell responses induced by anti-DCIR 
Gagp24 could be enhanced after priming with a recombinant 
modified vaccinia virus Ankara (MVA) encoding HIV Gag/Pol/
Nef. Boosting with anti-DCIR.Gagp24 plus poly I:C generated high 
titers of anti-Gagp24 antibody titers and strongly enhanced IFNγ-
producing T cells following priming with MVA HIV Gag/Pol/Nef.
Conclusion: Our results demonstrate that heterologous prime-
boost immunization with vectors and DC-targeting protein-
based vaccines is a promising vaccination approach to optimize 
humoral and cellular immunity for therapeutic and preventive 
applications against AIDS.
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Assessment of T Cell Immune Responses Towards 
HIV-1 Epitopes Designed by Reverse Immunogenetic 
Approach: Proof-of-Concept in HIV+ Cameroonian 
Children
E. Nemes1, M. Amicosante2, F. Ateba Ndongo3, N. Fainguem1,  
S. Moyo Tetang1, A. Bedin1, E. Temgoua1, V. Colizzi2, G. Cappelli4
1Chantal Biya International Reference Centre for Research 
on HIV/AIDS, Yaounde, Cameroon; 2University of Rome Tor 
Vergata, Rome, Italy; 3Centre Mère et Enfant (Chantal Biya 
Foundation), Yaounde, Cameroon; 4Higher Institute of Health 
(ISS), Rome, Italy
Background: We tested whether 23 HIV-1 epitopes designed 
using a bioinformatics approach were recognized by HIV-infected 
children living in ethnically diverse Cameroon, which harbors a 
high HIV strain variety.
Methods: Areas containing both promiscuous HLA-class I and II 
epitopes covering more than 90% of the HLA haplotypes present 
in the African population were identified within the most HIV-
1 conserved sequence of each protein. Twenty-three peptides 
have been designed targeting gag (10), nef (6), tat (4), vpr (2) and 
vpu (1) proteins.
We enrolled 33 children vertically infected with HIV (age range: 
3 months – 12 years), naïve for antiretroviral therapy, with CD4% 
>15% or CD4 count >350 cells/ml.
T cell recognition of single peptides was assessed by IFN-γ 
ELISpot. Pooled peptides (gag, nef, regulatory proteins) were 
used to assess helper (CD40L expression) and cytotoxic (CD107a 
expression on cell surface) functions, and proliferative capacity 
(CFSE dilution) by flow cytometry. 
Results: The majority (76%) of children recognized at least one 
peptide or peptide pool in at least one test, but none of the 
functional assays alone would have identified all responders.
Half (48%) of the peptides were recognized by at least one child 
in ELISpot assay, nef peptides being the most frequently targeted 
(by 67% of the responders). Three previously undescribed 
epitopes were identified, while 2 epitopes commonly considered 
immunodominant were not recognized.
In some children the same peptides were able to elicit different 
functions, while in other children diverse functions were induced 
by different peptides. The breadth of the epitope recognition 
and the number of different functions elicited were directly 
correlated and independent from the length of infection (age).
Conclusion: These data provide a proof-of-concept for the 
rational design of T cell immunogens by reverse immunogenetic 
approach and support the parallel use of different functional 
assays for epitope mapping.
P13.01
Pediatric HIV Infection Due to Maternal 
Transmission: A Solvable Problem in a Peri-urban 
Setting in Bamako, Mali
K. Tounkara1, A. Traore2, B. Aboubacar1, O. Koita1, B. Traore3,  
F. Siby Diallo3, F. Bougoudogo4, Y. Kone1, C. Gomez-Mira1,  
J. Toffoli1, L. Levitz1, M. Rochas1, A.S. De Groot1
1GAIA Vaccine Foundation, Bamako, Mali; 2Cellule Sectorielle 
de la Lutte Contre le SIDA, Bamako, Mali; 3Direction Regionale 
de la Sante, Bamako, Mali; 4Institut National pour la Sante 
Publique, Bamako, Mali
Background: In 2005, GAIA Vaccine Foundation established 
a mother-to-child transmission prevention (MTCTP) program 
(Chez Rosalie) in the community-based clinic of Sikoro, a peri-
urban low-resource setting in Bamako, Mali. HIV testing of the 
pediatric population by PCR was recently implemented. Here we 
report the status of children born to HIV-seropositive mothers 
followed at the clinic.
Methods: The MTCTP program at Chez Rosalie was one of the 
first such programs to be established. Standard finger-stick 
approaches to testing children for HIV at 18 months resulted in 
very few children tested, as women frequently did not return to 
the clinic with their children at this time. In 2010, PCR-testing 
of newborns was integrated into mothers’ postpartum follow-
up appointments, during which artificial milk and antiretrovirals 
(ARV) were also distributed as part of PMTCT. As a result of this 
change, the test has now been performed for 69 children of 
the 202 HIV-seropositive mothers enrolled in the Chez Rosalie 
PMTCT program in Sikoro.
Results: 62 children (90%) were HIV-negative by PCR, and seven 
children (10%) were HIV-positive. Of the seven HIV-positive 
children, only one was born to a mother followed at the clinic. 
This mother was diagnosed late in her pregnancy and did not 
strictly adhere to MTCTP, including exclusive formula feeding her 
child (the national policy at the time). The other six HIV-positive 
children were born either at home or in another clinic where 
MTCTP was not available.
Conclusion: PCR testing of newborns increased the number 
of children screened for HIV infection in this MTCTP program. 
Both treating mothers with ARVs prior to delivery and providing 
newborns with formula (or exclusive breastfeeding while on 
ARV) reduced prevalence of pediatric HIV infection by close to 
98%. Based on our results, the introduction of MTCTP at the 
community level is one of the most successful non-vaccine HIV 
prevention interventions.
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